

From: Vivlmore, Tracy
Sent: Monday, August 22, 2005 3:04 PM
To: STIC-Biotech/ChemLib
Subject: Sequence search request, application 10/828,394

Hello,

For application 10/828,394 please perform the following sequence searches:

For SEQ ID NO: 1, a score over length search of nucleotides 1-1643 with a length of 8-50 and a cutoff of 80%.

For SEQ ID NO: 5, a length limited search with a maximum length of 50.

Thank you,

Tracy Vivlmore PhD
Remsen 2B-02, AU 1635
Mailbox: 2C-18
Tel: 571-272-2914

STAFF USE ONLY

Searcher: _____
Searcher Phone: 2-_____
Date Searcher Picked up: _____
Date Completed: _____
Searcher Prep/Rev. Time: _____
Online Time: _____

Type of Search

NA#: _____ AA#: _____
Interference: _____ SPDI: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure#: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable

STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other(Specify): _____

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 80%

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 15:23:21 ; Search time 128 Seconds
(without alignments)
268.452 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21

Sequence: 1 cagcagcagagtcctcatcat 21

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 1209694

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents NA:*
- 1: /cgn2_6/ptodata/1/ina/5A COMB.seq.*
 - 2: /cgn2_6/ptodata/1/ina/5B COMB.seq.*
 - 3: /cgn2_6/ptodata/1/ina/6A COMB.seq.*
 - 4: /cgn2_6/ptodata/1/ina/6B COMB.seq.*
 - 5: /cgn2_6/ptodata/1/ina/PCTUS COMB.seq.*
 - 6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	17.8	84.8	50	4	US-09-485-632B-15
C 2	16.2	77.1	32	4	US-09-410-935B-6
C 3	16.2	77.1	32	4	US-09-784-403A-6
C 4	16	76.2	25	4	US-09-396-196G-7759
C 5	15.4	73.3	45	1	US-07-885-689A-7
C 6	15.2	72.4	22	4	US-09-823-549-46
C 7	14.8	70.5	20	4	US-10-007-010-43
C 8	14.8	70.5	31	2	US-08-467-603-35
C 9	14.8	70.5	31	2	US-08-466-793-35
C 10	14.8	70.5	31	2	US-08-491-861A-35
C 11	14.8	70.5	31	4	US-09-374-671A-35
C 12	14.6	69.5	25	4	US-09-396-196G-10991
C 13	14.6	69.5	25	4	US-09-396-196G-74836
C 14	14.6	69.5	40	3	US-09-110-359A-11
C 15	14.2	67.6	20	2	US-09-205-860-3
C 16	14.2	67.6	20	3	US-09-657-452A-163
C 17	14.2	67.6	24	3	US-09-360-545-57
C 18	14.2	67.6	25	4	US-09-396-196G-103491
C 19	14.2	67.6	30	3	US-09-130-663-10
C 20	14.2	67.6	30	3	US-09-432-335-10
C 21	14.2	67.6	30	3	US-09-254-023B-20
C 22	14.2	67.6	30	3	US-09-614-022-10
C 23	14.2	67.6	47	4	US-09-422-978-3015
C 24	13.8	65.7	18	2	US-09-256-496-15
C 25	13.8	65.7	25	4	US-09-396-196G-35606
C 26	13.8	65.7	25	4	US-09-396-196G-44424
C 27	13.8	65.7	25	4	US-09-396-196G-44425

28	13.8	65.7	25	4	US-09-396-196G-44426	Sequence 44426, A
29	13.8	65.7	25	4	US-09-396-196G-44427	Sequence 44427, A
C 30	13.8	65.7	25	4	US-09-396-196G-108268	Sequence 108268,
C 31	13.8	65.7	28	4	US-09-887-145-35	Sequence 35, Appl
C 32	13.8	65.7	30	4	US-09-586-216C-19	Sequence 19, Appl
C 33	13.8	65.7	37	2	US-08-467-603-54	Sequence 54, Appl
C 34	13.8	65.7	37	2	US-08-466-793-54	Sequence 54, Appl
C 35	13.8	65.7	37	2	US-08-491-861A-54	Sequence 54, Appl
C 36	13.8	65.7	37	4	US-09-374-671A-54	Sequence 4, Appl
C 37	13.8	65.7	41	4	US-09-586-216C-4	Sequence 87, Appl
C 38	13.6	64.8	20	3	US-09-517-467B-87	Sequence 4550, Ap
C 39	13.6	64.8	20	4	US-09-198-452A-4550	Sequence 6, Appl
C 40	13.6	64.8	23	3	US-09-489-085A-6	Sequence 10990, A
C 41	13.6	64.8	25	4	US-09-396-196G-7746	Sequence 68315, A
C 42	13.6	64.8	25	4	US-09-396-196G-10990	Patent No. 5463174
C 43	13.6	64.8	25	4	US-09-396-196G-68315	Patent No. 5463174
C 44	13.6	64.8	27	6	5463174-1	
C 45	13.6	64.8	27	6	5463174-1	

ALIGNMENTS

RESULT 1

US-09-485-632B-15/c
; Sequence 15, Application US/09485632B
; Patent No. 6605280
; GENERAL INFORMATION:
; APPLICANT: NO. 6605280ick, Daniela
; APPLICANT: Dinarello, Charles
; APPLICANT: Rubinstein, Menachem
; APPLICANT: Kim, Soo Hyun
; TITLE OF INVENTION: Interleukin-18 Binding Proteins, their Preparation and
; FILE REFERENCE: Use
; CURRENT APPLICATION NUMBER: 20993-001
; CURRENT FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: IL98/00379
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 125463
; PRIOR FILING DATE: 1998-07-22
; PRIOR APPLICATION NUMBER: 122134
; PRIOR FILING DATE: 1997-11-06
; PRIOR APPLICATION NUMBER: 121869
; PRIOR FILING DATE: 1997-09-29
; PRIOR APPLICATION NUMBER: 121639
; PRIOR FILING DATE: 1997-08-27
; PRIOR APPLICATION NUMBER: 121554
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Chemically synthesized
US-09-485-632B-15

Query Match 84.8%; Score 17.8; DB 4; Length 50;
Best Local Similarity 90.5%; Pred. No. 80;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CAGCAGCAGGCTTCATCAT,21

Db 42 CAGCAGCAGGCTTCATCAT 22

RESULT 2

US-09-410-935B-6
; Sequence 6, Application US/09410935B
; Patent No. 6504083
; GENERAL INFORMATION:

```

; APPLICANT: Barbour, Eric
; APPLICANT: EuClaire Meyer, Terry
; APPLICANT: Eid Saad, Mohammed
; TITLE OF INVENTION: No. 6504083el Maize Promoters
; FILE REFERENCE: 5718-72
; CURRENT APPLICATION NUMBER: US/09/410,935B
; PRIOR FILING DATE: 1999-10-04
; PRIOR APPLICATION NUMBER: US 60/107,201
; PRIOR FILING DATE: 1998-11-05
; PRIOR APPLICATION NUMBER: US 60/103,294
; PRIOR FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gene specific primer 1 for Gos-2
US-09-410-935B-6

Query Match          77.1%; Score 16.2; DB 4; Length 32;
Best Local Similarity 85.7%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
    ||||| ||||| ||||| |||||
Db 3 CAGCACCAGAGTCTTCAGCAT 23

RESULT 3
US-09-784-403A-6
; Sequence 6, Application US/09784403A
; Patent No. 6670467
; GENERAL INFORMATION:
; APPLICANT: Barbour, Eric
; APPLICANT: EuClaire Meyer, Terry
; APPLICANT: Eid Saad, Mohammed
; TITLE OF INVENTION: No. 6670467el Maize Promoters
; FILE REFERENCE: 35718/208067
; CURRENT APPLICATION NUMBER: US/09/784,403A
; PRIOR FILING DATE: 2001-02-15
; PRIOR APPLICATION NUMBER: US 60/107,201
; PRIOR FILING DATE: 1998-11-05
; PRIOR APPLICATION NUMBER: US 60/103,294
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 09/410,935
; PRIOR FILING DATE: 1999-10-04
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gene specific primer 1 for Gos-2
US-09-784-403A-6

Query Match          77.1%; Score 16.2; DB 4; Length 32;
Best Local Similarity 85.7%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
    ||||| ||||| ||||| |||||
Db 3 CAGCACCAGAGTCTTCAGCAT 23

RESULT 4
US-09-396-196G-7759/c
; Sequence 7759, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396.196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7759
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-7759

Query Match          76.2%; Score 16; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGTCTTCA 17
    ||||| ||||| ||||| |||||
Db 16 AGCAGCAGAGTCTTCA 1

RESULT 5
US-07-885-689A-7
; Sequence 7, Application US/07885689A
; Patent No. 5366876
; GENERAL INFORMATION:
; APPLICANT: Cho, Joong M.
; APPLICANT: Lee, Tae H.
; APPLICANT: Chung, Hyun H.
; APPLICANT: Lee, Yong B.
; APPLICANT: Lee, Tae G.
; APPLICANT: Park, Young W.
; APPLICANT: Han, Kyu B.
; TITLE OF INVENTION: Method for Production of Bovine Growth
; TITLE OF INVENTION: Hormone Using a Synthetic Gene.
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolash & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/885,689A
; FILING DATE: 19-MAY-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30,330
; REFERENCE/DOCKET NUMBER: 377-144P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHEetical: NO
; FEATURE:

```


Medium Type	Query Match	Score	DB 1	DB 2	Length	DB 3	DB 4	DB 5	DB 6	DB 7	DB 8	DB 9	DB 10	DB 11	DB 12	DB 13	DB 14	DB 15	DB 16	DB 17	DB 18	DB 19	DB 20	DB 21	DB 22	DB 23	DB 24	DB 25	DB 26	DB 27	DB 28	DB 29	DB 30	DB 31	DB 32	DB 33	DB 34	DB 35	DB 36	DB 37	DB 38	DB 39	DB 40	DB 41	DB 42	DB 43	DB 44	DB 45	DB 46	DB 47	DB 48	DB 49	DB 50	DB 51	DB 52	DB 53	DB 54	DB 55	DB 56	DB 57	DB 58	DB 59	DB 60	DB 61	DB 62	DB 63	DB 64	DB 65	DB 66	DB 67	DB 68	DB 69	DB 70	DB 71	DB 72	DB 73	DB 74	DB 75	DB 76	DB 77	DB 78	DB 79	DB 80	DB 81	DB 82	DB 83	DB 84	DB 85	DB 86	DB 87	DB 88	DB 89	DB 90	DB 91	DB 92	DB 93	DB 94	DB 95	DB 96	DB 97	DB 98	DB 99	DB 100	DB 101	DB 102	DB 103	DB 104	DB 105	DB 106	DB 107	DB 108	DB 109	DB 110	DB 111	DB 112	DB 113	DB 114	DB 115	DB 116	DB 117	DB 118	DB 119	DB 120	DB 121	DB 122	DB 123	DB 124	DB 125	DB 126	DB 127	DB 128	DB 129	DB 130	DB 131	DB 132	DB 133	DB 134	DB 135	DB 136	DB 137	DB 138	DB 139	DB 140	DB 141	DB 142	DB 143	DB 144	DB 145	DB 146	DB 147	DB 148	DB 149	DB 150	DB 151	DB 152	DB 153	DB 154	DB 155	DB 156	DB 157	DB 158	DB 159	DB 160	DB 161	DB 162	DB 163	DB 164	DB 165	DB 166	DB 167	DB 168	DB 169	DB 170	DB 171	DB 172	DB 173	DB 174	DB 175	DB 176	DB 177	DB 178	DB 179	DB 180	DB 181	DB 182	DB 183	DB 184	DB 185	DB 186	DB 187	DB 188	DB 189	DB 190	DB 191	DB 192	DB 193	DB 194	DB 195	DB 196	DB 197	DB 198	DB 199	DB 200	DB 201	DB 202	DB 203	DB 204	DB 205	DB 206	DB 207	DB 208	DB 209	DB 210	DB 211	DB 212	DB 213	DB 214	DB 215	DB 216	DB 217	DB 218	DB 219	DB 220	DB 221	DB 222	DB 223	DB 224	DB 225	DB 226	DB 227	DB 228	DB 229	DB 230	DB 231	DB 232	DB 233	DB 234	DB 235	DB 236	DB 237	DB 238	DB 239	DB 240	DB 241	DB 242	DB 243	DB 244	DB 245	DB 246	DB 247	DB 248	DB 249	DB 250	DB 251	DB 252	DB 253	DB 254	DB 255	DB 256	DB 257	DB 258	DB 259	DB 260	DB 261	DB 262	DB 263	DB 264	DB 265	DB 266	DB 267	DB 268	DB 269	DB 270	DB 271	DB 272	DB 273	DB 274	DB 275	DB 276	DB 277	DB 278	DB 279	DB 280	DB 281	DB 282	DB 283	DB 284	DB 285	DB 286	DB 287	DB 288	DB 289	DB 290	DB 291	DB 292	DB 293	DB 294	DB 295	DB 296	DB 297	DB 298	DB 299	DB 300	DB 301	DB 302	DB 303	DB 304	DB 305	DB 306	DB 307	DB 308	DB 309	DB 310	DB 311	DB 312	DB 313	DB 314	DB 315	DB 316	DB 317	DB 318	DB 319	DB 320	DB 321	DB 322	DB 323	DB 324	DB 325	DB 326	DB 327	DB 328	DB 329	DB 330	DB 331	DB 332	DB 333	DB 334	DB 335	DB 336	DB 337	DB 338	DB 339	DB 340	DB 341	DB 342	DB 343	DB 344	DB 345	DB 346	DB 347	DB 348	DB 349	DB 350	DB 351	DB 352	DB 353	DB 354	DB 355	DB 356	DB 357	DB 358	DB 359	DB 360	DB 361	DB 362	DB 363	DB 364	DB 365	DB 366	DB 367	DB 368	DB 369	DB 370	DB 371	DB 372	DB 373	DB 374	DB 375	DB 376	DB 377	DB 378	DB
-------------	-------------	-------	------	------	--------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	----

; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 742-4214
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-374-671A-35

Query Match 70.5%; Score 14.8; DB 4; Length 31;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGTCTTCATC 19
Db 24 AGGAGCAGGCTTCATC 7

RESULT 12
US-09-396-196G-10991
; Sequence 10991, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10991
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-10991

Query Match 69.5%; Score 14.6; DB 4; Length 25;
Best Local Similarity 81.0%; Pred. No. 1.9e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 3 CAACAGCAGGCTTCACAT 23

RESULT 13
US-09-396-196G-74836
; Sequence 74836, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 74836
; LENGTH: 25
; TYPE: DNA

; ORGANISM: mus musculus
US-09-396-196G-74836

Query Match 69.5%; Score 14.6; DB 4; Length 25;
Best Local Similarity 81.0%; Pred. No. 1.9e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 4 CAGCAGCAGAGCCTGAGCAT 24

RESULT 14
US-09-110-959A-11
; Sequence 11, Application US/09110959A
; Patent No. 6268197
; GENERAL INFORMATION:
; APPLICANT: Schulein, Martin
; APPLICANT: Outtrup, Helle
; APPLICANT: Jorgensen, Per Lina
; APPLICANT: Bjornvad, Mads Eskelund
; TITLE OF INVENTION: Alkaline Xyloglucanase
; FILE REFERENCE: 5206-200-US
; CURRENT APPLICATION NUMBER: US/09/110,959A
; CURRENT FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 0822/97
; PRIOR FILING DATE: 1997-07-07
; PRIOR APPLICATION NUMBER: 1213/97
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/054,039
; PRIOR FILING DATE: 1997-07-28
; PRIOR APPLICATION NUMBER: 60/063,694
; PRIOR FILING DATE: 1997-10-28
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 44
; TYPE: DNA
; ORGANISM: Bacillus sp.
US-09-110-959A-11

Query Match 69.5%; Score 14.6; DB 3; Length 44;
Best Local Similarity 81.0%; Pred. No. 2.1e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 12 CAGCAGCGCGGCTTCGICAT 32

RESULT 15
US-09-205-860-3
; Sequence 3, Application US/09205860
; Patent No. 5981732
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION
; FILE REFERENCE: RTS-0031
; CURRENT APPLICATION NUMBER: US/09/205,860
; CURRENT FILING DATE: 1998-12-04
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-205-860-3

Query Match 67.6%; Score 14.2; DB 2; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.8e+03;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Tue Sep 13 09:41:58 2005

Qy 1 CAGCAGCAGAGTCTTTCATC 19
|||
Db 2 CAGCAGCAGGATCTTTCACC 20

Search completed: September 3, 2005, 16:22:35
Job time : 131 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 15:24:25 ; Search time 603 Seconds
(without alignments)
228.072 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21

Sequence: 1 cagcagcagatcttcattcat 21

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 733684 seqs, 3274456166 residues

Total number of hits satisfying chosen parameters: 8349320

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_NA.*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq.*
- 2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq.*
- 3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq.*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq.*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq.*
- 6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq.*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq.*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq.*
- 9: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq.*
- 10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq.*
- 11: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq.*
- 12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq.*
- 13: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq.*
- 14: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq.*
- 15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq.*
- 16: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq.*
- 17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq.*
- 18: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq.*
- 19: /cgn2_6/ptodata/1/pubpna/US10G_PUBCOMB.seq.*
- 20: /cgn2_6/ptodata/1/pubpna/US10H_PUBCOMB.seq.*
- 21: /cgn2_6/ptodata/1/pubpna/US10I_PUBCOMB.seq.*
- 22: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq.*
- 23: /cgn2_6/ptodata/1/pubpna/US11_PUBCOMB.seq.*
- 24: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq.*
- 25: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq.*
- 26: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	21	100.0	21	9	US-09-944-326-4
2	21	100.0	21	10	US-09-967-726A-4
3	21	100.0	21	16	US-10-080-794-4
4	21	100.0	21	18	US-10-646-391A-4
5	21	100.0	21	20	US-10-828-394-5
6	21	100.0	21	20	US-10-828-395-5
7	21	100.0	23	18	US-10-646-436-66

Query Match 100.0%; Score 21; DB 9; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

c	8	20	95.2	21	18	US-10-646-391A-28	Sequence 28, Appl
c	9	20	95.2	21	18	US-10-646-436-9	Sequence 9, Appl
c	10	20	95.2	25	21	US-10-956-157-236817	Sequence 236817,
c	11	19	90.5	19	18	US-10-646-391A-42	Sequence 42, Appl
c	12	19	90.5	19	18	US-10-646-391A-43	Sequence 43, Appl
c	13	19	90.5	19	18	US-10-646-436-67	Sequence 67, Appl
c	14	19	90.5	19	18	US-10-646-436-68	Sequence 68, Appl
c	15	19	90.5	21	18	US-10-646-391A-29	Sequence 29, Appl
c	16	19	90.5	21	18	US-10-646-436-10	Sequence 10, Appl
c	17	17.8	84.8	21	10	US-09-967-726A-15	Sequence 15, Appl
c	18	17.8	84.8	21	16	US-10-080-794-15	Sequence 15, Appl
c	19	17.8	84.8	50	11	US-09-790-338A-17	Sequence 17, Appl
c	20	17.8	84.8	50	18	US-10-434-583-15	Sequence 15, Appl
c	21	17	81.0	25	21	US-10-956-157-285427	Sequence 285427,
c	22	16.4	78.1	25	22	US-10-719-956-187913	Sequence 187913,
c	23	16.4	78.1	25	22	US-10-719-956-217934	Sequence 217934,
c	24	16.2	77.1	25	21	US-10-956-157-174230	Sequence 174230,
c	25	16.2	77.1	32	14	US-10-278-255-6	Sequence 6, Appl
c	26	16.2	77.1	32	18	US-10-690-034-6	Sequence 6, Appl
c	27	16	76.2	25	21	US-10-809-189-7759	Sequence 7759, Ap
c	28	15.8	75.2	25	22	US-10-719-956-190997	Sequence 190997,
c	29	15.8	75.2	25	22	US-10-719-956-190998	Sequence 190998,
c	30	15.4	73.3	25	22	US-10-719-956-539340	Sequence 539340,
c	31	15.4	73.3	25	22	US-10-719-956-562252	Sequence 562252,
c	32	15.4	73.3	25	22	US-10-719-956-599108	Sequence 599108,
c	33	15.4	73.3	25	22	US-10-719-956-678358	Sequence 678358,
c	34	15.2	72.4	22	9	US-09-823-549-46	Sequence 46, Appl
c	35	15.2	72.4	22	20	US-10-685-992-46	Sequence 79840, A
c	36	15.2	72.4	25	21	US-10-719-900-79840	Sequence 99916, A
c	37	15.2	72.4	25	21	US-10-719-900-99916	Sequence 99916, A
c	38	15.2	72.4	25	21	US-10-719-900-516755	Sequence 516755,
c	39	15.2	72.4	25	21	US-10-719-900-859600	Sequence 859600,
c	40	15.2	72.4	25	22	US-10-719-956-74777	Sequence 74777, A
c	41	15.2	72.4	25	22	US-10-719-956-483005	Sequence 483005,
c	42	14.8	70.5	20	15	US-10-007-010-43	Sequence 43, Appl
c	43	14.8	70.5	21	9	US-09-944-326-1	Sequence 1, Appl
c	44	14.8	70.5	21	9	US-09-944-326-2	Sequence 2, Appl
c	45	14.8	70.5	21	10	US-09-967-726A-1	Sequence 1, Appl

ALIGNMENTS

RESULT 1

US-09-944-326-4
; Sequence 4, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-4

```
Qy 1 CAGCAGCAGAGTCTTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTTCATCAT 21

RESULT 2
US-09-967-726A-4
; Sequence 4, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-4

Query Match 100.0%; Score 21; DB 10; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTTCATCAT 21

RESULT 3
US-10-080-794-4
; Sequence 4, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-4

Query Match 100.0%; Score 21; DB 16; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTTCATCAT 21

RESULT 4
US-10-646-391A-4
; Sequence 4, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-4

Query Match 100.0%; Score 21; DB 18; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTTCATCAT 21

RESULT 5
US-10-828-394-5
; Sequence 5, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-5

Query Match 100.0%; Score 21; DB 20; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTTCATCAT 21
```

```
RESULT 6
US-10-828-395-5
; Sequence 5, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-5

Query Match          100.0%; Score 21; DB 20; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTCATCAT 21

RESULT 7
US-10-646-436-66/c
; Sequence 66, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-66

Query Match          100.0%; Score 21; DB 18; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 23 CAGCAGCAGAGTCTTCATCAT 3

RESULT 8
US-10-646-436-66

Query Match          100.0%; Score 21; DB 18; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 23 CAGCAGCAGAGTCTTCATCAT 3

RESULT 9
US-10-646-436-9/c
; Sequence 9, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-9

Query Match          95.2%; Score 20; DB 18; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGTCTTCATCAT 21
Db 20 AGCAGCAGAGTCTTCATCAT 1

RESULT 9
US-10-646-436-9/c
; Sequence 9, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-9

Query Match          95.2%; Score 20; DB 18; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGTCTTCATCAT 21
```

```
Db 20 AGCAGCAGAGTCTTCATCAT 1
|||||
RESULT 10
US-10-956-157-236817/c
; Sequence 236817, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Mounts, William
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236817
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-236817
Query Match 95.2%; Score 20; DB 21; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGTCTTCATCAT 21
|||||
Db 25 AGCAGCAGAGTCTTCATCAT 6
|||||

RESULT 11
US-10-646-391A-42/c
; Sequence 42, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: USC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42
; LENGTH: 19
; TYPE: RNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-42
Query Match 90.5%; Score 19; DB 18; Length 19;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
|||||
Db 19 GCAGCAGAGTCTTCATCAT 1
|||||

RESULT 12
US-10-646-391A-43
; Sequence 43, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: USC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
; LENGTH: 19
; TYPE: RNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-43
Query Match 90.5%; Score 19; DB 18; Length 19;
Best Local Similarity 73.7%; Pred. No. 31;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
|||||
Db 1 GCAGCAGAGUCUUCAUCAU 19
|||||

RESULT 13
US-10-646-436-67/c
; Sequence 67, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: USC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 67
; LENGTH: 19
; TYPE: RNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-67
Query Match 90.5%; Score 19; DB 18; Length 19;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
|||||
```

Db 19 GCAGCAGAGTCTTCATCAT 1

RESULT 14

US-10-646-436-68
; Sequence 68, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 68
; LENGTH: 19
; TYPE: RNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi fo rhuman clusterin
US-10-646-436-68

Query Match

Best Local Similarity 90.5%; Score 19; DB 18; Length 19;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
Db 1 GCAGCAGAGUCUUCAU 19

RESULT 15

US-10-646-391A-29
; Sequence 29, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-29

Query Match

90.5%; Score 19; DB 18; Length 21;

Best Local Similarity 73.7%; Pred. No. 31;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
Db 1 GCAGCAGAGUCUUCAU 19

Search completed: September 3, 2005, 16:32:54
Job time : 609 secs

THIS PAGE BLANK (uspto)

THIS PAGE BLANK (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 14:43:21 ; Search time 1859 Seconds
(without alignments)
547.369 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21
Sequence: 1 cagcagcagagcttcattcat 21

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 4708233 seqs, 24227607955 residues

Total number of hits satisfying chosen parameters: 1839042

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:
1: gb_ba:*
2: gb_hgt:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_ste:*
12: gb_sy:*
13: gb_uni:*
14: gb_vi:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	21	100.0	21	6	CQ786615
C 2	21	100.0	23	6	CQ786178
C 3	20	95.2	21	6	CQ786121
C 4	20	95.2	21	6	CQ786639
C 5	19	90.5	19	6	CQ786179
C 6	19	90.5	19	6	CQ786180
C 7	19	90.5	19	6	CQ786653
C 8	19	90.5	19	6	CQ786654
C 9	19	90.5	21	6	CQ786122
C 10	19	90.5	21	6	CQ786640
C 11	17.8	84.8	50	6	AR374192
C 12	16.2	77.1	32	6	AR274120
C 13	16.2	77.1	32	6	AR444937
C 14	16.2	77.1	48	6	A76301
C 15	16.2	77.1	48	6	E01067
C 16	15.4	73.3	39	6	A08489
C 17	15.4	73.3	39	6	A12568
C 18	15.4	73.3	45	6	A05116
C 19	15.2	72.4	22	6	AR439728

20	15.2	72.4	22	6	AX268965	AX268965 Sequence
21	14.8	70.5	21	6	CQ786613	CQ786613 Sequence
C 22	14.8	70.5	27	6	AX118356	AX118356 Sequence
C 23	14.8	70.5	31	6	AR070079	AR070079 Sequence
C 24	14.8	70.5	31	6	AR258163	AR258163 Sequence
C 25	14.8	70.5	31	6	AX670795	AX670795 Sequence
C 26	14.6	69.5	38	6	A76303	A76303 Sequence 9
C 27	14.4	68.6	30	6	BD186389	BD186389 Peptides
C 28	14.4	68.6	39	6	A08490	A08490 oligonucleo
C 29	14.4	68.6	39	6	A08491	A08491 oligonucleo
C 30	14.4	68.6	39	6	A12569	A12569 fragment of
C 31	14.4	68.6	39	6	A12570	A12570 fragment of
C 32	14.2	67.6	20	6	AR085567	AR085567 Sequence
C 33	14.2	67.6	20	6	AR221110	AR221110 Sequence
C 34	14.2	67.6	22	6	AX697095	AX697095 Sequence
C 35	14.2	67.6	24	6	AR222129	AR222129 Sequence
C 36	14.2	67.6	26	6	AX697096	AX697096 Sequence
C 37	14.2	67.6	30	6	A70102	A70102 Sequence 20
C 38	14.2	67.6	30	6	AR148235	AR148235 Sequence
C 39	14.2	67.6	30	6	AR204084	AR204084 Sequence
C 40	14.2	67.6	30	6	BD077090	BD077090 Lipocalin
C 41	14.2	67.6	38	6	CQ817644	CQ817644 Sequence
C 42	14.2	67.6	38	6	CQ817645	CQ817645 Sequence
C 43	14.2	67.6	38	6	CQ867639	CQ867639 Sequence
C 44	14.2	67.6	38	6	CQ867640	CQ867640 Sequence
C 45	14.2	67.6	47	6	AR291280	AR291280 Sequence

ALIGNMENTS

RESULT 1
CQ786615
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

Sequence 4 from Patent WO2004018675.
CQ786615
CQ786615.1 GI:45721635
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Jansen,B.
Treatment of melanoma by reduction in clusterin levels
Patent: WO 2004018675-A 4 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 100.0%; Score 21; DB 6; Length 21;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGCTTCATCAT 21
|||||
Db 1 CAGCAGCAGAGCTTCATCAT 21

RESULT 2
CQ786178/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

Sequence 66 from Patent WO2004018676.
CQ786178
CQ786178.1 GI:45721281
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 66 04-MAR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1..23
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 100.0%; Score 21; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTCATCAT 21
|||||
Db 23 CAGCAGCAGAGTCTTCATCAT 3

RESULT 3
CQ786121/c
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 9 from Patent WO2004018676.
ACCESSION CQ786121
VERSION CQ786121.1 GI:45721224
KEYWORDS .
synthetic construct
synthetic construct
other sequences; artificial sequences.
ORGANISM
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 9 04-MAR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

ORIGIN
Query Match 95.2%; Score 20; DB 6; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 AGCAGCAGAGTCTTCATCAT 21
|||||
Db 20 AGCAGCAGAGTCTTCATCAT 1

RESULT 4
CQ786639/c
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 28 from Patent WO2004018675.
ACCESSION CQ786639
VERSION CQ786639.1 GI:45721659
KEYWORDS .
synthetic construct
synthetic construct
other sequences; artificial sequences.
ORGANISM
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 28 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES Location/Qualifiers
source 1..21

ORIGIN
Query Match 95.2%; Score 20; DB 6; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 AGCAGCAGAGTCTTCATCAT 21
|||||
Db 20 AGCAGCAGAGTCTTCATCAT 1

RESULT 5
CQ786179/c
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 67 from Patent WO2004018676.
ACCESSION CQ786179
VERSION CQ786179.1 GI:45721282
KEYWORDS .
synthetic construct
synthetic construct
other sequences; artificial sequences.
ORGANISM
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 67 04-MAR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

ORIGIN
Query Match 90.5%; Score 19; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21
|||||
Db 19 GCAGCAGAGTCTTCATCAT 1

RESULT 6
CQ786180
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 68 from Patent WO2004018676.
ACCESSION CQ786180
VERSION CQ786180.1 GI:45721283
KEYWORDS .
synthetic construct
synthetic construct
other sequences; artificial sequences.
ORGANISM
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 68 04-MAR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

ORIGIN
Query Match 90.5%; Score 19; DB 6; Length 19;


```

Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
    |||||
Db 1 GCAGCAGAGTCTTCATCAT 19

RESULT 7
CQ786653/c
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 42 from Patent WO2004018675.
ACCESSION CQ786653
VERSION CQ786653.1 GI:45721673
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 42 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

ORIGIN
Query Match 90.5%; Score 19; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
    |||||
Db 19 GCAGCAGAGTCTTCATCAT 1

RESULT 8
CQ786654
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 43 from Patent WO2004018675.
ACCESSION CQ786654
VERSION CQ786654.1 GI:45721674
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 43 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

ORIGIN
Query Match 90.5%; Score 19; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
    |||||
Db 1 GCAGCAGAGTCTTCATCAT 19

RESULT 9
CQ786653/c
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 42 from Patent WO2004018675.
ACCESSION CQ786653
VERSION CQ786653.1 GI:45721673
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 42 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

ORIGIN
Query Match 90.5%; Score 19; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
    |||||
Db 1 GCAGCAGAGTCTTCATCAT 19

RESULT 10
CQ786640
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 29 from Patent WO2004018675.
ACCESSION CQ786640
VERSION CQ786640.1 GI:45721660
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 29 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

ORIGIN
Query Match 90.5%; Score 19; DB 6; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
    |||||
Db 1 GCAGCAGAGTCTTCATCAT 19

RESULT 11
CQ786640
LOCUS 50 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 15 from patent US 6605280.
ACCESSION AR374192
VERSION AR374192.1 GI:40076792
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.

```



```

FH Key Location/Qualifiers
FH sig_peptide 1..48
FT /product='human pancreas elastase-2 signal peptide'
FT
FEATURES
source
1..48
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'
ORIGIN
Query Match 77.1%; Score 16.2; DB 6; Length 48;
Best Local Similarity 85.7%; Pred. No. 9.3e+03;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 21 CAGCAGCAGAGTCTTCATCAT 1
Search completed: September 3, 2005, 15:29:38
Job time : 1864 secs

```

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 12:59:00 ; Search time 430 Seconds
(without alignments)
289.104 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21

Sequence: 1 cagcagcaggtcttcattcat 21

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 4167226

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N Geneseq_16Dec04:*

- 1: Geneseqn1980s:*
- 2: Geneseqn1990s:*
- 3: Geneseqn2000s:*
- 4: Geneseqn2001as:*
- 5: Geneseqn2001bs:*
- 6: Geneseqn2002as:*
- 7: Geneseqn2002bs:*
- 8: Geneseqn2003as:*
- 9: Geneseqn2003bs:*
- 10: Geneseqn2003cs:*
- 11: Geneseqn2003ds:*
- 12: Geneseqn2004as:*
- 13: Geneseqn2004bs:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	21	100.0	21	3	AAA94226 Human tes
2	21	100.0	21	10	ACF36398
3	21	100.0	21	11	ADH63069 Human TRP
4	21	100.0	21	12	ADL70406
5	21	100.0	23	12	ADL70521 Human glu
6	20	95.2	21	12	ADL70454 RNAi for
7	20	95.2	21	12	ADL70430 RNAi for
8	19	90.5	19	12	ADL70522 RNAi for
9	19	90.5	19	12	ADL70523 RNAi for
10	19	90.5	19	12	ADL70444 RNAi for
11	19	90.5	19	12	ADL70445 RNAi for
12	19	90.5	21	12	ADL70465 RNAi for
13	19	90.5	21	12	ADL70431 RNAi for
14	17.8	84.8	21	10	ACF36409 DNA seque
15	17.8	84.8	21	11	ADH63080 Control T
16	17.8	84.8	50	2	AAx24790 Interleuk
17	16.2	77.1	32	3	AAa09140 Gos-2 pro
18	16.2	77.1	50	3	AAa11024 Human mat
19	15.2	72.4	22	4	AAa15291 Mouse IL-
20	15.2	72.4	40	3	AAz96146 Polynucle

21	15	71.4	22	12	AD129045
22	15	71.4	33	6	ABQ80863
23	14.8	70.5	20	10	AA621195
24	14.8	70.5	21	3	AAa94224
25	14.8	70.5	21	3	AAa94223
26	14.8	70.5	21	10	ACF36395
27	14.8	70.5	21	10	ACF36396
28	14.8	70.5	21	11	ADH63067
29	14.8	70.5	21	11	ADH63066
30	14.8	70.5	21	12	ADL70404
31	14.8	70.5	27	4	AAH40683
32	14.8	70.5	30	2	AAZ12445
33	14.8	70.5	31	2	AAQ89972
34	14.6	69.5	24	6	ABL61345
35	14.6	69.5	33	6	ABK49118
36	14.6	69.5	34	4	AAH79384
37	14.6	69.5	44	2	AAx06964
38	14.4	68.6	30	8	ABZ77331
39	14.2	67.6	20	2	ABZ31857
40	14.2	67.6	20	6	ABK69555
41	14.2	67.6	20	12	ADH64379
42	14.2	67.6	20	12	ADH63983
43	14.2	67.6	22	3	AAc58494
44	14.2	67.6	22	3	AAa37208
45	14.2	67.6	22	4	AAf54314

ALIGNMENTS

RESULT 1

AAA94226

ID AAA94226 standard; DNA; 21 BP.

AC AAA94226;

DT 12-JAN-2001 (first entry)

XX Human testosterone-repressed prostate message-2 antisense oligo #2.

XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX Homo sapiens.
XX WO200049937-A2.
XX 31-AUG-2000.
XX 25-FEB-2000; 2000WO-US004875.
XX 26-FEB-1999; 99US-0121726P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX Gleave M, Rennie PS, Miyake H, Nelson C;
XX WPI; 2000-533132/48.
XX Treating prostatic tumors and renal cancers by antisense inhibition of
XX the testosterone-repressed prostate messenger-2 gene.
XX Claim 3; Page 36; 38pp; English.

The present sequence is an antisense oligonucleotide directed at the human testosterone-repressed prostate message-2 (TRPM-2, also known as clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to promote the regression of tumours, and oligonucleotides directed at human TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2 gene. These include prostate cancer, renal cell cancer and some breast cancer cells. In addition to this, they also increase the chemosensitivity of the cells, meaning that conventional chemotherapy is more effective

Tue Sep 13 09:41:58 2005

us-10-828-394-5.rng

```
XX SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 100.0%; Score 21; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTCATCAT 21

RESULT 2
ACF36398
ID ACF36398 standard; DNA; 21 BP.
AC ACF36398;
XX 18-DEC-2003 (first entry)
DE TRPM-2 antisense oligonucleotide.
XX TRPM-2; testosterone-repressed prostate message-2; cytosstatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX Synthetic.
OS Homo sapiens.
XX WO2003072591-A1.
XX 04-SEP-2003.
XX 20-FEB-2003; 2003WO-US005305.
XX 22-FEB-2002; 2002US-00080794.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX WPI; 2003-689981/65.
XX New modified antisense oligonucleotide, useful particularly for treating
XX prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX Claim 1; Page 25; 44pp; English.
XX The invention relates to a compound consisting of an oligonucleotide with
XX a phosphorothioate backbone throughout, in which: (a) sugars on
XX nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
XX remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
XX positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
XX ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
XX prostatic cancer cells to the androgen-independent state, in vivo or in
XX vitro; (b) to treat prostatic cancer (after initially withdrawing
XX androgens to induce apoptosis); and (c) to increase sensitivity of cancer
XX cells (prostatic, renal, non-small cell lung, urothelial transitional,
XX ovarian and some breast cancer cells) that express abnormal levels of
XX TRPM-2 to chemotherapy or radiation. The modifications present in (I)
XX increase stability in vivo and activity (both in vivo or in vitro) and
XX result in a synergistic increase in effect when (I) is used with
XX chemotherapeutic agents or other antisense oligonucleotides directed
XX against other antiapoptotic genes. The present sequence represents a
XX specific example of an anti-apoptotic protein TRPM-2 (testosterone-
XX repressed prostate message-2) antisense oligonucleotide
XX Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 100.0%; Score 21; DB 10; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTCATCAT 21

Db 1 CAGCAGCAGAGTCTTCATCAT 21
RESULT 3
ADM83069
ID ADM83069 standard; DNA; 21 BP.
XX ADM83069;
XX 03-JUN-2004 (first entry)
XX Human TRPM-2 antisense oligonucleotide #4.
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
XX radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
XX lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
XX antisense; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
XX modified_base 1..21 /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone"
XX US2003158130-A1.
XX 21-AUG-2003.
XX 28-SEP-2001; 2001US-00967726.
XX 25-FEB-2000; 2000WO-US004875.
XX 28-SEP-2000; 2000US-0236301P.
XX 10-AUG-2001; 2001US-00913325.
XX (GLEA/) GLEAVE M.
XX (RENN/) RENNIE P S.
XX (MIYA/) MIYAKE H.
XX (NELS/) NELSON C.
XX (ZELL/) ZELLWEGER T.
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweiger T;
XX WPI; 2003-778017/73.
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
XX that expresses testosterone-repressed prostate message-2 (TRPM-2)
XX comprises administering a composition that inhibits expression of TRPM-2.
XX Claim 4; SEQ ID NO 4; 14pp; English.
XX The present invention provides a method for treating cancer in which
XX cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
XX The invention is useful for enhancing the chemo-sensitivity or radiation-
XX sensitivity of cancer cells for treating cancer such as prostate cancer,
XX bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
XX (RCC). The invention is also useful in antisense gene therapy. The
XX present sequence is human testosterone-repressed prostate message-2 (TRPM
XX -2) antisense oligodeoxyribonucleotide (ODN).
XX Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 100.0%; Score 21; DB 11; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTCATCAT 21
```

RESULT 4
ADL70406
ID ADL70406 standard; DNA; 21 BP.
XX
AC ADL70406;
XX
DT 20-MAY-2004 (first entry)
XX
XX Antisense oligonucleotide to human clusterin.
DE
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
KW
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate nucleotides"
FT 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-methoxyethyl modifications"
FT 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-methoxyethyl modifications"
XX
PN WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYER-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
XX Jansen B;
PI
XX WPI; 2004-226851/21.
DR
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 7; SEQ ID NO 4; 32pp; English.
PS
XX The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) (MOE) modifications in the 5' and 3' 'wings'. The
CC present antisense oligonucleotide is particularly preferred. It is
CC targeted to the translation initiation codon and next 6 codons of the
CC human clusterin sequence. It has a phosphorothioate backbone throughout
CC and MOE wings, the remaining nucleotides being 2'-deoxynucleotides. In an
CC example from the invention, this antisense oligonucleotide provided a
CC dose-dependent down-regulation of clusterin in human melanoma cells,
CC leading to an increase in apoptotic cell death. In one melanoma cell line
CC (607B) this alone was sufficient to lead to complete cell death. In
CC another melanoma cell line, the surviving cells showed increased

CC sensitivity to subsequent treatment with cisplatin. A claimed method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 100.0%; Score 21; DB 12; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 1 CAGCAGCAGAGTCTTCATCAT 21
RESULT 5
ADL70521/c
ID ADL70521 standard; cDNA; 23 BP.
XX
AC ADL70521;
XX
XX 20-MAY-2004 (first entry)
XX Human clusterin target for RNAi.
XX
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004018676-A2.
PN
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYER-) UNIV BRITISH COLUMBIA.
PA
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
XX WPI; 2004-226852/21.
DR
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Example 6; SEQ ID NO 66; 63pp; English.
PS
XX The present sequence is a human clusterin cDNA target for a double-
CC stranded short interfering RNA (siRNA) of the invention ADL70522-
CC ADL70523. It was used in an example from the invention to demonstrate
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (Sgp-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment

Tue Sep 13 09:41:58 2005

CC of Alzheimer's disease.
XX
SQ Sequence 23 BP; 5 A; 5 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 100.0%; Score 21; DB 12; Length 23;
Best Local Similarity 100.0%; Pred. No. 8.3;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CAGCAGCAGAGTCTTCATCAT 21
Db 23 CAGCAGCAGAGTCTTCATCAT 3
RESULT 6
ADL70464/c
ID ADL70464 standard; RNA; 21 BP.
XX
AC ADL70464;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosstatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dTdT"
XX
PN WO2004018676-A2.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001277.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
DR WPI; 2004-226852/21.
XX
PT New RNA molecule less than 49 bases and having a sequence effective to
FT mediate degradation or block translation of mRNA that is the
FT transcriptional product of a target gene, useful for treating Alzheimer's
FT disease or cancer.
XX
PS Claim 4; SEQ ID NO 9; 63pp; English.
XX
CC The present sequence is the sense strand of a short interfering RNA
CC (siRNA) targeted to human clusterin. The antisense strand is also
CC provided ADL70465. The siRNA can be used to interfere with the expression
CC of clusterin. Clusterin, also known as testosterone-repressed prostate
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in
CC increased amounts by prostate tumour cells following androgen withdrawal,
CC and has also been shown to be critical for neuritic toxicity in mouse
CC models of Alzheimer's disease. siRNAs of the invention can be used alone
CC or in combination with other chemotherapy or apoptosis inducing
CC treatments for the treatment of prostate cancer, sarcomas such as
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and
CC melanoma, and also for the treatment of Alzheimer's disease.

XX
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;
Query Match 95.2%; Score 20; DB 12; Length 21;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 AGCAGCAGAGTCTTCATCAT 21
Db 20 AGCAGCAGAGTCTTCATCAT 1
RESULT 7
ADL70430/c
ID ADL70430 standard; RNA; 21 BP.
XX
AC ADL70430;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytosstatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
PI
DR WPI; 2004-226851/21.
XX
PT Treating melanoma in a mammalian subject comprises administering to the
FT subject a therapeutic agent effective to reduce the effective amount of
FT clusterin in the melanoma cells.
XX
PS Claim 20; SEQ ID NO 28; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;


```
Query Match      95.2%; Score 20; DB 12; Length 21;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  2 AGCAGCAGAGTCTTCATCAT 21
    |||||
DB  20 AGCAGCAGAGTCTTCATCAT 1

RESULT 8
ADL70522/c
ID  ADL70522 standard; RNA; 19 BP.
XX
AC  ADL70522;
XX
DT  20-MAY-2004 (first entry)
XX
DE  RNAi for human clusterin.
XX
KW  RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW  cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW  ss.
XX
OS  Homo sapiens.
OS  Synthetic.
XX
FH  Key      Location/Qualifiers
FT  modified_base 18..19
FT  /*tag= a
FT  /mod_base= OTHER
FT  /note= "OTHER= dtdt"
XX
PN  WO2004018676-A2.
XX
PD  04-MAR-2004.
XX
PF  21-AUG-2003; 2003WO-CA001277.
XX
PR  21-AUG-2002; 2002US-0405193P.
PR  03-SEP-2002; 2002US-0408152P.
PR  20-MAY-2003; 2003US-0472387P.
XX
PA  (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI  Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI  Gonos ES;
XX
XX  WPI; 2004-226852/21.
XX
PT  New RNA molecule less than 49 bases and having a sequence effective to
PT  mediate degradation or block translation of mRNA that is the
PT  transcriptional product of a target gene, useful for treating Alzheimer's
PT  disease or cancer.
XX
XX  Claim 4; SEQ ID NO 67; 63pp; English.
XX
CC  The present sequence is the sense strand of a short interfering RNA
CC  (siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.
CC  The antisense strand is also provided ADL70523. The siRNA can be used to
CC  interfere with the expression of clusterin. Clusterin, also known as
CC  testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC  glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC  tumour cells following androgen withdrawal, and has also been shown to be
CC  critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC  siRNAs of the invention can be used alone or in combination with other
CC  chemotherapy or apoptosis inducing treatments for the treatment of
CC  prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC  breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC  anaplastic large cell lymphoma and melanoma, and also for the treatment
CC  of Alzheimer's disease. In an example from the invention, the present
CC  siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC  prostate cancer cells. A reduction in clusterin transcript was observed.
XX
```

```
Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
Query Match      90.5%; Score 19; DB 12; Length 19;
Best Local Similarity 100.0%; Pred. No. 64;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  3 GCAGCAGAGTCTTCATCAT 21
    |||||
DB  19 GCAGCAGAGTCTTCATCAT 1

RESULT 9
ADL70523
ID  ADL70523 standard; RNA; 19 BP.
XX
AC  ADL70523;
XX
DT  20-MAY-2004 (first entry)
XX
DE  RNAi for human clusterin.
XX
KW  RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW  cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW  ss.
XX
OS  Homo sapiens.
OS  Synthetic.
XX
FH  Key      Location/Qualifiers
FT  modified_base 18..19
FT  /*tag= a
FT  /mod_base= OTHER
FT  /note= "OTHER= dtdt"
XX
PN  WO2004018676-A2.
XX
PD  04-MAR-2004.
XX
PF  21-AUG-2003; 2003WO-CA001277.
XX
PR  21-AUG-2002; 2002US-0405193P.
PR  03-SEP-2002; 2002US-0408152P.
PR  20-MAY-2003; 2003US-0472387P.
XX
PA  (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI  Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI  Gonos ES;
XX
XX  WPI; 2004-226852/21.
XX
PT  New RNA molecule less than 49 bases and having a sequence effective to
PT  mediate degradation or block translation of mRNA that is the
PT  transcriptional product of a target gene, useful for treating Alzheimer's
PT  disease or cancer.
XX
XX  Claim 4; SEQ ID NO 68; 63pp; English.
XX
CC  The present sequence is the antisense strand of a short interfering RNA
CC  (siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.
CC  The sense strand is also provided ADL70522. The siRNA can be used to
CC  interfere with the expression of clusterin. Clusterin, also known as
CC  testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC  glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC  tumour cells following androgen withdrawal, and has also been shown to be
CC  critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC  siRNAs of the invention can be used alone or in combination with other
CC  chemotherapy or apoptosis inducing treatments for the treatment of
CC  prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC  breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC  anaplastic large cell lymphoma and melanoma, and also for the treatment
CC  of Alzheimer's disease. In an example from the invention, the present
CC  siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC  prostate cancer cells. A reduction in clusterin transcript was observed.
XX
```


Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
|||||:|:|:|:|:
Db 1 GCAGCAGAGUCUUAUCAU 19

RESULT 12

ADL70465
ID ADL70465 standard; RNA; 21 BP.
XX
AC ADL70465;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
DE
XX
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytotatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dTdT"
XX
PN WO2004018676-A2.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001277.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
DR WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
PS Claim 4; SEQ ID NO 10; 63pp; English.

XX The present sequence is the antisense strand of a short interfering RNA
CC (siRNA) targeted to human clusterin. The sense strand is also provided
CC ADL70464. The siRNA can be used to interfere with the expression of
CC clusterin. Clusterin, also known as testosterone-repressed prostate
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in
CC increased amounts by prostate tumour cells following androgen withdrawal,
CC and has also been shown to be critical for neuritic toxicity in mouse
CC models of Alzheimer's disease. siRNAs of the invention can be used alone
CC or in combination with other chemotherapy or apoptosis inducing
CC treatments for the treatment of prostate cancer, sarcomas such as
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and
CC melanoma, and also for the treatment of Alzheimer's disease.
XX
SQ Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 21;

Best Local Similarity 73.7%; Pred. No. 65;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
|||||:|:|:|:|:
Db 1 GCAGCAGAGUCUUAUCAU 19

RESULT 13

ADL70431
ID ADL70431 standard; RNA; 21 BP.
XX
AC ADL70431;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
DE
XX
KW Human; clusterin; RNAi; melanoma; cytotatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
DR WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 20; SEQ ID NO 29; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.

SQ Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 21;

Best Local Similarity 73.7%; Pred. No. 65;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21
|||||:|:|:|:|:
Db 1 GCAGCAGAGUCUUAUCAU 19

[illegible]

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 14:58:36 ; Search time 3027 Seconds
(without alignments)
264.073 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21

Sequence: 1 cagcagcagcttcattcat 21

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 159776

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST: *
1: gb_est1: *
2: gb_est2: *
3: gb_hic: *
4: gb_est3: *
5: gb_est4: *
6: gb_est5: *
7: gb_est6: *
8: gb_gss1: *
9: gb_gss2: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	14.8	70.5	46	1	AA916352 oh80e11.s
2	14.6	69.5	44	7	W25663 zc64e08.r1
3	14	66.7	50	8	BH861678 SALK_0877
4	13.6	64.8	42	9	CC7941149 SALK_0439
5	13.4	63.8	50	9	CG869035 AB0164.Sa
6	13	61.9	21	8	AZ802584 2M0061I05
7	13	61.9	41	8	BH908888 SALK_0510
8	13	61.9	43	1	AA973632 oc48504.s
9	13	61.9	48	9	AL948370 Arabidops
10	12.8	61.0	50	1	AU107924 AU107924
11	12.8	61.0	50	1	AU107925 AU107925
12	12.8	61.0	50	1	AU107928 AU107928
13	12.8	61.0	50	1	AU107929 AU107929
14	12.6	60.0	39	9	AL760945 Arabidops
15	12.6	60.0	43	1	AI766391 wh61d04.x
16	12.6	60.0	46	1	AA581123 v141c01.f
17	12.6	60.0	46	6	CB213634 OML03914
18	12.6	60.0	47	9	CL212422 G040E10.G
19	12.6	60.0	50	1	AU105963 AU105963
20	12.6	60.0	50	1	AU105967 AU105967
21	12.6	60.0	50	1	AU105968 AU105968
22	12.6	60.0	50	1	AU105972 AU105972
23	12.6	60.0	50	1	AA566984 1038 Lob1
24	12.4	59.0	37	8	AZ797149 2M0053009

C 25	12.2	58.1	35	8	AZ332831	AZ332831 1M0061C05
C 26	12.2	58.1	36	9	AJ587667	AJ587667 Arabidops
C 27	12.2	58.1	43	8	AZ610505	AZ610505 1M0435N18
C 28	12.2	58.1	46	1	AA109083	AA109083 mp37b05.x
C 29	12.2	58.1	49	1	AA052336	AA052336 mb35b02.x
C 30	12.2	58.1	49	1	AA864073	AA864073 vx88f02.x
C 31	12.2	58.1	50	1	AU104442	AU104442 AU104442
C 32	12.2	58.1	50	9	CR155807	CR155807 Reverse s
C 33	12.2	57.1	33	8	AZ305164	AZ305164 1M0005M08
C 34	12.2	57.1	33	8	AZ318599	AZ318599 1M0037N24
C 35	12.2	57.1	34	1	AA116347	AA116347 mc70g12.x
C 36	12.2	57.1	34	4	BZ46596	BZ46596 602988318
C 37	12.2	57.1	34	9	AG201385	AG201385 Pan trogl
C 38	12.2	57.1	35	9	BX285461	BX285461 Arabidops
C 39	12.2	57.1	40	8	BH910804	BH910804 SALK_0626
C 40	12.2	57.1	40	9	CG774406	CG774406 1123018G0
C 41	12.2	57.1	41	8	BZ586362	BZ586362 3590.1.16
C 42	12.2	57.1	46	6	CA964065	CA964065 CILL02a07
C 43	12.2	57.1	46	7	H92446	H92446 Yr89b09.r1
C 44	12.2	57.1	46	7	T74174	T74174 YC60b12.s1
C 45	12.2	57.1	47	8	AZ772648	AZ772648 1M0583N12

ALIGNMENTS

RESULT 1
AA916352
LOCUS
DEFINITION
AA916352
46 bp mRNA linear EST 14-APR-1998
oh80e11.s1 NCI CGAP C08 Homo sapiens cDNA clone IMAGE:1473356 3'
similar to TR:Q15347 Q15347 RAGA. [1] ; mRNA sequence.
ACCESSION
AA916352
VERSION
AA916352.1 GI:3055744
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
REFERENCE
1 (bases 1 to 46)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TUMOR GENE INDEX
NATIONAL CANCER INSTITUTE, Cancer Genome Anatomy Project (CGAP),
UNPUBLISHED (1997)
CONTACT: Robert Strausberg, Ph.D.
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
CDNA LIBRARY PREPARATION: M. Bento Soares, Ph.D.
CDNA LIBRARY ARRANGED BY: Greg Lennon, Ph.D.
DNA SEQUENCING BY: Washington University Genome Sequencing Center
CLONE DISTRIBUTION: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
www.bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Seq primer: -40m13 fwd. ET from Amersham
High quality sequence stop: 1.

FEATURES

Location/Qualifiers
1..46
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:1473356"
/tissue_type="adenocarcinoma"
/lab_host="DH10B"
/clone_lib="NCI-CGAP_C08"
/note="Organ: colon; Vector: pTT3D-Pac (Pharmacia) with a
modified polylinker; 1st strand cDNA was prepared from
colon adenocarcinoma, and was then primed with a Not I-
oligo(dT) primer. Double-stranded cDNA was ligated to Eco
RI adaptors (Pharmacia), digested with Not I and cloned
into the Not I and Eco RI sites of the modified pT73
vector. Library is normalized. Library was constructed by

```

ORIGIN
Query Match          70.5%; Score 14.8; DB 1; Length 46;
Best Local Similarity 88.9%; Pred. No. 4.2e+04;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCAT 18
    ||||| ||||| |||||
Db 20 CAGCAGCTTAGTCTTCAT 37

RESULT 2
W25663/c 44 bp mRNA linear EST 25-NOV-1996
LOCUS zc64e08.r1 Soares_fetal_heart_NbHL19W Homo sapiens cDNA clone
DEFINITION IMAGE:327110 5' similar to gb:X15183_cds1 HEAT SHOCK PROTEIN HSP
90-ALPHA (HUMAN); mRNA sequence.
ACCESSION W25663
VERSION W25663.1 GI:1303517
KEYWORDS EST. Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 44)
AUTHORS Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M.,
Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M.,
Parsons, J., Rifkin, L., Kohlfing, T., Soares, M., Tan, F.,
Trevasakis, E., Waterston, R., Williamson, A., Wohlmann, P. and
Wilson, R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished (1995)
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LML; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Insert length: 596 Std Error: 0.00
Seq primer: mob.REGA+ET
High quality sequence stop: 1.
FEATURES
source 1..44
    /organism="Homo sapiens"
    /mol_type="mRNA"
    /db_xref="GDB:1261312"
    /db_xref="taxon:9606"
    /clone="IMAGE:327110"
    /sex="unknown"
    /dev_stage="19 weeks"
    /lab_host="DH10B (ampicillin resistant)"
    /clone_lib="Soares_fetal_heart_NbHL19W"
    /note="Organ: heart; Vector: pT73D (Pharmacia) with a
modified polylinker; Site 1: Not 1; Site 2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dT) primer [5',
TGTTACCAACTCTGAAGTGGGCGCGCATCTTTTTTTTTTTTTTTT 3'],
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified pT73 vector
(Pharmacia). Library went through one round of
normalization to a Cot = 5. Library was constructed by
M.Fatima Bonaldo. This library was constructed from the
same fetus as the fetal lung library. Soares fetal lung
NbHL19W."

ORIGIN
Query Match          69.5%; Score 14.6; DB 7; Length 44;
Best Local Similarity 81.0%; Pred. No. 5.2e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Bento Soares and M. Fatima Bonaldo. "

ORIGIN
Query Match          70.5%; Score 14.8; DB 1; Length 46;
Best Local Similarity 88.9%; Pred. No. 4.2e+04;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCAT 18
    ||||| ||||| |||||
Db 20 CAGCAGCTTAGTCTTCAT 37

RESULT 3
BH861678/c 50 bp DNA linear GSS 05-AUG-2002
LOCUS BH861678 Arabidopsis thaliana TDNA insertion lines Arabidopsis
DEFINITION SALK_087727 Arabidopsis thaliana TDNA insertion lines Arabidopsis
thaliana genomic clone SALK_087727, genomic survey sequence.
ACCESSION BH861678
VERSION BH861678.1 GI:22097004
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1 (bases 1 to 50)
AUTHORS Alonso, J.M., Leisse, T.J., Barajas, P., Chen, H., Cheuk, R.,
Gadrinab, C., Jeske, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L.,
Shinn, P., Zimmermann, J. and Ecker, J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGnAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA.
FEATURES
source 1..50
    /organism="Arabidopsis thaliana"
    /mol_type="genomic DNA"
    /ecotype="Col-0"
    /db_xref="taxon:3702"
    /clone="SALK_087727"
    /clone_lib="Arabidopsis thaliana TDNA insertion lines"
    /note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"

ORIGIN
Query Match          66.7%; Score 14; DB 8; Length 50;
Best Local Similarity 100.0%; Pred. No. 9.8e+04;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTC 16
    ||||| ||||| |||||
Db 41 GCAGCAGAGTCTTC 28

RESULT 4
CC794149/c 42 bp DNA linear GSS 01-JUL-2003
LOCUS CC794149 Arabidopsis thaliana TDNA insertion lines
DEFINITION SALK_043910.30.25.x Arabidopsis thaliana TDNA insertion lines
Arabidopsis thaliana genomic clone SALK_043910.30.25.x, genomic
survey sequence.
ACCESSION CC794149
VERSION CC794149.1 GI:32389372
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

```

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsie.

REFERENCE

1 (bases 1 to 42)
Alonso, J.M., Lelisse, T.J., Barajas, P., Chen, H., Cheuk, R.,
Gadrinab, C., Jeake, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L.,
Shinn, P., Zimmerman, J., and Ecker, J.R.

TITLE

A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome

JOURNAL

Unpublished (2001)

COMMENT

Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGnAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu

This is single pass sequence recovered from the left border of
TDNA.

Class: TDNA tagged.

FEATURES

Location/Qualifiers

1..42

/organism="Arabidopsis thaliana"

/mol_type="genomic DNA"

/ecotype="Col-0"

/db_xref="taxon:3702"

/clone="SALK_043910.30.25.x"

/notes="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"

ORIGIN

Query Match 64.8%; Score 13.6; DB 9; Length 42;

Best Local Similarity 80.0%; Pred. No. 1.5e+05;

Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY

2 AGCAGCAGAGCTTCATCAT 21

29 AGAAACGAGTCATCAT 10

Db

RESULT 5

CG869035/c

LOCUS

AB0164 Sanger Institute Gene Trap Library pGT01xr Mus musculus

DEFINITION

CDNA, mRNA sequence.

ACCESSION

CG869035

VERSION

CG869035.1

KEYWORDS

GSS.

SOURCE

Mus musculus

(house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

REFERENCE

AUTHORS

Sanger Institute Gene Trap Resource - SIGTR.

TITLE

http://www.sanger.ac.uk/PostGenomics/genetrap/

JOURNAL

Unpublished (2003)

COMMENT

Contact: Sanger Institute Gene Trap Resource - SIGTR

Wellcome Trust Sanger Institute

Email: info.genetrap@sanger.ac.uk

Sequence tag generated by 5' RACE of total RNA from gene trap ES

cell line. ES cell lines harboring insertion mutation of target

gene are available upon request from Sanger Institute Gene Trap

Resource. Annotation information available from

<http://www.sanger.ac.uk/PostGenomics/genetrap/>

Class: Gene Trap.

FEATURES

source

1..50

/organism="Mus musculus"

/mol_type="mRNA"

ORIGIN

Query Match 63.8%; Score 13.4; DB 9; Length 50;

Best Local Similarity 93.3%; Pred. No. 1.8e+05;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY

7 CAGAGCTTCATCAT 21

48 CAGAGCTTCATCAT 34

Db

RESULT 6

AZ802584

LOCUS

DEFINITION

2M0061105R Mouse 10kb plasmid UUGC1M library Mus musculus genomic

clone UUGC2M0061105 R, genomic survey sequence.

ACCESSION

AZ802584

VERSION

AZ802584.1

KEYWORDS

GSS.

SOURCE

Mus musculus

(house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

REFERENCE

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Becorn, T., Duval, B., Hamil, C.,

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von

Niederhauser, A. and Wright, D. Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah

Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000

Std Error: 0.00

Plate: 0061

row: 1

column: 05

Seq primer: CACACGAGAACAGCTATGACC

Class: plasmid ends

High quality sequence stop: 21.

Location/Qualifiers

1..21

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC2M0061105"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/note="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of PWD42 (gi|4732114|gb|AF129072.1), a copy-number

/strain="129 Ola"

/db_xref="taxon:10090"

/sex="Male"

/cell_type="Embryonic Stem Cell"

/clone_lib="Sanger Institute Gene Trap Library pGT01xr"

/notes="Vector: pGT01xr"


```

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
REFERENCE
AUTHORS Li, Y., Rosso, M.G., Strizhov, N., Viehoveer, P. and Weissshaar, B.
TITLE GABI-Kat Simplesearch: a flanking sequence tag (FST) database for
the identification of T-DNA insertion mutants in Arabidopsis
thaliana
JOURNAL Bioinformatics 19 (11), 1441-1442 (2003)
MEDLINE 22755829
PUBMED 12874060
REFERENCE
AUTHORS Rosso, M.G., Li, Y., Strizhov, N., Reiss, B., Dekker, K. and
Weissshaar, B.
TITLE An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for
flanking sequence tag-based reverse Genetics
JOURNAL Plant Mol. Biol. 53 (1-2), 247-259 (2003)
MEDLINE 23117147
PUBMED 14756321
REFERENCE
AUTHORS Strizhov, N., Li, Y., Rosso, M.G., Viehoveer, P., Dekker, K.A. and
Weissshaar, B.
TITLE High-throughput generation of sequence indexes from T-DNA
mutagenized Arabidopsis thaliana lines
JOURNAL Biotechniques 35 (6), 1164-1168 (2003)
PUBMED 14682050
REFERENCE
AUTHORS Strizhov, N., Rosso, M.G., Li, Y. and Weissshaar, B.
TITLE Direct Submission
JOURNAL Submitted (31-MAR-2004) Weissshaar B., Max-Planck-Institut fuer
Zuechtungsforschung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
COMMENT This sequence has been recovered from the left border of the T-DNA.
It indicates an insertion close to or within gene At1g34110.
Details on the protocols used for generation of the sequence are
described in References 1-3. The sequences are generated at the MPI
for Plant Breeding Research in the context of the GABI-Kat project.
GABI-Kat is part of the German Plant Genomics program designated
"GABI". Information on line availability can be found at:
http://www.mpiz-koeln.mpg.de/GABI-Kat/.
FEATURES
Location/Qualifiers
1..48
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="GK-311H09-015792"
/lib="Arabidopsis thaliana T-DNA insertion lines"
/ecotype="Col-0"
/note="PCR was performed on DNA from Arabidopsis thaliana
plants (Ti) which were transformed with the T-DNA from
vector pAC161 (GenBank accession number: AJ537514). The
lines contain one or more T-DNA insertions. The DNA
fragment(s) resulting from the PCR were directly sequenced
to determine the genomic sequence flanking the insertion.
T-DNA derived sequences were removed."
ORIGIN
Query Match 61.9%; Score 13; DB 9; Length 48;
Best Local Similarity 76.2%; Pred. No. 2.8e+05;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTTCATCAT 21
Db 37 CAGCAGCAGAGATTTTCAT 17

RESULT 10
AU107924
LOCUS AU107924 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HRC02185, mRNA sequence.
ACCESSION AU107924
VERSION AU107924.1 GI:13557446
KEYWORDS EST.
SOURCE Homo sapiens (human)
REFERENCE
AUTHORS Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and
Sugano, S.
TITLE Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
FEATURES
Location/Qualifiers
1..50
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HRC02185"
/clone_lib="Sugano Homo sapiens cDNA library"
ORIGIN
Query Match 61.0%; Score 12.8; DB 1; Length 50;
Best Local Similarity 87.5%; Pred. No. 3.5e+05;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGTCTTCA 17
Db 27 AGCAGCAGAGTCCGCA 42

RESULT 11
AU107925
LOCUS AU107925 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HSI06916, mRNA sequence.
ACCESSION AU107925
VERSION AU107925.1 GI:13557447
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Suzuki, Y., Taira, H., Taunoda, T., Mizushima-Sugano, J., Sese, J.,
Hata, Y., Oca, T., Isogai, T., Tanaka, T., Morishita, S., Okubo, K.,
Sakaki, Y., Nakamura, Y., Suyama, A. and Sugano, S.
TITLE Diverse transcriptional initiation revealed by fine, large-scale
mapping of mRNA start sites
JOURNAL EMBO Rep. 2 (5), 388-393 (2001)
MEDLINE 21270072
PUBMED 11375929
COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ims.u-tokyo.ac.jp
Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and
Sugano, S.
TITLE Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
FEATURES
Location/Qualifiers
1..50
/organism="Homo sapiens"
/mol_type="mRNA"

```

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Suzuki, Y., Taira, H., Taunoda, T., Mizushima-Sugano, J., Sese, J.,
Hata, Y., Oca, T., Isogai, T., Tanaka, T., Morishita, S., Okubo, K.,
Sakaki, Y., Nakamura, Y., Suyama, A. and Sugano, S.
TITLE Diverse transcriptional initiation revealed by fine, large-scale
mapping of mRNA start sites
JOURNAL EMBO Rep. 2 (5), 388-393 (2001)
MEDLINE 21270072
PUBMED 11375929
COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ims.u-tokyo.ac.jp
Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and
Sugano, S.
TITLE Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
FEATURES
Location/Qualifiers
1..50
/organism="Homo sapiens"
/mol_type="mRNA"

```

```

/db_xref="taxon:9606"
/clone="H5106916"
/clone_lib="Sugano Homo sapiens cDNA library"

ORIGIN
Query Match      61.0%; Score 12.8; DB 1; Length 50;
Best Local Similarity 87.5%; Pred. No. 3.5e+05;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2 AGCAGCAGAGTCTTCA 17
    |||||
Db   27 AGCAGCAGAGTCCGCA 42

RESULT 12
AUI07928
LOCUS      50 bp mRNA linear EST 28-JAN-2004
DEFINITION Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
            ZRV62348, mRNA sequence.
ACCESSION  AUI07928
VERSION    AUI07928.1 GI:13557450
KEYWORDS   EST.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 50)
AUTHORS   Suzuki, Y., Taira, H., Tsunoda, T., Mizushima-Sugano, J., Sese, J.,
            Hata, H., Ota, T., Isogai, T., Tanaka, T., Morishita, S., Okubo, K.,
            Sakaki, Y., Nakamura, Y., Suyama, A. and Sugano, S.
            Diverse transcriptional initiation revealed by fine, large-scale
            mapping of mRNA start sites
            EMBO Rep. 2 (5), 388-393 (2001)

TITLE      Diverse transcriptional initiation revealed by fine, large-scale
            mapping of mRNA start sites
JOURNAL    EMBO Rep. 2 (5), 388-393 (2001)
MEDLINE    21270072
PUBMED     11375929
COMMENT    Contact: Yutaka Suzuki
            Department of Virology
            Institute of Medical Science, University of Tokyo
            4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
            Email: yuzuki@ims.u-tokyo.ac.jp
            Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and
            Sugano, S. Construction and characterization of a full
            length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
            149-156 (1997).

FEATURES   Location/Qualifiers
            source          1..50
                        /organism="Homo sapiens"
                        /mol_type="mRNA"
                        /db_xref="taxon:9606"
                        /clone="ZRV62402"
                        /clone_lib="Sugano Homo sapiens cDNA library"

ORIGIN
Query Match      61.0%; Score 12.8; DB 1; Length 50;
Best Local Similarity 87.5%; Pred. No. 3.5e+05;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2 AGCAGCAGAGTCTTCA 17
    |||||
Db   29 AGCAGCAGAGTCCGCA 44

RESULT 14
AUI07945/c
LOCUS      39 bp DNA linear GSS 01-APR-2004
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-204B10-014508,
            genomic survey sequence.
ACCESSION  AL760945
VERSION    AL760945.1 GI:21501350
KEYWORDS   GSS.
SOURCE     Arabidopsis thaliana (thale cress)
ORGANISM   Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE  1
AUTHORS   Li, Y., Rosso, M.G., Strizhov, N., Viehoveer, P. and Weisshaar, B.
            GABI-Kat SimpleSearch: a flanking sequence tag (FST) database for
            the identification of T-DNA insertion mutants in Arabidopsis
            thaliana
            Bioinformatics 19 (11), 1441-1442 (2003)

JOURNAL    Bioinformatics 19 (11), 1441-1442 (2003)
MEDLINE    22755829
PUBMED     12874060

REFERENCE  2
AUTHORS   Rosso, M.G., Li, Y., Strizhov, N., Reiss, B., Dekker, K. and
            Weisshaar, B.
            An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for
            flanking sequence tag-based reverse genetics
            Plant Mol. Biol. 53 (1-2), 247-259 (2003)

JOURNAL    Plant Mol. Biol. 53 (1-2), 247-259 (2003)
MEDLINE    23117147
PUBMED     14756321

REFERENCE  3
AUTHORS   Strizhov, N., Li, Y., Rosso, M.G., Viehoveer, P., Dekker, K.A. and
            Weisshaar, B.
            High-throughput generation of sequence indexes from T-DNA
            mutagenized Arabidopsis thaliana lines
            Biotechniques 35 (6), 1164-1168 (2003)

JOURNAL    Biotechniques 35 (6), 1164-1168 (2003)
MEDLINE    14682050
PUBMED

```

REFERENCE 4 (bases 1 to 39)
 AUTHORS Strizhov,N., Rosso,M.G., Li,Y. and Weisshaar,B.
 TITLE Direct Submission
 JOURNAL Submitted (31-MAR-2004) Weisshaar B., Max-Planck-Institut fuer
 Zuechtungsforschung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
 COMMENT This sequence has been recovered from the left border of the T-DNA.
 It indicates an insertion within the locus defined by BAC clone
 t10j7. Details on the protocols used for generation of the sequence
 are described in References 1-3. The sequences are generated at the
 MPI for Plant Breeding Research in the context of the GABI-Kat
 project. GABI-Kat is part of the German Plant Genomics program
 designated 'GABI'. Information on line availability can be found
 at: <http://www.mpiz-koeln.mpg.de/GABI-Kat/>.

FEATURES

source
 1. .39
 Location/Qualifiers
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="GK-204B10-014508"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 /ecotype="Col-0"
 /note="PCR was performed on DNA from Arabidopsis thaliana
 plants (T1) which were transformed with the T-DNA from
 vector pAC161 (GenBank accession number: AJ537514). The
 lines contain one or more T-DNA insertions. The DNA
 fragment(s) resulting from the PCR were directly sequenced
 to determine the genomic sequence flanking the insertion.
 T-DNA derived sequences were removed."

ORIGIN

Query Match 60.0%; Score 12.6; DB 9; Length 39;
 Best Local Similarity 78.9%; Pred. No. 4.2e+05;
 Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 2 AGCAGCAGAGTCTTCATCA 20
 ||| ||||| ||| |||
 Db 38 AGCGGCAGAGTGTCTCCA 20

RESULT 15

AI766391/c
 LOCUS wh61d04.x1 NCI CGAP Kid11 Homo sapiens cDNA clone IMAGE:2385223 3'
 DEFINITION similar to SW:COX2_HUMAN P00403 CYTOCHROME C OXIDASE POLYPEPTIDE II
 ; mRNA sequence.
 ACCESSION AI766391
 VERSION AI766391.1 GI:5232900
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 43)
 NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgapsa-remail.nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
 Emmert-Buck, M.D., Ph.D.
 cDNA Library Preparation: M. Bento Soares, Ph.D.
 cDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LINL at:
www-bio.llnl.gov/bbrp/image/image.html

REFERENCE

AUTHORS NCI-CGAP
 TITLE NCI-CGAP
 JOURNAL Unpublished (1997)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgapsa-remail.nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
 Emmert-Buck, M.D., Ph.D.
 cDNA Library Preparation: M. Bento Soares, Ph.D.
 cDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LINL at:
www-bio.llnl.gov/bbrp/image/image.html
 Trace considered overall poor quality
 Insert Length: 641 Std Error: 0.00
 Seq primer: -40UP from Gibco
 High quality sequence stop: 1.

FEATURES

source

Location/Qualifiers

1. .43
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:2385223"
 /lab_host="DH10B"
 /clone_lib="NCI CGAP Kid11"
 /note="Organ: Kidney; Vector: pT7T3D-Pac (Pharmacia) with
 a modified polylinker; Site 1: Not 1; Site 2: Eco RI;
 Plasmid DNA from the normalized library NCI CGAP Kid3 was
 prepared, and ss circles were made in vitro. Following HAP
 purification, this DNA was used as tracer in a subtractive
 hybridization reaction. The driver was PCR-amplified cDNAs
 from a pool of 5,000 clones made from the same library
 (cloneIDs 1322376-1323911, 1456007-1456775, and
 1500552-1502855). Subtraction by Bento Soares and M.
 Fatima Bonaldo."

ORIGIN

Query Match 60.0%; Score 12.6; DB 1; Length 43;
 Best Local Similarity 78.9%; Pred. No. 4.2e+05;
 Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 CAGCAGCAGAGTCTTCATC 19
 ||| ||||| ||| |||
 Db 32 CATCATCATAGTCTTCATC 14

Search completed: September 3, 2005, 16:20:16
 Job time : 3031 secs

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:44:45 ; Search time 4 Seconds
(without alignments)
2.954 Million cell updates/sec

Title: us-10-828-394-1
Perfect score: 1643
Sequence: 1 gaattccgcgcgtaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 198 seqs, 3596 residues

Total number of hits satisfying chosen parameters: 396

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 198 summaries

Database : ruidb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	26	1.6	26	1	US-08-859-998-747
2	26	1.6	26	1	US-09-225-928-747
3	26	1.6	26	1	US-09-225-928-747
C 4	25	1.5	25	1	US-08-859-998-748
C 5	25	1.5	25	1	US-09-225-928-748
C 6	25	1.5	25	1	US-09-225-928-748
C 7	23	1.4	23	1	US-09-659-791A-5
8	21.8	1.3	25	1	US-09-396-196G-31760
9	21	1.3	21	1	US-08-410-540-21
10	21	1.3	21	1	US-09-659-791A-6
11	21	1.3	21	1	US-09-459-749D-14
12	20.6	1.3	21	1	US-09-657-472-2421
13	20.6	1.3	21	1	US-09-657-472-2422
14	20.6	1.3	21	1	US-09-657-472-2423
15	20.6	1.3	21	1	US-09-657-472-2424
16	20.2	1.2	25	1	US-09-396-196G-31758
C 17	20	1.2	20	1	US-09-659-791A-14
C 18	20	1.2	20	1	US-09-659-791A-15
C 19	20	1.2	20	1	US-09-659-791A-16
C 20	20	1.2	20	1	US-09-659-791A-17
C 21	20	1.2	20	1	US-09-659-791A-18
C 22	20	1.2	20	1	US-09-659-791A-19
C 23	20	1.2	20	1	US-09-659-791A-20
C 24	20	1.2	20	1	US-09-659-791A-21
C 25	20	1.2	20	1	US-09-659-791A-22
C 26	20	1.2	20	1	US-09-659-791A-23
C 27	20	1.2	20	1	US-09-659-791A-24
C 28	20	1.2	20	1	US-09-659-791A-25
C 29	20	1.2	20	1	US-09-659-791A-26
C 30	20	1.2	20	1	US-09-659-791A-27
C 31	20	1.2	20	1	US-09-659-791A-28
C 32	20	1.2	20	1	US-09-659-791A-29
C 33	20	1.2	20	1	US-09-659-791A-30

Sequence 31, Appl	1	US-09-659-791A-31	20	1.2	20	C 34
Sequence 32, Appl	1	US-09-659-791A-32	20	1.2	20	C 35
Sequence 33, Appl	1	US-09-659-791A-33	20	1.2	20	C 36
Sequence 34, Appl	1	US-09-659-791A-34	20	1.2	20	C 37
Sequence 35, Appl	1	US-09-659-791A-35	20	1.2	20	C 38
Sequence 36, Appl	1	US-09-659-791A-36	20	1.2	20	C 39
Sequence 37, Appl	1	US-09-659-791A-37	20	1.2	20	C 40
Sequence 38, Appl	1	US-09-659-791A-38	20	1.2	20	C 41
Sequence 39, Appl	1	US-09-659-791A-39	20	1.2	20	C 42
Sequence 40, Appl	1	US-09-659-791A-40	20	1.2	20	C 43
Sequence 41, Appl	1	US-09-659-791A-41	20	1.2	20	C 44
Sequence 42, Appl	1	US-09-659-791A-42	20	1.2	20	C 45
Sequence 43, Appl	1	US-09-659-791A-43	20	1.2	20	C 46
Sequence 44, Appl	1	US-09-659-791A-44	20	1.2	20	C 47
Sequence 45, Appl	1	US-09-659-791A-45	20	1.2	20	C 48
Sequence 46, Appl	1	US-09-659-791A-46	20	1.2	20	C 49
Sequence 47, Appl	1	US-09-659-791A-47	20	1.2	20	C 50
Sequence 48, Appl	1	US-09-659-791A-48	20	1.2	20	C 51
Sequence 49, Appl	1	US-09-659-791A-49	20	1.2	20	C 52
Sequence 50, Appl	1	US-09-659-791A-50	20	1.2	20	C 53
Sequence 51, Appl	1	US-09-659-791A-51	20	1.2	20	C 54
Sequence 52, Appl	1	US-09-659-791A-52	20	1.2	20	C 55
Sequence 53, Appl	1	US-09-659-791A-53	20	1.2	20	C 56
Sequence 54, Appl	1	US-09-659-791A-54	20	1.2	20	C 57
Sequence 55, Appl	1	US-09-659-791A-55	20	1.2	20	C 58
Sequence 56, Appl	1	US-09-659-791A-56	20	1.2	20	C 59
Sequence 57, Appl	1	US-09-659-791A-57	20	1.2	20	C 60
Sequence 58, Appl	1	US-09-659-791A-58	20	1.2	20	C 61
Sequence 59, Appl	1	US-09-659-791A-59	20	1.2	20	C 62
Sequence 60, Appl	1	US-09-659-791A-60	20	1.2	20	C 63
Sequence 61, Appl	1	US-09-659-791A-61	20	1.2	20	C 64
Sequence 62, Appl	1	US-09-659-791A-62	20	1.2	20	C 65
Sequence 63, Appl	1	US-09-659-791A-63	20	1.2	20	C 66
Sequence 64, Appl	1	US-09-659-791A-64	20	1.2	20	C 67
Sequence 65, Appl	1	US-09-659-791A-65	20	1.2	20	C 68
Sequence 66, Appl	1	US-09-659-791A-66	20	1.2	20	C 69
Sequence 67, Appl	1	US-09-659-791A-67	20	1.2	20	C 70
Sequence 68, Appl	1	US-09-659-791A-68	20	1.2	20	C 71
Sequence 69, Appl	1	US-09-659-791A-69	20	1.2	20	C 72
Sequence 70, Appl	1	US-09-659-791A-70	20	1.2	20	C 73
Sequence 71, Appl	1	US-09-659-791A-71	20	1.2	20	C 74
Sequence 72, Appl	1	US-09-659-791A-72	20	1.2	20	C 75
Sequence 73, Appl	1	US-09-659-791A-73	20	1.2	20	C 76
Sequence 74, Appl	1	US-09-659-791A-74	20	1.2	20	C 77
Sequence 75, Appl	1	US-09-659-791A-75	20	1.2	20	C 78
Sequence 76, Appl	1	US-09-659-791A-76	20	1.2	20	C 79
Sequence 77, Appl	1	US-09-659-791A-77	20	1.2	20	C 80
Sequence 78, Appl	1	US-09-659-791A-78	20	1.2	20	C 81
Sequence 79, Appl	1	US-09-659-791A-79	20	1.2	20	C 82
Sequence 80, Appl	1	US-09-659-791A-80	20	1.2	20	C 83
Sequence 81, Appl	1	US-09-659-791A-81	20	1.2	20	C 84
Sequence 82, Appl	1	US-09-659-791A-82	20	1.2	20	C 85
Sequence 83, Appl	1	US-09-659-791A-83	20	1.2	20	C 86
Sequence 84, Appl	1	US-09-659-791A-84	20	1.2	20	C 87
Sequence 85, Appl	1	US-09-659-791A-85	20	1.2	20	C 88
Sequence 86, Appl	1	US-09-659-791A-86	20	1.2	20	C 89
Sequence 87, Appl	1	US-09-659-791A-87	20	1.2	20	C 90
Sequence 88, Appl	1	US-09-659-791A-88	20	1.2	20	C 91
Sequence 89, Appl	1	US-09-659-791A-89	20	1.2	20	C 92
Sequence 90, Appl	1	US-09-659-791A-90	20	1.2	20	C 93
Sequence 91, Appl	1	US-09-659-791A-91	20	1.2	20	C 94
Sequence 92, Appl	1	US-09-659-791A-92	20	1.2	20	C 95
Sequence 93, Appl	1	US-09-659-791A-93	20	1.2	20	C 96
Sequence 94, Appl	1	US-09-659-791A-94	20	1.2	20	C 97
Sequence 95, Appl	1	US-09-659-791A-95	20	1.2	20	C 98
Sequence 96, Appl	1	US-09-659-791A-96	20	1.2	20	C 99
Sequence 97, Appl	1	US-09-659-791A-97	20	1.2	20	C 100
Sequence 98, Appl	1	US-09-659-791A-98	20	1.2	20	C 101
Sequence 99, Appl	1	US-09-659-791A-99	20	1.2	20	C 102
Sequence 100, Appl	1	US-09-659-791A-100	20	1.2	20	C 103
Sequence 101, Appl	1	US-09-659-791A-101	20	1.2	20	C 104
Sequence 102, Appl	1	US-09-659-791A-102	20	1.2	20	C 105
Sequence 103, Appl	1	US-09-659-791A-103	20	1.2	20	C 106
Sequence 104, Appl	1	US-09-659-791A-104	20	1.2	20	C 107
Sequence 105, Appl	1	US-09-659-791A-105	20	1.2	20	C 108
Sequence 106, Appl	1	US-09-659-791A-106	20	1.2	20	C 109

Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 TCGGATGAAGGACCAGTGTGACAAG 959
Db 1 TCGGATGAAGGACCAGTGTGACAAG 26

RESULT 2
US-09-225-928-747
; Sequence 747, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Bibilashvilli, Robert
; Jokhadze, George
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 747:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 747:
US-09-225-928-747

Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 TCGGATGAAGGACCAGTGTGACAAG 959
Db 1 TCGGATGAAGGACCAGTGTGACAAG 26

RESULT 3
US-09-225-201B-747
; Sequence 747, Application US/09225201B
; Patent No. 6489455
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Jokhadze, George

Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 747:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 747:
US-09-225-201B-747

Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 TCGGATGAAGGACCAGTGTGACAAG 959
Db 1 TCGGATGAAGGACCAGTGTGACAAG 26

RESULT 4
US-08-859-998-748/C
; Sequence 748, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95

```
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 748:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; US-08-859-998-748

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1190 GTACTATCTGCGGTCACACGGTG 1214
      |||||||
DB      25 GTACTATCTGCGGTCACACGGTG 1

RESULT 5
US-09-225-928-748/C
; Sequence 748, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
;           Jokhadze, George
;           Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;           EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 748:

QY      1190 GTACTATCTGCGGTCACACGGTG 1214
      |||||||
DB      25 GTACTATCTGCGGTCACACGGTG 1

RESULT 6
US-09-225-201B-748/c
; Sequence 748, Application US/09225201B
; Patent No. 6489455
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
;           Jokhadze, George
;           Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;           EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 748:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: linear
; TOPOLOGY: linear
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; US-09-225-928-748

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1190 GTACTATCTGCGGTCACACGGTG 1214
      |||||||
DB      25 GTACTATCTGCGGTCACACGGTG 1

RESULT 6
US-09-225-201B-748/c
; Sequence 748, Application US/09225201B
; Patent No. 6489455
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
;           Jokhadze, George
;           Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;           EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 748:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: linear
; TOPOLOGY: linear
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; US-09-225-928-748

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```



```

; APPLICANT: Strauss III, Jerome F.
; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
; STREET: 5 Palo Alto Square
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,540
; FILING DATE: 23-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neeley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-238/00US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816COOLEYPA
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-410-540-21

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AGAAGCGCTGCAGGAATACC 1374
DB 1 AGAAGCGCTGCAGGAATACC 21

RESULT 10
US-09-659-791A-6
; Sequence 6, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
; US-09-659-791A-6

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCCAGCCCT 786

```

```

; APPLICANT: Strauss III, Jerome F.
; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
; STREET: 5 Palo Alto Square
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,540
; FILING DATE: 23-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neeley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-238/00US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816COOLEYPA
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-410-540-21

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AGAAGCGCTGCAGGAATACC 1374
DB 1 AGAAGCGCTGCAGGAATACC 21

RESULT 10
US-09-659-791A-6
; Sequence 6, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
; US-09-659-791A-6

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCCAGCCCT 786

```

```

; APPLICANT: Strauss III, Jerome F.
; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
; STREET: 5 Palo Alto Square
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,540
; FILING DATE: 23-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neeley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-238/00US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816COOLEYPA
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-410-540-21

Query Match
Best Local Similarity 100.0%; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AGAAGCGCTGCAGGAATACC 1374
DB 1 AGAAGCGCTGCAGGAATACC 21

RESULT 10
US-09-659-791A-6
; Sequence 6, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
; US-09-659-791A-6

Query Match
Best Local Similarity 100.0%; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCCAGCCCT 786

```

```
Db      1  TCCAGGCCATGTTCCAGCCCT 21
|||||
RESULT 11
US-09-459-749D-14
; Sequence 14, Application US/09459749D
; Patent No. 6464975
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; CURRENT FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer_bind
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-09-459-749D-14

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2; Mismatches 0; Indels 0; Gaps 0;
Matches 21; Conservative 0;

Qy      274  AAGCCAAAGAAGAAAGAGG 294
|||||
Db      1  AAGCCAAAGAAGAAAGAGG 21
|||||

RESULT 12
US-09-657-472-2421
; Sequence 2421, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2421
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2421

Query Match      1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11; Mismatches 1; Indels 0; Gaps 0;
Matches 20; Conservative 1;

Qy      1050  GAGAGGTTGACCAAGAAATAC 1070
|||||
Db      1  GAGAGGTTGAYCAGGAATAC 21
|||||

RESULT 13
US-09-657-472-2422
; Sequence 2422, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2422
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2422

Query Match      1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11; Mismatches 1; Indels 0; Gaps 0;
Matches 20; Conservative 1;

Qy      999  CCTCTCCAGGCTAGCTCGG 1019
|||||
Db      1  CCTCTCCAGGYTAAGTGGG 21
|||||

RESULT 14
US-09-657-472-2423
; Sequence 2423, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2423
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2423

Query Match      1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11; Mismatches 1; Indels 0; Gaps 0;
Matches 20; Conservative 1;

Qy      1170  CTCACGAAGCGGAAGACCAG 1190
|||||
```

Db 1 CTCACGCAAGCGAAGACCAG 21
|||||:|||||

RESULT 15
US-09-472-2424
; Sequence 2424, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolck, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2424
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2424

Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1105 TCACACCTTCCTCTGTGG 1125
|||||:|||||

Db 1 TCACACCTTCCTCTGTGG 21

RESULT 16
US-09-396-196G-31758
; Sequence 31758, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mitmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31758
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31758

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 18;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1171 TCACGAGGCGAAGACCAAGTACTA 1195
|||||:|||||

Db 1 TCACGAGGCGAAGACCAAGTACTA 25

RESULT 17
US-09-659-791A-14/c
; Sequence 14, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-14

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGCGTCAAGAC 32
|||||:|||||

Db 20 TGACCGAGCGTCAAGAC 1

RESULT 18
US-09-659-791A-15/c
; Sequence 15, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-15

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 GCGTGCAAGACTCCAGAAT 40
|||||:|||||

Db 20 GCGTGCAAGACTCCAGAAT 1

RESULT 19
US-09-659-791A-16/c
; Sequence 16, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 16
; LENGTH: 20

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-16

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 39 ATTGAGGCATCATGACAC 58
    |||||
Db 20 ATTGAGGCATGATGAGAC 1

RESULT 20
US-09-659-791A-17/c
; Sequence 17, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-17

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 77 GCTGCTGCTGACCTGGGAGA 96
    |||||
Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 21
US-09-659-791A-18/c
; Sequence 18, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-18

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 101 GCAGGTCCTGGGGACCCAGA 120
    |||||
Db 20 GCAGGTCCTGGGGACCCAGA 1

RESULT 22
US-09-659-791A-19/c
; Sequence 19, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-19

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 122 GGTCTCAGACAATGAGCTCC 141
    |||||
Db 20 GGTCTCAGACAATGAGCTCC 1

RESULT 23
US-09-659-791A-20/c
; Sequence 20, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-20

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 GTCCAATCAGGGAAGTAAGT 168
    |||||
Db 20 GTCCAATCAGGGAAGTAAGT 1

RESULT 24
US-09-659-791A-21/c
; Sequence 21, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-21

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 166 AGTACGTCATAAGGAATT 185
|||||
DB 20 AGTACGTCATAAGGAATT 1

RESULT 25

US-09-659-791A-22/c
; Sequence 22, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-22

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 201 GGGGTGAACACAGATAAGAC 220
|||||
DB 20 GGGGTGAACACAGATAAGAC 1

RESULT 26

US-09-659-791A-23/c
; Sequence 23, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-23

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 GAAGAAGAAAGAGATGCC 300
|||||
DB 20 GAAGAAGAAAGAGATGCC 1

RESULT 27

US-09-659-791A-24/c
; Sequence 24, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-24

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 AGAAGAGATGCCCTTAAT 305
|||||
DB 20 AGAAGAGATGCCCTTAAT 1

RESULT 28

US-09-659-791A-25/c
; Sequence 25, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-25

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCCTAAATGAGACAGGGAA 317
|||||
DB 20 CCCTAAATGAGACAGGGAA 1

RESULT 29

US-09-659-791A-26/c
; Sequence 26, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

10828394-1_1-1643.rni.s1

Tue Sep 13 10:53:21 2005

```
;
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-26

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 307 AGACCAGGGAATCAGAGACA 326
    |||||
Db 20 AGACCAGGGAATCAGAGACA 1

RESULT 30
US-09-659-791A-27/c
; Sequence 27, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-29

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 364 TGATGCCCTCTGGGAAGAG 383
    |||||
Db 20 TGATGCCCTCTGGGAAGAG 1

RESULT 33
US-09-659-791A-30/c
; Sequence 30, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-30

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 380 AGAGTGAAGCCCTGCCTGA 399
    |||||
Db 20 AGAGTGAAGCCCTGCCTGA 1

RESULT 34
US-09-659-791A-31/c
; Sequence 31, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-31

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 359 GACCATGATGCCCTCTGGG 378
    |||||
Db 20 GACCATGATGCCCTCTGGG 1

RESULT 32
US-09-659-791A-29/c
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-31

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTCGATGAAGTTCTACGCAC 426
|||||
Db 20 CTCGATGAAGTTCTACGCAC 1

RESULT 35
US-09-659-791A-32/c
; Sequence 32, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-34

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TGGCGCCAGCTTGAGGAGT 474
|||||
Db 20 TGGCGCCAGCTTGAGGAGT 1

RESULT 38
US-09-659-791A-35/c
; Sequence 35, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-35

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 501
|||||
Db 20 CCAGAGCTCGCCCTTCTACT 1

RESULT 39
US-09-659-791A-36/c
; Sequence 36, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-33/c
; Sequence 33, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-33

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 CTCAGGCTGGTTGCCGCC 462
|||||
Db 20 CTCAGGCTGGTTGCCGCC 1

RESULT 36
US-09-659-791A-33/c
; Sequence 33, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-34/c
; Sequence 34, Application US/09659791A
```

10828394-1_1-1643.rni.sl

Tue Sep 13 10:53:21 2005

```
US-09-659-791A-36
Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 492 CCCTTCTACTCTCGATGAA 511
    |||||
Db 20 CCCTTCTACTTCTGGATGAA 1

RESULT 40
US-09-659-791A-37/c
; Sequence 37, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-37

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 517 ACCGATCGACTCCCTGCTG 536
    |||||
Db 20 ACCGATCGACTCCCTGCTG 1

RESULT 41
US-09-659-791A-38/c
; Sequence 38, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-38

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 533 GCTGGAGAACGACCGCAGC 552
    |||||
Db 20 GCTGGAGAACGACCGCAGC 1

RESULT 42
US-09-659-791A-39/c
; Sequence 39, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-39

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 GCAGACGCACATGCTGGATG 570
    |||||
Db 20 GCAGACGCACATGCTGGATG 1

RESULT 43
US-09-659-791A-40/c
; Sequence 40, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-40

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 553 AGACGCACATGCTGGATGTC 572
    |||||
Db 20 AGACGCACATGCTGGATGTC 1

RESULT 44
US-09-659-791A-41/c
; Sequence 41, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-41
```


Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 565 TGGATGTCATGACGAGCAC 584
|||||
Db 20 TGGATGTCATGACGAGCAC 1

RESULT 45
US-09-659-791A-42/c
; Sequence 42, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-42

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 567 GATGTCATGACGAGCAC 586
|||||
Db 20 GATGTCATGACGAGCAC 1

RESULT 46
US-09-659-791A-43/c
; Sequence 43, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-43

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 604 TCATAGACGAGCTCTCCAG 623
|||||
Db 20 TCATAGACGAGCTCTCCAG 1

RESULT 47
US-09-659-791A-44/c
; Sequence 44, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-44

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 608 AGACGAGCTCTCCAGGACA 627
|||||
Db 20 AGACGAGCTCTCCAGGACA 1

RESULT 48
US-09-659-791A-45/c
; Sequence 45, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-45

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 613 AGCTCTCCAGGACAGGTTTC 632
|||||
Db 20 AGCTCTCCAGGACAGGTTTC 1

RESULT 49
US-09-659-791A-46/c
; Sequence 46, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-46

```

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      690 AGGCCTCACTTCTCTTCC 709
      |||||
Db      20 AGGCCTCACTTCTCTTCC 1

RESULT 50
US-09-659-791A-47/c
; Sequence 47, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-47

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      721 TCGTCGCGAGCTTGATGCC 740
      |||||
Db      20 TCGTCGCGAGCTTGATGCC 1

RESULT 51
US-09-659-791A-48/c
; Sequence 48, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-48

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      775 TGTTCACGCCCTTCCTTGAG 794
      |||||
Db      20 TGTTCACGCCCTTCCTTGAG 1

RESULT 52
US-09-659-791A-49/c
; Sequence 49, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia

```

```

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-49

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      776 GTTCCAGCCCTTCCTTGAGA 795
      |||||
Db      20 GTTCCAGCCCTTCCTTGAGA 1

RESULT 53
US-09-659-791A-50/c
; Sequence 50, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-50

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      783 CCCTTCCTTGAGATGATACA 802
      |||||
Db      20 CCCTTCCTTGAGATGATACA 1

RESULT 54
US-09-659-791A-51/c
; Sequence 51, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-51

Query Match      1.2%; Score 20; DB 1; Length 20;

```

```
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 820 TGGACATCCACTTCCACAGC 839
Db 20 TGGACATCCACTTCCACAGC 1

RESULT 55
US-09-659-791A-52/c
; Sequence 52, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-52

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 848 CCAGCACCCGCCAACAGAAAT 867
Db 20 CCAGCACCCGCCAACAGAAAT 1

RESULT 56
US-09-659-791A-53/c
; Sequence 53, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-53

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 853 ACCCGCCCAACAGAAATTCATA 872
Db 20 ACCCGCCCAACAGAAATTCATA 1

RESULT 57
US-09-659-791A-54/c
; Sequence 54, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
```

```
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-54

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 893 GACTGTGTGCCGGGAGATCC 912
Db 20 GACTGTGTGCCGGGAGATCC 1

RESULT 58
US-09-659-791A-55/c
; Sequence 55, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-55

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 894 ACTGTGTGCCGGGAGATCCG 913
Db 20 ACTGTGTGCCGGGAGATCCG 1

RESULT 59
US-09-659-791A-56/c
; Sequence 56, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-56

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 894 ACTGTGTGCCGGGAGATCCG 913
Db 20 ACTGTGTGCCGGGAGATCCG 1

RESULT 59
US-09-659-791A-56/c
; Sequence 56, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-56

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
```

Matches	20:	Conservative	0:	Mismatches	0:	Indels	0:	Gaps	0:
---------	-----	--------------	----	------------	----	--------	----	------	----

Qy 906 GAGATCCGCCACAACCTCCAC 925
pb 20 GAGATCCGCCACAACCTCCAC 1

RESULT 60

US-09-659-791A-57/c
; Sequence 57, Application US/09659791A
: Patent No. 6383808

; PATENT NO. 6303898
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTIGENSE MODULATION OF CLAUSTERIN EXPRESSION

```

: TITLE OF INVENTION: ANTISENSE MODULATION
:
: FILE REFERENCE: RTS-Q156
: CURRENT APPLICATION NUMBER: US/09/659,791A
: CURRENT FILING DATE: 2000-09-11
:
: NUMBER OF SEQ ID NOS: 90
:
: SEQ ID NO 57
: LENGTH: 20
:

```

LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence

; ORGANISM: *Antisense oligonucleotide*
 ; FEATURE:
 ; OTHER INFORMATION: *Antisense oligonucleotide*
 US-09-659-791A-57

Query Match	1.2%;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 12;		
Matches	20;	Conservative	0;	Mismatches 0;
				Indels 0;

928 GCTGCCTGCGGATGAAGGAC 9
QY
20 GCTGCCTGCGGATGAAGGAC 1
Db

RESULT 61

US-09-659-791A-58/c
; Sequence 58, Application US/09659791A
: Patent No. 6383808

/ GENERAL INFORMATION:
 / APPLICANT: Brett P. Monia
 / APPLICANT: Susan M. Freier
 / TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
 / FILE REFERENCE: RTS-0156
 / CURRENT APPLICATION NUMBER: US/09/659,791A
 / CURRENT FILING DATE: 2000-09-11
 / NUMBER OF SEQ ID NOS: 90

; NUMBER OF S
; SEQ ID NO 58
; LENGTH: 30

```

; LENGTH: 20
;
; TYPE: DNA
;
; ORGANISM: Artificial Sequence
;
; FEATURE:
;
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-09-659-791A-58

```

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels

Qy 967 AGATCTTGTCTGTGGACTGT 986
|||
20 AGATCTTGTCTGTGGACTGT 1
pb

RESULT 62

US-09-659-791A-59/c
; Sequence 59, Application US/09659791A
; Patent No. 6383808

; Patent No. 6,903,303
 ;
 ; GENERAL INFORMATION:
 ;
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Susan M. Freier
 ;
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

```

; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 59
; LENGTH: 20
;

```

TYPE: DNA
ORGANISM: Artificial Sequence

```

; ORIGIN: ATTTCGAC sequence
;
; FEATURE:
;
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-59

```

Query Match	1.2%;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 12;		
Matches	20;	Conservative 0;	Mismatches 0;	Indels 0;

Qy 1009 CTAAGCTCGGCGGGAGCTC 1028
|||
Db 20 CTAAGCTCGGCGGGAGCTC 1

RESULT 63

US-09-659-791A-60/c
: Sequence 60. Application US/09659791A

; Patent No. 6383808

GENERAL INFORMATION: APPLICANT: Brett P. Monia

APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
FILE REFERENCE: RTS-0156

```

; FILE REFERENCE: R10-0150
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90

```

; NUMBER OF S. 20
; SEQ ID NO 60
; ENCTY. 20

```

;
; LENGTH: 20
;
; TYPE: DNA
;
; ORGANISM: Artificial Sequence

```

```

; ORGANISM: Artificial sequence
;
; FEATURE:
;
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-60

```

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels

QY 1022 GGAGCTCGACGAATCCCTCC 1041
|||||
20 GGAGCTCGACGAATCCCTCC 1

RESULT 64

US-09-659-791A-61/c
: Sequence 61. Application US/09659791A

; Patent N°: 6383808

; FACILE NO: 000000
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia

APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
FILE REFERENCE: RTS-0156

```

; FILE REFERENCE: RAS 0150
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90

```

```

; NUMBER OF S
; SEQ ID NO 61
; LENGTH: 20

```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

ORGANISM: *Helicobacter pylori*
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-61

```
Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20: Conservative 0; Mismatches 0; Indels
```

QY 1083 AAGTCTTACAGTGGAGAT 1102
|||||
Db 20 AAGTCTTACAGTGGAGAT 1

RESULT 65
US-09-659-791A-62/c
; Sequence 62, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-62

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 CCAGTGGAAGATGCTCAACA 1110
|||||
Db 20 CCAGTGGAAGATGCTCAACA 1

RESULT 66
US-09-659-791A-63/c
; Sequence 63, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-63

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1113 TCCTCTTGTGCTGAGCAGCT 1132
|||||
Db 20 TCCTCTTGTGCTGAGCAGCT 1

RESULT 67
US-09-659-791A-64/c
; Sequence 64, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-64

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 GCTGGAGCAGCTGAACGAGC 1140
|||||
Db 20 GCTGGAGCAGCTGAACGAGC 1

RESULT 68
US-09-659-791A-65/c
; Sequence 65, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-65

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 CTGGGTGTCCCGCTGGCAA 1167
|||||
Db 20 CTGGGTGTCCCGCTGGCAA 1

RESULT 69
US-09-659-791A-66/c
; Sequence 66, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-66

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1182 GAAGACCACTACTATCTCG 1201
|||||
Db 20 GAAGACCACTACTATCTCG 1

RESULT 70

US-09-659-791A-67/c
; Sequence 67, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-67

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1194 TATCTCGGGTCACACGGT 1213
|||||
Db 20 TATCTCGGGTCACACGGT 1

RESULT 71

US-09-659-791A-68/c
; Sequence 68, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-68

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1216 CTTCACACACTTCTGACTCG 1235
|||||
Db 20 CTTCACACACTTCTGACTCG 1

RESULT 72

US-09-659-791A-69/c
; Sequence 69, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-69

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1275 TTGACTCTGATCCCATCAC 1294
|||||
Db 20 TTGACTCTGATCCCATCAC 1

RESULT 73

US-09-659-791A-70/c
; Sequence 70, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-70

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1300 CGGTCCCTGTAGAGTCTCC 1319
|||||
Db 20 CGGTCCCTGTAGAGTCTCC 1

RESULT 74

US-09-659-791A-71/c
; Sequence 71, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-71

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1332 AAATTTATGGAGACCGTGC 1351

Db 20 AAATTATGGAGACCGTGC 1
|||||

RESULT 75

US-09-659-791A-72/c

; Sequence 72, Application US/09659791A

; Patent No. 6383808

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11

; NUMBER OF SEQ ID NOS: 90

; SEQ ID NO 72

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-659-791A-72

Query Match

Best Local Similarity 1.2%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GATGTGGATGTTGCTTTTGC 1417

Db 20 GATGTGGATGTTGCTTTTGC 1

|||||

RESULT 76

US-09-659-791A-73/c

; Sequence 73, Application US/09659791A

; Patent No. 6383808

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11

; NUMBER OF SEQ ID NOS: 90

; SEQ ID NO 73

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-659-791A-73

Query Match

Best Local Similarity 1.2%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGGATCCGCACTCTA 1564

Db 20 GCTCTGGATCCGCACTCTA 1

|||||

RESULT 77

US-09-659-791A-74/c

; Sequence 74, Application US/09659791A

; Patent No. 6383808

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11

; NUMBER OF SEQ ID NOS: 90

; SEQ ID NO 74

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-659-791A-74

Query Match

Best Local Similarity 1.2%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCTGCGATGCAACTAAT 1619

Db 20 TGCTCTGCGATGCAACTAAT 1

|||||

RESULT 78

US-09-659-791A-75/c

; Sequence 75, Application US/09659791A

; Patent No. 6383808

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11

; NUMBER OF SEQ ID NOS: 90

; SEQ ID NO 75

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-659-791A-75

Query Match

Best Local Similarity 1.2%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCATAAACTGTCT 1634

Db 20 CTAATTCATAAACTGTCT 1

|||||

RESULT 79

US-09-659-791A-78/c

; Sequence 78, Application US/09659791A

; Patent No. 6383808

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11

; NUMBER OF SEQ ID NOS: 90

; SEQ ID NO 78

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-659-791A-78

Query Match

Best Local Similarity 1.2%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 TGGACTGTTCCACCAAC 998

|||||

[illegible]


```
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Neeley, Richard L.
/ REGISTRATION NUMBER: 30,092
/ REFERENCE/DOCKET NUMBER: UCAL-238/00US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415 853 5070
/ TELEFAX: 415 857 0663
/ TELEX: 380816COOLRYPA
/ INFORMATION FOR SEQ ID NO: 22:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (synthetic)
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ US-08-410-540-22

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 GAGAGCTGTGACGTGAC 1492
DB 18 GAGAGCTGTGACGTGAC 1

RESULT 84
US-09-659-791A-4
/ Sequence 4, Application US/09659791A
/ Patent No. 6383808
/ GENERAL INFORMATION:
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/09/659,791A
/ CURRENT FILING DATE: 2000-09-11
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 4
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: PCR Primer
/ US-09-659-791A-4

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTGAA 763
DB 1 TCCGTACGAGCCCTGAA 18

RESULT 85
US-08-397-220B-43/c
/ Sequence 43, Application US/08397220B
/ Patent No. 6284458
/ GENERAL INFORMATION:
/ APPLICANT: Anderson et al.
/ TITLE OF INVENTION: Compositions And Methods For Treatment Of Hepatitis C Virus-Associated Diseases
/ NUMBER OF SEQUENCES: 98
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Jane Massey Licata, Esq.
/ STREET: 210 Lake Drive East, Suite 201
/ CITY: Cherry Hill
/ STATE: NJ
/ COUNTRY: USA
```

```
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM 486
OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/397,220B
FILING DATE: 09-Mar-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP93/01293
FILING DATE: 10-Sep-93
APPLICATION NUMBER: JP 5-87195
FILING DATE: 14-Apr-93
APPLICATION NUMBER: 07/945,289
FILING DATE: 10-Sep-92
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0031
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 43:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: nucleic acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-08-397-220B-43

Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GCCTCCAGGCCCCCAACTCC 1529
DB 20 GCCTCCAGGCCCCCAACTCC 1

RESULT 86
US-08-650-093C-43/c
/ Sequence 43, Application US/08650093C
/ Patent No. 6391542
/ GENERAL INFORMATION:
/ APPLICANT: Kevin P. Anderson et al.
/ TITLE OF INVENTION: Compositions And Methods For Treatment Of Hepatitis C Virus-Associated Diseases
/ NUMBER OF SEQUENCES: 118
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: LICATA & TYRRELL P.C.
/ STREET: 66 E. Main Street
/ CITY: Marlton
/ STATE: NJ
/ COUNTRY: USA
/ ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.1 for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/650,093C
FILING DATE: 17-May-1996
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/452,841
FILING DATE: May 30, 1995
APPLICATION NUMBER: 08/397,220
FILING DATE: March 9, 1995
```

10828394-1_1-1643.rni.sl

Tue Sep 13 10:53:21 2005

```

; APPLICATION NUMBER: 07/945,289
; FILING DATE: September 10, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-08-650-093C-43
      1.0%; Score 16.8; DB 1; Length 20;
Query Match
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1510 GCCTCAGGCCGCCCAACTCC 1529
Db 20 GCCTCAGGCCGCCCTCC 1

RESULT 87
US-10-023-649A-37/c
; Sequence 37, Application US/10023649A
; Patent No. 6800289
; GENERAL INFORMATION:
; APPLICANT: Negata, Leslie P.
; APPLICANT: Wong, Jonathan P.
; TITLE OF INVENTION: A STRAIN OF THE WESTERN EQUINE ENCEPHALITIS VIRUS (AS AMENDED)
; FILE REFERENCE: NEL-001
; CURRENT APPLICATION NUMBER: US/10/023,649A
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/256,948
; PRIOR FILING DATE: 2000-12-21
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: DNA Primer
US-10-023-649A-37
      1.0%; Score 16.8; DB 1; Length 20;
Query Match
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 524 CGACTCCCTCTGTGGAAGC 543
Db 20 CGACACGCTCTGTGGAAGC 1

RESULT 88
US-08-256-568B-97/c
; Sequence 97, Application US/08256568B
; Patent No. 5846704
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/256,568B
; FILING DATE: 18-JUL-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-08-256-568B-97
      1.0%; Score 16; DB 1; Length 16;
Query Match
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 89
US-09-038-369B-97/c
; Sequence 97, Application US/09038369B
; Patent No. 6171784
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,369B
```

```

; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-378-900A-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
DB 16 CAGCCTCCAGGCCCC 1

RESULT 91
US-09-899-044-97/c
; Sequence 97, Application US/09899044
; Patent No. 6548244
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,044
; FILING DATE: 06-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; US-09-378-900A-97

; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-038-369B-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
DB 16 CAGCCTCCAGGCCCC 1

RESULT 90
US-09-378-900A-97/c
; Sequence 97, Application US/09378900A
; Patent No. 6495670
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,900A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6

```

```

; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-378-900A-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
DB 16 CAGCCTCCAGGCCCC 1

RESULT 91
US-09-899-044-97/c
; Sequence 97, Application US/09899044
; Patent No. 6548244
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,044
; FILING DATE: 06-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002

```

```

; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 16 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: cDNA
;   HYPOTHETICAL: NO
;   ANTI-SENSE: YES
;   SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-09-899-044-97

Query Match          1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCAGGCCCC 1523
Db 16 CAGCCTCAGGCCCC 1

RESULT 92
US-08-173-489C-37
; Sequence 37, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173.489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: Nucleic Acid
;   STRANDEDNESS: double stranded
;   TOPOLOGY: linear
;   MOLECULE TYPE: Genomic DNA
;   DESCRIPTION: dystrophin gene (Accession # M18533, 5983
;   DESCRIPTION: M17154, M18026) nucleotides 5967 to 5983
;   HYPOTHETICAL: NO
;   ANTI-SENSE: NO
;   ORIGINAL SOURCE:
;   ORGANISM: Homo sapiens
;   POSITION IN GENOME:
;   CHROMOSOME/SEGMENT: X-chromosome
;   MAP POSITION: Xp21.3-p21.1

; PUBLICATION INFORMATION:
; AUTHORS: Koenig, M, Hoffman, E P, Bertelson, C J,
; AUTHORS: Monaco, A P, Feener, C, Kunkel, L M.
; TITLE: Complete cloning of the
; TITLE: Duchenne muscular dystrophy (DMD) cDNA and
; TITLE: preliminary genomic organization of the DMD
; TITLE: gene in normal and affected individuals
; JOURNAL: Cell
; VOLUME: 50
; PAGES: 509-517
; DATE: 1987
; AUTHORS: Hoffman, E P, Monaco, A P, Feener, C C,
; AUTHORS: Kunkel, L M.
; TITLE: Conservation of the Duchenne
; TITLE: muscular dystrophy gene in mice and humans
; JOURNAL: Science
; VOLUME: 238
; PAGES: 347-350
; DATE: 1987
; AUTHORS: Koenig, M, Monaco, A P, Kunkel, L M.
; TITLE: The complete sequence of
; TITLE: dystrophin predicts a rod-shaped cytoskeletal
; TITLE: protein
; JOURNAL: Cell
; VOLUME: 53
; PAGES: 219-228
; DATE: 1988
; RELEVANT RESIDUES IN SEQ ID NO: 37 :FROM 1 TO 17
US-08-173-489C-37

Query Match          1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 280 AGAAGAAGAAAGAGGA 295
Db 1 AGAAGAAGAAAGAGGA 16

RESULT 93
US-08-390-850-535/c
; Sequence 535, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
```

;; FILING DATE: No. 5612215ember 12, 1993
;; APPLICATION NUMBER: 07/989,848
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 211/084
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 535:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-390-850-535

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAAGAAATTCCTCC 1605
DB 17 AAGAACAAGAAATTCCTCC 1

RESULT 94
US-08-435-634-535/c
; Sequence 535, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Rayco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHEITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 535:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-435-634-535

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAAGAAATTCCTCC 1605
DB 17 AAGAACAAGAAATTCCTCC 1

RESULT 95
US-09-866-108A-8666
; Sequence 8666, Application US/09866108A
; Patent No. 6886188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6886188
; SEQ ID NO 8666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8666

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCAAGAAAGAGAA 289
DB 1 GAAGCCAAGAAAGAGAA 17

```

;
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/709,209
; FILING DATE: 21-AUG-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/105,483
; FILING DATE: 12-AUG-1993
; APPLICATION NUMBER: US 07/847,951
; FILING DATE: 06-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2400
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-709-209-280
;
; Query Match 0.9%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 63;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
Qy 222 CTCATAGAAAAAACCAAC 239
Db 18 CTAATAGAAAAAACCAAC 1

;
; RESULT 98
; US-08-458-101-280/c
; Sequence 280, Application US/08458101
; Patent No. 5766599
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Perkus, Marion E.
; APPLICANT: Taylor, Jill
; APPLICANT: Tartaglia, James
; APPLICANT: No. 5766599ton, Elizabeth K.
; APPLICANT: Riviere, Michel
; APPLICANT: de Taisne, Charles
; APPLICANT: Limbach, Keith J.
; APPLICANT: Johnson, Gerard P.
; APPLICANT: Pincus, Steven E.
; APPLICANT: Cox, William I.
; APPLICANT: Audonnet, Jean-Christophe Francis
; APPLICANT: Gettig, Russell Robert
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
; TITLE OF INVENTION: STRAIN
; NUMBER OF SEQUENCES: 467
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESSEE: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/458,101
; FILING DATE: 21-AUG-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/105,483
; FILING DATE: 12-AUG-1993
; APPLICATION NUMBER: US 07/847,951
; FILING DATE: 06-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2400
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-105-483-280
;
; Query Match 0.9%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 63;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
Qy 222 CTCATAGAAAAAACCAAC 239
Db 18 CTAATAGAAAAAACCAAC 1

;
; RESULT 97
; US-08-709-209-280/c
; Sequence 280, Application US/08709209
; Patent No. 5762938
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Perkus, Marion E.
; APPLICANT: Taylor, Jill
; APPLICANT: Tartaglia, James
; APPLICANT: No. 5762938ton, Elizabeth K.
; APPLICANT: Riviere, Michel
; APPLICANT: de Taisne, Charles
; APPLICANT: Limbach, Keith J.
; APPLICANT: Johnson, Gerard P.
; APPLICANT: Pincus, Steven E.
; APPLICANT: Cox, William I.
; APPLICANT: Audonnet, Jean-Christophe Francis
; APPLICANT: Gettig, Russell Robert
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
; TITLE OF INVENTION: STRAIN
; NUMBER OF SEQUENCES: 462
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESSEE: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/709,209
; FILING DATE: 21-AUG-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/105,483
; FILING DATE: 12-AUG-1993
; APPLICATION NUMBER: US 07/847,951
; FILING DATE: 06-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2400
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-105-483-280
;
; Query Match 0.9%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 63;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
Qy 222 CTCATAGAAAAAACCAAC 239
Db 18 CTAATAGAAAAAACCAAC 1

;
; RESULT 96
; US-08-105-483-280/c
; Sequence 280, Application US/08105483
; Patent No. 5494807
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Perkus, Marion E.
; APPLICANT: Taylor, Jill
; APPLICANT: Tartaglia, James
; APPLICANT: No. 5494807ton, Elizabeth K.
; APPLICANT: Riviere, Michel
; APPLICANT: de Taisne, Charles
; APPLICANT: Limbach, Keith J.
; APPLICANT: Johnson, Gerard P.
; APPLICANT: Pincus, Steven E.
; APPLICANT: Cox, William I.
; APPLICANT: Audonnet, Jean-Christophe Francis
; APPLICANT: Gettig, Russell Robert
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
; TITLE OF INVENTION: STRAIN
; NUMBER OF SEQUENCES: 462
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESSEE: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/105,483
; FILING DATE: 12-AUG-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/105,483
; FILING DATE: 12-AUG-1993
; APPLICATION NUMBER: US 07/847,951
; FILING DATE: 06-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2400
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-105-483-280
;
; Query Match 0.9%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 63;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
Qy 222 CTCATAGAAAAAACCAAC 239
Db 18 CTAATAGAAAAAACCAAC 1

;
; RESULT 95
; US-08-105-483-280/c
; Sequence 280, Application US/08105483
; Patent No. 5494807
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Perkus, Marion E.
; APPLICANT: Taylor, Jill
; APPLICANT: Tartaglia, James
; APPLICANT: No. 5494807ton, Elizabeth K.
; APPLICANT: Riviere, Michel
; APPLICANT: de Taisne, Charles
; APPLICANT: Limbach, Keith J.
; APPLICANT: Johnson, Gerard P.
; APPLICANT: Pincus, Steven E.
; APPLICANT: Cox, William I.
; APPLICANT: Audonnet, Jean-Christophe Francis
; APPLICANT: Gettig, Russell Robert
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
; TITLE OF INVENTION: STRAIN
; NUMBER OF SEQUENCES: 462
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESSEE: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/105,483
; FILING DATE: 12-AUG-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/105,483
; FILING DATE: 12-AUG-1993
; APPLICATION NUMBER: US 07/847,951
; FILING DATE: 06-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2400
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-105-483-280
;
; Query Match 0.9%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 63;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
Qy 222 CTCATAGAAAAAACCAAC 239
Db 18 CTAATAGAAAAAACCAAC 1

```

```
/ FILING DATE: 01-JUN-1995
/ CLASSIFICATION: 424
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Frommer, William S.
/ REGISTRATION NUMBER: 25,506
/ REFERENCE/DOCKET NUMBER: 454310-2740
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 840-3333
/ TELEFAX: (212) 840-0712
/ INFORMATION FOR SEQ ID NO: 280:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-08-458-101-280

Query Match          0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 63;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAACAAC 239
Db      18 CTAATAGAAAAACCAAC 1

RESULT 99
US-08-758-306-953/c
; Sequence 953, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 953:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-458-101-280

Query Match          0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 63;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAACAAC 239
Db      18 CTAATAGAAAAACCAAC 1

RESULT 100
US-08-390-850-536/c
; Sequence 536, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION NUMBER:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 536:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-390-850-536

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1589 AAGAACAGAAATGCTC 1604
Db      16 AAGAACAGAAATTCCTC 1

TOPOLOGY: linear
US-08-758-306-953
Query Match          0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 63;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

RESULT 101
US-08-435-536/c
; Sequence 536, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295 September 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 536:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-536
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1589 AAGACAGCAATGCTC 1604
DB 16 AAGAACAAGATTCTC 1
RESULT 102
US-09-282-146-7
; Sequence 7, Application US/09282146A
; Patent No. 6303847
; GENERAL INFORMATION:
; APPLICANT: KAWAOKA, Akiyoshi
; APPLICANT: EBINUMA, Hiroyasu

; TITLE OF INVENTION: TRANSCRIPTION FACTOR CONTROLLING PHENYLPROPANOID
; TITLE OF INVENTION: BIOSYNTHESIS PATHWAY
; FILE REFERENCE: 4859-0027-0
; CURRENT APPLICATION NUMBER: US/09/282,146A
; CURRENT FILING DATE: 1999-03-31
; EARLIER APPLICATION NUMBER: JP 10-125171
; EARLIER FILING DATE: 1998-03-31
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-09-282-146-7
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1104 CTCACACCTCTCTCT 1119
DB 2 CTCACCACTCTCTCT 17
RESULT 103
US-09-866-108A-8352/c
; Sequence 8352, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8352
Query Match 0.9%; Score 14.4; DB 1; Length 17;


```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8667

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      274 AAGCCAAAGAGAGAA 289
Db      1 AAGCCAAAGAGAGAA 16

RESULT 107
US-09-866-108A-10037/c
; Sequence 10037, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10037
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      715 CCGCATCGTCCGACAG 730
Db      17 CCGCATCGTCCACAG 2

RESULT 108
US-09-866-108A-10038/c
; Sequence 10038, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10038
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10038

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      715 CCGCATCGTCCGACAG 730
Db      16 CCGCATCGTCCACAG 1

RESULT 109
US-08-117-952-797/c
; Sequence 797, Application US/08117952
; Patent No. 5851760
; GENERAL INFORMATION:
; APPLICANT: Evans, Glen A.
; APPLICANT: Smith, Michael W.
; TITLE OF INVENTION: METHOD FOR GENERATION OF SEQUENCE
; TITLE OF INVENTION: SAMPLED MAPS OF COMPLEX GENOMES
```

NUMBER OF SEQUENCES: 797
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
STREET: 444 South Flower Street, Suite 2000
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/117,952
FILING DATE: 07-SEP-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/078,471
FILING DATE: 15-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Reiter, Stephen E.
REGISTRATION NUMBER: 31,192
REFERENCE/DOCKET NUMBER: P41 9423
TELEPHONE: 619-546-4737
TELEFAX: 619-546-9392
INFORMATION FOR SEQ ID NO: 797:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Oligonucleotide
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-117-952-797

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 73;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1520 CCCCAACTCGGCCGAG 1535
||| |||||
Db 18 CCCTAACTCGGCCGAG 3

RESULT 110
US-08-758-306-467
Sequence 467, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
ADDRESSEE: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 467:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-467

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 80;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 693 CCTCACTTCTTTCTTCC 709
||| ||||| :|||
Db 1 CCUCCUCCUCCUUCC 17

RESULT 111
US-08-599-455B-25
Sequence 25, Application US/08599455B
Patent No. 5972621
GENERAL INFORMATION:
APPLICANT: Tartaglia, Louis A.
ADDRESSEE: Tepper, Robert I.
TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT
MODULATE BODY WEIGHT USING THE OB RECEPTOR
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/599,455B
FILING DATE: 22-JAN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/583,153
FILING DATE: 28-DEC-1995
APPLICATION NUMBER: 08/570,142
FILING DATE: 11-DEC-1995
APPLICATION NUMBER: 08/569,485
FILING DATE: 08-DEC-1995
APPLICATION NUMBER: 08/566,622
FILING DATE: 04-DEC-1995
APPLICATION NUMBER: 08/562,663
FILING DATE: 27-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Melkijohn, Ph.D., Anita L.
REGISTRATION NUMBER: 35,283

```
; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-599-455B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGGCCCTTCAG 17

RESULT 112
US-08-599-455B-27
; Sequence 27, Application US/08599455B
; Patent No. 5972621
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT
; TITLE OF INVENTION: MODULATE BODY WEIGHT USING THE OB RECEPTOR
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: Fast-SEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/599,455B
; FILING DATE: 22-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-474-700B-21

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 222 CTCATAGAAAAACAAA 238
Db 17 CTCAAAGAAAAACAAA 1

RESULT 114
US-08-757-024-874/c
; Sequence 874, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
```

;; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
;; NUMBER OF SEQUENCES: 952
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
;; STREET: P.O. Drawer 34009
;; CITY: Charlotte
;; STATE: No. 6025339th Carolina
;; COUNTRY: USA
;; ZIP: 28234
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/757,024
;; FILING DATE: 26-NOV-1996
;; CLASSIFICATION: 514
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sibley, Kenneth D.
;; REGISTRATION NUMBER: 31,665
;; REFERENCE/DOCKET NUMBER: 5218-41
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 919-881-3140
;; TELEFAX: 919-881-3175
;; TELEX: 575102
;; INFORMATION FOR SEQ ID NO: 874:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-757-024-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCGC 1

RESULT 115
US-08-757-024-944/c
; Sequence 944, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: 919-881-3140
;; TELEFAX: 919-881-3175
;; TELEX: 575102
;; INFORMATION FOR SEQ ID NO: 944:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-757-024-944

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCGC 1

RESULT 116
US-09-069-781B-25
; Sequence 25, Application US/09069781B
; Patent No. 6287782
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/069,781B
; FILING DATE: 29-APRIL-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: US 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: US 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: US 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: US 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: US 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: US 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: US 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: US 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/082001
; TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-069-781B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGCGCCCTTCAG 17

RESULT 118
US-08-584-040-7759
Sequence 7759, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7759:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7759

TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-069-781B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGCGCCCTTCAG 17

RESULT 117
US-09-069-781B-27
Sequence 27, Application US/09069781B
Patent No. 6287782
GENERAL INFORMATION:
APPLICANT: Tartaglia, Louis A.
APPLICANT: Tepper, Robert I.
APPLICANT: Culpepper, Janice A.
APPLICANT: White, David W.
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
INCLUDING OBESITY AND CACHEXIA
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/069,781B
FILING DATE: 29-APRIL-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/864,564
FILING DATE: 28-MAY-1997
APPLICATION NUMBER: US 08/708,123
FILING DATE: 03-SEP-1996
APPLICATION NUMBER: US 08/638,524
FILING DATE: 26-APR-1996
APPLICATION NUMBER: US 08/599,455
FILING DATE: 22-JAN-1996
APPLICATION NUMBER: US 08/583,153
FILING DATE: 28-DEC-1995
APPLICATION NUMBER: US 08/570,142
FILING DATE: 11-DEC-1995
APPLICATION NUMBER: US 08/569,485
FILING DATE: 08-DEC-1995
APPLICATION NUMBER: US 08/566,622
FILING DATE: 04-DEC-1995
APPLICATION NUMBER: US 08/562,663
FILING DATE: 27-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Meiklejohn, Ph.D., Anita L.
REGISTRATION NUMBER: 35,283
REFERENCE/DOCKET NUMBER: 07334/082001
TELECOMMUNICATION INFORMATION:

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. NO. 80;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1112 CTCCTCTGCTGGAGC 1128
DB 1 CUCCCCUUGUGAGC 17

RESULT 119

US-08-679-645-687/c
; Sequence 687, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 687:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-679-645-687
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1213 TGGCTTCCACACTTCT 1229
DB 17 TGGCTGCCAACACTTCT 1

RESULT 120

US-09-137-132-25
; Sequence 25, Application US/09137132
; Patent No. 6380363
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/137,132
; FILING DATE: 18-AUG-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/838,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA

US-09-137-132-25
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
DB 1 CACTATTTGCCCTTCAG 17

RESULT 121
US-09-137-132-27
; Sequence 27, Application US/09137132
; Patent No. 6380363
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE OB RECEPTOR AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/137,132
; FILING DATE: 18-AUG-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-09-137-132-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
||||| ||||||||
Db 1 CACTATTGCGCTTCAG 17

RESULT 122
US-08-864-564A-25
; Sequence 25, Application US/08864564A
; Patent No. 6395498
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE OB RECEPTOR AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/864,564A
; FILING DATE: 28-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-864-564A-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
||||| ||||||||
Db 1 CACTATTGCGCTTCAG 17

RESULT 123

US-08-864-564A-27
; Sequence 27, Application US/08864564A
; Patent No. 6395498
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/864,564A
; FILING DATE: 28-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-864-564A-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
|||||
Db 1 CACTATTGGCCCTTCAG 17

RESULT 124

US-09-094-410-25

; Sequence 25, Application US/09094410
; Patent No. 6403552
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,410
; FILING DATE: 09-JUN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-09-094-410-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
|||||
Db 1 CACTATTGGCCCTTCAG 17

RESULT 125

US-09-094-410-27

; Sequence 27, Application US/09094410
; Patent No. 6403552
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,410
; FILING DATE: 09-JUN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-09-094-410-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 126
US-08-708-123D-25

; Sequence 25, Application US/08708123D
; Patent No. 6482927
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/708,123D
; FILING DATE: 03-SEP-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-708-123D-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 127
US-08-708-123D-27
; Sequence 27, Application US/08708123D
; Patent No. 6482927
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.

APPLICANT: Tepper, Robert I.
APPLICANT: Culpepper, Janice A.
APPLICANT: White, David W.
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
TITLE OF INVENTION: THE OB RECEPTOR AND TREATMENT OF BODY WEIGHT DISORDERS,
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESS: Fish & Richardson, P.C.
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/708,123D
FILING DATE: 03-SEP-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/538,524
FILING DATE: 26-APR-1996
APPLICATION NUMBER: 08/599,455
FILING DATE: 22-JAN-1996
APPLICATION NUMBER: 08/583,153
FILING DATE: 28-DEC-1995
APPLICATION NUMBER: 08/570,142
FILING DATE: 11-DEC-1995
APPLICATION NUMBER: 08/569,485
FILING DATE: 08-DEC-1995
APPLICATION NUMBER: 08/566,622
FILING DATE: 04-DEC-1995
APPLICATION NUMBER: 08/562,663
FILING DATE: 27-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Meiklejohn, Ph.D., Anita L.
REGISTRATION NUMBER: 35,283
REFERENCE/DOCKET NUMBER: 07334/019001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-542-5070
TELEFAX: 617-542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-708-123D-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
||||| |||||||
DB 1 CACTATTGCCCCCTCAG 17

RESULT 128
US-08-583-153A-25
Sequence 25, Application US/08583153A
Patent No. 6506877
GENERAL INFORMATION:
APPLICANT: Tartaglia, Louis A.
APPLICANT: Tepper, Robert I.
APPLICANT: Culpepper, Janice A.
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESS: Fish & Richardson P.C.
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

TITLE OF INVENTION: OBESITY AND CACHEXIA
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESS: Fish & Richardson P.C.
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/583,153A
FILING DATE: 28-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/570,142
FILING DATE: 11-DEC-1995
APPLICATION NUMBER: 08/569,485
FILING DATE: 08-DEC-1995
APPLICATION NUMBER: 08/566,622
FILING DATE: 04-DEC-1995
APPLICATION NUMBER: 08/562,663
FILING DATE: 27-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Meiklejohn, Anita L.
REGISTRATION NUMBER: 35,283
REFERENCE/DOCKET NUMBER: 07334/016001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-542-5070
TELEFAX: 617-542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-583-153A-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
||||| |||||||
DB 1 CACTATTGCCCCCTCAG 17

RESULT 129
US-08-583-153A-27
Sequence 27, Application US/08583153A
Patent No. 6506877
GENERAL INFORMATION:
APPLICANT: Tartaglia, Louis A.
APPLICANT: Tepper, Robert I.
APPLICANT: Culpepper, Janice A.
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESS: Fish & Richardson P.C.
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/583,153A
FILING DATE: 28-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/570,142
FILING DATE: 11-DEC-1995
APPLICATION NUMBER: 08/569,485
FILING DATE: 08-DEC-1995
APPLICATION NUMBER: 08/566,622
FILING DATE: 04-DEC-1995
APPLICATION NUMBER: 08/562,663
FILING DATE: 27-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Meiklejohn, Anita L.
REGISTRATION NUMBER: 35,283
REFERENCE/DOCKET NUMBER: 07334/016001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-542-5070
TELEFAX: 617-542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-583-153A-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGCCCTTCAG 17

RESULT 130
US-08-638-524B-25
Sequence 25, Application US/08638524B
Patent No. 6548269
GENERAL INFORMATION:
APPLICANT: Tartaglia, Louis A.
APPLICANT: Tepper, Robert I.
APPLICANT: Culpepper, Janice A.
APPLICANT: White, David W.
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING OB
TITLE OF INVENTION: CACHEXIA
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/638,524B
FILING DATE: 26-APR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/599,455
FILING DATE: 22-JAN-1996
APPLICATION NUMBER: 08/583,153

FILING DATE: 28-DEC-1995
APPLICATION NUMBER: 08/570,142
FILING DATE: 11-DEC-1995
APPLICATION NUMBER: 08/569,485
FILING DATE: 08-DEC-1995
APPLICATION NUMBER: 08/566,622
FILING DATE: 04-DEC-1995
APPLICATION NUMBER: 08/562,663
FILING DATE: 27-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Meiklejohn, Ph.D., Anita L.
REGISTRATION NUMBER: 35,283
REFERENCE/DOCKET NUMBER: 07334/018001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-542-5070
TELEFAX: 617-542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-638-524B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGCCCTTCAG 17

RESULT 131
US-08-638-524B-27
Sequence 27, Application US/08638524B
Patent No. 6548269
GENERAL INFORMATION:
APPLICANT: Tartaglia, Louis A.
APPLICANT: Tepper, Robert I.
APPLICANT: Culpepper, Janice A.
APPLICANT: White, David W.
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING OB
TITLE OF INVENTION: CACHEXIA
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/638,524B
FILING DATE: 26-APR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/599,455
FILING DATE: 22-JAN-1996
APPLICATION NUMBER: 08/583,153
FILING DATE: 28-DEC-1995
APPLICATION NUMBER: 08/570,142
FILING DATE: 11-DEC-1995
APPLICATION NUMBER: 08/569,485
FILING DATE: 08-DEC-1995
APPLICATION NUMBER: 08/566,622

/ FILING DATE: 04-DEC-1995
/ APPLICATION NUMBER: 08/562,663
/ FILING DATE: 27-NOV-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Meiklejohn, Ph.D.: Anita L.
/ REGISTRATION NUMBER: 35,283
/ REFERENCE/DOCKET NUMBER: 07334/018001
/ TELEPHONE: 617-542-5070
/ TELEFAX: 617-542-8906
/ TELEX: 200154
/ INFORMATION FOR SEQ ID NO: 27:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-638-524B-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
| | | | | | | | | | | | | | | |
Db 1 CACTATTGGCCCTTCAG 17

RESULT 132

US-09-371-772B-3543
/ Sequence 3543, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Jaime
/ APPLICANT: Escobedo, John
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 3543
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Mus sp.
US-09-371-772B-3543

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 80;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1112 CTCCTCTTGCTGGAGC 1128
| : | | : | : | : | | | | |
Db 1 CUCCCCCUUGCUGAAGC 17

RESULT 133

US-09-371-772B-4182
/ Sequence 4182, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim

/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 4182
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-371-772B-4182

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 80;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1115 CTCCTTGCTGGAGCAGC 1131
| : | | : | : | : | | | | |
Db 1 CUCCUGGCGGAGCGC 17

RESULT 134

US-09-866-108A-1895/c
/ Sequence 1895, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: Ji, Yonggang
/ APPLICANT: Penn, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aeomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1895
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108A-1895

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 80;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGGAGGTCTCT 109
 ||||| || ||||| |||||
 DB 17 GAGAGAGCCAGGTCTCT 1

RESULT 135
 US-09-866-108A-2643/c
 ; Sequence 2643, Application US/09866108A
 ; Patent No. 6686188
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEOMICA-7
 ; CURRENT APPLICATION NUMBER: US 09/866,108A
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aeomica Sequence Listing Engine
 ; Patent No. 6686188
 ; SEQ ID NO 7355
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-09-866-108A-7355

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 80;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 CTTCAGCAGCCGCCAA 861
 ||||| ||||| ||||| |||||
 DB 17 CTGCCAGGACCGCCAA 1

RESULT 136
 US-09-866-108A-7355
 ; Sequence 7355, Application US/09866108A
 ; Patent No. 6686188
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang

```
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-7485

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCACGCTCTCCCGC 1546
DB 17 GTCCAGCTCTCCTCGC 1

RESULT 138
US-09-866-108A-8568
; Sequence 8568, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
US-09-866-108A-8568

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 AGGATGCCCTAAATGAG 308
DB 1 AGGATGACCTGAATGAG 17

RESULT 139
US-09-866-108A-8660
; Sequence 8660, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8660

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 CTAGAAGAAGCCAGAA 283
DB 1 CTGGAGGAGGCCAGAA 17

RESULT 140
US-09-866-108A-8661
; Sequence 8661, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```

; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8661
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8661

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 268 TAGAAGAGCCAGAGAG 284
Db 1 TGAGGAGCCAGAGAG 17

RESULT 141
US-09-866-108A-8663
; Sequence 8663, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8661
; LENGTH: 17
; TYPE: DNA
US-09-866-108A-8661

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 270 GAGAGAGCCAGAGAG 286
Db 1 GAGAGAGCCAGAGAG 17

RESULT 142
US-09-866-108A-8664
; Sequence 8664, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8664
; LENGTH: 17
; TYPE: DNA
US-09-866-108A-8663
```


ORGANISM: Homo sapiens
US-09-866-108A-9686

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAGAG 287
| | | | | | | | | | | | | | | | | | |
Db 1 AGGAAGCCCAAGAGAG 17

RESULT 143

US-09-866-108A-9687/c
Sequence 9687, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOmica-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aemica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 9687

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-9687

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGTCTCT 109
| | | | | | | | | | | | | | | | | | |
Db 17 GAGAGTGGCAGGTCTCT 1

RESULT 144

US-09-866-108A-9688/c
Sequence 9688, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOmica-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aemica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 9688

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-9688

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 92 GGAGAGTGGCAGGTCC 108
| | | | | | | | | | | | | | | | | | |
Db 17 GGAGAGTGGCAGGTCC 1

RESULT 145

US-09-866-108A-9689/c
Sequence 9689, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOmica-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/093,972C
; FILING DATE: 09-Jun-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 08/757,024
; FILING DATE: 26-11-1996
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 09/016,464
; FILING DATE: 30-January-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 944:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 944:
US-09-093-972C-944

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCCAGCCTTCCCGC 1546
Db 17 GCCCAGCCTGCGCGC 1

RESULT 149
PCT-US95-05812-21/c
; Sequence 21, Application PC/TUS9505812
; GENERAL INFORMATION:
; APPLICANT: Wakita, Jack
; APPLICANT: Wands, Jack
; TITLE OF INVENTION: ANTISENSE INHIBITION OF
; HEPATITIS C VIRUS
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/05812
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/240,382
; FILING DATE: 10 May 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/221001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US95-05812-21

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 222 CTCATAGAAAAACAAA 238
Db 17 CTCATAGAAAAACAAA 1

RESULT 150
US-08-291-932A-160
; Sequence 160, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

```
;
; INFORMATION FOR SEQ ID NO: 160:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 15 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
US-08-291-932A-160

Query Match          0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 71;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1507 CCAGCCTCCAGGCC 1521
DB      1 CCAGCCUCCAGGCUC 15

RESULT 151
US-09-180-437-151/c
; Sequence 151, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshifumi
; APPLICANT: KUSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209P
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; NUMBER OF SEQ ID NOS: 289
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 151
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: other nucleic
US-09-180-437-151

Query Match          0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      432 TGCAGAGCTGGCTCA 446
DB      15 TGCAGCAGTGGCTCA 1

RESULT 152
US-09-081-646-174/c
; Sequence 174, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 174
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Primer
US-09-736-116-75

Query Match          0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      807 GCTCAGCAGGCCATG 821
DB      15 GCCCAGCAGGCCATG 1

RESULT 153
US-09-081-646-783/c
; Sequence 783, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 783
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION:
US-09-081-646-783

Query Match          0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      807 GCTCAGCAGGCCATG 821
DB      15 GCCCAGCAGGCCATG 1

RESULT 154
US-09-736-116-75/c
; Sequence 75, Application US/09736116
; Patent No. 6727085
; GENERAL INFORMATION:
; APPLICANT: Sejersgard, Tina
; APPLICANT: Mikkelsen, Frank
; TITLE OF INVENTION: Subtilase variants having an improved wash performance on egg stain
; FILE REFERENCE: 6108.410
; CURRENT APPLICATION NUMBER: US/09/736,116
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 75
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-736-116-75

Query Match          0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1076 GCTGCTAAGTCCTA 1090
DB      15 GCTGCTAAGTCCTA 1090
```

Db 15 GCTGTTAAAGTCCTA 1

RESULT 155
US-08-173-489C-32/c
; Sequence 32, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 bases
; TYPE: Nucleic Acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from dystrophin
; HYPOTHETICAL: Yes
; ANTI-SENSE: NO
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 32 :FROM 1 TO 16
US-08-173-489C-32

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0;

QY 271 AAGAAGCCAAAGA 285
Db 15 AAGAAGCCAAAGA 1

RESULT 156
US-09-034-205-67
; Sequence 67, Application US/09034205
; Patent No. 6194149
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Brow, Mary Ann D.
; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
; TITLE OF INVENTION: STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/034,205
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:

```
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-034-205-68

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1508 CAGCCTCCAGGCCCC 1522
Db      2 CAGCCTCCAGGCCCC 16

RESULT 158
US-09-677-218B-67
; Sequence 67, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
;           Brow, Mary Ann D.
;           Neri, Bruce P.
;           Fors, Lance
;           MacKnight, Kamrin T.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
;                   STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
; SEQUENCE DESCRIPTION: SEQ ID NO: 67:
US-09-677-218B-67
```

```
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
; SEQUENCE DESCRIPTION: SEQ ID NO: 68:
US-09-677-218B-68

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1508 CAGCCTCCAGGCCCC 1522
Db      2 CAGCCTCCAGGCCCC 16

RESULT 159
US-09-677-218B-68
; Sequence 68, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
;           Brow, Mary Ann D.
;           Neri, Bruce P.
;           Fors, Lance
;           MacKnight, Kamrin T.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
;                   STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
; SEQUENCE DESCRIPTION: SEQ ID NO: 68:
US-09-677-218B-68

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1508 CAGCCTCCAGGCCCC 1522
Db      2 CAGCCTCCAGGCCCC 16

RESULT 160
US-09-677-192-67
; Sequence 67, Application US/09677192
; Patent No. 6358691
; GENERAL INFORMATION:
```

; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Brow, Mary Ann D.
; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING STRUCTURE-BRIDGING
; FILE REFERENCE: OLIGONUCLEOTIDES
; CURRENT APPLICATION NUMBER: US/09/677,192
; CURRENT FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 09/034,205
; PRIOR FILING DATE: 1998-03-03
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 67
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-677-192-67

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGCCCC 16

RESULT 161
US-09-677-192-68
; Sequence 68, Application US/09677192
; Patent No. 6358691
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Brow, Mary Ann D.
; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING STRUCTURE-BRIDGING
; FILE REFERENCE: OLIGONUCLEOTIDES
; CURRENT APPLICATION NUMBER: US/09/677,192
; CURRENT FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 09/034,205
; PRIOR FILING DATE: 1998-03-03
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 68
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-677-192-68

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGCCCC 16

RESULT 162
US-09-402-618B-67
; Sequence 67, Application US/09402618B
; Patent No. 6709815
; GENERAL INFORMATION:
; APPLICANT: Dong, Fang
; APPLICANT: Lyamichev, Victor
; APPLICANT: Prudent, James

; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce
; APPLICANT: Brow, Mary Ann
; APPLICANT: Anderson, Todd
; APPLICANT: Dahlberg, James
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides
; FILE REFERENCE: FORS-04012
; CURRENT APPLICATION NUMBER: US/09/402,618B
; CURRENT FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/US98/03194
; PRIOR FILING DATE: 1998-05-05
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 67
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-402-618B-67

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGCCCC 16

RESULT 163
US-09-402-618B-68
; Sequence 68, Application US/09402618B
; Patent No. 6709815
; GENERAL INFORMATION:
; APPLICANT: Dong, Fang
; APPLICANT: Lyamichev, Victor
; APPLICANT: Prudent, James
; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce
; APPLICANT: Brow, Mary Ann
; APPLICANT: Anderson, Todd
; APPLICANT: Dahlberg, James
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides
; FILE REFERENCE: FORS-04012
; CURRENT APPLICATION NUMBER: US/09/402,618B
; CURRENT FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/US98/03194
; PRIOR FILING DATE: 1998-05-05
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 68
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-402-618B-68

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGCCCC 16

RESULT 164
US-08-796-031-1/c
; Sequence 1, Application US/08796031
; Patent No. 5849903
; GENERAL INFORMATION:

```
; APPLICANT: Zbigniew Pietrzkowski, Gordana Olbina and Dariusz Cieslak
; TITLE OF INVENTION: Inhibition of Tumor Growth by Antisense
; TITLE OF INVENTION: Oligonucleotides for 11-8 and 11-8 Receptor
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Crockett & Fish
; STREET: 3000 S. Augusta Court
; CITY: La Habra
; STATE: California
; COUNTRY: United States of America
; ZIP: 90631
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/796,031
; FILING DATE: 1 January 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/561,302
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Fish, Robert D.
; REGISTRATION NUMBER: 33,880
; REFERENCE/DOCKET NUMBER: 213/015-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-525-3433
; TELEFAX: 714-525-3303
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-08-796-031-1
;
; Query Match 0.8%; Score 13; DB 1; Length 14;
; Best Local Similarity 100.0%; Pred. No. 71;
; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Qy 1239 GTTCCTTCGGTG 1251
Db 13 GTTCCTTCGGTG 1

RESULT 165
US-09-055-913-1/c
; Sequence 1, Application US/09055913
; Patent No. 6017898
; GENERAL INFORMATION:
; APPLICANT: Zbigniew Pietrzkowski, Gordana Olbina and Dariusz Cieslak
; TITLE OF INVENTION: Inhibition of Tumor Growth by Antisense
; TITLE OF INVENTION: Oligonucleotides for 11-8 and 11-8 Receptor
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Crockett & Fish
; STREET: 3000 S. Augusta Court
; CITY: La Habra
; STATE: California
; COUNTRY: United States of America
; ZIP: 90631
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/055,913
; FILING DATE:
```

```
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/561,302
; FILING DATE: 1 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fish, Robert D.
; REGISTRATION NUMBER: 33,880
; REFERENCE/DOCKET NUMBER: 213/015-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-525-3433
; TELEFAX: 714-525-3303
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-09-055-913-1
;
; Query Match 0.8%; Score 13; DB 1; Length 14;
; Best Local Similarity 100.0%; Pred. No. 71;
; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Qy 1239 GTTCCTTCGGTG 1251
Db 13 GTTCCTTCGGTG 1

RESULT 166
US-08-985-090-23/c
; Sequence 23, Application US/08985090
; Patent No. 5885893
; GENERAL INFORMATION:
; APPLICANT: Andrew D.J. Goodearl
; TITLE OF INVENTION: MUSCARINIC RECEPTORS AND USES THEREFOR
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,090
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jean M. Silveri
; REGISTRATION NUMBER: 39,030
; REFERENCE/DOCKET NUMBER: MNI-032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-985-090-23
;
; Query Match 0.8%; Score 12.8; DB 1; Length 16;
```



```
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 72 GTGGGCTGCTGCTGA 87
    |||||
Db 16 GTGGGCTGCTGCTCA 1

RESULT 167
US-08-757-024-875/c
; Sequence 875, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 882:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-882

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCAGCCTCTCCCG 1545
    |||||
Db 16 GCCAGCCTGTGCCG 1

RESULT 169
US-08-757-024-945/c
; Sequence 945, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1531 CCAGCCTCTCCCGC 1546
    |||||
Db 16 CCAGCCTGTGCCGC 1

RESULT 168
US-08-757-024-882/c
; Sequence 882, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
```

<hr/>					
; MOLECULE TYPE: DNA (genomic)					
US-08-757-024-945					
Query Match 0.8%; Score 12.8; DB 1; Length 16;					
Best Local Similarity 87.5%; Pred. No. 99;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY 1530 GCCACGCTTCGCCG 1545					
Db 16 GCCACGCTGTGCCG 1					
RESULT 170					
US-09-165-543-25/c					
Sequence 25; Application US/09165543					
Patent No. 6093545					
GENERAL INFORMATION:					
APPLICANT: Andrew D.J. Goodearl and Sandra Gluckman					
TITLE OF INVENTION: Muscarinic Receptors and Uses Therefor					
NUMBER OF SEQUENCES: 39					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: LAHIVE & COCKFIELD, LLP					
STREET: 28 State Street					
CITY: Boston					
STATE: Massachusetts					
COUNTRY: USA					
ZIP: 02109					
COMPUTER READABLE FORM:					
MEDIUM TYPE: Floppy disk					
COMPUTER: IBM PC compatible					
OPERATING SYSTEM: PC-DOS/MS-DOS					
SOFTWARE: Patent In Release #1.0, Version #1.25					
CURRENT APPLICATION DATA:					
APPLICATION NUMBER: US/09/165,543					
FILING DATE:					
CLASSIFICATION:					
PRIOR APPLICATION DATA:					
APPLICATION NUMBER: 09/042,780					
FILING DATE:					
ATTORNEY/AGENT INFORMATION:					
NAME: Elizabeth A. Hanley					
REGISTRATION NUMBER: 33,505					
REFERENCE/DOCKET NUMBER: MNI-032CP					
TELECOMMUNICATION INFORMATION:					
TELEPHONE: (617)227-7400					
TELEFAX: (617)742-4214					
INFORMATION FOR SEQ ID NO: 25:					
SEQUENCE CHARACTERISTICS:					
LENGTH: 16 base pairs					
TYPE: nucleic acid					
STRANDEDNESS: single					
TOPOLOGY: linear					
MOLECULE TYPE: cDNA					
US-09-165-543-25					
Query Match 0.8%; Score 12.8; DB 1; Length 16;					
Best Local Similarity 87.5%; Pred. No. 99;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY 72 GTGGGGCTGTGCTGA 87					
Db 16 GTGGGGCAGTGTCTCA 1					
RESULT 171					
US-08-679-645-523					
Sequence 523; Application US/08679645					
Patent No. 6350934					
GENERAL INFORMATION:					
APPLICANT: Zwick, Michael G.					
APPLICANT: Edington, Brent E.					
APPLICANT: McSwiggen, James A.					
APPLICANT: Merlo, Patricia Ann Owens					
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION OF BRONCHOCONSTRUCTION, ALLERGY(IES) & INFLAMMATION					
NUMBER OF SEQUENCES: 996					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.					
STREET: 7 Clarke Drive					
CITY: Cranbury					
STATE: New Jersey					
COUNTRY: USA					
ZIP: 08512					
COMPUTER READABLE FORM:					
MEDIUM TYPE: storage					
COMPUTER: IBM Compatible					
OPERATING SYSTEM: IBM P.C. DOS 5.0					
SOFTWARE: Word Perfect 5.1					
CURRENT APPLICATION DATA:					
APPLICATION NUMBER: US/08/679,645					
FILING DATE: July 12, 1996					
CLASSIFICATION: 800					
PRIOR APPLICATION DATA:					
APPLICATION NUMBER: 60/001,135					
FILING DATE: July 13, 1995					
APPLICATION NUMBER: 08/300,726					
FILING DATE: September 2, 1994					
ATTORNEY/AGENT INFORMATION:					
NAME: Warburg, Richard J.					
REGISTRATION NUMBER: 32,327					
REFERENCE/DOCKET NUMBER: 219/247					
TELECOMMUNICATION INFORMATION:					
TELEPHONE: (213) 489-1600					
TELEFAX: (213) 955-0440					
TELEX: 67-3510					
INFORMATION FOR SEQ ID NO: 523:					
SEQUENCE CHARACTERISTICS:					
LENGTH: 16 base pairs					
TYPE: nucleic acid					
STRANDEDNESS: single					
TOPOLOGY: linear					
US-08-679-645-523					
Query Match 0.8%; Score 12.8; DB 1; Length 16;					
Best Local Similarity 62.5%; Pred. No. 99;					
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;					
QY 666 CTGCCCTTCAGCGTCG 681					
: : :					
Db 1 CUGCGGUUCAGCCUGC 16					
RESULT 172					
US-09-093-972C-875/c					
Sequence 875; Application US/09093972C					
Patent No. 6825174					
GENERAL INFORMATION:					
APPLICANT: Nyce, Jonathan W.					
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION OF BRONCHOCONSTRUCTION, ALLERGY(IES) & INFLAMMATION					
NUMBER OF SEQUENCES: 996					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.					
STREET: 7 Clarke Drive					
CITY: Cranbury					
STATE: New Jersey					
COUNTRY: USA					
ZIP: 08512					
COMPUTER READABLE FORM:					
MEDIUM TYPE: storage					
COMPUTER: IBM Compatible					
OPERATING SYSTEM: IBM P.C. DOS 5.0					
SOFTWARE: Word Perfect 5.1					
CURRENT APPLICATION DATA:					
APPLICATION NUMBER: US/08/679,645					
FILING DATE: July 12, 1996					
CLASSIFICATION: 800					
PRIOR APPLICATION DATA:					
APPLICATION NUMBER: 60/001,135					
FILING DATE: July 13, 1995					
APPLICATION NUMBER: 08/300,726					
FILING DATE: September 2, 1994					
ATTORNEY/AGENT INFORMATION:					
NAME: Warburg, Richard J.					
REGISTRATION NUMBER: 32,327					
REFERENCE/DOCKET NUMBER: 219/247					
TELECOMMUNICATION INFORMATION:					
TELEPHONE: (213) 489-1600					
TELEFAX: (213) 955-0440					
TELEX: 67-3510					
INFORMATION FOR SEQ ID NO: 523:					
SEQUENCE CHARACTERISTICS:					
LENGTH: 16 base pairs					
TYPE: nucleic acid					
STRANDEDNESS: single					
TOPOLOGY: linear					
US-08-679-645-523					

ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 875:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 875:
US-09-093-972C-875
Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1531 CCACGCTCTCCCGC 1546
|||||
Db 16 CCACGCTCTCCCGC 1
RESULT 173
US-09-093-972C-882/c
Sequence 882, Application US/09093972C
Patent No. 6825174
GENERAL INFORMATION:
APPLICANT: Nyce, Jonathan W.
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION
NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 882:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 882:
US-09-093-972C-882
Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1530 GCCACGCTCTCCCGC 1545
|||||
Db 16 GCCACGCTCTCCCGC 1
RESULT 174
US-09-093-972C-945/c
Sequence 945, Application US/09093972C
Patent No. 6825174
GENERAL INFORMATION:
APPLICANT: Nyce, Jonathan W.
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION
NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930

REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 945:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 945:
US-09-093-972C-945

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCACGCTCTCCCG 1545
|||||
Db 16 GCCACGCTGTCCCG 1

RESULT 175
US-08-650-093C-97
; Sequence 97, Application US/08650093C
; Patent No. 6391542
; GENERAL INFORMATION:
; APPLICANT: Kevin P. Anderson et al.
; TITLE OF INVENTION: Compositions And Methods For Treatment Of
; TITLE OF INVENTION: Hepatitis C Virus-Associated Diseases
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LICATA & TYRRELL P.C.
; STREET: 66 E. Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.1 for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/650,093C
FILING DATE: 17-May-1996
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/452,841
FILING DATE: May 30, 1995
APPLICATION NUMBER: 08/397,220
FILING DATE: March 9, 1995
APPLICATION NUMBER: 07/945,289
FILING DATE: September 10, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488

INFORMATION FOR SEQ ID NO: 97:
SEQUENCE CHARACTERISTICS:
LENGTH: 14
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: No
SEQUENCE DESCRIPTION: SEQ ID NO: 97:

US-08-650-093C-97

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 88;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1510 GCCTCCAGGCCCC 1523
|||||
Db 1 GCCUCCAGGACCC 14

RESULT 176
US-09-720-435A-172
; Sequence 172, Application US/09720435A
; Patent No. 6803187
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease
; TITLE OF INVENTION: Gene
; FILE REFERENCE: 11362.0030.PCUS00 INNS:030
; CURRENT APPLICATION NUMBER: US/09/720,435A
; PRIOR FILING DATE: 2001-06-25
; PRIOR APPLICATION NUMBER: PCT/EP99/04317
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 98870143.9
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 172
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Aids-associated retrovirus
US-09-720-435A-172

Query Match 0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 37 GAATTGGAGGCATG 50
|||||
Db 1 GAATTGGAGGCTTG 14

RESULT 177
US-08-050-073-65
; Sequence 65, Application US/08050073
; Patent No. 5567809
; GENERAL INFORMATION:
; APPLICANT: Apple, Raymond J.
; APPLICANT: Begovich, Ann B.
; APPLICANT: Bugawan, Teodorica L.
; APPLICANT: Erlich, Henry A.
; APPLICANT: Griffith, Robert L.
; APPLICANT: Scharf, Stephen J.
; TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 315
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingeland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/050,073
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry, Douglas A.

REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8769
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
US-08-050-073-65

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1074 GAGCTGCTTAAGTC 1087
|||||
DB 1 GAGCTGCTTAAGTC 14

RESULT 178
US-08-182-968A-2
Sequence 2, Application US/08182968A
Patent No. 5610054
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
CITY: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/182,968A
FILING DATE: 13-JANUARY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/882,888
FILING DATE: 14-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 205/277
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-182-968A-2

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1521
|||||
DB 2 CAGCCUCCAGGACC 15
RESULT 179
US-08-182-968A-422/c
Sequence 422, Application US/08182968A
Patent No. 5610054
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
CITY: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/182,968A
FILING DATE: 13-JANUARY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/882,888
FILING DATE: 14-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 205/277
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 422:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-182-968A-422

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGAAGCGCA 883
|||||
DB 15 ATACGATAAGCGCA 2

RESULT 180
US-08-182-968A-423/c
Sequence 423, Application US/08182968A
Patent No. 5610054
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street

```
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 423:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-182-968A-423

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGAGGCGA 883
Db 14 ATACGATAGGCGA 1

RESULT 181
US-08-363-240A-237
; Sequence 237, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-237

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1309 TAGAGTCTCCAGG 1322
Db 1 UAGAAGUCUCCAAG 14

RESULT 182
US-08-363-240A-528
; Sequence 528, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
```

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-528

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 841 CGGCTTCCAGCAC 854
Db 2 CGGCCUCCAGCGC 15

RESULT 183

US-08-363-240A-529
Sequence 529, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
PREVENTION, INHIBITION OF
PROGRESSION AND REGRESSION
OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 529:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-363-240A-529

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 841 CGGCTTCCAGCAC 854
Db 1 CGGCCUCCAGCGC 14

RESULT 184

US-08-363-240A-724/c
Sequence 724, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
PREVENTION, INHIBITION OF
PROGRESSION AND REGRESSION
OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 724:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-363-240A-724

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1471 CAGAGAGCTCTG 1484
Db 14 CGGAGAGCTCTG 1

RESULT 185

US-08-311-486C-533/c
Sequence 533, Application US/08311486C
Patent No. 5811300
GENERAL INFORMATION:
APPLICANT: Sean Sullivan
APPLICANT: Kenneth Draper
APPLICANT: Kevin Kisch
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen

TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
TNF-
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
TNF-
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
TNF-

```

; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 533:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-533

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1391 GGAGTGAGATGTGG 1404
Db 15 GGAGGGAGATGTGG 2

RESULT 186
US-08-311-486C-687/c
; Sequence 687, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 533:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-533

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1391 GGAGTGAGATGTGG 1404
Db 15 GGAGGGAGATGTGG 2

RESULT 186
US-08-311-486C-687/c
; Sequence 687, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 533:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-687

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 371 CCTCTGGGAGAGCT 384
Db 15 CCTCAGGAGAGCT 2

RESULT 187
US-08-452-724A-30/c
; Sequence 30, Application US/08452724A
; Patent No. 5830650
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: Walk-Through Mutagenesis
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: 2 Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,724A
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/930,600
; FILING DATE: 05-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/02362
; FILING DATE: 05-APR-1991
```

two

two

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 371 CCTCTGGGAGAGCT 384
Db 15 CCTCAGGAGAGCT 2

RESULT 187
US-08-452-724A-30/c
; Sequence 30, Application US/08452724A
; Patent No. 5830650
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: Walk-Through Mutagenesis
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: 2 Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,724A
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/930,600
; FILING DATE: 05-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/02362
; FILING DATE: 05-APR-1991

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/505,314
;; FILING DATE: 05-APR-1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Brook Esq., David E.
;; REGISTRATION NUMBER: 22,592
;; REFERENCE/DOCKET NUMBER: RC90-01A2
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (617) 861-6240
;; TELEFAX: (617) 861-9540
;; INFORMATION FOR SEQ ID NO: 30:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: unknown
US-08-452-724A-30

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1303 TCCTGTAGATC 1316
||| |||||
DB 14 TCCATGTAGATC 1

RESULT 188
US-08-774-306A-2
; Sequence 2, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-774-306A-2

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCAGGCC 1521
|||||:|||||
DB 2 CAGCCUCCAGGACC 15

RESULT 189
US-08-774-306A-422/c
; Sequence 422, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 422:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-306A-422

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGAGCGCA 883
|||||:|||||
DB 15 ATACGATAGCGCA 2

RESULT 190
US-08-774-306A-423/c
; Sequence 423, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:

;; APPLICANT: Draper, Kenneth G.
;; TITLE OF INVENTION: METHOD AND REAGENT FOR
;; TITLE OF INVENTION: INHIBITING HEPATITIS C
;; TITLE OF INVENTION: VIRUS REPLICATION
;; NUMBER OF SEQUENCES: 497
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/774,306A
;; FILING DATE: December 26, 1996
;; APPLICATION NUMBER: 08/182,968
;; FILING DATE: January 13, 1994
;; APPLICATION NUMBER: 07/882,888
;; FILING DATE: May 14, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 223/227
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 423:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-774-306A-423

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 870 ATACGAGAAGCGGA 883
Db 14 ATACGATAAGCGGA 1
|||||

RESULT 191
US-09-064-156A-2
; Sequence 2, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage

;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/064,156A
;; FILING DATE: April 21, 1998
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/774,306
;; FILING DATE: December 26, 1996
;; APPLICATION NUMBER: 08/182,968
;; FILING DATE: January 13, 1994
;; APPLICATION NUMBER: 07/882,888
;; FILING DATE: May 14, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 234/083
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-09-064-156A-2

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCC 1521
Db 2 CAGCCUCCAGGACC 15
|||||

RESULT 192
US-09-064-156A-422/c
; Sequence 422, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 422:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-422

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGNAGGCGA 883
||||| |||||

Db 15 ATACGATAGGCGA 2

RESULT 193

US-09-064-156A-423/c
Sequence 423, Application US/09064156A
Patent No. 6132966

GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 498
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/064,156A
FILING DATE: April 21, 1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/774,306
FILING DATE: December 26, 1996
APPLICATION NUMBER: 08/192,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 423:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-423

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGNAGGCGA 883
||||| |||||

Db 14 ATACGATAGGCGA 1

RESULT 194

US-09-081-646-126
Sequence 126, Application US/09081646
Patent No. 6333152

GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
Cancer Cells
FILE REFERENCE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
EARLIER FILING DATE: 1997-05-21
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 126
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-126

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 ATGCTCAACACCTC 1114
||||| |||||

Db 2 ATGCTCAACATCTC 15

RESULT 195

US-09-081-646-326
Sequence 326, Application US/09081646
Patent No. 6333152

GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
Cancer Cells
FILE REFERENCE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
EARLIER FILING DATE: 1997-05-21
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 326
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-326

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 923 CACGGGCTGCCTGC 936
||||| |||||

Search completed: September 13, 2005, 10:44:50
Job time : 5 secs

253	20.2	1.2	25	1	US-10-809-189-31758	Sequence 31758, A	c 326	20	1.2	20	1	US-10-380-124-80	Sequence 80, Appl
254	20.2	1.2	25	1	US-10-956-157-271151	Sequence 271151, A	327	20	1.2	20	1	US-10-980-850-17	Sequence 17, Appl
255	20.2	1.2	25	1	US-10-719-956-30750	Sequence 30750, A	328	20	1.2	20	1	US-10-980-850-18	Sequence 18, Appl
256	20.2	1.2	25	1	US-10-719-956-70566	Sequence 70566, A	c 329	20	1.2	20	1	US-10-980-850-33	Sequence 33, Appl
257	20.2	1.2	25	1	US-10-719-956-355802	Sequence 355802, A	330	20	1.2	21	1	US-10-646-331A-28	Sequence 28, Appl
258	20.2	1.2	25	1	US-10-719-956-374027	Sequence 374027, A	331	20	1.2	21	1	US-10-646-436-9	Sequence 9, Appl
259	20.2	1.2	25	1	US-10-719-956-501380	Sequence 501380, A	332	19.4	1.2	21	1	US-09-459-749D-13	Sequence 13, Appl
260	20.2	1.2	25	1	US-10-719-956-517912	Sequence 517912, A	333	19.4	1.2	21	1	US-10-270-871-13	Sequence 13, Appl
261	20.2	1.2	25	1	US-10-719-956-604881	Sequence 604881, A	334	19	1.2	19	1	US-10-646-391A-42	Sequence 42, Appl
262	20.2	1.2	25	1	US-10-719-956-612441	Sequence 612441, A	c 335	19	1.2	19	1	US-10-646-391A-43	Sequence 43, Appl
263	20	1.2	25	1	US-10-380-124-14	Sequence 14, Appl	336	19	1.2	19	1	US-10-646-436-67	Sequence 67, Appl
264	20	1.2	20	1	US-10-380-124-15	Sequence 15, Appl	c 337	19	1.2	19	1	US-10-646-436-68	Sequence 68, Appl
265	20	1.2	20	1	US-10-380-124-16	Sequence 16, Appl	338	19	1.2	19	1	US-10-828-394-16	Sequence 16, Appl
266	20	1.2	20	1	US-10-380-124-17	Sequence 17, Appl	339	19	1.2	19	1	US-10-828-394-17	Sequence 17, Appl
267	20	1.2	20	1	US-10-380-124-18	Sequence 18, Appl	340	19	1.2	19	1	US-10-828-394-18	Sequence 18, Appl
268	20	1.2	20	1	US-10-380-124-19	Sequence 19, Appl	341	19	1.2	19	1	US-10-828-395-16	Sequence 16, Appl
269	20	1.2	20	1	US-10-380-124-20	Sequence 20, Appl	342	19	1.2	19	1	US-10-828-395-17	Sequence 17, Appl
270	20	1.2	20	1	US-10-380-124-21	Sequence 21, Appl	343	19	1.2	19	1	US-10-828-395-18	Sequence 18, Appl
271	20	1.2	20	1	US-10-380-124-22	Sequence 22, Appl	c 344	19	1.2	21	1	US-10-646-391A-29	Sequence 29, Appl
272	20	1.2	20	1	US-10-380-124-23	Sequence 23, Appl	c 345	19	1.2	21	1	US-10-646-436-10	Sequence 10, Appl
273	20	1.2	20	1	US-10-380-124-24	Sequence 24, Appl	346	18	1.1	18	1	US-10-380-124-4	Sequence 4, Appl
274	20	1.2	20	1	US-10-380-124-25	Sequence 25, Appl	c 347	17.8	1.1	21	1	US-09-967-726A-15	Sequence 15, Appl
275	20	1.2	20	1	US-10-380-124-26	Sequence 26, Appl	c 348	17.8	1.1	21	1	US-10-080-794-15	Sequence 15, Appl
276	20	1.2	20	1	US-10-380-124-27	Sequence 27, Appl	349	17.8	1.1	21	1	US-10-751-736-11047	Sequence 11047, A
277	20	1.2	20	1	US-10-380-124-28	Sequence 28, Appl	c 350	16.8	1.0	20	1	US-10-921-868A-37	Sequence 37, Appl
278	20	1.2	20	1	US-10-380-124-29	Sequence 29, Appl	c 351	16.8	1.0	21	1	US-10-786-720-3371	Sequence 3371, Ap
279	20	1.2	20	1	US-10-380-124-30	Sequence 30, Appl	c 352	16.8	1.0	21	1	US-10-786-720-4073	Sequence 4073, Ap
280	20	1.2	20	1	US-10-380-124-31	Sequence 31, Appl	c 353	16.8	1.0	21	1	US-10-786-720-4811	Sequence 4811, Ap
281	20	1.2	20	1	US-10-380-124-32	Sequence 32, Appl	c 354	16.8	1.0	21	1	US-10-751-736-24026	Sequence 24026, A
282	20	1.2	20	1	US-10-380-124-33	Sequence 33, Appl	c 355	16.8	1.0	21	1	US-10-911-318-81	Sequence 81, Appl
283	20	1.2	20	1	US-10-380-124-34	Sequence 34, Appl	c 356	16	1.0	16	1	US-09-294-121A-97	Sequence 97, Appl
284	20	1.2	20	1	US-10-380-124-35	Sequence 35, Appl	c 357	16	1.0	16	1	US-09-899-082A-97	Sequence 97, Appl
285	20	1.2	20	1	US-10-380-124-36	Sequence 36, Appl	c 358	16	1.0	16	1	US-09-899-302-97	Sequence 97, Appl
286	20	1.2	20	1	US-10-380-124-37	Sequence 37, Appl	c 359	16	1.0	16	1	US-09-899-044-97	Sequence 97, Appl
287	20	1.2	20	1	US-10-380-124-38	Sequence 38, Appl	c 360	16	1.0	16	1	US-10-822-711-97	Sequence 97, Appl
288	20	1.2	20	1	US-10-380-124-39	Sequence 39, Appl	c 361	16	1.0	20	1	US-10-160-787-84	Sequence 84, Appl
289	20	1.2	20	1	US-10-380-124-40	Sequence 40, Appl	c 362	16	1.0	20	1	US-10-160-787-137	Sequence 137, Appl
290	20	1.2	20	1	US-10-380-124-41	Sequence 41, Appl	363	15.8	1.0	19	1	US-10-646-391A-24	Sequence 24, Appl
291	20	1.2	20	1	US-10-380-124-42	Sequence 42, Appl	364	15.8	1.0	19	1	US-10-646-391A-26	Sequence 26, Appl
292	20	1.2	20	1	US-10-380-124-43	Sequence 43, Appl	c 365	15.8	1.0	19	1	US-10-646-391A-27	Sequence 27, Appl
293	20	1.2	20	1	US-10-380-124-44	Sequence 44, Appl	c 366	15.8	1.0	19	1	US-10-646-436-7	Sequence 7, Appl
294	20	1.2	20	1	US-10-380-124-45	Sequence 45, Appl	c 367	15.8	1.0	19	1	US-10-646-436-8	Sequence 8, Appl
295	20	1.2	20	1	US-10-380-124-46	Sequence 46, Appl	c 368	15.8	1.0	19	1	US-10-667-271-305	Sequence 305, App
296	20	1.2	20	1	US-10-380-124-47	Sequence 47, Appl	c 369	15.8	1.0	19	1	US-10-667-271-1001	Sequence 1001, Ap
297	20	1.2	20	1	US-10-380-124-48	Sequence 48, Appl	370	15.4	0.9	17	1	US-09-866-108-8666	Sequence 8666, Ap
298	20	1.2	20	1	US-10-380-124-49	Sequence 49, Appl	c 371	15.4	0.9	17	1	US-09-780-533A-170	Sequence 170, App
299	20	1.2	20	1	US-10-380-124-50	Sequence 50, Appl	c 372	15.4	0.9	17	1	US-09-740-332-1542	Sequence 1542, Ap
300	20	1.2	20	1	US-10-380-124-51	Sequence 51, Appl	c 373	15.4	0.9	17	1	US-09-740-332-3013	Sequence 3013, Ap
301	20	1.2	20	1	US-10-380-124-52	Sequence 52, Appl	374	15.4	0.9	17	1	US-09-817-879-1542	Sequence 1542, Ap
302	20	1.2	20	1	US-10-380-124-53	Sequence 53, Appl	c 375	15.4	0.9	17	1	US-09-817-879-3013	Sequence 3013, Ap
303	20	1.2	20	1	US-10-380-124-54	Sequence 54, Appl	376	15.4	0.9	17	1	US-10-669-841-4135	Sequence 4135, Ap
304	20	1.2	20	1	US-10-380-124-55	Sequence 55, Appl	c 377	15.4	0.9	17	1	US-10-669-841-5606	Sequence 5606, Ap
305	20	1.2	20	1	US-10-380-124-56	Sequence 56, Appl	378	15.4	0.9	17	1	US-10-723-361-8666	Sequence 8666, Ap
306	20	1.2	20	1	US-10-380-124-57	Sequence 57, Appl	c 379	15.4	0.9	17	1	US-10-828-394-19	Sequence 19, Appl
307	20	1.2	20	1	US-10-380-124-58	Sequence 58, Appl	c 380	15.4	0.9	17	1	US-10-828-395-19	Sequence 19, Appl
308	20	1.2	20	1	US-10-380-124-59	Sequence 59, Appl	c 381	15	0.9	15	1	US-10-758-451-883	Sequence 883, App
309	20	1.2	20	1	US-10-380-124-60	Sequence 60, Appl	c 382	15	0.9	17	1	US-09-740-332-3014	Sequence 3014, Ap
310	20	1.2	20	1	US-10-380-124-61	Sequence 61, Appl	c 383	15	0.9	17	1	US-09-817-879-3014	Sequence 3014, Ap
311	20	1.2	20	1	US-10-380-124-62	Sequence 62, Appl	c 384	15	0.9	17	1	US-10-669-841-5607	Sequence 5607, Ap
312	20	1.2	20	1	US-10-380-124-63	Sequence 63, Appl	c 385	14.8	0.9	18	1	US-10-497-692-11	Sequence 11, Appl
313	20	1.2	20	1	US-10-380-124-64	Sequence 64, Appl	c 386	14.4	0.9	17	1	US-09-866-108-8352	Sequence 8352, Ap
314	20	1.2	20	1	US-10-380-124-65	Sequence 65, Appl	c 387	14.4	0.9	17	1	US-09-866-108-8353	Sequence 8353, Ap
315	20	1.2	20	1	US-10-380-124-66	Sequence 66, Appl	c 388	14.4	0.9	17	1	US-09-866-108-8665	Sequence 8665, Ap
316	20	1.2	20	1	US-10-380-124-67	Sequence 67, Appl	389	14.4	0.9	17	1	US-09-866-108-8667	Sequence 8667, Ap
317	20	1.2	20	1	US-10-380-124-68	Sequence 68, Appl	c 390	14.4	0.9	17	1	US-09-866-108-10037	Sequence 10037, A
318	20	1.2	20	1	US-10-380-124-69	Sequence 69, Appl	c 391	14.4	0.9	17	1	US-09-866-108-10038	Sequence 10038, A
319	20	1.2	20	1	US-10-380-124-70	Sequence 70, Appl	c 392	14.4	0.9	17	1	US-09-928-412-7	Sequence 7, Appl
320	20	1.2	20	1	US-10-380-124-71	Sequence 71, Appl	c 393	14.4	0.9	17	1	US-09-780-533A-171	Sequence 171, App
321	20	1.2	20	1	US-10-380-124-72	Sequence 72, Appl	c 394	14.4	0.9	17	1	US-09-877-478-1745	Sequence 1745, Ap
322	20	1.2	20	1	US-10-380-124-73	Sequence 73, Appl	c 395	14.4	0.9	17	1	US-09-740-332-1543	Sequence 1543, Ap
323	20	1.2	20	1	US-10-380-124-74	Sequence 74, Appl	396	14.4	0.9	17	1	US-09-817-879-1543	Sequence 1543, Ap
324	20	1.2	20	1	US-10-380-124-75	Sequence 75, Appl	397	14.4	0.9	17	1	US-10-298-255-4	Sequence 4, Appl
325	20	1.2	20	1	US-10-380-124-76	Sequence 76, Appl	c 398	14.4	0.9	17	1	US-10-238-700-2912	Sequence 2912, Ap

C 399	14.4	0.9	1	US-10-339-793-366	Sequence 366, App
C 400	14.4	0.9	17	US-10-342-902-1745	Sequence 1745, App
C 401	14.4	0.9	17	US-10-138-674-8431	Sequence 8431, App
C 402	14.4	0.9	17	US-10-287-949A-8431	Sequence 8431, App
C 403	14.4	0.9	17	US-10-669-841-1745	Sequence 1745, App
C 404	14.4	0.9	17	US-10-669-841-4136	Sequence 4136, App
C 405	14.4	0.9	17	US-10-723-361-8352	Sequence 8352, App
C 406	14.4	0.9	17	US-10-723-361-8353	Sequence 8353, App
C 407	14.4	0.9	17	US-10-723-361-8665	Sequence 8665, App
C 408	14.4	0.9	17	US-10-723-361-8667	Sequence 8667, App
C 409	14.4	0.9	17	US-10-723-361-10037	Sequence 10037, A
C 410	14.4	0.9	17	US-10-723-361-10038	Sequence 10038, A
C 411	14.4	0.9	17	US-10-712-633-3472	Sequence 3472, App
C 412	14.4	0.9	17	US-10-724-270-1591	Sequence 1591, App
C 413	14.4	0.9	17	US-11-016-291-4	Sequence 4, Appli
C 414	14.4	0.9	18	US-09-263-950A-5102	Sequence 1251, App
C 415	14.4	0.9	18	US-10-108-260A-5102	Sequence 5102, App
C 416	14	0.9	14	US-10-758-451-884	Sequence 884, App
C 417	14	0.9	17	US-09-930-423-9	Sequence 9, Appli
C 418	14	0.9	17	US-09-930-423-359	Sequence 359, App
C 419	14	0.9	17	US-09-930-423-360	Sequence 360, App
C 420	14	0.9	17	US-09-740-332-1541	Sequence 1541, App
C 421	14	0.9	17	US-09-745-237A-9	Sequence 9, Appli
C 422	14	0.9	17	US-09-745-237A-359	Sequence 359, App
C 423	14	0.9	17	US-09-745-237A-360	Sequence 360, App
C 424	14	0.9	17	US-09-817-879-1541	Sequence 1541, App
C 425	14	0.9	17	US-10-307-005-9355	Sequence 9355, App
C 426	14	0.9	17	US-10-307-005-956	Sequence 956, App
C 427	14	0.9	17	US-09-866-108-8568	Sequence 8568, App
C 428	13.8	0.8	17	US-09-866-108-8569	Sequence 8569, App
C 429	13.8	0.8	17	US-09-866-108-7355	Sequence 7355, App
C 430	13.8	0.8	17	US-09-866-108-7485	Sequence 7485, App
C 431	13.8	0.8	17	US-09-866-108-8568	Sequence 8568, App
C 432	13.8	0.8	17	US-09-866-108-8569	Sequence 8569, App
C 433	13.8	0.8	17	US-09-866-108-8661	Sequence 8661, App
C 434	13.8	0.8	17	US-09-866-108-8663	Sequence 8663, App
C 435	13.8	0.8	17	US-09-866-108-8664	Sequence 8664, App
C 436	13.8	0.8	17	US-09-866-108-8687	Sequence 8687, App
C 437	13.8	0.8	17	US-09-866-108-9687	Sequence 9687, App
C 438	13.8	0.8	17	US-09-866-108-9688	Sequence 9688, App
C 439	13.8	0.8	17	US-09-866-108-9689	Sequence 9689, App
C 440	13.8	0.8	17	US-09-776-291A-4	Sequence 4, Appli
C 441	13.8	0.8	17	US-09-864-785-115	Sequence 115, App
C 442	13.8	0.8	17	US-09-864-785-117	Sequence 117, App
C 443	13.8	0.8	17	US-09-864-785-213	Sequence 213, App
C 444	13.8	0.8	17	US-09-864-785-215	Sequence 215, App
C 445	13.8	0.8	17	US-09-864-785-336	Sequence 336, App
C 446	13.8	0.8	17	US-09-864-785-1519	Sequence 1519, App
C 447	13.8	0.8	17	US-09-864-785-1520	Sequence 1520, App
C 448	13.8	0.8	17	US-09-864-785-20326	Sequence 2036, App
C 449	13.8	0.8	17	US-09-961-077-687	Sequence 687, App
C 450	13.8	0.8	17	US-09-780-533A-1053	Sequence 1053, App
C 451	13.8	0.8	17	US-09-780-533A-1885	Sequence 1885, App
C 452	13.8	0.8	17	US-09-093-972C-874	Sequence 874, App
C 453	13.8	0.8	17	US-09-093-972C-944	Sequence 944, App
C 454	13.8	0.8	17	US-09-930-423-57	Sequence 57, Appli
C 455	13.8	0.8	17	US-09-827-395A-880	Sequence 880, App
C 456	13.8	0.8	17	US-09-740-332-632	

RESULT 1

RESULT 2
US-10-717-597-1315
; Sequence 1315, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:

Query Match	1.5%;	Score 25;	DB 1;	Length 25;
Best Local Similarity	100.0%;	Pred. No. 72;		
		Wm. matches	0.	Indels
			0.	Gaps
				0.

; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1315
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1315

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1177 AAGGCGAAGACCACTACTCTGCG 1201
|||||
DB 1 AAGGCGAAGACCACTACTCTGCG 25

RESULT 3
US-10-717-597-1316
; Sequence 1316, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1316
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1316

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1196 TCTGCGGGTCACCAAGGTGGCTTCC 1220
|||||
DB 1 TCTGCGGGTCACCAAGGTGGCTTCC 25

RESULT 4
US-10-717-597-1317
; Sequence 1317, Application US/10717597
; Publication No. US20040110221A1

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1317
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1317

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1256 TGAGTGGTGGTGAAGCTCTTTGAC 1280
|||||
DB 1 TGAGTGGTGGTGAAGCTCTTTGAC 25

RESULT 5
US-10-717-597-1318
; Sequence 1318, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1318
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1318

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1262 GGTCGTGAAGCTCTTTGACTCTGAT 1286
|||||
DB 1 GGTCGTGAAGCTCTTTGACTCTGAT 25

RESULT 6
US-10-717-597-1319
; Sequence 1319, Application US/10717597

```
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1319
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1319

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1268 GAAGCTCTTTGACTCTGATCCCATC 1292
      |||||
Db 1 GAAGCTCTTTGACTCTGATCCCATC 25
```

```
RESULT 7
US-10-717-597-1320
; Sequence 1320, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1320
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1320

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1274 CTTTGACTCTGATCCCATCCTGTG 1298
      |||||
Db 1 CTTTGACTCTGATCCCATCCTGTG 25
```

```
RESULT 8
US-10-717-597-1321
```

```
; Sequence 1321, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1321
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1321

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1397 AGATGGGATGTGCTTTGACCT 1421
      |||||
Db 1 AGATGGGATGTGCTTTGACCT 25
```

```
RESULT 9
US-10-717-597-1322
; Sequence 1322, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1322
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1322

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1470 CCAGAGAGAGCTCTGCACGTCACCA 1494
      |||||
Db 1 CCAGAGAGAGCTCTGCACGTCACCA 25
```

```
RESULT 10
```

US-10-717-597-1323
; Sequence 1323, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1323
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1323

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72; Indels 0; Gaps 0;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1474 AGAGAGCTCTGCACGTCACCAAGTA 1498
|||||
DB 1 AGAGAGCTCTGCACGTCACCAAGTA 25

RESULT 11
US-10-717-597-1324
; Sequence 1324, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1324
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1324

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72; Indels 0; Gaps 0;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1480 CTCTGCACGTCACCAAGTAACCAAG 1504
|||||
DB 1 CTCTGCACGTCACCAAGTAACCAAG 25

RESULT 12
US-10-717-597-1325
; Sequence 1325, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1325
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1325

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72; Indels 0; Gaps 0;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1550 GGATCCTGCACTCTAACACTCGACT 1574
|||||
DB 1 GGATCCTGCACTCTAACACTCGACT 25

RESULT 13
US-10-717-597-1326
; Sequence 1326, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1326
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1326

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72; Indels 0; Gaps 0;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1556 TGCACCTCTAACACTCGACTCTGCTG 1580
|||||
DB 1 TGCACCTCTAACACTCGACTCTGCTG 25

```
RESULT 14
US-10-717-597-1327
; Sequence 1327, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dornier, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1327
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1327

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1562 CTAACACTCGACTCTGCTGCTCATG 1586
Db 1 CTAACACTCGACTCTGCTGCTCATG 25

RESULT 15
US-10-717-597-1328
; Sequence 1328, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dornier, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1328

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1563 TAAACACTCGACTCTGCTGCTCATGG 1587
Db 1 TAAACACTCGACTCTGCTGCTCATGG 25
```

```
RESULT 16
US-10-717-597-1329
; Sequence 1329, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dornier, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1329
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1329

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1564 AACACTCGACTCTGCTGCTCATGG 1588
Db 1 AACACTCGACTCTGCTGCTCATGG 25

RESULT 17
US-10-956-157-25933
; Sequence 25933, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25933
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25933

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 494 CTTCTACTTCTGGATGATGGTGAC 518
Db 1 CTTCTACTTCTGGATGATGGTGAC 25

RESULT 18
US-10-956-157-25934
; Sequence 25934, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25934
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25934

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 493 CTTCTACTTCTGGATGAATGGTGA 517
      |||||||||||||||||||||||||
Db 1 CTTCTACTTCTGGATGAATGGTGA 25

RESULT 19
US-10-956-157-25935
; Sequence 25935, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25935
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25935

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 493 TTTCTACTTCTGGATGAATGGTGA 519
      |||||||||||||||||||||||||
Db 1 TTTCTACTTCTGGATGAATGGTGA 25

RESULT 20
US-10-956-157-25936
; Sequence 25936, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25936
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25936
```

```
Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 300 CTAATGAGACCGAGGAATCAGAGA 324
      |||||||||||||||||||||||||
Db 1 CTAATGAGACCGAGGAATCAGAGA 25

RESULT 21
US-10-956-157-25937
; Sequence 25937, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25937
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25937

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 301 TAAATGAGACCGAGGAATCAGAGAC 325
      |||||||||||||||||||||||||
Db 1 TAAATGAGACCGAGGAATCAGAGAC 25

RESULT 22
US-10-956-157-25938
; Sequence 25938, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25938
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25938

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 GAAGAAGAAAGAGGATGCCCTAAAT 305
      |||||||||||||||||||||||||
Db 1 GAAGAAGAAAGAGGATGCCCTAAAT 25

RESULT 23
US-10-956-157-25939
; Sequence 25939, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

Tue Sep 13 10:53:21 2005

```
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25939
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25939

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 282 AAGAAGAGGATGCCCTAAATG 306
    |||||||
Db 1 AAGAAGAGGATGCCCTAAATG 25

RESULT 24
US-10-956-157-25940
; Sequence 25940, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25940
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25940

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 284 GAAGAAGAGGATGCCCTAAATG 308
    |||||||
Db 1 GAAGAAGAGGATGCCCTAAATG 25

RESULT 25
US-10-956-157-25941
; Sequence 25941, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25941
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25941

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 284 GAAGAAGAGGATGCCCTAAATG 308
    |||||||
Db 1 GAAGAAGAGGATGCCCTAAATG 25
```

```
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 AAGAAGAGGATGCCCTAAATG 309
    |||||||
Db 1 AAGAAGAGGATGCCCTAAATG 25

RESULT 26
US-10-956-157-25942
; Sequence 25942, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25942
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25942

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 AGAAGAAAGAGGATGCCCTAAATGA 307
    |||||||
Db 1 AGAAGAAAGAGGATGCCCTAAATGA 25

RESULT 27
US-10-956-157-25943
; Sequence 25943, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25943
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25943

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAAGAGGATGCCCTAAA 304
    |||||||
Db 1 AGAAGAAAGAGGATGCCCTAAA 25

RESULT 28
US-10-956-157-25944
; Sequence 25944, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25944
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25944

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      279 AGAAGAAGAAAGAGATGCCCTAA 303
      |||||||
DB      1 AAGAAGAAGAAAGAGATGCCCTAA 25

RESULT 29
US-10-956-157-25945
; Sequence 25945, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25945
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25945

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      492 CCCTTCTACTTCTGGATGAATGGTG 516
      |||||||
DB      1 CCCTTCTACTTCTGGATGAATGGTG 25

RESULT 30
US-10-956-157-25946
; Sequence 25946, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25946
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25946

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      492 CCCTTCTACTTCTGGATGAATGGTG 516
      |||||||
DB      1 CCCTTCTACTTCTGGATGAATGGTG 25

RESULT 31
US-10-956-157-25947
; Sequence 25947, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25947
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25947

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      496 TCTACTTCTGGATGAATGGTGACCG 520
      |||||||
DB      1 TCTACTTCTGGATGAATGGTGACCG 25

RESULT 32
US-10-956-157-25948
; Sequence 25948, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25948
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25948

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      278 CAAGAAGAAGAAAGAGATGCCCTA 302
      |||||||
DB      1 CAAGAAGAAGAAAGAGATGCCCTA 25

RESULT 33
US-10-956-157-25949
; Sequence 25949, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```


; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25954
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25954

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1067 ATACACGAGCTGCTAAAGTCTCTAC 1091
|||||
Db 1 ATACACGAGCTGCTAAAGTCTCTAC 25

RESULT 39
US-10-956-157-25955
; Sequence 25955, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25955
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25955

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 398 GAAACAGACCTGCGATGAAGTCTTAC 422
|||||
Db 1 GAAACAGACCTGCGATGAAGTCTTAC 25

RESULT 40
US-10-956-157-25956
; Sequence 25956, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25956
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25956

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 304 ATGAGACCGGGAATCAGAGACAAA 328
|||||
Db 1 ATGAGACCGGGAATCAGAGACAAA 25

RESULT 41
US-10-956-157-122144
; Sequence 122144, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 122144
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-122144

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 850 AGCACCCGCCAACAGAATTCATACG 874
|||||
Db 1 AGCACCCGCCAACAGAATTCATACG 25

RESULT 42
US-10-956-157-127897
; Sequence 127897, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 127897
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-127897

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 411 ATGAAGTTCTACGACGCGTCTGCA 435
|||||
Db 1 ATGAAGTTCTACGACGCGTCTGCA 25

RESULT 43
US-10-956-157-131009
; Sequence 131009, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 131009
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-131009

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 ATGCTGGATGTCATGCAGGACCACT 595
|||||
Db 1 ATGCTGGATGTCATGCAGGACCACT 25

RESULT 44

US-10-956-157-134947
; Sequence 134947, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 134947
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-134947

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 334 AGGAGCTCCCGAGGAGTGTCGAATCA 358
|||||
Db 1 AGGAGCTCCCGAGGAGTGTCGAATCA 25

RESULT 45

US-10-956-157-135244
; Sequence 135244, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 135244
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-135244

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 292 AGGATGCCCTAAATGACGACGAGGA 316

Db 1 AGGATGCCCTAAATGACGACGAGGA 25
|||||

RESULT 46

US-10-956-157-139926
; Sequence 139926, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 139926
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-139926

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCAGGGAATCAGAGACAAAGCT 331
|||||
Db 1 AGACCAGGGAATCAGAGACAAAGCT 25

RESULT 47

US-10-956-157-140752
; Sequence 140752, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 140752
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-140752

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGAAGCGGACGATGACCGGACTGTG 899
|||||
Db 1 AGAAGCGGACGATGACCGGACTGTG 25

RESULT 48

US-10-956-157-141327
; Sequence 141327, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 141327
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-141327

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1299 ACGGTCCCTGTAGAAAGTCTCCAGGA 1323
|||||

Db 1 ACGGTCCCTGTAGAAAGTCTCCAGGA 25

RESULT 49

US-10-956-157-146594
; Sequence 146594, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146594
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-146594

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 889 ACCGGACTGTGTGCCGGGAGATCCG 913
|||||

Db 1 ACCGGACTGTGTGCCGGGAGATCCG 25

RESULT 50

US-10-956-157-146923
; Sequence 146923, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146923
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-146923

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 544 ACCGGCAGCAGCAGCATGTCTGGA 568
|||||

Db 1 ACCGGCAGCAGCAGCATGTCTGGA 25

RESULT 51

US-10-956-157-156812
; Sequence 156812, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 156812
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-156812

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1379 AAAGCACCAGGAGGTGAGATGTG 1403
|||||

Db 1 AAAGCACCAGGAGGTGAGATGTG 25

RESULT 52

US-10-956-157-158656
; Sequence 158656, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158656
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-158656

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 AAGTCCTACCAAGTGAAGATGCTCA 1107
|||||

Db 1 AAGTCCTACCAAGTGAAGATGCTCA 25

RESULT 53

US-10-956-157-159440
; Sequence 159440, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 159440
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-159440

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1071 AACGAGCTGCTAAAGTCTTACCAGT 1095
|||||
Db 1 AACGAGCTGCTAAAGTCTTACCAGT 25

RESULT 54
US-10-956-157-168291
; Sequence 168291, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168291
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-168291

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 182 AATTCAAAATGCTCTCAACGGGGTG 206
|||||
Db 1 AATTCAAAATGCTCTCAACGGGGTG 25

RESULT 55
US-10-956-157-172467
; Sequence 172467, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 172467
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-172467

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1140 CAGTTTAACGGGGTGTCGGCTGG 1164
|||||
Db 1 CAGTTTAACGGGGTGTCGGCTGG 25

RESULT 56

US-10-956-157-174696
; Sequence 174696, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 174696
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-174696

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 462 CAGCTTGAGGAGTTCCTGAACACAGA 486
|||||
Db 1 CAGCTTGAGGAGTTCCTGAACACAGA 25

RESULT 57

US-10-956-157-174708
; Sequence 174708, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 174708
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-174708

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 780 CAGCCCTTCCTTGAGATGATACACG 804
|||||
Db 1 CAGCCCTTCCTTGAGATGATACACG 25

RESULT 58

US-10-956-157-174902
; Sequence 174902, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 174902
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-174902

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1441 CAGCTCCCCCAGAGTACTGCAG 1465
|||
Db 1 CAGCTCCCCCAGAGTACTGCAG 25

RESULT 59

US-10-956-157-176821
; Sequence 176821, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 176821

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-176821

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 948 CAGTGTGACAAGTCCGGGAGATCT 972
|||
Db 1 CAGTGTGACAAGTCCGGGAGATCT 25

RESULT 60

US-10-956-157-178550
; Sequence 178550, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 178550

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-178550

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 602 CATCATAGACGAGCTCTCCAGGAC 626
|||
Db 1 CATCATAGACGAGCTCTCCAGGAC 25

RESULT 61

US-10-956-157-178867
; Sequence 178867, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 178867

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-178867

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1289 CATCACTGTGACGGTCCCTGTAGAA 1313
|||
Db 1 CATCACTGTGACGGTCCCTGTAGAA 25

RESULT 62

US-10-956-157-186901
; Sequence 186901, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 186901

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-186901

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1602 CTCCTGCATGCAACTTAATCAATAA 1626
|||
Db 1 CTCCTGCATGCAACTTAATCAATAA 25

RESULT 63

US-10-956-157-186902
; Sequence 186902, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

```
; SEQ ID NO 186902
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186902

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1602 CTCCTGCATGCAACTAATTCATAA 1626
      |||||
Db 1 CTCCTGCATGCAACTAATTCATAA 25

RESULT 64
US-10-956-157-186903
; Sequence 186903, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186903
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186903

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1602 CTCCTGCATGCAACTAATTCATAA 1626
      |||||
Db 1 CTCCTGCATGCAACTAATTCATAA 25

RESULT 65
US-10-956-157-186908
; Sequence 186908, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186908
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186908

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1482 CTCACGTCACCAAGTAACGAGCC 1506
      |||||
Db 1 CTCGACGTCACCAAGTAACGAGCC 25
```

```
RESULT 66
US-10-956-157-186914
; Sequence 186914, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186914
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186914

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 CTCACGTCGCTGAGAGGTTGACCA 1062
      |||||
Db 1 CTCACGTCGCTGAGAGGTTGACCA 25

RESULT 67
US-10-956-157-188008
; Sequence 188008, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188008
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-188008

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 78 CTGCTGCTGACCTGGGAGAGTGGGC 102
      |||||
Db 1 CTGCTGCTGACCTGGGAGAGTGGGC 25

RESULT 68
US-10-956-157-188038
; Sequence 188038, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188038
```

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-188038

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 407 CTGCATGAAGTTCTACGACGGTC 431

Db 1 CTGCATGAAGTTCTACGACGGTC 25

RESULT 69

US-10-956-157-189641

; Sequence 189641, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 189641

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-189641

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 976 CTGTGGACTGTTCCACCAACACC 1000

Db 1 CTGTGGACTGTTCCACCAACACC 25

RESULT 70

US-10-956-157-191487

; Sequence 191487, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 191487

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-191487

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 884 CGATGACCGGACTGTGTCGGGGAG 908

Db 1 CGATGACCGGACTGTGTCGGGGAG 25

RESULT 71

US-10-956-157-193107

; Sequence 193107, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 193107

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-193107

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 490 CGCCCTTCTACTTCTGGATGATGG 514

Db 1 CGCCCTTCTACTTCTGGATGATGG 25

RESULT 72

US-10-956-157-193726

; Sequence 193726, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 193726

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-193726

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 341 CCCAGGAGTGTGCAATGAGACCATG 365

Db 1 CCCAGGAGTGTGCAATGAGACCATG 25

RESULT 73

US-10-956-157-194937

; Sequence 194937, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 194937

; LENGTH: 25

```
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-194937

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 390 CCCTGCTGAAACAGACCTGCATGA 414
Db 1 CCCTGCTGAAACAGACCTGCATGA 25

RESULT 74
US-10-956-157-195328
; Sequence 195328, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-195328

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 854 CCGCCCAACAGAAATTCATACGAGAA 878
Db 1 CCGCCCAACAGAAATTCATACGAGAA 25

RESULT 75
US-10-956-157-195368
; Sequence 195368, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195368
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-195368

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1467 CCCCCAGAGAGCTCTGCACGTCA 1491
Db 1 CCCCCAGAGAGCTCTGCACGTCA 25

RESULT 76
US-10-956-157-196424
```

```
; Sequence 196424, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 196424
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-196424

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 590 CCGCGGCTCCAGCATCATAGACGAG 614
Db 1 CCGCGGCTCCAGCATCATAGACGAG 25

RESULT 77
US-10-956-157-199713
; Sequence 199713, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 199713
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-199713

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 106 TCCTGGGGGACACGCGTCTCAGA 130
Db 1 TCCTGGGGGACACGCGTCTCAGA 25

RESULT 78
US-10-956-157-206442
; Sequence 206442, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 206442
; LENGTH: 25
; TYPE: DNA
```



```
; ORGANISM: Probe Sequence
US-10-956-157-206442

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 782 GCCCTTCCTCGAGTATACACGAG 806
      |||||
Db 1 GCCCTTCCTCGAGTATACACGAG 25

RESULT 79
US-10-956-157-208499
; Sequence 208499, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208499
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-208499

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1121 GCTGAGCAGCTGAACGACGAGTTT 1145
      |||||
Db 1 GCTGAGCAGCTGAACGACGAGTTT 25

RESULT 80
US-10-956-157-212934
; Sequence 212934, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212934
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212934

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1364 GCAGGAATACCGCAAAAGCACCGG 1388
      |||||
Db 1 GCAGGAATACCGCAAAAGCACCGG 25

RESULT 81
US-10-956-157-215054
; Sequence 215054, Application US/10956157
```

```
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 215054
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-215054

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 GCAGACGCACATGCTGGATGTCATG 575
      |||||
Db 1 GCAGACGCACATGCTGGATGTCATG 25

RESULT 82
US-10-956-157-216983
; Sequence 216983, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216983
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216983

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 247 GCAGACACTGCTCAGCAACCTAGA 271
      |||||
Db 1 GCAGACACTGCTCAGCAACCTAGA 25

RESULT 83
US-10-956-157-218349
; Sequence 218349, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218349
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
```

US-10-956-157-218349

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1596 GAATTGCTCTCGCATCAACTAATT 1620
|||||
Db 1 GAATTGCTCTCGCATCAACTAATT 25

RESULT 84

US-10-956-157-218350
; Sequence 218350, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218350
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-218350

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1596 GAATTGCTCTCGCATCAACTAATT 1620
|||||
Db 1 GAATTGCTCTCGCATCAACTAATT 25

RESULT 85

US-10-956-157-218351
; Sequence 218351, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218351
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-218351

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1596 GAATTGCTCTCGCATCAACTAATT 1620
|||||
Db 1 GAATTGCTCTCGCATCAACTAATT 25

RESULT 86

US-10-956-157-219734
; Sequence 219734, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 219734
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-219734

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1311 GAAGTCTCCAGGAAGAACCTAAAT 1335
|||||
Db 1 GAAGTCTCCAGGAAGAACCTAAAT 25

RESULT 87

US-10-956-157-220245
; Sequence 220245, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 220245
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-220245

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 941 GAAGGACCAAGTGACAAAGTGCCGG 965
|||||
Db 1 GAAGGACCAAGTGACAAAGTGCCGG 25

RESULT 88

US-10-956-157-221279
; Sequence 221279, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 221279
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-221279

```
Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

Qy 1588 GAAGAACAGAAATGCTCTGCGATGC 1612
Db 1 GAAGAACAGAAATGCTCTGCGATGC 25

RESULT 89
US-10-956-157-221280
; Sequence 221280, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 221280
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-221280

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

Qy 1588 GAAGAACAGAAATGCTCTGCGATGC 1612
Db 1 GAAGAACAGAAATGCTCTGCGATGC 25

RESULT 90
US-10-956-157-222407
; Sequence 222407, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 222407
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-222407

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

Qy 1325 GAACCCAAATTTATGGAGACCGTG 1349
Db 1 GAACCCAAATTTATGGAGACCGTG 25

RESULT 91
US-10-956-157-225352
; Sequence 225352, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 225352
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-225352

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

Qy 1355 GAAAGCGCTGCAGGAATACCGCAA 1379
Db 1 GAAAGCGCTGCAGGAATACCGCAA 25

RESULT 92
US-10-956-157-228789
; Sequence 228789, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228789
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228789

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

Qy 1571 GACTCTGCTGCTCATGGAGAACA 1595
Db 1 GACTCTGCTGCTCATGGAGAACA 25

RESULT 93
US-10-956-157-229312
; Sequence 229312, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 229312
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-229312
```

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 119 GACGGTCTCAGACAATGAGCTCCAG 143
|||||
Db 1 GACGGTCTCAGACAATGAGCTCCAG 25

RESULT 94

US-10-956-157-230136
; Sequence 230136, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 230136
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-230136

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 404 GACCTGCATGAAGTCTACGCACGC 428
|||||
Db 1 GACCTGCATGAAGTCTACGCACGC 25

RESULT 95

US-10-956-157-230317
; Sequence 230317, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 230317
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-230317

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1185 GACCAGTACTATCTGCGGGTCACCA 1209
|||||
Db 1 GACCAGTACTATCTGCGGGTCACCA 25

RESULT 96

US-10-956-157-231573
; Sequence 231573, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 231573
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-231573

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 135 GAGCTCCAGGAATGTCCAATCAGG 159
|||||
Db 1 GAGCTCCAGGAATGTCCAATCAGG 25

RESULT 97

US-10-956-157-231724
; Sequence 231724, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 231724
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-231724

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1074 GAGCTGCTAAAGTCCTACCAGTGGG 1098
|||||
Db 1 GAGCTGCTAAAGTCCTACCAGTGGG 25

RESULT 98

US-10-956-157-231783
; Sequence 231783, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 231783
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-231783

Query Match 1.5%; Score 25; DB 1; Length 25;

```
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1137 GAGCAGTTTAACTGGGTGTCGCCGC 1161
|||||
Db 1 GAGCAGTTTAACTGGGTGTCGCCGC 25

RESULT 99
US-10-956-157-232704
; Sequence 232704, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 232704
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-232704

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1341 GAGACCGTGGCGGAGAAAGCGCTGC 1365
|||||
Db 1 GAGACCGTGGCGGAGAAAGCGCTGC 25

RESULT 100
US-10-956-157-233030
; Sequence 233030, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233030
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233030

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 GAGACAAAGCTGAAGAGCTCCAG 345
|||||
Db 1 GAGACAAAGCTGAAGAGCTCCAG 25

RESULT 101
US-10-956-157-233762
; Sequence 233762, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233762
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233762

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 966 GAGATCTTGTCTGTGGACTGTTCGA 990
|||||
Db 1 GAGATCTTGTCTGTGGACTGTTCGA 25

RESULT 102
US-10-956-157-235882
; Sequence 235882, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 235882
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-235882

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 GAGGAGTTCTCTGAACCGAGCTCGC 492
|||||
Db 1 GAGGAGTTCTCTGAACCGAGCTCGC 25

RESULT 103
US-10-956-157-236817
; Sequence 236817, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236817
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-236817

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 GAGGAGTTCTCTGAACCGAGCTCGC 492
|||||
Db 1 GAGGAGTTCTCTGAACCGAGCTCGC 25
```

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy 43	GAGGCATGATGAGACTCTGCTGCT 67
Db 1	GAGGCATGATGAGACTCTGCTGCT 25
RESULT 104	
US-10-956-157-237638	
; Sequence 237638, Application US/10956157	
; Publication No. US20050118625A1	
; GENERAL INFORMATION:	
; APPLICANT: Wyeth	
; APPLICANT: Mounts, William	
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH	
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES	
; FILE REFERENCE: 031896-043000 (AM 101081)	
; CURRENT APPLICATION NUMBER: US/10/956,157	
; CURRENT FILING DATE: 2004-10-04	
; NUMBER OF SEQ ID NOS: 319805	
; SOFTWARE: PatentIn version 3.2	
; SEQ ID NO 237638	
; LENGTH: 25	
; TYPE: DNA	
; ORGANISM: Probe Sequence	
US-10-956-157-237638	
Query Match 1.5%; Score 25; DB 1; Length 25;	
Best Local Similarity 100.0%; Pred. No. 72;	
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy 794	GATGATACACGAGGCTCAGCAGGCC 818
Db 1	GATGATACACGAGGCTCAGCAGGCC 25
RESULT 105	
US-10-956-157-238337	
; Sequence 238337, Application US/10956157	
; Publication No. US20050118625A1	
; GENERAL INFORMATION:	
; APPLICANT: Wyeth	
; APPLICANT: Mounts, William	
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH	
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES	
; FILE REFERENCE: 031896-043000 (AM 101081)	
; CURRENT APPLICATION NUMBER: US/10/956,157	
; CURRENT FILING DATE: 2004-10-04	
; NUMBER OF SEQ ID NOS: 319805	
; SOFTWARE: PatentIn version 3.2	
; SEQ ID NO 238337	
; LENGTH: 25	
; TYPE: DNA	
; ORGANISM: Probe Sequence	
US-10-956-157-238337	
Query Match 1.5%; Score 25; DB 1; Length 25;	
Best Local Similarity 100.0%; Pred. No. 72;	
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy 506	GATGAATGGTGACCGCATCGACTCC 530
Db 1	GATGAATGGTGACCGCATCGACTCC 25
RESULT 106	
US-10-956-157-243092	
; Sequence 243092, Application US/10956157	
; Publication No. US20050118625A1	
; GENERAL INFORMATION:	
; APPLICANT: Wyeth	
; APPLICANT: Mounts, William	
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH	

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES	
; FILE REFERENCE: 031896-043000 (AM 101081)	
; CURRENT APPLICATION NUMBER: US/10/956,157	
; CURRENT FILING DATE: 2004-10-04	
; NUMBER OF SEQ ID NOS: 319805	
; SOFTWARE: PatentIn version 3.2	
; SEQ ID NO 243092	
; LENGTH: 25	
; TYPE: DNA	
; ORGANISM: Probe Sequence	
US-10-956-157-243092	
Query Match 1.5%; Score 25; DB 1; Length 25;	
Best Local Similarity 100.0%; Pred. No. 72;	
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy 416	GTTCACGACGCGTCTGCAGAAGT 440
Db 1	GTTCACGACGCGTCTGCAGAAGT 25
RESULT 107	
US-10-956-157-252760	
; Sequence 252760, Application US/10956157	
; Publication No. US20050118625A1	
; GENERAL INFORMATION:	
; APPLICANT: Wyeth	
; APPLICANT: Mounts, William	
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH	
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES	
; FILE REFERENCE: 031896-043000 (AM 101081)	
; CURRENT APPLICATION NUMBER: US/10/956,157	
; CURRENT FILING DATE: 2004-10-04	
; NUMBER OF SEQ ID NOS: 319805	
; SOFTWARE: PatentIn version 3.2	
; SEQ ID NO 252760	
; LENGTH: 25	
; TYPE: DNA	
; ORGANISM: Probe Sequence	
US-10-956-157-252760	
Query Match 1.5%; Score 25; DB 1; Length 25;	
Best Local Similarity 100.0%; Pred. No. 72;	
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy 1044	GTGCTGAGAGGTTGACCAGAAAT 1068
Db 1	GTGCTGAGAGGTTGACCAGAAAT 25
RESULT 108	
US-10-956-157-253138	
; Sequence 253138, Application US/10956157	
; Publication No. US20050118625A1	
; GENERAL INFORMATION:	
; APPLICANT: Wyeth	
; APPLICANT: Mounts, William	
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH	
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES	
; FILE REFERENCE: 031896-043000 (AM 101081)	
; CURRENT APPLICATION NUMBER: US/10/956,157	
; CURRENT FILING DATE: 2004-10-04	
; NUMBER OF SEQ ID NOS: 319805	
; SOFTWARE: PatentIn version 3.2	
; SEQ ID NO 253138	
; LENGTH: 25	
; TYPE: DNA	
; ORGANISM: Probe Sequence	
US-10-956-157-253138	
Query Match 1.5%; Score 25; DB 1; Length 25;	
Best Local Similarity 100.0%; Pred. No. 72;	
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	

```
QY 596 GTCCAGCATCATAGACGAGCTCTTC 620
|||||
Db 1 GTCCAGCATCATAGACGAGCTCTTC 25

RESULT 109
US-10-956-157-255424
; Sequence 255424, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 255424
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-255424

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1394 GTGAGATGTGGATGTTGCTTTTGCA 1418
|||||
Db 1 GTGAGATGTGGATGTTGCTTTTGCA 25

RESULT 110
US-10-956-157-255957
; Sequence 255957, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 255957
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-255957

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 383 GTGTAAGCCCTCGCTGAACAGACC 407
|||||
Db 1 GTGTAAGCCCTCGCTGAACAGACC 25

RESULT 111
US-10-956-157-256203
; Sequence 256203, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
```

```
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 256203
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-256203

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 348 GTGTGCAATGAGACCATGATGCCCC 372
|||||
Db 1 GTGTGCAATGAGACCATGATGCCCC 25

RESULT 112
US-10-956-157-261789
; Sequence 261789, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 261789
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-261789

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1259 GGTGTCGTGAGCTCTTTGACTCT 1283
|||||
Db 1 GGTGTCGTGAGCTCTTTGACTCT 25

RESULT 113
US-10-956-157-266662
; Sequence 266662, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266662
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-266662

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 566 GGATGTCATGCAGGACCACTTCAGC 590
|||||
Db 1 GGATGTCATGCAGGACCACTTCAGC 25

RESULT 114

US-10-956-157-268124
; Sequence 268124, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268124
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-268124

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 GGAGAGTGGGCGAGTCTCTGGGGGAC 116
|||||
Db 1 GGAGAGTGGGCGAGTCTCTGGGGGAC 25

RESULT 115

US-10-956-157-269972
; Sequence 269972, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 269972
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-269972

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1163 GGCAAACTCTACGCAAGCGGAAGAC 1187
|||||
Db 1 GGCAAACTCTACGCAAGCGGAAGAC 25

RESULT 116

US-10-956-157-273702
; Sequence 273702, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 273702
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-273702

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 879 GGGACGATGACCGGACTGTGTGCC 903
|||||
Db 1 GGGACGATGACCGGACTGTGTGCC 25

RESULT 117

US-10-956-157-274079
; Sequence 274079, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274079
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274079

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 927 GGCTGCTCGGATGAAGGACCACT 951
|||||
Db 1 GGCTGCTCGGATGAAGGACCACT 25

RESULT 118

US-10-956-157-274264
; Sequence 274264, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274264
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274264

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1179 GGCGAAGACCACTACTATCTGCGGG 1203

Db 1 GCGGAGACCAAGTACTATCTGCGG 25
|||||

RESULT 119

US-10-956-157-274647
; Sequence 274647, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274647
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274647

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCGGTGCAAGACTCCAGAAATTGGA 44
|||||

Db 1 GCGGTGCAAGACTCCAGAAATTGGA 25

RESULT 120

US-10-956-157-279222
; Sequence 279222, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 279222
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-279222

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1295 TGTGACGGTCCCTGTAGAAGTCTCC 1319
|||||

Db 1 TGTGACGGTCCCTGTAGAAGTCTCC 25

RESULT 121

US-10-956-157-281215
; Sequence 281215, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 281215
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-281215

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 150 TCCAATCAGGAAGTAAGTACGTCA 174
|||||

Db 1 TCCAATCAGGAAGTAAGTACGTCA 25

RESULT 122

US-10-956-157-285427
; Sequence 285427, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285427
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-285427

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 52 TGAAGACTCTGCTGCTGTTTGTGGG 76
|||||

Db 1 TGAAGACTCTGCTGCTGTTTGTGGG 25

RESULT 123

US-10-956-157-285561
; Sequence 285561, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285561
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-285561

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 351 TCGAATGAGACCATGATGGCCCTCT 375
|||||

```
Db      1  TGCATGAGACCATGATGCCCTCT 25

RESULT 124
US-10-956-157-285688
; Sequence 285688, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285688
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-285688

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      256  TGCTCAGCAACTAGAGAAGCCAA 280
|||||
Db      1  TGCTCAGCAACTAGAGAAGCCAA 25

RESULT 125
US-10-956-157-287832
; Sequence 287832, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287832
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287832

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      960  TGCCGGGAGATCTTGTCTGTGGACT 984
|||||
Db      1  TGCCGGGAGATCTTGTCTGTGGACT 25

RESULT 126
US-10-956-157-291738
; Sequence 291738, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
```

```
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291738
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-291738

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1002  TCCAGCGTAAGCTGCGCGCGGAGC 1026
|||||
Db      1  TCCAGCGTAAGCTGCGCGCGGAGC 25

RESULT 127
US-10-956-157-292100
; Sequence 292100, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 292100
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-292100

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1264  TCGTGAAGCTCTTTGACTCTGATCC 1288
|||||
Db      1  TCGTGAAGCTCTTTGACTCTGATCC 25

RESULT 128
US-10-956-157-292272
; Sequence 292272, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 292272
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-292272

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1569  TCGACTCTGCTGCTCATGGGAAGAA 1593
|||||
Db      1  TCGACTCTGCTGCTCATGGGAAGAA 25
```

```
RESULT 129
US-10-956-157-297166
; Sequence 297166, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297166
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297166

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 TCACGCAAGGCGAAGACCACTACTA 1195
          |||||
DB      1 TCACGCAAGGCGAAGACCACTACTA 25

RESULT 130
US-10-956-157-302171
; Sequence 302171, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 302171
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-302171

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      871 TACGAGAAGCGCACCATGACCGGAC 895
          |||||
DB      1 TACGAGAAGCGCACCATGACCGGAC 25

RESULT 131
US-10-956-157-316681
; Sequence 316681, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 316681
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-316681

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1244 TTCGGGTGTCACTGAGGTGTCGTG 1268
          |||||
DB      1 TTCGGGTGTCACTGAGGTGTCGTG 25

RESULT 132
US-10-956-157-317598
; Sequence 317598, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 317598
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-317598

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1240 TTCCTTCGGGTGTCACTGAGGTGCT 1264
          |||||
DB      1 TTCCTTCGGGTGTCACTGAGGTGCT 25

RESULT 133
US-10-956-157-287991
; Sequence 287991, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287991
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287991

Query Match      1.5%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 GCCCTGACCGAGCGGTGCAAGA 31
          |||||
DB      2 GCCCTGACCGAGCGGTGCAAGA 25
```

RESULT 134

US-10-719-956-187214
; Sequence 187214, Application US/10719956
; Publication No. US20040146910A1

; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Rat

; FILE REFERENCE: 3527.1

; CURRENT APPLICATION NUMBER: US/10/719,956

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,836

; PRIOR FILING DATE: 2002-11-20

; NUMBER OF SEQ ID NOS: 699466

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 187214

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Rattus norvegicus

US-10-719-956-187214

Query Match 1.4%; Score 23.4; DB 1; Length 25;

Best Local Similarity 96.0%; Pred. No. 1e+02;

Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 969 ATCTGTCTGTGGACTCTTCACCA 993

Db 1 ATCTGTCTGTGGACTCTTCACCA 25

RESULT 135

US-10-080-794-16

; Sequence 16, Application US/10080794

; Publication No. US20030166591A1

; GENERAL INFORMATION:

; APPLICANT: Gleave, Martin

; APPLICANT: Rennie, Paul S.

; APPLICANT: Miyake, Hideaki

; APPLICANT: Nelson, Colleen

; APPLICANT: Monia, Brett P.

; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE

; FILE REFERENCE: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS

; CURRENT APPLICATION NUMBER: US/10/080,794

; CURRENT FILING DATE: 2002-02-22

; PRIOR APPLICATION NUMBER: 60/121,726

; PRIOR FILING DATE: 1999-02-26

; PRIOR APPLICATION NUMBER: 09/913,325

; PRIOR FILING DATE: 2001-08-10

; PRIOR APPLICATION NUMBER: 09/944,326

; PRIOR FILING DATE: 2001-08-30

; NUMBER OF SEQ ID NOS: 19

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 16

; LENGTH: 23

; TYPE: DNA

; ORGANISM: HUMAN

US-10-080-794-16

Query Match 1.4%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 93;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 177 AAGGAAATTCAAATGCTGCA 199

Db 1 AAGGAAATTCAAATGCTGCA 23

RESULT 136

US-10-080-794-17/c

; Sequence 17, Application US/10080794

; Publication No. US20030166591A1

; GENERAL INFORMATION:

; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.

; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE

; FILE REFERENCE: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS

; CURRENT APPLICATION NUMBER: US/10/080,794

; CURRENT FILING DATE: 2002-02-22

; PRIOR APPLICATION NUMBER: 60/121,726

; PRIOR FILING DATE: 1999-02-26

; PRIOR APPLICATION NUMBER: 09/913,325

; PRIOR FILING DATE: 2001-08-10

; PRIOR APPLICATION NUMBER: 09/944,326

; PRIOR FILING DATE: 2001-08-30

; NUMBER OF SEQ ID NOS: 19

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 17

; LENGTH: 23

; TYPE: DNA

; ORGANISM: HUMAN

US-10-080-794-17

Query Match 1.4%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 93;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 957 AAGTCCCGGAGATCTTGTGT 979

Db 23 AAGTCCCGGAGATCTTGTGT 1

RESULT 137

US-10-380-124-5/c

; Sequence 5, Application US/10380124

; Publication No. US20040053874A1

; GENERAL INFORMATION:

; APPLICANT: Isis Pharmaceuticals, Inc.

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/10/380,124

; CURRENT FILING DATE: 2003-03-10

; NUMBER OF SEQ ID NOS: 90

; SEQ ID NO 5

; LENGTH: 23

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: PCR Primer

US-10-380-124-5

Query Match 1.4%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 93;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 789 CTTGAGATGATACACGAGGTCA 811

Db 23 CTTGAGATGATACACGAGGTCA 1

RESULT 138

US-10-646-436-57

; Sequence 57, Application US/10646436

; Publication No. US20040096882A1

; GENERAL INFORMATION:

; APPLICANT: Jansen, Burkhard

; APPLICANT: Gleave, Martin

; APPLICANT: Signaevsky, Maxim

; APPLICANT: Beraldi, Eliana

; APPLICANT: Trougakos, Ioannis

; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-57

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AACGAGCTCGCCCTTCTACTT 502
|||||
Db 1 AACGAGCTCGCCCTTCTACTT 23

RESULT 139
US-10-646-436-60
; Sequence 60, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; CURRENT APPLICATION NUMBER: US/10/646,436
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-60

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCCGAGCTT 733
|||||
Db 1 AAGTCCCGCATCGTCCGAGCTT 23

RESULT 140
US-10-646-436-63
; Sequence 63, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin

; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 63
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-63

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATAAACTGTCTT 1635
|||||
Db 1 AACTAATTCATAAACTGTCTT 23

RESULT 141
US-10-646-436-66
; Sequence 66, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-66

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 46 GCATGATGAAGACTCTGCTGCTG 68
|||||
Db 1 GCATGATGAAGACTCTGCTGCTG 23

RESULT 142
US-10-956-157-291041
; Sequence 291041, Application US/10956157
; Publication No. US20050118625A1

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291041
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-291041

Query Match      1.3%; Score 23; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1114 CCTCCTTGCTGGAGCAGCTGAAC 1136
      |||||||
Db 3 CCTCCTTGCTGGAGCAGCTGAAC 25

RESULT 143
US-10-980-850-34/c
; Sequence 34, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Reverse Primer for OAS1
US-10-980-850-34

Query Match      1.3%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1072 ACGAGCTGCTAAAGTCTTACCA 1093
      |||||||
Db 22 ACGAGCTGCTAAAGTCTTACCA 1

RESULT 144
US-10-956-157-167169
; Sequence 167169, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167169
; LENGTH: 25
; TYPE: DNA
```

```
; ORGANISM: Probe Sequence
US-10-956-157-167169

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1622 AATAAAACTGCTCTGTGAGCTG 1643
      |||||||
Db 1 AATAAAACTGCTCTGTGAGCTG 22

RESULT 145
US-10-956-157-167170
; Sequence 167170, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167170
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-167170

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1622 AATAAAACTGCTCTGTGAGCTG 1643
      |||||||
Db 1 AATAAAACTGCTCTGTGAGCTG 22

RESULT 146
US-10-956-157-167171
; Sequence 167171, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167171
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-167171

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1622 AATAAAACTGCTCTGTGAGCTG 1643
      |||||||
Db 1 AATAAAACTGCTCTGTGAGCTG 22

RESULT 147
US-10-956-157-228788
; Sequence 228788, Application US/10956157
```

```
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228788
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228788

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1571 GACTCTGCTGCTCATGGGAAGA 1592
      ||||| ||||| ||||| ||||| |||||
Db 1 GACTCTGCTGCTCATGGGAAGA 22

RESULT 148
US-10-956-157-279365
; Sequence 279365, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 279365
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-279365

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1400 TGTGGATGTTGCTTTTGACACT 1421
      ||||| ||||| ||||| ||||| |||||
Db 1 TGTGGATGTTGCTTTTGACACT 22

RESULT 149
US-10-719-900-56804
; Sequence 56804, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 56804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-56804

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1269 AAGCTCTTTGACTCTGATCCCATCA 1293
      ||||| ||||| ||||| ||||| |||||
Db 1 AAGCTCTTTGACTCTGATCCCATCA 25

RESULT 150
US-10-719-900-417945
; Sequence 417945, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417945
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417945

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1133 GAACGACGAGTTTAACCTGGGTGTC 1157
      ||||| ||||| ||||| ||||| |||||
Db 1 GAACGACGAGTTTAACCTGGGTGTC 25

RESULT 151
US-10-719-900-417946
; Sequence 417946, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417946
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417946

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1133 GAACGACGAGTTTAACCTGGGTGTC 1157
      ||||| ||||| ||||| ||||| |||||
Db 1 GAACGACGAGTTTAACCTGGGTGTC 25

RESULT 152
US-10-719-900-815718
; Sequence 815718, Application US/10719900
; Publication No. US20050026164A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 815718
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-815718

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1245 TCCGGTGTCACTGAGGTGGTGTGTA 1269
Db      1 TCCGGTGTCACTGAGGTGGTGTGTA 25

RESULT 153
US-10-719-900-892165
; Sequence 892165, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 892165
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-892165

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1149 TGGGTGTCCCGCTGGCAACCTCA 1173
Db      1 TGGGTGTCCCGCTGGCTAACCTCA 25

RESULT 154
US-10-809-189-31760
; Sequence 31760, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 31760
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31760

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1270 AGCTCTTTGACTCTGATCCCATCAC 1294
Db      1 AGCTGTTTGACTCTGACCCCATCAC 25

RESULT 155
US-10-719-956-30749/c
; Sequence 30749, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 30749
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-30749

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1120 TGCTGGAGCAGCTGAACGAGCAGTT 1144
Db      25 TGCTGGAACAGCTGAACGACCAGTT 1

RESULT 156
US-10-719-956-187213
; Sequence 187213, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 187213
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-187213

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      969 ATCTTGTCTGTGGACTGTTCACCA 993
Db      1 ATCTTGTCTGTGCACCTGTTCACCA 25
```



```
RESULT 157
US-10-719-956-374026/c
; Sequence 374026, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 374026
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-374026
Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 975 TCTGTGGACTGTTCACCAACACC 999
Db 25 TCTGTGGACTGTTCACCAACATC 1

RESULT 158
US-10-719-956-501381
; Sequence 501381, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 501381
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-501381
Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1266 GTGAAGCTCTTTGACTCTGATCCCA 1290
Db 1 GTGAAGCTCTTTGACTCTGACCCCA 25

RESULT 159
US-10-719-956-612442/c
; Sequence 612442, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 612442
```

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-612442
Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 TGGGTGTCCCGCTGGCAAACTCA 1173
Db 25 TGGGTGTCCCGCTGGCTAACCTCA 1

RESULT 160
US-09-944-326-3/c
; Sequence 3, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-3
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGCGCTGCAGAACTCCA 36
Db 21 CCGAGCGCTGCAGAACTCCA 1

RESULT 161
US-09-944-326-4/c
; Sequence 4, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
```

```
;
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-4
    Query Match      1.3%; Score 21; DB 1; Length 21;
    Best Local Similarity 100.0%; Pred. No. 1.2e+02;
    Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
    |||||
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 162
US-09-944-326-5/c
; Sequence 5, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-5
    Query Match      1.3%; Score 21; DB 1; Length 21;
    Best Local Similarity 100.0%; Pred. No. 1.2e+02;
    Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
    |||||
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 163
US-09-944-326-6/c
; Sequence 6, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-6
    Query Match      1.3%; Score 21; DB 1; Length 21;
    Best Local Similarity 100.0%; Pred. No. 1.2e+02;
    Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
    |||||
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 165
US-09-944-326-8/c
; Sequence 8, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-8
    Query Match      1.3%; Score 21; DB 1; Length 21;
    Best Local Similarity 100.0%; Pred. No. 1.2e+02;
    Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
    |||||
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 166
US-09-944-326-7/c
; Sequence 7, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-7
    Query Match      1.3%; Score 21; DB 1; Length 21;
    Best Local Similarity 100.0%; Pred. No. 1.2e+02;
    Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
    |||||
Db 21 TGACCGCATCGACTCCCTGCT 1
```

US-09-944-326-8

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 716 CCGCATCGTCGCGAGCTTGAT 736
Db 21 CCGCATCGTCGCGAGCTTGAT 1

RESULT 166

US-09-944-326-9/c
; Sequence 9, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-9

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 916 ACAACTCCACGGGTGCTGTC 936
Db 21 ACAACTCCACGGGTGCTGTC 1

RESULT 167

US-09-944-326-10/c
; Sequence 10, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-10

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1115 CTCCTTCTGAGCAGCTGAA 1135
Db 21 CTCCTTCTGAGCAGCTGAA 1

RESULT 168

US-09-944-326-11/c
; Sequence 11, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-11

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1316 CTCGAGGAAGAACCTAAATT 1336
Db 21 CTCGAGGAAGAACCTAAATT 1

RESULT 169

US-09-944-326-12/c
; Sequence 12, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-12

```
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCGAGC 1536
Db      21 AGGCCCCCAACTCCGCCGAGC 1

RESULT 170
US-09-459-749D-14
; Sequence 14, Application US/09459749D
; Patent No. US20020136716A1
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; CURRENT FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer bind
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-09-459-749D-14

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCAAGAGAGAGAGAGG 294
Db      1 AAGCCAAGAGAGAGAGAGG 21

RESULT 171
US-09-967-726A-3/c
; Sequence 3, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-3

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGGGTGCAAGAGCTCCA 36
Db      21 CCGAGGGGTGCAAGAGCTCCA 1
```

```
RESULT 172
US-09-967-726A-4/c
; Sequence 4, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-4

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
Db      21 ATGATGAAGACTCTGCTGCTG 1

RESULT 173
US-09-967-726A-5/c
; Sequence 5, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-5

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
Db      21 GACCAGACGGTCTCAGACAAT 1

RESULT 174
US-09-967-726A-6/c
; Sequence 6, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
```

```
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      316 AATCAGAGACAAAGCTGAAGG 336
Db      21 AATCAGAGACAAAGCTGAAGG 1

RESULT 175
US-09-967-726A-7/c
; Sequence 7, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      515 TGACCGCATCGACTCCCTGCT 535
Db      21 TGACCGCATCGACTCCCTGCT 1

RESULT 176
US-09-967-726A-8/c
; Sequence 8, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
```

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      716 CCGCATCGTCGCGAGCTTGAT 736
Db      21 CCGCATCGTCGCGAGCTTGAT 1

RESULT 177
US-09-967-726A-9/c
; Sequence 9, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      916 ACAACTCCACGGCTGCTGC 936
Db      21 ACAACTCCACGGCTGCTGC 1

RESULT 178
US-09-967-726A-10/c
; Sequence 10, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-10

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 179
US-09-967-726A-11/c
; Sequence 11, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-11

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGGAGAACCTTAATT 1336
Db 21 CTCAGGAGAACCTTAATT 1

RESULT 180
US-09-967-726A-12/c
; Sequence 12, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-12

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCAGC 1536
Db 21 AGGCCCCCAACTCCGCCAGC 1

RESULT 181
US-10-270-871-14
; Sequence 14, Application US/10270871
; Publication No. US20030162702A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/10/270,871
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: US/09/459,749D
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer_bind
; FEATURE:
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-10-270-871-14

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCCAAGAGAAAGAGG 294
Db 1 AAGCCCAAGAGAAAGAGG 21

RESULT 182
US-10-080-794-3/c
; Sequence 3, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O- (2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-3

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGCGTCAAGACTCCA 16
Db 21 CCGAGGCGTCAAGACTCCA 1

RESULT 183
US-10-080-794-4/c
```

; Sequence 4, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTGCTGCTG 68
Db 21 ATGATGAAGACTGCTGCTG 1

RESULT 184
US-10-080-794-5/c
; Sequence 5, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-5

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 114 GACCAGACGGTCTCAGACAAT 134
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 185
US-10-080-794-6/c
; Sequence 6, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-6

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 316 AATCAGACAAAGCTGAAGG 336
Db 21 AATCAGACAAAGCTGAAGG 1

RESULT 186
US-10-080-794-7/c
; Sequence 7, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-7

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

[illegible]

; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; FILING DATE: 1993-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-11

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1316 CTCGAGGAGAACCTAAATT 1336
|||||
Db 21 CTCGAGGAGAACCTAAATT 1

RESULT 191
US-10-080-794-12/c
; Sequence 12, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-12

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1516 AGGCCCCCAACTCCGCCGAGC 1536
|||||
Db 21 AGGCCCCCAACTCCGCCGAGC 1

RESULT 192
US-10-380-124-6
; Sequence 6, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-380-124-6

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCACGCCATGTTCCAGCCCT 786
|||||
Db 1 TCCACGCCATGTTCCAGCCCT 21

RESULT 193
US-10-383-864-27
; Sequence 27, Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: SIDRANSKY, David
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-27

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 994 ACAACCCCTCCAGGCTAAGC 1014
|||||
Db 1 ACAACCCCTCCAGGCTAAGC 21

RESULT 194
US-10-383-864-28/c
; Sequence 28, Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SIDRANSKY, David
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA

```
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-28

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1334 ATTATGAGACCGTGGCGGA 1354
    |||||
Db 21 ATTATGAGACCGTGGCGGA 1

RESULT 195
US-10-646-391A-3/c
; Sequence 3, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-3

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGCGTGCAAGACTCCA 36
    |||||
Db 21 CCGAGGCGTGCAAGACTCCA 1

RESULT 196
US-10-646-391A-4/c
; Sequence 4, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-4

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
    |||||
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 198
US-10-646-391A-6/c
; Sequence 6, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-6
```

```

; ORGANISM: human
US-10-646-391A-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGAGACAAAGCTGAAGG 336
   |||||
DB 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 199
US-10-646-391A-7/c
; Sequence 7, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
   |||||
DB 21 TGACCGCATCGACTCCCTGCT 1

RESULT 200
US-10-646-391A-8/c
; Sequence 8, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCGCGAGCTTGAT 736
   |||||
DB 21 CCGCATCGTCGCGAGCTTGAT 1

RESULT 201
US-10-646-391A-9/c
; Sequence 9, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGGCTGCTGC 936
   |||||
DB 21 ACAACTCCACGGGCTGCTGC 1

RESULT 202
US-10-646-391A-10/c
; Sequence 10, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-10
```

```
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
    |||||
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 203
US-10-646-391A-11/c
; Sequence 11, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-11

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGAGAGAACCTTAATT 1336
    |||||
Db 21 CTCAGAGAGAACCTTAATT 1

RESULT 204
US-10-646-391A-12/c
; Sequence 12, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-12

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCCCAGC 1536
    |||||
Db 21 AGGCCCCCAACTCCGCCCCAGC 1

RESULT 205
US-10-646-391A-20
; Sequence 20, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-20

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
    |||||
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 206
US-10-646-391A-21/c
; Sequence 21, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
```

```
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-21

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACAGAGTCCGCTTCTAC 500
Db 21 AACAGAGTCCGCTTCTAC 1

RESULT 207
US-10-646-391A-22
; Sequence 22, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-22

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GATGCTCAACACCTCCTCTT 1120
Db 1 GAUGCUCAACACCUCCUCCCTT 21

RESULT 208
US-10-646-391A-23/c
; Sequence 23, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-23/c

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCAATAAACTGTC 1633
Db 21 AACTAATTCAATAAACTGTC 1

RESULT 210
US-10-646-391A-36
; Sequence 36, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-25

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1098 AAGATGCTCAACACCTCCTCC 1118
Db 21 AAGATGCTCAACACCTCCTCC 1

RESULT 209
US-10-646-391A-25/c
; Sequence 25, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-25
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-36

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
      |||||:|||||:|||||
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 211
US-10-646-391A-37/c
; Sequence 37, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-37

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACCGAGCTCGCCCTTCTAC 500
      |||||:|||||:|||||
Db 21 AACCGAGCTCGCCCTTCTAC 1

RESULT 212
US-10-646-391A-38
; Sequence 38, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-38

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AAGTCCGCGCATCGTCCGAGC 731
      |||||:|||||:|||||
Db 21 AAGTCCGCGCATCGTCCGAGC 1

RESULT 214
US-10-646-391A-40
; Sequence 40, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-09-03

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCCGCATCGTCCGAGCTT 733
      |||||:|||||:|||||
Db 1 GUCCCGCAUGCGCGAGCTT 21

RESULT 213
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AAGTCCGCGCATCGTCCGAGC 731
      |||||:|||||:|||||
Db 21 AAGTCCGCGCATCGTCCGAGC 1

RESULT 214
US-10-646-391A-40
; Sequence 40, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-09-03
```


GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-3

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1100 GATGCTCAACACCTCTCTT 1120
||:|||||:-||:||||
Db 1 GAUGCUCACACCUCCUCCCTT 21

RESULT 219
US-10-646-436-4/c
; Sequence 4, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1098 AAGATGCTCAACACCTCTCTCC 1118
|||||

Db 21 AAGATGCTCAACACCTCTCTCC 1

RESULT 220
US-10-646-436-5
; Sequence 5, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-5

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1615 CTAAATCAATAAAACTGTCTT 1635
|:|||||:-||:||||
Db 1 CUAUUCNAUAAACUGUCTT 21

RESULT 221
US-10-646-436-6/c
; Sequence 6, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-6


```
Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1613 AACTAATTCAATAAACTGTC 1633
|||
Db 21 AACTAATTCAATAAACTGTC 1

```

RESULT 222
US-10-646-436-58
; Sequence 58, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 58
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-58

```

QY 482 CCAGAGCTCGCCCTTCTACTT 502
|||||:||||:|
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 223
US-10-646-436-59/c
; Sequence 59, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2

```

; SEQ ID NO 59
;
; LENGTH: 21
;
; TYPE: DNA
;
; ORGANISM: artificial
;
; FEATURE:
;
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-59

```

Qy 480 AACGAGCTCGCCCTTCTAC 500
|
Db 21 AACGAGCTCGCCCTTCTAC 1

```

RESULT 224
US-10-646-436-61
; Sequence 61, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-61

```

Qy 713 GTCCGCGCATCGTCCGCAGCTT 733
| : | | | | | : | : | | | | |
Db 1 GUCCCGCAUCGUCCGCAGCTT 21

```

RESULT 225
US-10-646-436-62/c
; Sequence 62, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Sigmaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193

```

; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-62

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCCGCAGC 731
Db 21 AAGTCCCGCATCGTCCGCAGC 1

RESULT 226
US-10-646-436-64
; Sequence 64, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios

; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-64

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1615 CTAATTCATTAATAACTGCTT 1635
Db 1 CUAUAUCAAUAAACUGUCTT 21

RESULT 227
US-10-646-436-65/c
; Sequence 65, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana

; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 65
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-65

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATTAATAACTGTC 1633
Db 21 AACTAATTCATTAATAACTGTC 1

RESULT 228
US-10-828-394-4/c
; Sequence 4, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CCGAGGCGTGCAAGACTCCA 36
Db 21 CCGAGGCGTGCAAGACTCCA 1

RESULT 229
US-10-828-394-5/c
; Sequence 5, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders

```
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-5

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      48 ATGATGAAGACTCTGCTGCTG 68
Db      21 ATGATGAAGACTCTGCTGCTG 1

RESULT 230
US-10-828-394-6/c
; Sequence 6, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      114 GACCAGACGGTCTCAGACAAT 134
Db      21 GACCAGACGGTCTCAGACAAT 1

RESULT 231
US-10-828-394-7/c
; Sequence 7, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21

; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      515 TGACCGCATCGACTCCCTGCT 535
Db      21 TGACCGCATCGACTCCCTGCT 1

RESULT 233
US-10-828-394-9/c
; Sequence 9, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      716 CCGCATCGTCGCGAGCTTGAT 736
Db      21 CCGCATCGTCGCGAGCTTGAT 1
```

```
Db      21  CCGCATCGTCCGAGCTTGAT 1
|||||
RESULT 234
US-10-828-394-10/c
; Sequence 10, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-10
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      916  ACAACTCCACGGGCTGCTGC 936
|||||
Db      21  ACAACTCCACGGGCTGCTGC 1

RESULT 235
US-10-828-394-11/c
; Sequence 11, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-11
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1115 CTCCTTGCTGGAGCAGCTGAA 1135
|||||
Db      21  CTCCTTGCTGGAGCAGCTGAA 1

RESULT 236
US-10-828-394-12/c
; Sequence 12, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-12
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1516 AGGCCCCCACTCCGCCGAC 1536
|||||
Db      21  AGGCCCCCACTCCGCCGAC 1

RESULT 237
US-10-828-394-13/c
; Sequence 13, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-13
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1316 CTCGAGGAGACCCCTAAATT 1336
|||||
Db      21  CTCGAGGAGACCCCTAAATT 1

RESULT 238
US-10-828-395-4/c
; Sequence 4, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-4/c
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1516 AGGCCCCCACTCCGCCGAC 1536
|||||
Db      21  AGGCCCCCACTCCGCCGAC 1

RESULT 239
US-10-828-395-4/c
; Sequence 4, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-4/c
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1516 AGGCCCCCACTCCGCCGAC 1536
|||||
Db      21  AGGCCCCCACTCCGCCGAC 1
```

; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CCGAGGCGTGCAGACTCCA 36
|||||
Db 21 CCGAGGCGTGCAGACTCCA 1

RESULT 239

US-10-828-395-5/c
; Sequence 5, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-5

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGCTG 68
|||||
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 240

US-10-828-395-6/c
; Sequence 6, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-6

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 114 GACCAGACGGTCTCAGACAAT 134
|||||
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 241

US-10-828-395-7/c
; Sequence 7, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-7

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 316 AATCAGACAAAGCTGAAGG 336
|||||
Db 21 AATCAGACAAAGCTGAAGG 1

RESULT 242

US-10-828-395-8/c
; Sequence 8, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-8

Query Match		1.3%;	Score 21;	DB 1;	Length 21;
Best Local Similarity		100.0%;	Pred. No. 1.2e+02;		
Matches		21;	Conservative 0;	Mismatches 0;	Indels 0;
Gaps					0;
Qy	515	TGACCGCATCGACTCCCTGCT	535		
Db	21	TGACCGCATCGACTCCCTGCT	1		
RESULT 243					
US-10-828-395-9/c					
; Sequence 9, Application US/10828395					
; Publication No. US20040224914A1					
; GENERAL INFORMATION:					
; APPLICANT: Jackson, John					
; APPLICANT: Burt, Helen					
; APPLICANT: Springate, Christopher					
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders					
; FILE REFERENCE: UBC.P-032					
; CURRENT APPLICATION NUMBER: US/10/828,395					
; PRIOR FILING DATE: 2004-04-19					
; PRIOR APPLICATION NUMBER: US 60/464,159					
; PRIOR FILING DATE: 2003-04-18					
; PRIOR APPLICATION NUMBER: US 60/464,160					
; PRIOR FILING DATE: 2003-04-18					
; NUMBER OF SEQ ID NOS: 23					
; SOFTWARE: PatentIn version 3.2					
; SEQ ID NO 9					
; LENGTH: 21					
; TYPE: DNA					
; ORGANISM: human					
US-10-828-395-9					
Query Match					
Best Local Similarity					
Matches					
21; Conservative 0;					
Mismatches 0;					
Indels 0;					
Gaps 0;					
Qy	716	CGCATCGTCGCGACCTTGAT	736		
Db	21	CGCATCGTCGCGACCTTGAT	1		
RESULT 244					
US-10-828-395-10/c					
; Sequence 10, Application US/10828395					
; Publication No. US20040224914A1					
; GENERAL INFORMATION:					
; APPLICANT: Jackson, John					
; APPLICANT: Burt, Helen					
; APPLICANT: Springate, Christopher					
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders					
; FILE REFERENCE: UBC.P-032					
; CURRENT APPLICATION NUMBER: US/10/828,395					
; PRIOR FILING DATE: 2004-04-19					
; PRIOR APPLICATION NUMBER: US 60/464,159					
; PRIOR FILING DATE: 2003-04-18					
; PRIOR APPLICATION NUMBER: US 60/464,160					
; PRIOR FILING DATE: 2003-04-18					
; NUMBER OF SEQ ID NOS: 23					
; SOFTWARE: PatentIn version 3.2					
; SEQ ID NO 10					
; LENGTH: 21					
; TYPE: DNA					
; ORGANISM: human					
US-10-828-395-10					
Query Match					
Best Local Similarity					
Matches					
21; Conservative 0;					
Mismatches 0;					
Indels 0;					
Gaps 0;					
Qy	1316	CTCCAGGAGAACCTTAATT	1336		
Db	21	CTCCAGGAGAACCTTAATT	1		
Query Match					
Best Local Similarity					
Matches					
21; Conservative 0;					
Mismatches 0;					
Indels 0;					
Gaps 0;					

```
RESULT 247
US-10-828-395-13/c
; Sequence 13, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-13

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1516 AGGCCCCCACTCGCCGAGC 1536
Db      21 AGGCCCCCACTCGCCGAGC 1

RESULT 248
US-10-719-900-695781/c
; Sequence 695781, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 695781
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-695781

Query Match      1.3%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      565 TGGATGTCATCGAGCACCTTCA 588
Db      25 TGCATGTCATCGAGCACCTTCA 2

RESULT 249
US-10-719-900-56803
; Sequence 56803, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
```

```
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 56803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-56803

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1269 AAGCTCTTTGACTCTGATCCCATCA 1293
Db      1 AAGCTGTTGACACTGACCCCATCA 25

RESULT 250
US-10-719-900-452919
; Sequence 452919, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 452919
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-452919

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1137 GAGCAGTTAACTGGGTGTCGCCGCGC 1161
Db      1 GACCAGTTCAACTGGGTGTCGCCGAGC 25

RESULT 251
US-10-719-900-815717
; Sequence 815717, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 815717
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-815717

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1245 TCCGGTGTCACTGAGGTGTCGTGA 1269
```

```
Db 1 TCCCGTGTCTACTCAGGTGGTGTGA 25
|||||
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent version 3.2
; SEQ ID NO 271151
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-271151

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1588 GAAGAACAGAAATGCTCTGTCATGC 1612
|||||
Db 1 GGAAGACAGAAATGCTCTGTCATGC 25
|||||

RESULT 255
US-10-719-956-30750/c
; Sequence 30750, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 30750
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-30750

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1120 TCGTGGACGAGCTGAACGAGCAGTT 1144
|||||
Db 25 TCGTGGACGAGCAGAACGACCAGTT 1
|||||

RESULT 256
US-10-719-956-70566/c
; Sequence 70566, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 70566
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-70566

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1171 TCACGCAAGGCGAAGACCACTACTA 1195
|||||
Db 1 TCACAGGCGGCGAAGACCACTACTA 25
|||||

RESULT 254
US-10-956-157-271151
; Sequence 271151, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```


Best Local Similarity 88.0%; Pred. No. 2e+02;

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy	778 TCAGCCCTTCCTTGAGATGATACA 802
Db	25 TCAGCGCTTCCTTGAGTTGATCA 1
RESULT 262	
US-10-719-956-612441/c	
; Sequence 612441, Application US/10719956	
; Publication No. US20040146910A1	
; GENERAL INFORMATION: Zhou	
; APPLICANT: Xue Mei	
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat	
; FILE REFERENCE: 3527.1	
; CURRENT APPLICATION NUMBER: US/10/719,956	
; CURRENT FILING DATE: 2003-11-20	
; PRIOR APPLICATION NUMBER: 60/427,836	
; PRIOR FILING DATE: 2002 11 20	
; NUMBER OF SEQ ID NOS: 699466	
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1	
; SEQ ID NO 612441	
; LENGTH: 25	
; TYPE: DNA	
; ORGANISM: Rattus norvegicus	
US-10-719-956-612441	
Query Match	
Best Local Similarity 1.2%; Score 20.2; DB 1; Length 25;	
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy	1149 TGGGTGTCCTCCGGCTGGCAAACTCA 1173
Db	25 TGGGTGTCCTCCAGGTGGCTAACCTCA 1
RESULT 263	
US-10-380-124-14/c	
; Sequence 14, Application US/10380124	
; Publication No. US20040053874A1	
; GENERAL INFORMATION:	
; APPLICANT: Isis Pharmaceuticals, Inc.	
; APPLICANT: Brett P. Monia	
; APPLICANT: Susan M. Freier	
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION	
; FILE REFERENCE: RTS-0156	
; CURRENT APPLICATION NUMBER: US/10/380,124	
; CURRENT FILING DATE: 2003-03-10	
; NUMBER OF SEQ ID NOS: 90	
; SEQ ID NO 14	
; LENGTH: 20	
; TYPE: DNA	
; ORGANISM: Artificial Sequence	
; FEATURE:	
; OTHER INFORMATION: Antisense Oligonucleotide	
US-10-380-124-14	
Query Match	
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;	
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	13 TGACCGAGCGGTGCAAGAC 32
Db	20 TGACCGAGCGGTGCAAGAC 1
RESULT 264	
US-10-380-124-15/c	
; Sequence 15, Application US/10380124	
; Publication No. US20040053874A1	
; GENERAL INFORMATION:	
; APPLICANT: Isis Pharmaceuticals, Inc.	
; APPLICANT: Brett P. Monia	
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION	
; FILE REFERENCE: RTS-0156	
; CURRENT APPLICATION NUMBER: US/10/380,124	
; CURRENT FILING DATE: 2003-03-10	
; NUMBER OF SEQ ID NOS: 90	
; SEQ ID NO 17	
; LENGTH: 20	
; TYPE: DNA	
; ORGANISM: Artificial Sequence	
; FEATURE:	
; OTHER INFORMATION: Antisense Oligonucleotide	
US-10-380-124-17	
Query Match	
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;	
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	39 ATTGGAGGCATGATGAAGAC 58
Db	20 ATTGGAGGCATGATGAAGAC 1
RESULT 265	
US-10-380-124-16/c	
; Sequence 16, Application US/10380124	
; Publication No. US20040053874A1	
; GENERAL INFORMATION:	
; APPLICANT: Isis Pharmaceuticals, Inc.	
; APPLICANT: Brett P. Monia	
; APPLICANT: Susan M. Freier	
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION	
; FILE REFERENCE: RTS-0156	
; CURRENT APPLICATION NUMBER: US/10/380,124	
; CURRENT FILING DATE: 2003-03-10	
; NUMBER OF SEQ ID NOS: 90	
; SEQ ID NO 16	
; LENGTH: 20	
; TYPE: DNA	
; ORGANISM: Artificial Sequence	
; FEATURE:	
; OTHER INFORMATION: Antisense Oligonucleotide	
US-10-380-124-16	
Query Match	
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;	
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	39 ATTGGAGGCATGATGAAGAC 58
Db	20 ATTGGAGGCATGATGAAGAC 1
RESULT 266	
US-10-380-124-17/c	
; Sequence 17, Application US/10380124	
; Publication No. US20040053874A1	
; GENERAL INFORMATION:	
; APPLICANT: Isis Pharmaceuticals, Inc.	
; APPLICANT: Brett P. Monia	
; APPLICANT: Susan M. Freier	
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION	
; FILE REFERENCE: RTS-0156	
; CURRENT APPLICATION NUMBER: US/10/380,124	
; CURRENT FILING DATE: 2003-03-10	
; NUMBER OF SEQ ID NOS: 90	
; SEQ ID NO 17	
; LENGTH: 20	
; TYPE: DNA	
; ORGANISM: Artificial Sequence	
; FEATURE:	
; OTHER INFORMATION: Antisense Oligonucleotide	
US-10-380-124-17	

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 77 GCTGCTGCTGACCTGGGAGA 96
|||||
Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 267

US-10-380-124-18/c
; Sequence 18, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-18

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 101 GCAGGTCCTGGGGACCAGA 120
|||||
Db 20 GCAGGTCCTGGGGACCAGA 1

RESULT 268

US-10-380-124-19/c
; Sequence 19, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-19

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 122 GGTCTCAGACATGAGCTCC 141
|||||
Db 20 GGTCTCAGACATGAGCTCC 1

RESULT 269

US-10-380-124-20/c
; Sequence 20, Application US/10380124

Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-20

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 GTCCAATCAGGGAAGTAAGT 168
|||||
Db 20 GTCCAATCAGGGAAGTAAGT 1

RESULT 270

US-10-380-124-21/c
; Sequence 21, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-21

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 166 AGTACGTCATAAGAAATT 185
|||||
Db 20 AGTACGTCATAAGAAATT 1

RESULT 271

US-10-380-124-22/c
; Sequence 22, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-22

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 GGGGTGAACAGATAAAGAC 220
      |||||
Db 20 GGGGTGAACAGATAAAGAC 1

RESULT 272
US-10-380-124-23/c
; Sequence 23, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-23

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 281 GAAGAAGAAAGAGATGCC 300
      |||||
Db 20 GAAGAAGAAAGAGATGCC 1

RESULT 273
US-10-380-124-24/c
; Sequence 24, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-24

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 286 AGAAGAGGATGCCCTAAAT 305
      |||||
Db 20 AGAAGAGGATGCCCTAAAT 1
```

```

RESULT 274
US-10-380-124-25/c
; Sequence 25, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-25

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 298 CCCTAATGAGACCGGAA 317
      |||||
Db 20 CCCTAATGAGACCGGAA 1

RESULT 275
US-10-380-124-26/c
; Sequence 26, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-26

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 307 AGACCAGGGAATCAGAGACA 326
      |||||
Db 20 AGACCAGGGAATCAGAGACA 1

RESULT 276
US-10-380-124-27/c
; Sequence 27, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
```

Qy	364	TGATGGCCCTCTGGGAAGAG	383
Db	20	TGATGGCCCTCTGGGAAGAG	1
 RESULT 279			
US-10-380-124-30/c			
; Sequence 30, Application US/10380124			
; Publication No. US20040053874A1			
; GENERAL INFORMATION:			
; APPLICANT: Isis Pharmaceuticals, Inc.			
; APPLICANT: Brett P. Monia			
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION			
; FILE REFERENCE: RTS-0156			
; CURRENT APPLICATION NUMBER: US/10/380,124			
; CURRENT FILING DATE: 2003-03-10			
; SEQ ID NO 30			
; LENGTH: 20			
; TYPE: DNA			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Antisense Oligonucleotide			
US-10-380-124-30			
 Query Match 1.2%; Score 20; DB 1; Length 20;			
Best Local Similarity 100.0%; Pred. No. 1.3e+02;			
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	380	AGAGTGTAAAGCCTGCCTGA	399
Db	20	AGAGTGTAAAGCCTGCCTGA	1
 RESULT 280			
US-10-380-124-31/c			
; Sequence 31, Application US/10380124			
; Publication No. US20040053874A1			
; GENERAL INFORMATION:			
; APPLICANT: Isis Pharmaceuticals, Inc.			
; APPLICANT: Brett P. Monia			
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION			
; FILE REFERENCE: RTS-0156			
; CURRENT APPLICATION NUMBER: US/10/380,124			
; CURRENT FILING DATE: 2003-03-10			
; NUMBER OF SEQ ID NOS: 90			
; SEQ ID NO 31			
; LENGTH: 20			
; TYPE: DNA			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Antisense Oligonucleotide			
US-10-380-124-31			
 Query Match 1.2%; Score 20; DB 1; Length 20;			
Best Local Similarity 100.0%; Pred. No. 1.3e+02;			
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	407	CTGCATGAAGTTCTACGCAC	426
Db	20	CTGCATGAAGTTCTACGCAC	1
 RESULT 281			
US-10-380-124-32/c			
; Sequence 32, Application US/10380124			
; Publication No. US20040053874A1			
; GENERAL INFORMATION:			
; APPLICANT: Isis Pharmaceuticals, Inc.			
; APPLICANT: Brett P. Monia			
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION			
; FILE REFERENCE: RTS-0156			
; CURRENT APPLICATION NUMBER: US/10/380,124			
; CURRENT FILING DATE: 2003-03-10			
; NUMBER OF SEQ ID NOS: 90			
; SEQ ID NO 32			
; LENGTH: 20			
; TYPE: DNA			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Antisense Oligonucleotide			
US-10-380-124-32			
 Query Match 1.2%; Score 20; DB 1; Length 20;			
Best Local Similarity 100.0%; Pred. No. 1.3e+02;			
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-32

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 CTCAGGCTGGTTGGCGCC 462
DB 20 CTCAGGCTGGTTGGCGCC 1

RESULT 282

US-10-380-124-33/c
; Sequence 33, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-33

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 444 TCAGGCTGGTTGGCGCCA 463
DB 20 TCAGGCTGGTTGGCGCCA 1

RESULT 283

US-10-380-124-34/c
; Sequence 34, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-34

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TGGCCGCGAGCTTGAGGAGT 474
DB 20 TGGCCGCGAGCTTGAGGAGT 1

RESULT 284

US-10-380-124-35/c
; Sequence 35, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-35

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 501
DB 20 CCAGAGCTCGCCCTTCTACT 1

RESULT 285

US-10-380-124-36/c
; Sequence 36, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-36

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCCTTCTACTTCTGGATGAA 511
DB 20 CCCTTCTACTTCTGGATGAA 1

RESULT 286

US-10-380-124-37/c
; Sequence 37, Application US/10380124
; Publication No. US20040053874A1

```
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-37

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 517 ACCGATCGACTCCCTGCTG 536
Db 20 ACCGATCGACTCCCTGCTG 1

RESULT 287
US-10-380-124-38/c
; Sequence 38, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-38

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 533 GCTGGAAGACGACGGCAGC 552
Db 20 GCTGGAAGACGACGGCAGC 1

RESULT 288
US-10-380-124-39/c
; Sequence 39, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-39

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 GCAGCGCACATGCTGGATG 570
Db 20 GCAGCGCACATGCTGGATG 1

RESULT 289
US-10-380-124-40/c
; Sequence 40, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-40

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 553 AGACGCACATGCTGGATGTC 572
Db 20 AGACGCACATGCTGGATGTC 1

RESULT 290
US-10-380-124-41/c
; Sequence 41, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-41

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 565 TGGATGTCATGCAGGACCAC 584
Db 20 TGGATGTCATGCAGGACCAC 1
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-41

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 565 TGGATGTCATGCAGGACCAC 584
Db 20 TGGATGTCATGCAGGACCAC 1
```

```
RESULT 291
US-10-380-124-42/c
; Sequence 42, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-42

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      567 GATGTCATGCGAGGACCACTT 586
      |||||||
Db      20 GATGTCATGCGAGGACCACTT 1

RESULT 292
US-10-380-124-43/c
; Sequence 43, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-43

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      604 TCATAGACGAGCTCTTCCAG 623
      |||||||
Db      20 TCATAGACGAGCTCTTCCAG 1

RESULT 293
US-10-380-124-44/c
; Sequence 44, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-44

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      608 AGACGAGCTCTTCCAGGACA 627
      |||||||
Db      20 AGACGAGCTCTTCCAGGACA 1

RESULT 294
US-10-380-124-45/c
; Sequence 45, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-45

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      613 AGCTCTTCCAGGACAGGTTTC 632
      |||||||
Db      20 AGCTCTTCCAGGACAGGTTTC 1

RESULT 295
US-10-380-124-46/c
; Sequence 46, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-46

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      690 AGGCCTCACTTCTCTTCTTC 709
```



```
Db      20 AGGCTCACTCTCTTTCC 1
|||||
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-47/c
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      721 TCGTCCGAGCTTGATGCC 740
|||||
Db      20 TCGTCCGAGCTTGATGCC 1
|||||

RESULT 297
US-10-380-124-48/c
; Sequence 48, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-48
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      775 TGTTCAGCCCTTCTTGAG 794
|||||
Db      20 TGTTCAGCCCTTCTTGAG 1
|||||

RESULT 298
US-10-380-124-49/c
; Sequence 49, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-49
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      783 CCCTTCCTTGAGATGATACA 802
|||||
Db      20 CCCTTCCTTGAGATGATACA 1
|||||

RESULT 300
US-10-380-124-51/c
; Sequence 51, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-51
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      776 GTTCCAGCCCTTCTTGAGA 795
|||||
Db      20 GTTCCAGCCCTTCTTGAGA 1
|||||

RESULT 299
US-10-380-124-50/c
; Sequence 50, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-50
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      783 CCCTTCCTTGAGATGATACA 802
|||||
Db      20 CCCTTCCTTGAGATGATACA 1
|||||

RESULT 300
US-10-380-124-51/c
; Sequence 51, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-51
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Tue Sep 13 10:53:21 2005

10828394-1_1-1643.rnpb.sl

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0;

QY 820 TGGACATCCACTCCACAGC 839
    |||||
Db 20 TGGACATCCACTCCACAGC 1

RESULT 301
US-10-380-124-52/c
; Sequence 52, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-52

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 GACTGTGTGCGGAGATCC 912
    |||||
Db 20 GACTGTGTGCGGAGATCC 1

RESULT 304
US-10-380-124-55/c
; Sequence 55, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-55

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 894 ACTGTGTGCGGAGATCCG 913
    |||||
Db 20 ACTGTGTGCGGAGATCCG 1

RESULT 305
US-10-380-124-56/c
; Sequence 56, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-56
```

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0;

QY 820 TGGACATCCACTCCACAGC 839
    |||||
Db 20 TGGACATCCACTCCACAGC 1

RESULT 301
US-10-380-124-52/c
; Sequence 52, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-52

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 848 CCAGCACCCGCCACAGAAT 867
    |||||
Db 20 CCAGCACCCGCCACAGAAT 1

RESULT 302
US-10-380-124-53/c
; Sequence 53, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-53

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 ACCCGCCACAGAAATTCATA 872
    |||||
Db 20 ACCCGCCACAGAAATTCATA 1

RESULT 303
US-10-380-124-54/c
; Sequence 54, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-56

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 906 GAGATCCGCCCAACTCCAC 925
Db 20 GAGATCCGCCCAACTCCAC 1

RESULT 306
US-10-380-124-57/c
; Sequence 57, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-57

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 928 GCTGCTCGCATGAAGGAC 947
Db 20 GCTGCTCGCATGAAGGAC 1

RESULT 307
US-10-380-124-58/c
; Sequence 58, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-58

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 967 AGATCTTGCTGTGGACTGT 986
Db 20 AGATCTTGCTGTGGACTGT 1

RESULT 308
US-10-380-124-59/c
; Sequence 59, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-59

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1009 CTAAGCTGCGCGGAGCTC 1028
Db 20 CTAAGCTGCGCGGAGCTC 1

RESULT 309
US-10-380-124-60/c
; Sequence 60, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-60

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1022 GGAGCTCGAGCAATCCCTCC 1041
Db 20 GGAGCTCGAGCAATCCCTCC 1

RESULT 310
US-10-380-124-61/c
; Sequence 61, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 61
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-61

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 AAGTCCTACCAAGTGAAGAT 1102
|||||
Db 20 AAGTCCTACCAAGTGAAGAT 1

RESULT 311
US-10-380-124-62/c
; Sequence 62, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-62

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 CCAAGTGAAGATGCTCAACA 1110
|||||
Db 20 CCAAGTGAAGATGCTCAACA 1

RESULT 312
US-10-380-124-63/c
; Sequence 63, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-63

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1113 TCCTCCTTGTGGAGCAGCT 1132
|||||
```

```
Db 20 TCCTCCTTGTGGAGCAGCT 1

RESULT 313
US-10-380-124-64/c
; Sequence 64, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-64

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 GCTGGAGCAGCTGAACGAGC 1140
|||||
Db 20 GCTGGAGCAGCTGAACGAGC 1

RESULT 314
US-10-380-124-65/c
; Sequence 65, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-65

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 CTGGGTGTCCCGCTGGCAA 1167
|||||
Db 20 CTGGGTGTCCCGCTGGCAA 1

RESULT 315
US-10-380-124-66/c
; Sequence 66, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
```

```
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-66

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1182 GAAGACCACTACTATCTCGG 1201
Db 20 GAAGACCACTACTATCTCGG 1

RESULT 316
US-10-380-124-67/c
; Sequence 67, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-67

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1194 TATCTGCGGGTCACACGGT 1213
Db 20 TATCTGCGGGTCACACGGT 1

RESULT 317
US-10-380-124-68/c
; Sequence 68, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-68

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1216 CTTCCACACTTCTGACTCG 1235
Db 20 CTTCCACACTTCTGACTCG 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 318
US-10-380-124-69/c
; Sequence 69, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-69

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1275 TTTGACTCTGATCCCATCAC 1294
Db 20 TTTGACTCTGATCCCATCAC 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 319
US-10-380-124-70/c
; Sequence 70, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-70

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1300 CGGTCCCTGTAGAGTCTCC 1319
Db 20 CGGTCCCTGTAGAGTCTCC 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 320
US-10-380-124-71/c
; Sequence 71, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
```

```

US-10-380-124-73
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGGATCCTGCACCTCTA 1564
    |||||||
DB 20 GCTCTGGATCCTGCACCTCTA 1

RESULT 323
US-10-380-124-74/c
; Sequence 74, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-74

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCCTGCATGCAACTAAT 1619
    |||||||
DB 20 TGCTCCTGCATGCAACTAAT 1

RESULT 324
US-10-380-124-75/c
; Sequence 75, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-75

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCAATTAACCTGCT 1634
    |||||||
DB 20 CTAATTCAATTAACCTGCT 1

RESULT 325
US-10-380-124-78/c

```

```
; Sequence 78, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-78

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      979  TGGACTGTTCCACCAACAAC 998
Db      20  TGGACTGTTCCACCAACAAC 1

RESULT 326
US-10-380-124-80/c
; Sequence 80, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-80

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      979  TGGACTGTTCCACCAACAAC 998
Db      20  TGGACTGTTCCACCAACAAC 1

RESULT 327
US-10-980-850-17
; Sequence 17, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Forward Primer for CLU
US-10-980-850-17

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      762  AACTTCCACGCCCATGTTCCA 781
Db      1    AACTTCCACGCCCATGTTCCA 20

RESULT 328
US-10-980-850-18/c
; Sequence 18, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Reverse Primer for CLU
US-10-980-850-18

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      870  ATACGAGAGCGGACGATGA 889
Db      20  ATACGAGAGCGGACGATGA 1

RESULT 329
US-10-980-850-33
; Sequence 33, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Forward Primer for OAS1
US-10-980-850-33

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

	Query Match	1.2%; Score 20; DB 1; Length 21;
	Best Local Similarity	75.0%; Pred. No. 1.4e+02;
	Matches	15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY	48 ATGATGAAGACTCTGCTGCT 67	
DB	1 AUGAUGAAGACUCGCGUCT 20	
	:: : : : : : : :	
RESULT 332		
	US-09-459-749D-13	
	; Sequence 13, Application US/09459749D	
	; Patent No. US20020136716A1	
	; GENERAL INFORMATION:	
	; APPLICANT: Millis, Albert J. T.	
	; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration	
	; FILE REFERENCE: 0794.016A	
	; CURRENT APPLICATION NUMBER: US/09/459,749D	
	; CURRENT FILING DATE: 1999-12-10	
	; PRIOR APPLICATION NUMBER: 60/111,856	
	; PRIOR FILING DATE: 1998-12-11	
	; NUMBER OF SEQ ID NOS: 17	
	; SOFTWARE: PatentIn Ver. 2.1	
	; SEQ ID NO 13	
	; LENGTH: 21	
	; TYPE: DNA	
	; ORGANISM: Artificial Sequence	
	; FEATURE:	
	; OTHER INFORMATION: Description of Artificial Sequence:primer_bind	
	; OTHER INFORMATION: synthetic antisense primer based on murine clusterin	
	US-09-459-749D-13	
	Query Match	1.2%; Score 19.4; DB 1; Length 21;
	Best Local Similarity	95.2%; Pred. No. 1.6e+02;
	Matches	20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	271 AAGAAGCCCAAGAAGAAAG 291	
DB	1 AGGAAGCCNAGAAGAAAG 21	
	: : :	
RESULT 333		
	US-10-270-871-13	
	; Sequence 13, Application US/10270871	
	; Publication No. US20030162702A1	
	; GENERAL INFORMATION:	
	; APPLICANT: Millis, Albert J. T.	
	; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration	
	; FILE REFERENCE: 0794.016A	
	; CURRENT APPLICATION NUMBER: US/10/270,871	
	; CURRENT FILING DATE: 2002-10-15	
	; PRIOR APPLICATION NUMBER: US/09/459,749D	
	; PRIOR FILING DATE: 1999-12-10	
	; PRIOR APPLICATION NUMBER: 60/111,856	
	; PRIOR FILING DATE: 1998-12-11	
	; NUMBER OF SEQ ID NOS: 17	
	; SOFTWARE: PatentIn Ver. 2.1	
	; SEQ ID NO 13	
	; LENGTH: 21	
	; TYPE: DNA	
	; ORGANISM: Artificial Sequence	
	; FEATURE:	
	; OTHER INFORMATION: Description of Artificial Sequence:primer_bind	
	; OTHER INFORMATION: synthetic antisense primer based on murine clusterin	
	US-10-270-871-13	
	Query Match	1.2%; Score 19.4; DB 1; Length 21;
	Best Local Similarity	95.2%; Pred. No. 1.6e+02;
	Matches	20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	271 AAGAAGCCCAAGAAGAAAG 291	

```

Qy      977  TGTGGACTGTTCCACCAACA  996
Db      1    TGTGGACTGTTCCACCAACA  20

RESULT 330
US-10-646-391A-28
; Sequence 28, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC-P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-28

Query Match      1.2%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred: No. 1.4e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      48  ATGATGAAGACTCTGCTGCT  67
Db      1  AUGAUGAAGACUCUGCUGCT  20

RESULT 331
US-10-646-436-9
; Sequence 9, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathos
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC-P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-9

```



```
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi fo rhuman clusterin
US-10-646-436-68

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 338
US-10-828-394-16
; Sequence 16, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-10-828-394-16

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 482 CCAGAGCTCGCCCTTCTAC 500
Db 1 CCAGAGCTCGCCCUUCUAC 19

RESULT 339
US-10-828-394-17
; Sequence 17, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-394-17

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 482 CCAGAGCTCGCCCTTCTAC 500
Db 1 CCAGAGCTCGCCCUUCUAC 19

RESULT 340
US-10-828-394-18
; Sequence 18, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-394-18

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.4e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1615 CTAATTCAATAAACTGTC 1633
Db 1 CUNAUCAUAAACUGUC 19

RESULT 341
US-10-828-395-16
; Sequence 16, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-10-828-395-16

Query Match      1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 482 CCAGAGCTCGCCCTTCTAC 500
Db 1 CCAGAGCTCGCCCUUCUAC 19

RESULT 342
US-10-828-395-17
```

```
; Sequence 17, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-395-17

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1100 GATGCTCAACACCTCCTCC 1118
Db      1 GAUGCUCACACCUCCUCC 19
|||||:|||||:|||||:|||||:|||||:

RESULT 343
US-10-828-395-18
; Sequence 18, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-395-18

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.4e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1615 CTAATTCATAAAACTGTCTC 1633
Db      1 CUAUAUCAAAUAAACUGUC 19
|||||:|||||:|||||:|||||:|||||:

RESULT 344
US-10-646-391A-29/c
; Sequence 29, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
```

```
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-29

Query Match          1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      48 ATGATGAAGACTCTGCTGC 66
Db      19 ATGATGAAGACTCTGCTGC 1
|||||:|||||:|||||:|||||:|||||:

RESULT 345
US-10-646-436-10/c
; Sequence 10, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Elestathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-10

Query Match          1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      48 ATGATGAAGACTCTGCTGC 66
Db      19 ATGATGAAGACTCTGCTGC 1
|||||:|||||:|||||:|||||:|||||:

RESULT 346
US-10-380-124-4
```

; Sequence 4, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-380-124-4

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTGAA 763
|||||
Db 1 TCCGTACGAGCCCTGAA 18

RESULT 347
US-09-967-726A-15/c
; Sequence 15, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Neilson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: Oligonucleotides
; FILE REFERENCE: UBC-P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: 2 base mismatch primer from human TRPM-2
US-09-967-726A-15

Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
|||||
Db 21 ATGATAAATACTCTGCTGCTG 1

RESULT 348
US-10-080-794-15/c
; Sequence 15, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Neilson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE

; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC-P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
US-10-080-794-15

Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
|||||
Db 21 ATGATAAATACTCTGCTGCTG 1

RESULT 349
US-10-751-736-11047
; Sequence 11047, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11047
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11047

Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 35 CAGAAATGGAGGCGATGATGAA 55
|||||
Db 1 CAGTATTGGAGGCGATGATGAA 21

RESULT 350
US-10-921-868A-37/c
; Sequence 37, Application US/10921868A
; Publication No. US20050118251A1
; GENERAL INFORMATION:
; APPLICANT: Nagata, Leslie P.
; APPLICANT: Wong, Jonathan P.
; TITLE OF INVENTION: NOVEL DNA-BASED VACCINE AGAINST THE ENCEPHALITIS ALPHAVIRUSES
; FILE REFERENCE: NEL-0001/DIV1
; CURRENT APPLICATION NUMBER: US/10/921,868A
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: 10/023,649
; PRIOR FILING DATE: 2001-12-21

; Sequence 81, Application US/10911318
; Publication No. US20050130186A1
; GENERAL INFORMATION:
; APPLICANT: We Gene Technologies, Inc.
; TITLE OF INVENTION: MENINGITIS DETECTION CHIP AND FABRICATION METHOD THEREOF AND
; TITLE OF INVENTION: METHOD OF DETECTING MENINGITIS AND PRIMER SET FOR MENINGITIS
; TITLE OF INVENTION: DETECTION
; FILE REFERENCE: 12333-US-PA
; CURRENT APPLICATION NUMBER: US/10/911,318
; CURRENT FILING DATE: 2004-08-03
; PRIOR APPLICATION NUMBER: TW 92135134
; PRIOR FILING DATE: 2003-12-12
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 81
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-911-318-81

Query Match 1.0%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1281 TCTGATCCCATCACTGTGAC 1300
||||| |||||||
Db 21 TCTGGTCCCATCACTGTGAC 2

RESULT 356
US-09-294-121A-97/c
; Sequence 97, Application US/09294121A
; Patent No. US20020069422A1
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/294,121A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-09-294-121A-97
Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1508 CAGCCTCCAGGCCCC 1523
||||| |||||||
Db 16 CAGCCTCCAGGCCCC 1
RESULT 357
US-09-899-082A-97/c
; Sequence 97, Application US/09899082A
; Patent No. US20020106638A1
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,082A
; FILING DATE: 06-JUL-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA

```
;
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-09-899-082A-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 358
US-09-899-302-97/c
; Sequence 97, Application US/09899302
; Patent No. US20020168626A1
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,302
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/378,900
; FILING DATE:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-09-899-302-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 360
US-10-822-711-97/c
; Sequence 97, Application US/10822711
```


US-10-646-391A-24

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.8e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1616 TAATTCAATATAAACTGTCT 1634
:||||| |||||:|
Db 1 UAAUUCACAAACUGUTT 19

RESULT 364

US-10-646-391A-26
; Sequence 26, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
; LENGTH: 19
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-26

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.8e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1616 TAATTCAATATAAACTGTCT 1634
:||||| |||||:|
Db 1 UAAUUCACAAACUGUTT 19

RESULT 365

US-10-646-391A-27/c
; Sequence 27, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
; LENGTH: 19
; TYPE: DNA

; ORGANISM: artificial

; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-27

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1614 ACTAATTCAATATAAACTGT 1632
:||||| |||||:|
Db 19 AATAATTCAACAAACTGT 1

RESULT 366

US-10-646-436-7
; Sequence 7, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efethios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 19
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-7

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.8e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1616 TAATTCAATATAAACTGTCT 1634
:||||| |||||:|
Db 1 UAAUUCACAAACUGUTT 19

RESULT 367

US-10-646-436-8/c
; Sequence 8, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efethios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03

```

; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-8
Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1614 ACTAATTCATAATAAACTGT 1632
      | | | | | | | | | | | | | | | | | | |
Db      19 AATAATTCACAAAACCTGT 1

RESULT 368
US-10-667-271-305
; Sequence 305, Application US/10667271
; Publication No. US20040209831A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Beigelman, Leonid
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis C Virus (HCV)
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/129 (MHB02-763B)
; CURRENT APPLICATION NUMBER: US/10/667,271
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT / US03/05043
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT / US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: USSN 60/401,104
; PRIOR FILING DATE: 2002-08-05
; PRIOR APPLICATION NUMBER: USSN 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: USSN 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: USSN 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: USSN 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: USSN 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: USSN 60/409,293
; PRIOR FILING DATE: 2002-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1705
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1001
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-667-271-1001

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAAACCAACG 240
      | | | | | | | | | | | | | | | | | | |
Db      19 CTCAGAGAAAAAACCAACG 1

RESULT 370
US-09-866-108-8666
; Sequence 8666, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108

```

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCAGAAGAGAA 289
Db 1 GAAGCCAGAAGAGAA 17

RESULT 371
US-09-780-533A-170/c
; Sequence 170, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 170
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-170

Query Match 0.9%; Score 15.4; DB 1; Length 17;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCAGAAGAGAA 289
Db 1 GAAGCCAGAAGAGAA 17

RESULT 371
US-09-780-533A-170/c
; Sequence 170, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 170
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-170

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1619 TTCAATAAACTGCTT 1635
Db 17 TTCAATAAACTGCTT 1

RESULT 372
US-09-740-332-1542
; Sequence 1542, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1542
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1542

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 766 TCCAGCCATGTTCCAG 782
Db 1 UCCAGCCCAUGUCCGG 17

RESULT 373
US-09-740-332-3013/c
; Sequence 3013, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3013
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3013

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 767 CCAGCCATGTTCCAG 783
Db 17 CCAGCCATGTTCCGGC 1

RESULT 374

```
US-09-817-879-1542
; Sequence 1542, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1542
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-09-817-879-1542

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 766 TCCACGCCCATGTTCCAG 782
Db 1 UCCACGCCCAUGUCCGG 17

RESULT 375
US-09-817-879-3013/c
; Sequence 3013, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3013
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-09-817-879-3013

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 767 CCACGCCCATGTTCCAGC 783
Db 17 CCACGCCCATGTTCCGGC 1

RESULT 376
US-10-669-841-4135
; Sequence 4135, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Macejak
; APPLICANT: Dennis, Morrissey
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
```

```
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-4135

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 766 TCCACGCCCATGTTCCAG 782
Db 1 UCCACGCCCAUGUCCGG 17

RESULT 377
US-10-669-841-5606/c
; Sequence 5606, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Macejak
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
```

```
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5606
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5606

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 767 CCACGCCATGTTCCAGC 783
Db 17 CCACGCCATGTTCCGGC 1

RESULT 378
US-10-723-361-8666
; Sequence 8666, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8666

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCCAAGGAAGAA 289
Db 1 GAAGCCCAAGGAAGAA 17

RESULT 379
US-10-828-394-19/c
; Sequence 19, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: clusterin targeted sirna
US-10-828-394-19

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1616 TAATTCAATAAACTGT 1632
Db 17 TAATTCAACAAACTGT 1

RESULT 380
US-10-828-395-19/c
; Sequence 19, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
```

```

; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: clusterin targeted siRNA sequence
US-10-828-395-19

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1616 TAATTCAATAAACTGT 1632
Db 17 TAATTCAACAAACTGT 1

RESULT 381
US-10-758-451-883/c
; Sequence 883, Application US/10758451
; Publication No. US2005001471A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY (IES)
; TITLE OF INVENTION: INFLAMMATION
; FILE REFERENCE: 30775-705.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: 09/093,972
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 883
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-883

Query Match          0.9%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1531 CCCAGCCTCTCCCG 1545
Db 15 CCCAGCCTCTCCCG 1

RESULT 382
US-09-740-332-3014/c
; Sequence 3014, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3014
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate

```

```

US-09-740-332-3014

Query Match          0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCAGGCCCATGTTC 780
Db 15 TCCAGGCCCATGTTC 1

RESULT 383
US-09-817-879-3014/c
; Sequence 3014, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3014
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3014

Query Match          0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCAGGCCCATGTTC 780
Db 15 TCCAGGCCCATGTTC 1

RESULT 384
US-10-669-841-5607/c
; Sequence 5607, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124

```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5607
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5607

Query Match 0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCACGCCATGTTC 780
Db 15 TCCACGCCATGTTC 1

RESULT 385

US-10-497-692-11
; Sequence 11, Application US/10497692
; Publication No. US2005004056A1
; GENERAL INFORMATION:
; APPLICANT: Meise, Martin
; APPLICANT: Eulenberg, Karsten
; APPLICANT: Fritsch, Rudiger
; APPLICANT: Hader, Thomas
; APPLICANT: Bronner, Gunter
; APPLICANT: Steuernagel, Arnd
; TITLE OF INVENTION: PTP10D, Tec protein tyrosine kinase and EDP homologous proteins
; TITLE OF INVENTION: involved in the regulation of energy homeostasis
; FILE REFERENCE: 2923-632
; CURRENT APPLICATION NUMBER: US/10/497,692
; CURRENT FILING DATE: 2004-06-04
; PRIOR APPLICATION NUMBER: PCT/EP02/13744
; PRIOR FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: EP 01 000 010.5
; PRIOR FILING DATE: 2002-01-02
; PRIOR APPLICATION NUMBER: EP 01 129 138.2
; PRIOR FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: EP 01 128 844.6
; PRIOR FILING DATE: 2001-12-04
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: mouse PTPRB reverse primer
US-10-497-692-11

Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 764 CTTCCACGCCATGTTC 781
Db 17 CAGCTCCTCTTGTG 2

Db 1 CTTCCACGCCATGTTC 18

RESULT 386

US-09-866-108-8352/c
; Sequence 8352, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: SHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: A60MICA Sequence Listing Engine
; SEQ ID NO 8352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACCTCCTCTTGTG 1124
Db 17 CAGCTCCTCTTGTG 2

RESULT 387

US-09-866-108-8353/c
; Sequence 8353, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US 09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8353
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8353

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCCTCCTTGCTG 1124
DB 16 CAGCTCCTCCTTGCTG 1

RESULT 388
US-09-866-108-8665
Sequence 8665, Application US/09866108
Patent No. US2002004800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US 09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8665
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8665

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCCAAGAGAGA 288
DB 2 GAAGCCCAAGAGAGA 17

RESULT 389
US-09-866-108-8667
Sequence 8667, Application US/09866108
Patent No. US2002004800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US 09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8667

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 15; Conservative 0;

Qy 274 AAGCCAGAGAGAGAA 289
Db 1 AAGCCAGAGAGAGAA 16
|||||

RESULT 390
US-09-866-108-10037/c
; Sequence 10037, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10037

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 15; Conservative 0;

Qy 715 CCCGATCGTCCGAC 730
Db 17 CCCGATCGTCCAC 2
|||||

RESULT 391
US-09-866-108-10038/c
; Sequence 10038, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752

```
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10038
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10038

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCCGCATCGTCCGAC 730
Db 16 CCCGCATCGTCCACAG 1

RESULT 392
US-09-928-412-7
; Sequence 7, Application US/09928412
; Publication No. US20020123623A1
; GENERAL INFORMATION:
; APPLICANT: KAWAOKA, Akiyoshi
; APPLICANT: EBINUMA, Hiroyasu
; TITLE OF INVENTION: TRANSCRIPTION FACTOR CONTROLLING PHENYLPROPANOID
; FILE REFERENCE: BIOSYNTHESIS PATHWAY
; CURRENT FILING DATE: 2001-08-14
; PRIOR APPLICATION NUMBER: US/09/928,412
; PRIOR FILING DATE: 2001-08-14
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/282,146
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: JP 10-125171
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-03-31
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-928-412-7

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACACTCTCTCT 1119
Db 2 CTCACACACTCTCTCT 17

RESULT 393
US-09-780-533A-171/c
; Sequence 171, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 171
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-09-780-533A-171

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAAACTGTCT 1634
Db 16 TTCAATAAAACTGTCT 1

RESULT 394
US-09-877-478-1745/c
; Sequence 1745, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1745

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1519 CCCCCAACTCCGCCCA 1534
Db 16 CCCCCAACTCCTCCCA 1

RESULT 395
US-09-740-332-1543
; Sequence 1543, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1543
; LENGTH: 17
```

; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1543

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 768 CAGCCATGTTCCAGC 783
Db 1 CAGCGCAUGUCCGCG 16
|||||:|:|

RESULT 396

US-09-817-879-1543
; Sequence 1543, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1543
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1543

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 768 CAGCCATGTTCCAGC 783
Db 1 CAGCGCAUGUCCGCG 16
|||||:|:|

RESULT 397

US-10-298-255-4
; Sequence 4, Application US/10298255
; Publication No. US2003013412A1
; GENERAL INFORMATION:
; APPLICANT: BURGOYNE, LEIGH A.
; TITLE OF INVENTION: METHODS AND MATERIALS FOR DETECTING GENETIC MATERIAL
; FILE REFERENCE: 45858-56064
; CURRENT APPLICATION NUMBER: US/10/298,255
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: 60/336,005
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-298-255-4

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1508 CAGCCTCCAGGCCCCC 1523
Db 1 CAGCCTCCAGGCCCCC 16
|||||:|:|

RESULT 398

US-10-238-700-2912/c
; Sequence 2912, Application US/10238700
; Publication No. US2003015352A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2912
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2912

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1507 CCAGCCTCCAGGCCCCC 1522
Db 17 CCAGCCTGCAGGCCCCC 2
|||||:|:|

RESULT 399

US-10-339-793-366
; Sequence 366, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Shang, Jin
; APPLICANT: Bowen, Benjamin
; TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; FILE REFERENCE: 37-00031005
; CURRENT APPLICATION NUMBER: US/10/339,793
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 443
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-793-366

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 990 ACCAACCAACCCCTCCC 1005
Db 2 ATCAACAACCCCTCCC 17
|||||:|:|

RESULT 400

US-10-342-902-1745/c
; Sequence 1745, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:

Tue Sep 13 10:53:21 2005

```

; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1745

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1;

QY 1519 CCCCAACTCCGCCA 1534
DB 16 CCCCAACTCCGCCA 1

RESULT 401
US-10-138-674-8431/c
; Sequence 8431, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8431
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8431

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1;

QY 1545 GCTCTGGATCCTGCAC 1560
DB 17 GCTCTGCATCTCTGCAC 2

RESULT 402
US-10-138-674-8431/c
; Sequence 8431, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8431
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8431

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1;

QY 1545 GCTCTGGATCCTGCAC 1560
DB 17 GCTCTGCATCTCTGCAC 2

RESULT 402

```

```

US-10-287-949A-8431/c
; Sequence 8431, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8431
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8431

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1;

QY 1545 GCTCTGGATCCTGCAC 1560
DB 17 GCTCTGCATCTCTGCAC 2

RESULT 403
US-10-669-841-1745/c
; Sequence 1745, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0

```

; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1745

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1519 CCCCCAACTCCGCCA 1534
Db 16 CCCCCAACTCCTCCCA 1

RESULT 404

US-10-669-841-4136
; Sequence 4136, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4136
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4136

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 768 CACCCATGTTCCAGC 783
Db 1 CACGCCAUGUUCGGC 16

RESULT 405

US-10-723-361-8352/c
; Sequence 8352, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACCTCCTCTTGCTG 1124
Db 17 CAGCTCCTCTTGCTG 2

RESULT 406

US-10-723-361-8353/c
; Sequence 8353, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105

```
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8353

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACTCTCTCTTGCTG 1124
Db 16 CAGCTCTCTCTTGCTG 1

RESULT 407
US-10-723-361-8665
; Sequence 8665, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8665

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACTCTCTCTTGCTG 1124
Db 16 CAGCTCTCTCTTGCTG 1

RESULT 407
US-10-723-361-8665
; Sequence 8665, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8667

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 274 AAGCCCAAGAGAGAA 289
Db 1 AAGCCCAAGAGAGAA 16

RESULT 408
US-10-723-361-8667
; Sequence 8667, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8667

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 274 AAGCCCAAGAGAGAA 289
Db 1 AAGCCCAAGAGAGAA 16
```

RESULT 409

US-10-723-361-10037/c
; Sequence 10037, Application US/107233361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10037

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 715 CCCGCATCGTCCGCAG 730
Db 17 CCCGCATCGTCCACAG 2

RESULT 410

US-10-723-361-10038/c
; Sequence 10038, Application US/107233361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10038
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10038

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 715 CCCGCATCGTCCGCAG 730
Db 16 CCCGCATCGTCCACAG 1

RESULT 411

US-10-712-633-3472/c
; Sequence 3472, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3472
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens

US-10-712-633-3472

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTCTGGATCTGCAC 1560
|||||
Db 17 GCTCTGGATCTGCAC 2

RESULT 412

US-10-724-270-1591/c
; Sequence 1591, Application US/10724270
; Publication No. US2005008031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Leve

; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1591
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1591

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCCTCAGGCCCC 1522
|||||
Db 17 CCAGCCTCAGGCCCC 2

RESULT 413

US-11-016-291-4
; Sequence 4, Application US/11016291
; Publication No. US20050095641A1
; GENERAL INFORMATION:
; APPLICANT: BURGOWNE, LEIGH A.
; TITLE OF INVENTION: METHODS AND MATERIALS FOR DETECTING GENETIC MATERIAL
; FILE REFERENCE: 45858-56064
; CURRENT APPLICATION NUMBER: US/11/016,291
; CURRENT FILING DATE: 2004-12-17
; PRIOR APPLICATION NUMBER: 60/336,005
; PRIOR FILING DATE: 2001-11-15

; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-11-016-291-4

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCAGGCCCC 1523
|||||
Db 1 CAGCCTCAGGCCCC 16

RESULT 414

US-09-263-959-1251/c
; Sequence 1251, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/09/263,959
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 1251:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-1251

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 634 TCACCCGGGAGCCCA 649
|||||
Db 17 TCACCCGGGAGCCCA 2

RESULT 415

US-10-108-260A-5102
; Sequence 5102, Application US/10108260A
; Publication No. US2004000560A1


```
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US20040005560A1el full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5102
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized p
US-10-108-260A-5102

Query Match          0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1094 GTGGAAGATGCTCAAC 1109
Db 1 GTGGAAGATGCTCGAC 16

RESULT 416
US-10-758-451-884/c
; Sequence 884, Application US/10758451
; Publication No. US20050014711A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY (IES)
; FILE REFERENCE: 30775-706.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 884
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-884

Query Match          0.9%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1532 CCAGCCTCTCCCCG 1545
Db 14 CCAGCCTCTCCCCG 1

RESULT 417
US-09-930-423-9
; Sequence 9, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-930-423-9

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1531 CCAGCCTCTCCCC 1544
Db 1 CCAGCCUCUCUCCCC 14

RESULT 418
US-09-930-423-359
; Sequence 359, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 359
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-930-423-359

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1531 CCAGCCTCTCCCC 1544
Db 3 CCAGCCUCUCUCCCC 16

RESULT 419
US-09-930-423-360
; Sequence 360, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-930-423-360

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1531 CCAGCCTCTCCCC 1544
Db 2 CCAGCCUCUCUCCCC 15

RESULT 420
US-09-740-332-1541
; Sequence 1541, Application US/09740332
```

```
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1541

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCGCATGTTTC 779
      :|||||||:|:|
      4 UCCACGCCAUGUUC 17

RESULT 421
US-09-745-237A-9
; Sequence 9, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-9

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCGCATGTTTC 779
      :|||||||:|:|
      4 UCCACGCCAUGUUC 17

RESULT 422
US-09-745-237A-359
; Sequence 359, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 359
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-359

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1531 CCCAGCCTCTCCCC 1544
      :|||||||:|:|
      3 CCCAGCCUCUCCCC 16

RESULT 423
US-09-745-237A-360
; Sequence 360, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-360

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1531 CCCAGCCTCTCCCC 1544
      :|||||||:|:|
      2 CCCAGCCUCUCCCC 15

RESULT 424
US-09-817-879-1541
; Sequence 1541, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1541

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCGCATGTTTC 779
      :|||||||:|:|
      4 UCCACGCCAUGUUC 17
```

RESULT 425

US-10-307-005-955/c
; Sequence 955, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kniec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2002-11-26
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 955
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Eucalyptus camaldulensis
US-10-307-005-955

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1202 GGTCAACACGGTGG 1215
Db 14 GGTCAACACGGTGG 1

RESULT 426

US-10-307-005-956
; Sequence 956, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kniec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 956
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Eucalyptus camaldulensis
US-10-307-005-956

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1202 GGTCAACACGGTGG 1215
Db 4 GGTCAACACGGTGG 17

RESULT 427

US-10-669-841-4134
; Sequence 4134, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4134
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4134

Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCACGCCATGTC 779
Db 4 UCCACGCCAUGUC 17

RESULT 428

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2001-02-05
; PRIOR APPLICATION NUMBER: US 60/266,860
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7355

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 89.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAGAA 286
DB 1 GAAGAGCCCGCAGAA 17

RESULT 431

US-09-866-108-7485/c
; Sequence 7485, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7485

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCAGCCTCTCCCGC 1546
DB 17 GTCAGCCTCTCTCGC 1

RESULT 432

US-09-866-108-8568
; Sequence 8568, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8568

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

RESULT 433
US-09-866-108-8660
; Sequence 8660, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

```

; ORGANISM: Homo sapiens
US-09-866-108-8660

Query Match	0.8%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%	Pred. No. 3.3e+02;		
Matches 15; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

RESULT 434
US-09-866-108-8661
; Sequence 8661, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSTIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: AeoMica Sequence Listing Engine
; SEQ ID NO 8661
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8661

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      268 TAGAAGAAGCCAGAAG 284
          | | | | | | | | | | | | | | | |
Db      1 TGGAGGAAGCCAGAAG 17
          | | | | | | | | | | | | | | | |

```

RESULT 435

US-09-866-108-8663
; Sequence 8663, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8663
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8663

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 270 GAAGAAGCCAAAGAA 286
|||
Db 1 GAGGAAGCCAAAGGA 17

RESULT 436

US-09-866-108-8664
; Sequence 8664, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8664
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8664

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 271 AAGAAGCCAAAGAG 287
|||
Db 1 AGGAAGCCAAAGAG 17

RESULT 437

US-09-866-108-9687/c
; Sequence 9687, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9687

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 93 GAGAGTGGCGAGTCCT 109
|||||||
Db 17 GAGAGTGGCGAGTCCT 1

RESULT 438
US-09-866-108-9688/c
; Sequence 9688, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9688

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 92 GGAGAGTGGCGAGTCCT 108
|||||||
Db 17 GGAGAGTGGCGAGTCCT 1

RESULT 439
US-09-866-108-9689/c
; Sequence 9689, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Ascmica Sequence Listing Engine
; SEQ ID NO 9689
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9689

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GGGAGAGTGGCAGGTC 107
Db 17 GGGAGAGTGGCAGGTC 1

RESULT 440
US-09-776-291A-4/c
; Sequence 4, Application US/09776291A
; Patent No. US20020123046A1
; GENERAL INFORMATION:
; APPLICANT: SMITH, Lloyd M.
; APPLICANT: HOOD, Leroy E.
; APPLICANT: HUNKAPILLER, Michael W.
; APPLICANT: HUNKAPILLER, Tim J.
; APPLICANT: CONNELL, Charles R.
; TITLE OF INVENTION: AUTOMATED DNA SEQUENCING TECHNIQUE
; FILE REFERENCE: 24313200106
; CURRENT APPLICATION NUMBER: US/09/776,291A
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 08/484,340
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/361,176
; PRIOR FILING DATE: 1994-12-21
; PRIOR APPLICATION NUMBER: 07/898,019
; PRIOR FILING DATE: 1992-06-12
; PRIOR APPLICATION NUMBER: 07/660,160
; PRIOR FILING DATE: 1991-02-21
; PRIOR APPLICATION NUMBER: 07/106,232
; PRIOR FILING DATE: 1987-10-07
; PRIOR APPLICATION NUMBER: 06/722,742
; PRIOR FILING DATE: 1985-04-11
; PRIOR APPLICATION NUMBER: 06/689,013
; PRIOR FILING DATE: 1985-01-02
; PRIOR APPLICATION NUMBER: 06/570,973
; PRIOR FILING DATE: 1984-01-16
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct
US-09-776-291A-4

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1357 AAGCGCTGCAGGATAC 1373
Db 17 ATGCTCTGCAGGATAC 1

RESULT 441
US-09-864-785-115
; Sequence 115, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 115
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-115

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 988 CCACCAACACCCCTCC 1004
Db 1 CCAACACACCCCTCC 17

RESULT 442
US-09-864-785-117
; Sequence 117, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 117
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-117

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 992 CAACACCCCTCCAGG 1008
Db 1 CAACACCCCTCCAGG 17

RESULT 443
US-09-864-785-213
; Sequence 213, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 213
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
;
US-09-864-785-213

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1501 CAGCCCCCAGCTCCAG 1517
Db 1 CAGACCCCGCAGCCGCGAG 17

RESULT 444
US-09-864-785-215
; Sequence 215, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 215
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
;
US-09-864-785-215

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1505 CCCCAGCTCCAGGCC 1521
Db 1 CCCCAGCCGCGAGGCUC 17

RESULT 445
US-09-864-785-336
; Sequence 336, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
```

```
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
;
US-09-864-785-336

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1505 CCCCAGCTCCAGGCC 1521
Db 1 CCCCAGGCUCCAGCCCC 17

RESULT 446
US-09-864-785-1519
; Sequence 1519, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1519
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
;
US-09-864-785-1519

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1502 AGCCCCCAGCTCCAGG 1518
Db 1 AGACCCCGCAGCCGCGAG 17

RESULT 447
US-09-864-785-1520
; Sequence 1520, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1520
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1520

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1506 CCCAGCCTCCAGGCC 1522
Db 1 CCCAGCCUGCAGGCC 17

RESULT 448
US-09-864-785-2036
; Sequence 2036, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2036
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2036

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 989 CACCAACACCCCTCCC 1005
Db 1 CAACAACACCCCUCC 17

RESULT 449
US-09-961-077-687/c
; Sequence 687, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 687:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 687:
US-09-961-077-687

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1213 TGGCTTCCACACTTCT 1229
Db 17 TGGCTGCCACACTTCT 1

RESULT 450
US-09-780-533A-1053/c
; Sequence 1053, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1053
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; OTHER INFORMATION:
US-09-780-533A-1053

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1622 AATAAACTCTTTGTG 1638
Db 17 ATTAATACTCTTTTG 1
```

```
RESULT 451
US-09-780-533A-1885/c
; Sequence 1885, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1885
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-1885

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1621 CAATAAACTGCTCTGT 1637
||| ||||| ||||| |||
Db 17 CAATAAACTGCTCTTT 1

RESULT 452
US-09-093-972C-874/c
; Sequence 874, Application US/09093972C
; Publication No. US20030087845A1
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/093,972C
; FILING DATE: 09-Jun-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 08/757,024
; FILING DATE: 26-11-1996
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 09/016,464
; FILING DATE: 30-January-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 944:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

RESULT 453
US-09-093-972C-944/c
; Sequence 944, Application US/09093972C
; Publication No. US20030087845A1
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/093,972C
; FILING DATE: 09-Jun-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 08/757,024
; FILING DATE: 26-11-1996
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 09/016,464
; FILING DATE: 30-January-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 944:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 944:
US-09-093-972C-944

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCCAGCCTGCCCCGC 1546
Db 17 GCCCAGCCTGCCCCGC 1

RESULT 454

US-09-930-423-57/c
; Sequence 57, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A,400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 57
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-57

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 643 AGCCCCAGGATACCTAC 659
Db 17 AGCCCCAGGATGCCTTC 1

RESULT 455

US-09-827-395A-880
; Sequence 880, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 880
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-880

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 CCTTGCTGCAGCAGCTG 1133
||:|||||:

Db 1 CCCUCCUGGAGCAGCUG 17

RESULT 456

US-09-740-332-632
; Sequence 632, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-632

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 3.3e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 1400 TGTGGATGTTGCTTTTG 1416
:|||:|:|:|:
Db 1 UGUGGAUGAUCUGUUG 17

RESULT 457

US-09-740-332-2161
; Sequence 2161, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2161

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 689 GAGGCCTCACTTCTTCT 705
|||:|:|:|:|:
Db 1 GAUGACUCACUUCUUCU 17

RESULT 458

US-09-740-332-3012/c
; Sequence 3012, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3012
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3012

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 769 ACGCCATGTTCCAGCCC 785
Db 17 ACGCCATGTTCCGCTC 1

RESULT 459
US-09-792-818-440/c
; Sequence 440, Application US/09/792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insertion
; TITLE OF INVENTION: (GRD) Gens
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 440
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-440

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1539 CTCCTCCGCTCTGGATCC 1555
Db 17 CTCCTCCGCTGTGGAACC 1

RESULT 460
US-09-745-237A-57/c
; Sequence 57, Application US/09/745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 57
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-57

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 643 AGCCCCAGGATACCTAC 659
Db 17 AGCCCCAGGATGCCTTC 1

RESULT 461
US-09-817-879-632
; Sequence 632, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-632

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 3.3e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1400 TGTGGATGTTGCTTTTG 1416
Db 1 UGUGGAUGAUGCUGUG 17
```

```
RESULT 462
US-09-817-879-2161
; Sequence 2161, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2161

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```

; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-10-079-625-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 465
US-10-079-625-27
; Sequence 27, Application US/10079625
; Publication No. US20020182676A1
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/079,625
; FILING DATE: 2002-FEB-19
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996

```

```
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-10-079-625-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 466
US-10-060-756A-748
; Sequence 748, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 748
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-748

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 467
US-10-060-756A-749
; Sequence 749, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 749
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-749

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCCTGCTGG 538
Db 1 AGCGACTCACTGCTGG 17

RESULT 468
US-10-060-756A-1238
; Sequence 1238, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 748
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-748

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCCTGCTGG 538
Db 1 AGCGACTCACTGCTGG 17

RESULT 469
US-10-060-756A-1239
; Sequence 1239, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 749
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-749

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCCTGCTGG 538
Db 1 AGCGACTCACTGCTGG 17
```

```
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 521 CATCGACTCCCTGCTGG 537
Db 1 CAGCGACTCACTGCTGG 17

RESULT 467
US-10-060-756A-749
; Sequence 749, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 749
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-749

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCCTGCTGG 538
Db 1 AGCGACTCACTGCTGG 17

RESULT 468
US-10-060-756A-1238
; Sequence 1238, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 748
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1238

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCCTGCTGG 538
Db 1 AGCGACTCACTGCTGG 17
```


Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 3.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1117 CCTGCTGGAGCAGCTG 1133

```
Db      1  CCCUCCUGGAGCAGCUG 17

RESULT 473
US-10-138-674-3543
; Sequence 3543, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3543
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3543

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1112  CTCCTCTGCTGGAGC 1128
Db      1  CUCCCCUUGCUGAAGC 17
      |:|:|:|:|:|:|:|:|

RESULT 474
US-10-138-674-4182
; Sequence 4182, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4182
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4182

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1115  CTCCTTGTGGAGCAGC 1131
Db      1  CUCCUGGCGUGAGCGCG 17
      |:|:|:|:|:|:|:|:|

RESULT 475
US-10-287-949A-3543
; Sequence 3543, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3543
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3543

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1112  CTCCTCTGCTGGAGC 1128
Db      1  CUCCCCUUGCUGAAGC 17
      |:|:|:|:|:|:|:|:|

RESULT 476
US-10-287-949A-4182
; Sequence 4182, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4182
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4182

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1115  CTCCTTGTGGAGCAGC 1131
Db      1  CUCCUGGCGUGAGCGCG 17
      |:|:|:|:|:|:|:|:|

RESULT 477
US-10-712-672-564/C
; Sequence 564, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
```

; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 564
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-564

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 101 GCAGGTCCTGGGGACC 117
Db 17 GCAGGCCACGGGGACC 1

RESULT 478

US-10-712-672-1193
; Sequence 1193, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1193
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1193

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.3e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1321 GGAGGACCCCTAATTT 1337
Db 1 GGAAGACCCCAUAUU 17

RESULT 479

US-10-669-841-3225
; Sequence 3225, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA

; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3225
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3225

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 3.3e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 1400 TGTGGATGTGCTTTTG 1416
Db 1 UGUGGAUGAUGCUGUUG 17

RESULT 480

US-10-669-841-4754
; Sequence 4754, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055

```
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-4754
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      689 GAGGCCTCACCTCTCT 705
Db      1 GAUGACUCACUUCUCU 17
||| | | | | | | | | | | | | | | |
```

```
RESULT 481
US-10-669-841-5605/c
; Sequence 5605, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macsjak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Favco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS A VIRUS
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
```

```
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-5605
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      769 AGCCCATGTTCCAGCCC 785
Db      17 AGCCCATGTTCCGGCTC 1
||||| | | | | | | | | | | | |
```

```
RESULT 482
US-10-723-361-1895/c
; Sequence 1895, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANTI-ATROPHY
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1895
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
```

Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 93 GAGAGTGGCAGGTCCT 109
||||| ||||| ||||| ||||| |||||
Db 17 GAGAGAGCCAGGTCCT 1

RESULT 483

US-10-723-361-2643/c
; Sequence 2643, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2643
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2643

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 845 CTTCGAGCCAGCCGCAA 861
||||| ||||| ||||| ||||| |||||
Db 17 CTGCGAGCCAGCCGCAA 1
RESULT 484
US-10-723-361-7355
; Sequence 7355, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2643
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2643

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 845 CTTCGAGCCAGCCGCAA 861
||||| ||||| ||||| ||||| |||||
Db 17 CTGCGAGCCAGCCGCAA 1

RESULT 484

US-10-723-361-7355
; Sequence 7355, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2643
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7355

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7355

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 270 GAAGAAGCCCAAGAGAA 286
||||| ||||| ||||| ||||| |||||
Db 1 GAAGAAGCCCAAGAGAA 17

RESULT 485

US-10-723-361-7485/c
; Sequence 7485, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7485

US-10-723-361-7485/c
; Sequence 7485, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7485

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7485

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GTCCAGCCTCTCCCGC 1

RESULT 486
US-10-723-361-8568
; Sequence 8568, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8568

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 292 AGGATGCCCTAAATGAG 308
Db 1 AGGATGACCTGAATGAG 17
RESULT 487
US-10-723-361-8660
; Sequence 8660, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8660

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 267 CTAGAAGAGCAAGAA 283
Db 1 CTGGAGAGCAAGAA 17

RESULT 488
US-10-723-361-8661
; Sequence 8661, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8661
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8661

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 268 TAGAAGAGCCCAAGAG 284
Db 1 TGGAGGAGCCCAAGAG 17

RESULT 489
US-10-723-361-8663
; Sequence 8663, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8662
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8662

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8663
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8663

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 270 GAAGAAGCCCAAGAGAA 286
Db 1 GAGGAGCCCAAGAGGA 17

RESULT 490
US-10-723-361-8664
; Sequence 8664, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8664
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8664

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 271 AAGAAGCCCAAGAGAG 287
Db 1 AGGAAGCCCAAGAGAG 17

RESULT 491

US-10-723-361-9687/c
; Sequence 9687, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9687

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCGAGGTCT 109

Db 17 GAGAGTGGCGAGTCT 1

RESULT 492

US-10-723-361-9688/c
; Sequence 9688, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9688

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 92 GGAGAGTGGCGAGTCT 108

Db 17 GGAGAGTGGCGAGTCT 1

RESULT 493

US-10-723-361-9689/c
; Sequence 9689, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30


```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9689
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9689

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GGGAGAGTGGCAGATC 107
Db 17 GGGAGAGTGGCAGATC 1

RESULT 494
US-10-758-451-944/c
; Sequence 944, Application US/10758451
; Publication No. US20050014711A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY (IES)
; TITLE OF INVENTION: INFLAMMATION
; FILE REFERENCE: 30775-706.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: 09/093,972
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 944
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-944

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCCGC 1

RESULT 495
US-10-890-776A-748
; Sequence 748, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 749
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-749

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCCTGCTGG 538
Db 1 AGCGACTCACTGCTGG 17

RESULT 497
US-10-890-776A-1238
; Sequence 1238, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
```

```
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 748
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-748

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 521 CATCGACTCCCTGCTGG 537
Db 1 CAGCGACTCACTGCTGG 17

RESULT 496
US-10-890-776A-749
; Sequence 749, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 749
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-749

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCCTGCTGG 538
Db 1 AGCGACTCACTGCTGG 17

RESULT 497
US-10-890-776A-1238
; Sequence 1238, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
```

```
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Ascomica Sequence Listing Engine
; SEQ ID NO 1238
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-1238
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1273 TCTTGACTCTGATCCC 1289
      ||| ||||| |||||
Db 1 TCTGACTGTGATCCC 17
```

```
Search completed: September 13, 2005, 10:47:07
Job time : 12 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:39:51 ; Search time 5 Seconds
(without alignments)
3.649 Million cell updates/sec

Title: us-10-828-394-1
Perfect score: 1643
Sequence: 1 gaattccgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 298 seqs, 5552 residues

Total number of hits satisfying chosen parameters: 596

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 298 summaries

Database : rgedb.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	27.2	1.7	32	1	ACCESSION:A21575
2	26	1.6	26	1	ACCESSION:AR030627
3	26	1.6	26	1	ACCESSION:AR197662
4	26	1.6	26	1	ACCESSION:AR259816
5	25	1.5	25	1	ACCESSION:AR030628
6	25	1.5	25	1	ACCESSION:AR197663
7	25	1.5	25	1	ACCESSION:AR259817
8	23	1.4	23	1	ACCESSION:Q0786169
9	23	1.4	23	1	ACCESSION:Q0786172
10	23	1.4	23	1	ACCESSION:Q0786175
11	23	1.4	23	1	ACCESSION:Q0786178
12	23	1.4	23	1	ACCESSION:AR208706
13	21	1.3	21	1	ACCESSION:AR038687
14	21	1.3	21	1	ACCESSION:Q0786113
15	21	1.3	21	1	ACCESSION:Q0786114
16	21	1.3	21	1	ACCESSION:Q0786115
17	21	1.3	21	1	ACCESSION:Q0786116
18	21	1.3	21	1	ACCESSION:Q0786117
19	21	1.3	21	1	ACCESSION:Q0786118
20	21	1.3	21	1	ACCESSION:Q0786170
21	21	1.3	21	1	ACCESSION:Q0786171
22	21	1.3	21	1	ACCESSION:Q0786173
23	21	1.3	21	1	ACCESSION:Q0786174
24	21	1.3	21	1	ACCESSION:Q0786176
25	21	1.3	21	1	ACCESSION:Q0786177
26	21	1.3	21	1	ACCESSION:Q0786614
27	21	1.3	21	1	ACCESSION:Q0786615
28	21	1.3	21	1	ACCESSION:Q0786616
29	21	1.3	21	1	ACCESSION:Q0786617
30	21	1.3	21	1	ACCESSION:Q0786618
31	21	1.3	21	1	ACCESSION:Q0786619
32	21	1.3	21	1	ACCESSION:Q0786620
33	21	1.3	21	1	ACCESSION:Q0786621

C 34	21	1.3	21	1	Q0786622
C 35	21	1.3	21	1	Q0786623
C 36	21	1.3	21	1	Q0786631
C 37	21	1.3	21	1	Q0786632
C 38	21	1.3	21	1	Q0786633
C 39	21	1.3	21	1	Q0786634
C 40	21	1.3	21	1	Q0786636
C 41	21	1.3	21	1	Q0786647
C 42	21	1.3	21	1	Q0786648
C 43	21	1.3	21	1	Q0786649
C 44	21	1.3	21	1	Q0786650
C 45	21	1.3	21	1	Q0786651
C 46	21	1.3	21	1	Q0786652
C 47	21	1.3	21	1	AR208707
C 48	21	1.3	21	1	AR236282
C 49	20.8	1.3	24	1	BD230318
C 50	20.6	1.3	21	1	AR531218
C 51	20.6	1.3	21	1	AR531219
C 52	20.6	1.3	21	1	AR531220
C 53	20.6	1.3	21	1	AR531221
C 54	20.6	1.3	21	1	AX097243
C 55	20.6	1.3	21	1	AX097244
C 56	20.6	1.3	21	1	AX097245
C 57	20.6	1.3	21	1	AX097246
C 58	20	1.2	20	1	Q0803453
C 59	20	1.2	20	1	Q0803454
C 60	20	1.2	20	1	AR208715
C 61	20	1.2	20	1	AR208716
C 62	20	1.2	20	1	AR208717
C 63	20	1.2	20	1	AR208718
C 64	20	1.2	20	1	AR208719
C 65	20	1.2	20	1	AR208720
C 66	20	1.2	20	1	AR208721
C 67	20	1.2	20	1	AR208722
C 68	20	1.2	20	1	AR208723
C 69	20	1.2	20	1	AR208724
C 70	20	1.2	20	1	AR208725
C 71	20	1.2	20	1	AR208726
C 72	20	1.2	20	1	AR208727
C 73	20	1.2	20	1	AR208728
C 74	20	1.2	20	1	AR208729
C 75	20	1.2	20	1	AR208730
C 76	20	1.2	20	1	AR208731
C 77	20	1.2	20	1	AR208732
C 78	20	1.2	20	1	AR208733
C 79	20	1.2	20	1	AR208734
C 80	20	1.2	20	1	AR208735
C 81	20	1.2	20	1	AR208736
C 82	20	1.2	20	1	AR208737
C 83	20	1.2	20	1	AR208738
C 84	20	1.2	20	1	AR208739
C 85	20	1.2	20	1	AR208740
C 86	20	1.2	20	1	AR208741
C 87	20	1.2	20	1	AR208742
C 88	20	1.2	20	1	AR208743
C 89	20	1.2	20	1	AR208744
C 90	20	1.2	20	1	AR208745
C 91	20	1.2	20	1	AR208746
C 92	20	1.2	20	1	AR208747
C 93	20	1.2	20	1	AR208748
C 94	20	1.2	20	1	AR208749
C 95	20	1.2	20	1	AR208750
C 96	20	1.2	20	1	AR208751
C 97	20	1.2	20	1	AR208752
C 98	20	1.2	20	1	AR208753
C 99	20	1.2	20	1	AR208754
C 100	20	1.2	20	1	AR208755
C 101	20	1.2	20	1	AR208756
C 102	20	1.2	20	1	AR208757
C 103	20	1.2	20	1	AR208758
C 104	20	1.2	20	1	AR208759
C 105	20	1.2	20	1	AR208760
C 106	20	1.2	20	1	AR208761

ACCESSION:Q0786622	ACCESSION:Q0786623	ACCESSION:Q0786631	ACCESSION:Q0786632	ACCESSION:Q0786633	ACCESSION:Q0786634	ACCESSION:Q0786636	ACCESSION:Q0786647	ACCESSION:Q0786648	ACCESSION:Q0786649	ACCESSION:Q0786650	ACCESSION:Q0786651	ACCESSION:Q0786652	ACCESSION:AR208707	ACCESSION:AR236282	ACCESSION:BD230318	ACCESSION:AR531218	ACCESSION:AR531219	ACCESSION:AR531220	ACCESSION:AR531221	ACCESSION:AX097243	ACCESSION:AX097244	ACCESSION:AX097245	ACCESSION:AX097246	ACCESSION:Q0803453	ACCESSION:Q0803454	ACCESSION:AR208715	ACCESSION:AR208716	ACCESSION:AR208717	ACCESSION:AR208718	ACCESSION:AR208719	ACCESSION:AR208720	ACCESSION:AR208721	ACCESSION:AR208722	ACCESSION:AR208723	ACCESSION:AR208724	ACCESSION:AR208725	ACCESSION:AR208726	ACCESSION:AR208727	ACCESSION:AR208728	ACCESSION:AR208729	ACCESSION:AR208730	ACCESSION:AR208731	ACCESSION:AR208732	ACCESSION:AR208733	ACCESSION:AR208734	ACCESSION:AR208735	ACCESSION:AR208736	ACCESSION:AR208737	ACCESSION:AR208738	ACCESSION:AR208739	ACCESSION:AR208740	ACCESSION:AR208741	ACCESSION:AR208742	ACCESSION:AR208743	ACCESSION:AR208744	ACCESSION:AR208745	ACCESSION:AR208746	ACCESSION:AR208747	ACCESSION:AR208748	ACCESSION:AR208749	ACCESSION:AR208750	ACCESSION:AR208751	ACCESSION:AR208752	ACCESSION:AR208753	ACCESSION:AR208754	ACCESSION:AR208755	ACCESSION:AR208756	ACCESSION:AR208757	ACCESSION:AR208758	ACCESSION:AR208759	ACCESSION:AR208760	ACCESSION:AR208761
--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------

C 107	20	1.2	20	1	AR208762	ACCESSION:AR208762	C 180	14.4	0.9	17	1	AR466360	ACCESSION:AR466360
C 108	20	1.2	20	1	AR208763	ACCESSION:AR208763	C 181	14.4	0.9	17	1	AR466361	ACCESSION:AR466361
C 109	20	1.2	20	1	AR208764	ACCESSION:AR208764	C 182	14.4	0.9	17	1	AX214729	ACCESSION:AX214729
C 110	20	1.2	20	1	AR208765	ACCESSION:AR208765	C 183	14.4	0.9	17	1	AX688718	ACCESSION:AX688718
C 111	20	1.2	20	1	AR208766	ACCESSION:AR208766	C 184	14.4	0.9	17	1	AX688720	ACCESSION:AX688720
C 112	20	1.2	20	1	AR208767	ACCESSION:AR208767	C 185	14.4	0.9	17	1	AX732888	ACCESSION:AX732888
C 113	20	1.2	20	1	AR208768	ACCESSION:AR208768	C 186	14.4	0.9	17	1	AX760623	ACCESSION:AX760623
C 114	20	1.2	20	1	AR208769	ACCESSION:AR208769	C 187	14.4	0.9	18	1	AR067404	ACCESSION:AR067404
C 115	20	1.2	20	1	AR208770	ACCESSION:AR208770	C 188	14.4	0.9	18	1	AX837978	ACCESSION:AX837978
C 116	20	1.2	20	1	AR208771	ACCESSION:AR208771	C 189	14	0.9	17	1	AX324817	ACCESSION:AX324817
C 117	20	1.2	20	1	AR208772	ACCESSION:AR208772	C 190	14	0.9	17	1	AX324818	ACCESSION:AX324818
C 118	20	1.2	20	1	AR208773	ACCESSION:AR208773	C 191	13.8	0.8	17	1	AR039619	ACCESSION:AR039619
C 119	20	1.2	20	1	AR208774	ACCESSION:AR208774	C 192	13.8	0.8	17	1	AR081753	ACCESSION:AR081753
C 120	20	1.2	20	1	AR208775	ACCESSION:AR208775	C 193	13.8	0.8	17	1	AR081755	ACCESSION:AR081755
C 121	20	1.2	20	1	AR208776	ACCESSION:AR208776	C 194	13.8	0.8	17	1	AR094983	ACCESSION:AR094983
C 122	20	1.2	20	1	AR208777	ACCESSION:AR208777	C 195	13.8	0.8	17	1	AR167987	ACCESSION:AR167987
C 123	20	1.2	20	1	AR208778	ACCESSION:AR208778	C 196	13.8	0.8	17	1	AR167987	ACCESSION:AR167987
C 124	20	1.2	20	1	AR208781	ACCESSION:AR208781	C 197	13.8	0.8	17	1	BD254845	ACCESSION:BD254845
C 125	20	1.2	21	1	CQ786639	ACCESSION:CQ786639	C 198	13.8	0.8	17	1	CQ617155	ACCESSION:CQ617155
C 126	19.4	1.2	21	1	AR236281	ACCESSION:AR236281	C 199	13.8	0.8	17	1	CQ617903	ACCESSION:CQ617903
C 127	19	1.2	19	1	CQ786179	ACCESSION:CQ786179	C 200	13.8	0.8	17	1	CQ622745	ACCESSION:CQ622745
C 128	19	1.2	19	1	CQ786180	ACCESSION:CQ786180	C 201	13.8	0.8	17	1	CQ622745	ACCESSION:CQ622745
C 129	19	1.2	19	1	CQ786653	ACCESSION:CQ786653	C 202	13.8	0.8	17	1	CQ623828	ACCESSION:CQ623828
C 130	19	1.2	19	1	CQ786654	ACCESSION:CQ786654	C 203	13.8	0.8	17	1	CQ623920	ACCESSION:CQ623920
C 131	19	1.2	21	1	CQ786122	ACCESSION:CQ786122	C 204	13.8	0.8	17	1	CQ623921	ACCESSION:CQ623921
C 132	19	1.2	21	1	CQ786640	ACCESSION:CQ786640	C 205	13.8	0.8	17	1	CQ623923	ACCESSION:CQ623923
C 133	18.8	1.1	22	1	AR071119	ACCESSION:AR071119	C 206	13.8	0.8	17	1	CQ623924	ACCESSION:CQ623924
C 134	18.8	1.1	22	1	E15141	ACCESSION:E15141	C 207	13.8	0.8	17	1	CQ624947	ACCESSION:CQ624947
C 135	18	1.1	22	1	AR038688	ACCESSION:AR038688	C 208	13.8	0.8	17	1	CQ624948	ACCESSION:CQ624948
C 136	18	1.1	18	1	AR208705	ACCESSION:AR208705	C 209	13.8	0.8	17	1	CQ624949	ACCESSION:CQ624949
C 137	17	1.0	17	1	AX728619	ACCESSION:AX728619	C 210	13.8	0.8	17	1	B65210	ACCESSION:B65210
C 138	17	1.0	17	1	AR167026	ACCESSION:AR167026	C 211	13.8	0.8	17	1	AR192271	ACCESSION:AR192271
C 139	16.8	1.0	20	1	AR210681	ACCESSION:AR210681	C 212	13.8	0.8	17	1	AR196222	ACCESSION:AR196222
C 140	16.8	1.0	20	1	A39125	ACCESSION:A39125	C 213	13.8	0.8	17	1	AR213316	ACCESSION:AR213316
C 141	16	1.0	16	1	AR063448	ACCESSION:AR063448	C 214	13.8	0.8	17	1	AR213318	ACCESSION:AR213318
C 142	16	1.0	16	1	AR123639	ACCESSION:AR123639	C 215	13.8	0.8	17	1	AR256153	ACCESSION:AR256153
C 143	16	1.0	16	1	AR267380	ACCESSION:AR267380	C 216	13.8	0.8	17	1	AR256155	ACCESSION:AR256155
C 144	16	1.0	16	1	AR305790	ACCESSION:AR305790	C 217	13.8	0.8	17	1	AR275110	ACCESSION:AR275110
C 145	16	1.0	16	1	AR023187	ACCESSION:AR023187	C 218	13.8	0.8	17	1	AR275112	ACCESSION:AR275112
C 146	16	1.0	16	1	AX417393	ACCESSION:AX417393	C 219	13.8	0.8	17	1	AR306243	ACCESSION:AR306243
C 147	16	1.0	16	1	AR029848	ACCESSION:AR029848	C 220	13.8	0.8	17	1	AR306245	ACCESSION:AR306245
C 148	16	1.0	17	1	CQ881900	ACCESSION:CQ881900	C 221	13.8	0.8	17	1	AR326141	ACCESSION:AR326141
C 149	16	1.0	19	1	CQ861119	ACCESSION:CQ861119	C 222	13.8	0.8	17	1	AR326780	ACCESSION:AR326780
C 150	15.8	1.0	19	1	CQ786120	ACCESSION:CQ786120	C 223	13.8	0.8	17	1	AR371631	ACCESSION:AR371631
C 151	15.8	1.0	19	1	CQ786635	ACCESSION:CQ786635	C 224	13.8	0.8	17	1	AR371633	ACCESSION:AR371633
C 152	15.8	1.0	19	1	CQ786637	ACCESSION:CQ786637	C 225	13.8	0.8	17	1	AR458218	ACCESSION:AR458218
C 153	15.8	1.0	19	1	CQ786638	ACCESSION:CQ786638	C 226	13.8	0.8	17	1	AR458966	ACCESSION:AR458966
C 154	15.8	1.0	19	1	CQ623926	ACCESSION:CQ623926	C 227	13.8	0.8	17	1	AR463678	ACCESSION:AR463678
C 155	15.4	0.9	17	1	137522	ACCESSION:137522	C 228	13.8	0.8	17	1	AR463808	ACCESSION:AR463808
C 156	15.4	0.9	17	1	194372	ACCESSION:194372	C 229	13.8	0.8	17	1	AR464891	ACCESSION:AR464891
C 157	15.4	0.9	17	1	AR464989	ACCESSION:AR464989	C 230	13.8	0.8	17	1	AR464983	ACCESSION:AR464983
C 158	15.4	0.9	17	1	AX214728	ACCESSION:AX214728	C 231	13.8	0.8	17	1	AR464984	ACCESSION:AR464984
C 159	15.4	0.9	17	1	AX688719	ACCESSION:AX688719	C 232	13.8	0.8	17	1	AR464986	ACCESSION:AR464986
C 160	15.4	0.9	17	1	AX762505	ACCESSION:AX762505	C 233	13.8	0.8	17	1	AR464987	ACCESSION:AR464987
C 161	15.4	0.9	17	1	AR011407	ACCESSION:AR011407	C 234	13.8	0.8	17	1	AR466011	ACCESSION:AR466011
C 162	14.8	0.9	18	1	AR040105	ACCESSION:AR040105	C 235	13.8	0.8	17	1	AR466012	ACCESSION:AR466012
C 163	14.8	0.9	18	1	AX115178	ACCESSION:AX115178	C 236	13.8	0.8	17	1	AX215611	ACCESSION:AX215611
C 164	14.8	0.9	18	1	AX776586	ACCESSION:AX776586	C 237	13.8	0.8	17	1	AX216443	ACCESSION:AX216443
C 165	14.8	0.9	17	1	AR173373	ACCESSION:AR173373	C 238	13.8	0.8	17	1	AX272871	ACCESSION:AX272871
C 166	14.4	0.9	17	1	CQ623612	ACCESSION:CQ623612	C 239	13.8	0.8	17	1	AX423446	ACCESSION:AX423446
C 167	14.4	0.9	17	1	CQ623613	ACCESSION:CQ623613	C 240	13.8	0.8	17	1	AX423446	ACCESSION:AX423446
C 168	14.4	0.9	17	1	CQ623925	ACCESSION:CQ623925	C 241	13.8	0.8	17	1	AX475287	ACCESSION:AX475287
C 169	14.4	0.9	17	1	CQ623927	ACCESSION:CQ623927	C 242	13.8	0.8	17	1	AX475288	ACCESSION:AX475288
C 170	14.4	0.9	17	1	CQ625297	ACCESSION:CQ625297	C 243	13.8	0.8	17	1	AX475289	ACCESSION:AX475289
C 171	14.4	0.9	17	1	CQ625297	ACCESSION:CQ625297	C 244	13.8	0.8	17	1	AX475290	ACCESSION:AX475290
C 172	14.4	0.9	17	1	CQ625298	ACCESSION:CQ625298	C 245	13.8	0.8	17	1	AX475291	ACCESSION:AX475291
C 173	14.4	0.9	17	1	137523	ACCESSION:137523	C 246	13.8	0.8	17	1	AX475293	ACCESSION:AX475293
C 174	14.4	0.9	17	1	194373	ACCESSION:194373	C 247	13.8	0.8	17	1	AX475720	ACCESSION:AX475720
C 175	14.4	0.9	17	1	AR464675	ACCESSION:AR464675	C 248	13.8	0.8	17	1	AX499441	ACCESSION:AX499441
C 176	14.4	0.9	17	1	AR464676	ACCESSION:AR464676	C 249	13.8	0.8	17	1	AX499442	ACCESSION:AX499442
C 177	14.4	0.9	17	1	AR464698	ACCESSION:AR464698	C 250	13.8	0.8	17	1	AX499931	ACCESSION:AX499931
C 178	14.4	0.9	17	1	AR464698	ACCESSION:AR464698	C 251	13.8	0.8	17	1	AX687958	ACCESSION:AX687958
C 179	14.4	0.9	17	1	AR464699	ACCESSION:AR464699	C 252	13.8	0.8	17	1		

```
c 253 13.8 0.8 17 1 AX688721
254 13.8 0.8 17 1 AX690667
255 13.8 0.8 17 1 AX727197
c 256 13.8 0.8 17 1 AX728423
257 13.8 0.8 17 1 AX731740
258 13.8 0.8 17 1 AX734894
c 259 13.8 0.8 17 1 AX756729
260 13.4 0.8 15 1 I61606
c 261 13.4 0.8 15 1 AR180106
c 262 13.4 0.8 15 1 AR180715
c 263 13.4 0.8 15 1 AR532147
c 264 13.4 0.8 15 1 AX157089
265 13.4 0.8 15 1 AX635964
c 266 13.4 0.8 16 1 AR029843
267 13.4 0.8 16 1 AR131574
c 268 13.4 0.8 16 1 AR131575
c 269 13.4 0.8 16 1 CO796994
c 270 13.4 0.8 16 1 CO858546
271 13.4 0.8 16 1 AR199508
272 13.4 0.8 16 1 AR199509
273 13.4 0.8 16 1 AR200979
274 13.4 0.8 16 1 AR200980
275 13.4 0.8 16 1 AR488738
276 13.4 0.8 16 1 AR488739
277 13.4 0.8 16 1 AX419730
278 13.4 0.8 16 1 AX419731
279 13.4 0.8 16 1 BD084992
280 13.4 0.8 16 1 BD084993
c 281 13.4 0.8 16 1 S81287
c 282 13 0.8 14 1 AR086302
c 283 13 0.8 15 1 AX377347
c 284 13 0.8 15 1 ATH551605
285 13 0.8 16 1 CO806753
286 12.8 0.8 16 1 A88141
287 12.8 0.8 16 1 A89435
c 288 12.8 0.8 16 1 A90108
c 289 12.8 0.8 16 1 AR104209
c 290 12.8 0.8 16 1 CO786338
c 291 12.8 0.8 16 1 AR196058
292 12.8 0.8 16 1 AX003952
293 12.8 0.8 16 1 AX255603
294 12.8 0.8 16 1 AX255637
295 12.8 0.8 16 1 AX713247
296 12.8 0.8 16 1 BD065654
297 12.8 0.8 16 1 BD066948
c 298 12.8 0.8 16 1 BD086293
```

ALIGNMENTS

```
RESULT 1
A21575 A21575 32 bp DNA linear PAT 26-JUL-1994
LOCUS oligonucleotide.
DEFINITION A21575
ACCESSION A21575
VERSION A21575.1 GI:583580
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 32)
AUTHORS
TITLE CYTOLYSIS INHIBITOR PROTEINS (CLI) AND DNA SEQUENCES CODING FOR
SAID PROTEINS
JOURNAL Patent: WO 9105043-A 1 18-APR-1991;
FEATURES Location/Qualifiers
source
1..32
/mol_type="synthetic construct"
/db_xref="taxon:32830"
```

Query Match 1.7%; Score 27.2; DB 1; Length 32;

```
Best Local Similarity 90.6%; Pred. No. 8.1;
Matches 29; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 129 GACAATGAGCTCCAGGAATGTCCCAATCAGGG 160
|||||
DB 1 GACAAATGAGCTCCAGGAGATGTTCAACACGAGG 32
|||||

RESULT 2
AR090627 26 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 747 from patent US 5994076.
DEFINITION AR090627
ACCESSION AR090627
VERSION AR090627.1 GI:10017382
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 26)
AUTHORS Chenchik,A., Jekhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 5994076-A 747 30-NOV-1999;
FEATURES Location/Qualifiers
source
1..26
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 6.5;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 TCCGGATGAAGGACCAGTGTGACAAG 959
|||||
DB 1 TCCGGATGAAGGACCAGTGTGACAAG 26
|||||

RESULT 3
AR197662 26 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 747 from patent US 6352829.
DEFINITION AR197662
ACCESSION AR197662
VERSION AR197662.1 GI:20247511
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 26)
AUTHORS Chenchik,A., Jekhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6352829-A 747 05-MAR-2002;
FEATURES Location/Qualifiers
source
1..26
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 6.5;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 TCCGGATGAAGGACCAGTGTGACAAG 959
|||||
DB 1 TCCGGATGAAGGACCAGTGTGACAAG 26
|||||

RESULT 4
AR259816 26 bp DNA linear PAT 20-DEC-2002
LOCUS Sequence 747 from patent US 6489455.
DEFINITION AR259816
ACCESSION AR259816
VERSION AR259816.1 GI:27310327
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
```

Homo sapiens
Homo sapiens
Mammalia; Eutheria;
Mammalia; Eutheria;
Chordata; Vertebrata; Euteleostomi;
Carnivora; Canidae; Canis
Canis lupus familiaris

REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 60 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
source
1. .23
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AAGTCCCGCATCGCCGAGCTT 733
Db 1 AAGTCCCGCATCGCCGAGCTT 23

RESULT 10
LOCUS CQ786175 23 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 63 from Patent WO2004018676.
ACCESSION CQ786175
VERSION CQ786175.1 GI:45721278
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 63 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
source
1. .23
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGCTT 1635
Db 1 AACTAATTCATAAACTGCTT 23

RESULT 11
LOCUS CQ786178 23 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 66 from Patent WO2004018676.
ACCESSION CQ786178
VERSION CQ786178.1 GI:45721281
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 66 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
source
1. .23
/organism="Homo sapiens"

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 GCATGATGAAGACTCTGCTGCTG 68
Db 1 GCATGATGAAGACTCTGCTGCTG 23

RESULT 12
LOCUS AR208706/c 23 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 5 from patent US 6383808.
ACCESSION AR208706
VERSION AR208706.1 GI:21509931
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 23)
AUTHORS Monia,B.P. and Priester,S.M.
TITLE Antisense inhibition of Clusterin expression
JOURNAL Patent: US 6383808-A 5 07-MAY-2002;
FEATURES
source
1. .23
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 789 CTTGAGATGATACACGAGGCTCA 811
Db 23 CTTGAGATGATACACGAGGCTCA 1

RESULT 13
LOCUS AR038687 21 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5807678.
ACCESSION AR038687
VERSION AR038687.1 GI:5958050
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 21)
AUTHORS Miller,W.L., Lin,D. and Strauss,J.F. III.
TITLE Identification of gene mutations associated with congenital lipid
JOURNAL adrenal hyperplasia
FEATURES
source
1. .21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AGAAGCGCTGCAGGATACC 1374
Db 1 AGAAGCGCTGCAGGATACC 21

RESULT 14
LOCUS CQ786113 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 1 from Patent WO2004018676.

```
ACCESSION CQ786113
VERSION CQ786113.1 GI:45721216
KEYWORDS .
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
        Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 1 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 482 CCAGAGCTCGCCTTCTACTT 502
    |||||
Db 1 CCAGAGCTCGCCTTCTACTT 21
    |||||
RESULT 15
CQ786114/c
LOCUS CQ786114 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 2 from Patent WO2004018676.
ACCESSION CQ786114
VERSION CQ786114.1 GI:45721217
KEYWORDS .
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
        Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 2 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 482 CCAGAGCTCGCCTTCTACTT 502
    |||||
Db 1 CCAGAGCTCGCCTTCTACTT 21
    |||||
RESULT 16
CQ786115
LOCUS CQ786115 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 3 from Patent WO2004018676.
ACCESSION CQ786115
VERSION CQ786115.1 GI:45721218
KEYWORDS .
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
        Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 3 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 480 AACGAGCTGCGCTTCTAC 500
    |||||
Db 21 AACGAGCTGCGCTTCTAC 1
    |||||
RESULT 17
CQ786116/c
LOCUS CQ786116 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 4 from Patent WO2004018676.
ACCESSION CQ786116
VERSION CQ786116.1 GI:45721219
KEYWORDS .
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
        Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 4 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1098 AAGATGCTCAACACCTCTCC 1118
    |||||
Db 21 AAGATGCTCAACACCTCTCC 1
    |||||
RESULT 18
CQ786117
LOCUS CQ786117 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 5 from Patent WO2004018676.
ACCESSION CQ786117
VERSION CQ786117.1 GI:45721220
KEYWORDS .
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
        Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 5 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"
```



```
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCATAAAACTGCTT 1635
Db 1 CTAATTCATAAAACTGCTT 21
|||||

RESULT 19
LOCUS CQ786118/c
DEFINITION Sequence 6 from Patent WO2004018676.
ACCESSION CQ786118
VERSION CQ786118.1 GI:45721221
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
          Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 6 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633
Db 21 AACTAATTCATAAACTGTC 1
|||||

RESULT 20
LOCUS CQ786170
DEFINITION Sequence 58 from Patent WO2004018676.
ACCESSION CQ786170
VERSION CQ786170.1 GI:45721273
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
          Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 58 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633
Db 21 AACTAATTCATAAACTGTC 1
|||||

RESULT 21
LOCUS CQ786171/c
DEFINITION Sequence 59 from Patent WO2004018676.
ACCESSION CQ786171
VERSION CQ786171.1 GI:45721274
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
          Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 59 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACCAGAGCTCGCCCTTCTAC 500
Db 21 AACCAGAGCTCGCCCTTCTAC 1
|||||

RESULT 22
LOCUS CQ786173
DEFINITION Sequence 61 from Patent WO2004018676.
ACCESSION CQ786173
VERSION CQ786173.1 GI:45721276
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
          Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 61 04-MAR-2004;
        The University of British Columbia (CA)
FEATURES
    source
    1..21
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCCGCATCGTCCGAGCTT 733
Db 1 GTCCCGCATCGTCCGAGCTT 21
|||||

RESULT 23
LOCUS CQ786174/c
DEFINITION Sequence 62 from Patent WO2004018676.
ACCESSION CQ786174
VERSION CQ786174.1 GI:45721277
KEYWORDS
SOURCE synthetic construct
```

ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 62 04-MAR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AAGTCCGCGATCGTCGCGAGC 731
Db 21 AAGTCCGCGATCGTCGCGAGC 1
|||||
CO786176 21 bp DNA linear PAT 24-MAR-2004
LOCUS Sequence 64 from Patent WO2004018676.
ACCESSION CO786176
VERSION CO786176.1 GI:45721279
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 64 04-MAR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCATAATAAACTGCTT 1635
Db 1 CTAATTCATAATAAACTGCTT 21
|||||
CO786177 21 bp DNA linear PAT 24-MAR-2004
LOCUS Sequence 65 from Patent WO2004018676.
ACCESSION CO786177
VERSION CO786177.1 GI:45721280
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 65 04-MAR-2004;
The University of British Columbia (CA)
FEATURES Location/Qualifiers

source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAATAAACTGTC 1633
Db 21 AACTAATTCATAATAAACTGTC 1
|||||
CO786614 21 bp DNA linear PAT 24-MAR-2004
LOCUS Sequence 3 from Patent WO2004018675.
DEFINITION
ACCESSION CO786614
VERSION CO786614.1 GI:45721634
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 3 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES Location/Qualifiers
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGCGGTGCAAGACTCCA 36
Db 21 CCGAGCGGTGCAAGACTCCA 1
|||||
CO786615 21 bp DNA linear PAT 24-MAR-2004
LOCUS Sequence 4 from Patent WO2004018675.
DEFINITION
ACCESSION CO786615
VERSION CO786615.1 GI:45721635
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 4 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES Location/Qualifiers
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGNAGACTCTGCTGCTG 68

```
|||||
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 28
CQ786616/c
LOCUS
DEFINITION
Sequence 5 from Patent WO2004018675.
ACCESSION
CQ786616
VERSION
CQ786616.1 GI:45721636
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Jansen, B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 5 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGCGGTCCTCAGACAAAT 134
|||||
Db 21 GACCAGCGGTCCTCAGACAAAT 1

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGCGGTCCTCAGACAAAT 134
|||||
Db 21 GACCAGCGGTCCTCAGACAAAT 1

RESULT 29
CQ786617/c
LOCUS
DEFINITION
Sequence 6 from Patent WO2004018675.
ACCESSION
CQ786617
VERSION
CQ786617.1 GI:45721637
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Jansen, B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 6 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGAGACAAAGCTGAAGG 336
|||||
Db 21 AATCAGAGACAAAGCTGAAGG 1

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGAGACAAAGCTGAAGG 336
|||||
Db 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 30
CQ786618/c
LOCUS
DEFINITION
Sequence 7 from Patent WO2004018675.
ACCESSION
CQ786618
VERSION
CQ786618.1 GI:45721638
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Jansen, B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 7 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGAGACAAAGCTGAAGG 336
|||||
Db 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 31
CQ786619/c
LOCUS
DEFINITION
Sequence 8 from Patent WO2004018675.
ACCESSION
CQ786619
VERSION
CQ786619.1 GI:45721639
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Jansen, B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 8 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
|||||
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 32
CQ786620/c
LOCUS
DEFINITION
Sequence 9 from Patent WO2004018675.
ACCESSION
CQ786620
VERSION
CQ786620.1 GI:45721640
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Jansen, B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 9 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGAGCTTGAT 736
|||||
Db 21 CCGCATCGTCCGAGCTTGAT 1

RESULT 33
CQ786621/c
LOCUS
DEFINITION
Sequence 10 from Patent WO2004018675.
ACCESSION
CQ786621
VERSION
CQ786621.1 GI:45721641
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Jansen, B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 10 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 817 CCGCATCGTCCGAGCTTGAT 838
|||||
Db 21 CCGCATCGTCCGAGCTTGAT 1
```

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGCGCTGCTGC 936
Db 21 ACAACTCCACGGCGCTGCTGC 1

RESULT 33
LOCUS      CQ786621/c
DEFINITION Sequence 10 from Patent WO2004018675.
ACCESSION  CQ786621
VERSION     CQ786621.1 GI:45721641
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 10 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCGCCGAGC 1536
Db 21 AGGCCCCCAACTCGCCGAGC 1

RESULT 36
LOCUS      CQ786631
DEFINITION Sequence 20 from Patent WO2004018675.
ACCESSION  CQ786631
VERSION     CQ786631.1 GI:45721651
KEYWORDS    synthetic construct
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 20 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 37
LOCUS      CQ786632/c
DEFINITION Sequence 21 from Patent WO2004018675.
ACCESSION  CQ786632
VERSION     CQ786632.1 GI:45721652
KEYWORDS    synthetic construct
SOURCE      synthetic construct
ORGANISM    synthetic construct

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCCAGGAAGAACCTAAATT 1336
Db 21 CTCCAGGAAGAACCTAAATT 1

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGAGCAGCTGAA 1

RESULT 34
LOCUS      CQ786622/c
DEFINITION Sequence 11 from Patent WO2004018675.
ACCESSION  CQ786622
VERSION     CQ786622.1 GI:45721642
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 11 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGAGCAGCTGAA 1

RESULT 34
LOCUS      CQ786622/c
DEFINITION Sequence 11 from Patent WO2004018675.
ACCESSION  CQ786622
VERSION     CQ786622.1 GI:45721642
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 11 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCCAGGAAGAACCTAAATT 1336
Db 21 CTCCAGGAAGAACCTAAATT 1

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCCAGGAAGAACCTAAATT 1336
Db 21 CTCCAGGAAGAACCTAAATT 1
```

```
other sequences; artificial sequences.
1
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 21 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTCTTAC 500
Db 21 AACGAGCTCGCCCTCTTAC 1

RESULT 38
CQ786633
LOCUS
DEFINITION Sequence 22 from Patent WO2004018675.
ACCESSION CQ786633
VERSION CQ786633.1 GI:45721653
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 22 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GATGCTCAACACCTCTCTT 1120
Db 1 GATGCTCAACACCTCTCTT 21

RESULT 39
CQ786634/c
LOCUS
DEFINITION Sequence 23 from Patent WO2004018675.
ACCESSION CQ786634
VERSION CQ786634.1 GI:45721654
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 23 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

other sequences; artificial sequences.
1
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 25 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633
Db 21 AACTAATTCATAAACTGTC 1

RESULT 41
CQ786647
LOCUS
DEFINITION Sequence 36 from Patent WO2004018675.
ACCESSION CQ786647
VERSION CQ786647.1 GI:45721667
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 36 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1098 AGATGCTCAACACCTCTCTC 1118
Db 21 AGATGCTCAACACCTCTCTC 1

RESULT 40
CQ786636/c
LOCUS
DEFINITION Sequence 25 from Patent WO2004018675.
ACCESSION CQ786636
VERSION CQ786636.1 GI:45721656
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 25 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCTCGCCCTTCTACTT 21

/note="RNAi for human clusterin"
```

```
RESULT 42
CQ786648/c
LOCUS          21 bp      DNA
DEFINITION     Sequence 37 from Patent WO2004018675.
ACCESSION      CQ786648
VERSION        CQ786648.1 GI:45721668
KEYWORDS       .
SOURCE         synthetic construct
ORGANISM       other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B.
TITLE          Treatment of melanoma by reduction in clusterin levels
JOURNAL        Patent: WO 2004018675-A 37 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 480 AACGAGCTCGCCCTTCTAC 500
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 43
CQ786649
LOCUS          21 bp      DNA
DEFINITION     Sequence 38 from Patent WO2004018675.
ACCESSION      CQ786649
VERSION        CQ786649.1 GI:45721669
KEYWORDS       .
SOURCE         synthetic construct
ORGANISM       other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B.
TITLE          Treatment of melanoma by reduction in clusterin levels
JOURNAL        Patent: WO 2004018675-A 38 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 713 GTCCGCGCATCGTCGCAGCTT 733
Db 1 GTCCGCGCATCGTCGCAGCTT 21

RESULT 44
CQ786650/c
LOCUS          21 bp      DNA
DEFINITION     Sequence 39 from Patent WO2004018675.
ACCESSION      CQ786650
VERSION        CQ786650.1 GI:45721670
KEYWORDS       .
SOURCE         synthetic construct
ORGANISM       other sequences; artificial sequences.
REFERENCE      1
```

```
AUTHORS        Jansen,B.
TITLE          Treatment of melanoma by reduction in clusterin levels
JOURNAL        Patent: WO 2004018675-A 39 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 711 AAGTCCCGCATCGTCGCAGC 731
Db 21 AAGTCCCGCATCGTCGCAGC 1

RESULT 45
CQ786651
LOCUS          21 bp      DNA
DEFINITION     Sequence 40 from Patent WO2004018675.
ACCESSION      CQ786651
VERSION        CQ786651.1 GI:45721671
KEYWORDS       .
SOURCE         synthetic construct
ORGANISM       other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B.
TITLE          Treatment of melanoma by reduction in clusterin levels
JOURNAL        Patent: WO 2004018675-A 40 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1615 CTAATTCATAAAACTGCTT 1635
Db 1 CTAATTCATAAAACTGCTT 21

RESULT 46
CQ786652/c
LOCUS          21 bp      DNA
DEFINITION     Sequence 41 from Patent WO2004018675.
ACCESSION      CQ786652
VERSION        CQ786652.1 GI:45721672
KEYWORDS       .
SOURCE         synthetic construct
ORGANISM       other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B.
TITLE          Treatment of melanoma by reduction in clusterin levels
JOURNAL        Patent: WO 2004018675-A 41 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
```

```
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633
Db 21 AACTAATTCATAAACTGTC 1

RESULT 47
AR208707
LOCUS AR208707 21 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 6 from patent US 6383808.
ACCESSION AR208707
VERSION AR208707.1 GI:21509932
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 21)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 6 07-MAY-2002;
FEATURES
source
Location/Qualifiers
1..21
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCCAGCCCT 786
Db 1 TCCACGCCATGTTCCAGCCCT 21

RESULT 48
AR236282
LOCUS AR236282 21 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 14 from patent US 6464975.
ACCESSION AR236282
VERSION AR236282.1 GI:27280110
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 21)
AUTHORS Millis,A.J.T.
TITLE Compositions and methods for altering cell migration
JOURNAL Patent: US 6464975-A 14 15-OCT-2002;
FEATURES
source
Location/Qualifiers
1..21
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCAAGAGAAGAAGAGG 294
Db 1 AAGCCAAGAGAAGAAGAGG 21

RESULT 49
BD230318
LOCUS BD230318 24 bp DNA linear PAT 17-JUL-2003
DEFINITION Total genome radiation hybrid map of canine genome and its use for
identification of interesting genes.
ACCESSION BD230318
VERSION BD230318.1 GI:33040088
KEYWORDS JP 2002530091-A/187.

SOURCE Canis familiaris (dog)
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.

REFERENCE 1 (bases 1 to 24)
AUTHORS Galibert,F. and Andre,C.
TITLE Total genome radiation hybrid map of canine genome and its use for
identification of interesting genes
JOURNAL Patent: JP 2002530091-A 187 17-SEP-2002;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
COMMENT OS Canis familiaris (dog)
PN JP 2002530091-A/187
PD 17-SEP-2002
PF 15-NOV-1999 JP 2000582596
PR 13-NOV-1998 US 60/108193
PI FRANCIS GALIBERT, CATHERINE ANDRE
PC C12N15/09,C12Q1/68,C12N15/00
CC A0133
FH Key
FT source
Location/Qualifiers
1..24
/mol_type="genomic DNA"
/db_xref="taxon:9615"

FEATURES
source
Location/Qualifiers
1..24
/mol_type="genomic DNA"
/db_xref="taxon:9615"

Query Match 1.3%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CCCCCAGAGAGAGCTCTGCACGTC 1490
Db 1 CCCCCTAGAGAGAGCTCTGCATGTC 24

RESULT 50
AR531218
LOCUS AR531218 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 2421 from patent US 6727063.
ACCESSION AR531218
VERSION AR531218.1 GI:53919655
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,S.S., Cargill,M., Ireland,J.S., Bolik,S., Daley,G.O. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2421 27-APR-2004;
FEATURES
source
Location/Qualifiers
1..21
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GAGAGTTGACCCAGGAATAC 1070
Db 1 GAGAGTTGACCCAGGAATAC 21

RESULT 51
AR531219
LOCUS AR531219 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 2422 from patent US 6727063.
ACCESSION AR531219
VERSION AR531219.1 GI:53919656
KEYWORDS
SOURCE
```

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2422 27-APR-2004;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 999 CCTCCAGGCTAAGCTGCGG 1019
Db 1 CCTCCAGGCTAAGCTGCGG 21
RESULT 52
AR531220
LOCUS AR531220 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 2423 from patent US 6727063.
ACCESSION AR531220
VERSION AR531220.1 GI:53919657
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2423 27-APR-2004;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1170 CTCACGCAAGCGAAGACCAG 1190
Db 1 CTCACGCAAGCGAAGACCAG 21
RESULT 53
AR531221
LOCUS AR531221 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 2424 from patent US 6727063.
ACCESSION AR531221
VERSION AR531221.1 GI:53919658
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2424 27-APR-2004;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1105 TCAACACCTCTCTCTGCTGG 1125
Db 1 TCAACACCTCTCTCTGCTGG 21
RESULT 54
AX097243
LOCUS AX097243 21 bp DNA linear PAT 30-MAR-2001
DEFINITION Sequence 2421 from Patent WO0118250.
ACCESSION AX097243
VERSION AX097243.1 GI:13513638
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 2421 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1050 GAGAGGTTGACGAGGAATAC 1070
Db 1 GAGAGGTTGACGAGGAATAC 21
RESULT 55
AX097244
LOCUS AX097244 21 bp DNA linear PAT 30-MAR-2001
DEFINITION Sequence 2422 from Patent WO0118250.
ACCESSION AX097244
VERSION AX097244.1 GI:13513640
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 2422 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 999 CCTCCAGGCTAAGCTGCGG 1019
Db 1 CCTCCAGGCTAAGCTGCGG 21
RESULT 56

AX097245
LOCUS 21 bp DNA linear PAT 30-MAR-2001
DEFINITION Sequence 2423 from Patent WO0118250.
ACCESSION AX097245
VERSION AX097245.1 GI:13513642
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and McCarthy, J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 2423 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1170 CTCACGCGAGCGGAGACCCAG 1190
Db 1 CTCACGCGAGCGGAGACCCAG 21
RESULT 57
AX097246
LOCUS 21 bp DNA linear PAT 30-MAR-2001
DEFINITION Sequence 2424 from Patent WO0118250.
ACCESSION AX097246
VERSION AX097246.1 GI:13513644
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and McCarthy, J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 2424 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 23;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1105 TCAACACCTCTCTCTGCTGG 1125
Db 1 TCAACACCTCTCTCTGCTGG 21
RESULT 58
CQ803453
LOCUS 20 bp DNA linear PAT 10-MAY-2004
DEFINITION Sequence 5 from Patent WO2004035827.
ACCESSION CQ803453
VERSION CQ803453.1 GI:47110310
KEYWORDS
SOURCE unidentified

ORGANISM unidentified
REFERENCE 1 unclassified.
AUTHORS Breban, M., Gidrol, X., Marion, S. and Chiochia, G.
TITLE Microarrays allowing molecular profiling of rheumatoid arthritis comparatively to osteoarthritis and their use
JOURNAL Patent: WO 2004035827-A 5 29-APR-2004;
INSERM, The French Institute of Health and Medical Research (FR); ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR); COMMISSARIAT A L'ENERGIE ATOMIQUE (FR)
FEATURES
source Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
misc_feature 1..20
/note="CLU forward primer for PCR"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1180 GCGAAGACCACTACTATCTG 1199
Db 1 GCGAAGACCACTACTATCTG 20
RESULT 59
CQ803454/c
LOCUS 20 bp DNA linear PAT 10-MAY-2004
DEFINITION Sequence 6 from Patent WO2004035827.
ACCESSION CQ803454
VERSION CQ803454.1 GI:47110311
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 unclassified.
AUTHORS Breban, M., Gidrol, X., Marion, S. and Chiochia, G.
TITLE Microarrays allowing molecular profiling of rheumatoid arthritis comparatively to osteoarthritis and their use
JOURNAL Patent: WO 2004035827-A 6 29-APR-2004;
INSERM, The French Institute of Health and Medical Research (FR); ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR); COMMISSARIAT A L'ENERGIE ATOMIQUE (FR)
FEATURES
source Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
misc_feature 1..20
/note="CLU reverse primer for PCR"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1361 GCTGCAGGAATACCCGAAAA 1380
Db 20 GCTGCAGGAATACCCGAAAA 1
RESULT 60
AR208715/c
LOCUS 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 14 from patent US 6383808.
ACCESSION AR208715
VERSION AR208715.1 GI:21509942
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20) unclassified.

```
AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 14 07-MAY-2002;
FEATURES     Location/Qualifiers
SOURCE       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGGCGTCCAAAGAC 32
Db 20 TGACCGAGGCGTCCAAAGAC 1

RESULT 61
AR208716/c
LOCUS      AR208716
DEFINITION Sequence 15 from patent US 6383808.
ACCESSION  AR208716
VERSION     AR208716.1 GI:21509944
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 15 07-MAY-2002;
FEATURES   Location/Qualifiers
SOURCE     1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 GCGTGAAGACTCCGAAT 40
Db 20 GCGTGAAGACTCCGAAT 1

RESULT 62
AR208717/c
LOCUS      AR208717
DEFINITION Sequence 16 from patent US 6383808.
ACCESSION  AR208717
VERSION     AR208717.1 GI:21509945
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 16 07-MAY-2002;
FEATURES   Location/Qualifiers
SOURCE     1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 ATTGGAGGCATGATGAAGAC 58
Db 20 ATTGGAGGCATGATGAAGAC 1

AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 14 07-MAY-2002;
FEATURES     Location/Qualifiers
SOURCE       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGGCGTCCAAAGAC 32
Db 20 TGACCGAGGCGTCCAAAGAC 1

RESULT 63
AR208718/c
LOCUS      AR208718
DEFINITION Sequence 17 from patent US 6383808.
ACCESSION  AR208718
VERSION     AR208718.1 GI:21509946
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 17 07-MAY-2002;
FEATURES   Location/Qualifiers
SOURCE     1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCTGCTGCTGACCTGGGAGA 96
Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 64
AR208719/c
LOCUS      AR208719
DEFINITION Sequence 18 from patent US 6383808.
ACCESSION  AR208719
VERSION     AR208719.1 GI:21509947
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 18 07-MAY-2002;
FEATURES   Location/Qualifiers
SOURCE     1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 GCAGGTCTCTGGGGACCAGA 120
Db 20 GCAGGTCTCTGGGGACCAGA 1

RESULT 65
AR208720/c
LOCUS      AR208720
DEFINITION Sequence 19 from patent US 6383808.
ACCESSION  AR208720
VERSION     AR208720.1 GI:21509949
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 19 07-MAY-2002;
FEATURES   Location/Qualifiers
SOURCE     1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 GCAGGTCTCTGGGGACCAGA 120
Db 20 GCAGGTCTCTGGGGACCAGA 1
```

```
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 122 GGTCTCAGACAAATGAGCTCC 141
|||||
DB 20 GGTCTCAGACAAATGAGCTCC 1

RESULT 66
AR208721/c
LOCUS AR208721 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 20 from patent US 6383808.
ACCESSION AR208721
VERSION AR208721.1 GI:21509950
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 20 07-MAY-2002;
FEATURES
    Location/Qualifiers
        source
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 201 GGGGTGAACACAGATAAGAC 220
|||||
DB 20 GGGGTGAACACAGATAAGAC 1

RESULT 69
AR208724/c
LOCUS AR208724 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 23 from patent US 6383808.
ACCESSION AR208724
VERSION AR208724.1 GI:21509954
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 23 07-MAY-2002;
FEATURES
    Location/Qualifiers
        source
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 GAAGAAGAAAGAGGATGCC 300
|||||
DB 20 GAAGAAGAAAGAGGATGCC 1

RESULT 70
AR208725/c
LOCUS AR208725 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 24 from patent US 6383808.
ACCESSION AR208725
VERSION AR208725.1 GI:21509955
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 24 07-MAY-2002;
FEATURES
    Location/Qualifiers
        source
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 166 AGTACGTCATAGGAATTT 185
|||||
DB 20 AGTACGTCATAGGAATTT 1

RESULT 68
AR208723/c
LOCUS AR208723 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 22 from patent US 6383808.
ACCESSION AR208723
VERSION AR208723.1 GI:21509952
```

```
QY 286 AGAAGAGGATGCCCTTAAT 305
Db 20 AGAAGAGGATGCCCTTAAT 1

RESULT 71
AR208726/c
LOCUS AR208726 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 25 from patent US 6383808.
ACCESSION AR208726
VERSION AR208726.1 GI:21509956
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 25 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCTAAATGAGACCAGGGAA 317
Db 20 CCTAAATGAGACCAGGGAA 1

RESULT 72
AR208727/c
LOCUS AR208727 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 26 from patent US 6383808.
ACCESSION AR208727
VERSION AR208727.1 GI:21509957
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 26 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCAGGGAATCAGAGACA 326
Db 20 AGACCAGGGAATCAGAGACA 1

RESULT 73
AR208728/c
LOCUS AR208728 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 27 from patent US 6383808.
ACCESSION AR208728
VERSION AR208728.1 GI:21509959
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.

TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 27 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 324 ACAAGAGCTGAAGAGCTCCC 343
Db 20 ACAAGAGCTGAAGAGCTCCC 1

RESULT 74
AR208729/c
LOCUS AR208729 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 28 from patent US 6383808.
ACCESSION AR208729
VERSION AR208729.1 GI:21509960
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 28 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 359 GACCATGATGCCCTCTGGG 378
Db 20 GACCATGATGCCCTCTGGG 1

RESULT 75
AR208730/c
LOCUS AR208730 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 29 from patent US 6383808.
ACCESSION AR208730
VERSION AR208730.1 GI:21509961
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 29 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 364 TGATGGCCCTCTGGGAAGAG 383
Db 20 TGATGGCCCTCTGGGAAGAG 1

RESULT 76
```

```
AR208731/c
LOCUS       AR208731                20 bp    DNA             linear     PAT 20-JUN-2002
DEFINITION   Sequence 30 from patent US 6383808.
ACCESSION    AR208731
VERSION      AR208731.1 GI:21509962
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 30 07-MAY-2002;
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      380 AGAGTGAAGCCCTGCCTGA 399
        |||||
Db       20 AGAGTGAAGCCCTGCCTGA 1

RESULT 77
AR208732/c
LOCUS       AR208732                20 bp    DNA             linear     PAT 20-JUN-2002
DEFINITION   Sequence 31 from patent US 6383808.
ACCESSION    AR208732
VERSION      AR208732.1 GI:21509964
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 31 07-MAY-2002;
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      407 CTGCATGAAGTCTACGCAC 426
        |||||
Db       20 CTGCATGAAGTCTACGCAC 1

RESULT 78
AR208733/c
LOCUS       AR208733                20 bp    DNA             linear     PAT 20-JUN-2002
DEFINITION   Sequence 32 from patent US 6383808.
ACCESSION    AR208733
VERSION      AR208733.1 GI:21509965
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 32 07-MAY-2002;
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      443 CTCAGGCTGTTGGCGGCC 462
        |||||
Db       20 CTCAGGCTGTTGGCGGCC 1

RESULT 79
AR208734/c
LOCUS       AR208734                20 bp    DNA             linear     PAT 20-JUN-2002
DEFINITION   Sequence 33 from patent US 6383808.
ACCESSION    AR208734
VERSION      AR208734.1 GI:21509966
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 33 07-MAY-2002;
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      444 TCAGGCTGTTGGCGGCCA 463
        |||||
Db       20 TCAGGCTGTTGGCGGCCA 1

RESULT 80
AR208735/c
LOCUS       AR208735                20 bp    DNA             linear     PAT 20-JUN-2002
DEFINITION   Sequence 34 from patent US 6383808.
ACCESSION    AR208735
VERSION      AR208735.1 GI:21509967
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 34 07-MAY-2002;
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      455 TGGCCGCCACGTTGAGGACT 474
        |||||
Db       20 TGGCCGCCACGTTGAGGACT 1

RESULT 81
AR208736/c
LOCUS       AR208736                20 bp    DNA             linear     PAT 20-JUN-2002
DEFINITION   Sequence 35 from patent US 6383808.
ACCESSION    AR208736
VERSION      AR208736.1 GI:21509969
KEYWORDS     .
```

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 35 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 501
|||||
Db 20 CCAGAGCTCGCCCTTCTACT 1

RESULT 82
AR208737/c
LOCUS 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 36 from patent US 6383808.
ACCESSION AR208737
VERSION AR208737.1 GI:21509970
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 36 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCCTTCTACTCTGGATGAA 511
|||||
Db 20 CCCTTCTACTCTGGATGAA 1

RESULT 83
AR208738/c
LOCUS 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 37 from patent US 6383808.
ACCESSION AR208738
VERSION AR208738.1 GI:21509971
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 37 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 ACCGATCGACTCCCTGCTG 536

Db 20 ACCGATCGACTCCCTGCTG 1
|||||

RESULT 84
AR208739/c
LOCUS 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 38 from patent US 6383808.
ACCESSION AR208739
VERSION AR208739.1 GI:21509972
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 38 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 533 GCTGAGAACGACCGGCAGC 552
|||||
Db 20 GCTGAGAACGACCGGCAGC 1

RESULT 85
AR208740/c
LOCUS 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 39 from patent US 6383808.
ACCESSION AR208740
VERSION AR208740.1 GI:21509974
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 39 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 GCAGACGCACATGCTGGATG 570
|||||
Db 20 GCAGACGCACATGCTGGATG 1

RESULT 86
AR208741/c
LOCUS 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 40 from patent US 6383808.
ACCESSION AR208741
VERSION AR208741.1 GI:21509975
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression

```
JOURNAL Patent: US 6383808-A 40 07-MAY-2002;
FEATURES
source
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGACGCACATGCTGGGATGC 572
Db 20 AGACGCACATGCTGGGATGC 1

RESULT 87
AR208742/c
LOCUS AR208742 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 41 from patent US 6383808.
ACCESSION AR208742
VERSION AR208742.1 GI:21509976
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 41 07-MAY-2002;
FEATURES
source
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCAGGACCAC 584
Db 20 TGGATGTCATGCAGGACCAC 1

RESULT 88
AR208743/c
LOCUS AR208743 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 42 from patent US 6383808.
ACCESSION AR208743
VERSION AR208743.1 GI:21509977
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 42 07-MAY-2002;
FEATURES
source
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 567 GATGTCATGCAGGACCATT 586
Db 20 GATGTCATGCAGGACCATT 1

RESULT 89
AR208744/c
LOCUS AR208744 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 43 from patent US 6383808.
ACCESSION AR208744
VERSION AR208744.1 GI:21509979
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 43 07-MAY-2002;
FEATURES
source
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 TCATAGACGAGCTCTTCCAG 623
Db 20 TCATAGACGAGCTCTTCCAG 1

RESULT 90
AR208745/c
LOCUS AR208745 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 44 from patent US 6383808.
ACCESSION AR208745
VERSION AR208745.1 GI:21509980
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 44 07-MAY-2002;
FEATURES
source
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 608 AGACGAGCTCTTCCAGGACA 627
Db 20 AGACGAGCTCTTCCAGGACA 1

RESULT 91
AR208746/c
LOCUS AR208746 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 45 from patent US 6383808.
ACCESSION AR208746
VERSION AR208746.1 GI:21509981
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 45 07-MAY-2002;
FEATURES
source
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"
```

```
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      613 AGCTCTTCCAGGACAGGTTTC 632
Db      20 AGCTCTTCCAGGACAGGTTTC 1

RESULT 92
AR208747/c
LOCUS      AR208747      20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION Sequence 46 from patent US 6383808.
ACCESSION AR208747
VERSION    AR208747.1 GI:21509982
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 46 07-MAY-2002;
FEATURES    Location/Qualifiers
            source
              1..20
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      690 AGGCTCACCTCTCTTTTC 709
Db      20 AGGCTCACCTCTCTTTTC 1

RESULT 93
AR208748/c
LOCUS      AR208748      20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION Sequence 47 from patent US 6383808.
ACCESSION AR208748
VERSION    AR208748.1 GI:21509984
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 47 07-MAY-2002;
FEATURES    Location/Qualifiers
            source
              1..20
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      721 TCGTCCGAGCTTGATGCC 740
Db      20 TCGTCCGAGCTTGATGCC 1

RESULT 94
AR208749/c
LOCUS      AR208749      20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION Sequence 48 from patent US 6383808.
ACCESSION AR208749
VERSION    AR208749.1 GI:21509985
KEYWORDS   .
SOURCE     Unknown.

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      775 TGTTCAGCCCTTCCTTGAG 794
Db      20 TGTTCAGCCCTTCCTTGAG 1

RESULT 95
AR208750/c
LOCUS      AR208750      20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION Sequence 49 from patent US 6383808.
ACCESSION AR208750
VERSION    AR208750.1 GI:21509986
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 49 07-MAY-2002;
FEATURES    Location/Qualifiers
            source
              1..20
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      776 GTTCCAGCCCTTCCTTGAGA 795
Db      20 GTTCCAGCCCTTCCTTGAGA 1

RESULT 96
AR208751/c
LOCUS      AR208751      20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION Sequence 50 from patent US 6383808.
ACCESSION AR208751
VERSION    AR208751.1 GI:21509987
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 50 07-MAY-2002;
FEATURES    Location/Qualifiers
            source
              1..20
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      783 CCCTTCCTTGAGATGATACA 802
Db      783 CCCTTCCTTGAGATGATACA 802
```



```
Db      20 CCCTTCTTGAGATGATACA 1
RESULT 97
AR208752/c
LOCUS   AR208752          20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION   Sequence 51 from patent US 6383808.
ACCESSION   AR208752
VERSION     AR208752.1 GI:21509989
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 51 07-MAY-2002;
FEATURES
source
Location/Qualifiers
1..20
/mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      820 TGGACATCCACTTCCACAGC 839
|||||
Db      20 TGGACATCCACTTCCACAGC 1

RESULT 98
AR208753/c
LOCUS   AR208753          20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION   Sequence 52 from patent US 6383808.
ACCESSION   AR208753
VERSION     AR208753.1 GI:21509990
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 52 07-MAY-2002;
FEATURES
source
Location/Qualifiers
1..20
/mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      848 CCAGCACCCGCCCAACAGAT 867
|||||
Db      20 CCAGCACCCGCCCAACAGAT 1

RESULT 99
AR208754/c
LOCUS   AR208754          20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION   Sequence 53 from patent US 6383808.
ACCESSION   AR208754
VERSION     AR208754.1 GI:21509991
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 53 07-MAY-2002;

FEATURES
source
Location/Qualifiers
1..20
/mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      853 ACCCGCCCAACAGATTCATA 872
|||||
Db      20 ACCCGCCCAACAGATTCATA 1

RESULT 100
AR208755/c
LOCUS   AR208755          20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION   Sequence 54 from patent US 6383808.
ACCESSION   AR208755
VERSION     AR208755.1 GI:21509992
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 54 07-MAY-2002;
FEATURES
source
Location/Qualifiers
1..20
/mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      893 GACTGTGTGCGCGGAGATCC 912
|||||
Db      20 GACTGTGTGCGCGGAGATCC 1

RESULT 101
AR208756/c
LOCUS   AR208756          20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION   Sequence 55 from patent US 6383808.
ACCESSION   AR208756
VERSION     AR208756.1 GI:21509994
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Monia,B.P. and Freier,S.M.
TITLE       Antisense inhibition of clusterin expression
JOURNAL     Patent: US 6383808-A 55 07-MAY-2002;
FEATURES
source
Location/Qualifiers
1..20
/mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      894 ACTGTGTGCGCGGAGATCCG 913
|||||
Db      20 ACTGTGTGCGCGGAGATCCG 1

RESULT 102
AR208757/c
LOCUS   AR208757          20 bp      DNA      linear      PAT 20-JUN-2002
FEATURES
source
Location/Qualifiers
1..20
/mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      894 ACTGTGTGCGCGGAGATCCG 913
|||||
Db      20 ACTGTGTGCGCGGAGATCCG 1
```

```
DEFINITION Sequence 56 from patent US 6383808.
ACCESSION AR208757
VERSION AR208757.1 GI:21509995
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 56 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 906 GAGATCGGCACAACTCCAC 925
Db 20 GAGATCGGCACAACTCCAC 1

RESULT 103
AR208758/c
LOCUS AR208758 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 57 from patent US 6383808.
ACCESSION AR208758
VERSION AR208758.1 GI:21509996
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 57 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 GCTGCTCGGATGAAGGAC 947
Db 20 GCTGCTCGGATGAAGGAC 1

RESULT 104
AR208759/c
LOCUS AR208759 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 58 from patent US 6383808.
ACCESSION AR208759
VERSION AR208759.1 GI:21509997
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 58 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 967 AGATCTTGCTGTGGACTGT 986
Db 20 AGATCTTGCTGTGGACTGT 1

RESULT 105
AR208760/c
LOCUS AR208760 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 59 from patent US 6383808.
ACCESSION AR208760
VERSION AR208760.1 GI:21509999
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 59 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTCGCGGGAGCTC 1028
Db 20 CTAAGCTCGCGGGAGCTC 1

RESULT 106
AR208761/c
LOCUS AR208761 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 60 from patent US 6383808.
ACCESSION AR208761
VERSION AR208761.1 GI:21510000
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 60 07-MAY-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1022 GGAGCTCGAGGAATCCCTCC 1041
Db 20 GGAGCTCGAGGAATCCCTCC 1

RESULT 107
AR208762/c
LOCUS AR208762 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 61 from patent US 6383808.
ACCESSION AR208762
VERSION AR208762.1 GI:21510001
KEYWORDS
SOURCE
ORGANISM
```



```
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 GAAGACCACTACTATCTGG 1201
|||||
Db 20 GAAGACCACTACTATCTGG 1

RESULT 113
AR208768/c
LOCUS AR208768 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 67 from patent US 6383808.
ACCESSION AR208768
VERSION AR208768.1 GI:21510008
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 67 07-MAY-2002;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1216 CTTCCACACTTCTGACTCG 1235
|||||
Db 20 CTTCCACACTTCTGACTCG 1

RESULT 115
AR208770/c
LOCUS AR208770 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 69 from patent US 6383808.
ACCESSION AR208770
VERSION AR208770.1 GI:21510011
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 69 07-MAY-2002;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1275 TTGACTCTGATCCATCAC 1294
|||||
Db 20 TTGACTCTGATCCATCAC 1

RESULT 116
AR208771/c
LOCUS AR208771 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 70 from patent US 6383808.
ACCESSION AR208771
VERSION AR208771.1 GI:21510012
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 70 07-MAY-2002;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAGTCTCC 1319
|||||
Db 20 CGGTCCCTGTAGAGTCTCC 1

RESULT 117
AR208772/c
LOCUS AR208772 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 71 from patent US 6383808.
ACCESSION AR208772
VERSION AR208772.1 GI:21510013
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 71 07-MAY-2002;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1319 CTTCCACACTTCTGACTCG 1335
|||||
Db 20 CTTCCACACTTCTGACTCG 1
```

```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1332 AAATTTATGAGACCGTGGC 1351
|||||
Db 20 AAATTTATGAGACCGTGGC 1

RESULT 118
AR208773/c
LOCUS
DEFINITION Sequence 72 from patent US 6383808.
ACCESSION AR208773
VERSION AR208773.1 GI:21510015
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 72 07-MAY-2002;
FEATURES
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1 (bases 1 to 20)
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCTGTCATGCAACTAAT 1619
|||||
Db 20 TGCTCTGTCATGCAACTAAT 1

RESULT 121
AR208776/c
LOCUS
DEFINITION Sequence 75 from patent US 6383808.
ACCESSION AR208776
VERSION AR208776.1 GI:21510018
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 75 07-MAY-2002;
FEATURES
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1 (bases 1 to 20)
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAAATTCATTAAGTCTCT 1634
|||||
Db 20 CTAAATTCATTAAGTCTCT 1

RESULT 122
AR208779/c
LOCUS
DEFINITION Sequence 78 from patent US 6383808.
ACCESSION AR208779
VERSION AR208779.1 GI:21510022
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 78 07-MAY-2002;
FEATURES
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1 (bases 1 to 20)
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 TGGACTGTTCACCAACAC 998
|||||
Db 20 TGGACTGTTCACCAACAC 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1332 AAATTTATGAGACCGTGGC 1351
|||||
Db 20 AAATTTATGAGACCGTGGC 1

RESULT 118
AR208773/c
LOCUS
DEFINITION Sequence 72 from patent US 6383808.
ACCESSION AR208773
VERSION AR208773.1 GI:21510015
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 72 07-MAY-2002;
FEATURES
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1 (bases 1 to 20)
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GATGTGGATGCTTTTGC 1417
|||||
Db 20 GATGTGGATGCTTTTGC 1

RESULT 119
AR208774/c
LOCUS
DEFINITION Sequence 73 from patent US 6383808.
ACCESSION AR208774
VERSION AR208774.1 GI:21510016
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 73 07-MAY-2002;
FEATURES
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1 (bases 1 to 20)
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGGATCCTGCACTCTA 1564
|||||
Db 20 GCTCTGGATCCTGCACTCTA 1

RESULT 120
AR208775/c
LOCUS
DEFINITION Sequence 74 from patent US 6383808.
ACCESSION AR208775
VERSION AR208775.1 GI:21510017
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 74 07-MAY-2002;
FEATURES
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1 (bases 1 to 20)
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGGATCCTGCACTCTA 1564
|||||
Db 20 GCTCTGGATCCTGCACTCTA 1

RESULT 120
AR208775/c
LOCUS
DEFINITION Sequence 74 from patent US 6383808.
ACCESSION AR208775
VERSION AR208775.1 GI:21510017
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 74 07-MAY-2002;
FEATURES
    Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1 (bases 1 to 20)
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 TGGACTGTTCACCAACAC 998
|||||
Db 20 TGGACTGTTCACCAACAC 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
RESULT 123
AR208781/c
LOCUS
DEFINITION
Sequence 80 from patent US 6383808.
ACCESSION
AR208781
VERSION
AR208781.1 GI:21510025
KEYWORDS
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 20)
AUTHORS
Monia,B.P. and Freier,S.M.
TITLE
Antisense inhibition of clusterin expression
JOURNAL
Patent: US 6383808-A 80 07-MAY-2002;
FEATURES
Location/Qualifiers
1..20
/mol_type="unassigned DNA"
/mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1383 CACCGGAGGAGTGAGATGT 1402
|||||
Db 20 CACCGGAGGAGTGAGATGT 1

RESULT 124
CO786121
LOCUS
DEFINITION
Sequence 9 from Patent WO2004018676.
ACCESSION
CO786121
VERSION
CO786121.1 GI:45721224
KEYWORDS
synthetic construct
SOURCE
synthetic construct
other sequences; artificial sequences.
ORGANISM
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE
Rnai probes targeting cancer-related proteins
JOURNAL
Patent: WO 2004018676-A 9 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
Location/Qualifiers
1..21
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"
Query Match 1.2%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCT 67
|||||
Db 1 ATGATGAAGACTCTGCTGCT 20

RESULT 125
CO786639
LOCUS
DEFINITION
Sequence 28 from Patent WO2004018675.
ACCESSION
CO786639
VERSION
CO786639.1 GI:45721659
KEYWORDS
synthetic construct
SOURCE
synthetic construct
other sequences; artificial sequences.
ORGANISM
Jansen,B.
REFERENCE
1
AUTHORS
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE
Rnai probes targeting cancer-related proteins
JOURNAL
Patent: WO 2004018676-A 67 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
Location/Qualifiers
1..19
/mol_type="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 28 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
Location/Qualifiers
1..21
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"
Query Match 1.2%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCT 67
|||||
Db 1 ATGATGAAGACTCTGCTGCT 20

RESULT 126
AR236281
LOCUS
DEFINITION
Sequence 13 from patent US 6464975.
ACCESSION
AR236281
VERSION
AR236281.1 GI:27280109
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 21)
AUTHORS
Millis,A.J.T.
TITLE
Compositions and methods for altering cell migration
JOURNAL
Patent: US 6464975-A 13 15-OCT-2002;
LOCATION/Qualifiers
1..21
/mol_type="unknown"
/mol_type="genomic DNA"
Query Match 1.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 35;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 271 AAGAGCCCAAGAGAGAAAG 291
|||||
Db 1 AGGAGCCCAAGAGAGAAAG 21

RESULT 127
CO786179
LOCUS
DEFINITION
Sequence 67 from Patent WO2004018676.
ACCESSION
CO786179
VERSION
CO786179.1 GI:45721282
KEYWORDS
synthetic construct
SOURCE
synthetic construct
other sequences; artificial sequences.
ORGANISM
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE
Rnai probes targeting cancer-related proteins
JOURNAL
Patent: WO 2004018676-A 67 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
Location/Qualifiers
1..19
/mol_type="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 48 ATGATGAAGACTCTGCTGC 66
Db 1 ATGATGAAGACTCTGCTGC 19

RESULT 128
CQ786180/c
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 68 from Patent WO2004018676.
ACCESSION CQ786180
VERSION CQ786180.1 GI:45721283
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 68 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 129
CQ786653
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 42 from Patent WO2004018675.
ACCESSION CQ786653
VERSION CQ786653.1 GI:45721673
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 42 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66
Db 1 ATGATGAAGACTCTGCTGC 19

RESULT 130
CQ786654/c
LOCUS 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 43 from Patent WO2004018675.
ACCESSION CQ786654
VERSION CQ786654.1 GI:45721674
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 43 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 131
CQ786122/c
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 10 from Patent WO2004018676.
ACCESSION CQ786122
VERSION CQ786122.1 GI:45721225
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 10 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 132
CQ786640/c
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 29 from Patent WO2004018675.
ACCESSION CQ786640
VERSION CQ786640.1 GI:45721660
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 29 04-MAR-2004;
```

The University of British Columbia (CA); Gleave, Martin E. (CA)

FEATURES
source
Location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAGACTCTGCTGC 66
|||||
Db 19 ATGATGAGACTCTGCTGC 1

RESULT 133
AR071119
LOCUS AR071119 22 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 10 from patent US 5910412.
ACCESSION AR071119
VERSION AR071119.1 GI:7222007
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Akamatsu, T. and Suzuki, T.
TITLE Method for identifying the sex of spinach by DNA markers
JOURNAL Patent: US 5910412-A 10 08-JUN-1999;
Location/Qualifiers
FEATURES 1..22
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.1%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 50;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 865 AATTCATACGAGGCGGACGA 886
|||||
Db 1 AATTCATACGAGGCGGACGA 22

RESULT 134
E15141
LOCUS E15141 22 bp DNA linear PAT 28-JUL-1999
DEFINITION PCR primer for detecting male spinach DNA.
ACCESSION E15141
VERSION E15141.1 GI:5709824
KEYWORDS JP 1998052284-A/10.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Akamatsu, T., Suzuki, T. and Uchimiya, H.
TITLE DETERMINATION OF MALE OR FEMALE OF SPINACH BY USING DNA MARKER
JOURNAL Patent: JP 1998052284-A 10 24-FEB-1998;
SAKATA NO TANE:KK
COMMENT OS None
OC Artificial sequences.
FN JP 1998052284-A/10
PD 24-FEB-1998
PR 14-MAY-1997 JP 1997124012
PF 14-MAY-1996 JP 96P 119124
PI AKAMATSU TOYOKAZU, SUZUKI TAKAO, UCHIMIYA HIROBUMI PC
C12N15/09,C07H21/04,C12Q1/68;
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No; Location/Qualifiers
FH Key

1..22
source /organism="Artificial sequences".

FEATURES
source
Location/Qualifiers
1..22
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 1.1%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 50;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 865 AATTCATACGAGGCGGACGA 886
|||||
Db 1 AATTCATACGAGGCGGACGA 22

RESULT 135
AR038688/c
LOCUS AR038688 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 22 from patent US 5807678.
ACCESSION AR038688
VERSION AR038688.1 GI:5958051
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Miller, W.L., Lin, D. and Strauss, J.F. III.
TITLE Identification of gene mutations associated with congenital lipoid
adrenal hyperplasia
JOURNAL Patent: US 5807678-A 22 15-SEP-1998;
Location/Qualifiers
FEATURES 1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 GAGAGCTCTGCACGTCAC 1492
|||||
Db 18 GAGAGCTCTGCACGTCAC 1

RESULT 136
AR208705
LOCUS AR208705 18 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 4 from patent US 6383808.
ACCESSION AR208705
VERSION AR208705.1 GI:21509929
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia, B.P. and Freier, S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 4 07-MAY-2002;
Location/Qualifiers
FEATURES 1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTGAA 763
|||||
Db 1 TCCGTACGAGCCCTGAA 18


```
RESULT 137
AX728619
LOCUS AX728619 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 253 from Patent WO03025175.
ACCESSION AX728619
VERSION AX728619.1 GI:30507962
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Teitelman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 253 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1551 GATCCTGCACTCTAACA 1567
|||||
Db 1 GATCCTGCACTCTAACA 17

RESULT 138
AX762710
LOCUS AX762710 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 6031 from Patent WO03040369.
ACCESSION AX762710
VERSION AX762710.1 GI:32257326
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Teitelman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 6031 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1551 GATCCTGCACTCTAACA 1567
|||||
Db 1 GATCCTGCACTCTAACA 17

RESULT 139
AR167026/c
LOCUS AR167026/c 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 43 from patent US 6284458.
ACCESSION AR167026
VERSION AR167026.1 GI:21513473
KEYWORDS virus-associated diseases
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Anderson,K.P., Hanecak,R.C., Hoshiko,K., Nozaki,C., Nishihara,T.,
Nakatake,H., Hamada,F., Eto,T. and Furukawa,S.
TITLE Compositions and methods for treatment of hepatitis C
virus-associated diseases
JOURNAL Patent: US 6284458-A 43 04-SEP-2001;
Molecular Engines Laboratories (FR)
FEATURES
source
1..20
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GCCTCCAGGCCCCCAACTCC 1529
|||||
Db 20 GCCTCCAGGCCCCCAACTCC 1

RESULT 140
AR210681/c
LOCUS AR210681/c 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 43 from patent US 6391542.
ACCESSION AR210681
VERSION AR210681.1 GI:21513473
KEYWORDS virus-associated diseases
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Anderson,K.P., Hanecak,R.C., Hoshiko,K., Nozaki,C., Nishihara,T.,
Nakatake,H., Hamada,F., Eto,T., Furukawa,S., Furusako,S.,
Bruce,T.W. and Lima,W.F.
TITLE Compositions and methods for treatment of Hepatitis C
virus-associated diseases
JOURNAL Patent: US 6391542-A 43 21-MAY-2002;
Molecular Engines Laboratories (FR)
FEATURES
source
1..20
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GCCTCCAGGCCCCCAACTCC 1529
|||||
Db 20 GCCTCCAGGCCCCCAACTCC 1

RESULT 141
A39125/c
LOCUS A39125/c 16 bp DNA linear PAT 05-MAR-1997
DEFINITION Sequence 97 from Patent WO9412670.
ACCESSION A39125
VERSION A39125.1 GI:2295500
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van,H.H.
TITLE PROCESS FOR TYPING OF HCV ISOLATES
JOURNAL Patent: WO 9412670-A 97 09-JUN-1994;
INNOGENETICS NV (BE)
COMMENT Other publication AU 5628294 940622
Other publication CA 2128528 940609
```

```
Other publication JP 7503143T 950406.
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="unidentified"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32644"

Query Match
  1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
    |||||
Db 16 CAGCCTCCAGGCCCC 1

RESULT 142
AR063448/c
LOCUS AR063448 16 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 97 from patent US 5846704.
ACCESSION AR063448
VERSION AR063448.1 GI:5992756
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
TITLE Process for typing of HCV isolates
JOURNAL Patent: US 5846704-A 97 08-DEC-1998;
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
  1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
    |||||
Db 16 CAGCCTCCAGGCCCC 1

RESULT 143
AR123639/c
LOCUS AR123639 16 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 97 from patent US 6171784.
ACCESSION AR123639
VERSION AR123639.1 GI:14109000
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
TITLE Process for typing of HCV isolates
JOURNAL Patent: US 6171784-A 97 09-JAN-2001;
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
  1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
    |||||
Db 16 CAGCCTCCAGGCCCC 1

RESULT 144
AR123639/c
LOCUS AR123639 16 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 97 from patent US 6171784.
ACCESSION AR123639
VERSION AR123639.1 GI:14109000
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
TITLE Process for typing of HCV isolates
JOURNAL Patent: US 6171784-A 97 09-JAN-2001;
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
  1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
    |||||
Db 16 CAGCCTCCAGGCCCC 1

RESULT 145
AR305790/c
LOCUS AR305790 16 bp mRNA linear PAT 12-JUN-2003
DEFINITION Sequence 97 from patent US 6548244.
ACCESSION AR305790
VERSION AR305790.1 GI:31695399
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
TITLE Process for typing HCV isolates
JOURNAL Patent: US 6548244-A 97 15-APR-2003;
FEATURES
  source
    Location/Qualifiers
      1..16
        /organism="unknown"
        /mol_type="mRNA"

Query Match
  1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
    |||||
Db 16 CAGCCTCCAGGCCCC 1

RESULT 146
AR023187/c
LOCUS AR023187 16 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 97 from Patent EP0905258.
ACCESSION AR023187
VERSION AR023187.1 GI:10046644
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS
TITLE Method for detecting nucleic acid sequences based on the use of
JOURNAL solid phase immobilised nucleotide probes (line probe assay)
FEATURES Patent: EP 0905258-A 97 31-MAR-1999;
  source INNOGENETICS NV (BE)
    Location/Qualifiers
      1..16
```

```
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 147
AX417393/c
LOCUS AX417393 16 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 97 from Patent EP1197568.
ACCESSION AX417393
VERSION AX417393.1 GI:21522686
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Hepatitis C virus
Hepatitis C virus
Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
Hepacivirus.
1
Maertens,G., Rossau,R., Stuyver,L. and van Heuverswyn,H.
Detection and typing of hcv using 5'utr and ns5 nucleic acid
sequences
JOURNAL
Innogenetics N.V. (BE)
Patent: EP 1197568-A 97 17-APR-2002;
Location/Qualifiers
1. .16
/organism="Hepatitis C virus"
/mol_type="unassigned DNA"
/db_xref="taxon:11103"

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 148
AR029848
LOCUS AR029848 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 37 from patent US 5861244.
ACCESSION AR029848
VERSION AR029848.1 GI:5943062
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Unknown.
Unknown.
Unclassified.
1 (bases 1 to 17)
Wang,C.-G. and Hepburn,A.G.
Genetic sequence assay using DNA triple strand formation
Patent: US 5861244-A 37 19-JAN-1999;
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAGAAGAGGA 295
Db 1 AGAAGAAGAAGAGGA 16

/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 149
CQ881900/c
LOCUS CQ881900 19 bp RNA linear PAT 11-OCT-2004
DEFINITION Sequence 15 from Patent WO2004083446.
ACCESSION CQ881900
VERSION CQ881900.1 GI:54034672
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
synthetic construct
synthetic construct
other sequences; artificial sequences.
1
van Ommeren,G.J., van Deutekom,J.C., den Dunnen,J.T. and
Aartsma-Rus,A.
Modulation of exon recognition in pre-mrna by interfering with the
secondary rna structure
Patent: WO 2004083446-A 15 30-SEP-2004;
Academisch Ziekenhuis Leiden (NL)
Location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: h41AONI"

Query Match 1.0%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAGAAGAGGA 295
Db 17 AGAAGAAGAAGAGGA 2

RESULT 150
CQ786119
LOCUS CQ786119 19 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 7 from Patent WO2004018676.
ACCESSION CQ786119
VERSION CQ786119.1 GI:45721222
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
synthetic construct
synthetic construct
other sequences; artificial sequences.
1
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
Rnai probes targeting cancer-related proteins
Patent: WO 2004018676-A 7 04-MAR-2004;
The University of British Columbia (CA)
Location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"

Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATAAAACTGTCT 1634
Db 1 TAATTCACAAAACGTGTT 19

RESULT 151
CQ786120/c
LOCUS CQ786120 19 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 8 from Patent WO2004018676.
ACCESSION CQ786120
VERSION CQ786120.1 GI:45721223
KEYWORDS
SOURCE
synthetic construct
```

```
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018675-A 8 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1614 ACTAATTCATAAACTGTCT 1632
| | | | | | | | | | | | | | |
Db 19 AATAATTCACAAACTGT 1

RESULT 152
CQ786635
LOCUS      19 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 24 from Patent WO2004018675.
ACCESSION  CQ786635
VERSION     CQ786635.1 GI:45721655
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B.
TITLE        Treatment of melanoma by reduction in clusterin levels
JOURNAL      Patent: WO 2004018675-A 24 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1614 ACTAATTCATAAACTGTCT 1632
| | | | | | | | | | | | | | |
Db 19 AATAATTCACAAACTGT 1

RESULT 152
CQ786635
LOCUS      19 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 24 from Patent WO2004018675.
ACCESSION  CQ786635
VERSION     CQ786635.1 GI:45721655
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B.
TITLE        Treatment of melanoma by reduction in clusterin levels
JOURNAL      Patent: WO 2004018675-A 24 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATAAACTGTCT 1634
| | | | | | | | | | | | | | |
Db 1 TAATTCACAAACTGT 19

RESULT 153
CQ786637
LOCUS      19 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 26 from Patent WO2004018675.
ACCESSION  CQ786637
VERSION     CQ786637.1 GI:45721657
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B.
TITLE        Treatment of melanoma by reduction in clusterin levels
JOURNAL      Patent: WO 2004018675-A 26 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATAAACTGTCT 1634
| | | | | | | | | | | | | | |
Db 1 TAATTCACAAACTGT 19

RESULT 153
CQ623926
LOCUS      17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8666 from Patent WO0192524.
ACCESSION  CQ623926
VERSION     CQ623926.1 GI:41674144
KEYWORDS   .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8666 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCAAAGAGAGAA 289
| | | | | | | | | | | | | | |
```

Db 1 GAAGCCAGAGGAGAA 17

RESULT 156
I37522/c

LOCUS 17 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 535 from patent US 5612215.

ACCESSION I37522

VERSION I37522.1 GI:2085482

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE

AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and Stinchcomb, D.T.

TITLE Stromelysin targeted ribozymes

JOURNAL Patent: US 5612215-A 535 18-MAR-1997;

FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAAGAGATTCTCC 1605
|||||

Db 17 AAGACAGATTCTCC 1

RESULT 157
I94372/c

LOCUS 17 bp DNA linear PAT 01-DEC-1998

DEFINITION Sequence 535 from patent US 5731295.

ACCESSION I94372

VERSION I94372.1 GI:3938842

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE

AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and Stinchcomb, D.T.

TITLE Method of reducing stromelysin RNA via ribozymes

JOURNAL Patent: US 5731295-A 535 24-MAR-1998;

FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAAGAGATTCTCC 1605
|||||

Db 17 AAGACAGATTCTCC 1

RESULT 158
AR464989

LOCUS 17 bp DNA linear PAT 20-FEB-2004

DEFINITION Sequence 8666 from patent US 6686188.

ACCESSION AR464989

VERSION AR464989.1 GI:42700046

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and

Shannon, M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
Patent: US 6686188-A 8666 03-FEB-2004;

JOURNAL Location/Qualifiers

FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCAGAGGAGAA 289
|||||

Db 1 GAAGCCAGAGGAGAA 17

RESULT 159
AX214728/c

LOCUS 17 bp RNA linear PAT 07-SEP-2001

DEFINITION Sequence 170 from Patent WO0159103.

ACCESSION AX214728

VERSION AX214728.1 GI:15524771

KEYWORDS

SOURCE synthetic construct

ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE

AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.

TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression

JOURNAL Patent: WO 0159103-A 170 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAAACGTCTT 1635
|||||

Db 17 TTCATTAACGTCTT 1

RESULT 160
AX688719/c

LOCUS 17 bp DNA linear PAT 31-MAR-2003

DEFINITION Sequence 1451 from Patent EP1281758.

ACCESSION AX688719

VERSION AX688719.1 GI:29411423

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE

AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12

JOURNAL Patent: EP 1281758-A 1451 05-FEB-2003;
Aeomica, Inc. (US)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  928 GCTGCTGGCGGTGAAG 944
    |||||
Db  17 GCTGCTGGCGGTGAAG 1

RESULT 161
LOCUS      AX762505
DEFINITION Sequence 5826 from Patent WO03040369.
ACCESSION  AX762505
VERSION     AX762505.1 GI:32257121
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Amson,R. and Tuijnder,M.
TITLE      Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL    Patent: WO 03040369-A 5826 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES   source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  1551 GATCTTGCACTCTAACA 1567
    |||||
Db  1 GATCTTGCACTCTACCA 17

RESULT 162
LOCUS      AR011407/c
DEFINITION Sequence 280 from patent US 5762938.
ACCESSION  AR011407
VERSION     AR011407.1 GI:3969397
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Paoletti,E., Perkus,M.E., Taylor,J., Tartaglia,J., Norton,E.K.,
            Riviere,M., de Taisene,C., Limbach,K.J., Johnson,G.P., Pincus,S.E.,
            Cox,W.I., Audonnet,J.-C.Francis, and Gettig,R.Robert.
            Modified recombinant vaccinia virus and expression vectors thereof
            Patent: US 5762938-A 280 09-JUN-1998;
            Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  222 CTCATAGAAAAAACCAAC 239
    |||||
Db  18 CTAATAGAAAAAACCAAC 1

RESULT 165
LOCUS      AX115178
DEFINITION Sequence 301 from Patent WO0129262.
ACCESSION  AX115178
VERSION     AX115178.1 GI:14032120
KEYWORDS   .
SOURCE     synthetic construct
            synthetic construct
            other sequences; artificial sequences.
ORGANISM   1
REFERENCE  1
AUTHORS    Picoult-Newbury,L. and Pohl,M.
TITLE      Genotyping reagents, kits and methods of use thereof
            Patent: WO 0129262-A 301 26-APR-2001;
            Orchid Biosciences, Inc. (US)

```

```

RESULT 163
LOCUS      AR040105/c
DEFINITION Sequence 953 from patent US 5807743.
ACCESSION  AR040105
VERSION     AR040105.1 GI:5959468
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
            Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Stinchcomb,D.T. and McSwiggen,J.A.
TITLE      Interleukin-2 receptor gamma-chain ribozymes
            Patent: US 5807743-A 953 15-SEP-1998;
            Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1121 GCTGGAGCAGCTGAACGA 1138
    |||||
Db  18 GCAGGAGCAGCTGAAGCA 1

RESULT 164
LOCUS      I18045/c
DEFINITION Sequence 280 from patent US 5494807.
ACCESSION  I18045
VERSION     I18045.1 GI:1598400
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Paoletti,E., Perkus,M.E., Taylor,J., Tartaglia,J., Norton,E.K.,
            Riviere,M., de Taisene,C., Limbach,K.J., Johnson,G.P., Pincus,S.E.,
            Cox,W.I., Audonnet,J.-C.F. and Gettig,R.R.
            NYVAC vaccinia virus recombinants comprising heterologous inserts
            Patent: US 5494807-A 280 27-FEB-1996;
            Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  222 CTCATAGAAAAAACCAAC 239
    |||||
Db  18 CTAATAGAAAAAACCAAC 1

RESULT 165
LOCUS      AX115178
DEFINITION Sequence 301 from Patent WO0129262.
ACCESSION  AX115178
VERSION     AX115178.1 GI:14032120
KEYWORDS   .
SOURCE     synthetic construct
            synthetic construct
            other sequences; artificial sequences.
ORGANISM   1
REFERENCE  1
AUTHORS    Picoult-Newbury,L. and Pohl,M.
TITLE      Genotyping reagents, kits and methods of use thereof
            Patent: WO 0129262-A 301 26-APR-2001;
            Orchid Biosciences, Inc. (US)

```

```
FEATURES
  source
    Location/Qualifiers
      1..18
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Primer"

Query Match
  Best Local Similarity 88.9%; Score 14.8; DB 1; Length 18;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1492 CCAAGTAACAGGCCCA 1509
Db 1 CCAGGTGACCAAGGCCCA 18

RESULT 166
AX776586
LOCUS AX776586 18 bp DNA linear PAT 14-JUL-2003
DEFINITION Sequence 11 from Patent WO03047611.
ACCESSION AX776586
VERSION AX776586.1 GI:32694120
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
  1
  AUTHORS Weise,M., Eulenberger,K., Fritsch,R., Haeder,T., Broenner,G. and
  Steuernagel,A.
  TITLE Pp10d, tec protein tyrosine kinase and edtp homologous proteins
  JOURNAL Involved in the regulation of energy homeostasis
  Patent: WO 03047611-A 11 12-JUN-2003;
  Develogen Aktiengesellschaft fuer entwicklungsbiologische Forschung
  (DE)
FEATURES
  source
    Location/Qualifiers
      1..18
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="mouse PTPRB reverse primer"

Query Match
  Best Local Similarity 88.9%; Score 14.8; DB 1; Length 18;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 764 CTTCCACGCCATCTTCCA 781
Db 1 CTTCCACGCCATCTTCCA 18

RESULT 167
AR173373
LOCUS AR173373 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 7 from patent US 6303847.
ACCESSION AR173373
VERSION AR173373.1 GI:17912864
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  AUTHORS Kawaoka,A. and Ebina,H.
  TITLE DNA encoding a transcription factor controlling phenylpropanoid
  biosynthesis pathway
  JOURNAL Patent: US 6303847-A 7 16-OCT-2001;
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACCTCTCTCT 1119
Db 2 CTCACACCTCTCTCT 17

RESULT 169
CQ623612
LOCUS CQ623612 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8352 from Patent WO0192524.
ACCESSION CQ623612
VERSION CQ623612.1 GI:41673830
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
  1
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 8352 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTCTCTCTG 1124
Db 17 CAGCTCTCTCTCTCTG 2

RESULT 169
CQ623613/c
LOCUS CQ623613 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8353 from Patent WO0192524.
ACCESSION CQ623613
VERSION CQ623613.1 GI:41673831
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
  1
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 8353 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTCTCTCTG 1124
Db 16 CAGCTCTCTCTCTCTG 1

RESULT 170
CQ623925
LOCUS CQ623925 17 bp DNA linear PAT 02-FEB-2004
```

```
DEFINITION      Sequence 8665 from Patent WO0192524.
ACCESSION       CQ623925
VERSION         CQ623925.1  GI:41674143
KEYWORDS        Homo sapiens (human)
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
REFERENCE
AUTHORS         Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
                Shannon, M.E.
TITLE           Myosin-like gene expressed in human heart and muscle
JOURNAL         Patent: WO 0192524-A 8665 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES
source          1. .17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 273 GAAGCCAGAGAGAGAA 288
Db 2 GAAGCCAGAGAGAGAA 17
RESULT 171
LOCUS           CQ623927 17 bp DNA linear PAT 02-FEB-2004
DEFINITION      Sequence 8667 from Patent WO0192524.
ACCESSION       CQ623927
VERSION         CQ623927.1  GI:41674145
KEYWORDS        Homo sapiens (human)
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
REFERENCE
AUTHORS         Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
                Shannon, M.E.
TITLE           Myosin-like gene expressed in human heart and muscle
JOURNAL         Patent: WO 0192524-A 8667 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES
source          1. .17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 274 AAGCCAGAGAGAGAA 289
Db 1 AAGCCAGAGAGAGAA 16
RESULT 172
LOCUS           CQ625297 17 bp DNA linear PAT 02-FEB-2004
DEFINITION      Sequence 10037 from Patent WO0192524.
ACCESSION       CQ625297
VERSION         CQ625297.1  GI:41675515
KEYWORDS        Homo sapiens (human)
SOURCE          Homo sapiens
ORGANISM        Homo sapiens
REFERENCE
AUTHORS         Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and
                Stinchcomb, D.T.
TITLE           Stronelysin targeted ribozymes
JOURNAL         Patent: US 5612215-A 536 18-MAR-1997;
                Aeomica, Inc. (US)
FEATURES
source          1. .17
                /organism="unknown"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 715 CCCGCATCGTCCGAC 730
Db 16 CCCGCATCGTCCACAG 1
RESULT 174
LOCUS           I37523 17 bp DNA linear PAT 13-MAY-1997
DEFINITION      Sequence 536 from patent US 5612215.
ACCESSION       I37523
VERSION         I37523.1  GI:2085483
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE
AUTHORS         Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and
                Stinchcomb, D.T.
TITLE           Stronelysin targeted ribozymes
JOURNAL         Patent: US 5612215-A 536 18-MAR-1997;
                Aeomica, Inc. (US)
FEATURES
source          1. .17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 715 CCCGCATCGTCCGAC 730
Db 16 CCCGCATCGTCCACAG 1
RESULT 173
LOCUS           CQ625298 17 bp DNA linear PAT 02-FEB-2004
DEFINITION      Sequence 10038 from Patent WO0192524.
ACCESSION       CQ625298
VERSION         CQ625298.1  GI:41675516
KEYWORDS        Homo sapiens (human)
SOURCE          Homo sapiens
ORGANISM        Homo sapiens
REFERENCE
AUTHORS         Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
                Shannon, M.E.
TITLE           Myosin-like gene expressed in human heart and muscle
JOURNAL         Patent: WO 0192524-A 10038 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES
source          1. .17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 715 CCCGCATCGTCCGAC 730
Db 16 CCCGCATCGTCCACAG 1
RESULT 174
LOCUS           I37523 17 bp DNA linear PAT 13-MAY-1997
DEFINITION      Sequence 536 from patent US 5612215.
ACCESSION       I37523
VERSION         I37523.1  GI:2085483
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE
AUTHORS         Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and
                Stinchcomb, D.T.
TITLE           Stronelysin targeted ribozymes
JOURNAL         Patent: US 5612215-A 536 18-MAR-1997;
                Aeomica, Inc. (US)
FEATURES
source          1. .17
                /organism="unknown"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 715 CCCGCATCGTCCGAC 730
Db 16 CCCGCATCGTCCACAG 1
```


Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 15; Conservative 0;

QY 1589 AAGAACAAGATTGCTC 1604
|||||
Db 16 AAGAACAAGATTCTC 1

RESULT 175
194373/c
LOCUS 194373 17 bp DNA PAT 01-DEC-1998
DEFINITION Sequence 536 from patent US 5731295.
ACCESSION 194373
VERSION 194373.1 GI:3938843
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 536 24-MAR-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 15; Conservative 0;

QY 1109 CACCTCTCTCTGCTG 1124
|||||
Db 16 CAGCTCTCTCTGCTG 1

RESULT 178
AR464988
LOCUS AR464988 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 8665 from patent US 6686188.
ACCESSION AR464988
VERSION AR464988.1 GI:42700045
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8665 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 15; Conservative 0;

QY 273 GAAGCCAAGAAGAAGA 288
|||||
Db 2 GAAGCCAAGAAGGAGA 17

RESULT 179
AR464990
LOCUS AR464990 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 8667 from patent US 6686188.
ACCESSION AR464990
VERSION AR464990.1 GI:42700047
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8667 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 15; Conservative 0;

QY 1589 AAGAACAAGATTGCTC 1604
|||||
Db 16 AAGAACAAGATTCTC 1

RESULT 176
AR464675/c
LOCUS AR464675 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 8352 from patent US 6686188.
ACCESSION AR464675
VERSION AR464675.1 GI:42699732
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8352 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 0; Indels 1; Gaps 0;
Matches 15; Conservative 0;

QY 1109 CACCTCTCTCTGCTG 1124
|||||
Db 17 CAGCTCTCTCTGCTG 2

RESULT 177
AR464676/c
LOCUS AR464676 17 bp DNA PAT 20-FEB-2004
DEFINITION Sequence 8353 from patent US 6686188.
ACCESSION AR464676
VERSION AR464676.1 GI:42699733

```
/mol_type="genomic DNA"

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 274 AAGCCAAGAAGAGAA 289
    |||||
Db 1 AAGCCAAGAAGAGAA 16

RESULT 180
AX466360/c
LOCUS          17 bp DNA linear PAT 20-FEB-2004
DEFINITION     Sequence 10037 from patent US 6686188.
ACCESSION      AR466360
VERSION        AR466360.1 GI:42701417
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE         Polynucleotide encoding a human myosin-like polypeptide expressed
              predominantly in heart and muscle
JOURNAL        Patent: US 6686188-A 10037 03-FEB-2004;
              Location/Qualifiers
FEATURES       source
              1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCCGAC 730
    |||||
Db 17 CCGCATCGTCCACAG 2

RESULT 181
AX466361/c
LOCUS          17 bp DNA linear PAT 20-FEB-2004
DEFINITION     Sequence 10038 from patent US 6686188.
ACCESSION      AR466361
VERSION        AR466361.1 GI:42701418
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE         Polynucleotide encoding a human myosin-like polypeptide expressed
              predominantly in heart and muscle
JOURNAL        Patent: US 6686188-A 10038 03-FEB-2004;
              Location/Qualifiers
FEATURES       source
              1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCCGAC 730
    |||||
Db 16 CCGCATCGTCCACAG 1

RESULT 182
AX214729/c

LOCUS          17 bp RNA linear PAT 07-SEP-2001
DEFINITION     Sequence 171 from Patent WO0159103.
ACCESSION      AX214729
VERSION        AX214729.1 GI:15524772
KEYWORDS       .
SOURCE         synthetic construct
              other sequences; artificial sequences.
ORGANISM       .
REFERENCE      1
AUTHORS       Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE         Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
JOURNAL        Patent: WO 0159103-A 171 16-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
              McSwiggen, James (US); Chowrira, Bharat M. (US)
              Location/Qualifiers
FEATURES       source
              1..17
                /organism="synthetic construct"
                /mol_type="unassigned RNA"
                /db_xref="taxon:32630"
                /note="Nucleic Acid"

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAAACTGTCT 1634
    |||||
Db 16 TTCAATAAAACTGTCT 1

RESULT 183
AX688718/c
LOCUS          17 bp DNA linear PAT 31-MAR-2003
DEFINITION     Sequence 1450 from Patent EP1281758.
ACCESSION      AX688718
VERSION        AX688718.1 GI:29411422
KEYWORDS       .
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS       Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE         Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL        Patent: EP 1281758-A 1450 05-FEB-2003;
              Aeomica, Inc. (US)
              Location/Qualifiers
FEATURES       source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 929 CTGCCTGCGGATGAAG 944
    |||||
Db 17 CTGCCTGCGGCTGAAG 2

RESULT 184
AX688720/c
LOCUS          17 bp DNA linear PAT 31-MAR-2003
DEFINITION     Sequence 1452 from Patent EP1281758.
ACCESSION      AX688720
VERSION        AX688720.1 GI:29411424
KEYWORDS       .
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```

REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 1452 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 928 GCTGCTCGCGATGAA 943
16 GCTGCTCGCGCTGAA 1

RESULT 185
AX732888/c
LOCUS AX732888 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4522 from Patent WO03025175.
ACCESSION AX732888
VERSION AX732888.1 GI:30512231
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telesman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 4522 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 326 AAAGCTGAAGGAGCTC 341
16 AAAGCTGAAGGAGATC 1

RESULT 186
AX760623
LOCUS AX760623 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3944 from Patent WO03040369.
ACCESSION AX760623
VERSION AX760623.1 GI:32255239
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telesman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 3944 15-MAY-2003;
Molecular Engines Laboratories (FR)

```

```

FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 154 ATCAGGGGAAGTAAGTA 169
2 ATCAGGGGAAGTAAGTA 17

RESULT 187
AR067404/c
LOCUS AR067404 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 797 from patent US 5851760.
ACCESSION AR067404
VERSION AR067404.1 GI:5998626
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Evans,G.A. and Smith,M.W.
TITLE Method for generation of sequence sampled maps of complex genomes
JOURNAL Patent: US 5851760-A 797 22-DEC-1998;
FEATURES
source Location/Qualifiers
1.18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1520 CCCCAACTCCGCCAG 1535
18 CCTTAACTCCGCCAG 3

RESULT 188
AX837978
LOCUS AX837978 18 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 5102 from Patent EP1347046.
ACCESSION AX837978
VERSION AX837978.1 GI:39921670
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Isogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S., Yamamoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R., Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and Masuho,Y.
TITLE Full-length cDNA sequences
JOURNAL Patent: EP 1347046-A 5102 24-SEP-2003;
Research Association for Biotechnology (JP)
FEATURES
source Location/Qualifiers
1.18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Description of Artificial Sequence: an artificially synthesized primer se q"

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1094 GTGGAAGATGCTCAAC 1109 17 bp DNA linear PAT 02-SEP-2002
Db 1 GTGGAAGATGCTCGAC 16
RESULT 189
AX324817/c
LOCUS AX324817 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 955 from Patent WO0192512.
ACCESSION AX324817
VERSION AX324817.1 GI:18095570
KEYWORDS
SOURCE Eucalyptus camaldulensis (Murray red gum)
ORGANISM Eucalyptus camaldulensis
REFERENCE Eucalyptus camaldulensis
AUTHORS Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
TITLE Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
JOURNAL Rosids; Myrtales; Myrtaceae; Eucalyptus.
FEATURES
source 1
Location/Qualifiers
1..17
/organism="Eucalyptus camaldulensis"
/mol_type="unassigned DNA"
/db_xref="taxon:34316"
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0
QY 1202 GGTCAACCGGTGG 1215
Db 14 GGTCAACCGGTGG 1
RESULT 190
AX324818
LOCUS AX324818 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 956 from Patent WO0192512.
ACCESSION AX324818
VERSION AX324818.1 GI:18095571
KEYWORDS
SOURCE Eucalyptus camaldulensis (Murray red gum)
ORGANISM Eucalyptus camaldulensis
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
AUTHORS Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
TITLE Rosids; Myrtales; Myrtaceae; Eucalyptus.
JOURNAL
FEATURES
source 1
Location/Qualifiers
1..17
/organism="Eucalyptus camaldulensis"
/mol_type="unassigned DNA"
/db_xref="taxon:34316"
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0
QY 1202 GGTCAACCGGTGG 1215
Db 4 GGTCAACCGGTGG 17
RESULT 191
AR039619

LOCUS AR039619 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 467 from patent US 5807743.
ACCESSION AR039619
VERSION AR039619.1 GI:5958982
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 467 15-SEP-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2
QY 693 CCTCAGTCTCTTTC 709
Db 1 CCTCCTCTCTCTTTC 17
RESULT 192
AR081753
LOCUS AR081753 17 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 25 from patent US 5972621.
ACCESSION AR081753
VERSION AR081753.1 GI:10008479
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Methods of identifying compounds that modulate body weight using the OB receptor
JOURNAL Patent: US 5972621-A 25 26-OCT-1999;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2
QY 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGGCCCTTCAG 17
RESULT 193
AR081755
LOCUS AR081755 17 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 27 from patent US 5972621.
ACCESSION AR081755
VERSION AR081755.1 GI:10008481
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Methods of identifying compounds that modulate body weight using the OB receptor
JOURNAL Patent: US 5972621-A 27 26-OCT-1999;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"

```
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCCTTCAG 676
    ||||| ||||| |||||
Db 1 CACTATTGCGCCTTCAG 17

RESULT 194
AR094983/c
LOCUS AR094983 17 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 21 from patent US 6001990.
ACCESSION AR094983
VERSION AR094983.1 GI:10022419
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Wanda, J.R., Wakita, T. and Moradpour, D.
TITLE Antisense inhibition of hepatitis C virus
JOURNAL Patent: US 6001990-A 21 14-DEC-1999;
FEATURES
    source
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAACAAA 238
    ||||| ||||| |||||
Db 17 CTCAAAAGAAAACAAA 1

RESULT 195
AR167985
LOCUS AR167985 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 25 from patent US 6287782.
ACCESSION AR167985
VERSION AR167985.1 GI:17903799
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.
TITLE Methods of using the Ob receptor to identify therapeutic compounds
JOURNAL Patent: US 6287782-A 25 11-SEP-2001;
FEATURES
    source
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCCTTCAG 676
    ||||| ||||| |||||
Db 1 CACTATTGCGCCTTCAG 17

RESULT 196
AR167987
LOCUS AR167987 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 27 from patent US 6287782.
ACCESSION AR167987
VERSION AR167987.1 GI:17903801

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.
TITLE Methods of using the Ob receptor to identify therapeutic compounds
JOURNAL Patent: US 6287782-A 27 11-SEP-2001;
FEATURES
    source
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCCTTCAG 676
    ||||| ||||| |||||
Db 1 CACTATTGCGCCTTCAG 17

RESULT 197
BD254845
LOCUS BD254845 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254845
VERSION BD254845.1 GI:33064615
KEYWORDS JP 2002541795-A/2638.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2638 10-DEC-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
    OS Eukaryote
    PN JP 2002541795-A/2638
    PD 10-DEC-2002
    PF 11-APR-2000 JP 2000611654
    PR 12-APR-1999 US 60/129390
    PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
    C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
    C12P21/02,
    PC
    C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
    C12R1:91),
    PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
    PC A61K37/02,
    PC (C12N5/00, C12R1:91)
    CC Regulation of repressor genes using nucleic acid molecules FH
    Key Location/Qualifiers
    FT source 1..17
    FT /organism='Eukaryote'.

FEATURES
    source
        Location/Qualifiers
        1..17
        /organism="unidentified"
        /mol_type="genomic DNA"
        /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 116 CCAGACGGTCTCAGACA 132
    ||||| ||||| |||||
Db 1 CCAGACGGTCTCAGTCA 17

RESULT 198
CQ617155/c
LOCUS CQ617155 17 bp DNA linear PAT 02-FEB-2004
```

```
DEFINITION      Sequence 1895 from Patent WO0192524.
ACCESSION        CQ617155
VERSION          CQ617155.1  GI:41667373
KEYWORDS         Homo sapiens (human)
SOURCE           Homo sapiens
ORGANISM         Homo sapiens
REFERENCE        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
JOURNAL          Shannon, M.E.
                Myosin-like gene expressed in human heart and muscle
                Patent: WO 0192524-A 1895 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES         Location/Qualifiers
source           1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCGAGTCTCT 109
      ||||| ||||| |||||
Db 17 GAGAGAGGCCAGTCTCT 1

RESULT 199
CQ617903/c
LOCUS            CQ617903 17 bp DNA linear PAT 02-FEB-2004
DEFINITION      Sequence 2643 from Patent WO0192524.
ACCESSION        CQ617903
VERSION          CQ617903.1  GI:41668121
KEYWORDS         Homo sapiens (human)
SOURCE           Homo sapiens
ORGANISM         Homo sapiens
REFERENCE        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
JOURNAL          Shannon, M.E.
                Myosin-like gene expressed in human heart and muscle
                Patent: WO 0192524-A 2643 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES         Location/Qualifiers
source           1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 CTTCCAGCACCGCCAA 861
      ||||| ||||| |||||
Db 17 CTGCCAGCACCGCCAA 1

RESULT 200
CQ622615
LOCUS            CQ622615 17 bp DNA linear PAT 02-FEB-2004
DEFINITION      Sequence 7355 from Patent WO0192524.
ACCESSION        CQ622615
VERSION          CQ622615.1  GI:41672833
KEYWORDS         Homo sapiens (human)
SOURCE           Homo sapiens
ORGANISM         Homo sapiens
REFERENCE        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
JOURNAL          Shannon, M.E.
                Myosin-like gene expressed in human heart and muscle
                Patent: WO 0192524-A 7355 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES         Location/Qualifiers
source           1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
      ||||| ||||| |||||
Db 17 GTCCAGCCTCTCCTCGC 1

RESULT 202
CQ623828
LOCUS            CQ623828 17 bp DNA linear PAT 02-FEB-2004
DEFINITION      Sequence 8568 from Patent WO0192524.
ACCESSION        CQ623828
VERSION          CQ623828.1  GI:41674046
KEYWORDS         Homo sapiens (human)
SOURCE           Homo sapiens
ORGANISM         Homo sapiens
REFERENCE        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
JOURNAL          Shannon, M.E.
                Myosin-like gene expressed in human heart and muscle
                Patent: WO 0192524-A 8568 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES         Location/Qualifiers
source           1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
      ||||| ||||| |||||
Db 17 GTCCAGCCTCTCCTCGC 1

RESULT 203
CQ622745/c
LOCUS            CQ622745 17 bp DNA linear PAT 02-FEB-2004
DEFINITION      Sequence 7485 from Patent WO0192524.
ACCESSION        CQ622745
VERSION          CQ622745.1  GI:41672963
KEYWORDS         Homo sapiens (human)
SOURCE           Homo sapiens
ORGANISM         Homo sapiens
REFERENCE        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
JOURNAL          Shannon, M.E.
                Myosin-like gene expressed in human heart and muscle
                Patent: WO 0192524-A 7485 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES         Location/Qualifiers
source           1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAA 286
      ||||| ||||| |||||
Db 1 GAAGAAGCCCAAGAA 17
```

/db_xref="taxon:9606"

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 AGGATGCCCTAATGAG 308
||||| ||| |||||
Db 1 AGGATGACCTGAATGAG 17

RESULT 203
CQ623920
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8660 from Patent WO0192524.
ACCESSION CQ623920
VERSION    CQ623920.1 GI:41674138
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
AUTHORS    Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8660 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 CTAGAAGAGCCCAAGAA 283
||||| ||| |||||
Db 1 CTGGAGAGCCCAAGAA 17

RESULT 204
CQ623921
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8661 from Patent WO0192524.
ACCESSION CQ623921
VERSION    CQ623921.1 GI:41674139
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
AUTHORS    Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8661 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 TAGAAGAGCCCAAGAG 284
||||| ||| |||||
Db 1 TGGAGGAGCCCAAGAG 17
```

```
RESULT 205
CQ623923
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8663 from Patent WO0192524.
ACCESSION CQ623923
VERSION    CQ623923.1 GI:41674141
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
AUTHORS    Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8663 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAGAA 286
||||| ||| |||||
Db 1 GAGGAGCCCAAGAGGA 17

RESULT 206
CQ623924
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8664 from Patent WO0192524.
ACCESSION CQ623924
VERSION    CQ623924.1 GI:41674142
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
AUTHORS    Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8664 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAGAGAG 287
||||| ||| |||||
Db 1 AGGAGCCCAAGAGGAG 17

RESULT 207
CQ624947/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 9687 from Patent WO0192524.
ACCESSION CQ624947
VERSION    CQ624947.1 GI:41675165
KEYWORDS
```

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9687 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 93 GAGAGTGGCGAGTCCT 109
|||||
Db 17 GAGAGTGGCGCGAGTCCT 1
RESULT 208
CO624948/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9688 from Patent WO0192524.
ACCESSION CO624948
VERSION CO624948.1 GI:41675166
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9688 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 92 GGAGAGTGGCGAGTCCT 108
|||||
Db 17 GGAGAGTGGCGCGAGTCCT 1
RESULT 209
CO624949/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9689 from Patent WO0192524.
ACCESSION CO624949
VERSION CO624949.1 GI:41675167
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9689 06-DEC-2001;

Aeomica, Inc. (US)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 91 GGGAGAGTGGCGAGTC 107
|||||
Db 17 GGGAGAGTGGCGCGAGTC 1
RESULT 210
E65210/c
LOCUS 17 bp DNA linear PAT 18-JUN-2001
DEFINITION Method for analyzing oligonucleotide.
ACCESSION E65210
VERSION E65210.1 GI:13025986
KEYWORDS JP 1999046800-A/4.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
AUTHORS Leroy,E.H., Michael,W.H., Lloyd,M.S. and Tim,J.H.
TITLE Method for analyzing oligonucleotide
JOURNAL Patent: JP 1999046800-A 4 23-FEB-1999;
CALIFORNIA INSTITUTE OF TECHNOLOGY
COMMENT OS Artificial Sequence
PN JP 1999046800-A/4
PD 23-FEB-1999
PF 12-FEB-1998 JP 1998030272
PI 16-JAN-1984 US 570973
PC C12Q1/68, G01N21/76, G01N27/447, G01N33/50, G01N33/58//C12N15/09
CC Leroy,E.H., Michael,W.H., Lloyd,M.S. and Tim,J.H.
FH Leroy,E.H., Michael,W.H., Lloyd,M.S. and Tim,J.H.
FT source 1..17
Key Location/Qualifiers
FT source 1..17
/organism="Artificial Sequence".
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1357 AAGCGCTGCAGGATAC 1373
|||||
Db 17 ATGCTCTGCAGGATAC 1
RESULT 211
AR192271
LOCUS 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7759 from patent US 6346398.
ACCESSION AR192271
VERSION AR192271.1 GI:20238236
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7759 12-FEB-2002;
FEATURES
source Location/Qualifiers


```
source 1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1112 CTCCTCTTCTGAGC 1128
|||||
Db 1 CTCCTCTTCTGAGC 17

RESULT 212
AR196222/c
LOCUS AR196222 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 687 from patent US 6350934.
ACCESSION AR196222
VERSION AR196222.1 GI:20245659
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
TITLE Nucleic acid encoding delta-9 desaturase
JOURNAL Patent: US 6350934-A 687 26-FEB-2002;
FEATURES
source Location/Qualifiers
1. .17
/mol_type="unknown"
/organism="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1213 TGGCTTCCCACTTCT 1229
|||||
Db 17 TGGCTGCAACTTCT 1

RESULT 213
AR213316
LOCUS AR213316 17 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 25 from patent US 6403552.
ACCESSION AR213316
VERSION AR213316.1 GI:23310499
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.
TITLE Ob receptor and methods for the diagnosis and treatment of body
weight disorders
JOURNAL Patent: US 6403552-A 25 11-JUN-2002;
FEATURES
source Location/Qualifiers
1. .17
/mol_type="unknown"
/organism="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCTTCAG 676
|||||
Db 1 CACTATTGCGCTTCAG 17

RESULT 214
AR213318
LOCUS AR213318 17 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 27 from patent US 6482927.
ACCESSION AR213318
VERSION AR213318.1 GI:27305557
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.
TITLE Chimeric proteins comprising the extracellular domain of murine Ob
receptor
JOURNAL Patent: US 6482927-A 27 19-NOV-2002;
FEATURES
source Location/Qualifiers
1. .17
/mol_type="unknown"
/organism="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCTTCAG 676
|||||
Db 1 CACTATTGCGCTTCAG 17

RESULT 215
AR256153
LOCUS AR256153 17 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 25 from patent US 6482927.
ACCESSION AR256153
VERSION AR256153.1 GI:27305555
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.
TITLE Chimeric proteins comprising the extracellular domain of murine Ob
receptor
JOURNAL Patent: US 6482927-A 25 19-NOV-2002;
FEATURES
source Location/Qualifiers
1. .17
/mol_type="unknown"
/organism="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCTTCAG 676
|||||
Db 1 CACTATTGCGCTTCAG 17

RESULT 216
AR256155
LOCUS AR256155 17 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 27 from patent US 6482927.
ACCESSION AR256155
VERSION AR256155.1 GI:27305557
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.
TITLE Chimeric proteins comprising the extracellular domain of murine Ob
receptor
JOURNAL Patent: US 6482927-A 27 19-NOV-2002;
FEATURES
source Location/Qualifiers
1. .17
/mol_type="unknown"
/organism="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCTTCAG 676
|||||
Db 1 CACTATTGCGCTTCAG 17

RESULT 214
AR213318
LOCUS AR213318 17 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 27 from patent US 6403552.
ACCESSION AR213318
VERSION AR213318.1 GI:23310501
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.
TITLE Ob receptor and methods for the diagnosis and treatment of body
weight disorders
JOURNAL Patent: US 6403552-A 27 11-JUN-2002;
FEATURES
source Location/Qualifiers
1. .17
/mol_type="unknown"
/organism="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCTTCAG 676
|||||
Db 1 CACTATTGCGCTTCAG 17
```

```
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGGCCCTTCAG 17

RESULT 217
LOCUS AR275110 17 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 25 from patent US 6506877.
ACCESSION AR275110
VERSION AR275110.1 GI:29708051
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor
JOURNAL Patent: US 6506877-A 25 14-JAN-2003;
FEATURES
source
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGGCCCTTCAG 17

RESULT 218
LOCUS AR275112 17 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 27 from patent US 6506877.
ACCESSION AR275112
VERSION AR275112.1 GI:29708053
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor
JOURNAL Patent: US 6506877-A 27 14-JAN-2003;
FEATURES
source
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGGCCCTTCAG 17

RESULT 219
LOCUS AR306243 17 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 25 from patent US 6548269.
ACCESSION AR306243
```

```
VERSION AR306243.1 GI:31695966
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor and methods for the diagnosis and treatment of body
weight disorders, including obesity and cachexia
JOURNAL Patent: US 6548269-A 25 15-APR-2003;
FEATURES
source
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGGCCCTTCAG 17

RESULT 220
LOCUS AR306245 17 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 27 from patent US 6548269.
ACCESSION AR306245
VERSION AR306245.1 GI:31695968
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor and methods for the diagnosis and treatment of body
weight disorders, including obesity and cachexia
JOURNAL Patent: US 6548269-A 27 15-APR-2003;
FEATURES
source
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
||||| |||||||
Db 1 CACTATTGGCCCTTCAG 17

RESULT 221
LOCUS AR326141 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3543 from patent US 6566127.
ACCESSION AR326141
VERSION AR326141.1 GI:33711949
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3543 20-MAY-2003;
FEATURES
source
/organism="unknown"
/mol_type="unassigned RNA"
```


RESULT 229	17 bp	DNA	linear	PAT 20-FEB-2004	JOURNAL	TITLE
AR464891						Shannon, M.E.
LOCUS	AR464891					Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
						Patent: US 6866188-A 8661 03-FEB-2004;

```
FEATURES
  source      Location/Qualifiers
  1..17
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 TAGAAGAGCCAGAG 284
Db 1 TCGAGGAGCCAGAG 17

RESULT 232
AR464986
LOCUS      17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8663 from patent US 6686188.
ACCESSION AR464986
VERSION AR464986.1 GI:42700043
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL
FEATURES
  source      Location/Qualifiers
  1..17
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCGAGTCTCT 109
Db 17 GAGAGTGGCGAGTCTCT 1

RESULT 235
AR466011/c
LOCUS      17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9688 from patent US 6686188.
ACCESSION AR466011
VERSION AR466011.1 GI:42701068
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL
FEATURES
  source      Location/Qualifiers
  1..17
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 92 GGAGAGTGGCGAGTCTCT 108
Db 17 GGAGAGTGGCGAGTCTCT 1

RESULT 236
AR466012/c
LOCUS      17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9689 from patent US 6686188.
ACCESSION AR466012
VERSION AR466012.1 GI:42701069
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
```

```

Shannon, M.S.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle.
JOURNAL Patent: US 6686188-A 9689 03-FEB-2004;
FEATURES Location/Qualifiers
    source
        1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GGGAGAGTGGGCGAGTC 107
Db 17 GGGAGAGTGGGCGAGTC 1

RESULT 237
AX215611/c
LOCUS AX215611 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1053 from Patent WO0159103.
ACCESSION AX215611
VERSION AX215611.1 GI:15525654
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., Mcswiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 1053 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
Mcswiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
    source
        1..17
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Nucleic Acid"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1622 AATAAACTGCTCTGTG 1638
Db 17 AATAAACTGCTCTTTG 1

RESULT 238
AX216443/c
LOCUS AX216443 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1895 from Patent WO0159103.
ACCESSION AX216443
VERSION AX216443.1 GI:15526504
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., Mcswiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 1885 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
Mcswiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
    source
        1..17
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"

```

/note="Nucleic Acid"

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1621 CAATAAACTGCTCTGT 1637
Db 17 CATTAATACTGCTCTTT 1

RESULT 239
AX272871/c
LOCUS AX272871 17 bp RNA linear PAT 29-OCT-2001
DEFINITION Sequence 440 from Patent WO0162911.
ACCESSION AX272871
VERSION AX272871.1 GI:16545608
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 440 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES Location/Qualifiers
    source
        1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1539 CTCCCCGCTCTGGATCC 1555
Db 17 CTCCCCGCTGTGAACC 1

RESULT 240
AX422540
LOCUS AX422540 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 876 from Patent WO0188124.
ACCESSION AX422540
VERSION AX422540.1 GI:21525922
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 876 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES Location/Qualifiers
    source
        1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1504 GCCCCAGCTCCAGGCC 1520
Db 1 GCCCCAGCTCCAGGCC 17

```

```

RESULT 241
AX423446
LOCUS AX423446 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1782 from Patent WO018124.
ACCESSION AX423446
VERSION AX423446.1 GI:21526828
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 018124-A 1782 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 218 GACTCTCATGAGAAAAA 234
||||| ||||| |||||
DB 1 GACTCAGAGAAAAA 17

RESULT 242
AX475287
LOCUS AX475287 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 508 from Patent WO0224750.
ACCESSION AX475287
VERSION AX475287.1 GI:22214572
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Zhang,J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 508 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 520 GCATCGACTCCCTGCTG 536
||||| ||||| |||||
DB 1 GCATCTACTCCAGCTG 17

RESULT 243
AX475288
LOCUS AX475288 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 509 from Patent WO0224750.
ACCESSION AX475288
VERSION AX475288.1 GI:22214573
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Zhang,J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 511 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 522 ATCGACTCCCTGCTGGA 538
||||| ||||| |||||
DB 1 ATCTACTCCAGCTGGA 17

RESULT 245
AX475290
LOCUS AX475290 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 511 from Patent WO0224750.
ACCESSION AX475290
VERSION AX475290.1 GI:22214575
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Zhang,J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 511 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 521 CATCGACTCCCTGCTGG 537
||||| ||||| |||||
DB 1 CATCTACTCCAGCTGG 17

RESULT 244
AX475289
LOCUS AX475289 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 510 from Patent WO0224750.
ACCESSION AX475289
VERSION AX475289.1 GI:22214574
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Zhang,J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 510 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 521 CATCGACTCCCTGCTGG 537
||||| ||||| |||||
DB 1 CATCTACTCCAGCTGG 17
```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 TCGACTCCCTGCTGGAG 539
      |||||||
Db 1 TCTACTCCAGCTGGAG 17

RESULT 246
AX475291
LOCUS      17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 512 from Patent WO0224750.
ACCESSION AX475291
VERSION AX475291.1 GI:22214576
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 512 28-MAR-2002;
          Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 524 CGACTCCCTGCTGGAGA 540
      |||||||
Db 1 CTACTCCAGCTGGAGA 17

RESULT 247
AX475293
LOCUS      17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 514 from Patent WO0224750.
ACCESSION AX475293
VERSION AX475293.1 GI:22214578
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 514 28-MAR-2002;
          Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 526 ACTCCCTGCTGGAGAAC 542
      |||||||
Db 1 ACTCCGAGCTGGAGACC 17

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 TCGACTCCCTGCTGGAG 539
      |||||||
Db 1 TCTACTCCAGCTGGAG 17

RESULT 248
AX475720
LOCUS      17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 941 from Patent WO0224750.
ACCESSION AX475720
VERSION AX475720.1 GI:22215005
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 941 28-MAR-2002;
          Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1203 GTCACACAGGTGGCTTC 1219
      |||||||
Db 1 GTCACCACTGTGGCTGC 17

RESULT 249
AX499441
LOCUS      17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 748 from Patent EP1229046.
ACCESSION AX499441
VERSION AX499441.1 GI:23381734
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 748 07-AUG-2002;
          Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 521 CATCGACTCCCTGCTGG 537
      |||||||
Db 1 CAGCGACTCACTGCTGG 17

RESULT 250
AX499442
LOCUS      17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 749 from Patent EP1229046.
ACCESSION AX499442
VERSION AX499442.1 GI:23381735
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```



```
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Zhan,J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 749 07-AUG-2002;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 522 ATCGACTCCCTGCTGGA 538
Db 1 AGCGACTCACTGCTGGA 17

RESULT 251
AX499931
LOCUS      AX499931      17 bp      DNA      linear      PAT 27-SEP-2002
DEFINITION Sequence 1238 from Patent EP1229046.
ACCESSION  AX499931
VERSION    AX499931.1 GI:23382224
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Zhan,J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 1238 07-AUG-2002;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1273 TCTTGACTCTGATCCC 1289
Db 1 TCTGTGACTGTGATCCC 17

RESULT 252
AX687958
LOCUS      AX687958      17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 690 from Patent EP1281758.
ACCESSION  AX687958
VERSION    AX687958.1 GI:29410656
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 690 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 690 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 1453 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 926 GGGCTGCGCTGCGATGA 942
Db 17 GTGCTGCGCTGCGCTGA 1

RESULT 254
AX690667
LOCUS      AX690667      17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 3399 from Patent EP1281758.
ACCESSION  AX690667
VERSION    AX690667.1 GI:29413548
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 3399 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 464 GCTTGAGGAGTTCCTGA 480
Db 1 GCTGGAGCAGTTCCTGA 17

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Zhan,J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 749 07-AUG-2002;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 788 CCTTGAGATGATACAG 804
Db 1 CCTGGAGATGAGACAG 17

RESULT 253
AX688721/C
LOCUS      AX688721      17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 1453 from Patent EP1281758.
ACCESSION  AX688721
VERSION    AX688721.1 GI:29411425
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 1453 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 926 GGGCTGCGCTGCGATGA 942
Db 17 GTGCTGCGCTGCGCTGA 1

RESULT 254
AX690667
LOCUS      AX690667      17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 3399 from Patent EP1281758.
ACCESSION  AX690667
VERSION    AX690667.1 GI:29413548
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 3399 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES
source
1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 464 GCTTGAGGAGTTCCTGA 480
Db 1 GCTGGAGCAGTTCCTGA 17
```


AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 50 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GCGAGAGCTGGCAGGTC 107
|||||
Db 17 GCGAGGTTGGCAGATC 1

RESULT 260
I61606
LOCUS I61606 15 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 160 from patent US 5658780.
ACCESSION I61606
VERSION I61606.1 GI:2479554
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
TITLE Rel a targeted ribozymes
JOURNAL Patent: US 5658780-A 160 19-AUG-1997;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCTCCAGGCC 1521
|||||
Db 1 CCAGCTCCAGGTC 15

RESULT 261
AR180106/c
LOCUS AR180106 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 174 from patent US 6333152.
ACCESSION AR180106
VERSION AR180106.1 GI:20222139
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 174 25-DEC-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCGCCCATG 821

Db 15 GCCCAGCAGGCCATG 1
|||||

RESULT 262
AR180715/c
LOCUS AR180715 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 783 from patent US 6333152.
ACCESSION AR180715
VERSION AR180715.1 GI:20222748
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 783 25-DEC-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
|||||
Db 15 GCCCAGCAGGCCATG 1

RESULT 263
AR532147/c
LOCUS AR532147 15 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 75 from patent US 6727085.
ACCESSION AR532147
VERSION AR532147.1 GI:53920820
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Fano,T.S. and Mikkelsen,F.
TITLE Subtilase variants having an improved wash performance on egg stains
JOURNAL Patent: US 6727085-A 75 27-APR-2004;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1076 GCTGCTAAAGTCCTA 1090
|||||
Db 15 GCTGTTAAAGTCCTA 1

RESULT 264
AX167089/c
LOCUS AX167089 15 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 75 from Patent WO0144452.
ACCESSION AX167089
VERSION AX167089.1 GI:14596577
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Fan,T.S. and Mikkelsen,F.F.

TITLE Subtilase variants having an improved wash performance on egg stains

JOURNAL Patent: WO 0144452-A 75 21-JUN-2001;

Novozymes A/S (DK)

FEATURES Location/Qualifiers

source 1..15

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Antisense primer"

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1076 GCTGCTAAAGTCTCTA 1090

Db 15 GCTGTAAAGTCTCTA 1

RESULT 265

AX635964

LOCUS

AX635964 15 bp RNA linear PAT 21-FEB-2003

DEFINITION Sequence 3103 from Patent EP1260586.

ACCESSION

AX635964

VERSION

AX635964.1 GI:28471578

KEYWORDS

unidentified

SOURCE

unidentified

ORGANISM

unclassified.

REFERENCE

AUTHORS

Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,

Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,

Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,

Wessler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and

Woolf,I.

Method and reagent for inhibiting the expression of disease related

genes

JOURNAL Patent: EP 1260586-A 3103 27-NOV-2002;

RIBOZYME PHARMACEUTICALS, INC. (US)

FEATURES Location/Qualifiers

source 1..15

/organism="unidentified"

/mol_type="unassigned RNA"

/db_xref="taxon:32644"

Query Match 0.8%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCCTCCAGGCC 1521

Db 1 CCAGCCTCCAGGCTC 15

RESULT 266

AR029843/c

LOCUS

AR029843 16 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 32 from patent US 5861244.

ACCESSION

AR029843

VERSION

AR029843.1 GI:5943057

KEYWORDS

Unknown.

SOURCE

Unknown.

ORGANISM

unclassified.

REFERENCE

AUTHORS

Wang,C.-G. and Hepburn,A.G.

TITLE Genetic sequence assay using DNA triple strand formation

JOURNAL Patent: US 5861244-A 32 19-JAN-1999;

FEATURES Location/Qualifiers

source 1..16

/organism="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAAGA 285

Db 15 AAGAAGCCCAAGAAGA 1

RESULT 267

AR131574

LOCUS

AR131574 16 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 67 from patent US 6194149.

ACCESSION

AR131574

VERSION

AR131574.1 GI:14120477

KEYWORDS

Unknown.

SOURCE

Unknown.

ORGANISM

Unclassified.

REFERENCE

1 (bases 1 to 16)

AUTHORS

Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.

TITLE Target-dependent reactions using structure-bridging

oligonucleotides

JOURNAL Patent: US 6194149-A 67 27-FEB-2001;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02; 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522

Db 2 CAGCCTCCAGGACCC 16

RESULT 268

AR131575

LOCUS

AR131575 16 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 68 from patent US 6194149.

ACCESSION

AR131575

VERSION

AR131575.1 GI:14120478

KEYWORDS

Unknown.

SOURCE

Unknown.

ORGANISM

Unclassified.

REFERENCE

1 (bases 1 to 16)

AUTHORS

Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.

TITLE Target-dependent reactions using structure-bridging

oligonucleotides

JOURNAL Patent: US 6194149-A 68 27-FEB-2001;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02; 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522

Db 2 CAGCCTCCAGGACCC 16

RESULT 269

CQ796994/c

LOCUS

CQ796994 16 bp DNA linear PAT 19-APR-2004

DEFINITION Sequence 11 from Patent WO2004027066.

ACCESSION

CQ796994

```
VERSION CQ796994.1 GI:46408576
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1
AUTHORS Letourneur,O.
TITLE Chimeric recombinant protein and in vitro diagnosis
JOURNAL Patent: WO 2004027066-A 11 01-APR-2004;
Biomerieux (FR)
FEATURES
source Location/Qualifiers
1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/notes="artificial sequence"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 476 CCTGAACCGAGCTC 490
Db 15 CCTGAACCGAGCTC 1
RESULT 270
LOCUS CQ858546/c
DEFINITION Sequence 8 from Patent WO2004069991.
ACCESSION CQ858546
VERSION CQ858546.1 GI:51852513
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Hansen,B., Thruue,C.A., Petersen,K.D., Westergaard,M. and
Wissenbach,M.
TITLE Oligomeric compounds for the modulation of survivin expression
JOURNAL Patent: WO 2004069991-A 8 19-AUG-2004;
Santaris Pharma A/S (DK)
FEATURES
source Location/Qualifiers
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 278 CAAGAGAGAGAAAGA 292
Db 16 CAATAAGAGAGAAAGA 2
RESULT 271
LOCUS AR199508
DEFINITION Sequence 67 from patent US 6355437.
ACCESSION AR199508
VERSION AR199508.1 GI:20249582
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M,Ann.D. and Fors,L.
TITLE Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6355437-A 67 12-MAR-2002;
FEATURES
source Location/Qualifiers
1..16
/organism="unassigned DNA"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
Db 2 CAGCCTCCAGGCCCC 16
RESULT 272
LOCUS AR199509
DEFINITION Sequence 68 from patent US 6355437.
ACCESSION AR199509
VERSION AR199509.1 GI:20249583
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M,Ann.D. and Fors,L.
TITLE Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6355437-A 68 12-MAR-2002;
FEATURES
source Location/Qualifiers
1..16
/organism="unassigned DNA"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
Db 2 CAGCCTCCAGGCCCC 16
RESULT 273
LOCUS AR200979
DEFINITION Sequence 67 from patent US 6358691.
ACCESSION AR200979
VERSION AR200979.1 GI:20251867
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M,Ann.D. and Fors,L.
TITLE Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6358691-A-67 19-MAR-2002;
FEATURES
source Location/Qualifiers
1..16
/organism="unassigned DNA"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
Db 2 CAGCCTCCAGGCCCC 16
RESULT 274
LOCUS AR200979
DEFINITION Sequence 67 from patent US 6358691.
ACCESSION AR200979
VERSION AR200979.1 GI:20251867
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M,Ann.D. and Fors,L.
TITLE Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6358691-A-67 19-MAR-2002;
FEATURES
source Location/Qualifiers
1..16
/organism="unassigned DNA"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
Db 2 CAGCCTCCAGGCCCC 16
RESULT 274
LOCUS AR199508
DEFINITION Sequence 67 from patent US 6355437.
ACCESSION AR199508
VERSION AR199508.1 GI:20249582
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M,Ann.D. and Fors,L.
TITLE Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6355437-A 67 12-MAR-2002;
```

AR200980
LOCUS AR200980 16 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 68 from patent US 6358691.
ACCESSION AR200980
VERSION AR200980.1 GI:20251868
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 16)
Neri, B., Dong, F., Lyamichev, V., Brow, M. Ann. D. and Fors, L.
Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6358691-A 68 19-MAR-2002;
FEATURES
source
Location/Qualifiers
1. .16
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGACCC 16
RESULT 275
LOCUS AR488738 16 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 67 from patent US 6709815.
ACCESSION AR488738
VERSION AR488738.1 GI:47254936
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 16)
Dong, F., Lyamichev, V. I., Prudent, J. R., Fors, L., Neri, B. P.,
Brow, M. A. D., Anderson, T. A. and Dahlberg, J. E.
Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6709815-A 67 23-MAR-2004;
FEATURES
source
Location/Qualifiers
1. .16
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGACCC 16
RESULT 276
LOCUS AR488739 16 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 68 from patent US 6709815.
ACCESSION AR488739
VERSION AR488739.1 GI:47254937
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 16)
Dong, F., Lyamichev, V. I., Prudent, J. R., Fors, L., Neri, B. P.,
Brow, M. A. D., Anderson, T. A. and Dahlberg, J. E.
Target-dependent reactions using structure-bridging
oligonucleotides

JOURNAL Patent: US 6709815-A 68 23-MAR-2004;
FEATURES
source
Location/Qualifiers
1. .16
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGACCC 16
RESULT 277
LOCUS AX419730 16 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 67 from Patent WO0198537.
ACCESSION AX419730
VERSION AX419730.1 GI:21524097
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1
Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.
Nucleic acid accessible hybridization sites
Patent: WO 0198537-A 67 27-DEC-2001;
JOURNAL THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
Location/Qualifiers
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGACCC 16
RESULT 278
LOCUS AX419731 16 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 68 from Patent WO0198537.
ACCESSION AX419731
VERSION AX419731.1 GI:21524098
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1
Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.
Nucleic acid accessible hybridization sites
Patent: WO 0198537-A 68 27-DEC-2001;
JOURNAL THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
Location/Qualifiers
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
|||||
Db 2 CAGCCTCCAGGACCC 16

```
RESULT 279
BD084992
LOCUS
DEFINITION Target-dependent reactions using structure-bridging
oligonucleotides.
ACCESSION BD084992
VERSION BD084992.1 GI:22630602
KEYWORDS JP 2001523111-A/67.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Neri,B.P.,
Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.
TITLE Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: JP 2001523111-A 67 20-NOV-2001;
THIRD WAVE TECHNOLOGIES INC
COMMENT OS Unidentified
PN JP 2001523111-A/67
PD 20-NOV-2001
PF 05-MAY-1998 JP 1998548047
PR 05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR
PI FANG DONG,VICTOR I LYAMICHEV,JAMES R PRUDENT,LANCE FORS,BRUCE
PI P NERI.
PI MARY ANN D BROW TODD A ANDERSON,JAMES E DAHLBERG PC
CO7H21/04,CO7H21/02,CI2Q1/68
CC Strandedness: Single;
CC Topology: Linear;
CC /desc = 'DNA'
FH Key Location/Qualifiers
FT source 1..16
FT /organism='Unidentified'.

FEATURES
source
1..16
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522
|||||
DB 2 CAGCCTCCAGGCC 16

RESULT 280
BD084993
LOCUS
DEFINITION Target-dependent reactions using structure-bridging
oligonucleotides.
ACCESSION BD084993
VERSION BD084993.1 GI:22630603
KEYWORDS JP 2001523111-A/68.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Neri,B.P.,
Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.
TITLE Target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: JP 2001523111-A 68 20-NOV-2001;
THIRD WAVE TECHNOLOGIES INC
COMMENT OS Unidentified
PN JP 2001523111-A/68
PD 20-NOV-2001
PF 05-MAY-1998 JP 1998548047
```

```
PR 05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR
03-MAR-1998 US 09/034205
PI FANG DONG,VICTOR I LYAMICHEV,JAMES R PRUDENT,LANCE FORS,BRUCE
PI P NERI.
PI MARY ANN D BROW TODD A ANDERSON,JAMES E DAHLBERG PC
CO7H21/04,CO7H21/02,CI2Q1/68
CC Strandedness: Single;
CC Topology: Linear;
CC /desc = 'DNA'
FH Key Location/Qualifiers
FT source 1..16
FT /organism='Unidentified'.

FEATURES
source
1..16
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522
|||||
DB 2 CAGCCTCCAGGCC 16

RESULT 281
S81287/c
LOCUS
DEFINITION mitochondrial acetoacetyl-coenzyme A thiolase [human, Genomic
Mutant, 16 nt].
ACCESSION S81287
VERSION S81287.1 GI:245359
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 16)
AUTHORS Fukao,T., Yamaguchi,S., Orii,T., Schutgens,R.B., Osumi,T. and
Hashimoto,T.
TITLE Identification of three mutant alleles of the gene for
mitochondrial acetoacetyl-coenzyme A thiolase. A complete analysis
of two generations of a family with 3-ketothiolase deficiency
J. Clin. Invest. 89 (2), 474-479 (1992)
JOURNAL
MEDLINE 92147861
PUBMED 1346617
REMARK GenBank staff at the National Library of Medicine created this
entry [NCBI gibseq 81287] from the original journal article.
COMMENT A->C mutation at 3'splice site intron 10.
FEATURES
source
1..16
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

gene
1..16
/gene='mitochondrial acetoacetyl-coenzyme A thiolase'

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1323 AAGAACCCCTAAATTT 1337
|||||
DB 15 AAGAACCCGTAATTT 1

RESULT 282
AR066302/c
LOCUS
DEFINITION Sequence 1 from patent US 5849903.
ACCESSION AR066302
PATENT PAT 29-SEP-1999
```

EMBO Rep. 3 (12), 1152-1157 (2002)

JOURNAL MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 15)
AUTHORS Balzergue, S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'genoplatane' (<http://www.genoplatane.com> and <http://genoplatane-info.inbio.fr>).

FEATURES
source
1..15
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="282G05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..15
/note="T-DNA flanking sequence
left border"

Query Match 0.8%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 229 AAAAAACAAACGA 241
Db 14 AAAAAACAAACGA 2

RESULT 285
LOCUS C0806753 16 bp DNA linear PAT 10-MAY-2004
DEFINITION Sequence 203 from Patent WO2004035803.
ACCESSION C0806753
VERSION C0806753.1 GI:47112135
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Poekens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F., Nimrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and Marx, A.
TITLE Method and nucleic acids for the improved treatment of breast cell proliferative disorders
JOURNAL Patent: WO 2004035803-A 203 29-APR-2004;
Epigenomics AG (DE)
FEATURES
source
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1345 CCGTGGCGGAGAA 1357
Db 3 CCGTGGCGGAGAA 15


```
RESULT 286
A88141
LOCUS       A88141                16 bp    DNA    linear    PAT 22-JAN-2000
DEFINITION  Sequence 289 from Patent WO9833904.
ACCESSION  A88141
VERSION    A88141.1  GI:6736711
KEYWORDS   .
SOURCE     unidentified
           unclassified
REFERENCE  1 (bases 1 to 16)
AUTHORS   Brysch,W. and Schlingensiepen,K.
TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL   PATENT: WO 9833904-A 289 06-AUG-1998;
          BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES   Location/Qualifiers
            source          1..16
                           /organism="unidentified"
                           /mol_type="unassigned DNA"
                           /db_xref="taxon:32644"

Query Match      0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      456  GCGCGCCAGCTTGAGG 471
Db      1    GCGCGCCACCTTGGGG 16

RESULT 287
A89435
LOCUS       A89435                16 bp    DNA    linear    PAT 22-JAN-2000
DEFINITION  Sequence 1593 from Patent WO9833904.
ACCESSION  A89435
VERSION    A89435.1  GI:6738005
KEYWORDS   .
SOURCE     unidentified
           unclassified
REFERENCE  1 (bases 1 to 16)
AUTHORS   Brysch,W. and Schlingensiepen,K.
TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL   PATENT: WO 9833904-A 1593 06-AUG-1998;
          BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES   Location/Qualifiers
            source          1..16
                           /organism="unidentified"
                           /mol_type="unassigned DNA"
                           /db_xref="taxon:32644"

Query Match      0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      456  GCGCGCCAGCTTGAGG 471
Db      1    GCGCGCCACCTTGGGG 16

RESULT 288
A90108
LOCUS       A90108                16 bp    DNA    linear    PAT 22-JAN-2000
DEFINITION  Sequence 289 from Patent EP0856579.
ACCESSION  A90108
VERSION    A90108.1  GI:6738622
KEYWORDS   .
SOURCE     unidentified
           unclassified
REFERENCE  1 (bases 1 to 16)
AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.

TITLE     An antisense oligonucleotide preparation method
JOURNAL   Patent: EP 0856579-A 289 05-AUG-1998;
          BIOGNOSTIK GES (DE)
FEATURES   Location/Qualifiers
            source          1..16
                           /organism="unidentified"
                           /mol_type="unassigned DNA"
                           /db_xref="taxon:32644"

Query Match      0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      630  TTCTTCACCGGAGC 645
Db      1    TTCTTCATCCGGAGC 16

RESULT 289
A90108
LOCUS       A90108                16 bp    DNA    linear    PAT 14-FEB-2001
DEFINITION  Sequence 25 from patent US 6093545.
ACCESSION  A90108
VERSION    A90108.1  GI:12816917
KEYWORDS   .
SOURCE     Unknown.
           Unclassified.
REFERENCE  1 (bases 1 to 16)
AUTHORS   Goodearl,A.D.J. and Glucksmann,M.Alexandra.
TITLE     Methods for detecting nucleic acid molecules encoding a member of
          the muscarinic family of receptors
JOURNAL   Patent: US 6093545-A 25 25-JUL-2000;
          Location/Qualifiers
            source          1..16
                           /organism="unknown"
                           /mol_type="unassigned DNA"

Query Match      0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      72  GTGGGGCTGCTGCTGA 87
Db      16  GTGGGGCAGCTGCTCA 1

RESULT 290
CQ786338/c
LOCUS       CQ786338              16 bp    DNA    linear    PAT 24-MAR-2004
DEFINITION  Sequence 146 from Patent WO2004020668.
ACCESSION  CQ786338
VERSION    CQ786338.1  GI:45721440
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           other sequences; artificial sequences.
REFERENCE  1
AUTHORS   Nakamura,Y. and Katagiri,T.
TITLE     Method for treating synovial sarcoma
JOURNAL   Patent: WO 2004020668-A 146 11-MAR-2004;
          Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES   Location/Qualifiers
            source          1..16
                           /organism="synthetic construct"
                           /mol_type="unassigned DNA"
                           /db_xref="taxon:32630"
                           /note="Description of Artificial Sequence: synthetic
                           oligonucleotide"

Query Match      0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 70 TTGTGGGCTGCTGCT 85
Db 16 TTTTGGTGTGCTGCT 1

RESULT 291
LOCUS AR196058 16 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 523 from patent US 6350934.
ACCESSION AR196058
VERSION AR196058.1 GI:20245495
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P,Ann.Owens.,
Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
TITLE Nucleic acid encoding delta-9 desaturase
JOURNAL Patent: US 6350934-A 523 26-FEB-2002;
FEATURES
source
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 666 CTGCCCTTCAGCCTGC 681
Db 1 CTGCGGTTCAGCCTGC 16

RESULT 292
LOCUS AX003952 16 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 12 from Patent WO9923249.
ACCESSION AX003952
VERSION AX003952.1 GI:9927612
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Kessler C., Bartl K., Habershausen,G. and Orum,H.
TITLE Specific and sensitive method for detecting nucleic acids
JOURNAL Patent: WO 9923249-A 12 14-MAY-1999;
KESSELER CHRISTOPH (DE); BARTL KNUT (DE); HABERHAUSEN GERD (DE);
ROCHE DIAGNOSTICS GMBH (DE); ORUM HENRIK (DK)
FEATURES
source
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="MPF2"

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1514 CCAGGCCCCCACTCC 1529
Db 1 CCAGGACCCCACTCC 16

RESULT 293
LOCUS AX255603 16 bp RNA linear PAT 10-OCT-2001
DEFINITION Sequence 24 from Patent WO0170982.
ACCESSION AX255603
VERSION AX255603.1 GI:16074659

KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Waschuetza,S., Schnakenberg,E. and Lustig,M.
TITLE Method and diagnostic kit for the molecular diagnosis of
pharmacologically relevant genes
JOURNAL Patent: WO 03018837-A 133 06-MAR-2003;
Adnagen AG (DE)
FEATURES
Location/Qualifiers

KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Beger,C., Barber,J. and Wong-Staal,F.
TITLE Brca-1 regulators and methods of use
JOURNAL Patent: WO 0170982-A 24 27-SEP-2001;
Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES
source
1..16
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="Synthetic oligonucleotide"

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 530 CCTGCTGGAGAACGAC 545
Db 1 CCGGATGGAGAACGAC 16

RESULT 294
LOCUS AX255637 16 bp DNA linear PAT 10-OCT-2001
DEFINITION Sequence 58 from Patent WO0170982.
ACCESSION AX255637
VERSION AX255637.1 GI:16074693
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Beger,C., Barber,J. and Wong-Staal,F.
TITLE Brca-1 regulators and methods of use
JOURNAL Patent: WO 0170982-A 58 27-SEP-2001;
Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES
source
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 530 CCTGCTGGAGAACGAC 545
Db 1 CCGGATGGAGAACGAC 16

RESULT 295
LOCUS AX713247 16 bp DNA linear PAT 11-APR-2003
DEFINITION Sequence 133 from Patent WO03018837.
ACCESSION AX713247
VERSION AX713247.1 GI:29823836
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Waschuetza,S., Schnakenberg,E. and Lustig,M.
TITLE Method and diagnostic kit for the molecular diagnosis of
pharmacologically relevant genes
JOURNAL Patent: WO 03018837-A 133 06-MAR-2003;
Adnagen AG (DE)
FEATURES
Location/Qualifiers

```

```
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonukleotid"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 669 CCCTTCAGCTGCCCC 684
Db 1 CCCACCAGCCTGCCCC 16

RESULT 296
BD065654
LOCUS 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065654
VERSION BD065654.1 GI:22611257
KEYWORDS JP 2001511000-A/289.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlengensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 289 07-AUG-2001;
COMMENT BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/289
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source 1. .16
/organism="Unknown"
/Location/Qualifiers
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 630 TTCTTCACCCGGGAGC 645
Db 1 TTCTTCATCCGGGAGC 16

RESULT 298
BD086293/c
LOCUS 16 bp DNA linear PAT 27-AUG-2002
DEFINITION G protein-coupled receptor and utilization thereof.
ACCESSION BD086293
VERSION BD086293.1 GI:22631903
KEYWORDS JP 2001525174-A/9.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Goodearl,A.D.J., Glucksmann,A.M., Xie,M. and Distefano,P.
TITLE G protein-coupled receptor and utilization thereof
JOURNAL Patent: JP 2001525174-A 9 11-DEC-2001;
COMMENT MILLENNIUM PHARMACEUTICALS INC
OS Unidentified
PN JP 2001525174-A/9
PD 11-DEC-2001
PF 04-DEC-1998 JP 2000523346
PR 04-DEC-1997 US 08/985090,17-MAR-1998 US 09/042780 PT
ANDREW D J GOODEARL,ALEXANDRA M GLUCKSMANN,MICHAEL XIE,PETER P1
DISTEFANO
PC C12N15/09,C07K14/705,C07K16/28,C12N5/10,C12P21/02,C12Q1/68//
CC (C12P21/02,C12R1:91),C12N15/00,C12N5/00
CC Strandedness: Single;
CC Topology: Linear;
CC G protein-coupled receptor and utilization thereof FH Key
FT source 1. .16
/organism="Unidentified"
/Location/Qualifiers
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 72 GTGGGGCTGCTGCTGA 87
Db 16 GTGGGGCAGCTGCTCA 1

Search completed: September 13, 2005, 10:39:58
Job time : 7 secs
```

```
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonukleotid"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 456 GGCGCCAGCTTGAGG 471
Db 1 GGCGCCAGCCTTGAGG 16

RESULT 297
BD066948
LOCUS 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066948
VERSION BD066948.1 GI:22612551
KEYWORDS JP 2001511000-A/1583.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlengensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1583 07-AUG-2001;
COMMENT BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/1583
```

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:42:36 ; Search time 8 Seconds
(without alignments)
3.180 Million cell updates/sec

Title: us-10-828-394-1
Perfect score: 1643
Sequence: 1 Gaattccgcgctgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 411 seqs, 7741 residues

Total number of hits satisfying chosen parameters: 822

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 411 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	27.2	1.7	32	1	AAQ11501
2	26	1.6	26	1	ABK66659
3	25	1.5	25	1	ABK66660
4	25	1.5	25	1	ADP14589
5	25	1.5	25	1	ADP14593
6	25	1.5	25	1	ADP14570
7	25	1.5	25	1	ADP14583
8	25	1.5	25	1	ADP14580
9	25	1.5	25	1	ADP14590
10	25	1.5	25	1	ADP14585
11	25	1.5	25	1	ADP14587
12	25	1.5	25	1	ADP14592
13	25	1.5	25	1	ADP14584
14	25	1.5	25	1	ADP14586
15	25	1.5	25	1	ADP14588
16	25	1.5	25	1	ADP14592
17	25	1.5	25	1	ADP14579
18	25	1.5	25	1	ADP14581
19	25	1.5	25	1	ADP14591
20	23	1.4	23	1	ABN99658
21	23	1.4	23	1	ACF36411
22	23	1.4	23	1	ACF36410
23	23	1.4	23	1	ADM83082
24	23	1.4	23	1	ADM83081
25	23	1.4	23	1	ADL70521
26	23	1.4	23	1	ADL70512
27	23	1.4	23	1	ADL70515
28	23	1.4	23	1	ADL70518
29	21	1.3	21	1	AAAT39500
30	21	1.3	21	1	AAAT52783
31	21	1.3	21	1	AAA94227
32	21	1.3	21	1	AAA94231
33	21	1.3	21	1	AAA94230

C 34	21	1.3	21	1	AAA94232	Human testosterone
C 35	21	1.3	21	1	AAA94233	Human testosterone
C 36	21	1.3	21	1	AAA94229	Human testosterone
C 37	21	1.3	21	1	AAA94226	Human testosterone
C 38	21	1.3	21	1	AAA94234	Human testosterone
C 39	21	1.3	21	1	AAA94228	Human testosterone
C 40	21	1.3	21	1	AAA94225	Human testosterone
C 41	21	1.3	21	1	AAF97658	Human gene single
C 42	21	1.3	21	1	AAF97656	Human gene single
C 43	21	1.3	21	1	AAF97657	Human gene single
C 44	21	1.3	21	1	AAF97659	Human gene single
C 45	21	1.3	21	1	ABN99659	Human clusterin PC
C 46	21	1.3	21	1	ACF36397	TRPM-2 antisense o
C 47	21	1.3	21	1	ACF36405	TRPM-2 antisense o
C 48	21	1.3	21	1	ACF36406	TRPM-2 antisense o
C 49	21	1.3	21	1	ACF36399	TRPM-2 antisense o
C 50	21	1.3	21	1	ACF36402	TRPM-2 antisense o
C 51	21	1.3	21	1	ACF36401	TRPM-2 antisense o
C 52	21	1.3	21	1	ACF36398	TRPM-2 antisense o
C 53	21	1.3	21	1	ACF36403	TRPM-2 antisense o
C 54	21	1.3	21	1	ACF36404	TRPM-2 antisense o
C 55	21	1.3	21	1	ACF36400	TRPM-2 antisense o
C 56	21	1.3	21	1	ADF75347	Human RT-PCR prime
C 57	21	1.3	21	1	ADF75348	Human RT-PCR prime
C 58	21	1.3	21	1	ADM83075	Human TRPM-2 antis
C 59	21	1.3	21	1	ADM83077	Human TRPM-2 antis
C 60	21	1.3	21	1	ADM83072	Human TRPM-2 antis
C 61	21	1.3	21	1	ADM83074	Human TRPM-2 antis
C 62	21	1.3	21	1	ADM83076	Human TRPM-2 antis
C 63	21	1.3	21	1	ADM83068	Human TRPM-2 antis
C 64	21	1.3	21	1	ADM83069	Human TRPM-2 antis
C 65	21	1.3	21	1	ADM83070	Human TRPM-2 antis
C 66	21	1.3	21	1	ADM83073	Human TRPM-2 antis
C 67	21	1.3	21	1	ADM83071	Human TRPM-2 antis
C 68	21	1.3	21	1	ADL70456	RNAi for human clu
C 69	21	1.3	21	1	ADL70460	RNAi for human clu
C 70	21	1.3	21	1	ADL70513	RNAi for human clu
C 71	21	1.3	21	1	ADL70458	RNAi for human clu
C 72	21	1.3	21	1	ADL70520	RNAi for human clu
C 73	21	1.3	21	1	ADL70461	RNAi for human clu
C 74	21	1.3	21	1	ADL70519	RNAi for human clu
C 75	21	1.3	21	1	ADL70517	RNAi for human clu
C 76	21	1.3	21	1	ADL70516	RNAi for human clu
C 77	21	1.3	21	1	ADL70457	RNAi for human clu
C 78	21	1.3	21	1	ADL70459	RNAi for human clu
C 79	21	1.3	21	1	ADL70514	RNAi for human clu
C 80	21	1.3	21	1	ADL70410	Antisense oligonuc
C 81	21	1.3	21	1	ADL70440	RNAi for human clu
C 82	21	1.3	21	1	ADL70422	RNAi for human clu
C 83	21	1.3	21	1	ADL70413	Antisense oligonuc
C 84	21	1.3	21	1	ADL70408	Antisense oligonuc
C 85	21	1.3	21	1	ADL70412	Antisense oligonuc
C 86	21	1.3	21	1	ADL70425	RNAi for human clu
C 87	21	1.3	21	1	ADL70442	RNAi for human clu
C 88	21	1.3	21	1	ADL70406	Antisense oligonuc
C 89	21	1.3	21	1	ADL70423	RNAi for human clu
C 90	21	1.3	21	1	ADL70441	RNAi for human clu
C 91	21	1.3	21	1	ADL70443	RNAi for human clu
C 92	21	1.3	21	1	ADL70411	Antisense oligonuc
C 93	21	1.3	21	1	ADL70439	RNAi for human clu
C 94	21	1.3	21	1	ADL70438	Antisense oligonuc
C 95	21	1.3	21	1	ADL70414	Antisense oligonuc
C 96	21	1.3	21	1	ADL70409	Antisense oligonuc
C 97	21	1.3	21	1	ADL70427	RNAi for human clu
C 98	21	1.3	21	1	ADL70405	Antisense oligonuc
C 99	21	1.3	21	1	ADL70407	Antisense oligonuc
C 100	20.8	1.3	21	1	ADL70424	RNAi for human clu
C 101	20.8	1.3	24	1	AAA66325	Dog genomic marker
C 102	20	1.2	20	1	ABN99680	Human clusterin in
C 103	20	1.2	20	1	ABN99682	Human clusterin in
C 104	20	1.2	20	1	ABN99684	Human clusterin in
C 105	20	1.2	20	1	ABN99686	Human clusterin in
C 106	20	1.2	20	1	ABN99709	Human clusterin in

253	14.4	0.9	17	1	ADL18587	RT-PCR primer HP6.	326	13.8	0.8	17	1	ABK18229	Human ERG hammerhe
c 254	14.4	0.9	17	1	ADMS9611	Hepatitis B virus	327	13.8	0.8	17	1	ABK19135	Human ERG anberzym
255	14.4	0.9	17	1	ADI84297	HCV DNazyme subutr	328	13.8	0.8	17	1	AAD38269	Mouse Ob receptor
c 256	14.4	0.9	17	1	ADI85767	HCV DNazyme subutr	329	13.8	0.8	17	1	AAD38271	Mouse Ob receptor
257	14.4	0.9	17	1	ACN171763	Human GMPLP-1 prob	c 330	13.8	0.8	17	1	ACN05936	WNV Amberzyme subs
c 258	14.4	0.9	17	1	ACN731136	Human GMPLP-1 prob	331	13.8	0.8	17	1	ACN08391	WNV minus strand H
c 259	14.4	0.9	17	1	ACN731135	Human GMPLP-1 prob	332	13.8	0.8	17	1	ACN15008	WNV minus strand A
c 260	14.4	0.9	17	1	ACN714450	Human GMPLP-1 prob	c 333	13.8	0.8	17	1	ACN00398	WNV Hammerhead Rib
c 261	14.4	0.9	17	1	ACN71451	Human GMPLP-1 prob	334	13.8	0.8	17	1	ACN14016	WNV minus strand D
262	14.4	0.9	17	1	ACN71765	Human GMPLP-1 prob	335	13.8	0.8	17	1	ACN15009	WNV minus strand A
c 263	14.4	0.9	18	1	AAQ080949	PCR primer to gene	c 336	13.8	0.8	17	1	ACN06460	WNV Amberzyme subs
264	14.4	0.9	18	1	ADM06417	Human PCR primer S	c 337	13.8	0.8	17	1	ACN01953	WNV inozyme subutr
265	14.4	0.9	18	1	ADM92954	SNP-containing car	338	13.8	0.8	17	1	ACN08392	WNV minus strand H
c 266	14.4	0.9	18	1	ADH71057	Human Vbeta point	c 339	13.8	0.8	17	1	ACN11835	WNV minus strand I
267	14.4	0.9	15	1	AAF47085	IGFBP3 oligonucleo	c 340	13.8	0.8	17	1	ACN05385	WNV DNazyme subutr
268	14.4	0.9	15	1	AAF47084	IGFBP3 oligonucleo	341	13.8	0.8	17	1	ACN08973	WNV minus strand H
c 269	14.4	0.9	17	1	ABK25595	Stress tolerance c	c 342	13.8	0.8	17	1	ABT34420	Tumour suppression
270	14.4	0.9	17	1	ABK25596	Stress tolerance c	343	13.8	0.8	17	1	ABT37717	Tumour suppression
271	14.4	0.9	17	1	ADIS9851	HCV DNazyme subutr	344	13.8	0.8	17	1	ACA06296	NFKB sub-unit modu
c 272	14.4	0.9	17	1	ADI84295	HCV DNazyme subutr	345	13.8	0.8	17	1	ACA07700	NFKB sub-unit modu
c 273	14.4	0.9	17	1	ADN44286	Mutant cell identi	346	13.8	0.8	17	1	ACA07701	NFKB sub-unit modu
274	14.4	0.9	17	1	ADN44287	Mutant cell identi	347	13.8	0.8	17	1	ACA08217	NFKB sub-unit modu
c 275	13.8	0.8	17	1	AAT05231	Hepatitis C virus	348	13.8	0.8	17	1	ACA06298	NFKB sub-unit modu
c 276	13.8	0.8	17	1	AAK55009	Mouse fit-1 VEGF r	349	13.8	0.8	17	1	ACA06394	NFKB sub-unit modu
c 277	13.8	0.8	17	1	AAK52812	Delta-9 desaturase	350	13.8	0.8	17	1	ACA06396	NFKB sub-unit modu
278	13.8	0.8	17	1	AAT69614	Murine obr gene fo	351	13.8	0.8	17	1	ACA06517	NFKB sub-unit modu
279	13.8	0.8	17	1	AAV61074	Synthetic DNA frag	352	13.8	0.8	17	1	ADA99701	Human MD23 scannin
c 280	13.8	0.8	17	1	AAV47411	Antisense oligonuc	c 353	13.8	0.8	17	1	ADB00467	Human MD24 scannin
c 281	13.8	0.8	17	1	AAV46535	Antisense oligonuc	354	13.8	0.8	17	1	ADB02413	HCV DNazyme subutr
c 282	13.8	0.8	17	1	AAV94804	Human IL-2 recepto	355	13.8	0.8	17	1	ACD58046	HCV DNazyme subutr
c 283	13.8	0.8	17	1	AAV92651	Human A-Raf subutr	356	13.8	0.8	17	1	ACD61087	HCV DNazyme subutr
c 284	13.8	0.8	17	1	AAK53788	Human adenosine A1	c 357	13.8	0.8	17	1	ACD62816	HCV minus strand D
c 285	13.8	0.8	17	1	AAK52912	Human adenosine A1	358	13.8	0.8	17	1	ACC67637	Murine oligonucleo
c 286	13.8	0.8	17	1	AAA33231	Low adenosine anti	c 359	13.8	0.8	17	1	ADB39727	Tumour suppression
c 287	13.8	0.8	17	1	AAA32356	Low adenosine anti	360	13.8	0.8	17	1	ADI47981	Human tumour suppr
c 288	13.8	0.8	17	1	AAZ57766	Hepatitis C virus	c 361	13.8	0.8	17	1	AB294171	Human adenosine A1
c 289	13.8	0.8	17	1	AAA03590	Human adenosine A1	c 362	13.8	0.8	17	1	AB295047	Human adenosine A1
c 290	13.8	0.8	17	1	AAA03660	Human adenosine A1	363	13.8	0.8	17	1	ADL48005	Human IKK-gamma su
c 291	13.8	0.8	17	1	AAF19353	Human adenosine A1	c 364	13.8	0.8	17	1	ADL50256	Human PKR subutr
c 292	13.8	0.8	17	1	AAF18477	Human adenosine A1	365	13.8	0.8	17	1	ADL48380	Human IKK-gamma su
c 293	13.8	0.8	17	1	AAF02647	Hammerhead ribozym	366	13.8	0.8	17	1	ADM09485	Human NOD recepto
c 294	13.8	0.8	17	1	ABK01885	Human NOD Zinzyne	c 367	13.8	0.8	17	1	ADM54165	Human GRID mRNA su
c 295	13.8	0.8	17	1	ABK01053	Human NOD Inozyme	c 368	13.8	0.8	17	1	ABD18019	Human adenosine A1
c 296	13.8	0.8	17	1	AAD20527	Mouse Obr genozyme	c 369	13.8	0.8	17	1	ABD18895	Human adenosine A1
297	13.8	0.8	17	1	AAD20529	Mouse famj5312 Obr	370	13.8	0.8	17	1	ADG63002	Mouse genomic DNA
298	13.8	0.8	17	1	AAF79852	DNA sequencing met	371	13.8	0.8	17	1	ADG63000	Mouse genomic DNA
c 299	13.8	0.8	17	1	ABL46807	Human GRID NCH rib	c 372	13.8	0.8	17	1	ADK98279	Primer of the inve
300	13.8	0.8	17	1	AAD41482	Mouse Ob receptor	373	13.8	0.8	17	1	ADK98279	HCV DNazyme subutr
301	13.8	0.8	17	1	AAD41484	Mouse Ob receptor	374	13.8	0.8	17	1	ADL83386	HCV DNazyme subutr
302	13.8	0.8	17	1	AAD42341	Mouse obesity rece	c 375	13.8	0.8	17	1	ACN64993	Human GMPLP-1 prob
303	13.8	0.8	17	1	AAD42339	Mouse obesity rece	376	13.8	0.8	17	1	ACN71759	Human GMPLP-1 prob
c 304	13.8	0.8	17	1	ABN01903	Human GMPLP-1 17-m	c 377	13.8	0.8	17	1	ACN72785	Human GMPLP-1 prob
c 305	13.8	0.8	17	1	ABN07493	Human GMPLP-1 17-m	c 378	13.8	0.8	17	1	ACN72787	Human GMPLP-1 prob
c 306	13.8	0.8	17	1	ABN08576	Human GMPLP-1 17-m	379	13.8	0.8	17	1	ACN71758	Human GMPLP-1 prob
c 307	13.8	0.8	17	1	ABN09695	Human GMPLP-1 17-m	c 380	13.8	0.8	17	1	ACN71761	Human GMPLP-1 prob
c 308	13.8	0.8	17	1	ABN08671	Human GMPLP-1 17-m	c 381	13.8	0.8	17	1	ACN65741	Human GMPLP-1 prob
c 309	13.8	0.8	17	1	ABN09696	Human GMPLP-1 17-m	c 382	13.8	0.8	17	1	ACN70453	Human GMPLP-1 prob
c 310	13.8	0.8	17	1	ABN09697	Human GMPLP-1 17-m	c 383	13.8	0.8	17	1	ACN70583	Human GMPLP-1 prob
311	13.8	0.8	17	1	ABN07363	Human GMPLP-1 17-m	384	13.8	0.8	17	1	ACN71762	Human GMPLP-1 prob
312	13.8	0.8	17	1	ABN08672	Human GMPLP-1 17-m	385	13.8	0.8	17	1	ACN71686	Human GMPLP-1 prob
313	13.8	0.8	17	1	ABN08669	Human GMPLP-1 17-m	c 386	13.8	0.8	17	1	ACN72786	Human GMPLP-1 prob
c 314	13.8	0.8	17	1	ABN02651	Human GMPLP-1 17-m	c 387	13.6	0.8	15	1	ABL52123	Human PER1 allele
315	13.8	0.8	17	1	ABN08668	Human GMPLP-1 17-m	c 388	13.6	0.8	15	1	AA595535	Human IL8RB gene a
316	13.8	0.8	17	1	ABQ63736	Human KTM1a porti	389	13.4	0.8	15	1	AAV54903	Mouse rela hammerh
317	13.8	0.8	17	1	ABQ63734	Human KTM1a porti	c 390	13.4	0.8	15	1	AAV31959	Peptide nucleic ac
318	13.8	0.8	17	1	ABQ63732	Human KTM1a porti	c 391	13.4	0.8	15	1	AAV31970	Peptide nucleic ac
319	13.8	0.8	17	1	ABQ63733	Human KTM1a porti	c 392	13.4	0.8	15	1	AAV31967	Peptide nucleic ac
320	13.8	0.8	17	1	ABQ63735	Human KTM1a porti	c 393	13.4	0.8	15	1	AAV31120	Tag sequence of a
321	13.8	0.8	17	1	ABQ63738	Human KTM1a porti	c 394	13.4	0.8	15	1	AAV31728	Transcript tag seq
322	13.8	0.8	17	1	ABQ64165	Human KTM1a porti	c 395	13.4	0.8	15	1	AAV50848	IGF-1 oligonucleot
323	13.8	0.8	17	1	ABV79503	Human HTPL scannin	c 396	13.4	0.8	15	1	ABK32682	Human colorectal a
324	13.8	0.8	17	1	ABV79592	Human HTPL scannin	c 397	13.4	0.8	15	1	ABK32073	Human colon cancer
325	13.8	0.8	17	1	ABV79502	Human HTPL scannin	398	13.4	0.8	15	1	ABX01805	Hepatitis C virus

399 13.4 0.8 15 1 ABX01804 Hepatitis C virus
400 13.4 0.8 16 1 AAV70490 Sequence ID# 68 fr
401 13.4 0.8 16 1 AAV70489 Sequence ID# 67 fr
c 402 13.4 0.8 16 1 AAX14645 Triple helix third
403 13.4 0.8 16 1 ABL46101 Hepatitis C virus
404 13.4 0.8 16 1 ABL46100 Hepatitis C virus
405 13.4 0.8 16 1 ADR82290 Nucleic acid analy
406 13.4 0.8 16 1 ADR82291 Nucleic acid analy
c 407 13.4 0.8 16 1 ADM80152 Linker peptide enc
408 13.4 0.8 16 1 ADR32381 E. coli nicking ag
409 13.4 0.8 16 1 ADR32430 E. coli fingerprin
410 13.4 0.8 16 1 ADR33575 E. coli strain K12
c 411 13.4 0.8 16 1 ADR69939 Human survivin gen

ALIGNMENTS

RESULT 1
AAQ11501
ID AAQ11501 standard; DNA; 32 BP.
AC AAQ11501;
XX 20-JUN-1991 (first entry)
DT
DE Probe based on amino acids 6-15 of the Cytolysis Inhibitor A-chain.
XX
KW cytolysis inhibitor; perforin; immunological effector molecule;
KW infertility; ss.
XX Homo sapiens.
XX DE3933850-A.
XX
XX 18-APR-1991.
XX
XX 06-OCT-1989; 89DE-03933850.
XX
XX 06-OCT-1989; 89DE-03933850.
XX
XX (SCHD) SCHERING AG.
XX
XX Tachopp J, Jenne D;
XX WPI; 1991-118338/17.
XX
XX DNA sequence coding for cytolysis inhibitor - is strong inhibitor of
XX terminal complement protein, e.g. perforin secreted by killer cells.
XX
XX Example 1; Page 4; 15pp; German.
XX
XX The partial amino acid sequences of both chains of the Cytolysis
XX Inhibitor were known. This probe is one of two which were prepared based
XX on the N-terminal sequences of the inhibitor. It corresponds to the
XX sequence DNLQEMSNQG. Both probes were radioactively labelled and used to
XX screen a liver-specific cDNA library. One clone which hybridised
XX positively to both probes was found to contain a 1.7kb BamHI-KpnI
XX fragment. This was inserted into plasmid pGEM4, to give DSM 5269, and
XX sequenced. See also AAQ11502 and AAQ11503
XX
SQ Sequence 32 BP; 10 A; 7 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 27.2; DB 1; Length 32;
Best Local Similarity 90.6%; Pred. No. 23;
Matches 29; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 129 GACAATGAGCTCCAGGAATGTCCATCAGG 160
|||||
DB 1 GACAATGAGCTCGAGGATGTCCACACGAGG 32
|||||
RESULT 2

ABK66659
ID ABK66659 standard; DNA; 26 BP.
XX
AC ABK66659;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human gene specific PCR primer #747.
XX
KW Primer; ss; DNA microarray; differential expression analysis; human.
XX
OS Homo sapiens.
XX
XX US6352829-B1.
XX
XX 05-MAR-2002.
XX
XX 05-JAN-1999; 99US-00225928.
XX
XX 21-MAY-1997; 97US-00859998.
XX
XX (CLON-) CLONTECH LAB INC.
XX
XX Chenchik A, Johadze G, Bibilashvili R;
XX
XX WPI; 2002-314699/35.
XX
XX Producing sub-population of labeled nucleic acids, useful for analyzing
XX differences in RNA profiles between several different physiological
XX sources, using set of distinct gene specific primers.
XX
XX Example 3; SEQ ID NO 747; 11pp; English.
XX
XX The invention relates to producing a sub-population of labeled nucleic
XX acids (NAs) comprising contacting a NA sample from a physiological
XX source, with a pool of 50 distinct gene specific primers under suitable
XX conditions to enzymatically generate sub-population of NAs, where each
XX gene specific primer has a sequence complementary to a distinct mRNA, and
XX each labeled NA is generated using a single gene specific primer. The
XX method is useful for producing a sub-population of labeled NAs which is
XX useful for analysing the differences in the RNA profiles between several
XX different physiological sources, where the method comprises producing
XX subpopulation of labeled NAs for the different physiological sources,
XX comprising the populations for each physiological source to identify
XX differences in the population, where the comparison is preferably
XX performed by hybridising the labeled NAs for each of the distinct
XX physiological sources to an array of probe NAs stably associated with the
XX surface of a substrate to produce a hybridisation pattern for each of the
XX sources, and comparing the patterns for each of the sources, where
XX differential gene expression assays are utilised in differential
XX expression analysis of diseased a normal tissue e.g. neoplastic a normal
XX tissue, or different tissue or subtypes. The present sequence is a
XX human gene specific PCR primer used in the method of the invention. Note:
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from USPTO
XX at <http://wipo.segdata.uspto.gov/sequence.html?DocID=6352829B1>
XX
SQ Sequence 26 BP; 8 A; 4 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 934 TCCGGATGAGGACCACTGTGACAG 959
|||||
DB 1 TCCGGATGAGGACCACTGTGACAG 26
|||||
RESULT 3
ABK66660/c
ID ABK66660 standard; DNA; 25 BP.
XX
XX ABK66660;
XX

XX 02-JUL-2002 (first entry)
 XX Human gene specific PCR primer #748.
 DE
 XX
 XX Primer; ss; DNA microarray; differential expression analysis; human.
 XX
 XX Homo sapiens.
 OS
 XX US6352829-B1.
 PN
 XX
 XX 05-MAR-2002.
 PD
 XX
 XX 05-JAN-1999; 99US-00225928.
 PF
 XX 21-MAY-1997; 97US-00859998.
 PR
 XX (CLON-) CLONTECH LAB INC.
 PA
 XX Chenchik A, Jokhadze G, Bibilashvili R;
 PI WPI; 2002-314699/35.
 XX
 XX Producing sub-population of labeled nucleic acids, useful for analyzing
 PT differences in RNA profiles between several different physiological
 PT sources, using set of distinct gene specific primers.
 XX
 XX Example 3; SEQ ID NO 748; 11pp; English.
 PS
 XX
 CC The invention relates to producing a sub-population of labeled nucleic
 CC acids (NAs) comprising contacting a NA sample from a physiological
 CC source, with a pool of 50 distinct gene specific primers under suitable
 CC conditions to enzymatically generate sub-population of NAs, where each
 CC gene specific primer has a sequence complementary to a distinct mRNA, and
 CC each labeled NA is generated using a single gene specific primer. The
 CC method is useful for producing a sub-population of labeled NAs which is
 CC useful for analysing the differences in the RNA profiles between several
 CC different physiological sources, where the method comprises producing
 CC subpopulation of labeled NAs for the different physiological sources,
 CC comprising the populations for each physiological source to identify
 CC differences in the population, where the comparison is preferably
 CC performed by hybridising the labeled NAs for each of the distinct
 CC physiological sources to an array of probe NAs stably associated with the
 CC surface of a substrate to produce a hybridisation pattern for each of the
 CC sources, and comparing the patterns for each of the sources, where
 CC differential gene expression assays are utilised in differential
 CC expression analysis of diseased a normal tissue e.g. neoplastic a normal
 CC tissue, or different tissue or subtype types. The present sequence is a
 CC human gene specific PCR primer used in the method of the invention. Note:
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from USPTO
 CC at <http://wipo.segdata.uspto.gov/sequence.html?docID=6352829B1>
 XX
 SQ Sequence 25 BP; 6 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 1.5%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 19;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1190 GTACTATCTCGGGGTCCACCGGTG 1214
 |||||
 Db 25 GTACTATCTCGGGGTCCACCGGTG 1
 |||||
 RESULT 4
 ADP14589
 ID ADP14589 standard; DNA; 25 BP.
 XX
 AC ADP14589;
 XX
 XX 26-AUG-2004 (first entry)
 DT
 XX Renal cell carcinoma differentially expressed gene probe #994.
 DE

XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
 KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
 KW head/neck cancer; differential expression; probe.
 XX
 XX Homo sapiens.
 OS
 XX WO2004048933-A2.
 PN
 XX 10-JUN-2004.
 PD
 XX
 XX 21-NOV-2003; 2003WO-US037481.
 PF
 XX 21-NOV-2002; 2002US-0427982P.
 PR
 XX 03-APR-2003; 2003US-0459782P.
 PR
 XX (AMHP) WYETH.
 PA (TWIN/) TWINE N C.
 PA (BURC/) BURCZYNSKI M E.
 PA (TREP/) TREPICCHIO W L.
 PA (DORN/) DORNER A.
 PA (STOV/) STOVER J A.
 PA (SLON/) SLONI D K.
 XX
 XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
 PI Sloni DK;
 XX
 XX WPI; 2004-460799/43.
 DR
 XX
 PT Diagnosing non-blood disease such as solid tumor, involves comparing
 PT differential expression profile of specific genes in peripheral blood
 PT sample of subject with reference expression profile of specific genes.
 XX
 PS Disclosure; SEQ ID NO 1325; 350pp; English.
 XX
 CC The invention relate to a method of diagnosing (M1) non-blood disease
 CC such as solid tumor by providing peripheral blood sample of human having
 CC non-blood disease, and comparing an expression profile of specific genes
 CC in the peripheral blood sample to reference expression profile of the
 CC genes, where each of the genes is differentially expressed in peripheral
 CC blood mononuclear cells (PBMCs) of patients having the disease as
 CC compared to PBMCs of normal humans. The method is useful for diagnosing
 CC non-blood disease such as solid tumor. The solid tumor is chosen from
 CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
 CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
 CC sample is a whole blood sample (claimed). (M1) is useful for identifying
 CC genes that are differentially expressed in peripheral blood samples
 CC isolated at different stages of progression, development or treatment of
 CC RCC and/or other solid tumors. This sequence corresponds to a probe to
 CC detect a gene that is differentially expressed and detected by the method
 CC of the invention.
 XX
 SQ Sequence 25 BP; 6 A; 9 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 1.5%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 19;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1550 GGATCCTGCACCTTAACACTCGACT 1574
 |||||
 Db 1 GGATCCTGCACCTTAACACTCGACT 25
 |||||
 RESULT 5
 ADP14593
 ID ADP14593 standard; DNA; 25 BP.
 XX
 AC ADP14593;
 XX
 XX 26-AUG-2004 (first entry)
 DT
 XX Renal cell carcinoma differentially expressed gene probe #998.
 DE
 XX

KW ss; diagnosis; non-blood disease; solid tumor; gene expression;
 KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
 KW head/neck cancer; differential expression; probe.

OS Homo sapiens.

FN WO2004048933-A2.

PD 10-JUN-2004.

XX 21-NOV-2003; 2003WO-US037481.

PF 21-NOV-2002; 2002US-0427982P.

PR 03-APR-2003; 2003US-0459782P.

XX (AMHP) WYETH.

PA (TWIN/) TWINE N C.

PA (BURC/) BURCZYNSKI M E.

PA (TREP/) TREPICCHIO W L.

PA (DORN/) DORNER A.

PA (STOV/) STOVER J A.

PA (SLON/) SLONI D K.

XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;

PI Sloni DK;

XX WPI; 2004-460799/43.

XX Diagnosing non-blood disease such as solid tumor, involves comparing
 PT differential expression profile of specific genes in peripheral blood
 PT sample of subject with reference expression profile of specific genes.
 XX Disclosure; SEQ ID NO 1329; 350pp; English.

XX The invention relate to a method of diagnosing (M1) non-blood disease
 CC such as solid tumor by providing peripheral blood sample of human having
 CC non-blood disease, and comparing an expression profile of specific genes
 CC in the peripheral blood sample to reference expression profile of the
 CC genes, where each of the genes is differentially expressed in peripheral
 CC blood mononuclear cells (PBMcs) of patients having the disease as
 CC compared to PBMcs of normal humans. The method is useful for diagnosing
 CC non-blood disease such as solid tumor. The solid tumor is chosen from
 CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
 CC peripheral blood sample comprises enriched PBMcs. The peripheral blood
 CC sample is a whole blood sample (claimed). (M1) is useful for identifying
 CC genes that are differentially expressed in peripheral blood samples
 CC isolated at different stages of progression, development or treatment of
 CC RCC and/or other solid tumors. This sequence corresponds to a probe to
 CC detect a gene that is differentially expressed and detected by the method
 CC of the invention.

XX SQ Sequence 25 BP; 5 A; 8 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 19;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1564 AACACTCGACTCTGCTGCTCATGGG 1588

|||||

1 AACACTCGACTCTGCTGCTCATGGG 25

DB

RESULT 6

ADP14578

ID ADP14578 standard; DNA; 25 BP.

XX AC ADP14578;

XX 26-AUG-2004 (first entry)

DE Renal cell carcinoma differentially expressed gene probe #983.

XX ss; diagnosis; non-blood disease; solid tumor; gene expression;

KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
 KW head/neck cancer; differential expression; probe.

OS Homo sapiens.

FN WO2004048933-A2.

PD 10-JUN-2004.

XX 21-NOV-2003; 2003WO-US037481.

PF 21-NOV-2002; 2002US-0427982P.

PR 03-APR-2003; 2003US-0459782P.

XX (AMHP) WYETH.

PA (TWIN/) TWINE N C.

PA (BURC/) BURCZYNSKI M E.

PA (TREP/) TREPICCHIO W L.

PA (DORN/) DORNER A.

PA (STOV/) STOVER J A.

PA (SLON/) SLONI D K.

XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;

PI Sloni DK;

XX WPI; 2004-460799/43.

XX Diagnosing non-blood disease such as solid tumor, involves comparing
 PT differential expression profile of specific genes in peripheral blood
 PT sample of subject with reference expression profile of specific genes.
 XX Disclosure; SEQ ID NO 1314; 350pp; English.

XX The invention relate to a method of diagnosing (M1) non-blood disease
 CC such as solid tumor by providing peripheral blood sample of human having
 CC non-blood disease, and comparing an expression profile of specific genes
 CC in the peripheral blood sample to reference expression profile of the
 CC genes, where each of the genes is differentially expressed in peripheral
 CC blood mononuclear cells (PBMcs) of patients having the disease as
 CC compared to PBMcs of normal humans. The method is useful for diagnosing
 CC non-blood disease such as solid tumor. The solid tumor is chosen from
 CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
 CC peripheral blood sample comprises enriched PBMcs. The peripheral blood
 CC sample is a whole blood sample (claimed). (M1) is useful for identifying
 CC genes that are differentially expressed in peripheral blood samples
 CC isolated at different stages of progression, development or treatment of
 CC RCC and/or other solid tumors. This sequence corresponds to a probe to
 CC detect a gene that is differentially expressed and detected by the method
 CC of the invention.

XX SQ Sequence 25 BP; 8 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 19;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1088 CTACCAGTGGAGATGCTCAACACC 1112

|||||

1 CTACCAGTGGAGATGCTCAACACC 25

DB

RESULT 7

ADP14583

ID ADP14583 standard; DNA; 25 BP.

XX AC ADP14583;

XX 26-AUG-2004 (first entry)

DE Renal cell carcinoma differentially expressed gene probe #988.

XX ss; diagnosis; non-blood disease; solid tumor; gene expression;

KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;

KW head/neck cancer; differential expression; probe.

XX Homo sapiens.

XX WO2004048933-A2.

XX 10-JUN-2004.

XX 21-NOV-2003; 2003WO-US037481.

XX 21-NOV-2002; 2002US-0427982P.

XX 03-APR-2003; 2003US-0459782P.

XX (AMHP) WYETH.

XX (TWIN/) TWINE N C.

XX (BURC/) BURCZYNSKI M E.

XX (TREP/) TREPICCHIO W L.

XX (DORNA/) DORNER A.

XX (STOV/) STOVER J A.

XX (SLON/) SLONI D K.

XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;

XX WPI; 2004-460799/43.

XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.

XX Disclosure; SEQ ID NO 1319; 350pp; English.

XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.

XX Sequence 25 BP; 5 A; 8 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1268 GAAGCTCTTTGACTCTGATCCCATC 1292

Db 1 GAAGCTCTTTGACTCTGATCCCATC 25

RESULT 8

ADP14580

ID ADP14580 standard; DNA; 25 BP.

XX AC ADP14580;

XX 26-AUG-2004 (first entry)

XX Renal cell carcinoma differentially expressed gene probe #985.

XX ss; diagnosis; non-blood disease; solid tumor; gene expression;

KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;

KW head/neck cancer; differential expression; probe.

XX Homo sapiens.

XX WO2004048933-A2.

XX 10-JUN-2004.

XX 21-NOV-2003; 2003WO-US037481.

XX 21-NOV-2002; 2002US-0427982P.

XX 03-APR-2003; 2003US-0459782P.

XX (AMHP) WYETH.

XX (TWIN/) TWINE N C.

XX (BURC/) BURCZYNSKI M E.

XX (TREP/) TREPICCHIO W L.

XX (DORNA/) DORNER A.

XX (STOV/) STOVER J A.

XX (SLON/) SLONI D K.

XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;

XX WPI; 2004-460799/43.

XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.

XX Disclosure; SEQ ID NO 1316; 350pp; English.

XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.

XX Sequence 25 BP; 2 A; 9 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1196 TCTGGCGGTACACACGGTGCTTCC 1220

Db 1 TCTGGCGGTACACACGGTGCTTCC 25

RESULT 9

ADP14590

ID ADP14590 standard; DNA; 25 BP.

XX AC ADP14590;

XX 26-AUG-2004 (first entry)

XX Renal cell carcinoma differentially expressed gene probe #995.

XX ss; diagnosis; non-blood disease; solid tumor; gene expression;

KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;

KW head/neck cancer; differential expression; probe.

```

OS Homo sapiens.
XX WO2004048933-A2.
XX PD 10-JUN-2004.
XX PF 21-NOV-2003; 2003WO-US037481.
XX PR 21-NOV-2002; 2002US-0427982P.
XX PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1326; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX Sequence 25 BP; 5 A; 9 C; 4 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1556 TGCACCTTAACACTCGACTCTGCTG 1580
Db 1 TGCACCTTAACACTCGACTCTGCTG 25
RESULT 10
ADP14585
ID ADP14585 standard; DNA; 25 BP.
XX AC ADP14585;
XX DT 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #990.
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
OS Homo sapiens.
XX

```

```

XX WO2004048933-A2.
XX PD 10-JUN-2004.
XX PF 21-NOV-2003; 2003WO-US037481.
XX PR 21-NOV-2002; 2002US-0427982P.
XX PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1321; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX Sequence 25 BP; 4 A; 4 C; 7 G; 10 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1397 AGATGTGATGTTGCTTTTGACCT 1421
Db 1 AGATGTGATGTTGCTTTTGACCT 25
RESULT 11
ADP14587
ID ADP14587 standard; DNA; 25 BP.
XX AC ADP14587;
XX DT 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #992.
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
OS Homo sapiens.
XX

```

```
PN WO2004048933-A2.
XX 10-JUN-2004.
XX 21-NOV-2003; 2003WO-US037481.
XX 21-NOV-2002; 2002US-0427982P.
XX 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1323; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX Sequence 25 BP; 8 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1474 AGAGAGCTCTGCACGTCACCAAGTA 1498
DB 1 AGAGAGCTCTGCACGTCACCAAGTA 25
RESULT 12
ADP14582
ID ADP14582 standard; DNA; 25 BP.
XX ADP14582;
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #987.
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX Homo sapiens.
XX WO2004048933-A2.
PN
```

```
XX 10-JUN-2004.
XX 21-NOV-2003; 2003WO-US037481.
XX 21-NOV-2002; 2002US-0427982P.
XX 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1318; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX Sequence 25 BP; 4 A; 5 C; 7 G; 9 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1262 GGTCGTGAAGCTCTTTGACTCTGAT 1286
DB 1 GGTCGTGAAGCTCTTTGACTCTGAT 25
RESULT 13
ADP14584
ID ADP14584 standard; DNA; 25 BP.
XX ADP14584;
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #989.
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX Homo sapiens.
XX WO2004048933-A2.
PN
```

```

PD 10-JUN-2004.
XX
XX 21-NOV-2003; 2003WO-US037481.
XX
XX 21-NOV-2002; 2002US-0427982P.
XX
XX 03-APR-2003; 2003US-0459782P.
XX
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX
XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;
XX Sloni DK;
XX
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
XX differential expression profile of specific genes in peripheral blood
XX sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1320; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
XX such as solid tumor by providing peripheral blood sample of human having
XX non-blood disease, and comparing an expression profile of specific genes
XX in the peripheral blood sample to reference expression profile of the
XX genes, where each of the genes is differentially expressed in peripheral
XX blood mononuclear cells (PBMCs) of patients having the disease as
XX compared to PBMCs of normal humans. The method is useful for diagnosing
XX non-blood disease such as solid tumor. The solid tumor is chosen from
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood
XX sample is a whole blood sample (claimed). (M1) is useful for identifying
XX genes that are differentially expressed in peripheral blood samples
XX isolated at different stages of progression, development or treatment of
XX RCC and/or other solid tumors. This sequence corresponds to a probe to
XX detect a gene that is differentially expressed and detected by the method
XX of the invention.
XX
XX Sequence 25 BP; 4 A; 8 C; 9 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 25; DB 1; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 19;
XX Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1274 CTTTGACTCTGATCCCATCACTGTG 1298
XX |||||
XX Db 1 CTTTGACTCTGATCCCATCACTGTG 25
XX
XX RESULT 14
XX ADP14586
XX ID ADP14586 standard; DNA; 25 BP.
XX
XX AC ADP14586;
XX
XX DT 26-AUG-2004 (first entry)
XX
XX Renal cell carcinoma differentially expressed gene probe #991.
XX
XX as; diagnosis; non-blood disease; solid tumor; gene expression;
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
XX head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
XX
XX OS
XX WO2004048933-A2.
XX
XX 10-JUN-2004.
XX

```

```

XX 21-NOV-2003; 2003WO-US037481.
XX
XX 21-NOV-2002; 2002US-0427982P.
XX
XX 03-APR-2003; 2003US-0459782P.
XX
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX
XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;
XX Sloni DK;
XX
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
XX differential expression profile of specific genes in peripheral blood
XX sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1322; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
XX such as solid tumor by providing peripheral blood sample of human having
XX non-blood disease, and comparing an expression profile of specific genes
XX in the peripheral blood sample to reference expression profile of the
XX genes, where each of the genes is differentially expressed in peripheral
XX blood mononuclear cells (PBMCs) of patients having the disease as
XX compared to PBMCs of normal humans. The method is useful for diagnosing
XX non-blood disease such as solid tumor. The solid tumor is chosen from
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood
XX sample is a whole blood sample (claimed). (M1) is useful for identifying
XX genes that are differentially expressed in peripheral blood samples
XX isolated at different stages of progression, development or treatment of
XX RCC and/or other solid tumors. This sequence corresponds to a probe to
XX detect a gene that is differentially expressed and detected by the method
XX of the invention.
XX
XX Sequence 25 BP; 7 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 25; DB 1; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 19;
XX Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1470 CCAGAGAGAGCTCTGCAGTCACCA 1494
XX |||||
XX Db 1 CCAGAGAGAGCTCTGCAGTCACCA 25
XX
XX RESULT 15
XX ADP14588
XX ID ADP14588 standard; DNA; 25 BP.
XX
XX AC ADP14588;
XX
XX DT 26-AUG-2004 (first entry)
XX
XX Renal cell carcinoma differentially expressed gene probe #993.
XX
XX as; diagnosis; non-blood disease; solid tumor; gene expression;
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
XX head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
XX
XX OS
XX WO2004048933-A2.
XX
XX 10-JUN-2004.
XX

```

```

PF 21-NOV-2003; 2003WO-US037481.
XX
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX
PA (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLOW/) SLONI D K.
XX
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1324; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
XX Sequence 25 BP; 7 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1480 CTCTGCACGTACCAAGTACCAGG 1504
DB 1 CTCTGCACGTACCAAGTACCAGG 25
RESULT 16
ADP14592
ID ADP14592 standard; DNA; 25 BP.
AC ADP14592;
XX
XX 26-AUG-2004 (first entry)
DE Renal cell carcinoma differentially expressed gene probe #997.
XX
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
XX
XX WO2004048933-A2.
XX
XX 10-JUN-2004.
XX
XX 21-NOV-2003; 2003WO-US037481.
XX

```

```

XX
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX
PA (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLOW/) SLONI D K.
XX
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1328; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
XX Sequence 25 BP; 5 A; 8 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1563 TAACACTCGACTCTGCTGCTCATGG 1587
DB 1 TAACACTCGACTCTGCTGCTCATGG 25
RESULT 17
ADP14579
ID ADP14579 standard; DNA; 25 BP.
XX
XX AC ADP14579;
XX
XX 26-AUG-2004 (first entry)
XX
XX Renal cell carcinoma differentially expressed gene probe #984.
XX
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
XX
XX WO2004048933-A2.
XX
XX 10-JUN-2004.
XX
XX 21-NOV-2003; 2003WO-US037481.
XX

```

```
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1315; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX Sequence 25 BP; 8 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1177 AAGGCGAAGACCAGTACTATCTGCG 1201
Db 1 AAGGCGAAGACCAGTACTATCTGCG 25
RESULT 18
ADP14581
ID ADP14581 standard; DNA; 25 BP.
XX AC ADP14581;
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #986.
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX Homo sapiens.
XX OS
XX WO2004048933-A2.
XX 10-JUN-2004.
XX 21-NOV-2003; 2003WO-US037481.
XX 21-NOV-2002; 2002US-0427982P.
PR
```

```
PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1317; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX Sequence 25 BP; 4 A; 4 C; 9 G; 8 T; 0 U; 0 Other;
SQ Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1256 TGAGTGCTCGTGAAGCTCTTTGAC 1280
Db 1 TGAGTGCTCGTGAAGCTCTTTGAC 25
RESULT 19
ADP14591
ID ADP14591 standard; DNA; 25 BP.
XX AC ADP14591;
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #996.
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX Homo sapiens.
XX OS
XX WO2004048933-A2.
XX 10-JUN-2004.
XX 21-NOV-2003; 2003WO-US037481.
XX 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
PR
```


XX (AMHP) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STON/) STOVER J A.
PA (SLON/) SLONI D K.
XX
PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1327; 350pp; English.
XX
CC The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
SQ Sequence 25 BP; 5 A; 9 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1562 CTAACACTCGACTCTGCTGCTCATG 1586
Db 1 CTAACACTCGACTCTGCTGCTCATG 25
RESULT 20
ABN99658/C
ID ABN99658 standard; DNA; 23 BP.
XX
AC ABN99658;
XX
XX 16-AUG-2002 (first entry)
DT
XX Human clusterin PCR primer 2.
DE
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss; PCR; primer;
KW hyperproliferative disorder; hyperlipidemic disorder.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
PN
XX 21-MAR-2002.
PD
XX 10-SEP-2001; 2001WO-US028235.
PF
XX 11-SEP-2000; 2000US-00659791.
PR
XX (ISIS-) ISIS PHARM INC.
PA

XX Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 13; Page 80; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a PCR primer used to amplify the human clusterin
CC gene
XX
SQ Sequence 23 BP; 5 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 789 CTTGAGATGATACACGAGGCTCA 811
Db 23 CTTGAGATGATACACGAGGCTCA 1
RESULT 21
ACF36411/C
ID ACF36411 standard; DNA; 23 BP.
XX
AC ACF36411;
XX
XX 18-DEC-2003 (first entry)
DT
XX Human TRPM-2 cDNA amplifying RT-PCR antisense primer.
DE
XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; RT-PCR;
KW androgen; prostate cancer; anti-apoptotic protein; antisense; primer; ss.
XX
OS Homo sapiens.
XX
XX WO2003072591-A1.
PN
XX 04-SEP-2003.
PD
XX 20-FEB-2003; 2003WO-US005305.
PF
XX 22-FEB-2002; 2002US-00080794.
PR
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
PI
XX WPI; 2003-689981/65.
XX
XX New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
PT
XX
XX Example 13; Page 20; 44pp; English.
XX
XX The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in

CC vitro; (b) to treat prostatic cancer (after initially withdrawing
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. The present sequence represents a RT-
CC PCR primer for amplifying the anti-apoptotic protein TRPM-2 (testosterone
CC -repressed prostate message-2) cDNA
XX
XX Sequence 23 BP; 7 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 AAGTCCGGGAGATCTTGTCTGT 979

Db 23 AAGTCCGGGAGATCTTGTCTGT 1

RESULT 22

ACF36410
ID ACF36410 standard; DNA; 23 BP.

XX AC ACF36410;

XX 18-DEC-2003 (first entry)

XX Human TRPM-2 cDNA amplifying RT-PCR sense primer.

XX TRPM-2; testosterone-repressed prostate message-2; cytosolic; RT-PCR;
KW androgen; prostate cancer; anti-apoptotic protein; antisense; primer; ss.

XX Homo sapiens.

XX WO2003072591-A1.

XX 04-SEP-2003.

XX 20-FEB-2003; 2003WO-US005305.

XX 22-FEB-2002; 2002US-00080794.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;

XX WPI; 2003-689981/65.

XX New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.

XX Example 13; Page 20; 44pp; English.

XX The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
CC vitro; (b) to treat prostatic cancer (after initially withdrawing
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. The present sequence represents a RT-

CC PCR primer for amplifying the anti-apoptotic protein TRPM-2 (testosterone
CC -repressed prostate message-2) cDNA

XX Sequence 23 BP; 11 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.4%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 28;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 177 AAGGAAATTCAAAATGCTGTCAA 199

Db 1 AAGGAAATTCAAAATGCTGTCAA 23

RESULT 23

ADM83082/c

ID ADM83082 standard; DNA; 23 BP.

XX AC ADM83082;

XX 03-JUN-2004 (first entry)

XX Human TRPM-2 amplifying antisense RT-PCR primer.

XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
KW reverse transcription; RT-PCR; primer; ss.

XX Homo sapiens.

XX US2003158130-A1.

XX 21-AUG-2003.

XX 28-SEP-2001; 2001US-00967726.

XX 25-FEB-2000; 2000WO-US004875.

XX 28-SEP-2000; 2000US-0236301P.

XX 10-AUG-2001; 2001US-00913325.

XX (GLEA/) GLEAVE M.

XX (RENN/) RENNIE P S.

XX (MIYA/) MIYAKE H.

XX (NELS/) NELSON C.

XX (ZELL/) ZELLWEGER T.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX WPI; 2003-778017/73.

XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells

PT that expresses testosterone-repressed prostate message-2 (TRPM-2)

PT comprises administering a composition that inhibits expression of TRPM-2.

XX Disclosure; SEQ ID NO 17; 14pp; English.

XX The present invention provides a method for treating cancer in which
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
CC The invention is useful for enhancing the chemo-sensitivity or radiation-
CC sensitivity of cancer cells for treating cancer such as prostate cancer,
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
CC (RCC). The invention is also useful in antisense gene therapy. The
CC present sequence is human testosterone-repressed prostate message-2 (TRPM
CC -2) amplifying RT-PCR primer. The primer is used in the exemplification
CC of the invention.

XX Sequence 23 BP; 7 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.4%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 28;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 957 AAGTGGCGGAGATCTGTCTGT 979
DB 23 AAGTGGCGGAGATCTGTCTGT 1

RESULT 24
ADM83081
ID ADM83081 standard; DNA; 23 BP.
XX
XX
AC ADM83081;
XX
XX 03-JUN-2004 (first entry)
XX
XX Human TRPM-2 amplifying sense RT-PCR primer.
XX
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
XX radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
XX lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
XX reverse transcription; RT-PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX US2003158130-A1.
XX
XX 21-AUG-2003.
XX
XX 28-SEP-2001; 2001US-00967726.
XX
XX 25-FEB-2000; 2000NO-US004875.
XX
XX 28-SEP-2000; 2000US-0236301P.
XX
XX 10-AUG-2001; 2001US-00913325.
XX
XX (GLEA/) GLEAVE M.
XX (RENN/) RENNIE P S.
XX (MIYA/) MIYAKE H.
XX (NELS/) NELSON C.
XX (ZELL/) ZELLWEGER T.
XX
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;
XX WPI; 2003-778017/73.
XX
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
XX that expresses testosterone-repressed prostate message-2 (TRPM-2)
XX comprises administering a composition that inhibits expression of TRPM-2.
XX
XX Disclosure; SEQ ID NO 16; 14pp; English.
XX
XX The present invention provides a method for treating cancer in which
XX cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
XX The invention is useful for enhancing the chemo-sensitivity or radiation-
XX sensitivity of cancer cells for treating cancer such as prostate cancer,
XX bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
XX (RCC). The invention is also useful in antisense gene therapy. The
XX present sequence is human testosterone-repressed prostate message-2 (TRPM
XX -2) amplifying RT-PCR primer. The primer is used in the exemplification
XX of the invention.
XX
XX Sequence 23 BP; 11 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.4%; Score 23; DB 1; Length 23;
XX Best Local Similarity 100.0%; Pred. No. 28;
XX Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 177 AAGGAATTCAAATGCTGTCAA 199
DB 1 AAGGAATTCAAATGCTGTCAA 23

RESULT 25
ADM70521
ID ADM70521 standard; cDNA; 23 BP.
XX
XX
```

```
AC ADL70521;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human clusterin target for RNAi.
XX
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
XX ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
XX Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
XX mediate degradation or block translation of mRNA that is the
XX transcriptional product of a target gene, useful for treating Alzheimer's
XX disease or cancer.
XX
XX Example 6; SEQ ID NO 66; 63pp; English.
XX
XX The present sequence is a human clusterin cDNA target for a double-
XX stranded short interfering RNA (siRNA) of the invention to demonstrate
XX ADL70523. It was used in an example from the invention to demonstrate
XX clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
XX known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
XX tumour cells following androgen withdrawal, and has also been shown to be
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.
XX siRNAs of the invention can be used alone or in combination with other
XX chemotherapy or apoptosis inducing treatments for the treatment of
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
XX anaplastic large cell lymphoma and melanoma, and also for the treatment
XX of Alzheimer's disease.
XX
XX Sequence 23 BP; 5 A; 5 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.4%; Score 23; DB 1; Length 23;
XX Best Local Similarity 100.0%; Pred. No. 28;
XX Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 GCATGATGAAGACTCTGCTGCTG 68
DB 1 GCATGATGAAGACTCTGCTGCTG 23

RESULT 26
ADM70512
ID ADM70512 standard; cDNA; 23 BP.
XX
XX ADL70512;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human clusterin target for RNAi.
XX
```

```
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Example 6; SEQ ID NO 57; 63pp; English.
XX
XX The present sequence is a human clusterin cDNA target for a double-
CC stranded short interfering RNA (siRNA) of the invention ADL70513-
CC ADL70514. It was used in an example from the invention to demonstrate
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapies or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease.
XX
XX Sequence 23 BP; 5 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 480 AACGAGCTCGCCCTTCTACTT 502
DB 1 AACGAGCTCGCCCTTCTACTT 23
RESULT 27
ADL70515
ID ADL70515 standard; cDNA; 23 BP.
XX
XX ADL70515;
AC
XX 20-MAY-2004 (first entry)
DT
XX Human clusterin target for RNAi.
DE
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
```

```
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Example 6; SEQ ID NO 60; 63pp; English.
XX
XX The present sequence is a human clusterin cDNA target for a double-
CC stranded short interfering RNA (siRNA) of the invention ADL70516-
CC ADL70517. It was used in an example from the invention to demonstrate
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapies or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease.
XX
XX Sequence 23 BP; 4 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 711 AAGTCCGCGATCGTCCGAGCTT 733
DB 1 AAGTCCGCGATCGTCCGAGCTT 23
RESULT 28
ADL70518
ID ADL70518 standard; cDNA; 23 BP.
XX
XX ADL70518;
AC
XX 20-MAY-2004 (first entry)
DT
XX Human clusterin target for RNAi.
DE
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
XX Homo sapiens.
OS Synthetic.
OS WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX
```

XX 21-AUG-2002; 2002US-0405193P.
 PR 03-SEP-2002; 2002US-0408152P.
 PR 20-MAY-2003; 2003US-0472387P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX
 PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
 PI Gonos ES;
 XX
 XX WPI; 2004-226852/21.
 DR
 XX New RNA molecule less than 49 bases and having a sequence effective to
 PT mediate degradation or block translation of mRNA that is the
 PT transcriptional product of a target gene, useful for treating Alzheimer's
 PT disease or cancer.
 XX
 XX Example 6; SEQ ID NO 63; 63pp; English.
 PS
 XX The present sequence is a human clusterin cDNA target for a double-
 CC stranded short interfering RNA (siRNA) of the invention ADL70519-
 CC ADL70520. It was used in an example from the invention to demonstrate
 CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
 CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
 CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
 CC tumour cells following androgen withdrawal, and has also been shown to be
 CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
 CC siRNAs of the invention can be used alone or in combination with other
 CC chemotherapy or apoptosis inducing treatments for the treatment of
 CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
 CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
 CC anaplastic large cell lymphoma and melanoma, and also for the treatment
 CC of Alzheimer's disease.
 XX
 XX Sequence 23 BP; 10 A; 4 C; 1 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 1.4%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 28;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1613 AACTAATTCGTAATAACTGCTT 1635
 DB 1 AACTAATTCGTAATAACTGCTT 23
 RESULT 29
 AAT39500
 ID AAT39500 standard; DNA; 21 BP.
 AC AAT39500;
 XX
 XX 21-MAY-1997 (first entry)
 DT
 XX
 DE Chromosome 8p clusterin gene (CL1) specific primer (nt 2504-2524).
 XX
 KW Chromosome 8p; polymerase chain reaction; PCR; primer; CL1;
 KW clusterin gene; human; steroidogenesis; acute regulatory protein;
 KW regional mapping; confirmation; hStAR; ss.
 XX
 OS Synthetic.
 OS
 XX WO9629338-A1.
 PN
 XX
 XX 26-SEP-1996.
 PD
 XX
 XX 22-MAR-1996; 96WO-US003896.
 PF
 XX
 XX 23-MAR-1995; 95US-00410540.
 PR
 XX (REGC) UNIV CALIFORNIA.
 PA (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Miller WL, Lin D, Strauss JF;
 PI

XX WPI; 1996-443130/44.
 XX Isolated human steroidogenesis acute regulatory protein gene - used for
 PT detection of mutation(s) of this gene that cause congenital lipid
 PT adrenal hyperplasia.
 PT
 XX Example 7; Page 51; 89pp; English.
 PS
 XX The present sequence is a human chromosome 8p clusterin gene (CL1)
 CC specific PCR primer, which was used in the confirmation of the regional
 CC mapping of the human steroidogenesis acute regulatory protein (hStAR)
 CC
 XX Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1354 AGAAGCGCTGCAGGAATACC 1374
 DB 1 AGAAGCGCTGCAGGAATACC 21
 RESULT 30
 AAA52783
 ID AAA52783 standard; DNA; 21 BP.
 XX
 XX AAA52783;
 AC
 XX 03-JAN-2001 (first entry)
 DT
 XX Porcine clusterin PCR primer #1.
 DE
 XX Pig; clusterin; cell migration; wound healing; angiogenesis; cancer;
 KW vascular trauma; vascular disease; atherosclerosis; restenosis;
 KW complement cytolysis inhibitor; SP-40; 40; apoJ;
 KW testosterone repressed prostate message-2; sulfated glycoprotein-2;
 KW PCR primer; ss.
 XX
 XX Sus scrofa.
 OS
 XX WO200034469-A1.
 PN
 XX 15-JUN-2000.
 PD
 XX 10-DEC-1999; 99WO-US029262.
 PF
 XX 11-DEC-1998; 98US-0111856P.
 PR
 XX (UYNY) UNIV NEW YORK STATE RES FOUND.
 PA
 XX Millis AJT;
 PI
 XX WPI; 2000-431300/37.
 DR
 XX Clusterin and gp38K-related peptide capable of altering cell migration
 PT useful for treating atherosclerosis, cancer and stenosis following
 PT vascular trauma or disease.
 PT
 XX Disclosure; Page 12; 43pp; English.
 PS
 XX The present sequence is a PCR primer for the porcine clusterin gene.
 CC Clusterin (also known as complement cytolysis inhibitor, sulfated
 CC glycoprotein-2, testosterone repressed prostate message-2, SP-40, 40 and
 CC ApoJ) is essential for the migration of vascular smooth muscle cells
 CC (VSMC). The gene and protein can, therefore, be used to promote wound
 CC healing, angiogenesis and vasculogenesis, in the treatment of stenosis
 CC following vascular trauma or disease and to treat atherosclerosis, and
 CC antisense sequences can be used to treat cancer, as angiogenesis is vital
 CC for tumour survival
 XX
 XX Sequence 21 BP; 12 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
 SQ

```

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCAAAGAGAGAGAGAGG 294
    |||||
    1 AAGCCAGAGAGAGAGAGAGG 21
DB

RESULT 31
AAA94227/c
ID AAA94227 standard; DNA; 21 BP.
XX
AC AAA94227;
XX
DT 12-JAN-2001 (first entry)
XX
DE Human testosterone-repressed prostate message-2 antisense oligo #3.
XX
KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200049937-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004875.
XX
PR 26-FEB-1999; 99US-0121726P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX
PS WPI; 2000-533132/48.
XX
CC The present sequence is an antisense oligonucleotide directed at the
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
CC promote the regression of tumours, and oligonucleotides directed at human
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
CC gene. These include prostate cancer, renal cell cancer and some breast
CC cancer cells. In addition to this, they also increase the
CC chemosensitivity of the cells, meaning that conventional chemotherapy is
CC more effective
XX
SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACACTCCACGGCTGCCTGC 936
    |||||
    21 ACACTCCACGGCTGCCTGC 1
DB

RESULT 33
AAA94230/c
ID AAA94230 standard; DNA; 21 BP.
XX
AC AAA94230;
XX
DT 12-JAN-2001 (first entry)
XX
DE Human testosterone-repressed prostate message-2 antisense oligo #6.
XX
KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200049937-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004875.
XX
PR 26-FEB-1999; 99US-0121726P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;
PI

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
    |||||
    21 GACCAGACGGTCTCAGACAAT 1
DB

RESULT 32
AAA94231/c
ID AAA94231 standard; DNA; 21 BP.
XX
AC AAA94231;
XX
DT 12-JAN-2001 (first entry)
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;
PI
```

```
XX WPI; 2000-533132/48.
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX PT Treating prostatic tumors and renal cancers by antisense inhibition of
XX PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Example 5; Page 37; 38pp; English.
XX
XX The present sequence is an antisense oligonucleotide directed at the
XX CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX CC promote the regression of tumours, and oligonucleotides directed at human
XX CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
XX CC gene. These include prostate cancer, renal cell cancer and some breast
XX CC cancer cells. In addition to this, they also increase the
XX CC chemosensitivity of the cells, meaning that conventional chemotherapy is
XX CC more effective
XX
XX Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX PT Best Local Similarity 100.0%; Pred. No. 39;
XX PT Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 716 CCGCATCGTCCGAGCTTGAT 736
XX DB 21 CCGCATCGTCCGAGCTTGAT 1
XX
XX RESULT 34
XX AA94232/c
XX ID AAA94232 standard; DNA; 21 BP.
XX AC AAA94232;
XX
XX 12-JAN-2001 (first entry)
XX
XX Human testosterone-repressed prostate message-2 antisense oligo #8.
XX
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX OS
XX WO200049937-A2.
XX PN
XX 31-AUG-2000.
XX PD
XX 25-FEB-2000; 2000WO-US004875.
XX PF
XX 26-FEB-1999; 99US-0121726P.
XX PR
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX PA
XX Gleave M, Rennie PS, Miyake H, Nelson C;
XX PI WPI; 2000-533132/48.
XX
XX Treating prostatic tumors and renal cancers by antisense inhibition of
XX PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Example 5; Page 37; 38pp; English.
XX
XX The present sequence is an antisense oligonucleotide directed at the
XX CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX CC promote the regression of tumours, and oligonucleotides directed at human
XX CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
XX CC gene. These include prostate cancer, renal cell cancer and some breast
XX CC cancer cells. In addition to this, they also increase the
XX CC chemosensitivity of the cells, meaning that conventional chemotherapy is
XX CC more effective
XX
```

```
SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX PT Best Local Similarity 100.0%; Pred. No. 39;
XX PT Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1115 CTCCTTGCTGGAGCAGCTGAA 1135
XX DB 21 CTCCTTGCTGGAGCAGCTGAA 1
XX
XX RESULT 35
XX AA94233/c
XX ID AAA94233 standard; DNA; 21 BP.
XX AC AAA94233;
XX
XX 12-JAN-2001 (first entry)
XX
XX Human testosterone-repressed prostate message-2 antisense oligo #9.
XX
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX OS
XX WO200049937-A2.
XX PN
XX 31-AUG-2000.
XX PD
XX 25-FEB-2000; 2000WO-US004875.
XX PF
XX 26-FEB-1999; 99US-0121726P.
XX PR
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX PA
XX Gleave M, Rennie PS, Miyake H, Nelson C;
XX PI WPI; 2000-533132/48.
XX
XX Treating prostatic tumors and renal cancers by antisense inhibition of
XX PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Example 5; Page 38; 38pp; English.
XX
XX The present sequence is an antisense oligonucleotide directed at the
XX CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX CC promote the regression of tumours, and oligonucleotides directed at human
XX CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
XX CC gene. These include prostate cancer, renal cell cancer and some breast
XX CC cancer cells. In addition to this, they also increase the
XX CC chemosensitivity of the cells, meaning that conventional chemotherapy is
XX CC more effective
XX
XX Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX PT Best Local Similarity 100.0%; Pred. No. 39;
XX PT Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1316 CTCACGAGAGAACCTTAATT 1336
XX DB 21 CTCACGAGAGAACCTTAATT 1
XX
XX RESULT 36
XX AA94229/c
XX ID AAA94229 standard; DNA; 21 BP.
XX AC AAA94229;
XX
XX 12-JAN-2001 (first entry)
XX
```

XX DE Human testosterone-repressed prostate message-2 antisense oligo #5.
XX KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX PN WO200049937-A2.
XX PD 31-AUG-2000.
XX PF 25-FEB-2000; 2000WO-US004875.
XX PR 26-FEB-1999; 99US-0121726P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX DR WPI; 2000-533132/48.
XX PT Treating prostatic tumors and renal cancers by antisense inhibition of
XX PT the testosterone-repressed prostate messenger-2 gene.
XX PS Example 5; Page 37; 38pp; English.
XX CC The present sequence is an antisense oligonucleotide directed at the
XX CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX CC promote the regression of tumours, and oligonucleotides directed at human
XX CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
XX CC gene. These include prostate cancer, renal cell cancer and some breast
XX CC cancer cells. In addition to this, they also increase the
XX CC chemosensitivity of the cells, meaning that conventional chemotherapy is
XX CC more effective
XX CC Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX DE Query Match 1.3%; Score 21; DB 1; Length 21;
XX DE Best Local Similarity 100.0%; Pred. No. 39;
XX DE Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 515 TGACCGCATCGACTCCCTGCT 535
Db 21 TGACCGCATCGACTCCCTGCT 1
RESULT 37
AAA94226/c
ID AAA94226 standard; DNA; 21 BP.
AC AAA94226;
XX DT 12-JAN-2001 (first entry)
XX DE Human testosterone-repressed prostate message-2 antisense oligo #2.
XX KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX PN WO200049937-A2.
XX PD 31-AUG-2000.
XX PF 25-FEB-2000; 2000WO-US004875.
XX PR 26-FEB-1999; 99US-0121726P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.

PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX DR WPI; 2000-533132/48.
XX PT Treating prostatic tumors and renal cancers by antisense inhibition of
XX PT the testosterone-repressed prostate messenger-2 gene.
XX PS Claim 3; Page 36; 38pp; English.
XX CC The present sequence is an antisense oligonucleotide directed at the
XX CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX CC promote the regression of tumours, and oligonucleotides directed at human
XX CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
XX CC gene. These include prostate cancer, renal cell cancer and some breast
XX CC cancer cells. In addition to this, they also increase the
XX CC chemosensitivity of the cells, meaning that conventional chemotherapy is
XX CC more effective
XX CC Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
XX DE Query Match 1.3%; Score 21; DB 1; Length 21;
XX DE Best Local Similarity 100.0%; Pred. No. 39;
XX DE Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGCTG 68
Db 21 ATGATGAAGACTCTGCTGCTG 1
RESULT 38
AAA94234/c
ID AAA94234 standard; DNA; 21 BP.
XX AC AAA94234;
XX DT 12-JAN-2001 (first entry)
XX DE Human testosterone-repressed prostate message-2 antisense oligo #10.
XX KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX PN WO200049937-A2.
XX PD 31-AUG-2000.
XX PF 25-FEB-2000; 2000WO-US004875.
XX PR 26-FEB-1999; 99US-0121726P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX DR WPI; 2000-533132/48.
XX PT Treating prostatic tumors and renal cancers by antisense inhibition of
XX PT the testosterone-repressed prostate messenger-2 gene.
XX PS Example 5; Page 38; 38pp; English.
XX CC The present sequence is an antisense oligonucleotide directed at the
XX CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX CC promote the regression of tumours, and oligonucleotides directed at human
XX CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
XX CC gene. These include prostate cancer, renal cell cancer and some breast
XX CC cancer cells. In addition to this, they also increase the
XX CC chemosensitivity of the cells, meaning that conventional chemotherapy is
XX CC more effective


```
XX SQ Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCACTCGCCGAGC 1536
Db 21 AGGCCCCCACTCGCCGAGC 1

RESULT 39
AAA94228/c
ID AAA94228 standard; DNA; 21 BP.
XX AC AAA94228;
XX DT 12-JAN-2001 (first entry)
XX Human testosterone-repressed prostate message-2 antisense oligo #4.
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX PN WO200049937-A2.
XX PD 31-AUG-2000.
XX PF 25-FEB-2000; 2000WO-US004875.
XX PR 26-FEB-1999; 99US-0121726P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX WPI; 2000-533132/48.
XX Treating prostatic tumors and renal cancers by antisense inhibition of
XX the testosterone-repressed prostate messenger-2 gene.
XX PS Example 5; Page 36; 38pp; English.
XX CC The present sequence is an antisense oligonucleotide directed at the
XX human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX promote the regression of tumors, and oligonucleotides directed at human
XX TRPM-2 can be used in the treatment of tumor cells expressing the TRPM-2
XX gene. These include prostate cancer, renal cell cancer and some breast
XX cancer cells. In addition to this, they also increase the
XX chemosensitivity of the cells, meaning that conventional chemotherapy is
XX more effective
XX SQ Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGAGACAAAGCTGAAGG 336
Db 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 40
AAA94225/c
ID AAA94225 standard; DNA; 21 BP.
XX AC AAA94225;
XX XX
```

```
DT 12-JAN-2001 (first entry)
XX Human testosterone-repressed prostate message-2 antisense oligo #1.
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX PN WO200049937-A2.
XX PD 31-AUG-2000.
XX PF 25-FEB-2000; 2000WO-US004875.
XX PR 26-FEB-1999; 99US-0121726P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX WPI; 2000-533132/48.
XX Treating prostatic tumors and renal cancers by antisense inhibition of
XX the testosterone-repressed prostate messenger-2 gene.
XX PS Example 5; Page 36; 38pp; English.
XX CC The present sequence is an antisense oligonucleotide directed at the
XX human testosterone-repressed prostate message-2 (TRPM-2, also known as
XX clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
XX promote the regression of tumors, and oligonucleotides directed at human
XX TRPM-2 can be used in the treatment of tumor cells expressing the TRPM-2
XX gene. These include prostate cancer, renal cell cancer and some breast
XX cancer cells. In addition to this, they also increase the
XX chemosensitivity of the cells, meaning that conventional chemotherapy is
XX more effective
XX SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGCGTGCAAGACTCCA 36
Db 21 CCGAGGCGTGCAAGACTCCA 1

RESULT 41
AAF97658
ID AAF97658 standard; DNA; 21 BP.
XX AC AAF97658;
XX DT 18-NOV-2004 (revised)
XX DT 06-JUN-2001 (first entry)
XX Human gene single nucleotide polymorphism #2419.
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX polymorphism; vascular disease; coronary artery disease; forensics;
XX myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX pulmonary embolism; paternity test; ds.
XX OS Homo sapiens.
XX OS Unidentified.
XX FH Key Location/Qualifiers
XX FT variation 11
XX FT /*tag= a
XX FT /standard_name= "Single nucleotide polymorphism"
XX XX
```

PN WO200118250-A2.
XX 15-MAR-2001.
XX 07-SEP-2000; 2000WO-US024503.
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
PI WPI; 2001-226749/23.
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX Example; Page 212; 242pp; English.
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a captial V
XX Sequence 21 BP; 7 A; 7 C; 6 G; 1 T; 0 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1170 CTCACCGAAGGCGAGACCAG 1190
Db | | | | | | | | | | | | | | | | | | | |
1 CTCACCGAAGGCGAGACCAG 21
RESULT 42
AAF97656
ID AAF97656 standard; DNA; 21 BP.
XX AAF97656;
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX Human gene single nucleotide polymorphism #2417.
DE Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX Homo sapiens.
OS Unidentified.
XX Key Location/Qualifiers
FH Variation 11
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"

XX WO200118250-A2.
XX 15-MAR-2001.
XX 07-SEP-2000; 2000WO-US024503.
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
PI WPI; 2001-226749/23.
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX Example; Page 212; 242pp; English.
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a captial V
XX Sequence 21 BP; 8 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1050 GAGAGGTTGACCGAGAAATAC 1070
Db | | | | | | | | | | | | | | | | | | | |
1 GAGAGGTTGACCGAGAAATAC 21
RESULT 43
AAF97657
ID AAF97657 standard; DNA; 21 BP.
XX AAF97657;
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX Human gene single nucleotide polymorphism #2418.
DE Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX Homo sapiens.
OS Unidentified.
XX Key Location/Qualifiers
FH Variation 11
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"

```
FT /standard_name= "Single nucleotide polymorphism"
XX WO200118250-A2.
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
XX 26-JUL-2000; 2000US-0220947P.
XX 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX PT applications such as forensics, paternity testing, medicine, genetic
XX PT analysis and phenotype correlations to diseases such as diabetes and
XX PT atherosclerosis.
XX
XX Example; Page 212; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
XX CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX CC genes. The sequences at a number of polymorphic sites are also provided
XX CC in the specification. In particular, the method can be used in the
XX CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX CC useful in forensics, paternity testing, genetic analysis and phenotype
XX CC correlations to diseases. The present sequence is an example of one of
XX CC the human gene SNPs shown in the specification
XX
XX Revised record issued on 18-NOV-2004 : The variantion feature was
XX CC incorrectly given a captial V
XX
XX Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 39;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 999 CCCTCCAGGCTAAGCTGGG 1019
XX 1 CCCTCCAGGCTAAGCTGGG 21
XX
XX RESULT 44
XX AAF97659
XX ID AAF97659 standard; DNA; 21 BP.
XX
XX AC AAF97659;
XX
XX 18-NOV-2004 (revised)
XX DT 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #2420.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX KW polymorphism; vascular disease; coronary artery disease; forensics;
XX KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX KW pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
XX OS Unidentified.
XX
XX Key Location/Qualifiers
XX FT Variation 11
```

```
FT /*tag= a
XX /standard_name= "Single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
XX 26-JUL-2000; 2000US-0220947P.
XX 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX PT applications such as forensics, paternity testing, medicine, genetic
XX PT analysis and phenotype correlations to diseases such as diabetes and
XX PT atherosclerosis.
XX
XX Example; Page 213; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
XX CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX CC genes. The sequences at a number of polymorphic sites are also provided
XX CC in the specification. In particular, the method can be used in the
XX CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX CC useful in forensics, paternity testing, genetic analysis and phenotype
XX CC correlations to diseases. The present sequence is an example of one of
XX CC the human gene SNPs shown in the specification
XX
XX Revised record issued on 18-NOV-2004 : The variantion feature was
XX CC incorrectly given a captial V
XX
XX Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 39;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1105 TCAACACCTCTCCTTGCTGG 1125
XX 1 TCAACACCTCTCCTTGCTGG 21
XX
XX RESULT 45
XX ABN99659
XX ID ABN99659 standard; DNA; 21 BP.
XX
XX AC ABN99659;
XX
XX 16-AUG-2002 (first entry)
XX DT
XX Human clusterin PCR probe.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss; PCR; probe;
XX KW hyperproliferative disorder; hyperlipidemic disorder.
XX
XX Homo sapiens.
XX OS
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
```

PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 13; Page 80; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a PCR probe specific for the human clusterin
CC gene. NOTE: The present sequence is labelled with a fluorescent reporter
CC dye (FAM) and a quencher dye (TAMRA)
XX
XX Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;
SQ

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 766 TCACGCCCATGTTCCAGCCCT 786
DB 1 TCACGCCCATGTTCCAGCCCT 21

RESULT 46
• ACF36397/C
ID ACF36397 standard; DNA; 21 BP.
XX
AC ACF36397;
XX
DT 18-DEC-2003 (first entry)
XX
DE TRPM-2 antisense oligonucleotide.
XX
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
FN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX WPI; 2003-689981/65.
XX
XX New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 5; Page 40; 44pp; English.

CC The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
CC vitro; (b) to treat prostatic cancer (after initially withdrawing
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. The present sequence represents an
CC anti-apoptotic protein TRPM-2 (testosterone-repressed prostate message-2)
XX antisense oligonucleotide

Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;
SQ

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 16 CCGAGGGCGTGCAAGACTCCA 36
DB 21 CCGAGGGCGTGCAAGACTCCA 1

RESULT 47
ACF36405/C
ID ACF36405 standard; DNA; 21 BP.
XX
AC ACF36405;
XX
DT 18-DEC-2003 (first entry)
XX
DE TRPM-2 antisense oligonucleotide #11.
XX
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
FN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX WPI; 2003-689981/65.
XX
XX New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 5; Page 42; 44pp; English.

The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
CC vitro; (b) to treat prostatic cancer (after initially withdrawing
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. The present sequence represents an
CC anti-apoptotic protein TRPM-2 (testosterone-repressed prostate message-2)
XX antisense oligonucleotide

CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
 CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
 CC ovarian and some breast cancer cells) that express abnormal levels of
 CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
 CC increase stability in vivo and activity (both in vivo or in vitro) and
 CC result in a synergistic increase in effect when (I) is used with
 CC chemotherapeutic agents or other antisense oligonucleotides directed
 CC against other antiapoptotic genes. Sequences ACF36399-406 represent
 CC antisense oligonucleotides targeted against human anti-apoptotic protein
 CC TRPM-2 (testosterone-repressed prostate message-2) gene
 XX
 SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1316 CTCGAGGAGACCCCTAAATT 1336
 |||||
 Db 21 CTCGAGGAGACCCCTAAATT 1
 RESULT 48
 ACF36406/C
 ID ACF36406 standard; DNA; 21 BP.
 XX
 AC ACF36406;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE TRPM-2 antisense oligonucleotide #12.
 XX
 KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
 KW prostate cancer; anti-apoptotic protein; antisense; ss.
 XX
 XX Synthetic.
 OS Homo sapiens.
 OS
 XX WO2003072591-A1.
 PN
 XX
 PD 04-SEP-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005305.
 PF
 XX 22-FEB-2002; 2002US-00080794.
 PR
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA
 XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
 PI WPI; 2003-689981/65.
 XX
 DR New modified antisense oligonucleotide, useful particularly for treating
 XX prostatic cancer, inhibits the testosterone-repressed prostate message-2.
 XX
 PS Example 5; Page 42; 44pp; English.
 XX
 CC The invention relates to a compound consisting of an oligonucleotide with
 CC a phosphorothioate backbone throughout, in which: (a) sugars on
 CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
 CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
 CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
 CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
 CC prostatic cancer cells to the androgen-independent state, in vivo or in
 CC vitro; (b) to treat prostatic cancer (after initially withdrawing
 CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
 CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
 CC ovarian and some breast cancer cells) that express abnormal levels of
 CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
 CC increase stability in vivo and activity (both in vivo or in vitro) and
 CC result in a synergistic increase in effect when (I) is used with
 CC chemotherapeutic agents or other antisense oligonucleotides directed
 CC against other antiapoptotic genes. Sequences ACF36399-406 represent
 CC antisense oligonucleotides targeted against human anti-apoptotic protein
 CC TRPM-2 (testosterone-repressed prostate message-2) gene
 XX

CC antisense oligonucleotides targeted against human anti-apoptotic protein
 CC TRPM-2 (testosterone-repressed prostate message-2) gene
 XX
 SQ Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;
 Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1516 AGGCCCCCAACTCCGCCAGC 1536
 |||||
 Db 21 AGGCCCCCAACTCCGCCAGC 1
 RESULT 49
 ACF36399/C
 ID ACF36399 standard; DNA; 21 BP.
 XX
 AC ACF36399;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE TRPM-2 antisense oligonucleotide #5.
 XX
 KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
 KW prostate cancer; anti-apoptotic protein; antisense; ss.
 XX
 XX Synthetic.
 OS Homo sapiens.
 OS
 XX WO2003072591-A1.
 PN
 XX
 PD 04-SEP-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005305.
 PF
 XX 22-FEB-2002; 2002US-00080794.
 PR
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA
 XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
 PI WPI; 2003-689981/65.
 XX
 DR New modified antisense oligonucleotide, useful particularly for treating
 XX prostatic cancer, inhibits the testosterone-repressed prostate message-2.
 XX
 PS Example 5; Page 40; 44pp; English.
 XX
 CC The invention relates to a compound consisting of an oligonucleotide with
 CC a phosphorothioate backbone throughout, in which: (a) sugars on
 CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
 CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
 CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
 CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
 CC prostatic cancer cells to the androgen-independent state, in vivo or in
 CC vitro; (b) to treat prostatic cancer (after initially withdrawing
 CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
 CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
 CC ovarian and some breast cancer cells) that express abnormal levels of
 CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
 CC increase stability in vivo and activity (both in vivo or in vitro) and
 CC result in a synergistic increase in effect when (I) is used with
 CC chemotherapeutic agents or other antisense oligonucleotides directed
 CC against other antiapoptotic genes. Sequences ACF36399-406 represent
 CC antisense oligonucleotides targeted against human anti-apoptotic protein
 CC TRPM-2 (testosterone-repressed prostate message-2) gene
 XX
 SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
 Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY      114 GACCAGCGGTCTCAGACAAT 134
Db      21 GACCAGCGGTCTCAGACAAT 1

RESULT 50
ACF36402/c
ID ACF36402 standard; DNA; 21 BP.
XX
AC ACF36402;
XX
DT 18-DEC-2003 (first entry)
XX
DE TRPM-2 antisense oligonucleotide #8.
XX
TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US05305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX
DR WPI; 2003-689981/65.
XX
PT New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
PS Example 5; Page 41; 44pp; English.
XX
CC The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
CC vitro; (b) to treat prostatic cancer (after initially withdrawing
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. Sequences ACF36399-406 represent
CC antisense oligonucleotides targeted against human anti-apoptotic protein
CC TRPM-2 (testosterone-repressed prostate message-2) gene
XX
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      716 CCGCATCGTCCGACGCTTGAT 736
Db      21 CCGCATCGTCCGACGCTTGAT 1

RESULT 51
ACF36401/c
ID ACF36401 standard; DNA; 21 BP.
XX
AC ACF36401;
XX
DT 18-DEC-2003 (first entry)
XX
DE TRPM-2 antisense oligonucleotide #7.
XX
TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX
DR WPI; 2003-689981/65.
XX
PT New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
PS Example 5; Page 41; 44pp; English.
XX
CC The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
CC vitro; (b) to treat prostatic cancer (after initially withdrawing
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. Sequences ACF36399-406 represent
CC antisense oligonucleotides targeted against human anti-apoptotic protein
CC TRPM-2 (testosterone-repressed prostate message-2) gene
XX
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      515 TGACCGCATCGACTCCCTGCT 535
Db      21 TGACCGCATCGACTCCCTGCT 1

RESULT 52
ACF36398/c
ID ACF36398 standard; DNA; 21 BP.
XX
AC ACF36398;
XX
DT 18-DEC-2003 (first entry)
XX
DE TRPM-2 antisense oligonucleotide.
```

KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
 KW prostate cancer; anti-apoptotic protein; antisense; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX WO2003072591-A1.
 PN
 XX
 PD 04-SEP-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005305.
 PF
 XX 22-FEB-2002; 2002US-00080794.
 PR
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA
 XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
 PI WPI; 2003-689981/65.
 XX
 XX New modified antisense oligonucleotide, useful particularly for treating
 PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
 XX
 XX Claim 1; Page 25; 44pp; English.
 PS
 XX The invention relates to a compound consisting of an oligonucleotide with
 CC a phosphorothioate backbone throughout, in which: (a) sugars on
 CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
 CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
 CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
 CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
 CC prostatic cancer cells to the androgen-independent state, in vivo or in
 CC vitro; (b) to treat prostatic cancer (after initially withdrawing
 CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
 CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
 CC ovarian and some breast cancer cells) that express abnormal levels of
 CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
 CC increase stability in vivo and activity (both in vivo or in vitro) and
 CC result in a synergistic increase in effect when (I) is used with
 CC chemotherapeutic agents or other antisense oligonucleotides directed
 CC against other antiapoptotic genes. The present sequence represents a
 CC specific example of an anti-apoptotic protein TRPM-2 (testosterone-
 CC repressed prostate message-2) antisense oligonucleotide
 XX
 SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 48 ATGATGAAGACTCTGCTGCTG 68
 DB 21 ATGATGAAGACTCTGCTGCTG 1
 RESULT 53
 ACF36403/c
 ID ACF36403 standard; DNA; 21 BP.
 XX
 XX ACF36403;
 AC
 XX 18-DEC-2003 (first entry)
 DT
 XX TRPM-2 antisense oligonucleotide #9.
 DE
 KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
 KW prostate cancer; anti-apoptotic protein; antisense; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX WO2003072591-A1.
 PN

PD 04-SEP-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005305.
 XX
 XX 22-FEB-2002; 2002US-00080794.
 PR
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA
 XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
 PI WPI; 2003-689981/65.
 XX
 XX New modified antisense oligonucleotide, useful particularly for treating
 PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
 XX
 XX Example 5; Page 41; 44pp; English.
 PS
 XX The invention relates to a compound consisting of an oligonucleotide with
 CC a phosphorothioate backbone throughout, in which: (a) sugars on
 CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
 CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
 CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
 CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
 CC prostatic cancer cells to the androgen-independent state, in vivo or in
 CC vitro; (b) to treat prostatic cancer (after initially withdrawing
 CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
 CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
 CC ovarian and some breast cancer cells) that express abnormal levels of
 CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
 CC increase stability in vivo and activity (both in vivo or in vitro) and
 CC result in a synergistic increase in effect when (I) is used with
 CC chemotherapeutic agents or other antisense oligonucleotides directed
 CC against other antiapoptotic genes. Sequences ACF36399-406 represent
 CC antisense oligonucleotides targeted against human anti-apoptotic protein
 CC TRPM-2 (testosterone-repressed prostate message-2) gene
 XX
 SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 916 ACAACTCCACGGGCTGCTGTC 936
 DB 21 ACAACTCCACGGGCTGCTGTC 1
 RESULT 54
 ACF36404/c
 ID ACF36404 standard; DNA; 21 BP.
 XX
 XX ACF36404;
 AC
 XX 18-DEC-2003 (first entry)
 DT
 XX TRPM-2 antisense oligonucleotide #10.
 DE
 KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
 KW prostate cancer; anti-apoptotic protein; antisense; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX WO2003072591-A1.
 PN
 XX 04-SEP-2003.
 PD
 XX 20-FEB-2003; 2003WO-US005305.
 PF
 XX 22-FEB-2002; 2002US-00080794.
 PR
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA

```
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX WPI; 2003-689981/65.
DR
XX
XX New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 5; Page 41; 44pp; English.
XX
XX The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
CC vitro; (b) to treat prostatic cancer (after initially withdrawing
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. Sequences ACF36399-406 represent
CC antisense oligonucleotides targeted against human anti-apoptotic protein
CC TRPM-2 (testosterone-repressed prostate message-2) gene
XX
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
SQ

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGACGACTGAA 1135
Db 21 CTCCTTGCTGGACGACTGAA 1

RESULT 55
ACF36400/C
ID ACF36400 standard; DNA; 21 BP.
XX
XX ACF36400;
AC
XX
XX 18-DEC-2003 (first entry)
DT
XX
XX TRPM-2 antisense oligonucleotide #6.
DE
XX
XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX WO2003072591-A1.
PN
XX
XX 04-SEP-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005305.
PF
XX
XX 22-FEB-2002; 2002US-00080794.
PR
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
PI
XX WPI; 2003-689981/65.
DR
XX
XX New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 5; Page 40; 44pp; English.
PS

The invention relates to a compound consisting of an oligonucleotide with
a phosphorothioate backbone throughout, in which: (a) sugars on
nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
prostatic cancer cells to the androgen-independent state, in vivo or in
vitro; (b) to treat prostatic cancer (after initially withdrawing
androgens to induce apoptosis); and (c) to increase sensitivity of cancer
cells (prostatic, renal, non-small cell lung, urothelial transitional,
ovarian and some breast cancer cells) that express abnormal levels of
TRPM-2 to chemotherapy or radiation. The modifications present in (I)
increase stability in vivo and activity (both in vivo or in vitro) and
result in a synergistic increase in effect when (I) is used with
chemotherapeutic agents or other antisense oligonucleotides directed
against other antiapoptotic genes. Sequences ACF36399-406 represent
antisense oligonucleotides targeted against human anti-apoptotic protein
TRPM-2 (testosterone-repressed prostate message-2) gene

Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGACACAAAGCTGAAGG 336
Db 21 AATCAGACACAAAGCTGAAGG 1

RESULT 56
ADF75347
ID ADF75347 standard; DNA; 21 BP.
XX
XX ADF75347;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human RT-PCR primer to amplify an epigenetically silenced gene (SeqID27) .
DE
XX
XX human; primer; RT-PCR; PCR; ss; epigenetically silenced gene;
KW tumour suppressor; cancer; proliferative disorder; head and neck cancer;
KW oesophageal squamous cell carcinoma; ESCC; gene therapy;
KW methyltransferase inhibitor; 5aza-dC; histone deacetylase inhibitor.
XX
XX Homo sapiens.
OS
XX
XX WO2003076594-A2.
PN
XX
XX 18-SEP-2003.
PD
XX
XX 07-MAR-2003; 2003WO-US007245.
PF
XX
XX 07-MAR-2002; 2002US-0362577P.
PR
XX
XX (UYJO ) UNIV JOHNS HOPKINS.
PA
XX
XX Sidransky D;
PI
XX
XX WPI; 2003-756817/71.
DR
XX
XX Identifying at least one epigenetically silenced gene associated with
PT cancer useful for treating cancer comprises contacting an array of genome
PT with nucleic acid molecule that reactivates expression of epigenetically
PT silenced gene.
XX
XX Example 1; SEQ ID NO 27; 97pp; English.
PS
XX
XX This invention relates to novel methods of screening to identify
CC epigenetically silenced genes. Specifically, it refers to the detection
CC of epigenetically silenced tumour suppressor genes in cancer cells, which
CC are transcriptionally inactive due to aberrant methylation at normally
```


CC unmethylated CpG islands. Accordingly, these genes provide diagnostic
 CC markers for immortalised and transformed cells and hence can be used to
 CC diagnose various proliferative disorders, particularly oesophageal cancer
 CC and head and neck cancer. The present invention describes a genomic
 CC screening method to identify silenced genes in a cell suspected of a
 CC predisposition to, or exhibiting, unregulated growth. Accordingly,
 CC oligonucleotides of the genes identified herein are useful for detecting
 CC oesophageal squamous cell carcinoma (ESCC) or neck squamous cell
 CC carcinoma. Furthermore, treatment can occur via gene therapy, using a
 CC demethylation agent such as a methyltransferase inhibitor (5Aza-dC) or a
 CC histone deacetylase inhibitor to restore expression of at least one
 CC methylation silenced gene in cancer cells. This oligonucleotide sequence
 CC is an RT-PCR primer used to amplify those genes that were up-regulated as
 CC a result of treatment with a demethylation agent i.e epigenetically
 CC silenced genes of the invention.

SQ Sequence 21 BP; 6 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 ACAACCCCTCCAGGCTAAGC 1014
 DB 1 ACAACCCCTCCAGGCTAAGC 21

RESULT 57

ADP75348/c
 ID ADP75348 standard; DNA; 21 BP.

AC ADP75348;

XX 26-FEB-2004 (first entry)

DE Human RT-PCR primer to amplify an epigenetically silenced gene (SeqID28).
 XX human; primer; RT-PCR; PCR; ss; epigenetically silenced gene;
 KW tumour suppressor; cancer; proliferative disorder; head and neck cancer;
 KW oesophageal squamous cell carcinoma; ESCC; gene therapy;
 KW methyltransferase inhibitor; 5Aza-dC; histone deacetylase inhibitor.

XX Homo sapiens.

XX WO2003076594-A2.

XX 18-SEP-2003.

XX 07-MAR-2003; 2003WO-US007245.

XX 07-MAR-2002; 2002US-0362577P.

XX (UYJO) UNIV JOHNS HOPKINS.

XX Sidransky D;

XX WPI; 2003-756817/71.

PT Identifying at least one epigenetically silenced gene associated with
 PT cancer useful for treating cancer comprises contacting an array of genome
 PT with nucleic acid molecule that reactives expression of epigenetically
 PT silenced gene.

PS Example 1; SEQ ID NO 28; 97pp; English.

CC This invention relates to novel methods of screening to identify
 CC epigenetically silenced genes. Specifically, it refers to the detection
 CC of epigenetically silenced tumour suppressor genes in cancer cells, which
 CC are transcriptionally inactive due to aberrant methylation at normally
 CC unmethylated CpG islands. Accordingly, these genes provide diagnostic
 CC markers for immortalised and transformed cells and hence can be used to
 CC diagnose various proliferative disorders, particularly oesophageal cancer
 CC and head and neck cancer. The present invention describes a genomic

CC screening method to identify silenced genes in a cell suspected of a
 CC predisposition to, or exhibiting, unregulated growth. Accordingly,
 CC oligonucleotides of the genes identified herein are useful for detecting
 CC oesophageal squamous cell carcinoma (ESCC) or neck squamous cell
 CC carcinoma. Furthermore, treatment can occur via gene therapy, using a
 CC demethylation agent such as a methyltransferase inhibitor (5Aza-dC) or a
 CC histone deacetylase inhibitor to restore expression of at least one
 CC methylation silenced gene in cancer cells. This oligonucleotide sequence
 CC is an RT-PCR primer used to amplify those genes that were up-regulated as
 CC a result of treatment with a demethylation agent i.e epigenetically
 CC silenced genes of the invention.

SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1334 ATTTATGGAGACCGTGGCGGA 1354
 DB 21 ATTTATGGAGACCGTGGCGGA 1

RESULT 58

ADM83075/c

ID ADM83075 standard; DNA; 21 BP.

XX ADM83075;

XX 03-JUN-2004 (first entry)

XX Human TRPM-2 antisense oligonucleotide #10.

XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
 KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
 KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
 KW antisense; ss.

XX Homo sapiens.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..21

FT /tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

XX US2003158130-A1.

XX 21-AUG-2003.

XX 28-SEP-2001; 2001US-00967726.

XX 25-FEB-2000; 2000WO-US004875.

XX 28-SEP-2000; 2000US-0236301P.

XX 10-AUG-2001; 2001US-00913325.

XX (GLEA/) GLEAVE M.

XX (RENN/) RENNIE P S.

XX (MIYA/) MIYAKE H.

XX (NELS/) NELSON C.

XX (ZELL/) ZELLWEGER T.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX WPI; 2003-778017/73.

XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
 PT that expresses testosterone-repressed prostate message-2 (TRPM-2)
 PT comprises administering a composition that inhibits expression of TRPM-2.

XX Disclosure; SEQ ID NO 10; 14pp; English.

CC The present invention provides a method for treating cancer in which
 CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
 CC The invention is useful for enhancing the chemo-sensitivity or radiation-
 CC sensitivity of cancer cells for treating cancer such as prostate cancer,
 CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
 CC (RCC). The invention is also useful in antisense gene therapy. The
 CC present sequence is human testosterone-repressed prostate message-2 (TRPM
 CC -2) antisense oligodeoxyribonucleotide (ODN).

XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
 |||||
 Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 59

ADM83077/c

ID ADM83077 standard; DNA; 21 BP.

AC ADM83077;

XX

DT 03-JUN-2004 (first entry)

DE Human TRPM-2 antisense oligonucleotide #12.

XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
 KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
 KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
 KW antisense; ss.

OS Homo sapiens.

XX Synthetic.

XX

Key Location/Qualifiers

FT modified_base 1..21

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

FT

XX US2003158130-A1.

XX

PD 21-AUG-2003.

XX

PF 28-SEP-2001; 2001US-00967726.

XX

PR 25-FEB-2000; 2000WO-US004875.

PR 28-SEP-2000; 2000US-0236301P.

PR 10-AUG-2001; 2001US-00913325.

XX

(GLEA/) GLEAVE M.

PA (RENN/) RENNIE P S.

PA (MIYA/) MIYAKE H.

PA (NELS/) NELSON C.

PA (ZELL/) ZELLWEGER T.

XX

PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX WPI; 2003-778017/73.

XX

PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
 PT that expresses testosterone-repressed prostate message-2 (TRPM-2)
 PT comprises administering a composition that inhibits expression of TRPM-2.

XX Claim 6; SEQ ID NO 12; 14pp; English.

XX

XX The present invention provides a method for treating cancer in which
 CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
 CC The invention is useful for enhancing the chemo-sensitivity or radiation-

CC sensitivity of cancer cells for treating cancer such as prostate cancer,
 CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
 CC (RCC). The invention is also useful in antisense gene therapy. The
 CC present sequence is human testosterone-repressed prostate message-2 (TRPM
 CC -2) antisense oligodeoxyribonucleotide (ODN).

XX Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCGAGC 1536

|||||

Db 21 AGGCCCCCAACTCCGCCGAGC 1

|||||

RESULT 60

ADM83072/c

ID ADM83072 standard; DNA; 21 BP.

AC ADM83072;

XX

DT 03-JUN-2004 (first entry)

XX Human TRPM-2 antisense oligonucleotide #7.

DE Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
 KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
 KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
 KW antisense; ss.

XX Homo sapiens.

OS Synthetic.

XX

Key Location/Qualifiers

FT modified_base 1..21

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

FT

XX US2003158130-A1.

XX

PD 21-AUG-2003.

XX

PF 28-SEP-2001; 2001US-00967726.

XX

PR 25-FEB-2000; 2000WO-US004875.

PR 28-SEP-2000; 2000US-0236301P.

PR 10-AUG-2001; 2001US-00913325.

XX

(GLEA/) GLEAVE M.

PA (RENN/) RENNIE P S.

PA (MIYA/) MIYAKE H.

PA (NELS/) NELSON C.

PA (ZELL/) ZELLWEGER T.

XX

PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX WPI; 2003-778017/73.

XX

PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
 PT that expresses testosterone-repressed prostate message-2 (TRPM-2)
 PT comprises administering a composition that inhibits expression of TRPM-2.

XX Disclosure; SEQ ID NO 7; 14pp; English.

XX

CC The present invention provides a method for treating cancer in which
 CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
 CC The invention is useful for enhancing the chemo-sensitivity or radiation-

CC sensitivity of cancer cells for treating cancer such as prostate cancer,
 CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
 CC (RCC). The invention is also useful in antisense gene therapy. The

CC present sequence is human testosterone-repressed prostate message-2 (TRPM-2)
CC -2) antisense oligodeoxyribonucleotide (ODN).

XX Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGATCGACTCCTGCT 535

DB 21 TGACCGATCGACTCCTGCT 1

RESULT 61

ADM83074/c

ID ADM83074 standard; DNA; 21 BP.

XX

AC ADM83074;

XX

DT 03-JUN-2004 (first entry)

XX

DE Human TRPM-2 antisense oligonucleotide #9.

XX

KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
KW antisense; ss.

XX

OS Homo sapiens.

OS Synthetic.

XX

Key Location/Qualifiers

FT modified_base 1..21

FT /tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

XX

US2003158130-A1.

XX

PD 21-AUG-2003.

XX

PF 28-SEP-2001; 2001US-00967726.

XX

PR 25-FEB-2000; 2000WO-US004875.

PR

PR 28-SEP-2000; 2000US-0236301P.

PR

PR 10-AUG-2001; 2001US-00913325.

XX

(GLEA/) GLEAVE M.

(RENN/) RENNIE P S.

(MIYA/) MIYAKE H.

(NELS/) NELSON C.

(ZELL/) ZELLWEGER T.

XX

PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX

WPI; 2003-778017/73.

XX

PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells

PT that expresses testosterone-repressed prostate message-2 (TRPM-2)

PT comprises administering a composition that inhibits expression of TRPM-2.

XX

PS Disclosure; SEQ ID NO 9; 14pp; English.

XX

CC The present invention provides a method for treating cancer in which
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
CC The invention is useful for enhancing the chemo-sensitivity or radiation-
CC sensitivity of cancer cells for treating the cancer such as prostate cancer,
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
CC (RCC). The invention is also useful in antisense gene therapy. The
CC present sequence is human testosterone-repressed prostate message-2 (TRPM

CC -2) antisense oligodeoxyribonucleotide (ODN).

XX

XX

SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGGCTGCTGC 936

DB 21 ACAACTCCACGGGCTGCTGC 1

RESULT 62

ADM83076/c

ID ADM83076 standard; DNA; 21 BP.

XX

AC ADM83076;

XX

DT 03-JUN-2004 (first entry)

XX

DE Human TRPM-2 antisense oligonucleotide #11.

XX

KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
KW antisense; ss.

XX

OS Homo sapiens.

OS Synthetic.

XX

Key Location/Qualifiers

FT modified_base 1..21

FT /tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

XX

US2003158130-A1.

XX

PD 21-AUG-2003.

XX

PF 28-SEP-2001; 2001US-00967726.

XX

PR 25-FEB-2000; 2000WO-US004875.

PR

PR 28-SEP-2000; 2000US-0236301P.

PR

PR 10-AUG-2001; 2001US-00913325.

XX

(GLEA/) GLEAVE M.

(RENN/) RENNIE P S.

(MIYA/) MIYAKE H.

(NELS/) NELSON C.

(ZELL/) ZELLWEGER T.

XX

PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX

WPI; 2003-778017/73.

XX

PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells

PT that expresses testosterone-repressed prostate message-2 (TRPM-2)

PT comprises administering a composition that inhibits expression of TRPM-2.

XX

PS Disclosure; SEQ ID NO 11; 14pp; English.

XX

CC The present invention provides a method for treating cancer in which
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
CC The invention is useful for enhancing the chemo-sensitivity or radiation-
CC sensitivity of cancer cells for treating the cancer such as prostate cancer,
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
CC (RCC). The invention is also useful in antisense gene therapy. The
CC present sequence is human testosterone-repressed prostate message-2 (TRPM

CC -2) antisense oligodeoxyribonucleotide (ODN).

XX

XX

SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;

```
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGGAGAGACCCCTAAATT 1336
Db 21 CTCAGGAGAGACCCCTAAATT 1

RESULT 63
ADM83068/c
ID ADM83068 standard; DNA; 21 BP.
XX
AC ADM83068;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human TRPM-2 antisense oligonucleotide #3.
XX
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
US2003158130-A1.
XX
PD 21-AUG-2003.
XX
PF 28-SEP-2001; 2001US-00967726.
XX
PR 25-FEB-2000; 2000WO-US004875.
PR 28-SEP-2000; 2000US-0236301P.
PR 10-AUG-2001; 2001US-00913325.
XX
( GLEA/) GLEAVE M.
PA (RENN/) RENNIE P S.
PA (MIYA/) MIYAKE H.
PA (NELS/) NELSON C.
PA (ZELL/) ZELLWEGER T.
XX
Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;
WPI; 2003-778017/73.
XX
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
that expresses testosterone-repressed prostate message-2 (TRPM-2)
comprises administering a composition that inhibits expression of TRPM-2.
XX
PS Disclosure; SEQ ID NO 3; 14pp; English.
XX
CC The present invention provides a method for treating cancer in which
cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
The invention is useful for enhancing the chemo-sensitivity or radiation-
sensitivity of cancer cells for treating cancer such as prostate cancer,
bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
(RCC). The invention is also useful in antisense gene therapy. The
present sequence is human testosterone-repressed prostate message-2 (TRPM
-2) antisense oligodeoxyribonucleotide (ODN).
XX
SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGGAGAGACCCCTAAATT 1336
Db 21 CTCAGGAGAGACCCCTAAATT 1

RESULT 64
ADM83069/c
ID ADM83069 standard; DNA; 21 BP.
XX
AC ADM83069;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human TRPM-2 antisense oligonucleotide #4.
XX
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
US2003158130-A1.
XX
PD 21-AUG-2003.
XX
PF 28-SEP-2001; 2001US-00967726.
XX
PR 25-FEB-2000; 2000WO-US004875.
PR 28-SEP-2000; 2000US-0236301P.
PR 10-AUG-2001; 2001US-00913325.
XX
( GLEA/) GLEAVE M.
PA (RENN/) RENNIE P S.
PA (MIYA/) MIYAKE H.
PA (NELS/) NELSON C.
PA (ZELL/) ZELLWEGER T.
XX
Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;
WPI; 2003-778017/73.
XX
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
that expresses testosterone-repressed prostate message-2 (TRPM-2)
comprises administering a composition that inhibits expression of TRPM-2.
XX
PS Claim 4; SEQ ID NO 4; 14pp; English.
XX
CC The present invention provides a method for treating cancer in which
cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
The invention is useful for enhancing the chemo-sensitivity or radiation-
sensitivity of cancer cells for treating cancer such as prostate cancer,
bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
(RCC). The invention is also useful in antisense gene therapy. The
present sequence is human testosterone-repressed prostate message-2 (TRPM
-2) antisense oligodeoxyribonucleotide (ODN).
XX
SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
Db 21 ATGATGAAGACTCTGCTGCTG 1
```

```
RESULT 65
ADM83070/c
ID ADM83070 standard; DNA; 21 BP.
XX
XX
AC ADM83070;
XX
XX
DT 03-JUN-2004 (first entry)
XX
XX
DE Human TRPM-2 antisense oligonucleotide #5.
XX
XX
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
antisense; ss.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
XX
US2003158130-A1.
XX
XX
PD 21-AUG-2003.
XX
XX
PF 28-SEP-2001; 2001US-00967726.
XX
XX
PR 25-FEB-2000; 2000WO-US004875.
PR 28-SEP-2000; 2000US-0236301P.
PR 10-AUG-2001; 2001US-00913325.
XX
XX
PA (GLEA/) GLEAVE M.
PA (RENN/) RENNIE P S.
PA (MIYA/) MIYAKE H.
PA (NELS/) NELSON C.
PA (ZELL/) ZELLWEGER T.
XX
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;
WPI; 2003-778017/73.
XX
XX
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
that expresses testosterone-repressed prostate message-2 (TRPM-2).
PT comprises administering a composition that inhibits expression of TRPM-2.
XX
XX
PS Claim 5; SEQ ID NO 5; 14pp; English.
XX
XX
CC The present invention provides a method for treating cancer in which
cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
CC The invention is useful for enhancing the chemo-sensitivity or radiation-
sensitivity of cancer cells for treating cancer such as prostate cancer,
bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
(RCC). The invention is also useful in antisense gene therapy. The
present sequence is human testosterone-repressed prostate message-2 (TRPM
-2) antisense oligodeoxyribonucleotide (ODN).
XX
XX
SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 114 GACCAGACGGTCTCAGACAAAT 134
|||||
Db 21 GACCAGACGGTCTCAGACAAAT 1
|||||
```

RESULT 66

```
ADM83073/c
ID ADM83073 standard; DNA; 21 BP.
XX
XX
AC ADM83073;
XX
XX
DT 03-JUN-2004 (first entry)
XX
XX
DE Human TRPM-2 antisense oligonucleotide #8.
XX
XX
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
antisense; ss.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
XX
US2003158130-A1.
XX
XX
PD 21-AUG-2003.
XX
XX
PF 28-SEP-2001; 2001US-00967726.
XX
XX
PR 25-FEB-2000; 2000WO-US004875.
PR 28-SEP-2000; 2000US-0236301P.
PR 10-AUG-2001; 2001US-00913325.
XX
XX
PA (GLEA/) GLEAVE M.
PA (RENN/) RENNIE P S.
PA (MIYA/) MIYAKE H.
PA (NELS/) NELSON C.
PA (ZELL/) ZELLWEGER T.
XX
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;
WPI; 2003-778017/73.
XX
XX
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
that expresses testosterone-repressed prostate message-2 (TRPM-2)
PT comprises administering a composition that inhibits expression of TRPM-2.
XX
XX
PS Disclosure; SEQ ID NO 8; 14pp; English.
XX
XX
CC The present invention provides a method for treating cancer in which
cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
CC The invention is useful for enhancing the chemo-sensitivity or radiation-
sensitivity of cancer cells for treating cancer such as prostate cancer,
bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
(RCC). The invention is also useful in antisense gene therapy. The
present sequence is human testosterone-repressed prostate message-2 (TRPM
-2) antisense oligodeoxyribonucleotide (ODN).
XX
XX
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 716 CCGCATCGTCGCGCAGCTTGAT 736
|||||
Db 21 CCGCATCGTCGCGCAGCTTGAT 1
|||||
```

RESULT 67

```
ADM83071/c
ID ADM83071 standard; DNA; 21 BP.
XX
```

```
AC ADM83071;
XX
XX 03-JUN-2004 (first entry)
XX
XX Human TRPM-2 antisense oligonucleotide #6.
DE
DE
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
KW antisense; ss.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= a
FT /*mod_base= OTHER
FT /*note= "Phosphorothioate backbone"
XX
XX US2003158130-A1.
XX
XX 21-AUG-2003.
XX
XX 28-SEP-2001; 2001US-00967726.
XX
XX 25-FEB-2000; 2000WO-US004875.
XX 28-SEP-2000; 2000US-0236301P.
XX 10-AUG-2001; 2001US-00913325.
XX
XX (GLEA/) GLEAVE M.
XX (RENN/) RENNE P S.
XX (MIYA/) MIYAKE H.
XX (NELS/) NELSON C.
XX (ZELL/) ZELLWEGER T.
XX
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;
XX WPI; 2003-778017/73.
XX
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)
PT comprises administering a composition that inhibits expression of TRPM-2.
XX
XX Disclosure; SEQ ID NO 6; 14pp; English.
XX
XX The present invention provides a method for treating cancer in which
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
CC The invention is useful for enhancing the chemo-sensitivity or radiation-
CC sensitivity of cancer cells for treating cancer such as prostate cancer,
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
CC (RCC). The invention is also useful in antisense gene therapy. The
CC present sequence is human testosterone-repressed prostate message-2 (TRPM
CC -2) antisense oligodeoxyribonucleotide (ODN).
XX
XX Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 316 AATCAGACAAAGCTGAAGG 336
Db 21 AATCAGACAAAGCTGAAGG 1
|||||
RESULT 68
ADL70456
ID ADL70456 standard; RNA; 21 BP.
XX
XX AC ADL70456;
XX
XX DT 20-MAY-2004 (first entry)
```

```
XX RNAi for human clusterin.
DE
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /*mod_base= OTHER
FT /*note= "OTHER= GdT"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
XX Gonos ES;
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Claim 4; SEQ ID NO 1; 63pp; English.
XX
XX The present sequence is the sense strand of a short interfering RNA
CC (siRNA) targeted to nucleotides 487-505 of human clusterin cDNA. The
CC antisense strand is also provided ADL70457. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumor cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease.
XX
XX Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCUCCGCCUUCUACCT 21
|||||
RESULT 69
ADL70460
ID ADL70460 standard; RNA; 21 BP.
XX
XX AC ADL70460;
XX
XX DT 20-MAY-2004 (first entry)
```


XX		20-MAY-2004	(first entry)
DT			
XX		RNAi for human clusterin.	
DE			
XX		RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;	
KW		cystostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;	
KW		ss.	
XX		Homo sapiens.	
OS		Synthetic.	
OS			
XX		Key	Location/Qualifiers
FH		modified_base	20..21
FT			/tag= a
FT			/mod_base= OTHER
FT			/note= "OTHER= dTdt"
XX		WO2004018676-A2.	
PN			
XX		04-MAR-2004.	
PD			
XX		21-AUG-2003; 2003WO-CA001277.	
PF			
XX		21-AUG-2002; 2002US-0405193P.	
PR		23-SEP-2002; 2002US-0408152P.	
PR		20-MAY-2003; 2003US-0472387P.	
PR			
XX		(UYBR-) UNIV BRITISH COLUMBIA.	
PA			
XX		Jansen B, Gleave MB, Signaevsky M, Beraldi E, Trougakos IP;	
PI		Gonos ES;	
PI			
XX		WPI; 2004-226852/21.	
DR			
XX		New RNA molecule less than 49 bases and having a sequence effective to	
PT		mediate degradation or block translation of mRNA that is the	
PT		transcriptional product of a target gene, useful for treating Alzheimer's	
PT		disease or cancer.	
PT			
XX		Claim 4; SEQ ID NO 65; 63pp; English.	
PS			
XX		The present sequence is the antisense strand of a short interfering RNA	
CC		(siRNA) targeted to a specific portion ADL70518 of human clusterin cDNA.	
CC		The sense strand is also provided ADL70519. The siRNA can be used to	
CC		interfere with the expression of clusterin. Clusterin, also known as	
CC		testosterone-repressed prostate message-2 (TRPM-2) or sulfated	
CC		glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate	
CC		tumour cells following androgen withdrawal, and has also been shown to be	
CC		critical for neuritic toxicity in mouse models of Alzheimer's disease.	
CC		siRNAs of the invention can be used alone or in combination with other	
CC		chemotherapy or apoptosis inducing treatments for the treatment of	
CC		prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,	
CC		breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,	
CC		anaplastic large cell lymphoma and melanoma, and also for the treatment	
CC		of Alzheimer's disease. In an example from the invention, the present	
CC		siRNA was used to examine the effects of clusterin gene silencing in PC-3	
CC		prostate cancer cells. A reduction in clusterin transcript was observed.	
XX			
SQ		Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;	
		Query Match	1.3%; Score 21; DB 1; Length 21;
		Best Local Similarity	100.0%; Pred No. 39;
		Matches 21; Conservative	0; Mismatches 0; Indels 0; Gaps 0
Oy		1613 AACTAATTCAATAAAACTGTC 1633	
Dd		21 AACTAATTCAATAAAACTGTC 1	
		RESULT 73	
		ADL70461/c	
ID		ADL70461 standard; RNA; 21 BP.	


```
XX AC ADL70461;
XX DT 20-MAY-2004 (first entry)
XX DE RNAi for human clusterin.
XX KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX KW cytosolic; neuroprotective; nontoxic; gene silencing; DNA-RNA hybrid;
XX KW ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 20..21
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= dtGt"
XX PN WO2004018676-A2.
XX PD 04-MAR-2004.
XX PF 21-AUG-2003; 2003WO-CA001277.
XX PR 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;
XX PI Gonos ES;
XX XX WPI; 2004-226852/21.
XX XX New RNA molecule less than 49 bases and having a sequence effective to
XX PT mediate degradation or block translation of mRNA that is the
XX PT transcriptional product of a target gene, useful for treating Alzheimer's
XX PT disease or cancer.
XX PS Claim 4; SEQ ID NO 6; 63pp; English.
XX CC The present sequence is the antisense strand of a short interfering RNA
XX CC (siRNA) targeted to nucleotides 1620-1638 of human clusterin cDNA. The
XX CC sense strand is also provided ADL70460. The siRNA can be used to
XX CC interfere with the expression of clusterin. Clusterin, also known as
XX CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
XX CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
XX CC tumour cells following androgen withdrawal, and has also been shown to be
XX CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
XX CC siRNAs of the invention can be used alone or in combination with other
XX CC chemotherapy or apoptosis inducing treatments for the treatment of
XX CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
XX CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
XX CC anaplastic large cell lymphoma and melanoma, and also for the treatment
XX CC of Alzheimer's disease.
XX SQ Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1613 AACTAATTCATAAACTGTC 1633
|||||
Db 21 AACTAATTCATAAACTGTC 1
|||||
RESULT 74
ADL70519
ID ADL70519 standard; RNA; 21 BP.
```

```
XX AC ADL70519;
XX DT 20-MAY-2004 (first entry)
XX DE RNAi for human clusterin.
XX KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX KW cytosolic; neuroprotective; nontoxic; gene silencing; DNA-RNA hybrid;
XX KW ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 20..21
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= dtGt"
XX PN WO2004018676-A2.
XX PD 04-MAR-2004.
XX PF 21-AUG-2003; 2003WO-CA001277.
XX PR 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;
XX PI Gonos ES;
XX XX WPI; 2004-226852/21.
XX XX New RNA molecule less than 49 bases and having a sequence effective to
XX PT mediate degradation or block translation of mRNA that is the
XX PT transcriptional product of a target gene, useful for treating Alzheimer's
XX PT disease or cancer.
XX PS Claim 4; SEQ ID NO 64; 63pp; English.
XX CC The present sequence is the sense strand of a short interfering RNA
XX CC (siRNA) targeted to a specific portion ADL70518 of human clusterin cDNA.
XX CC The antisense strand is also provided ADL70520. The siRNA can be used to
XX CC interfere with the expression of clusterin. Clusterin, also known as
XX CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
XX CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
XX CC tumour cells following androgen withdrawal, and has also been shown to be
XX CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
XX CC siRNAs of the invention can be used alone or in combination with other
XX CC chemotherapy or apoptosis inducing treatments for the treatment of
XX CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
XX CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
XX CC anaplastic large cell lymphoma and melanoma, and also for the treatment
XX CC of Alzheimer's disease. In an example from the invention, the present
XX CC siRNA was used to examine the effects of clusterin gene silencing in PC-3
XX CC prostate cancer cells. A reduction in clusterin transcript was observed.
XX SQ Sequence 21 BP; 8 A; 4 C; 1 G; 2 T; 6 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 39;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1615 CTAATTCATAAACTGCTT 1635
|||||
Db 1 CUAUUCAAUAAACUGUCTT 21
|||||
RESULT 75
```

```
ADL70517/C
ID ADL70517 standard; RNA; 21 BP.
XX
AC ADL70517;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 20..21 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dtdt"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Claim 4; SEQ ID NO 62; 63pp; English.
XX
XX The present sequence is the antisense strand of a short interfering RNA
CC (siRNA) targeted to a specific portion ADL70515 of human clusterin cDNA.
CC The sense strand is also provided ADL70516. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease. In an example from the invention, the present
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC prostate cancer cells. A reduction in clusterin transcript was observed.
XX
XX Sequence 21 BP; 3 A; 5 C; 9 G; 2 T; 2 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 711 AAGTCCCGCATCGTCGCGAGC 731
DB 21 AAGTCCCGCATCGTCGCGAGC 1
```

```
RESULT 76
ADL70516
ID ADL70516 standard; RNA; 21 BP.
XX
AC ADL70516;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosstatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 20..21 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dtdt"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Claim 4; SEQ ID NO 61; 63pp; English.
XX
XX The present sequence is the sense strand of a short interfering RNA
CC (siRNA) targeted to a specific portion ADL70515 of human clusterin cDNA.
CC The antisense strand is also provided ADL70517. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease. In an example from the invention, the present
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC prostate cancer cells. A reduction in clusterin transcript was observed.
XX
XX Sequence 21 BP; 2 A; 9 C; 5 G; 2 T; 3 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 39;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
OY 713 GTCCCGCATCGTCGCGAGCTT 733
|:|||||:|:|||||
```

```
Db 1 GUCCCGCAUCGCGCAGCTT 21
RESULT 77
ADL70457/c
ID ADL70457 standard; RNA; 21 BP.
XX
AC ADL70457;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dtdt"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX
XX 03-SEP-2002; 2002US-0408152P.
XX
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
XX Gonos ES;
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
XX mediate degradation or block translation of mRNA that is the
XX transcriptional product of a target gene, useful for treating Alzheimer's
XX disease or cancer.
XX
XX Claim 4; SEQ ID NO 2; 63pp; English.
XX
XX The present sequence is the antisense strand of a short interfering RNA
XX (siRNA) targeted to nucleotides 487-505 of human clusterin cDNA. The
XX sense strand is also provided ADL70456. The siRNA can be used to
XX interfere with the expression of clusterin. Clusterin, also known as
XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
XX tumour cells following androgen withdrawal, and has also been shown to be
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.
XX siRNAs of the invention can be used alone or in combination with other
XX chemotherapy or apoptosis inducing treatments for the treatment of
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
XX anaplastic large cell lymphoma and melanoma, and also for the treatment
XX of Alzheimer's disease.
XX
XX Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;
XX
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 480 AACGAGCTCGCCCTTCTAC 500
|||||

Db 21 AACGAGCTCGCCCTTCTAC 1
RESULT 78
ADL70459/c
ID ADL70459 standard; RNA; 21 BP.
XX
AC ADL70459;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dtdt"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX
XX 03-SEP-2002; 2002US-0408152P.
XX
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
XX Gonos ES;
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
XX mediate degradation or block translation of mRNA that is the
XX transcriptional product of a target gene, useful for treating Alzheimer's
XX disease or cancer.
XX
XX Claim 4; SEQ ID NO 4; 63pp; English.
XX
XX The present sequence is the antisense strand of a short interfering RNA
XX (siRNA) targeted to nucleotides 1105-1123 of human clusterin cDNA. The
XX sense strand is also provided ADL70458. The siRNA can be used to
XX interfere with the expression of clusterin. Clusterin, also known as
XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
XX tumour cells following androgen withdrawal, and has also been shown to be
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.
XX siRNAs of the invention can be used alone or in combination with other
XX chemotherapy or apoptosis inducing treatments for the treatment of
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
XX anaplastic large cell lymphoma and melanoma, and also for the treatment
XX of Alzheimer's disease.
XX
XX Sequence 21 BP; 4 A; 2 C; 9 G; 2 T; 4 U; 0 Other;
XX
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1098 AAGATGCTCAGACCTCTCC 1118
|||||
```

Db 21 AAGATGCTCAACACCTCTCC 1

RESULT 79
ADL70514/c
ID ADL70514 standard; RNA; 21 BP.
XX
AC ADL70514;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dtdt"
XX
PN W02004018676-A2.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001277.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
PI WPI; 2004-226852/21.
XX
DR New RNA molecule less than 49 bases and having a sequence effective to
XX mediate degradation or block translation of mRNA that is the
XX transcriptional product of a target gene, useful for treating Alzheimer's
XX disease or cancer.
XX
PS Claim 4; SEQ ID NO 59; 63pp; English.
XX
CC The present sequence is the antisense strand of a short interfering RNA
CC (siRNA) targeted to a specific portion ADL70512 of human clusterin cDNA.
CC The sense strand is also provided ADL70513. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapeutic or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease. In an example from the invention, the present
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC prostate cancer cells. A reduction in clusterin transcript was observed.
XX
SQ Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACACAGCTCGCCCTTCTAC 500
Db 21 AACACAGCTCGCCCTTCTAC 1

RESULT 80
ADL70410/c
ID ADL70410 standard; DNA; 21 BP.
XX
AC ADL70410;
XX
DT 20-MAY-2004 (first entry)
XX
DE Antisense oligonucleotide to human clusterin.
XX
KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
XX
PN W02004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
PI WPI; 2004-226851/21.
XX
DR Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX
PS Claim 6; SEQ ID NO 8; 32pp; English.
XX
CC The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor

```
CC of apoptosis.
XX SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGCGAGTTGAT 736
DB 21 CCGCATCGTCCGCGAGTTGAT 1

RESULT 81
ADL70440
ID ADL70440 standard; RNA; 21 BP.
XX AC ADL70440;
XX DT 20-MAY-2004 (first entry)
XX DE RNAi for human clusterin.
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
XX KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 20..21
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= TT"
XX PN WO2004018675-A1.
XX PD 04-MAR-2004.
XX PF 21-AUG-2003; 2003WO-CA001276.
XX PR 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
XX PT subject a therapeutic agent effective to reduce the effective amount of
XX PT clusterin in the melanoma cells.
XX PS Claim 20; SEQ ID NO 38; 32pp; English.
XX CC The present sequence is that of a short interfering RNA (siRNA) molecule
XX CC targeted to human clusterin ADL70403. The invention relates to the
XX CC treatment of melanoma through reduction in the effective amount of
XX CC clusterin. The therapeutic agent may be an antisense oligonucleotide
XX CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX CC line comprises administering an agent effective to modulate the amount of
XX CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX CC is down-regulated when the effective amount of clusterin is reduced. Such
XX CC inhibition is significant because bcl-xL is known to act as an inhibitor
XX CC of apoptosis.
XX SQ Sequence 21 BP; 2 A; 9 C; 5 G; 2 T; 3 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCGCGATCGTCCGCGAGCTT 733
DB 1 GUCCCGCAUCGUCCGCGAGCTT 21

RESULT 82
ADL70422
ID ADL70422 standard; RNA; 21 BP.
XX AC ADL70422;
XX DT 20-MAY-2004 (first entry)
XX DE RNAi for human clusterin.
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
XX KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 20..21
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= TT"
XX PN WO2004018675-A1.
XX PD 04-MAR-2004.
XX PF 21-AUG-2003; 2003WO-CA001276.
XX PR 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
XX PT subject a therapeutic agent effective to reduce the effective amount of
XX PT clusterin in the melanoma cells.
XX PS Claim 10; SEQ ID NO 20; 32pp; English.
XX CC The present sequence is that of a short interfering RNA (siRNA) molecule
XX CC targeted to human clusterin ADL70403. The invention relates to the
XX CC treatment of melanoma through reduction in the effective amount of
XX CC clusterin. The therapeutic agent may be an antisense oligonucleotide
XX CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX CC line comprises administering an agent effective to modulate the amount of
XX CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX CC is down-regulated when the effective amount of clusterin is reduced. Such
XX CC inhibition is significant because bcl-xL is known to act as an inhibitor
XX CC of apoptosis.
XX SQ Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
```

Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
|||||:|||||:|||||
Db 1 CCAGAGCUCGCCCUUUAATT 21

RESULT 83
ADL70413/c
ID ADL70413 standard; DNA; 21 BP.
XX AC ADL70413;
XX DT 20-MAY-2004 (first entry)
XX DE Antisense oligonucleotide to human clusterin.
XX KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
FT modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
XX WO2004018675-A1.
XX 04-MAR-2004.
XX 21-AUG-2003; 2003WO-CA001276.
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX Claim 6; SEQ ID NO 11; 32pp; English.
XX The present sequence is that of an antisense oligonucleotide targeted to
XX human clusterin ADL70403. The invention relates to the treatment of
XX melanoma through reduction in the effective amount of clusterin. The
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
XX The antisense oligonucleotides are complementary to a region of the
XX clusterin mRNA spanning either the translation initiation site or the
XX termination site. They may be modified to increase stability in vivo,
XX e.g. they may be employed as phosphorothioate derivatives and may have 2'
XX -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
XX regulating expression of bcl-xL in a subject or cell line comprises
XX administering an agent effective to modulate the amount of clusterin
XX expression. In clusterin-expressing cells, expression of bcl-xL is down-

CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1316 CTCGAGGAGACCTTAATT 1336
|||||:|||||:|||||
Db 21 CTCGAGGAGACCTTAATT 1

RESULT 84
ADL70408/c
ID ADL70408 standard; DNA; 21 BP.
XX AC ADL70408;
XX DT 20-MAY-2004 (first entry)
XX DE Antisense oligonucleotide to human clusterin.
XX KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
FT modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
XX WO2004018675-A1.
XX 04-MAR-2004.
XX 21-AUG-2003; 2003WO-CA001276.
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX Claim 6; SEQ ID NO 6; 32pp; English.
XX The present sequence is that of an antisense oligonucleotide targeted to
XX human clusterin ADL70403. The invention relates to the treatment of
XX melanoma through reduction in the effective amount of clusterin. The
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.

CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 316 AATCAGAGACAAAGCTGAAGG 336
DB 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 85
ADL70412/c
ID ADL70412 standard; DNA; 21 BP.
XX
AC ADL70412;
XX
DT 20-MAY-2004 (first entry)
XX
DE Antisense oligonucleotide to human clusterin.
XX
KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
FT modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
XX
PN WO2004018675-A1.

XX
XX
PD 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.

XX
PS Claim 6; SEQ ID NO 10; 32pp; English.
XX
CC The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
DB 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 86
ADL70425/c
ID ADL70425 standard; RNA; 21 BP.
XX
AC ADL70425;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
PN WO2004018675-A1.
XX
XX
PD 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of

```
PT clusterin in the melanoma cells.
XX
XX Claim 10; SEQ ID NO 23; 32pp; English.
XX
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 4 A; 2 C; 9 G; 2 T; 4 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1098 AAGATGCTCAACACCTCTCC 1118
Db 21 AAGATGCTCAACACCTCTCC 1
RESULT 87
ADL70442
ID ADL70442 standard; RNA; 21 BP.
XX
XX ADL70442;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX RNAi for human clusterin.
DE
XX
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 20..21
FT /tag= a
FT /mod_base= OTHER
FT /note= "OTHER= FT"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226951/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX
XX Claim 20; SEQ ID NO 40; 32pp; English.
PT
```

```
XX
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 8 A; 4 C; 1 G; 2 T; 6 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 39;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
Qy 1615 CTAATTCATAATAAACTGCTT 1635
Db 1 CUAUUCACAAUAAAACUGCTT 21
RESULT 88
ADL70406/c
ID ADL70406 standard; DNA; 21 BP.
XX
XX ADL70406;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Antisense oligonucleotide to human clusterin.
DE
XX
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..21
FT /tag= b
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate nucleotides"
XX
XX modified_base 1..4
XX /tag= a
XX /mod_base= OTHER
XX /note= "OTHER= 2'O-methoxyethyl modifications"
XX
XX modified_base 18..21
XX /tag= c
XX /mod_base= OTHER
XX /note= "OTHER= 2'O-methoxyethyl modifications"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226951/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
XX
```


PT subject a therapeutic agent effective to reduce the effective amount of
 XX clusterin in the melanoma cells.

PS Claim 7; SEQ ID NO 4; 32pp; English.

XX The present sequence is that of an antisense oligonucleotide targeted to
 CC human clusterin ADL70403. The invention relates to the treatment of
 CC melanoma through reduction in the effective amount of clusterin. The
 CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
 CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
 CC The antisense oligonucleotides are complementary to a region of the
 CC clusterin mRNA spanning either the translation initiation site or the
 CC termination site. They may be modified to increase stability in vivo,
 CC e.g. they may be employed as phosphorothioate derivatives and may have 2',
 CC -O-(2-methoxyethyl) (MOE) modifications in the 5' and 3' 'wings'. The
 CC present antisense oligonucleotide is particularly preferred. It is
 CC targeted to the translation initiation codon and next 6 codons of the
 CC human clusterin sequence. It has a phosphorothioate backbone throughout
 CC and MOE wings, the remaining nucleotides being 2'-deoxynucleotides. In an
 CC example from the invention, this antisense oligonucleotide provided a
 CC dose-dependent down-regulation of clusterin in human melanoma cells,
 CC leading to an increase in apoptotic cell death. In one melanoma cell line
 CC (6078) this alone was sufficient to lead to complete cell death. In
 CC another melanoma cell line, the surviving cells showed increased
 CC sensitivity to subsequent treatment with cisplatin. A claimed method for
 CC regulating expression of bcl-xL in a subject or cell line comprises
 CC administering an agent effective to modulate the amount of clusterin
 CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
 CC regulated when the effective amount of clusterin is reduced. Such
 CC inhibition is significant because bcl-xL is known to act as an inhibitor
 CC of apoptosis.

SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
 |||||
 DB 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 89

ADL70423/c
 ID ADL70423 standard; RNA; 21 BP.

XX AC ADL70423;

XX 20-MAY-2004 (first entry)

XX RNAi for human clusterin.

XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
 XX short interfering RNA; siRNA; DNA-RNA hybrid; ss.

XX Homo sapiens.

XX Synthetic.

XX Key Location/Qualifiers
 FH modified_base 20..21
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= TT"

XX WO2004018675-A1.

XX 04-MAR-2004.

XX 21-AUG-2003; 2003WO-CA001276.

XX 21-AUG-2002; 2002US-0405193P.

XX 03-SEP-2002; 2002US-0408152P.

PR 02-DEC-2002; 2002US-0319748P.
 XX 20-MAY-2003; 2003US-0472387P.
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 XX (GLEA/) GLEAVE M E.

XX Jansen B;

XX WPI; 2004-226851/21.

XX Treating melanoma in a mammalian subject comprises administering to the
 PT subject a therapeutic agent effective to reduce the effective amount of
 PT clusterin in the melanoma cells.

XX Claim 10; SEQ ID NO 21; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule
 CC targeted to human clusterin ADL70403. The invention relates to the
 CC treatment of melanoma through reduction in the effective amount of
 CC clusterin. The therapeutic agent may be an antisense oligonucleotide
 CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
 CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
 CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
 CC line comprises administering an agent effective to modulate the amount of
 CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
 CC is down-regulated when the effective amount of clusterin is reduced. Such
 CC inhibition is significant because bcl-xL is known to act as an inhibitor
 CC of apoptosis.

XX Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGAGCTCGCCCTTCTAC 500
 |||||
 DB 21 AACGAGAGCTCGCCCTTCTAC 1

RESULT 90

ADL70441/c

ID ADL70441 standard; RNA; 21 BP.

XX AC ADL70441;

XX 20-MAY-2004 (first entry)

XX RNAi for human clusterin.

XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
 XX short interfering RNA; siRNA; DNA-RNA hybrid; ss.

XX Homo sapiens.

XX Synthetic.

XX Key Location/Qualifiers
 FH modified_base 20..21
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= TT"

XX WO2004018675-A1.

XX 04-MAR-2004.

XX 21-AUG-2003; 2003WO-CA001276.

XX 21-AUG-2002; 2002US-0405193P.

XX 03-SEP-2002; 2002US-0408152P.

XX 02-DEC-2002; 2002US-0319748P.

XX 20-MAY-2003; 2003US-0472387P.

PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX Claim 20; SEQ ID NO 39; 32pp; English.
XX The present sequence is that of a short interfering RNA (siRNA) molecule
XX targeted to human clusterin ADL70403. The invention relates to the
XX treatment of melanoma through reduction in the effective amount of
XX clusterin. The therapeutic agent may be an antisense oligonucleotide
XX ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX line comprises administering an agent effective to modulate the amount of
XX clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX is down-regulated when the effective amount of clusterin is reduced. Such
XX inhibition is significant because bcl-xL is known to act as an inhibitor
XX of apoptosis.
XX Sequence 21 BP; 3 A; 5 C; 9 G; 2 T; 2 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 711 AAGTCCCGCATCGTCGCAGC 731
DB 21 AAGTCCCGCATCGTCGCAGC 1
RESULT 91
ADL70443/c
ID ADL70443 standard; RNA; 21 BP.
XX AC ADL70443;
XX 20-MAY-2004 (first entry)
XX RNAi for human clusterin.
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= IT"
XX WO2004018675-A1.
XX 04-MAR-2004.
XX 21-AUG-2003; 2003WO-CA001276.
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.

PI Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX Claim 20; SEQ ID NO 41; 32pp; English.
XX The present sequence is that of a short interfering RNA (siRNA) molecule
XX targeted to human clusterin ADL70403. The invention relates to the
XX treatment of melanoma through reduction in the effective amount of
XX clusterin. The therapeutic agent may be an antisense oligonucleotide
XX ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX line comprises administering an agent effective to modulate the amount of
XX clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX is down-regulated when the effective amount of clusterin is reduced. Such
XX inhibition is significant because bcl-xL is known to act as an inhibitor
XX of apoptosis.
XX Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1613 AACTAATTCAATAAACTGTC 1633
DB 21 AACTAATTCAATAAACTGTC 1
RESULT 92
ADL70411/c
ID ADL70411 standard; DNA; 21 BP.
XX AC ADL70411;
XX 20-MAY-2004 (first entry)
XX Antisense oligonucleotide to human clusterin.
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
XX modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
XX modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
XX WO2004018675-A1.
XX 04-MAR-2004.
XX 21-AUG-2003; 2003WO-CA001276.
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.

```
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI Jansen B;
XX XX WPI; 2004-226851/21.
XX DR
XX XX
XX PT Treating melanoma in a mammalian subject comprises administering to the
XX PT subject a therapeutic agent effective to reduce the effective amount of
XX PT clusterin in the melanoma cells.
XX XX
XX PS Claim 6; SEQ ID NO 9; 32pp; English.
XX XX
XX CC The present sequence is that of an antisense oligonucleotide targeted to
XX CC human clusterin ADL70403. The invention relates to the treatment of
XX CC melanoma through reduction in the effective amount of clusterin. The
XX CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
XX CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
XX CC The antisense oligonucleotides are complementary to a region of the
XX CC clusterin mRNA spanning either the translation initiation site or the
XX CC termination site. They may be modified to increase stability in vivo,
XX CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
XX CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
XX CC regulating expression of bcl-xL in a subject or cell line comprises
XX CC administering an agent effective to modulate the amount of clusterin
XX CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
XX CC regulated when the effective amount of clusterin is reduced. Such
XX CC inhibition is significant because bcl-xL is known to act as an inhibitor
XX CC of apoptosis.
XX SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGCTGCCTGC 936
Db 21 ACAACTCCACGGCTGCCTGC 1

RESULT 93
ADL70439/c
ID ADL70439 standard; RNA; 21 BP.
XX AC
XX ADL70439;
XX DT
XX DE
XX DE RNAi for human clusterin.
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
XX KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 20..21
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= TT"
XX PN WO2004018675-A1.
XX PD
XX PD 04-MAR-2004.
XX XX
XX XX 21-AUG-2003; 2003WO-CA001276.
XX PF
XX PF 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
```

```
PR 20-MAY-2003; 2003US-0472387P.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX XX
XX PI Jansen B;
XX XX
XX DR WPI; 2004-226851/21.
XX XX
XX PT Treating melanoma in a mammalian subject comprises administering to the
XX PT subject a therapeutic agent effective to reduce the effective amount of
XX PT clusterin in the melanoma cells.
XX XX
XX PS Claim 20; SEQ ID NO 37; 32pp; English.
XX XX
XX CC The present sequence is that of a short interfering RNA (siRNA) molecule
XX CC targeted to human clusterin ADL70403. The invention relates to the
XX CC treatment of melanoma through reduction in the effective amount of
XX CC clusterin. The therapeutic agent may be an antisense oligonucleotide
XX CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX CC line comprises administering an agent effective to modulate the amount of
XX CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX CC is down-regulated when the effective amount of clusterin is reduced. Such
XX CC inhibition is significant because bcl-xL is known to act as an inhibitor
XX CC of apoptosis.
XX SQ Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 RACCAGAGCTCGCCCTCTCTAC 500
Db 21 RACCAGAGCTCGCCCTCTCTAC 1

RESULT 94
ADL70438
ID ADL70438 standard; RNA; 21 BP.
XX AC
XX ADL70438;
XX DT
XX DT 20-MAY-2004 (first entry)
XX DE
XX DE RNAi for human clusterin.
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
XX KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 20..21
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= TT"
XX PN WO2004018675-A1.
XX PD
XX PD 04-MAR-2004.
XX XX
XX XX 21-AUG-2003; 2003WO-CA001276.
XX PF
XX PF 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
```

PA (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 20; SEQ ID NO 36; 32pp; English.
XX
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
DB 1 CCAGAGCGCCCUUUAUCTT 21

RESULT 95
ADL70414/c
ID ADL70414 standard; DNA; 21 BP.
XX
XX ADL70414;
XX
XX 20-MAY-2004 (first entry)
XX
XX Antisense oligonucleotide to human clusterin.
XX
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
FT modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
XX
PN WO2004018675-A1.
XX
XX 04-WAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX
XX 03-SEP-2002; 2002US-0408152P.

PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYER-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 6; SEQ ID NO 12; 32pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCGGCCAGC 1536
DB 21 AGGCCCCCAACTCGGCCAGC 1

RESULT 96
ADL70409/c
ID ADL70409 standard; DNA; 21 BP.
XX
XX ADL70409;
XX
XX 20-MAY-2004 (first entry)
XX
XX Antisense oligonucleotide to human clusterin.
XX
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
FT modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
XX

```
PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
XX
PR 03-SEP-2002; 2002US-0408152P.
XX
PR 02-DEC-2002; 2002US-0319748P.
XX
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
PI WPI; 2004-226851/21.
XX
DR
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 6; SEQ ID NO 7; 32pp; English.
XX
CC The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 515 TGACCGCATCGACTCCCTGCT 535
DB 21 TGACCGCATCGACTCCCTGCT 1
RESULT 97
ADL70427/c
ID ADL70427 standard; RNA; 21 BP.
XX
AC ADL70427;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
FT FT

PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
XX
PR 03-SEP-2002; 2002US-0408152P.
XX
PR 02-DEC-2002; 2002US-0319748P.
XX
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
PI WPI; 2004-226851/21.
XX
DR
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 10; SEQ ID NO 25; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1613 AACTAATTCAATAAACTGTC 1633
DB 21 AACTAATTCAATAAACTGTC 1
RESULT 98
ADL70405/c
ID ADL70405 standard; DNA; 21 BP.
XX
AC ADL70405;
XX
DT 20-MAY-2004 (first entry)
XX
DE Antisense oligonucleotide to human clusterin.
XX
KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..21
FT /tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
FT FT
```

```

FT modified_base 18..21      /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX
XX Claim 6; SEQ ID NO 3; 32pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
XX human clusterin ADL70403. The invention relates to the treatment of
XX melanoma through reduction in the effective amount of clusterin. The
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
XX The antisense oligonucleotides are complementary to a region of the
XX clusterin mRNA spanning either the translation initiation site or the
XX termination site. They may be modified to increase stability in vivo,
XX e.g. they may be employed as phosphorothioate derivatives and may have 2'
XX -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
XX regulating expression of bcl-xL in a subject or cell line comprises
XX administering an agent effective to modulate the amount of clusterin
XX expression. In clusterin-expressing cells, expression of bcl-xL is down-
XX regulated when the effective amount of clusterin is reduced. Such
XX inhibition is significant because bcl-xL is known to act as an inhibitor
XX of apoptosis.
XX
XX Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 39;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 16 CCGAGGCGTGCAGAGACTCCA 16
XX |||||
XX 21 CCGAGGCGTGCAGAGACTCCA 1
XX
XX RESULT 99
XX ADL70407/c
XX ID ADL70407 standard; DNA; 21 BP.
XX
XX AC ADL70407;
XX
XX 20-MAY-2004 (first entry)
XX
XX Antisense oligonucleotide to human clusterin.
XX
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers

```

```

FT modified_base 1..21      /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
XX
XX modified_base 1..4
XX /tag= a
XX /mod_base= OTHER
XX /note= "OTHER= optional 2'O-methoxyethyl modifications"
XX
XX modified_base 18..21
XX /tag= c
XX /mod_base= OTHER
XX /note= "OTHER= optional 2'O-methoxyethyl modifications"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX
XX Claim 6; SEQ ID NO 5; 32pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
XX human clusterin ADL70403. The invention relates to the treatment of
XX melanoma through reduction in the effective amount of clusterin. The
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
XX The antisense oligonucleotides are complementary to a region of the
XX clusterin mRNA spanning either the translation initiation site or the
XX termination site. They may be modified to increase stability in vivo,
XX e.g. they may be employed as phosphorothioate derivatives and may have 2'
XX -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
XX regulating expression of bcl-xL in a subject or cell line comprises
XX administering an agent effective to modulate the amount of clusterin
XX expression. In clusterin-expressing cells, expression of bcl-xL is down-
XX regulated when the effective amount of clusterin is reduced. Such
XX inhibition is significant because bcl-xL is known to act as an inhibitor
XX of apoptosis.
XX
XX Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.3%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 39;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 114 GACCAGACGGTCTCAGACAAT 134
XX |||||
XX 21 GACCAGACGGTCTCAGACAAT 1
XX
XX RESULT 100
XX ADL70424
XX ID ADL70424 standard; RNA; 21 BP.
XX
XX AC ADL70424;
XX
XX 20-MAY-2004 (first entry)
XX
XX

```

DE RNAi for human clusterin.
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
PA
XX Jansen B;
XX
XX WPI; 2004-226851/21.
DR
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 10; SEQ ID NO 22; 32pp; English.
XX
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 4 A; 9 C; 2 G; 2 T; 4 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1100 GATGCTCAACACCTCTCTCTT 1120
Db 1 GAUGGCUCAACACCCUCCUCTT 21
RESULT 101
AAA66325
ID AAA66325 standard; DNA; 24 BP.
XX
XX AAA66325;
XX
XX 09-OCT-2000 (first entry)
DT
XX Dog genomic marker oligonucleotide sequence SEQ ID NO:187.
DE
XX Dog; genome; genomic marker; radiation hybrid map; identification;
KW

KW chromosome location; gene marker; polymorphic microsatellite marker;
KW phenotype; behaviour; pedigree; ss.
XX Canis familiaris.
OS
PN WO200029615-A2.
XX
XX 25-MAY-2000.
XX
XX 15-NOV-1999; 99WO-IB001907.
PF
XX 13-NOV-1998; 98US-0108193P.
PR
XX (CNRS) CNRS CENT NAT RECH SCI.
PA
XX Galibert F, Andre C;
XX
XX WPI; 2000-387821/33.
DR
XX New radiation hybrid map of the dog, Canine familiaris, genome, useful
PT for e.g. identifying genes implicated in phenotypic and behavioral traits
PT or in genetic diseases and for studying dog pedigrees.
XX
XX Claim 1; Page 61; 87pp; English.
XX
XX The present invention describes a radiation hybrid map of the dog (Canine
CC familiaris) genome comprising the genome location of a marker selected
CC from AA66139 to AA66942. The radiation hybrid map is useful for
CC identifying and localising dog genes, since it covers approximately 80 %
CC of the dog genome and provides a dense map integrating different types
CC (i.e. Type I and Type II) of markers. The map and the dog genome markers
CC (or complementary sequences) are especially useful to identify genes
CC responsible for phenotypic and behavioural traits in dogs, to identify
CC morbid genes, to analyse diseases and identify implicated genes in such
CC diseases and their alleles, and to study dog pedigrees. They may also be
CC useful for isolating corresponding human gene sequences e.g. genes
CC involved in genetic diseases
XX
XX Sequence 24 BP; 5 A; 8 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 67;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1467 CCCCCAGAGAGAGCTGCGACGTC 1490
Db 1 CCCCTAGAGAGAGCTGCGATGTC 24
RESULT 102
ABN99680/C
ID ABN99680 standard; DNA; 20 BP.
XX
XX AC ABN99680;
XX
XX 16-AUG-2002 (first entry)
DT
XX Human clusterin inhibiting antisense oligonucleotide 14.
DE
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
OS
XX WO200222635-A1.
PN
XX 21-MAR-2002.
PD
XX 10-SEP-2001; 2001WO-US028235.
PF
XX 11-SEP-2000; 2000US-00659791.
PR

XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 83; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
SQ Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 324 ACAAGCTGAAGAGCTCCC 343
Db 20 ACAAGCTGAAGAGCTCCC 1
RESULT 103
ID ABN99682/c
AC ABN99682;
XX 16-AUG-2002 (first entry)
XX Human clusterin inhibiting antisense oligonucleotide 16.
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX Homo sapiens.
XX WO200222635-A1.
XX 21-MAR-2002.
XX 10-SEP-2001; 2001WO-US028235.
XX 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 83; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of

CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 364 TGATGGCCCTCTGGGAAGAG 383
Db 20 TGATGGCCCTCTGGGAAGAG 1
RESULT 104
ID ABN99684/c
AC ABN99684 standard; DNA; 20 BP.
XX AC ABN99684;
XX 16-AUG-2002 (first entry)
XX Human clusterin inhibiting antisense oligonucleotide 18.
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX Homo sapiens.
XX WO200222635-A1.
XX 21-MAR-2002.
XX 10-SEP-2001; 2001WO-US028235.
XX 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 83; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 84; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 8 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 967 AGATCTTCTCTGGACTGT 986
DB 20 AGATCTTCTCTGGACTGT 1
|||||
RESULT 108
ABN99718/c
ID ABN99718 standard; DNA; 20 BP.
XX
AC ABN99718;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 52.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX

PS Claim 3; Page 84; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;
SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1148 CTGGGTGTCCCGGTGGCAA 1167
DB 20 CTGGGTGTCCCGGTGGCAA 1
|||||
RESULT 109
ABN99677/c
ID ABN99677 standard; DNA; 20 BP.
XX
AC ABN99677;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 11.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;
SQ

XX PD 21-MAR-2002.
 XX PF 10-SEP-2001; 2001WO-US028235.
 XX PR 11-SEP-2000; 2000US-00659791.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Monia BP, Freier SM;
 XX WPI; 2002-404805/43.
 XX DR Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX Sequence 20 BP; 2 A; 7 C; 2 G; 9 T; 0 U; 0 Other;
 PS Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX Sequence 20 BP; 2 A; 7 C; 2 G; 9 T; 0 U; 0 Other;
 SQ Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 201 GGGGTGAACACAGATAAAGAC 220
 DB 20 GGGGTGAACACAGATAAAGAC 1
 RESULT 113
 ABN99695/c
 ID ABN99695 standard; DNA; 20 BP.
 AC ABN99695;
 XX 16-AUG-2002 (first entry)
 DT Human clusterin inhibiting antisense oligonucleotide 29.
 DE Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX Homo sapiens.
 OS WO200222635-A1.
 PN 21-MAR-2002.
 PD 10-SEP-2001; 2001WO-US028235.
 PF 11-SEP-2000; 2000US-00659791.
 XX (ISIS-) ISIS PHARM INC.
 PA Monia BP, Freier SM;
 PI WPI; 2002-404805/43.
 XX Novel antisense compound targeted to nucleic acid molecule encoding

PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
 SQ Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 567 GATGTCATGCAGGACCACCTT 586
 DB 20 GATGTCATGCAGGACCACCTT 1
 RESULT 114
 ABN99697/c
 ID ABN99697 standard; DNA; 20 BP.
 AC ABN99697;
 XX 16-AUG-2002 (first entry)
 DT Human clusterin inhibiting antisense oligonucleotide 31.
 DE Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX Homo sapiens.
 OS WO200222635-A1.
 PN 21-MAR-2002.
 PD 10-SEP-2001; 2001WO-US028235.
 PF 11-SEP-2000; 2000US-00659791.
 XX (ISIS-) ISIS PHARM INC.
 PA Monia BP, Freier SM;
 PI WPI; 2002-404805/43.
 XX Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

```
CC and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 608 AGACGAGCTCTTCCAGGACA 627
DB 20 AGACGAGCTCTTCCAGGACA 1

RESULT 115
ABN99701/c
ID ABN99701 standard; DNA; 20 BP.
XX
AC ABN99701;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 35.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 7 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 775 TGTTCAGCCCTTCCTTGAG 794
DB 20 TGTTCAGCCCTTCCTTGAG 1

RESULT 116
ABN99702/c
ID ABN99702 standard; DNA; 20 BP.
XX
AC ABN99702;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 36.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GTTCAGCCCTTCCTTGAGA 795
DB 20 GTTCAGCCCTTCCTTGAGA 1

RESULT 117
ABN99704/c
ID ABN99704 standard; DNA; 20 BP.
XX
AC ABN99704;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 38.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
```


CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings

SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGATCCTGCACTCTA 1564

DB 20 GCTCTGATCCTGCACTCTA 1

RESULT 120

ABN99727/c

ID ABN99727 standard; DNA; 20 BP.

XX AC ABN99727;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 61.

XX DE Human; antisense inhibition; antisense oligonucleotide; clusterin;

XX KW hypercholesterolaemia; cardiovascular disorder; ss;

XX KW hyperproliferative disorder; hyperlipidemic disorder;

XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX PN WO200222635-A1.

XX PD 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX DR WPI; 2002-404805/43.

XX PT Novel antisense compound targeted to nucleic acid molecule encoding
XX clusterin, useful for treating animal having disease associated with
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX PS Claim 3; Page 84; 125pp; English.

XX CC The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings

SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCTGATGCACTAAT 1619

DB 20 TGCTCTGATGCACTAAT 1

RESULT 121

ABN99670/c

ID ABN99670 standard; DNA; 20 BP.

XX AC ABN99670;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 4.

XX DE Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX PN WO200222635-A1.

XX PD 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX DR WPI; 2002-404805/43.

XX PT Novel antisense compound targeted to nucleic acid molecule encoding
XX clusterin, useful for treating animal having disease associated with
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX PS Example 15; Page 83; 125pp; English.

XX CC The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCTGCTGCTGACCTGGGAGA 96

DB 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 122

ABN99683/c

ID ABN99683 standard; DNA; 20 BP.

XX AC ABN99683;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 17.

XX DE Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;

```
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
XX clusterin, useful for treating animal having disease associated with
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 45;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 380 AGAGTGTAAGCCCTGCTGA 399
XX |||||
XX 20 AGAGTGTAAGCCCTGCTGA 1
XX
XX RESULT 123
XX ABN99722/C
XX ID ABN99722 standard; DNA; 20 BP.
XX
XX AC ABN99722;
XX
XX 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 56.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX hypercholesterolaemia; cardiovascular disorder; ss;
XX hyperproliferative disorder; hyperlipidemic disorder;
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
XX clusterin, useful for treating animal having disease associated with
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 45;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 380 AGAGTGTAAGCCCTGCTGA 399
XX |||||
XX 20 AGAGTGTAAGCCCTGCTGA 1
XX
XX RESULT 124
XX ABN99667/C
XX ID ABN99667 standard; DNA; 20 BP.
XX
XX AC ABN99667;
XX
XX 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 1.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX hypercholesterolaemia; cardiovascular disorder; ss;
XX hyperproliferative disorder; hyperlipidemic disorder;
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
XX clusterin, useful for treating animal having disease associated with
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 15; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 45;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1275 TTTCAGCTCTGATCCCATCAC 1294
XX |||||
XX 20 TTTCAGCTCTGATCCCATCAC 1
XX
XX RESULT 124
XX ABN99667/C
XX ID ABN99667 standard; DNA; 20 BP.
XX
XX AC ABN99667;
XX
XX 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 1.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX hypercholesterolaemia; cardiovascular disorder; ss;
XX hyperproliferative disorder; hyperlipidemic disorder;
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
XX clusterin, useful for treating animal having disease associated with
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 15; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
XX
```


CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGCGGTGCAAGAC 32
 |||||
 DB 20 TGACCGAGCGGTGCAAGAC 1

RESULT 125
 ABN99687/C
 ID ABN99687 standard; DNA; 20 BP.

XX
 AC ABN99687;

XX DT. 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 21.

XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX PN WO200222635-A1.

XX PD 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TCGCCGCCAGCTTGAGGACT 474
 |||||
 DB 20 TCGCCGCCAGCTTGAGGACT 1

RESULT 126

ABN99712/C

XX ID ABN99712 standard; DNA; 20 BP.

XX AC ABN99712;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 46.

XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX PN WO200222635-A1.

XX PD 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 84; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTGCGCGGAGCTC 1028
 |||||
 DB 20 CTAAGCTGCGCGGAGCTC 1

RESULT 127

ABN99725/C

XX ID ABN99725 standard; DNA; 20 BP.

XX AC ABN99725;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 59.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
OS Homo sapiens.
XX WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 84; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 9 A; 7 C; 2 G; 2 T; 0 U; 0 Other;
SQ Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1398 GATGTGGATGTTGCTTTTC 1417
Db 20 GATGTGGATGTTGCTTTTC 1
RESULT 128
ABN99671/c
ID ABN99671 standard; DNA; 20 BP.
AC ABN99671;
XX 16-AUG-2002 (first entry)
XX Human clusterin inhibiting antisense oligonucleotide 5.
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
OS Homo sapiens.
XX WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX

PR 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
XX PA Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 83; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 101 GCAGGTCTCTGGGGACCAGA 120
Db 20 GCAGGTCTCTGGGGACCAGA 1
RESULT 129
ABN99678/c
ID ABN99678 standard; DNA; 20 BP.
AC ABN99678;
XX 16-AUG-2002 (first entry)
XX Human clusterin inhibiting antisense oligonucleotide 12.
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
OS Homo sapiens.
XX WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
XX PA Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 83; 125pp; English.
XX

CC The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCTTAATGAGACCGGAA 317
DB 20 CCTTAATGAGACCGGAA 1
|||||

RESULT 130
ABN99694/c
ID ABN99694 standard; DNA; 20 BP.
AC ABN99694;
XX
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 28.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX Homo sapiens.
XX
XX WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCAGGACCAC 584
DB 20 TGGATGTCATGCAGGACCAC 1
|||||

RESULT 131
ABN99700/c
ID ABN99700 standard; DNA; 20 BP.
XX
XX
AC ABN99700;
XX
XX 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 34.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Freier SM;

XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 TCGTCCGCGAGCTTGATGCC 740
DB 20 TCGTCCGCGAGCTTGATGCC 1
|||||

RESULT 132
ABN99721/c
ID ABN99721 standard; DNA; 20 BP.
XX
XX
AC ABN99721;

```
DT 16-AUG-2002 (first entry)
XX Human clusterin inhibiting antisense oligonucleotide 55.
DE
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
OS
XX WO200222635-A1.
XX
XX 21-MAR-2002.
PD
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 84; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 45;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1216 CTTCCACACTTCTGACTCG 1235
XX
XX Db 20 CTTCCACACTTCTGACTCG 1
XX
XX RESULT 133
XX ABN99669/c
XX ID ABN99669 standard; DNA; 20 BP.
XX
XX AC ABN99669;
XX
XX 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 3.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
OS
XX WO200222635-A1.
XX
XX 21-MAR-2002.
PD
```

```
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 15; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 45;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 39 ATTGGAGGCATGATGAAGAC 58
XX
XX Db 20 ATTGGAGGCATGATGAAGAC 1
XX
XX RESULT 134
XX ABN99685/c
XX ID ABN99685 standard; DNA; 20 BP.
XX
XX AC ABN99685;
XX
XX 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 19.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
OS
XX WO200222635-A1.
XX
XX 21-MAR-2002.
PD
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
```

XX
PS Claim 3; Page 83; 125pp; English.
CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 CTCAGGCGCTGGTTGGCGGCC 462
DB 20 CTCAGGCGCTGGTTGGCGGCC 1

RESULT 135
ABN99689/c
ID ABN99689 standard; DNA; 20 BP.
XX
AC ABN99689;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 23.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
DR WPI; 2002-404805/43.
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX

SQ Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCCCTTCTACTTCTGGATGAA 511
DB 20 CCCCTTCTACTTCTGGATGAA 1

RESULT 136
ABN99703/c
ID ABN99703 standard; DNA; 20 BP.
XX
AC ABN99703;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 37.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
DR WPI; 2002-404805/43.
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 783 CCCCTTCTCTTGAGATGATACA 802
DB 20 CCCCTTCTCTTGAGATGATACA 1

RESULT 137
ABN99720/c
ID ABN99720 standard; DNA; 20 BP.

```
XX AC ABN99720;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 54.
XX DE
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 84; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1194 TATCTGCGGGTACACACGGT 1213
Db 20 TATCTGCGGGTACACACGGT 1
RESULT 138
ABN99691/c
ID ABN99691 standard; DNA; 20 BP.
XX AC ABN99691;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 25.
XX DE
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX
```

```
PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 83; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 533 GCTGAGACGACCGGCAGC 552
Db 20 GCTGAGACGACCGGCAGC 1
RESULT 139
ABN99713/c
ID ABN99713 standard; DNA; 20 BP.
XX AC ABN99713;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 47.
XX DE
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX
```

PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX
PS Claim 3; Page 84; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1022 GGAGCTCGACGAATCCCTCC 1041

Db 20 GGAGCTCGACGAATCCCTCC 1

RESULT 140

ABN99724/C

ID ABN99724 standard; DNA; 20 BP.

XX

AC ABN99724;

XX 16-AUG-2002 (first entry)

DE Human clusterin inhibiting antisense oligonucleotide 58.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX Homo sapiens.

XX WO200222635-A1.

XX 21-MAR-2002.

XX 10-SEP-2001; 2001WO-US028235.

XX 11-SEP-2000; 2000US-00659791.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Freier SM;

XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 84; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the

CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1332 AAATTTATGGAGACCGTGGC 1351

Db 20 AAATTTATGGAGACCGTGGC 1

RESULT 141

ABN99690/C

ID ABN99690 standard; DNA; 20 BP.

XX

AC ABN99690;

XX 16-AUG-2002 (first entry)

DE Human clusterin inhibiting antisense oligonucleotide 24.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX Homo sapiens.

XX WO200222635-A1.

XX 21-MAR-2002.

XX 10-SEP-2001; 2001WO-US028235.

XX 11-SEP-2000; 2000US-00659791.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Freier SM;

XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 ACCGATCGACTCCCTGCTG 536

Db 20 ACCGATCGACTCCCTGCTG 1

10828394-1_1-1643.rng.s1

Tue Sep 13 10:53:20 2005

```

XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX XX
XX XX 10-SEP-2001; 2001WO-US028235.
XX XX 11-SEP-2000; 2000US-00659791.
XX PR (ISIS-) ISIS PHARM INC.
XX PA Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX DR Novel antisense compound targeted to nucleic acid molecule encoding
XX XX clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PT
XX PS Claim 3; Page 84; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 GCTGGAGCAGCTGAACGAGC 1140
Db 20 GCTGGAGCAGCTGAACGAGC 1

RESULT 144
ABN99672/c
ID ABN99672 standard; DNA; 20 BP.
XX AC ABN99672;
XX XX
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 6.
XX XX
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX XX
XX XX 10-SEP-2001; 2001WO-US028235.
XX XX 11-SEP-2000; 2000US-00659791.
XX PR (ISIS-) ISIS PHARM INC.
XX PA Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX DR Novel antisense compound targeted to nucleic acid molecule encoding
XX XX clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PT
XX PS Claim 3; Page 83; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 894 ACTGTGTCGGGAGATCCG 913
Db 20 ACTGTGTCGGGAGATCCG 1

RESULT 143
ABN99717/c
ID ABN99717 standard; DNA; 20 BP.
XX AC ABN99717;
XX XX
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 51.
XX XX
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

```


XX WPI; 2002-404805/43.
 XX Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 122 GGCTCTCAGACATGAGCTCC 141
 |||||
 Db 20 GGCTCTCAGACATGAGCTCC 1

RESULT 145
 ABN99693/c
 ID ABN99693 standard; DNA; 20 BP.
 XX
 AC ABN99693;
 XX
 DT 16-AUG-2002 (first entry)
 XX
 DE Human clusterin inhibiting antisense oligonucleotide 27.
 XX
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX
 OS Homo sapiens.
 XX
 PN WO200222635-A1.
 XX
 PD 21-MAR-2002.
 XX
 PF 10-SEP-2001; 2001WO-US028235.
 XX
 PR 11-SEP-2000; 2000US-00659791.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Freier SM;
 XX
 DR WPI; 2002-404805/43.
 XX
 PT Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 SQ

CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGACGCACATGCTGGATGTC 572
 |||||
 Db 20 AGACGCACATGCTGGATGTC 1

RESULT 146
 ABN99698/c
 ID ABN99698 standard; DNA; 20 BP.
 XX
 AC ABN99698;
 XX
 DT 16-AUG-2002 (first entry)
 XX
 DE Human clusterin inhibiting antisense oligonucleotide 32.
 XX
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX
 OS Homo sapiens.
 XX
 PN WO200222635-A1.
 XX
 PD 21-MAR-2002.
 XX
 PF 10-SEP-2001; 2001WO-US028235.
 XX
 PR 11-SEP-2000; 2000US-00659791.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Freier SM;
 XX
 DR WPI; 2002-404805/43.
 XX
 PT Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 613 AGCTTTCAGACAGGTTTC 632
 |||||

Db	20	AGCTCTTCCAGGACAGGTTTC 1	hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.
RESULT 147			
ABN99715/c			
ID	ABN99715	standard; DNA; 20 BP.	
XX	XX		
AC	ABN99715;		
XX	XX		
DT	16-AUG-2002	(first entry)	
XX	XX		
DE	Human clusterin inhibiting antisense oligonucleotide 49.		
XX	XX		
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;		
KW	hypercholesterolaemia; cardiovascular disorder; ss;		
KW	hyperproliferative disorder; hyperlipidemic disorder;		
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.		
XX	XX		
OS	Homo sapiens.		
XX	XX		
PN	WO200222635-A1.		
XX	XX		
PD	21-MAR-2002.		
XX	XX		
PF	10-SEP-2001; 2001WO-US028235.		
XX	XX		
PR	11-SEP-2000; 2000US-00659791.		
XX	XX		
PA	(ISIS-) ISIS PHARM INC.		
XX	XX		
PI	Monia BP, Freier SM;		
XX	XX		
DR	WPI; 2002-404805/43.		
XX	XX		
PT	Novel antisense compound targeted to nucleic acid molecule encoding		
PT	clusterin, useful for treating animal having disease associated with		
PT	clusterin such as hyperlipidemic disorder, cardiovascular disorder.		
XX	XX		
PS	Claim 3; Page 84; 125pp; English.		
XX	XX		
CC	The invention comprises antisense oligonucleotides that are capable of		
CC	inhibiting expression of the human clusterin gene. The antisense		
CC	oligonucleotides of the invention are useful for inhibiting the		
CC	expression of clusterin in cells. The antisense oligonucleotides are also		
CC	useful for treating an animal with a disease or condition associated with		
CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;		
CC	hyperproliferative disorders; and hyperlipidemic disorders). The present		
CC	DNA sequence represents a clusterin antisense oligonucleotide of the		
CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone		
CC	and also contains 2'-O-methoxyethyl wings		
XX	XX		
SQ	Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;		
XX	XX		
Query Match	1.2%; Score 20; DB 1; Length 20;		
Best Local Similarity	100.0%; Pred. No. 45;		
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	1091 CCAGTGAAGATGCTCAACA 1110		
Db	20 CCAGTGAAGATGCTCAACA 1		
RESULT 148			
ABN99719/c			
ID	ABN99719	standard; DNA; 20 BP.	
XX	XX		
AC	ABN99719;		
XX	XX		
DT	16-AUG-2002	(first entry)	
XX	XX		
DE	Human clusterin inhibiting antisense oligonucleotide 53.		
XX	XX		
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;		

KW	hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.	
XX	Homo sapiens.	
XX	WO200222635-A1.	
XX	21-MAR-2002.	
XX	10-SEP-2001; 2001WO-US028235.	
XX	11-SEP-2000; 2000US-00659791.	
XX	(ISIS-) ISIS PHARM INC.	
XX	Monia BP, Freier SM;	
XX	WPI; 2002-404805/43.	
XX	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.	
XX	Claim 3; Page 84; 125pp; English.	
XX	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings	
XX	Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;	
Query Match	1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity	100.0%; Pred. No. 45;	
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1182 GAAGACCAAGTACTATCTGCG 1201	
Db	20 GAAGACCAAGTACTATCTGCG 1	
RESULT 149		
ABN99728/c		
ID	ABN99728	standard; DNA; 20 BP.
XX	XX	
AC	ABN99728;	
XX	XX	
DT	16-AUG-2002	(first entry)
XX	XX	
DE	Human clusterin inhibiting antisense oligonucleotide 62.	
XX	XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;	
KW	hypercholesterolaemia; cardiovascular disorder; ss;	
KW	hyperproliferative disorder; hyperlipidemic disorder;	
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.	
XX	XX	
OS	Homo sapiens.	
XX	XX	
PN	WO200222635-A1.	
XX	XX	
PD	21-MAR-2002.	
XX	XX	
PF	10-SEP-2001; 2001WO-US028235.	
XX	XX	
PR	11-SEP-2000; 2000US-00659791.	
XX	XX	

PA (ISIS-) ISIS PHARM INC.
 XX Monia BP, Freier SM;
 PI WPI; 2002-404805/43.
 DR
 XX Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX
 PS Claim 3; Page 84; 125pp; English.
 XX
 CC The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 SQ Sequence 20 BP; 7 A; 1 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1615 CTATTTCATAAAGTGTCT 1634
 DB 20 CTATTTCATAAAGTGTCT 1
 RESULT 150
 ABN99733/c
 ID ABN99733 standard; DNA; 20 BP.
 XX
 AC ABN99733;
 XX
 DT 16-AUG-2002 (first entry)
 XX
 DE Human clusterin inhibiting antisense oligonucleotide 67.
 XX
 DE Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX
 OS Homo sapiens.
 XX
 PN WO200222635-A1.
 XX
 AC ABN99733;
 XX
 DT 16-AUG-2002 (first entry)
 XX
 DE Human clusterin inhibiting antisense oligonucleotide 67.
 XX
 DE Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX
 OS Homo sapiens.
 XX
 PN WO200222635-A1.
 XX
 PD 21-MAR-2002.
 XX
 PF 10-SEP-2001; 2001WO-US028235.
 XX
 PR 11-SEP-2000; 2000US-00659791.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Freier SM;
 XX
 WPI; 2002-404805/43.
 DR
 XX Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX
 PS Claim 3; Page 84; 125pp; English.
 XX
 CC The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 SQ Sequence 20 BP; 7 A; 1 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1615 CTATTTCATAAAGTGTCT 1634
 DB 20 CTATTTCATAAAGTGTCT 1

CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1383 CACCGGAGGAGTGAGATGT 1402
 DB 20 CACCGGAGGAGTGAGATGT 1
 RESULT 151
 ABN99673/c
 ID ABN99673 standard; DNA; 20 BP.
 XX
 AC ABN99673;
 XX
 DT 16-AUG-2002 (first entry)
 XX
 DE Human clusterin inhibiting antisense oligonucleotide 7.
 XX
 DE Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX
 OS Homo sapiens.
 XX
 PN WO200222635-A1.
 XX
 PD 21-MAR-2002.
 XX
 PF 10-SEP-2001; 2001WO-US028235.
 XX
 PR 11-SEP-2000; 2000US-00659791.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Freier SM;
 XX
 WPI; 2002-404805/43.
 DR
 XX Novel antisense compound targeted to nucleic acid molecule encoding
 PT clusterin, useful for treating animal having disease associated with
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX
 PS Claim 3; Page 83; 125pp; English.
 XX
 CC The invention comprises antisense oligonucleotides that are capable of
 CC inhibiting expression of the human clusterin gene. The antisense
 CC oligonucleotides of the invention are useful for inhibiting the
 CC expression of clusterin in cells. The antisense oligonucleotides are also
 CC useful for treating an animal with a disease or condition associated with
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present
 CC DNA sequence represents a clusterin antisense oligonucleotide of the
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
 CC and also contains 2'-O-methoxyethyl wings
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 1.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 45;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 83; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 1 A; 3 C; 9 G; 7 T; 0 U; 0 Other;
SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 848 CCAGCACCCGCCACACAGAAAT 867
DB 20 CCAGCACCCGCCACACAGAAAT 1
|||||

RESULT 155
ABN99706/C
ID ABN99706 standard; DNA; 20 BP.
XX
AC ABN99706;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 40.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
DR Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 3 A; 2 C; 7 G; 8 T; 0 U; 0 Other;
SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 ACCCGCCACACAGAAATTCATA 872
DB 20 ACCCGCCACACAGAAATTCATA 1
|||||

RESULT 156
ABN99723/C
ID ABN99723 standard; DNA; 20 BP.
XX
AC ABN99723;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 57.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
DR Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX Claim 3; Page 84; 125pp; English.
XX
PS The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ

Tue Sep 13 10:53:20 2005

10828394-1_1-1643.rng.s1

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAGTCTCC 1319
DB 20 CGGTCCCTGTAGAGTCTCC 1

RESULT 157
ABN99731/c
ID ABN99731 standard; DNA; 20 BP.
XX
AC ABN99731;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 65.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 84; 125pp; English.
XX
CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 TGGACTGTTCACCAACAAC 998
DB 20 TGGACTGTTCACCAACAAC 1

RESULT 158
ABN99699/c
ID ABN99699 standard; DNA; 20 BP.
XX
AC ABN99699;

XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 33.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 8 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 AGGCTCACTTCTTCTTCC 709
DB 20 AGGCTCACTTCTTCTTCC 1

RESULT 159
ABN99714/c
ID ABN99714 standard; DNA; 20 BP.
XX
AC ABN99714;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 48.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX

PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 84; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 AGTCTTACGATGGGAAGAT 1102
DB 20 AAGTCTTACGATGGGAAGAT 1
|||||

RESULT 160
ABN99674/C
ID ABN99674 standard; DNA; 20 BP.
XX
AC ABN99674;
XX
DT 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 8.
DE
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
XX
AC ABN99674;
XX
DT 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 8.
DE
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with

PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;
SQ

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 166 AGTACGTCAATAAGGAATT 185
DB 20 AGTACGTCAATAAGGAATT 1
|||||

RESULT 161
ABN99688/C
ID ABN99688 standard; DNA; 20 BP.
XX
AC ABN99688;
XX
DT 16-AUG-2002 (first entry)
XX
XX Human clusterin inhibiting antisense oligonucleotide 22.
DE
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
XX
AC ABN99688;
XX
DT 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 83; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX

```
XX Sequence 20 BP; 5 A; 3 C; 9 G; 3 T; 0 U; 0 Other;
SQ Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 501
DB 20 CCAGAGCTCGCCCTTCTACT 1

RESULT 162
ABN99710/c
ID ABN99710 standard; DNA; 20 BP.
XX AC ABN99710;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 44.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 84; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 GCTGCTCGCGGATGAAGAC 947
DB 20 GCTGCTCGCGGATGAAGAC 1

RESULT 163
ABN99676/c
ID ABN99676 standard; DNA; 20 BP.
XX AC ABN99676;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 26.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 83; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 GAAGAGAAAGAGATGCC 300
DB 20 GAAGAGAAAGAGATGCC 1

RESULT 164
ABN99692/c
ID ABN99692 standard; DNA; 20 BP.
XX AC ABN99692;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 26.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 83; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;
```


XX WO200222635-A1.
 XX 21-MAR-2002.
 XX 10-SEP-2001; 2001WO-US028235.
 XX 11-SEP-2000; 2000US-00659791.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Freier SM;
 XX WPI; 2002-404805/43.
 XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
 XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 XX Query Match 1.2%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 45;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 551 GCAGACGCACATGCTGGATG 570
 DB 20 GCAGACGCACATGCTGGATG 1
 RESULT 165
 ABN99707/c
 ID ABN99707 standard; DNA; 20 BP.
 XX AC ABN99707;
 XX 16-AUG-2002 (first entry)
 XX Human clusterin inhibiting antisense oligonucleotide 41.
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
 KW hypercholesterolaemia; cardiovascular disorder; ss;
 KW hyperproliferative disorder; hyperlipidemic disorder;
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
 XX Homo sapiens.
 XX WO200222635-A1.
 XX 21-MAR-2002.
 XX 10-SEP-2001; 2001WO-US028235.
 XX 11-SEP-2000; 2000US-00659791.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Freier SM;
 XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
 XX Claim 3; Page 83; 125pp; English.
 XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 XX Query Match 1.2%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 45;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 893 GACTGTGTGCGCGGAGATCC 912
 DB 20 GACTGTGTGCGCGGAGATCC 1
 RESULT 166
 ADO07105
 ID ADO07105 standard; DNA; 20 BP.
 XX AC ADO07105;
 XX 15-JUL-2004 (first entry)
 XX CLU gene forward PCR primer.
 XX Rheumatoid arthritis; osteoarthritis; microarray; molecular profiling;
 KW diagnosis; antiarthritic; CLU; PCR; primer; human; ss.
 XX Homo sapiens.
 XX WO2004035827-A2.
 XX 29-APR-2004.
 XX 20-OCT-2003; 2003WO-IB005143.
 XX 18-OCT-2002; 2002US-0419650P.
 XX (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 XX (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
 XX (COMS) COMMISSARIAT ENERGIE ATOMIQUE.
 XX Breban M, Gidrol X, Marion S, Chiocchia G;
 XX WPI; 2004-348476/32.
 XX New library of polynucleotide sequences expressed in cells from synovial tissues, useful for diagnosing and treating rheumatoid arthritis or osteoarthritis.
 XX Disclosure; SEQ ID NO 5; 71pp; English.
 XX The present invention concerns an analysis of genes differentially expressed in synovial tissues from rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Microarray technology was used to compare gene expression profiles, and sets of genes were identified based on over expression or under-expression in RA samples compared to OA samples. Results for 6 of the selected genes (GBPI, CLU, RH70, GLO1, DMS and CTSL) were verified by real-time, quantitative PCR using samples identical to

CC those used in the microarray experiments and also entirely separate
CC samples. The present sequence is that of a forward PCR primer for CLU; a
CC reverse primer is also provided ADO07106. CLU was shown to be under-
CC expressed in RA relative to OA samples. The invention provides libraries
CC and arrays of polynucleotide sequences useful for prognosticating or
CC diagnosing RA or OA. Methods are also provided for following the
CC efficiency of a treatment against RA or OA, and for screening potential
CC therapeutic agents for treating RA or OA.
XX
SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1180 GCGAGACCACTACTCTG 1199
Db 1 GCGAGACCACTACTCTG 20

RESULT 167
ADO07106/c
ID ADO07106 standard; DNA; 20 BP.
XX
AC ADO07106;
DT 15-JUL-2004 (first entry)
XX
DE CLU gene reverse PCR primer.
XX
KW Rheumatoid arthritis; osteoarthritis; microarray; molecular profiling;
KW diagnosis; antiarthritic; CLU; PCR; primer; human; ss.
XX
OS Homo sapiens.
XX
PN WO2004035827-A2.
XX
PD 29-APR-2004.
XX
PF 20-OCT-2003; 2003WO-IB005143.
XX
PR 18-OCT-2002; 2002US-0419650P.
XX
PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
PA (COMS) COMMISSARIAT ENERGIE ATOMIQUE.
XX
PI Breban M, Gidrol X, Marion S, Chiocchia G;
XX
DR WPI; 2004-348476/32.
XX
PT New library of polynucleotide sequences expressed in cells from synovial
PT tissues, useful for diagnosing and treating rheumatoid arthritis or
PT osteoarthritis.
XX
PS Disclosure; SEQ ID NO 6; 71pp; English.
XX
CC The present invention concerns an analysis of genes differentially
CC expressed in synovial tissues from rheumatoid arthritis (RA) and
CC osteoarthritis (OA) patients. Microarray technology was used to compare
CC gene expression profiles, and sets of genes were identified based on over
CC expression or under-expression in RA samples compared to OA samples.
CC Results for 6 of the selected genes (GBP1, CLU, RH70, GLO1, DMS and CTSL)
CC were verified by real-time, quantitative PCR using samples identical to
CC those used in the microarray experiments and also entirely separate
CC samples. The present sequence is that of a reverse PCR primer for CLU; a
CC forward primer is also provided ADO07105. CLU was shown to be under-
CC expressed in RA relative to OA samples. The invention provides libraries
CC and arrays of polynucleotide sequences useful for prognosticating or
CC diagnosing RA or OA. Methods are also provided for following the
CC efficiency of a treatment against RA or OA, and for screening potential
CC therapeutic agents for treating RA or OA.
XX

SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1361 GCTGCAGGAATACCGCAAAA 1380
Db 20 GCTGCAGGAATACCGCAAAA 1

RESULT 168
ADL70464
ID ADL70464 standard; RNA; 21 BP.
XX
AC ADL70464;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dtdt"
XX
PN WO2004018676-A2.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001277.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
DR WPI; 2004-226852/21.
XX
PT New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
PS Claim 4; SEQ ID NO 9; 63pp; English.
XX
CC The present sequence is the sense strand of a short interfering RNA
CC (siRNA) targeted to human clusterin. The antisense strand is also
CC provided ADL70465. The siRNA can be used to interfere with the expression
CC of clusterin. Clusterin, also known as testosterone-repressed prostate
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in
CC increased amounts by prostate tumour cells following androgen withdrawal,
CC and has also been shown to be critical for neuritic toxicity in mouse
CC models of Alzheimer's disease. siRNAs of the invention can be used alone
CC or in combination with other chemotherapy or apoptosis inducing
CC treatments for the treatment of prostate cancer, sarcomas such as
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and
CC melanoma, and also for the treatment of Alzheimer's disease.
XX
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;

XX AC ADL70444;
XX XX
DT 20-MAY-2004 (first entry)
XX DE
XX XX
XX KX RNAi for human clusterin.
XX DE
XX XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX OS
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 18..19
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX XX
XX PN WO2004018675-A1.
XX PD
XX XX
XX PF 04-MAR-2004.
XX XX
XX PF 21-AUG-2003; 2003WO-CA001276.
XX XX
XX PR 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI
XX PI Jansen B;
XX DR
XX DR WPI; 2004-226851/21.
XX XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX XX
PS Claim 20; SEQ ID NO 42; 32pp; English.
XX XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX XX
SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
XX XX
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 52;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGC 66
Db 1 AUGAUGAGACUCUGCUGC 19
RESULT 174
ADL70445/c
ID ADL70445 standard; RNA; 19 BP.
XX AC
XX ADL70445;
XX XX

DT 20-MAY-2004 (first entry)
XX XX
XX DE RNAi for human clusterin.
XX XX
XX KX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX OS
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 18..19
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX XX
XX PN WO2004018675-A1.
XX PD
XX XX
XX PF 04-MAR-2004.
XX XX
XX PF 21-AUG-2003; 2003WO-CA001276.
XX XX
XX PR 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI
XX PI Jansen B;
XX DR
XX DR WPI; 2004-226851/21.
XX XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX XX
PS Claim 20; SEQ ID NO 43; 32pp; English.
XX XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX XX
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX XX
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGC 66
Db 19 ATGATGAAGACTCTGCTGC 1
RESULT 175
ADL70465/c
ID ADL70465 standard; RNA; 21 BP.
XX AC
XX ADL70465;
XX XX
XX DT 20-MAY-2004 (first entry)
XX XX
XX DE RNAi for human clusterin.

XX	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW	cystostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KW	ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
XX	Key
FH	Location/Qualifiers
FT	modified_base
FT	20..21
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= dtdt"
XX	
XX	WQ2004018676-A2.
XX	
PD	04-MAR-2004.
XX	
XX	21-AUG-2003; 2003WO-CA001277.
XX	
PR	21-AUG-2002; 2002US-0405193P.
PR	03-SEP-2002; 2002US-0408152P.
PR	20-MAY-2003; 2003US-0472387P.
XX	
XX	(UYBR-) UNIV BRITISH COLUMBIA.
XX	
XX	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI	Gonos ES;
XX	
XX	WPI; 2004-226852/21.
DR	
XX	New RNA molecule less than 49 bases and having a sequence effective to
FT	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
XX	
XX	Claim 4; SEQ ID NO 10; 63pp; English.
PS	
XX	The present sequence is the antisense strand of a short interfering RNA
CC	(siRNA) targeted to human clusterin. The sense strand is also provided
CC	ADL70464. The siRNA can be used to interfere with the expression of
CC	clusterin. Clusterin, also known as testosterone-repressed prostate
CC	message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in
CC	increased amounts by prostate tumour cells following androgen withdrawal,
CC	and has also been shown to be critical for neuritic toxicity in mouse
CC	models of Alzheimer's disease. siRNAs of the invention can be used alone
CC	or in combination with other chemotherapy or apoptosis inducing
CC	treatments for the treatment of prostate cancer, sarcomas such as
CC	osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung
CC	cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and
CC	melanoma, and also for the treatment of Alzheimer's disease.
XX	
XX	Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;
SQ	
Query Match 1.2%; Score 19; DB 1; Length 21;	
Best Local Similarity 100.0%; Pred. No. 75;	
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	48 ATGATGAAGACTCTGCTGC 66
DB	19 ATGATGAAGACTCTGCTGC 1
RESULT 176	
ADL70431/c	
ID	ADL70431 standard; RNA; 21 BP.
XX	
AC	ADL70431;
XX	
XX	20-MAY-2004 (first entry)
XX	
XX	RNAi for human clusterin.
XX	

Db 18 CAACGAGCTGCTAAAGTC 1

RESULT 179
AAT41527
ID AAT41527 standard; DNA; 18 BP.
XX
AC AAT41527;
XX
DT 24-JUN-1997 (first entry)
XX
DE Human apolipoprotein-J gene exon 2-specific 5' PCR primer.
XX
KW Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;
KW diagnosis; ss.
XX
OS Synthetic.
XX
PN WO9632502-A1.
XX
PD 17-OCT-1996.
XX
PF 02-APR-1996; 96WO-US004510.
XX
PR 11-APR-1995; 95US-00420291.
XX
PA (UYCO) UNIV COLUMBIA NEW YORK.
XX
PI Mayeux R, Tycko B;
XX
DR WPI; 1996-477152/47.
XX
PT New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used
PT to identify patients susceptible to Alzheimer's disease or prostate
PT cancer.
XX
PS Example 1; Page 20; 62pp; English.
XX
CC AAT41527-T41541 are exon-specific PCR primers used for the amplification
CC of exons 2-8 of the human apolipoprotein-J (ApoJ) gene. The primers were
CC used in a method for detecting polymorphisms associated with an allelic
CC variation in the ApoJ gene. The oligonucleotide (OG) detects the
CC probability of a person developing Alzheimer's disease (AD), preferably
CC in patients of African or Hispanic descent. The OG also detects the
CC probability of a person developing a cognitive disorder, or a prostatic
CC carcinoma. Transgenic mammals expressing an allelic variant of an ApoJ
CC gene may be used as a prognostic and diagnostic means for studying AD,
CC and to determine the effectiveness of therapeutic drugs
XX
SQ Sequence 18 BP; 7 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 60;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 22 CGTGCAAGACTCCAGAA 39
Db 1 CGTGCAAGACTCCAGAA 18

RESULT 180
AAT39501/c
ID AAT39501 standard; DNA; 18 BP.
XX
AC AAT39501;
XX
DT 21-MAY-1997 (first entry)
XX
DE Chromosome 8p clustrin gene (CL1) specific primer (nt 2836-2854).
XX
KW Chromosome 8p; polymerase chain reaction; PCR; primer; CL1;
KW clustrin gene; human; steroidogenesis; acute regulatory protein;
KW

KW regional mapping; confirmation; hSTAR; ss.
XX
OS Synthetic.
XX
PN WO9629338-A1.
XX
PD 26-SEP-1996.
XX
PF 22-MAR-1996; 96WO-US003896.
XX
PR 23-MAR-1995; 95US-00410540.
XX
PA (REGC) UNIV CALIFORNIA.
PA (UYPE-) UNIV PENNSYLVANIA.
PI Miller WL, Lin D, Strauss JF;
XX
DR WPI; 1996-443130/44.
XX
PT Isolated human steroidogenesis acute regulatory protein gene - used for
PT detection of mutation(s) of this gene that cause congenital lipoid
PT adrenal hyperplasia.
XX
PS Example 7; Page 51; 89pp; English.
XX
CC The present sequence is a human chromosome 8p clustrin gene (CL1)
CC specific PCR primer, which was used in the confirmation of the regional
CC mapping of the human steroidogenesis acute regulatory protein (hSTAR)
XX
SQ Sequence 18 BP; 3 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 60;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1475 GAGAGCTCTGCACGTCAC 1492
Db 18 GAGAGCTCTGCACGTCAC 1

RESULT 181
ABN99657
ID ABN99657 standard; DNA; 18 BP.
XX
AC ABN99657;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clustrin PCR primer 1.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clustrin;
KW hypercholesterolaemia; cardiovascular disorder; ss; PCR; primer;
KW hyperproliferative disorder; hyperlipidemic disorder.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
DR WPI; 2002-404805/43.
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding
PT clustrin, useful for treating animal having disease associated with
PT clustrin such as hyperlipidemic disorder, cardiovascular disorder.

XX Example 13; Page 80; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of

CC inhibiting expression of the human clusterin gene. The antisense

CC oligonucleotides of the invention are useful for inhibiting the

CC expression of clusterin in cells. The antisense oligonucleotides are also

CC useful for treating an animal with a disease or condition associated with

CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

CC hyperproliferative disorders; and hyperlipidemic disorders). The present

CC DNA sequence represents a PCR primer used to amplify the human clusterin

CC gene

XX

SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.1%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 60;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTGAA 763

DB 1 TCCGTACGAGCCCTGAA 18

RESULT 192

ACF36409/C

ID ACF36409 standard; DNA; 21 BP.

XX

AC ACF36409;

XX

DT 18-DEC-2003 (first entry)

XX

DE DNA sequence of a TRPM-2 mismatch control oligonucleotide.

XX

KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;

KW prostate cancer; anti-apoptotic protein; antisense; ss.

XX

OS Synthetic.

XX

PN WO2003072591-A1.

XX

PD 04-SEP-2003.

XX

PF 20-FEB-2003; 2003WO-US005305.

XX

PR 22-FEB-2002; 2002US-00080794.

XX

PA (UYBR-) UNIV BRITISH COLUMBIA.

XX

PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;

XX

DR WPI; 2003-689981/65.

XX

PT New modified antisense oligonucleotide, useful particularly for treating

PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.

XX

PS Example 13; Page 20; 44pp; English.

XX

CC The invention relates to a compound consisting of an oligonucleotide with

CC a phosphorothioate backbone throughout, in which: (a) sugars on

CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the

CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at

CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence

CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive

CC prostatic cancer cells to the androgen-independent state, in vivo or in

CC vitro; (b) to treat prostatic cancer (after initially withdrawing

CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer

CC cells (prostatic, renal, non-small cell lung, urothelial transitional,

CC ovarian and some breast cancer cells) that express abnormal levels of

CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)

CC increase stability in vivo and activity (both in vivo or in vitro) and

CC result in a synergistic increase in effect when (I) is used with

CC chemotherapeutic agents or other antisense oligonucleotides directed

CC against other antiapoptotic genes. The present sequence represents a

CC mismatch control oligonucleotide, used in antisense assays of anti-

CC apoptotic protein TRPM-2 (testosterone-repressed prostate message-2)

XX

SQ Sequence 21 BP; 7 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.1%; Score 17.8; DB 1; Length 21;

Best Local Similarity 90.5%; Pred. No. 1.1e+02;

Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 ATGATGACAGACTCTGCTGCTG 68

DB 21 ATGATAAATACTCTGCTGCTG 1

RESULT 183

ADM83080/C

ID ADM83080 standard; DNA; 21 BP.

XX

AC ADM83080;

XX

DT 03-JUN-2004 (first entry)

XX

DE Control TRPM-2 mismatch oligonucleotide.

XX

KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;

KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;

KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; ss.

XX

OS Unidentified.

XX

PN US2003158130-A1.

XX

PD 21-AUG-2003.

XX

PF 28-SEP-2001; 2001US-00967726.

XX

PR 25-FEB-2000; 2000WO-US004875.

PR 28-SEP-2000; 2000US-0236301P.

PR 10-AUG-2001; 2001US-00913325.

XX

PA (GLEA/) GLEAVE M.

PA (RENN/) RENNIE P S.

PA (MIYA/) MIYAKE H.

PA (NELS/) NELSON C.

PA (ZELL/) ZELLWEGER T.

XX

PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX

DR WPI; 2003-778017/73.

XX

PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells

PT that expresses testosterone-repressed prostate message-2 (TRPM-2)

PT comprises administering a composition that inhibits expression of TRPM-2.

XX

PS Disclosure; SEQ ID NO 15; 14pp; English.

XX

CC The present invention provides a method for treating cancer in which

CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).

CC The invention is useful for enhancing the chemo-sensitivity or radiation-

CC sensitivity of cancer cells for treating cancer such as prostate cancer,

CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma

CC (RCC). The invention is also useful in antisense gene therapy. The

CC present sequence is control testosterone-repressed prostate message-2

CC (TRPM-2) mismatch oligonucleotide. The oligonucleotide is used in the

CC exemplification of the invention.

XX

SQ Sequence 21 BP; 7 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.1%; Score 17.8; DB 1; Length 21;

Best Local Similarity 90.5%; Pred. No. 1.1e+02;

Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 48 ATGATGAAGACTCTGCTGCTG 68
Db 21 ATGATAAATACCTCTGCTGCTG 1

RESULT 184
AAT41526
ID AAT41526 standard; DNA; 17 BP.
XX AAT41526;
AC AAT41526;
DT 24-JUN-1997 (first entry)
XX Human apolipoprotein-J gene J3-allelic variant primer/probe.
DE Human apolipoprotein-J gene J3-allelic variant primer/probe.
XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;
KW diagnosis; ss.
XX Synthetic.
OS Synthetic.
XX WO9632502-A1.
PN WO9632502-A1.
XX 17-OCT-1996.
PD 17-OCT-1996.
XX 02-APR-1996; 96WO-US004510.
PF 02-APR-1996; 96WO-US004510.
XX 11-APR-1995; 95US-00420291.
PR 11-APR-1995; 95US-00420291.
XX (UYCO ) UNIV COLUMBIA NEW YORK.
PA (UYCO ) UNIV COLUMBIA NEW YORK.
XX Mayeux R, Tycko B;
PI Mayeux R, Tycko B;
XX WPI; 1996-477152/47.
DR WPI; 1996-477152/47.
XX New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used
PT to identify patients susceptible to Alzheimer's disease or prostate
PT cancer.
XX Claim 29; Page 41; 62pp; English.
PS Claim 29; Page 41; 62pp; English.
XX AAT41526 is a primer/probe used to detect a J3 allelic variation in the
CC human apolipoprotein-J (ApoJ) gene. The primer/probe is used for
CC detecting polymorphisms associated with an allelic variation in the ApoJ
CC gene. The oligonucleotide (OG) detects the probability of a person
CC developing Alzheimer's disease (AD), preferably in patients of African or
CC Hispanic descent. The OG also detects the probability of a person
CC developing a cognitive disorder, or a prostatic carcinoma. Transgenic
CC mammals expressing an allelic variant of an ApoJ gene may be used as a
CC prognostic and diagnostic means for studying AD, and to determine the
CC effectiveness of therapeutic drugs
XX Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1023 GAGCTCGACGATCCCT 1039
Db 1 GAGCTCGACGATCCCT 17

RESULT 185
AAT41542
ID AAT41542 standard; DNA; 17 BP.
XX AAT41542;
AC AAT41542;
DT 24-JUN-1997 (first entry)
XX Human apolipoprotein-J gene J1-allelic specific primer/probe.
DE Human apolipoprotein-J gene J1-allelic specific primer/probe.
XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;
KW diagnosis; ss.
XX Synthetic.
OS Synthetic.
XX WO9632502-A1.
PN WO9632502-A1.
XX 17-OCT-1996.
PD 17-OCT-1996.
XX 02-APR-1996; 96WO-US004510.
PF 02-APR-1996; 96WO-US004510.
XX 11-APR-1995; 95US-00420291.
PR 11-APR-1995; 95US-00420291.
XX (UYCO ) UNIV COLUMBIA NEW YORK.
PA (UYCO ) UNIV COLUMBIA NEW YORK.
XX Mayeux R, Tycko B;
PI Mayeux R, Tycko B;
XX WPI; 1996-477152/47.
DR WPI; 1996-477152/47.
XX New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used
PT to identify patients susceptible to Alzheimer's disease or prostate
PT cancer.
XX Claim 29; Page 41; 62pp; English.
PS Claim 29; Page 41; 62pp; English.
XX AAT41542 and AAT41543 are J1 allele-specific primer/probes used as
CC controls in an example of a method for detecting polymorphisms associated
CC with an allelic variation in the human apolipoprotein-J (ApoJ) gene. The
CC oligonucleotide (OG) detects the probability of a person developing
CC Alzheimer's disease (AD), preferably in patients of African or Hispanic
CC descent. The OG also detects the probability of a person developing a
CC cognitive disorder, or a prostatic carcinoma. Transgenic mammals
CC expressing an allelic variant of an ApoJ gene may be used as a prognostic
CC and diagnostic means for studying AD, and to determine the effectiveness
CC of therapeutic drugs
XX Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 984 TGTTCCACCAACACCC 1000
Db 1 TGTTCCACCAACACCC 17

RESULT 186
ABT34616
ID ABT34616 standard; DNA; 17 BP.
XX ABT34616;
AC ABT34616;
XX 12-JUN-2003 (first entry)
DT 12-JUN-2003 (first entry)
XX Tumour suppression related human fukutin oligo SEQ ID No 253.
DE Tumour suppression related human fukutin oligo SEQ ID No 253.
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX Homo sapiens.
OS Homo sapiens.
XX WO2003025175-A2.
PN WO2003025175-A2.
XX 27-MAR-2003.
PD 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004208.
PF 17-SEP-2002; 2002WO-IB004208.
XX 17-SEP-2001; 2001FR-00011978.
PR 17-SEP-2001; 2001FR-00011978.
XX

```

PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 DR
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 PT
 XX
 XX Disclosure; Page 63; 720pp; French.
 PS
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 1.0%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1551 GATCCTGCACCTTAACA 1567
 Db 1 GATCCTGCACCTTAACA 17
 RESULT 187
 ADB45708
 ID ADB45708 standard; DNA; 17 BP.
 AC
 AC ADB45708;
 XX
 XX 18-DEC-2003 (first entry)
 DT
 XX
 XX Tumour suppression/reversion associated nucleotide #6031.
 DE
 XX
 XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW Primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX
 XX Homo sapiens.
 OS
 XX WO2003040369-A2.
 PN
 XX
 XX 15-MAY-2003.
 PD
 XX
 XX 17-SEP-2002; 2002WO-IB004219.
 PF
 XX
 XX 17-SEP-2001; 2001FR-00011981.
 PR
 XX
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-441574/41.
 XX
 XX New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.
 PT
 XX
 XX Disclosure; Page 737; 771pp; French.
 PS
 XX
 CC The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80 % identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 1.0%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1551 GATCCTGCACCTTAACA 1567
 Db 1 GATCCTGCACCTTAACA 17
 RESULT 188
 AAQ58405/c
 ID AAQ58405 standard; DNA; 20 BP.
 XX
 AC AAQ58405;
 XX
 XX 25-MAR-2003 (revised)
 DT
 DT 04-OCT-1994 (first entry)
 XX
 XX Antisense oligonucleotide CAS-110-G-119 to HCV 5'-UTR.
 DE
 XX
 KW Hepatitis C virus; HCV; non-A, non-B hepatitis virus; NANBHV;
 KW antisense oligonucleotide; translation inhibition; therapy; 5'-UTR;
 KW 5'-untranslated region; loop C; ss.
 XX
 OS Synthetic.
 XX
 XX WO9405813-A1.
 PN
 XX
 XX 17-MAR-1994.
 PD
 XX
 XX 10-SEP-1993; 93WO-JP001293.
 PF
 XX
 XX 10-SEP-1992; 92US-00945289.
 PR
 XX 14-APR-1993; 93JP-00087195.
 PR
 XX
 XX (MOCH) MOCHIDA PHARM CO LTD.
 PA (KAGA) CEMO SERO THERAPEUTIC RES INST.
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX
 XX Anderson KP, Hanecak RC, Hoshiko K, Nozaki C, Nishihara T;

PI Nakatake H, Hamada F, Eto T, Furukawa S;
XX WPI; 1994-101217/12.
XX Anti-sense oligo:nucleotide(s) complementary to hepatitis C viral genome
PT - useful for inhibiting HCV replication, to treat related diseases.
XX
XX Example 7; Page 24; 91pp; English.
XX
XX Antisense oligonucleotides were synthesised which are complementary to
CC target sequences located at 10-nucleotide intervals from nucleotide 1 to
CC 339 in the HCV RNA 5'-untranslated region. Of these sequences (CAS-1 to
CC CAS-320), oligonucleotide CAS-110 (AAQ58403), which is complementary to a
CC portion of loop C, was found to cause greater than 80% inhibition of core
CC protein translation. The nucleotide at position 119 in loop C has a high
CC variation rate among HCV strains so oligonucleotide CAS-110-I-119 was
CC synthesised in which inosine replaced the T (corresp. to A at position
CC 119) in CAS-110. The CAS-110-I-119 showed an inhibitory activity of more
CC than 70%. A control oligonucleotide (CAS-110-G-119) showed much lower
CC activity. See AAQ58388-Q58422, AAQ44885-Q44892 and AAQ58383. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 2 A; 3 C; 14 G; 1 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1510 GCTCCAGGCCCCCACTCC 1529
Db 20 GCTCCAGGCCCCCCCCCTCC 1
RESULT 189
ADN02449/C
ID ADN02449 standard; DNA; 20 BP.
XX
XX ADN02449;
DT 17-JUN-2004 (first entry)
XX
XX Western equine encephalomyelitis virus 26S region PCR primer WEEP2.
DE
XX ss; expression vector; western equine encephalitis; WEE;
KW anti-encephalitis; Venezuelan equine encephalitis virus; encephalitis;
KW PCR; primer.
XX
XX Western equine encephalomyelitis virus.
OS
XX CA2327189-A1.
FN
XX 21-JUN-2002.
PD
XX 21-DEC-2000; 2000CA-02327189.
PF
XX 21-DEC-2000; 2000CA-02327189.
PR
XX (MIND) CANADA MIN NAT DEFENCE.
PA
XX Wong JP, Nagata LP;
PI
XX WPI; 2002-600289/65.
DR
XX A western equine encephalitis (WEE) virus strain used to develop DNA
PT vaccines to WEE virus and related alphaviruses.
PT
XX Disclosure; Page 28; 52pp; English.
PS
XX The invention relates to a novel mammalian expression vector, under which
CC expression of the structural genes of western equine encephalitis (WEE)
CC virus strain 71V-1658 have been placed under the control of a eukaryotic
CC promoter. The expression vector has anti-encephalitis activity. The
CC invention provides a means of developing a vaccine to the WEE virus which

CC is important for protection against an aerosol challenge of WEE used in
CC biological warfare. The prophylactic method of the invention is used for
CC inducing a protective immune response to eastern equine encephalitis
CC virus and Venezuelan equine encephalitis virus in a mammal. The present
CC sequence represents a WEE virus 26S region PCR primer.
XX
XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 524 CGACTCCCTGCTCGAGAACG 543
Db 20 CGACAGCTGCTCGAGAACG 1
RESULT 190
AAQ68062/C
ID AAQ68062 standard; DNA; 16 BP.
XX
XX AAQ68062;
AC
XX 25-MAR-2003 (revised)
DT 19-DEC-1994 (first entry)
XX
XX Antisense probe 155 for HCV LiPA typing.
DE
XX Hepatitis C virus; HCV; NABH; genotyping; hybridisation;
KW non-A, non-B hepatitis; NANBH; amplification; primer;
KW polymerase chain reaction; PCR; line probe assay; LiPA; ss.
XX
XX Synthetic.
OS
XX WO9412670-A2.
FN
XX 09-JUN-1994.
PD
XX 26-NOV-1993; 93WO-EP003325.
PF
XX 27-NOV-1992; 92EP-00403222.
PR
XX 31-AUG-1993; 93EP-00402129.
XX
XX (INNO-) INNOGENETICS NV SA.
PA
XX Maertens G, Stuyver L, Rousseau R, Van Heuverswyn H;
PI
XX WPI; 1994-200296/24.
DR
XX Process for genotyping Hepatitis C virus (HCV) isolates - utilises probes
PT hybridising to HCV isolate domains.
PT
XX Disclosure; Page 29; 96pp; English.
PS
XX Genotyping HCV utilises probes hybridising to HCV isolate domains. HCV
CC types 2, 3, 4, 5 or 6 and subtypes 1a, 1b, 2a, 2b, 3a, 3b, 3c, 4a, 4b,
CC 4c, 4d, 4e, 4f, 4g and 4h can be typed. Antisense probe 155 was used in
CC the identification of type 4 isolates. (Updated on 25-MAR-2003 to correct
CC PN field.)
XX
XX Sequence 16 BP; 1 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1508 CAGCTCCAGGCCCCC 1523
Db 16 CAGCTCCAGGCCCCC 1
RESULT 191
AAK14650

```

ID AAX14650 standard; DNA; 17 BP.
XX
AC AAX14650;
XX
DT 24-MAR-1999 (first entry)
XX
DE Triple helix forming nucleotides 5967-5983 of the dystrophin gene.
XX
KW Triple-helix forming region; Triplex formation; DNA detection;
KW identification; bacteria; oncogene; virus; ds.
XX
OS Homo sapiens.
XX
PN US5861244-A.
XX
PD 19-JAN-1999.
XX
PF 22-DEC-1993; 93US-00173489.
XX
PR 29-OCT-1992; 92US-00968436.
XX
PA (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
PI Hepburn AG, Wang C;
XX
WPI; 1999-130384/11.
XX
DR Assay of genetic sequences based on triplex formation from double
PT stranded analyte - and hybrid of anchor and reporter sequences, with
PT reporter released if triplex formation occurs, used e.g. to identify
PT bacteria.
XX
PS Disclosure; Col 15-16; 168pp; English.
XX
CC The present sequence represents a potential triple-helix forming region.
CC It can be used to demonstrate the assay of the invention. The assay
CC comprises adding a sample containing double-stranded DNA test sequences,
CC e.g. containing the present sequence, to an aqueous medium containing at
CC least one complex of anchor DNA, attached to a solid support, and
CC reporter DNA, where either a part of the anchor DNA or reporter DNA is
CC designed to form a triple-strand structure with part of the test
CC sequence. Triplex formation results in displacement of the reporter DNA
CC which is detected as an indication of the presence of the DNA test
CC sequence. The method is used to detect DNA sequences, particularly for
CC identification of bacteria (by detecting genes for ribosomal RNA) in
CC clinical samples, but also detection of oncogenes and Hepatitis B virus
XX
SQ Sequence 17 BP; 10 A; 0 C; 7 G; 0 T; 0 U; 0 Other;
  Query Match 1.0%; Score 16; DB 1; Length 17;
  Best Local Similarity 100.0%; Pred. No. 94;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  QY 280 AGAAGAGAAAGAGGGA 295
  Db 1 AGAAGAGAAAGAGGGA 16
  |||||
RESULT 192
ADS00161/c
ID ADS00161 standard; RNA; 19 BP.
XX
AC ADS00161;
XX
DT 16-DEC-2004 (first entry)
XX
DE Duchenne muscular dystrophy gene-specific antisense oligonucleotide #7.
XX
KW antisense oligonucleotide; Duchenne muscular dystrophy gene; DMD gene;
KW pre-mRNA recognition alteration; inherited disease;
KW pre-mRNA exon skipping induction; splicing machinery efficiency; ss.
XX
OS Unidentified.

```

```

XX Key Location/Qualifiers
FH modified_base 1..19
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER = Phosphorothioate backbone"
XX
PN WO2004083432-A1.
XX
PD 30-SEP-2004.
XX
PF 21-MAR-2003; 2003WO-NL000214.
XX
PR 21-MAR-2003; 2003WO-NL000214.
XX
PA (ZIEK-) ACAD ZIEKENHUIS LEIDEN.
XX
PI Van Ommen GB, Van Deutekom JCT, Den Dunnen JT, Aartsma-Rus A;
XX
WPI; 2004-691055/67.
XX
DR Generating an oligonucleotide for treating diseases, comprises
PT determining from a structure of RNA from an exon, a region that assumes a
PT structure hybridized to another part of the RNA and a region that is not
PT hybridized in the structure.
XX
PS Example 2; Page 48; 71pp; English.
XX
CC The invention comprises a method for generating an oligonucleotide
CC involving: determining from a secondary structure of RNA from an exon, a
CC region that assumes a structure that is hybridized to another part of the
CC RNA (closed structure) and a region that is not hybridized in the
CC structure (open structure); and subsequently generating an
CC oligonucleotide, where at least one part of the oligonucleotide is
CC complementary to the closed structure and at least one part of the
CC oligonucleotide is complementary to the open structure. The gene from
CC which the RNA comprising the exon is transcribed, may be selected from:
CC an aberrant Duchenne muscular dystrophy gene (DMD), a collagen VI alpha 1
CC gene (COL6A1), a myotubular myopathy 1 gene (MTM1), a dysferlin gene
CC (DYSF), a laminin-alpha 2 gene (LAMA2), an emery-dreyfuss muscular
CC dystrophy gene (EMD), and/or a calpain 3 gene (CAPN3). The
CC oligonucleotides produced by the method of the invention are useful for:
CC for the treatment of an inherited disease; for inducing exon skipping in
CC a pre-mRNA; for altering exon-recognition in a pre-mRNA; and for altering
CC the efficiency with which a splice donor or splice acceptor sequence is
CC used by a splicing machinery. The present RNA sequence represents an
CC antisense oligonucleotide that is targeted to the DMD gene.
XX
SQ Sequence 19 BP; 0 A; 8 C; 1 G; 0 T; 10 U; 0 Other;
  Query Match 1.0%; Score 16; DB 1; Length 19;
  Best Local Similarity 100.0%; Pred. No. 1.4e+02;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  QY 280 AGAAGAGAAAGAGGGA 295
  Db 17 AGAAGAGAAAGAGGGA 2
  |||||
RESULT 193
ADS73873/c
ID ADS73873 standard; RNA; 19 BP.
XX
AC ADS73873;
XX
DT 16-DEC-2004 (first entry)
XX
DE DMD gene specific antisense oligonucleotide h41A0N1.
XX
KW DMD; Duchenne muscular dystrophy; collagen VI alpha 1; COL6A1;
KW myotubular myopathy 1; MTM1; dysferlin; DYSF; laminin-alpha 2; LAMA2;
KW emery-dreyfuss muscular dystrophy; EMD; calpain 3; CAPN3; antisense; ss.
XX

```

```
OS Synthetic.
FN WO2004083446-A2.
XX
XX 30-SEP-2004.
XX
XX 22-MAR-2004; 2004WO-NL000196.
XX
XX 21-MAR-2003; 2003WO-NL000214.
XX
XX (ZIEK-) ACAD ZIEKENHUIS LEIDEN.
XX
XX Van Ommeren GB, Van Deutekom JCT, Den Dunnen JT, Aartsma-Rus A;
XX WPI; 2004-691060/67.
XX
XX Generating an oligonucleotide for treating diseases, comprises
XX determining from a structure of RNA from an exon, a region that assumes a
XX structure hybridized to another part of the RNA and a region that is not
XX hybridized in the structure.
XX
XX Example 1; Page 88; 117pp; English.
XX
XX The invention relates to generating an oligonucleotide and involves
XX determining from a secondary structure of RNA from an exon, a region that
XX assumes a structure that is hybridized to another part of the RNA (closed
XX structure) and a region that is not hybridized in the structure (open
XX structure), and subsequently generating an oligonucleotide, where at
XX least a part of the oligonucleotide is complementary to the closed
XX structure and at least another part of the oligonucleotide is
XX complementary to the open structure. In generating an oligonucleotide,
XX the open and closed structures are adjacent to each other. The
XX oligonucleotide is complementary to a consecutive part of 14-50
XX nucleotides of the RNA. It also comprises RNA, where the RNA contains a
XX modification, preferably a 2'-O-methyl modified ribose (RNA) or
XX deoxyribose (DNA) modification. The pre-mRNA comprising the exon exhibits
XX undesired splicing in a subject. The absence of the exon from mRNA
XX produced from the pre-mRNA generates a coding region for a protein. The
XX gene from which the RNA comprising the exon is transcribed encodes an
XX aberrant Duchenne muscular dystrophy gene (DMD), a collagen VI alpha 1
XX gene (COL6A1), a myotubular myopathy 1 gene (MTM1), a dysferlin gene
XX (DYSPF), a laminin-alpha 2 gene (LAMA2), an emery-dreyfuss muscular
XX dystrophy gene (EMD), and/or a calpain 3 gene (CAPN3). Preferably, the
XX gene is the DMD gene. The oligonucleotide, its equivalent, or the
XX compound is useful for at least in part altering recognition of the exon
XX or exons in a pre-mRNA; for the preparation of a medicament for the
XX treatment of an inherited disease; for inducing exon skipping in a pre-
XX mRNA; for altering exon-recognition in a pre-mRNA; for altering the
XX efficiency with which a splice donor or splice acceptor sequence is used
XX by a splicing machinery; for inducing exon-skipping of two, three, or
XX more exons in a pre-mRNA; or for inducing skipping of the at least two
XX exons and a sequence located between the at least two exons (intervening
XX sequence) on the pre-mRNA, where intervening sequence further comprises
XX exon or exons. Sequences ADS73865-ADS73903 represent antisense
XX oligonucleotides (AONs) used to study targeted skipping of 15 different
XX DMD exons.
XX
XX Sequence 19 BP; 0 A; 8 C; 1 G; 0 T; 10 U; 0 Other;
XX
XX Query Match 1.0%; Score 16; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+02;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 280 AGAAGAAGAAAGAGGA 295
XX Db 17 AGAAGAAGAAAGAGGA 2
XX
XX RESULT 194
XX ADI19217/c
XX ID ADI19217 standard; DNA; 20 BP.
XX
XX AC ADI19217;
```

```
XX
XX 22-APR-2004 (first entry)
XX Human PCTAIRE protein kinase 2 antisense oligonucleotide #71.
XX DE
XX gene therapy; antisense technology; PCTAIRE protein kinase 2;
XX KW neurological disorder; human; PCTAIRE protein kinase 2; ss.
XX OS
XX Homo sapiens.
XX PH
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "OTHER= Phosphorothioate backbone. All cytidines
XX are 5-methylcytidines"
XX modified_base 1..5
XX /tag= a
XX /mod_base= OTHER
XX /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX modified_base 15..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2003225256-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160787.
XX
XX 31-MAY-2002; 2002US-00160787.
XX (ISIS-) ISIS PHARM INC.
XX Watt AT;
XX WPI; 2004-022085/02.
XX
XX New antisense oligonucleotide, having a sequence targeted to a nucleic
XX acid encoding PCTAIRE protein kinase 2, useful for preparing a
XX composition for treating neurological disorders.
XX
XX Claim 1; SEQ ID NO 84; 58pp; English.
XX
XX The invention describes a new antisense oligonucleotide, having a
XX sequence comprising 8-80 bp targeted to a nucleic acid encoding PCTAIRE
XX protein kinase 2, that specifically hybridises with the nucleic acid
XX encoding PCTAIRE protein kinase 2 and having a sequence comprising 20 bp.
XX The antisense oligonucleotide is useful for preparing a composition for
XX treating e.g., neurological disorders. This sequence represents a human
XX PCTAIRE protein kinase 2 antisense oligonucleotide.
XX
XX Sequence 20 BP; 1 A; 8 C; 2 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 16; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1583 CATGGGAAGAACAGAA 1598
XX Db 17 CATGGGAAGAACAGAA 2
XX
XX RESULT 195
XX ADI19270
XX ID ADI19270 standard; DNA; 20 BP.
XX
XX AC ADI19270;
XX
XX 22-APR-2004 (first entry)
XX Human PCTAIRE protein kinase 2 antisense oligonucleotide #124.
```

```

XX KW gene therapy; antisense technology; PCTAIRE protein kinase 2;
XX KW neurological disorder; human; PCTAIRE protein kinase 2; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "OTHER= Phosphorothioate backbone. All cytidines
XX modified_base 1..5
XX /tag= a
XX /mod_base= OTHER
XX modified_base 15..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX US2003225256-A1.
XX PD 04-DEC-2003.
XX
XX PF 31-MAY-2002; 2002US-00160787.
XX
XX PR 31-MAY-2002; 2002US-00160787.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Watt AT;
XX
XX DR WPI; 2004-022085/02.
XX
XX PT New antisense oligonucleotide, having a sequence targeted to a nucleic
XX acid encoding PCTAIRE protein kinase 2, useful for preparing a
XX composition for treating neurological disorders.
XX
XX PS Example 15; SEQ ID NO 137; 58pp; English.
XX
XX CC The invention describes a new antisense oligonucleotide, having a
XX sequence comprising 8-80 bp targeted to a nucleic acid encoding PCTAIRE
XX protein kinase 2, that specifically hybridises with the nucleic acid
XX encoding PCTAIRE protein kinase 2 and having a sequence comprising 20 bp.
XX The antisense oligonucleotide is useful for preparing a composition for
XX treating e.g., neurological disorders. This sequence represents a human
XX PCTAIRE protein kinase 2 antisense oligonucleotide.
XX
XX SQ Sequence 20 BP; 9 A; 2 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 1.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1583 CATGGGAAGAACAGAA 1598
Db 4 CATGGGAAGAACAGAA 19
|||||
RESULT 196
ABN88070
ID ABN88070 standard; DNA; 19 BP.
XX
XX AC ABN88070;
XX
XX DT 12-AUG-2002 (first entry)
XX
XX DE Caenorhabditis elegans related dsRNA2 upstream primer.
XX
XX KW Caenorhabditis elegans; C. elegans; reproduction; development;
XX antineurocyst; nematocyst; plant protectant; gene therapy; infection;
XX calabar swelling; lymphatic filariasis; elephantiasis; onchocerca;

```

```

KW primer; ss.
XX
XX OS Caenorhabditis elegans.
XX OS Synthetic.
XX
XX PN WO200238600-A2.
XX
XX PD 16-MAY-2002.
XX
XX PF 09-NOV-2001; 2001WO-EP013038.
XX
XX PR 09-NOV-2000; 2000US-0246721P.
XX
XX PA (CENT-) CENIX BIOSCIENCE GMBH.
XX
XX PI Echeverri C, Goenczy P, Hyman A, Coulson A, Jones S, Oegema K;
XX PI Kirkham M;
XX
XX DR WPI; 2002-471547/50.
XX
XX PT New Caenorhabditis elegans genes required for viability, growth or
XX reproduction of nematodes, useful for diagnosing or treating e.g.
XX onchocerca or elephantiasis in humans or animals, or plant diseases
XX caused by e.g. Heterodera.
XX
XX PS Example 2; Page 28; 35pp; English.
XX
XX CC The present invention describes an isolated nucleic acid molecule (I),
XX which encodes a polypeptide (II) required for the viability and/or growth
XX and/or reproduction of nematodes (Caenorhabditis elegans), or its
XX fragment. (I) and (II) have nematocyst and plant protectant activities,
XX and can be used in gene therapy. (I) is useful for producing (II)
XX required for the viability, growth and/or reproduction of nematodes.
XX Nucleic acids, probes, polypeptides, fusion proteins and antibodies from
XX the present invention are also useful in a screening assay for
XX interacting drugs that inhibit, stimulate or affect worm growth,
XX viability or reproduction. They are useful for diagnosing or treating
XX human or animal diseases associated with the infection or presence of
XX nematode worms, e.g. Wuchereria bancrofti, Brugia malayi, Loa loa or
XX Onchocerca volvulus. These diseases include calabar swellings, lymphatic
XX filariasis (elephantiasis) or onchocercosis. The nucleic acids, probes,
XX polypeptides, fusion proteins and antibodies are also useful for
XX diagnosing or treating plant diseases associated with the infection or
XX presence of nematode worms. Furthermore, the nucleic acid and amino acid
XX sequences are useful for developing computational models, structural
XX models or other models for evaluating drug binding and efficacy. The
XX present sequence represents a primer which is used in an example from the
XX present invention in RNAi experiments
XX
XX SQ Sequence 19 BP; 6 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 551 GCAGACGCGACATGCTGGAT 569
Db 1 GCAGAGAGCAGATGCTGGAT 19
|||||
RESULT 197
ADD00110
ID ADD00110 standard; RNA; 19 BP.
XX
XX AC ADD00110;
XX
XX DT 01-JAN-2004 (first entry)
XX
XX DE HCV coding region-derived 60% conserved RNA sequence 56.
XX
XX KW HCV infection; replication; pathogenesis; virucide; vaccine;
XX gene therapy; ds.
XX

```

```
OS Hepatitis C virus.
XX WO2003016572-A1.
PN
XX
XX 27-FEB-2003.
PD
XX
XX 16-AUG-2002; 2002WO-US021843.
PF
XX
XX 17-AUG-2001; 2001US-0313076P.
PR
XX 20-DEC-2001; 2001US-0344116P.
PR
XX 01-FEB-2002; 2002US-0353750P.
XX
XX (ELIL ) LILLY & CO ELI.
PA
XX
PI Zhao G, Lu J, Glass JI, Martinez A, Yang Y;
XX WPI; 2003-268345/26.
XX
XX New double stranded RNA oligonucleotide, useful for preparing a
PT composition for treating or preventing hepatitis C virus.
PT
XX
XX Disclosure; Page 48; 173pp; English.
XX
XX The invention relates to a novel isolated double stranded RNA
CC oligonucleotide about 19 to about 25 ribonucleotides in length or its
CC equivalent. One strand of the oligonucleotide comprises the same
CC nucleotide sequence as a region of a hepatitis C virus (HCV) target RNA
CC polynucleotide sequence required for hepatitis C virus infection,
CC replication or pathogenesis in vitro or in vivo in a host cell. The
CC oligonucleotide of the invention demonstrates virucide activity and may
CC be useful for preparing a composition or vaccine for treating or
CC preventing hepatitis C virus, as well as during gene therapy procedures.
CC The current sequence is that of the HCV coding region-derived conserved
CC RNA sequence of the invention.
XX
XX Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;
SQ
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.5e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 222 CTCATAGAAAAAACAACG 240
Db 1 CUCAAGAAAAACAACG 19
|:| | | | | | | | | | |
|:| | | | | | | | | | |
RESULT 198
ADD00259
ID ADD00259 standard; RNA; 19 BP.
XX
XX ADD00259;
AC
XX
XX 01-JAN-2004 (first entry)
DT
XX HCV coding region-derived 50% conserved RNA sequence 205.
DE
XX HCV infection; replication; pathogenesis; virucide; vaccine;
KW gene therapy; ds.
KW
XX Hepatitis C virus.
OS
XX WO2003016572-A1.
PN
XX
XX 27-FEB-2003.
PD
XX
XX 16-AUG-2002; 2002WO-US021843.
PF
XX
XX 17-AUG-2001; 2001US-0313076P.
PR
XX 20-DEC-2001; 2001US-0344116P.
PR
XX 01-FEB-2002; 2002US-0353750P.
XX
XX (ELIL ) LILLY & CO ELI.
PA
XX
```

```
PI Zhao G, Lu J, Glass JI, Martinez A, Yang Y;
XX WPI; 2003-268345/26.
XX
XX New double stranded RNA oligonucleotide, useful for preparing a
PT composition for treating or preventing hepatitis C virus.
PT
XX
XX Disclosure; Page 61; 173pp; English.
XX
XX The invention relates to a novel isolated double stranded RNA
CC oligonucleotide about 19 to about 25 ribonucleotides in length or its
CC equivalent. One strand of the oligonucleotide comprises the same
CC nucleotide sequence as a region of a hepatitis C virus (HCV) target RNA
CC polynucleotide sequence required for hepatitis C virus infection,
CC replication or pathogenesis in vitro or in vivo in a host cell. The
CC oligonucleotide of the invention demonstrates virucide activity and may
CC be useful for preparing a composition or vaccine for treating or
CC preventing hepatitis C virus, as well as during gene therapy procedures.
CC The current sequence is that of the HCV coding region-derived conserved
CC RNA sequence of the invention.
XX
XX Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;
SQ
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.5e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 222 CTCATAGAAAAAACAACG 240
Db 1 CUCAAGAAAAACAACG 19
|:| | | | | | | | | | |
|:| | | | | | | | | | |
RESULT 199
ADF51715
ID ADF51715 standard; RNA; 19 BP.
XX
XX ADF51715;
AC
XX
XX 12-FEB-2004 (first entry)
DT
XX Hepatitis C virus short interfering nucleic acid sense strand SeqID305.
DE
XX short interfering nucleic acid; siNA; virus replication inhibition;
KW hepatitis C virus; HCV; sugar modification; virucide; antiinflammatory;
KW hepatotropic; cytostatic; RNA interference; HCV infection; liver failure;
KW hepatocellular cancer; cirrhosis; ss.
XX
XX Hepatitis C virus.
OS
XX WO2003070750-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005043.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 26-MAR-2002; 2002WO-US009187.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 05-AUG-2002; 2002US-0401104P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Mcswiggen J, Beigelman L, Macejak D, Morrissey D;
PI
XX WPI; 2003-689778/65.
XX
XX New double-stranded short interfering nucleic acid comprises sugar-
PT modified pyrimidine bases useful for treating infection with hepatitis C
```


PT virus.
 PS Example 3; SEQ ID NO 305; 183pp; English.
 XX
 CC This invention relates to novel double-stranded short interfering nucleic
 CC acids (siNA) that inhibits replication of hepatitis C virus (HCV), where
 CC one strand is an antisense strand (ASS) that is complementary to (part
 CC of) an HCV RNA (portion) and a sense strand (SS) that is complementary to
 CC ASS, and where most of the pyrimidine nucleotides comprise a sugar
 CC modification. The invention may allow development of compounds with
 CC virucide, antiinflammatory, hepatotropic or cytostatic activities by
 CC modulation (inhibition) of expression or activity of HCV RNA, by RNA
 CC interference. The siNA's of the invention may be used to inhibit
 CC replication of HCV, in cells, tissue explants or organisms, for treating
 CC HCV infection and its consequences (liver failure; hepatocellular cancer
 CC and cirrhosis), and also for drug screening, diagnosis, target
 CC identification and validation, genetic engineering, pharmacogenomics,
 CC studying gene function and gene mapping (for example of single-nucleotide
 CC polymorphisms). The chemical modification improves stability, activity,
 CC cellular uptake and/or binding affinity. The siNA can be directed to
 CC conserved regions of HCV genes, so are active against many different
 CC strains.
 XX
 SQ Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;
 Query Match 1.0%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.5e+02;
 Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 222 CTCATAGAAAAACAACG 240
 Db 1 CUCAAAGAAAAACCAACG 19
 RESULT 200
 ADF52411/C
 ID ADF52411 standard; RNA; 19 BP.
 XX ADF52411;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Hepatitis C virus siNA antisense strand SeqID1001.
 XX
 KW short interfering nucleic acid; siNA; virus replication inhibition;
 KW hepatitis C virus; HCV; sugar modification; virucide; antiinflammatory;
 KW hepatotropic; cytostatic; RNA interference; HCV infection; liver failure;
 KW hepatocellular cancer; cirrhosis; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO2003070750-A2.
 XX
 PD 28-AUG-2003.
 XX
 PF 20-FEB-2003; 2003WO-US005043.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 26-MAR-2002; 2002WO-US009187.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 05-AUG-2002; 2002US-0401104P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 XX Mcswiggen J, Beigelman L, Macejak D, Morrissey D;
 PI WPI; 2003-689778/65.
 XX

PT New double-stranded short interfering nucleic acid comprises sugar-
 PT modified pyrimidine bases useful for treating infection with hepatitis C
 PT virus.
 XX
 PS Example 3; SEQ ID NO 1001; 183pp; English.
 XX
 CC This invention relates to novel double-stranded short interfering nucleic
 CC acids (siNA) that inhibits replication of hepatitis C virus (HCV), where
 CC one strand is an antisense strand (ASS) that is complementary to (part
 CC of) an HCV RNA (portion) and a sense strand (SS) that is complementary to
 CC ASS, and where most of the pyrimidine nucleotides comprise a sugar
 CC modification. The invention may allow development of compounds with
 CC virucide, antiinflammatory, hepatotropic or cytostatic activities by
 CC modulation (inhibition) of expression or activity of HCV RNA, by RNA
 CC interference. The siNA's of the invention may be used to inhibit
 CC replication of HCV, in cells, tissue explants or organisms, for treating
 CC HCV infection and its consequences (liver failure; hepatocellular cancer
 CC and cirrhosis), and also for drug screening, diagnosis, target
 CC identification and validation, genetic engineering, pharmacogenomics,
 CC studying gene function and gene mapping (for example of single-nucleotide
 CC polymorphisms). The chemical modification improves stability, activity,
 CC cellular uptake and/or binding affinity. The siNA can be directed to
 CC conserved regions of HCV genes, so are active against many different
 CC strains.
 XX
 SQ Sequence 19 BP; 1 A; 2 C; 5 G; 0 T; 11 U; 0 Other;
 Query Match 1.0%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 222 CTCATAGAAAAACAACG 240
 Db 19 CTCAAAGAAAAACCAACG 1
 RESULT 201
 ADL70462
 ID ADL70462 standard; RNA; 19 BP.
 XX ADL70462;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE RNAi for human clusterin.
 XX
 KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
 KW cytostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
 KW ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 18..19
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= dTdT"
 XX
 XX WO2004018676-A2.
 XX
 PD 04-MAR-2004.
 XX
 PF 21-AUG-2003; 2003WO-CA001277.
 XX
 PR 21-AUG-2002; 2002US-0405193P.
 PR 03-SEP-2002; 2002US-0408152P.
 PR 20-MAY-2003; 2003US-0472387P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX
 XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
 PI Gonos ES;

XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 20; SEQ ID NO 27; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 19 BP; 5 A; 1 C; 3 G; 2 T; 8 U; 0 Other;
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1614 ACTAATTCAATAAACTGT 1632
Db 19 AATAATTCAACAAACTGT 1
RESULT 204
ADL70426
ID ADL70426 standard; RNA; 19 BP.
XX
AC ADL70426;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
XX Synthetic.
FH Key Location/Qualifiers
FT modified_base 18..19
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of

PT clusterin in the melanoma cells.
XX
PS Claim 10; SEQ ID NO 24; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 19 BP; 8 A; 3 C; 1 G; 2 T; 5 U; 0 Other;
Query Match 1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1616 TAAATTCATATAAACTGTCT 1634
Db 1 UAAUUCACAAACACUGUTT 19
RESULT 205
ADL70428
ID ADL70428 standard; RNA; 19 BP.
XX
AC ADL70428;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
XX Synthetic.
FH Key Location/Qualifiers
FT modified_base 18..19
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 20; SEQ ID NO 26; 32pp; English.

XX
DT 20-JUL-1999 (first entry)
DE Rabbit stromelysin hammerhead target SEQ ID NO:535.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
XX Oryctolagus cuniculus.
OS
XX WO9618736-A2.
PN
XX 20-JUN-1996.
XX
XX 22-NOV-1995; 95WO-US015516.
XX
PR 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0000951P.
PR 07-JUL-1995; 95US-0000974P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX
XX Example 1: Page 154; 307pp; English.
XX
XX The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX
SQ Sequence 17 BP; 4 A; 2 C; 4 G; 0 T; 7 U; 0 Other;
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. NO. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1589 AGAACAGAAATTCCTCC 1605
|||||
DB 17 AAGAACAGAAATTCCTCC 1

RESULT 209
ABK00170/c
ID ABK00170 standard; RNA; 17 BP.
XX
AC ABK00170;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Hammerhead Ribozyme #170.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNzyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 68; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an amberyne (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapeutics. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the

CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e-02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1619 TTCATATAAAGCTGCTT 1635
 Db ||||| ||||| ||||| ||||| |||||
 17 TTCATATAAAGCTGCTT 1

RESULT 210
 ABN08674
 ID ABN08674 standard; DNA; 17 BP.
 XX
 AC ABN08674;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPL-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8666.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPL-1; hGDMPL-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPL-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPL-1.
 XX
 PS Disclosure; SEQ ID NO 8666; 214pp; English.

XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPL-1). The protein and polynucleotide sequences of hGDMPL-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPL-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPL-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPL-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPL-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPL
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPL proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPL-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPL-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPL-1, in particular heart
 CC and skeletal muscle disorders. hGDMPL-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPL-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 273 GAGCCCAAGAGAGAGAA 289
 Db ||||| ||||| ||||| ||||| |||||
 1 GAGCCCAAGAGAGAGAA 17
 RESULT 211
 ADB00465/c
 ID ADB00465 standard; DNA; 17 BP.
 XX
 AC ADB00465;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MDZ3 scanning oligonucleotide SEQ ID 1451.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 DR WPI; 2003-423107/40.
 XX
 PT New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MDZ3,
 PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 1451; 103pp; English.

CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.

XX
 SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 928 GCTGCTCGCGATGAG 944
 |||||
 DB 17 GCTGCTCGCGCTGAAG 1

RESULT 212
 ACDS2817/C
 ID ACDS2817 standard; RNA; 17 BP.
 AC ACDS2817;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV minus strand DNazyme substrate sequence #736.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW viricide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US0009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX

DR WPI; 2003-229207/22.
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 PS Claim 1; Page 288; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 767 CCACGCCATGTTCCAGC 783
 |||||
 DB 17 CCACGCCATGTTCCGCG 1

RESULT 213
 ACDS9852
 ID ACDS9852 standard; RNA; 17 BP.
 XX
 AC ACDS9852;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV DNazyme substrate sequence #1542.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW viricide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US0009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEF/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 261; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention
XX
XX Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 766 TCCACGCCATGTTCCAG 782
Db :|||||:|:|:|
1 UCCACGCCAUGUUCGG 17
RESULT 214
ADB4503
ID ADB45503 standard; DNA; 17 BP.
XX
XX ADB45503;
XX
XX 18-DEC-2003 (first entry)
DT
XX Tumour suppression/reversion associated nucleotide #5826.
DE
XX cytotstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
XX Homo sapiens.
OS
XX W02003040369-A2.
PN
XX 15-MAY-2003.
PD
XX 17-SEP-2002; 2002W0-1B004219.
PF
XX 17-SEP-2001; 2001FR-00011981.
PR

(MOLE-) MOLECULAR ENGINES LAB.
Telerman A, Amson R, Tuijnder M;
WPI; 2003-441574/41.
New nucleic acid encoding human prostate membrane-specific antigen,
useful e.g. for treatment of tumors and viral infection, also related
polypeptide and antibodies.
Disclosure; Page 713; 771pp; French.
The invention relates to the isolation of 6327 nucleotide sequences,
fragments of at least 15 consecutive nucleotides of these nucleotides, a
sequence having at least 80% identity, after optimal alignment, with the
nucleotides, a sequence that hybridizes under stringent conditions with
the nucleotides, or the complement, or corresponding RNA, of the
nucleotides. The nucleotides are used as probes or primers for detecting,
identifying, quantifying and/or amplifying nucleic acids, as in vitro
sense and antisense sequences, of nucleotides involved in tumour
suppression or reversion, apoptosis and or viral resistance, to produce
recombinant polypeptides, and to prepare transgenic animals, as
experimental models. The nucleotides (also vectors containing them and
cells containing the vectors), the encoded polypeptides and antibodies
(Ab) against the polypeptide are useful for prevention and/or treatment
of viral infections or diseases characterized by development of tumours
or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
Analysis of the expression of the nucleotides can be used for diagnosis
and/or prognosis of these diseases. The nucleotides and polypeptides can
also be used to screen for their specific interactive molecules,
potentially useful for treating diseases associated with abnormal
expression of the nucleotides.
Sequence 17 BP; 4 A; 7 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1551 GATCCTGCACCTCTAACA 1567
Db :|||||:|:|:|
1 GATCCTGCACCTCTACCA 17
RESULT 215
ADI84296
ID ADI84296 standard; RNA; 17 BP.
XX
XX ADI84296;
XX
XX 03-JUN-2004 (first entry)
DT
XX HCV DNazyme substrate sequence #1542.
DE
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX 03-JUL-2003.
PD
XX 18-DEC-2000; 2000US-00740332.
PF
XX 18-DEC-2000; 2000US-00740332.
PR
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.

PT study and regulation of angiogenesis and for developing inhibitors.

XX Example 3; Page 55; 56pp; English.

XX PCR primers AX85603-04 were used to amplify DNA encoding a human growth factor designated zapol. Zapol is an angiotensin homologue. The polypeptide is used to stimulate cell growth and tissue development. The polypeptides form multimeric proteins. Zapol has angiogenic or hematopoietic activity. The proteins can be used in assays for angiogenic activity. Zapol proteins may be used therapeutically to stimulate revascularization of tissue. Specific applications include treatment of full-thickness skin wounds, including venous stasis ulcers and other chronic, non-healing wounds, as well as fracture repair, skin grafting, reconstructive surgery, and establishment of vascular networks in transplanted cells and tissues. Zapol is also useful as a research agent, such as in the expansion of hematopoietic cells (including stem cells) and endothelial cells. The polypeptides are added to tissue culture media for these cell types

XX Sequence 18 BP; 1 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 284 GAAGAAAGAGGATGCC 300
DB 18 GAAGAAAGAGGATGCC 2

RESULT 218
AD74784
ID AD74784 standard; DNA; 18 BP.
AC AD74784;
XX
XX 16-DEC-2004 (first entry)
XX Allele specific primer A for human stenosis marker hCV25612495.
XX Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
XX angina; ischaemic chest pain; myocardial infarction;
XX sudden cardiac death; SNP; single nucleotide polymorphism.
XX Homo sapiens.
XX WO2004081186-A2.
XX 23-SEP-2004.
XX 10-MAR-2004; 2004WO-US007140.
XX 10-MAR-2003; 2003US-0453050P.
XX 30-APR-2003; 2003US-0466437P.
XX (APPL-) APPLERA CORP.
XX Cargill M, Devlin JJ, Luke WM;
XX WPI; 2004-668949/65.
XX
XX Identifying an individual who has altered risk for developing stenosis comprises detecting single nucleotide polymorphism (SNP), in the individual's nucleic acids.
XX Claim 19; SEQ ID NO 68096; 146pp; English.
XX The invention relates to identifying an individual who has altered risk for developing coronary stenosis comprising detecting a single nucleotide polymorphism (SNP) in any one of the 67073 nucleotide sequences (not given in the specification), in the individual's nucleic acids, where the presence of the SNP is correlated with an altered risk for stenosis in the individual. Also included are an isolated nucleic acid molecule

CC (comprising at least 8 contiguous nucleotides where one of the nucleotides is an SNP as cited above, or their complement), an isolated polypeptide comprising an amino acid sequence selected from any of the 696 amino acid sequences (not defined in the specification), an antibody that specifically binds to the polypeptide (or its antigen-binding fragment), an amplified polynucleotide containing the SNP as cited (where the amplified polynucleotide is between about 16 and about 1,000 nucleotides to a nucleic acid molecule containing the SNP, a kit for detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid molecule, detecting a variant polypeptide and identifying an agent useful in therapeutically or prophylactically treating stenosis. The detection step of the method is carried out by a process selected from allele-specific probe hybridisation, allele-specific primer extension, allele-specific amplification, sequencing, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism. The method is useful for identifying an individual who has altered risk for developing coronary stenosis, which can lead to angina (ischaemic chest pain), myocardial infarction and ultimately sudden cardiac death. The present sequence is an allele specific primer for amplifying a SNP-containing region of a human marker gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the specification but are provided on a CD-R named CL001510CDR which was not supplied with the specification.

XX Sequence 18 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 1 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 500 CTTCTGGATGAATGGTGA 517
DB 1 CTTCTGGATGAATGGTGA 18

RESULT 219
AAV31968/C
ID AAV31968 standard; DNA; 15 BP.
XX
XX AAV31968;
XX 21-AUG-1998 (first entry)
XX Peptide nucleic acid probe 111.
XX Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
XX ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
XX Synthetic.
XX Mycobacterium sp.
XX
XX Key Location/Qualifiers
FH modified_base 1..15
FT /*tag= a
FT /note= "This sequence contains a polyamide backbone
FT instead of a deoxyribose backbone"
XX
XX WO9815648-A1.
XX
XX 16-APR-1998.
XX
XX 03-OCT-1997; 97WO-DK000425.
XX
XX 04-OCT-1996; 96DK-00001096.
XX 18-OCT-1996; 96DK-00001156.
XX 05-MAY-1997; 97DK-00000512.
XX (DAKO-) DAKO AS.
XX Stender H, Lund K, Mollerup TA;
XX WPI; 1998-240831/21.
XX

XX Peptide nucleic acid probes for detection of ribosomal nucleic acid of
PT mycobacteria - allow differentiation between species of tuberculosis
PT complex and others and can penetrate cell membranes without pretreatment.
XX
XX Claim 22; Page 67; 106pp; English.
XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe
CC used in the method of the invention, to detect ribosomal nucleic acid of
CC mycobacteria. The probes are used, in situ or in vitro, for detection of
CC the Mycobacterium tuberculosis complex (MTC), specifically M.
CC tuberculosis, and especially in sputum samples, but also in other body
CC fluids, biopsy specimens, foods, soil, air and water. Particularly, they
CC are used to diagnose, stage or monitor infection, or for identification
CC of drug-resistant strains (which generally have mutations in rRNA)
XX
SQ Sequence 15 BP; 3 A; 2 C; 1 G; 9 T; 0 U; 0 Other;
Query Match 0.9%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 177 AAGGAAATTCAAAAT 191
DB 15 AAGGAAATTCAAAAT 1
RESULT 220
ACD62818/c
ID ACD62818 standard; RNA; 17 BP.
XX
AC ACD62818;
XX
DT 24-SEP-2003 (first entry)
XX
DE HCV minus strand DNazyme substrate sequence #737.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW ambarzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW viricide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PP 26-MAR-2002; 2002NO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORE/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX

DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 288; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, ambarzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 766 TCCACGCCCATGTTC 780
DB 15 TCCACGCCCATGTTC 1
RESULT 221
ADI85768/c
ID ADI85768 standard; RNA; 17 BP.
XX
AC ADI85768;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNazyme substrate sequence #3014.
XX
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PP 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P.A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen J, Roberts E, Pavco P, Macejack D;
XX WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX

PT especially in combination with type I interferon therapy.

PS Claim 1; SEQ ID NO 3014; 198pp; English.

XX The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNase substrate
 CC sequence.

XX Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCCCATGTTCC 780

DB 15 TCCAGCCCATGTTCC 1

RESULT 222

AD079635/c
 ID AD079635 standard; DNA; 17 BP.

AC AD079635;

DT 26-AUG-2004 (first entry)

XX KIAA0783 extend primer #27.

XX Cytostatic; Gene therapy; breast cancer; human; DLG1; KIAA0783; DPF3;
 KW CENPCL; SNF; single nucleotide polymorphism; PHF14;
 KW PHD finger protein 14; chromosome 7p21.3; zinc finger protein;
 KW transcription factor; extend; primer; ss.

XX Homo sapiens.

XX WO2004047514-A2.

XX 10-JUN-2004.

XX 25-NOV-2003; 2003WO-US037943.

XX 25-NOV-2002; 2002US-0429136P.

PR 24-JUL-2003; 2003US-0490234P.

XX (SEQU-) SEQUENOM INC.

PA Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;

XX WPI; 2004-441037/41.

XX Identifying a subject at risk of breast cancer by detecting the presence
 PT of polymorphic variations in the DLG1, KIAA0783, DPF3 or CENPCL regions
 PT which are associated with breast cancer in a nucleic acid sample from a
 PT subject.

PS Example 4; Page 78; 227pp; English.

XX The present invention relates to a method for identifying a subject at
 CC risk of breast cancer. The method comprising detecting the presence or
 CC absence of one or more polymorphic variations associated with breast
 CC cancer in a nucleic acid sample from a subject. The nucleic acid sample
 CC comprises the DLG1 region (AD079402), KIAA0783 region (AD079403), DPF3
 CC region (AD079404) or CENPCL region (AD079405). The gene DLG1 (disc.
 CC large homolog 1 (Drosophila)) is also known as synapse-associated protein
 CC 97, hdlg or SAP97. DLG1 has been mapped to chromosomal position 3q29. The
 CC gene KIAA0783 is also known as PHF14 and PHD finger protein 14. KIAA0783
 CC has been mapped to chromosomal position 7p21.3. The KIAA0783 protein is a

CC novel gene with unknown function, however, being a zinc finger protein,
 CC it likely to be a transcription factor. The gene DPF3 (D4, zinc and
 CC double PHD fingers, family 3) is also known as CERD4, cer-d4, FLN14079
 CC and 2810403B03Rik. DPF3 is a Rho family guanine-nucleotide exchange
 CC factor. DPF3 has been mapped to chromosomal position 14q24.3-q31.1. The
 CC gene CENPCL (centromere protein C1) is also known as Centromere
 CC autoantigen C1. CENPCL has been mapped to chromosomal position 4q12-
 CC q13.3. CENPCL is a centromere autoantigen and a component of the inner
 CC kinetochore plate. The CENPCL protein is required for maintaining proper
 CC kinetochore size and a timely transition to anaphase. The method is
 CC useful for identifying a subject at risk of breast cancer, for early
 CC diagnosis, prevention and treatment of breast cancer, and in clinical drug
 CC trials. The present sequence was used in an example from the invention.

XX Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 AGTGGCTCAGGCCTG 452

DB 15 AGTGGCTCAGGCCTG 1

RESULT 223

AAQ35721/c
 ID AAQ35721 standard; DNA; 18 BP.

XX AAQ35721;

DT 25-MAR-2003 (revised)

DT 24-FEB-1993 (first entry)

XX EIV primer EIVAIP7A.

XX Expression cassette; equine influenza virus; EIV; hemagglutinin; HA;
 KW Al/Prague/56; NYVAC; ALVAC; recombinant vector; PCR; amplify; pCPCV1;
 KW polymerase chain reaction; pRW764.2; H6 promoter; canarypox virus;
 KW Copenhagen vaccine; vaccinia virus; virulence factors; deletion loci;
 KW recipient loci; ss.

XX Synthetic.

XX WO9215672-A1.

PD 17-SEP-1992.

XX 09-MAR-1992; 92WO-US001906.

XX 07-MAR-1991; 91US-00666056.

PR 11-JUN-1991; 91US-00713967.

PR 06-MAR-1992; 92US-00847951.

XX (VIRO-) VIROGENETICS CORP.

XX Paoletti B, Perkus ME, Taylor J, Tartaglia J, Norton EK;

PI Riviere M, De Taine C, Limbach KJ, Johnson GP, Pincus SE, Cox WT;

XX Francis J, Gettig RR;

XX WPI; 1992-331718/40.

XX Vaccine comprises recombinant, attenuated pox-virus - use for vaccinating
 PT against viral infections such as rabies, hepatitis B, HIV, HSV, EBV, CMV,
 PT mumps etc.

PS Disclosure; Page 220; 456pp; English.

XX The sequences given in AAQ35720-23 were used to generate an expression
 CC cassette for the insertion of the equine influenza virus (EIV)
 CC hemagglutinin (HA) (Al/Prague/56) into NVVAC and ALVAC recombinant
 CC vectors. The HA gene sequence was isolated from an EIV cDNA library and

CC was amplified by polymerase chain reaction. The amplified sequence was
 CC inserted into the linearised plasmid pRW764.2. The resultant plasmid was
 CC designated pPCV1 and contains the vaccinia virus H6 promoter followed by
 CC a polylinker region and flanked by canarypox virus homologous sequences.
 CC NYVAC is derived from a Copenhagen vaccine strain of vaccinia virus and
 CC ALVAC is derived from a canarypox virus which has been modified by
 CC deletion of non-essential regions of the genome encoding known or
 CC potential virulence factors. The deletion loci of both vectors were
 CC engineered as recipient loci for the insertion of foreign genes. See also
 CC AAQ35501-864. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 18 BP; 2 A; 1 C; 4 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.7e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCNTAGAAAAACCAAC 239

DB 18 CTAATAGAAAAACCAAC 1

RESULT 224

AAV95047/C

ID AAV95047 standard; RNA; 18 BP.

AC AAV95047;

XX 24-FEB-1999 (first entry)

DE Mouse IL-2 receptor g-chain substrate position 51.

XX Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
 KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
 KW autoimmune disease; psoriasis; allergy; inflammatory disease;
 KW graft rejection; ss.

OS Mus sp.

XX WO9824913-A2.

XX 11-JUN-1998.

XX 02-DEC-1997; 97WO-US021748.

XX 03-DEC-1996; 96US-00758306.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, McSwiggen JA;

XX WPI; 1998-333332/29.

XX Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,
 PT autoimmune disease and allergies.

XX Claim 4; Page 44; 61pp; English.

XX The present sequence invention describes ribozymes targeted to modulate
 CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.
 CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and
 CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
 CC from the present invention. The ribozymes can be used for the treatment
 CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy
 CC and other inflammatory conditions. The ribozymes are also used to induce
 CC tolerance in a recipient to alloantigen from a donor

XX Sequence 18 BP; 1 A; 8 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.7e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 GCTGAGAGCAGCTGAACGA 1138

DB 18 GCAGGAGCAGCTGAACGA 1

RESULT 225

AAH37505

ID AAH37505 standard; DNA; 18 BP.

XX AAH37505;

XX 14-AUG-2001 (first entry)

XX SNP specific upper PCR primer SEQ ID 301.

XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;
 KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
 KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
 KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
 KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.

OS Homo sapiens.

XX WO200129262-A2.

XX 26-APR-2001.

XX 13-OCT-2000; 2000WO-US028436.

XX 15-OCT-1999; 99US-0160096P.

XX (ORCH-) ORCHID BIOSCIENCES INC.

XX Picoult-Newburg L, Pohl M;

XX WPI; 2001-290930/30.

XX New genotyping oligonucleotide, useful for detecting the presence,
 PT absence or identity of single polynucleotide polymorphism in a nucleic
 PT acid sample.

XX Claim 1; Page 51; 83pp; English.

XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
 CC primer extension (SNPE) primers, and the sequences of regions flanking
 CC sites of single nucleotide polymorphisms SNPs. The present invention
 CC includes kits for determining the presence or absence of a SNP, using the
 CC oligonucleotides of the invention. The PCR primers are used to amplify a
 CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
 CC The oligonucleotides are useful for genotyping a nucleic acid sample by
 CC performing a single-nucleotide primer extension reaction. The
 CC oligonucleotides are useful for determining the presence, absence or
 CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
 CC assess by association analysis the genotype of an individual or group of
 CC individuals, having a pathological phenotypic trait suspected of being
 CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
 CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
 CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
 CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
 CC traits also include symptoms of or susceptibility to multifactorial
 CC disease of which a component is or may be genetic such as autoimmune
 CC diseases, including, rheumatoid arthritis, multiple sclerosis,
 CC inflammation, cancer, nervous system diseases and infection by pathogenic
 CC microorganism. The method is also useful in forensic investigations and
 CC paternity analysis. The present sequence represents a PCR primer specific
 CC for a human SNP containing DNA sequence

XX Sequence 18 BP; 4 A; 8 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.7e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
QY      1492 CCAAGTACCAAGGCCCA 1509
DB      1 CCAAGTGACCAAGGCCCA 18
RESULT 226
ACCT9773
ID ACCT9773 standard; DNA; 18 BP.
XX
AC ACCT9773;
XX
DT 02-SEP-2003 (first entry)
XX
DE Mouse PTPRB reverse PCR primer SEQ ID NO:11.
XX
KW Tec; protein tyrosine kinase; protein tyrosine phosphatase; PTP10D;
KW egg derived tyrosine phosphatase; EDRP; anti-diabetic; hypotensive;
KW cardiant; antilipaeamic; osteopathic; cytostatic; anorectic; obesity;
KW immunomodulator; gene therapy; metabolic disease; eating disorder;
KW body weight regulation disorder; cachexia; diabetes mellitus; cancer;
KW hypertension; coronary heart disease; hypercholesterolaemia; gallstone;
KW dyslipidaemia; osteoarthritis; sleep apnea; mouse; PTPRB;
KW protein tyrosine phosphatase receptor type B precursor; PCR primer; ss.
XX
OS Mus sp.
OS Synthetic.
XX
PN WO2003047611-A2.
XX
PD 12-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-EP013744.
XX
PR 04-DEC-2001; 2001EP-00128844.
PR 07-DEC-2001; 2001EP-00129138.
PR 02-JAN-2002; 2002EP-00000010.
XX
PA (DEVE-) DEVELOPEN ENTWICKLUNGSBIOLOGISCHE FORSCH.
XX
PI Meise M, Eulenberg K, Fritsch R, Haeder T, Broenner G;
PI Steuernagel A;
XX
XX WPI; 2003-532801/50.
XX
XX New compositions comprising tyrosine phosphatase PTP10D, protein tyrosine
PT kinase Tec or egg-derived tyrosine phosphatase genes or proteins, useful
PT for treating or preventing metabolic diseases, e.g. as obesity or
PT cachexia.
XX
XX Example 4; Page 52; 83pp; English.
XX
XX The present invention describes a pharmaceutical composition comprising a
CC nucleic acid (I) protein tyrosine phosphatase PTP10D, non-receptor
CC protein tyrosine kinase Tec, egg derived tyrosine phosphatase (EDTP) gene
CC family or encoded polypeptide, fragment or variant of nucleic acid
CC molecule or polypeptide, an antibody, an aptamer or receptor recognising
CC a nucleic acid molecule of PTP10D, Tec, or EDRP gene family or encoded
CC polypeptide, and a carrier, diluent and/or adjuvant. The pharmaceutical
CC composition can have anti-diabetic, hypotensive, cardiant, antilipaeamic,
CC osteopathic, cytostatic, anorectic and immunomodulator activities, and
CC can be used in gene therapy. The composition is useful for the
CC manufacture of an agent for detecting and/or verifying, for treating and
CC alleviating and/or preventing a disorder, including metabolic diseases
CC such as obesity and other body weight regulation disorders, as well as
CC related disorders such as eating disorder, cachexia, diabetes mellitus,
CC hypertension, coronary heart disease, hypercholesterolaemia,
CC dyslipidaemia, osteoarthritis, gallstones, cancers (cancers of the
CC reproductive organ), sleep apnea, and other diseases, in cells, cell
CC masses, organs and/or subjects. The components of the composition may
CC also be used in controlling the function of a gene and/or gene product
CC which is influenced and/or modified by a PTP10D, Tec, or EDRP homologous
CC polypeptide, and for identifying substances capable of interacting with a
```

```
CC PTP10D, Tec or EDRP homologous polypeptide. The nucleic acid molecule of
CC PTP10D, Tec, or EDRP family or their fragments, may be used in the
CC preparation of a non-human animal which over- or under-expresses the
CC PTP10D, Tec, or EDRP gene product. The present sequence represents a PCR
CC primer for mouse protein tyrosine phosphatase receptor type B precursor
CC (PTPRB), which is used in an example from the present invention
XX
SQ Sequence 18 BP; 3 A; 10 C; 1 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 764 CTTCCACGCCCATGTCCA 781
DB 1 CTCCACGCCCATCTCCA 18
RESULT 227
ACFO4428
ID ACFO4428 standard; DNA; 18 BP.
XX
AC ACFO4428;
XX
DT 04-DEC-2003 (first entry)
XX
DE Hepatitis C virus RNA probe.
XX
KW Silicon; silicon containing magnetic particle; superparamagnetic;
KW silicon dioxide; nucleic acid isolation; probe; ss; HCV.
XX
OS Hepatitis C virus.
FH Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /*mod_base= OTHER
FT /*note= "modified by FAM"
FT modified_base 18
FT /*tag= b
FT /*mod_base= OTHER
FT /*note= "modified by TAMRA"
XX
XX WO2003058649-A1.
XX
XX 17-JUL-2003.
XX
XX 07-JAN-2003; 2003WO-EP0000054.
XX
XX 14-JAN-2002; 2002DE-01001084.
XX
XX (FARB ) BAYER AG.
XX
XX Hennig G, Hildenbrand K;
XX
XX WPI; 2003-542203/51.
XX
XX Silicon-coated magnetic particles, useful for purification of nucleic
PT acid from body samples, do not need to be separated before quantification
PT by polymerase chain reaction.
XX
XX Example 7; Page 23; 35pp; German.
XX
XX The present invention relates to silicon-coated magnetic particles in
XX which the silicon content is less than 20wt.% of total. These can be used
CC to isolate nucleic acids from body samples, especially serum,
CC particularly for diagnostic detection of RNA from hepatitis C virus or
CC HIV. The present sequence is a probe used to isolate RNA from hepatitis C
CC virus from serum in the exemplification of the invention
XX
SQ Sequence 18 BP; 2 A; 11 C; 3 G; 1 T; 0 U; 1 Other;
Query Match 0.9%; Score 14.6; DB 1; Length 18;
```

Best Local Similarity 93.3%; Pred. No. 1.8e+02; Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1509 AGCTCCAGGCCCCC 1523
Db 1 AGCTCCAGGCCCCC 15

RESULT 228
AA63904/c
ID AAX63904 standard; RNA; 17 BP.
XX AC AAX63904;
XX DT
XX DT
XX DT
XX DE Rabbit stromelysin hammerhead target SEQ ID NO:536.
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX OS Oryctolagus cuniculus.
XX PN WO9618736-A2.
XX PD 20-JUN-1996.
XX PF 22-NOV-1995; 95WO-US015516.
XX PR 13-DEC-1994; 94US-00354920.
XX PR 23-DEC-1994; 94US-00363253.
XX PR 23-DEC-1994; 94US-00363254.
XX PR 17-FEB-1995; 95US-00390850.
XX PR 20-APR-1995; 95US-00426124.
XX PR 02-MAY-1995; 95US-00432874.
XX PR 04-MAY-1995; 95US-00434509.
XX PR 07-JUL-1995; 95US-0000951P.
XX PR 07-JUL-1995; 95US-0000974P.
XX PR 07-AUG-1995; 95US-00512861.
XX PR 05-OCT-1995; 95US-00541365.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX PS Example 1; Page 154; 307pp; English.
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis.
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment

CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAGAAATTCCTC 1604
Db 16 AAGAACAGAAATTCCTC 1

RESULT 229
AAV93469
ID AAV93469 standard; RNA; 17 BP.
XX AC AAV93469;
XX DT 18-FEB-1999 (first entry)
XX DE Human B-raf substrate nucleotide position 1085.
XX KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW screening; identification; synthesis; deprotection; purification; cancer;
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW restenosis; rheumatoid arthritis; ss.
XX OS Homo sapiens.
XX PN WO9850530-A2.
XX PD 12-NOV-1998.
XX PF 05-MAY-1998; 98WO-US009249.
XX PR 09-MAY-1997; 97US-0046059P.
XX PR 09-JUN-1997; 97US-0049002P.
XX PR 03-JUL-1997; 97US-0051718P.
XX PR 22-AUG-1997; 97US-0056808P.
XX PR 02-OCT-1997; 97US-0061321P.
XX PR 02-OCT-1997; 97US-0061324P.
XX PR 05-NOV-1997; 97US-0064866P.
XX PR 19-DEC-1997; 97US-0068212P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
PI Parry T, Beigelman L, McSwiggen JA, Karpeisky A, Burgin A;
PI Thompson J, Workman CT, Beaudry A, Sweedler D;
XX WPI; 1999-009494/01.
XX PT Identifying new catalytic nucleic acid that modulates selected processes
PT - especially ribozymes that cleave Raf RNA for treating cancer,
PT restenosis, and also new ribozymes and modified nucleoside triphosphates
PT used as antiviral agents and synthons.
XX PS Claim 177; Page 168; 259pp; English.
XX CC A method has been developed for the identification of a nucleic acid
CC capable of modulating a process in a biological system. The method
CC comprises: (a) introducing into the system a random library of nucleic
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence
CC of at least part of the SBDs in such systems. Nucleic acid molecules with
CC endonuclease activity and catalytic activity, from the present invention,
CC are used to modulate gene expression in plant and mammalian cells and to
CC cleave target nucleic acid, particularly for treating systemic diseases

CC	caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic	CC	The invention relates to a nucleic acid molecule which down regulates
CC	ascites and infection. They may also be used to detect genetic drift and	CC	expression of a CD20 gene and a nucleic acid molecule which down
CC	mutations in diseased cells and to determine c-rat RNA. Specifically NACs	CC	regulates expression of a neurite growth inhibitor gene (NOGO). The
CC	with RNA-cleaving activity that modulate expression of the Raf gene, are	CC	nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC	used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or	CC	DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC	generally any condition associated with the level of c-rat. Introduction	CC	possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC	of sugar/phosphate modifications increases stability against nuclease and	CC	an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC	activity. AA950922 to AA93877 represent NACs that can be used in the	CC	with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC	method, specifically for modulating the expression of a Raf gene	CC	of CD20 in the presence of a divalent cation that is preferably Mg ²⁺ .
XX		CC	Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX		CC	the cell and treat a patient having a condition associated with the level
XX	Sequence 17 BP; 4 A; 8 C; 1 G; 0 T; 4 U; 0 Other;	CC	of CD20. The treatment may further comprise the use of one or more
XX		CC	therapies. In particular, the CD20 targeting nucleic acid may be used to
XX	Query Match 0.9%; Score 14.4; DB 1; Length 17;	CC	treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX	Best Local Similarity 75.0%; Pred. No. 1.6e+02;	CC	Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX	Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;	CC	leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
QY	826 TCCACTTCCACAGCCC 841	CC	lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
Db	2 UCCAAUCCACAGCCC 17	CC	immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
	:	CC	targeting nucleic acid is used to cleave RNA of the NOGO gene in the
RESULT 230		CC	presence of a divalent cation that is preferably Mg ²⁺ . Furthermore, the
ABK00171/c		CC	nucleic acid may be contacted with a cell to reduce NOGO activity of the
ID ABK00171 standard; RNA; 17 BP.		CC	cell and treat a patient having a condition associated with the level of
AC ABK00171;		CC	NOGO. The treatment may further comprise the use of one or more
XX		CC	therapies. In particular, the NOGO-targeting nucleic acid may be used to
XX	12-MAR-2002 (first entry)	CC	treat central nervous system (CNS) injury and cerebrovascular accident
DT		CC	(CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
DE	Human NOGO Hammerhead Ribozyme #171.	CC	chemotherapy-induced neuropathy, amyotrophic disease, Creutzfeldt-Jakob
XX		CC	Parkinson's disease, ataxia, Huntington's disease, neurodegenerative disease
XX	Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;	CC	states which respond to the modulation of NOGO expression. The present
KW	cerebroprotective; neuroprotective; antiparkinsonian;	CC	sequence is a hammerhead ribozyme of the invention
KW	muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;	XX	
KW	DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;	QY	1619 TTCAATATAAACTGTCT 1634
KW	B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;	Db	16 TTCAATATAAACTGTCT 1
KW	human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;		
KW	MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;	RESULT 231	
KW	inflammatory arthropathy; central nervous system injury;	ABN08360/c	
KW	cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;	ID ABN08360 standard; DNA; 17 BP.	
KW	chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;	XX	
KW	Parkinson's disease; ataxia; Huntington's disease;	XX	
KW	Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.	AC ABN08360;	
XX		XX	
OS	Homo sapiens.	DT	29-MAY-2002 (first entry)
OS	Synthetic.	XX	
XX		XX	
PN	WO200159103-A2.	DE	Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8352.
XX		XX	
PD	16-AUG-2001.	XX	
XX		XX	
PF	09-FEB-2001; 2001WO-US004273.	KW	Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
XX		KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
PR	11-FEB-2000; 2000US-0181797P.	XX	
PR	28-FEB-2000; 2000US-0185516P.	XX	
PR	06-MAR-2000; 2000US-0187128P.	XX	
XX		OS	Homo sapiens.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	XX	
PA	(BLAT/) BLATT L.	FN	WO200192524-A2.
PA	(MCSW/) MCSWIGGEN J.	XX	
PA	(CHOW/) CHOWRIRA B M.	PD	06-DEC-2001.
XX		XX	
PI	Blatt L, Mcswiggen J, Chowrira BM;	XX	
XX		XX	
DR	WPI, 2001-607195/69.	XX	
XX		XX	
XX	Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense	XX	
PT	constructs, which down regulate expression of a CD20 gene or neurite	XX	
PT	growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and	XX	
PT	central nervous system injury.	XX	
XX		XX	
PS	Claim 88; Page 68; 200pp; English.	XX	

PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 8352; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1109 CACCTCTCTCTGCTG 1124
 Db 17 CAGCTCTCTCTGCTG 2
 RESULT 232
 ABN08675
 ID ABN08675 standard; DNA; 17 BP.
 XX
 AC ABN08675;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8667.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD

XX 25-MAY-2001; 2001WO-US016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR
 PR 21-SEP-2000; 2000US-0234687P.
 PR
 PR 27-SEP-2000; 2000US-0236359P.
 PR
 PR 04-OCT-2000; 2000GB-00024263.
 PR
 PR 30-JAN-2001; 2001WO-US000661.
 PR
 PR 30-JAN-2001; 2001WO-US000662.
 PR
 PR 30-JAN-2001; 2001WO-US000663.
 PR
 PR 30-JAN-2001; 2001WO-US000664.
 PR
 PR 30-JAN-2001; 2001WO-US000665.
 PR
 PR 30-JAN-2001; 2001WO-US000666.
 PR
 PR 30-JAN-2001; 2001WO-US000667.
 PR
 PR 30-JAN-2001; 2001WO-US000668.
 PR
 PR 30-JAN-2001; 2001WO-US000669.
 PR
 PR 30-JAN-2001; 2001WO-US000670.
 PR
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 8667; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 274 AAGCCAAGAAGAGAA 289
 Db 1 AAGCCAAGAAGAGAA 16
 RESULT 233
 ABN08361/c
 ID ABN08361 standard; DNA; 17 BP.
 XX
 AC ABN08361;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 XX

DE	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8353.	Db	16 CAGCTCCTCCTTGCTG 1
XX	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;	RESULT 234	
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;	ABN10046/c	
KW	skeletal muscle disorder; amplicon; screening; ss.	ID ABN10046 standard; DNA; 17 BP.	
OS	Homo sapiens.	XX AC ABN10046;	
XX	WO200192524-A2.	XX DT 29-MAY-2002 (first entry)	
XX	06-DEC-2001.	DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10038.	
XX	25-MAY-2001; 2001WO-US016981.	XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;	
XX	26-MAY-2000; 2000US-0207456P.	KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;	
PR	21-SEP-2000; 2000US-0234687P.	KW skeletal muscle disorder; amplicon; screening; ss.	
PR	27-SEP-2000; 2000US-0236359P.	OS Homo sapiens.	
PR	04-OCT-2000; 2000GB-00024263.	XX WO200192524-A2.	
PR	30-JAN-2001; 2001WO-US000661.	XX PD 06-DEC-2001.	
PR	30-JAN-2001; 2001WO-US000662.	XX PF 25-MAY-2001; 2001WO-US016981.	
PR	30-JAN-2001; 2001WO-US000663.	XX PR 26-MAY-2000; 2000US-0207456P.	
PR	30-JAN-2001; 2001WO-US000664.	XX PR 21-SEP-2000; 2000US-0234687P.	
PR	30-JAN-2001; 2001WO-US000665.	XX PR 27-SEP-2000; 2000US-0236359P.	
PR	30-JAN-2001; 2001WO-US000666.	XX PR 04-OCT-2000; 2000GB-00024263.	
PR	30-JAN-2001; 2001WO-US000667.	XX PR 30-JAN-2001; 2001WO-US000661.	
PR	30-JAN-2001; 2001WO-US000668.	XX PR 30-JAN-2001; 2001WO-US000662.	
PR	30-JAN-2001; 2001WO-US000669.	XX PR 30-JAN-2001; 2001WO-US000663.	
PR	30-JAN-2001; 2001WO-US000670.	XX PR 30-JAN-2001; 2001WO-US000664.	
PR	05-FEB-2001; 2001US-0268660P.	XX PR 30-JAN-2001; 2001WO-US000665.	
XX	(AEOM-) AEOMICA INC.	XX PR 30-JAN-2001; 2001WO-US000666.	
XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;	XX PR 30-JAN-2001; 2001WO-US000667.	
XX	WPI; 2002-179446/23.	XX PR 30-JAN-2001; 2001WO-US000668.	
XX	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,	XX PR 30-JAN-2001; 2001WO-US000669.	
PT	or as specific biomolecule capture probes for surface-enhanced laser	XX PR 30-JAN-2001; 2001WO-US000670.	
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.	XX PR 05-FEB-2001; 2001US-0268660P.	
XX	Disclosure; SEQ ID NO 8353; 214pp; English.	XX PA (AEOM-) AEOMICA INC.	
XX	The present invention describes a human genome-derived myosin-like	XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;	
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-	XX WPI; 2002-179446/23.	
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1	XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,	
CC	nucleic acids can be used as probes to detect, characterise and quantify	PT or as specific biomolecule capture probes for surface-enhanced laser	
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to	PT desorption ionization, comprises human myosin-like protein hGDMLP-1.	
CC	provide initial substrates for the recombinant engineering of hGDMLP-1	XX Disclosure; SEQ ID NO 10038; 214pp; English.	
CC	protein variants having desired phenotypic improvements, and for	XX The present invention describes a human genome-derived myosin-like	
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be	XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-	
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP	CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1	
CC	-1 proteins, as standards in assays used to determine the concentration	CC nucleic acids can be used as probes to detect, characterise and quantify	
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule	CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to	
CC	capture probes for surface-enhanced laser desorption/ionisation, as	CC provide initial substrates for the recombinant engineering of hGDMLP-1	
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1	CC protein variants having desired phenotypic improvements, and for	
CC	production, and in vaccines or for replacement therapy. The	CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be	
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a	CC used as immunogens to raise antibodies that specifically recognise hGDMLP	
CC	disorder associated with the expression of hGDMLP-1, in particular heart	CC -1 proteins, as standards in assays used to determine the concentration	
CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.	CC and/or amount specifically of hGDMLP proteins, as specific biomolecule	
CC	The present sequence represents an oligomer used in the screening of the	CC capture probes for surface-enhanced laser desorption/ionisation, as	
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.	CC therapeutic supplement in patients having specific deficiency in hGDMLP-1	
CC	The sequence data for this patent did not form part of the printed	CC production, and in vaccines or for replacement therapy. The	
CC	specification, but was obtained in electronic format directly from WIPO	CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a	
CC	at ftp.wipo.int/pub/published_pct_sequence	CC disorder associated with the expression of hGDMLP-1, in particular heart	
XX	Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;	CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.	
XX	Query Match 0.98; Score 14.4; DB 1; Length 17;	CC The present sequence represents an oligomer used in the screening of the	
XX	Best Local Similarity 93.88; Pred. No. 1.6e+02;	CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.	
XX	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	CC The sequence data for this patent did not form part of the printed	
XX	1109 CAGCTCCTCCTTGCTG 1124	CC specification, but was obtained in electronic format directly from WIPO	
XX		CC at ftp.wipo.int/pub/published_pct_sequence	

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCGCAG 730
Db 16 CCGCATCGTCACAG 1

RESULT 235
ABN08673
ID ABN08673 standard; DNA; 17 BP.
XX
AC ABN08673;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8665.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
DR
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 8665; 214pp; English.
XX
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP

CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCCAAGAGAGA 288
Db 2 GAAGCCCAAGAGAGA 17

RESULT 236
ABN10045/c
ID ABN10045 standard; DNA; 17 BP.
XX
AC ABN10045;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10037.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX

PS Disclosure; SEQ ID NO 10037; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence

XX

XX Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

SQ

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCGCGAG 730

DB 17 CCGCATCGTCACAG 2

RESULT 237

ACN07604

ID ACN07604 standard; RNA; 17 BP.

XX

AC ACN07604;

XX

DT 22-APR-2004 (first entry)

XX

DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7607.

XX

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

XX virucide; neuroprotective; antibacterial; replication; pancreatitis;

XX encephalitis; myocarditis; meningitis; infection; hepatitis;

XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

XX Amberzyme; Zinzyne; ss.

XX

OS West Nile Virus.

XX

XX WO200268637-A2.

XX

XX 06-SEP-2002.

XX

XX 19-OCT-2001; 2001WO-US048350.

XX

XX 20-OCT-2000; 2000US-0242411P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX

PI Blatt L, Mcswiggen JA;

XX

XX WPI; 2002-706994/76.

XX

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PT

PS Claim 23; SEQ ID NO 7607; 495pp; English.

XX

XX The invention relates to nucleic acid molecules that modulate replication

XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for

XX treating a condition related to WNV infection e.g. pancreatitis,

XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

XX molecule is selected from the group of ribozymes consisting of

XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The

XX nucleic acid molecules further comprise at least five ribose residues, at

XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at

XX least three of the 5' terminal nucleotides and a 3' end modification of a

XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

XX in the specification. The present sequence is that of a nucleic acid

XX molecule of the invention

SQ

Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 1.6e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1234 CGGACGTTCTTCGCG 1249

DB 1 CGGACGUUCCAUCCGG 16

RESULT 238

ACN09975

ID ACN09975 standard; RNA; 17 BP.

XX

AC ACN09975;

XX

DT 22-APR-2004 (first entry)

XX

DE WNV minus strand Inozyme substrate SEQ ID NO 9978.

XX

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

XX virucide; neuroprotective; antibacterial; replication; pancreatitis;

XX encephalitis; myocarditis; meningitis; infection; hepatitis;

XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

XX Amberzyme; Zinzyne; ss.

XX

OS West Nile Virus.

XX

XX WO200268637-A2.

XX

XX 06-SEP-2002.

XX

XX 19-OCT-2001; 2001WO-US048350.

XX

XX 20-OCT-2000; 2000US-0242411P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX

PI Blatt L, Mcswiggen JA;

XX

XX WPI; 2002-706994/76.

XX

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PT

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The CC nucleic acid molecules further comprise at least five ribose residues, at CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at CC least three of the 5' terminal nucleotides and a 3' end modification of a CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given CC in the specification. The present sequence is that of a nucleic acid CC molecule of the invention

XX
SQ Sequence 17 BP; 2 A; 9 C; 2 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. NO. 1.6e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACCTCTCTCT 1119
DB 1 CUCGACACCUCCUCCU 16

RESULT 239
ACN07053/C
ID ACN07053 standard; RNA; 17 BP.
XX AC ACN07053;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Amberzyme substrate SEQ ID NO 7056.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 7056; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX
SQ Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 2 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. NO. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACCTCTCTCT 1119
DB 17 CTCGACACCTCTCTCT 2

RESULT 240
ACN07193/C
ID ACN07193 standard; RNA; 17 BP.
XX AC ACN07193;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Amberzyme substrate SEQ ID NO 7196.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 7196; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1234 CGGACGTTCTCTCCGG 1249
Db 17 CGGACGTTCTCTCCGG 2

RESULT 241

ACN04500/C

ID ACN04500 standard; RNA; 17 BP.

XX ACN04500;

XX 22-APR-2004 (first entry)

XX WNV Zinzyne substrate SEQ ID NO 4503.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 4503; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication

XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for

XX treating a condition related to WNV infection e.g. pancreatitis,

XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

XX molecule is selected from the group of ribozymes consisting of

XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The

XX nucleic acid molecules further comprise at least five ribose residues, at

XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at

XX least three of the 5' terminal nucleotides and a 3' end modification of a

XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

XX in the specification. The present sequence is that of a nucleic acid

XX molecule of the invention

XX Sequence 17 BP; 4 A; 1 C; 10 G; 0 T; 2 U; 0 Other;

XX Query Match 0.9%; Score 14.4; DB 1; Length 17;

XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;

XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1104 CTCACACCTCTCTCT 1119

Db 16 CTCGACACCTCTCTCT 1

RESULT 242

ACN07603

ID ACN07603 standard; RNA; 17 BP.

XX ACN07603;

XX 22-APR-2004 (first entry)

XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7606.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 7606; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication

XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for

XX treating a condition related to WNV infection e.g. pancreatitis,

XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

XX molecule is selected from the group of ribozymes consisting of

XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The

XX nucleic acid molecules further comprise at least five ribose residues, at

XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at

XX least three of the 5' terminal nucleotides and a 3' end modification of a

XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

XX in the specification. The present sequence is that of a nucleic acid

XX molecule of the invention

XX Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

XX Query Match 0.9%; Score 14.4; DB 1; Length 17;

XX Best Local Similarity 75.0%; Pred. No. 1.6e+02;

XX Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1234 CGGACGTTCTCTCCGG 1249

Db 2 CGGACGTTCTCTCCGG 17

RESULT 243

ABT3885/C

ID ABT3885 standard; DNA; 17 BP.

XX ABT3885;

XX

DT 12-JUN-2003 (first entry)
XX Tumour suppression related human fukutin oligo SEQ ID No 4522.
DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX Homo sapiens.
OS
XX
XX WO2003025175-A2.
PN
XX
XX 27-MAR-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004208.
PF
XX
XX 17-SEP-2001; 2001FR-00011978.
PR
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX
XX Telerman A, Amson R, Tuijnder M;
PI
XX
XX WPI; 2003-313353/30.
DR
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
PT
XX
XX Disclosure; Page 562; 720pp; French.
PS
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
XX
SQ Sequence 17 BP; 2 A; 6 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 326 AAAGCTGAAGGAGCTC 341
Db 16 AAAGCTGAAGGAGATC 1
RESULT 244
ADB00466/c
ID ADB00466 standard; DNA; 17 BP.
XX
XX ADB00466;
AC
XX 20-NOV-2003 (first entry)
DT
XX

DE Human MD23 scanning oligonucleotide SEQ ID 1452.
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX
XX EP1281758-A2.
PN
XX
XX 05-FEB-2003.
PD
XX
XX 30-JUL-2002; 2002EP-00016874.
PF
XX
XX 02-AUG-2001; 2001US-00922181.
PR
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Shannon M, Gu Y, Nguyen C;
PI
XX
XX WPI; 2003-423107/40.
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 1452; 103pp; English.
PS
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 928 GCTGCTGCGGATGAA 943
Db 16 GCTGCTGCGGCTGAA 1
RESULT 245
ADB00464/c
ID ADB00464 standard; DNA; 17 BP.
XX
XX ADB00464;
AC
XX 20-NOV-2003 (first entry)
DT
XX
XX Human MD23 scanning oligonucleotide SEQ ID 1450.
DE
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
XX Homo sapiens.
OS

PR 10-SEP-2001; 2001US-0318471P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Mcswiggen J;
XX WPI; 2003-140484/13.
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX Claim 58; Page 116; 185pp; English.
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX Sequence 17 BP; 1 A; 5 C; 9 G; 0 T; 2 U; 0 Other;
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1507 CCAGCTTCGAGGCCCC 1522
Db 17 CCAGCTTCGAGGCCCC 2
RESULT 247
ACD59853
ID ACD59853 standard; RNA; 17 BP.
XX AC ACD59853;
XX 24-SEP-2003 (first entry)
DT HCV DNase substrate sequence #1543.
DE Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNase; zinzyme;
XX amberyse; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.
XX Hepatitis C virus.
OS WO200281494-A1.
PN 17-OCT-2002.
PD 26-MAR-2002; 2002WO-US009187.
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.

XX EPI281758-A2.
XX 05-FEB-2003.
XX 30-JUL-2002; 2002EP-00016874.
XX 02-AUG-2001; 2001US-00922181.
XX (AEOM-) AEOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX Example 8; SEQ ID NO 1450; 103pp; English.
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 929 CTGCTGCGGATGAAG 944
Db 17 CTGCTGCGGATGAAG 2
RESULT 246
ABZ61479/C
ID ABZ61479 standard; RNA; 17 BP.
XX AC ABZ61479;
XX 21-MAR-2003 (first entry)
DT Human H-Ras DNase target #270.
DE Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX anti-rheumatic; cancer; AIDS; ss.
XX Homo sapiens.
OS WO200297114-A2.
PN 05-DEC-2002.
PD 29-MAY-2002; 2002WO-US016840.
XX 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.

PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LESP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX
 XX WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT
 XX
 PS Claim 1; Page 261; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNzyme or minus strand DNzyme sequences disclosed in the present
 CC invention
 CC
 SQ Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 1.6e+02;
 Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 768 CACGCCATGTTCCAGC 783
 |||||:|:|:|
 DB 1 CACGCCAUGUUCGCG 16
 RESULT 248
 ACDS3920/C
 ID ACDS3920 standard; RNA; 17 BP.
 XX
 AC ACDS3920;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HBV zinzyme substrate sequence #90.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW viricide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis B virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.
 XX
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LESP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX
 XX WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT
 XX
 PS Example 1; Page 175; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HBV
 CC ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberyne sequences
 CC disclosed in the present invention
 CC
 SQ Sequence 17 BP; 3 A; 0 C; 11 G; 0 T; 3 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1519 CCCCCAACTCCGCCCA 1534
 |||||:|:|:|
 DB 16 CCCCCAACTCCGCCCA 1
 RESULT 249
 ADB43621
 ID ADB43621 standard; DNA; 17 BP.
 XX
 AC ADB43621;
 XX
 DT 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)
 XX
 DE Tumour suppression/reversion associated nucleotide #3944.
 XX
 KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;

KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX Homo sapiens.
XX WO2003040369-A2.
XX 15-MAY-2003.
XX 17-SEP-2002; 2002WO-IB004219.
XX 17-SEP-2001; 2001FR-00011981.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijinder M;
XX WPI; 2003-441574/41.
XX New nucleic acid encoding human prostate membrane-specific antigen,
XX useful e.g. for treatment of tumors and viral infection, also related
XX polypeptide and antibodies.
XX Disclosure; Page 493; 771pp; French.
XX The invention relates to the isolation of 6327 nucleotide sequences,
XX fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX sequence having at least 80% identity, after optimal alignment, with the
XX nucleotides, a sequence that hybridizes under stringent conditions with
XX the nucleotides, or the complement, or corresponding RNA, of the
XX nucleotides. The nucleotides are used as probes or primers for detecting,
XX identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX sense and antisense sequences, of nucleotides involved in tumour
XX suppression or reversion, apoptosis and or viral resistance, to produce
XX recombinant polypeptides, and to prepare transgenic animals, as
XX experimental models. The nucleotides (also vectors containing them and
XX cells containing the vectors), the encoded polypeptides and antibodies
XX (Ab) against the polypeptide are useful for prevention and/or treatment
XX of viral infections or diseases characterized by development of tumours
XX or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX Analysis of the expression of the nucleotides can be used for diagnosis
XX and/or prognosis of these diseases. The nucleotides and polypeptides can
XX also be used to screen for their specific interactive molecules,
XX potentially useful for treating diseases associated with abnormal
XX expression of the nucleotides.
XX Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 154 ATCAGGGGAAGTAAGTA 169
DB 2 ATCAGGGGAAGTAAGTA 17
RESULT 250
ADE30979
ID ADE30979 standard; DNA; 17 BP.
XX ADE30979;
XX 29-JAN-2004 (first entry)
XX Cholesterol homeostasis/adipogenesis related DNA seq id 366.
XX expression vector; anorectic; antiarteriosclerotic; cardiant;
XX anti-diabetic; elevated cholesterol; elevated lipid; adipogenesis;
KW obesity; atherosclerosis; diabetes mellitus;
KW coronary artery heart disease; cholesterol homeostasis; ss;
KW differential expression.
XX

OS Homo sapiens.
XX US2003180764-A1.
XX 25-SEP-2003.
XX 08-JAN-2003; 2003US-00339793.
XX 09-JAN-2002; 2002US-0347286P.
XX (LYNX-) LYNX THERAPEUTICS INC.
XX Shang J, Bowen B;
XX WPI; 2003-830986/77.
XX Polynucleotides differentially regulated in response to cholesterol and
XX PT adipogenesis are useful to detect and treat associated conditions such as
XX PT obesity, atherosclerosis, diabetes mellitus and coronary artery heart
XX PT disease.
XX Claim 8; SEQ ID NO 366; 59pp; English.
XX The invention describes a composition comprising at least one expression
XX vector comprising a polynucleotide of the invention. The composition has
XX anorectic, antiarteriosclerotic, cardiant and anti-diabetic properties.
XX The invention is used to detect and treat conditions associated with
XX elevated cholesterol and lipid or during adipogenesis, particularly
XX obesity, atherosclerosis, diabetes mellitus or coronary artery heart
XX disease. This sequence represents a polynucleotide differentially
XX expressed during cholesterol homeostasis and adipogenesis.
XX Sequence 17 BP; 5 A; 9 C; 1 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 990 ACCAAGACCCCTCCC 1005
DB 2 ATCAACACCCCTCCC 17
RESULT 251
ABX95832
ID ABX95832 standard; DNA; 17 BP.
XX ABX95832;
XX 24-JUL-2003 (first entry)
XX Human Phe311Ileu mutant Abl kinase, allele specific PCR primer F311T.
XX Human; Abl kinase domain; tyrosine kinase activity; leukaemia;
KW N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4-;
KW (4-methyl-piperazin-1-ylmethyl)-benzamide; PCR; primer; ss.
XX Homo sapiens.
OS Synthetic.
XX WO2003031608-A2.
XX 17-APR-2003.
XX 04-OCT-2002; 2002WO-EP011144.
XX 05-OCT-2001; 2001US-0327389P.
PR 12-OCT-2001; 2001US-0328740P.
PR 11-JAN-2002; 2002US-0347351P.
XX (NOVS) NOVARTIS AG.
PA (UYBO-) UNIV BORDEAUX 2 SEGALLEN VICTOR.
PA (UYMU-) UNIV TECH MUEENCHEN.

```
PA (UYOR-) UNIV OREGON HEALTH SCI.
PA (UYHE-) UNIV HEIDELBERG.
PA (CHRU-) CHRU LILLE.
PA (MEDV-) MEDVET SCI PTY LTD.
XX
PI Barthe C, Branford S, Corbin A, Druker BJ, Duyster J, Hochhaus A;
PI Hughes T, Kreil S, Leguay T, Mahon F, Marit G, Mueller M;
PI Peschel C, Preudhomme C, Roche Lestienne C, Rudzki Z;
XX
DR WPI; 2003-363366/34.
XX
PT New isolated polypeptide having mutated native human Abl kinase domains,
PT useful for screening compounds that inhibit tyrosine kinase activity and
PT for diagnosing leukemias.
XX
PS Example 6; Page 34; 57pp; English.
XX
CC The present invention relates to mutated human Abl kinase domains that
CC are functional and resistant to inhibition of their tyrosine kinase
CC activity by N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4
CC -(4-methyl-piperazin-1-ylmethyl)-benzamide, or its salt. The mutant Abl
CC polypeptides are useful in screening for compounds that inhibit the
CC tyrosine kinase activity of such polypeptides. Polynucleotide sequences
CC encoding the mutant polypeptides are useful for the production of the
CC mutant polypeptides. The mutant polypeptides are also useful in the
CC diagnosis of leukaemias. The present sequence represents a PCR primer
CC used in the examples of the present invention
XX
SQ Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 635 CACCCGGGAGCCCCAG 650
Db 1 CACCCGGGAGCCCCCG 16
RESULT 252
ABX95833
ID ABX95833 standard; DNA; 17 BP.
XX
AC ABX95833;
XX
DT 24-JUL-2003 (first entry)
XX
DE Human Phe311Leu mutant Abl kinase, allele specific PCR primer F311C.
XX
KW Human; Abl kinase domain; tyrosine kinase activity; leukaemia;
KW N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4-;
KW (4-methyl-piperazin-1-ylmethyl)-benzamide; PCR; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003031608-A2.
XX
PD 17-APR-2003.
XX
PF 04-OCT-2002; 2002WO-EP011144.
XX
PR 05-OCT-2001; 2001US-0327389P.
PR 12-OCT-2001; 2001US-0328740P.
PR 11-JAN-2002; 2002US-0347351P.
XX
(NOVS ) NOVARTIS AG.
PA (UYBO-) UNIV BORDEAUX 2 SEGALEN VICTOR.
PA (UYMU-) UNIV TECH MUENCHEN.
PA (UYOR-) UNIV OREGON HEALTH SCI.
PA (UYHE-) UNIV HEIDELBERG.
PA (CHRU-) CHRU LILLE.
PA (MEDV-) MEDVET SCI PTY LTD.
XX
Barthe C, Branford S, Corbin A, Druker BJ, Duyster J, Hochhaus A;
Hughes T, Kreil S, Leguay T, Mahon F, Marit G, Mueller M;
Peschel C, Preudhomme C, Roche Lestienne C, Rudzki Z;
WPI; 2003-363366/34.
New isolated polypeptide having mutated native human Abl kinase domains,
useful for screening compounds that inhibit tyrosine kinase activity and
for diagnosing leukemias.
Example 6; Page 34; 57pp; English.
The present invention relates to mutated human Abl kinase domains that
are functional and resistant to inhibition of their tyrosine kinase
activity by N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4
-(4-methyl-piperazin-1-ylmethyl)-benzamide, or its salt. The mutant Abl
polypeptides are useful in screening for compounds that inhibit the
tyrosine kinase activity of such polypeptides. Polynucleotide sequences
encoding the mutant polypeptides are useful for the production of the
mutant polypeptides. The mutant polypeptides are also useful in the
diagnosis of leukaemias. The present sequence represents a PCR primer
used in the examples of the present invention
Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 635 CACCCGGGAGCCCCAG 650
Db 1 CACCCGGGAGCCCCCG 16
RESULT 253
ADL18587
ID ADL18587 standard; DNA; 17 BP.
XX
AC ADL18587;
XX
DT 06-MAY-2004 (first entry)
XX
DE RT-PCR primer HP6.
XX
KW DNA storage; DNA analysis; virus identification; bacteria identification;
KW reverse transcriptase; RT-PCR; primer; ss; HP6.
XX
OS Synthetic.
XX
US2003134312-A1.
PD 17-JUL-2003.
XX
PF 15-NOV-2002; 2002US-00298255.
XX
PR 15-NOV-2001; 2001US-0336005P.
XX
(WHAT-) WHATMAN INC.
XX
Burgoyne LA;
XX
WPI; 2003-843261/78.
XX
New device comprising a filter layer comprising a dry solid medium
comprising a hydrophilic solid matrix, and an isolation layer, useful for
storing and analyzing a nucleic acid containing moiety.
Example 1; SEQ ID NO 4; 14pp; English.
The invention relates to a device for storage and analysis of a nucleic
acid containing a moiety in a biological sample, comprising a filter
layer comprising a dry solid medium comprising a hydrophilic solid
```

CC matrix, and an isolation layer comprising a dry solid medium comprising a
 CC neutral solid matrix attached to a composition comprising a detergent.
 CC Storing and analysing a nucleic acid containing a moiety in a biological
 CC sample comprises applying a biological sample to the filter layer,
 CC filtering the components of the biological sample through the filter
 CC layer to the isolation layer, retaining the nucleic acid components in
 CC the isolation layer while removing the non-nucleic acid components,
 CC drying the isolation layer, providing a primer and analysing the nucleic
 CC acid components using at least one primer. The device and method are
 CC useful for storing and analysing a nucleic acid containing a moiety in a
 CC biological sample. They are also useful for identifying known or unknown
 CC viruses or bacteria contained in a fluid. This sequence represents a
 CC reverse transcriptase PCR (RT-PCR) primer used in the scope of the
 CC invention.

XX SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523

DB 1 CAGCCTCCAGGCCCC 16

RESULT 254

ADMS9611/c
 ID ADM59611 standard; RNA; 17 BP.

XX AC ADM59611;

XX DT 03-JUN-2004 (first entry)

XX DE Hepatitis B virus (HBV) RNA target sequence #1745.

XX KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
 KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
 KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
 KW virucide; hepatotropic; antiinflammatory; cytostatic.

XX OS Hepatitis B virus.

XX PN US2004054156-A1.

XX PD 18-MAR-2004.

XX PF 15-JAN-2003; 2003US-00342902.

XX PR 14-MAY-1992; 92US-00882712.

XX PR 07-FEB-1994; 94US-00193627.

XX PR 08-NOV-1999; 99US-00436430.

XX PR 20-MAR-2000; 2000US-00531025.

XX PR 09-AUG-2000; 2000US-00636385.

XX PR 24-OCT-2000; 2000US-00696347.

XX PR 08-JUN-2001; 2001US-00877478.

XX PI (DRAP/) DRAPER K.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J A.

XX PA (MORR/) MORRISSEY D.

XX XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;

XX WPI; 2004-247781/23.

XX XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes

XX PT specifically cleaving RNA derived from hepatitis B virus and comprising

XX PT one or more binding arms, useful for treating hepatitis and cirrhosis.

XX XX Disclosure; SEQ ID NO 1745; 122pp; English.

XX XX The invention relates to an enzymatic nucleic acid molecule that

CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
 CC comprising one or more binding arms, without requiring the presence of a
 CC 2'-OH group within the molecule for activity. The nucleic acids are
 CC useful for treating hepatitis B virus infection, hepatitis,
 CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
 CC combination with other therapies such as lamivudine and interferons. The
 CC nucleic acids are useful as diagnostic tools to examine genetic drift and
 CC mutations within diseased cells, for detecting the presence of HBV RNA in
 CC a cell, for the study of RNA and for down-regulating gene expression of
 CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
 CC sequence represents an HBV RNA target sequence, used in the scope of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 17 BP; 3 A; 0 C; 11 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1519 CCCCCCACTCCGCCCA 1534

DB 16 CCCCCCACTCCGCCCA 1

RESULT 255

AD184297
 ID AD184297 standard; RNA; 17 BP.

XX AC AD184297;

XX DT 03-JUN-2004 (first entry)

XX DE HCV DNazyme substrate sequence #1543.

XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
 KW HCV infection; type I interferon; DNazyme.

XX OS Hepatitis C virus.

XX PN US2003125270-A1.

XX PD 03-JUL-2003.

XX PF 18-DEC-2000; 2000US-00740332.

XX PR 18-DEC-2000; 2000US-00740332.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J.

XX PA (ROBE/) ROBERTS E.

XX PA (PAVC/) PAVCO P A.

XX PA (MACE/) MACEJACK D.

XX XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;

XX WPI; 2004-031273/03.

XX XX Enzymatic nucleic acid molecules which specifically cleave RNA derived

XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,

XX PT especially in combination with type I interferon therapy.

XX XX Claim 1; SEQ ID NO 1543; 198pp; English.

XX CC The invention relates to an enzymatic nucleic acid molecule which

XX CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which

XX CC the binding arms of the enzymatic nucleic acid molecule comprises

XX CC sequences complementary to any of the defined substrate sequences given

XX CC in the specification. The nucleic acid molecule may be administered for

XX CC the treatment of HCV infections, especially in combination with type I

XX CC interferons. The present sequence represents a HCV DNazyme substrate

XX CC sequence.

SQ Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 768 CAGGCCATGTCAGC 783
|||||:|:|:|
Db 1 CAGCCCAUGUCCGCC 16

RESULT 256

ADI85767/c

ID ADI85767 standard; RNA; 17 BP.

XX AC ADI85767;

XX DT 03-JUN-2004 (first entry)

XX DE HCV DNAzyme substrate sequence #3013.

XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;

XX KW HCV infection; type I interferon; DNAzyme.

XX OS Hepatitis C virus.

XX PN US2003125270-A1.

XX PD 03-JUL-2003.

XX PF 18-DEC-2000; 2000US-00740332.

XX PR 18-DEC-2000; 2000US-00740332.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J.

XX PA (ROBE/) ROBERTS E.

XX PA (PVC/) PAVCO P A.

XX PA (MACE/) MACEJACK D.

XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;

XX DR WPI; 2004-031273/03.

XX PT Enzymatic nucleic acid molecules which specifically cleave RNA derived

PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,

PT especially in combination with type I interferon therapy.

XX PS Claim 1; SEQ ID NO 3013; 198pp; English.

XX CC The invention relates to an enzymatic nucleic acid molecule which

CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which

CC the binding arms of the enzymatic nucleic acid molecule comprises

CC sequences complementary to any of the defined substrate sequences given

CC in the specification. The nucleic acid molecule may be administered for

CC the treatment of HCV infections, especially in combination with type I

CC interferons. The present sequence represents a HCV DNAzyme substrate

XX sequence.

SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 768 CAGGCCATGTCAGC 783

|||||:|:|:|

Db 16 CAGGCCATGTCGCC 1

RESULT 257

ACN71763

ID ACN71763 standard; DNA; 17 BP.

XX AC ACN71763;

XX DT 02-DEC-2004 (first entry)

XX DE Human GDMPLP-1 probe SEQ ID NO:8665.

XX KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

XX KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

XX KW skeletal muscle function.

XX OS Homo sapiens.

XX PN US2004137589-A1.

XX PD 15-JUL-2004.

XX PF 26-NOV-2003; 2003US-00723361.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 05-FEB-2001; 2001WO-US000670.

XX PR 25-MAY-2001; 2001US-00866108.

XX PA (GUY/) GU Y.

XX PA (JIY/) JI Y.

XX PA (PENN/) PENN S G.

XX PA (HANZ/) HANZEL D K.

XX PA (RANK/) RANK D.

XX PA (CHEN/) CHEN W.

XX PA (SHAN/) SHANNON M E.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX DR WPI; 2004-533378/51.

XX PT Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

XX function.

XX PS Disclosure; SEQ ID NO 8665; Opp; English.

XX CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 35% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103

XX SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 768 CAGGCCATGTCAGC 783

|||||:|:|:|

Db 16 CAGGCCATGTCGCC 1

QY 273 GAAGCCAGAGAGA 288
DB 2 GAAGCCAGAGAGAGA 17

RESULT 258
ACN73136/c

ID ACN73136 standard; DNA; 17 BP.

XX ACN73136;
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:10038.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX OS
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024283.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 10038; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103
XX Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCGCAG 730
DB 16 CCGCATCGTCACAG 1

RESULT 259
ACN73135/c

ID ACN73135 standard; DNA; 17 BP.
XX ACN73135;
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:10037.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX OS
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 10037; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCGCAG 730

Db 17 CCGCATCGTCGCAG 2

RESULT 260

ACN71450/c

ID ACN71450 standard; DNA; 17 BP.

XX ACN71450;

XX 02-DEC-2004 (first entry)

DE Human GDMLP-1 probe SEQ ID NO:8352.

XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;

KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

PA (JIY/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

DR Novel myosin-like protein-1, useful for treating or preventing disorder

PT

PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 8352; Opp; English.

CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX

SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTCTGCTG 1124

Db 17 CAGCTCTCTCTGCTG 2

RESULT 261

ACN71451/c

ID ACN71451 standard; DNA; 17 BP.

XX ACN71451;

XX 02-DEC-2004 (first entry)

XX Human GDMLP-1 probe SEQ ID NO:8353.

KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;

KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

PA (JIY/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX MPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 8353; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1109 CACCTCCTCTTGCTG 1124
DB 16 CAGCTCCTCTTGCTG 1
RESULT 262
ACN71765
ID ACN71765 standard; DNA; 17 BP.
XX ACN71765;
XX
XX 02-DEC-2004 (first entry)
XX Human GDMLP-1 probe SEQ ID NO:8667.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX MPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 8667; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 274 AGCCCAAGAGAGAA 289
DB 1 AGCCCAAGAGAGAGAA 16
RESULT 263
AAQ80949/C
ID AAQ80949 standard; DNA; 18 BP.
XX AAQ80949;
XX
XX 25-MAR-2003 (revised)
XX 24-AUG-1995 (first entry)
XX
XX PCR primer to generate probe flanking the sCos-1 T7 promoter site.
XX
XX sequence sampled mapping; genomic analysis; complex genome mapping;
XX cosmid library; Giardia lamblia; T7 promoter; ss.
XX Synthetic.
XX
XX WO9429486-A1.
XX
XX 22-DEC-1994.
XX
XX 15-JUN-1994; 94WO-US006810.
XX
XX 15-JUN-1993; 93US-00078471.
XX
XX 07-SEP-1993; 93US-00117952.
XX
XX (SALK) SALK INST BIOLOGICAL STUDIES.
XX
XX Evans GA, Smith MW;
PI

XX WPI; 1995-036508/05.
 XX Sequencing complex genomes, present as fragments in a cosmid library - by
 PT sequencing end-specific nucleotides of each clone then correlating with
 PT spatial relationship of cosmid, esp. for mammalian chromosomes.
 XX
 PS Example 3; Page 44; 128pp; English.
 XX
 CC In a sequence-sample mapping procedure using a Giardia lamblia 20-genome
 CC equivalent cosmid library, each end of the genomic insert in a cosmid was
 CC detected as a vector/genomic chimera by hybridisation with probes
 CC flanking the T3 and T7 promoter sites of sCos-1. The 1046 bp T3 probe was
 CC amplified from sCos-1 with the primers AAQ80946 and AAQ80947 and the 1004
 CC bp T7 probe was amplified with primers AAQ80948 and AAQ80949. The T7
 CC probe was labelled with 35S- dATP and the T3 probe with 33P-dATP for dual
 CC -label hybridisations. Maps were constructed by determining an order of
 CC fragments with no gaps using a computer program. (Updated on 25-MAR-2003
 CC to correct PN field.)
 XX
 SQ Sequence 18 BP; 4 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1520 CCCCAACTCCGCCGAC 1535
 DB 18 CCTAATCTCCGCCGAC 3
 RESULT 264
 ADM06417
 ID ADM06417 standard; DNA; 18 BP.
 XX
 AC ADM06417;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PCR primer SEQ ID NO:5102.
 XX
 KW human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.
 XX
 OS Homo sapiens.
 XX
 PN EPI347046-A1.
 XX
 PD 24-SEP-2003.
 XX
 PF 12-APR-2002; 2002EP-00008400.
 XX
 PR 22-MAR-2002; 2002JP-00137785.
 XX
 PA (REAS-) RES ASSOC BIOTECHNOLOGY.
 XX
 PI Isegai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
 PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
 PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
 XX WPI; 2003-723558/69.
 DR
 XX
 PT New polynucleotides and polypeptides are useful in gene therapy, for
 PT developing a diagnostic marker or medicines for regulating their
 PT expression and activity, or as a target of gene therapy.
 XX
 PS Example 8; SEQ ID NO 5102; 305pp; English.
 XX
 CC The invention relates to a novel human polynucleotide and the encoded
 CC polypeptide. A polynucleotide of the invention may have a use in gene
 CC therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful
 CC as a primer for synthesizing the polynucleotide or as a probe for
 CC detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are
 CC useful in gene therapy, for developing a diagnostic marker or medicines

CC for regulating their expression and activity, or as a target of gene
 CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
 CC are useful as pharmaceutical agents. The present sequence represents an
 CC oligonucleotide used in the invention.
 XX
 SQ Sequence 18 BP; 4 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1094 GTGGAAGATGCTCAAC 1109
 DB 1 GTGGAAGATGCTCGAC 16
 RESULT 265
 ADM92954
 ID ADM92954 standard; DNA; 18 BP.
 XX
 AC ADM92954;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE SNP-containing cardiovascular associated gene primer #285.
 XX
 KW SNP; single nucleotide polymorphism; cardiovascular associated gene;
 KW allelic variation; atherosclerosis; ischemia; reperfusion; hypertension;
 KW restenosis; arterial inflammation; myocardial infarction; stroke; primer;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003057911-A2.
 XX
 PD 17-JUL-2003.
 XX
 PF 07-JAN-2003; 2003WO-EP0000060.
 XX
 PR 08-JAN-2002; 2002EP-00000153.
 XX
 PA (FARB) BAYER AG.
 XX
 PI Stropp U, Schwes S, Kallabis H;
 XX WPI; 2003-577532/54.
 DR
 XX
 PT New isolated polynucleotides comprising single nucleotide polymorphisms
 PT of the cardiovascular gene, useful for assessing predisposition or
 PT susceptibility to a cardiovascular disease, e.g. atherosclerosis,
 PT restenosis or stroke.
 XX
 PS Disclosure; Page 78; 187pp; English.
 XX
 CC The invention relates an isolated polynucleotide (I) encoded by a
 CC cardiovascular associated (CA) gene, having allelic variation contained
 CC in a functional surrounding like full length cDNA for CA gene
 CC polypeptide, and with or without the CA gene promoter sequence. (I) is a
 CC polynucleotide comprising single nucleotide polymorphisms predicting
 CC cardiovascular disease. The polynucleotides are useful for assessing
 CC predisposition or susceptibility to a cardiovascular disease, e.g.
 CC atherosclerosis, ischemia/reperfusion, hypertension, restenosis, arterial
 CC inflammation, myocardial infarction, and stroke. These may also be used
 CC to predict personal medication schemes omitting adverse drug reactions.
 CC or as probes for detecting genetic polymorphisms and as templates for the
 CC recombinant production of normal or variant peptides/polypeptides encoded
 CC by the genes. This sequence corresponds to a PCR primer to amplify one of
 CC the genes of the invention.
 XX
 SQ Sequence 18 BP; 8 A; 5 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.9e+02;

SQ	Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;	Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Query Match 0.9%; Score 14; DB 1; Length 15;		
Best Local Similarity 100.0%; Pred. No. 1.2e+02;		
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	136 AGCTCCAGGAATG 149	
DB	1 AGCTCCAGGAATG 14	
RESULT 268		
AAF47084		
ID	AAF47084 standard; DNA; 15 BP.	
XX	AC AAF47084;	
XX	DT 30-MAR-2001 (first entry)	
XX	IGFBP3 oligonucleotide #504.	
KW	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;	
KW	cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;	
KW	skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;	
KW	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;	
KW	growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;	
KW	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;	
KW	hyponeovascular condition; hyperplasia; kidney disease;	
KW	neovascular condition of the retina; ss.	
XX	Homo sapiens.	
OS	WO200078341-A1.	
PN	28-DEC-2000.	
PD	21-JUN-2000; 2000WO-AU000693.	
PF	21-JUN-1999; 99US-0140345P.	
PR	(MURD-) MURDOCH CHILDRENS RES INST.	
PA	Wright CJ, Werther GA, Edmondson SR;	
PI	WPI; 2001-041421/05.	
DR	Ameliorating the effects of a disorder, e.g. psoriasis, by administering	
XX	UV (ultra-violet) treatment (optional) and an antisense nucleic acid that	
PT	inhibits or reduces growth factor mediated cell proliferation and/or	
PT	inflammation.	
XX	Example 7; Page 47; 201pp; English.	
PS	The present invention relates to a method for ameliorating the effects of	
CC	skin disorders. The method comprises contacting the skin with an	
CC	antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1	
CC	receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of	
CC	inhibiting or reducing growth factor mediated cell proliferation,	
CC	inflammation and/or other disorders. The present sequence is an	
CC	oligonucleotide which can be used to design the antisense	
CC	oligonucleotides of the present invention (see AAF45151 and AAF45153-	
CC	F45161). The method is useful for ameliorating the effects of psoriasis,	
CC	ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,	
CC	neoplasias, scleroderma, warts, benign growths, cancers of the skin, a	
CC	hyponeovascular condition such as a neovascular condition of the retina,	
CC	brain or skin, growth factor-mediated malignancies, other sclerotic	
CC	disease, kidney disease, hyperproliferation of the inside of blood	
CC	vessels or any other hyperplasia	
XX	Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;	
Query Match 0.9%; Score 14; DB 1; Length 15;		
Best Local Similarity 100.0%; Pred. No. 1.2e+02;		
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	136 AGCTCCAGGAATG 149	
DB	1 AGCTCCAGGAATG 14	
RESULT 269		
ABK25595/c		
ID	ABK25595 standard; DNA; 17 BP.	
XX	AC ABK25595;	
XX	DT 09-APR-2002 (first entry)	
XX	Stress tolerance conferring genome altering oligonucleotide #63.	
DE	Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;	
KW	o-methyl modification; LNA modification; phosphorothioate linkage;	
KW	DNA repair; DNA alteration; environmental tolerance; hygromycin-B;	
KW	abiotic stress tolerance; improved nutritional value; hygromycin-B;	
KW	amino acid over production; herbicide resistance; glyphosate resistance;	
KW	imidazolinone herbicide resistance; sulphonylurea herbicide resistance;	
KW	porphyric herbicide resistance; triazine resistance; disease resistance;	
KW	modified oil production; modified starch production; waxy starch;	
KW	altered floral morphology; male-sterile plant; albino mutant;	
KW	modified fatty acid content; reduced palmitate production; albino plant;	
KW	increased stearate production; reduced linolenic acid production;	
KW	photosynthetic process.	
XX	Eucalyptus camaldulensis.	
OS	Synthetic.	
XX	WO200192512-A2.	
PN	06-DEC-2001.	
PD	01-JUN-2001; 2001WO-US017672.	
XX	01-JUN-2000; 2000US-0208538P.	
PR	30-OCT-2000; 2000US-0244989P.	
PR	27-MAR-2001; 2001US-00818875.	
XX	(UYDE) UNIV DELAWARE.	
PA	Kmiec EB, Gamper HB, Rice MC, Kim J;	
XX	WPI; 2002-106307/14.	
DR	New oligonucleotides with modified nuclease-resistant termini, useful for	
PT	creating plants with desired phenotypes, e.g. stress tolerance, improved	
PT	nutritional value, herbicide or disease resistance, or modified oil	
PT	production.	
XX	Claim 7; Page 100; 220pp; English.	
PS	The invention relates to an oligonucleotide for targeted alteration of a	
CC	genetic sequence, which comprises a single-stranded oligonucleotide	
CC	having a DNA domain. The DNA domain has at least one mismatch with	
CC	respect to the genetic sequence to be altered and further comprises	
CC	chemical modifications of the oligonucleotide. The chemical modifications	
CC	consist of o-methyl modification, an LNA modification, two or more	
CC	phosphorothioate linkages on a terminus, or a combination of any two or	
CC	more of these modifications. The oligonucleotides are useful for	
CC	directing repair or alteration of plant genetic information. The	
CC	oligonucleotides are particularly useful for creating plants with desired	
CC	phenotypes, e.g. environmental or abiotic stress tolerance, improved	
CC	nutritional value (e.g. altering amino acid content of plants or	
CC	conferring amino acid over production), herbicide resistance (e.g.	
CC	glyphosate resistance, imidazolinone and sulphonylurea herbicide	
CC	resistance, porphyric herbicide resistance or triazine resistance).	
CC	disease resistance, modified oil production, modified starch production	
CC	(e.g. increased starch or production of waxy starch), altered floral	

CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1202 GGTACACACGGTGG 1215
 DB 14 GGTACACACGGTGG 1
 RESULT 270
 ABK25596
 ID ABK25596 standard; DNA; 17 BP.
 XX
 AC ABK25596;
 XX
 DT 09-APR-2002 (first entry)
 DE
 DE Stress tolerance conferring genome altering oligonucleotide #64.
 XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; improved nutritional tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.
 XX Eucalyptus camaldulensis.
 OS Synthetic.
 XX
 XX WO200192512-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-US017672.
 XX
 XX 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 PR 27-MAR-2001; 2001US-00818875.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamber HB, Rice MC, Kim J;
 PI
 XX WPI; 2002-106307/14.
 DR
 XX New oligonucleotides with modified nuclease-resistant termini, useful for
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved
 PT nutritional value, herbicide or disease resistance, or modified oil
 PT production.
 XX
 XX Claim 7; Page 100; 220pp; English.
 PS
 XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or

CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1202 GGTACACACGGTGG 1215
 DB 4 GGTACACACGGTGG 17

RESULT 271
 ACD59851
 ID ACD59851 standard; RNA; 17 BP.
 XX
 AC ACD59851;
 XX
 DT 24-SEP-2003 (first entry)
 DE
 DE HCV DNAzyme substrate sequence #1541.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinczyme;
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.

XX Hepatitis C virus.

OS
 XX WO200281494-A1.

XX 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.

XX 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWISSEN J.

PA (MORR/) MORRISSEY D.

PA (PAVC/) PAVCO P.

PA (LEEP/) LEE P.

PA (DRAP/) DRAPER K.

PA (ROBE/) ROBERTS E.

XX Blatt L, Macejak D, Mcswiggen J, Morrissey J, Pavco P, Lee P;

PI Draper K, Roberts E;

XX

DR WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 XX Claim 1; Page 261; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNzyme or minus strand DNzyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 0.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 71.4%; Pred. No. 1.8e+02;
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 766 TCCAGCGCCATGTC 779
 Db :|||||:|:|
 4 UCCAGCGCCAUGUUC 17
 RESULT 272
 ADI84295
 ID ADI84295 standard; RNA; 17 BP.
 XX
 AC ADI84295;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE HCV DNzyme substrate sequence #1541.
 XX
 KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
 KW HCV infection; type I interferon; DNzyme.
 XX
 OS Hepatitis C virus.
 XX
 PN US2003125270-A1.
 XX
 PD 03-JUL-2003.
 XX
 PF 18-DEC-2000; 2000US-00740332.
 XX
 PR 18-DEC-2000; 2000US-00740332.
 XX
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (ROBE/) ROBERTS E.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
 XX WPI; 2004-031273/03.
 XX
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,

PT especially in combination with type I interferon therapy.
 XX
 PS Claim 1; SEQ ID NO 1541; 198pp; English.
 XX
 CC The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNzyme substrate
 CC sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 0.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 71.4%; Pred. No. 1.8e+02;
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 766 TCCAGCGCCATGTC 779
 Db :|||||:|:|
 4 UCCAGCGCCAUGUUC 17
 RESULT 273
 ADN44286/C
 ID ADN44286 standard; DNA; 17 BP.
 XX
 AC ADN44286;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Mutant cell identification-related mutagenic oligonucleotide SeqID955.
 XX
 KW cell identification; oligonucleotide-directed sequence alteration;
 KW selectable phenotype; transgenic plant; herbicide resistance;
 KW sterile plant; abiotic stress tolerance; albino plant;
 KW amino acid production; ss.
 XX
 OS Eucalyptus camaldulensis.
 OS Synthetic.
 XX
 PN WO2004033708-A2.
 XX
 PD 22-APR-2004.
 XX
 PF 07-OCT-2003; 2003WO-US031862.
 XX
 PR 07-OCT-2002; 2002US-0416983P.
 PR 07-MAR-2003; 2003US-0453360P.
 XX
 PA (UYDE) UNIV DELAWARE.
 PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
 XX
 PI Kmiec EB, Van Brabant A;
 XX
 PI WPI; 2004-340941/31.
 XX
 PT Identifying a cell with a desired oligonucleotide-directed sequence
 PT alteration at a nucleic acid target site within the cell by identifying
 PT the desired sequence alteration in cells selected for the presence of a
 PT selectable phenotype.
 XX
 PS Example 25; SEQ ID NO 955; 303pp; English.
 XX
 CC This invention relates to a novel method of identifying a cell having a
 CC desired oligonucleotide-directed sequence alteration at a first nucleic
 CC acid target site within the cell. The method comprises identifying the
 CC desired sequence alteration in cells that have been selected for the
 CC presence of a selectable phenotype conferred by a concurrent
 CC oligonucleotide-directed sequence alteration at a second nucleic acid
 CC target site within the cells. The method is useful in identifying a cell
 CC having a desired oligonucleotide-directed sequence alteration at a first

CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.

XX SQ Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1202 GGTACACACGGTGG 1215
Db 14 GGTACACACGGTGG 1

RESULT 274
ADN44287
ID ADN44287 standard; DNA; 17 BP.
XX
AC ADN44287;
XX
DT 15-JUL-2004 (first entry)
XX
DE Mutant cell identification-related mutagenic oligonucleotide SeqID956.
XX
KW cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
OS Eucalyptus camaldulensis.
OS Synthetic.
XX
XX WO2004033708-A2.
XX
XX 22-APR-2004.
XX
XX 07-OCT-2003; 2003WO-US031862.
XX
XX 07-OCT-2002; 2002US-0415983P.
XX
XX 07-MAR-2003; 2003US-0453360P.
XX
XX (UYDE) UNIV DELAWARE.
XX (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
XX Kmiec EB, Van Brabant A;
XX
XX WPI; 2004-340941/31.
XX
XX Identifying a cell with a desired oligonucleotide-directed sequence
XX alteration at a nucleic acid target site within the cell by identifying
XX the desired sequence alteration in cells selected for the presence of a
XX selectable phenotype.

XX Example 25; SEQ ID NO 956; 303pp; English.

XX
XX This invention relates to a novel method of identifying a cell having a
XX desired oligonucleotide-directed sequence alteration at a first nucleic
XX acid target site within the cell. The method comprises identifying the
XX desired sequence alteration in cells that have been selected for the
XX presence of a selectable phenotype conferred by a concurrent
XX oligonucleotide-directed sequence alteration at a second nucleic acid
XX target site within the cells. The method is useful in identifying a cell
XX having a desired oligonucleotide-directed sequence alteration at a first
XX nucleic acid target site within the cell. The method may be useful for
XX the production of plants with herbicide resistance, male or female
XX sterile plants, abiotic stress tolerance, albino plants or plants with
XX altered amino acid production as well as for use in mammalian cell lines.
XX The present sequence is that of a mutagenic oligonucleotide which was
XX used in the exemplification of the invention.

XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1202 GGTACACACGGTGG 1215
Db 4 GGTACACACGGTGG 17

RESULT 275
AAT05231/c
ID AAT05231 standard; DNA; 17 BP.
XX
AC AAT05231;
XX
DT 13-JUN-1996 (first entry)
XX
DE Hepatitis C virus antisense oligonucleotide A377 (17).
XX
KW Inhibition; expression; hepatitis C virus; HCV; non-A; non-B; RNA;
KW translation; in vivo; ex vivo; in vitro; treatment; prevention;
KW infection; antisense; non coding; region; NCR; core region; ss.
XX
OS Synthetic.
XX
XX WO9530746-A1.
XX
XX 16-NOV-1995.
XX
XX 08-MAY-1995; 95WO-US005812.
XX
XX 10-MAY-1994; 94US-00240382.
XX
XX (GEHO) GEN HOSPITAL CORP.
XX
XX Wakita T, Wands JR;
XX
XX WPI; 1995-404113/51.
XX
XX New anti-sense hepatitis C virus oligonucleotide(s) - used for
XX inhibiting HCV RNA translation, for the treatment or prevention of HCV
XX infection.

XX Claim 1; Page 31; 50pp; English.

XX The present oligonucleotide (ON) inhibits the expression of hepatitis C
XX virus (HCV) RNA, specifically HCV type II protein synthesis is inhibited
XX by about 50%. The ONs of the invention inhibit translation of HCV types I
XX -V RNA in vivo, ex vivo or in vitro, and can therefore be used to treat
XX or prevent HCV infection. The antisense ONs comprise 10-28 nucleotides
XX complementary to the entire HCV 5'-non-coding and part of the core
XX region. The A or S in the ONs name denotes antisense or sense, and the
XX no. indicates the position of the 5'-end of the ON. The ON was tested at
XX 10 fold molar excess to HCV RNA

XX SQ Sequence 17 BP; 1 A; 1 C; 4 G; 11 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAAACAAA 238
Db 17 CTCATAGAAAAACAAA 1

RESULT 276
AAX75009
ID AAX75009 standard; RNA; 17 BP.
XX

```

AC AAX75009;
XX
XX 28-JUL-1999 (first entry)
XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #537.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fme-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Mus sp.
XX
XX WO9715662-A2.
XX
XX 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
XX
XX 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 171; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
XX synthesis, expression and/or stability of a mRNA encoding 1 or more
XX receptors of vascular endothelial growth factor (VEGF). A patient
XX (preferably human) having a condition associated with the level of the
XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
XX treated by administering the nucleic acid molecule or the expression
XX vector to the patient. AAX67275 to AAX75752 represent specific examples
XX of nucleic acid molecules from the present invention
XX
XX Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 64.7%; Pred. No. 1.9e+02;
XX Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1112 CTCCTCTTGTGCTGGAGC 1128
Db 1 CUCCCCCUUGCUGAGC 17

RESULT 277
AAX62812/c
ID AAX62812 standard; RNA; 17 BP.
XX
XX AAX62812;
XX
XX 16-JUL-1999 (first entry)
XX
XX Delta-9 desaturase hamerhead ribozyme target SEQ ID NO:687.
XX
XX Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW modulation; gene expression; transgenic plant; cleavage; canola plant;
KW caffeine synthesis; coffee plant; nicotine production; tobacco;
KW fruit ripening; flower pigmentation; lignin production; ss.

```

```

XX Zea mays.
XX
XX WO9710328-A2.
XX
XX 20-MAR-1997.
XX
XX 12-JUL-1996; 96WO-US011689.
XX
XX 13-JUL-1995; 95US-0001135P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (DMWC) DOWELANCO.
XX
XX Zwick MG, Edington BE, Mcswiggen JA, Merlo PAO, Guo L, Skokut TA;
XX Young SA, Folkerts O, Merlo DJ;
XX
XX WPI; 1997-202224/18.
XX
XX Ribozyme which modulates plant gene expression - preferably modulates
XX expression of DELTA-9 desaturase or granule bound starch synthase in
XX maize or canola.
XX
XX Claim 38; Page 85; 155pp; English.
XX
XX The present invention describes an enzymatic nucleic acid molecule (I)
XX with RNA cleaving activity, which modulates the expression of a plant
XX gene. Also described is a gene comprising a cDNA sequence encoding maize
XX Delta-9 desaturase. (I) can be used to modulate expression of a gene,
XX preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
XX gene, in a plant (preferably a maize or canola plant). (I) can be used to
XX modulate caffeine synthesis in a coffee plant, nicotine production in a
XX tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
XX or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
XX marigold plant or lignin production in a tobacco, aspen, poplar or pine
XX plant
XX
XX Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1213 TGGCTTCCACACTTCT 1229
Db 17 TGGCTGCCACACTTCT 1

RESULT 278
AAT69614
ID AAT69614 standard; DNA; 17 BP.
XX
XX AAT69614;
XX
XX 26-AUG-1997 (first entry)
XX
XX Murine obr gene forward primer.
XX
XX Ob receptor; ObR; cytokine receptor; signal transduction;
KW eating disorder; obesity; cachexia; anorexia; bulimia; diagnosis;
KW gene therapy; polymerase chain reaction; PCR; primer; ss.
XX
XX Synthetic.
XX
XX WO9719952-A1.
XX
XX 05-JUN-1997.
XX
XX 27-NOV-1996; 96WO-US019128.
XX
XX 27-NOV-1995; 95US-00562663.
XX
XX 04-DEC-1995; 95US-00566622.
XX
XX 08-DEC-1995; 95US-00569485.

```

PR 11-DEC-1995; 95US-00570142.
 PR 28-DEC-1995; 95US-00583153.
 PR 22-JAN-1996; 95US-00599455.
 PR 26-APR-1996; 96US-00638524.
 PR 03-SEP-1996; 96US-00708123.
 XX (MILL-) MILLENNIUM PHARM INC.
 XX PA
 XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;
 PI WPI; 1997-310525/28.
 XX Isolated Ob receptor genes and polypeptide(s) - useful to develop
 PT products for diagnosis or treatment of body weight disorders, e.g.
 PT obesity, cachexia, anorexia and bulimia.
 XX
 XX Example; Page 122; 265pp; English.
 XX Forward and reverse PCR primers (AAT69614 and AAT69615) are based on the
 CC 3' sequence of mouse Ob receptor (OBR) cDNA clone famj5312 (see also
 CC AAT69590). They revealed a polymorphism on SSCP gels between C57Bl/6J
 CC genomic DNA and wild-derived Mus spretus strain SPRET/Ei DNA. The
 CC polymorphism allowed the genetic mapping of famj5312 to murine chromosome
 CC 4, approx. 2.2 cm distal to the marker D4Mit9 and 4.6 cm proximal to the
 CC marker D4Mit46. This mapping confirmed the results obtd. using another
 CC primer pair (AAT69612-13) derived from famj5312
 XX
 XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 660 CACTACCTGCCCTTCAG 676
 Db 1 CACTATTGCGCTTCAG 17
 RESULT 279
 AAV61074
 ID AAV61074 standard; DNA; 17 BP.
 XX AC AAV61074;
 XX 09-DEC-1998 (first entry)
 DT Synthetic DNA fragment from US5821058.
 DE Electrophoretic analysis; DNA fragment; sequencing; chromophore;
 XX fluorophore; tag; electrophoresis; primer; ss.
 KW Synthetic.
 XX OS
 XX US5821058-A.
 XX 13-OCT-1998.
 PD 21-DEC-1994; 94US-00361176.
 XX 16-JAN-1984; 84US-00570973.
 PR 02-JAN-1985; 85US-00689013.
 PR 11-APR-1985; 85US-00727242.
 PR 07-OCT-1987; 87US-00108232.
 PR 21-FEB-1991; 91US-00660160.
 PR 12-JUN-1992; 92US-00898019.
 XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
 XX Hood LE, Connell CR, Hunkapiller MW, Smith LM, Hunkapiller TJ;
 PI WPI; 1998-567653/48.
 XX Electrophoretic analysis of DNA fragments - tagged with chromophore or

PT fluorophore.
 XX Disclosure; Fig 1; 16pp; English.
 PS A method has been developed of separating and detecting tagged
 CC polynucleotides. The method comprises: providing a set of
 CC polynucleotides, each tagged with a chromophore or fluorophore; resolving
 CC to separate one of the tagged polynucleotides from other tagged
 CC polynucleotides differing in length by a single nucleotide using an
 CC electrophoretic procedure capable of resolving tagged polynucleotides
 CC differing by a single nucleotide; and detecting the resolved tagged
 CC polynucleotides by means of the chromophore or fluorophore. The present
 CC invention also describes a method of determining the sequence of a
 CC polynucleotide by analysing tagged polynucleotide fragments generated by
 CC a polynucleotide sequencing technique which comprises: introducing the
 CC tagged polynucleotide fragments into an electrophoretic medium;
 CC separating the tagged polynucleotide fragments in the electrophoretic
 CC medium using an electrophoretic procedure capable of resolving the
 CC polynucleotide fragments differing in length by a single nucleotide;
 CC detecting the separated tagged polynucleotide fragments by means of the
 CC chromophore or fluorophore; and determining the polynucleotide sequence
 CC from the polynucleotide fragments detected. The present sequence
 CC represents a DNA fragment used in an example for end-labeling the DNA
 CC fragment with a fluorescent tag
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1357 AAGCGCTGCAGGAATAC 1373
 Db 1 ATGCTCTGCAGGAATAC 17
 RESULT 280
 AAV47411/C
 ID AAV47411 standard; DNA; 17 BP.
 XX AC AAV47411;
 XX 10-NOV-1998 (first entry)
 DT Antisense oligonucleotide 911, targeting adenosine A1 receptor.
 DE Secondary structure; mRNA; phosphorothioate backbone; G-protein;
 XX bronchoconstriction; lung inflammation; asthma; pulmonary disease;
 KW allergy; emphysema; cystic fibrosis; ss.
 XX OS Synthetic.
 XX Homo sapiens.
 XX Key Location/Qualifiers
 FH modified_base 1..17
 FT /*tag= a
 FT /note= "contains phosphorothioate internucleotide
 FT linkages"
 XX WO9823294-A1.
 XX 04-JUN-1998.
 XX 26-NOV-1997; 97WO-US022017.
 XX 26-NOV-1996; 96US-00757024.
 XX (UYEC-) UNIV EAST CAROLINA.
 XX Nyce JW;
 XX WPI; 1998-322464/28.
 XX

PT Treating respiratory disease with antisense sequences directed against
PT adenosine or bradykinin receptors - with localised delivery to the
PT respiratory system, suitable for long term treatment of asthma, adult
PT respiratory distress syndrome etc.
XX
XX
PS Claim 12; Page 8-24; 47pp; English.
XX
CC Sequences AAV46501-VA7446 are anti-sense oligonucleotides that target the
CC human adenosine A1 receptor, the design of which required the secondary
CC structure of this target mRNA. The adenosine receptor mRNA secondary
CC structure was both analysed and used to construct antisense
CC oligonucleotides containing a phosphorothioate backbone. Once the
CC antisense molecules are created they can be used to target their
CC predetermined target, thus causing the gene product to decrease. The
CC antisense oligonucleotides were targeted to specific mRNA regions
CC containing either a junction between the intron and exon, or where they
CC may overlap the initiation codon. The receptor is a member of the G-
CC protein coupled family of cell surface receptors that have 7-
CC transmembrane segments. These oligonucleotides can be used to treat or
CC prevent conditions associated with bronchoconstriction and/or lung
CC inflammation in humans or other animals e.g. asthma, pulmonary disease,
CC allergy, emphysema and cystic fibrosis
XX
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCACGCTCTCCCGC 1546
|||||
DB 17 GCCACGCTGTGCCGC 1

RESULT 281
AAV46535/c
ID AAV46535 standard; DNA; 17 BP.
AC
AC AAV46535;
XX
DT 10-NOV-1998 (first entry)
XX
DE Antisense oligonucleotide 35, targeting adenosine A1 receptor.
XX
KW Secondary structure; mRNA; phosphorothioate backbone; G-protein;
KW bronchoconstriction; lung inflammation; asthma; pulmonary disease;
KW allergy; emphysema; cystic fibrosis; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..17
FT /tag= a
FT /note= "contains phosphorothioate internucleotide
FT linkages"
XX
PN WO9823294-A1.
XX
PD 04-JUN-1998.
XX
PF 26-NOV-1997; 97WO-US022017.
XX
PR 26-NOV-1996; 96US-00757024.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
XX WPI; 1998-322464/28.
XX
PT Treating respiratory disease with antisense sequences directed against
PT adenosine or bradykinin receptors - with localised delivery to the

PT respiratory system, suitable for long term treatment of asthma, adult
PT respiratory distress syndrome etc.
XX
XX
PS Claim 12; Page 8-24; 47pp; English.
XX
CC Sequences AAV46501-VA7446 are anti-sense oligonucleotides that target the
CC human adenosine A1 receptor, the design of which required the secondary
CC structure of this target mRNA. The adenosine receptor mRNA secondary
CC structure was both analysed and used to construct antisense
CC oligonucleotides containing a phosphorothioate backbone. Once the
CC antisense molecules are created they can be used to target their
CC predetermined target, thus causing the gene product to decrease. The
CC antisense oligonucleotides were targeted to specific mRNA regions
CC containing either a junction between the intron and exon, or where they
CC may overlap the initiation codon. The receptor is a member of the G-
CC protein coupled family of cell surface receptors that have 7-
CC transmembrane segments. These oligonucleotides can be used to treat or
CC prevent conditions associated with bronchoconstriction and/or lung
CC inflammation in humans or other animals e.g. asthma, pulmonary disease,
CC allergy, emphysema and cystic fibrosis
XX
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCACGCTCTCCCGC 1546
|||||
DB 17 GCCACGCTGTGCCGC 1

RESULT 282
AAV94804
ID AAV94804 standard; RNA; 17 BP.
XX
AC AAV94804;
XX
DT 24-FEB-1999 (first entry)
XX
DE Human IL-2 receptor g-chain substrate position 1385.
XX
KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
KW autoimmune disease; psoriasis; allergy; inflammatory disease;
KW graft rejection; ss.
XX
OS Homo sapiens.
XX
PN WO9824913-A2.
XX
PD 11-JUN-1998.
XX
PF 02-DEC-1997; 97WO-US021748.
XX
PR 03-DEC-1996; 96US-00758306.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen JA;
XX
XX WPI; 1998-333332/29.
XX
DR Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,
PT autoimmune disease and allergies.
PT
XX
PS Claim 4; Page 37; 61pp; English.
XX
CC The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC from the present invention. The ribozymes can be used for the treatment

CC diseases and conditions. Typical diseases and conditions are those
 CC associated with impaired respiration and inflammation, including lung
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
 CC acute asthma, allergies, asthma, impaired respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
 CC well as all types of cancers which may metastasize or have metastasized
 CC to the lungs, including breast and prostate cancer
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
 |||||
 DB 17 GCCCAGCCTGTGCCGC 1

RESULT 285
 AAX52912/C
 ID AAX52912 standard; DNA; 17 BP.

XX
 AC AAX52912;

XX
 DT 05-JUL-1999 (first entry)

XX
 DE Human adenosine A1 receptor antisense oligonucleotide fragment.

XX Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impaired respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.

XX Synthetic.

XX WO9913886-A1.

XX
 PD 25-MAR-1999.

XX
 PF 17-SEP-1998; 98WO-US019419.

XX
 PR 17-SEP-1997; 97US-0059160P.

XX
 PR 09-JUN-1998; 98US-00093972.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX
 DR WPI; 1999-229400/19.

XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction.

XX Disclosure; Page 28; 120pp; English.

XX The specification describes antisense oligonucleotides (AAX52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene initiation
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
 CC end and the junction-section between coding and non-coding regions and all
 CC segments of RNAs encoding proteins associated with one or more diseases,
 CC conditions or mixtures. The antisense oligonucleotides may be derived

CC from sequences AAX55272-74. These multiple target oligonucleotides
 CC (specifically AAX55180-271) can be used for the antisense treatment of
 CC diseases and conditions. Typical diseases and conditions are those
 CC associated with impaired respiration and inflammation, including lung
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
 CC acute asthma, allergies, asthma, impaired respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
 CC well as all types of cancers which may metastasize or have metastasized
 CC to the lungs, including breast and prostate cancer
 XX

SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. NO. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
 |||||
 DB 17 GCCCAGCCTGTGCCGC 1

RESULT 286

AAA33231/C

ID AAA33231 standard; DNA; 17 BP.

XX
 AC AAA33231;

XX
 DT 28-JUL-2000 (first entry)

XX Low adenosine antisense oligonucleotide SEQ ID NO:920.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

XX WO200009525-A2.

XX
 PD 24-FEB-2000.

XX
 PF 03-AUG-1999; 99WO-US017712.

XX
 PR 03-AUG-1998; 98US-0095212P.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX
 DR WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers.

XX Claim 18; Page 380; 1343pp; English.

XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,

CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONS reduces side effects. The A-containing ONS break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 185, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONS from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 CC
 XX SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1530 GCCCAGCCTCTCCCGC 1546
 DB 17 GCCCAGCCTGTGCGCGC 1
 AAA32356/c
 ID AAA32356 standard; DNA; 17 BP.
 XX AC AAA32356;
 XX
 XX 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:44.
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200009525-A2.
 XX
 XX 24-FEB-2000.
 XX
 XX 03-AUG-1999; 99WO-US017712.
 XX
 XX 03-AUG-1998; 98US-0095212P.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 XX
 XX Nyce JW;
 XX
 XX WPI; 2000-205971/18.
 XX
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 XX vasoconstriction, inflammation, allergies, asthma, hypertension,
 XX bronchitis, emphysema, respiratory distress syndrome, ischemia or
 XX cancers.
 XX
 XX Claim 18; Page 272; 134pp; English.

CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONS reduces side effects. The A-containing ONS break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONS from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 CC
 XX SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1530 GCCCAGCCTCTCCCGC 1546
 DB 17 GCCCAGCCTGTGCGCGC 1
 AAA32356/c
 ID AAA32356 standard; DNA; 17 BP.
 XX AC AAA32356;
 XX
 XX 05-APR-2000 (first entry)
 XX
 DE Hepatitis C virus antisense inhibitor oligonucleotide #21.
 XX Hepatitis C virus; HCV; antisense oligonucleotide; hepatotropic; ss;
 KW anti-inflammatory; translation inhibition; HCV infection; virucide.
 KW
 XX Hepatitis C virus.
 OS
 XX US6001990-A.
 XX
 XX 14-DEC-1999.
 XX
 XX 07-JUN-1995; 95US-00474700.
 XX
 XX 10-MAY-1994; 94US-00240382.
 XX
 XX (GEHO) GEN HOSPITAL CORP.
 XX
 XX Moradpour D, Wands JR, Wakita T;
 XX
 XX WPI; 2000-104900/09.
 XX
 XX Antisense oligonucleotide to Hepatitis C virus RNA, useful for treating
 XX Hepatitis C virus infections.
 XX
 XX Claim 24; Col 25; 31pp; English.
 XX
 XX This sequence is an antisense oligonucleotide that hybridises to
 CC Hepatitis C virus (HCV) RNA, under physiological conditions. The

CC invention relates to HCV antisense oligonucleotides, and also for a
 CC vector comprising a nucleotide sequence which is transcribed in an animal
 CC cell to generate an antisense oligonucleotide. The oligonucleotides have
 CC virucide, hepatotropic and anti-inflammatory activity, and are useful for
 CC treating HCV infection by inhibiting translation of type I-V HCV RNA.
 CC Hepatitis C virus is a positive strand RNA virus, and is the major
 CC causative agent of post-transfusion hepatitis. Persistent HCV infection
 CC can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma
 XX

Sequence 17 BP; 1 A; 1 C; 4 G; 11 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02; Mismatches 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 222 CTCATAGAAAAACAAA 238

DB 17 CTCGAAGAAACACAAA 1

RESULT 289

AAA03590/c
 ID AAA03590 standard; DNA; 17 BP.

XX
 AC AAA03590;

XX
 DT 19-MAY-2000 (first entry)

XX Human adenosine A1 receptor antisense oligonucleotide SEQ ID NO:874.

XX Human; adenosine A1 receptor; antisense oligonucleotide; hypoxia;
 KW adenosine A2a receptor; adenosine Ab receptor; adenosine A3 receptor;
 KW phosphorothioate; cardiopulmonary failure; renal failure; ischaemia;
 KW endotoxin release; ARDS; acute respiratory distress syndrome;
 KW cytoprotective; anti-allergic; anti-inflammatory; anti-hypoxic;
 KW supraventricular tachycardia; allergic rhinitis; acute inflammation;
 KW chronic obstructive pulmonary disease; ss.

XX Homo sapiens.
 OS Synthetic.

XX WO9963938-A2.

XX 16-DEC-1999.

XX 08-JUN-1999; 99WO-US012775.

XX 08-JUN-1998; 98US-0088501P.

XX 09-JUN-1998; 98US-00093972.

XX 09-JUN-1998; 98US-0088657P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Hill JL;

XX WPI; 2000-116433/10.

XX Novel composition for treating or preventing e.g. cardiopulmonary and renal injury.

XX Claim 17; Page 36; 252pp; English.

XX The present invention describes a pharmaceutical composition, comprising
 CC at least one agent (I) that prevents, alleviates and/or inhibits
 CC adenosine-mediated cardiopulmonary and/or renal damage and/or failure.
 CC (I) is an adenosine A2a receptor agonist (Ia), or an oligonucleotide
 CC (Ib), containing less than 15% adenosine (A), that is antisense to target
 CC genes or corresponding RNA, to genomic flanking regions (i.e. 5' or 3'
 CC ends or segments between coding and non-coding sequences), or to all
 CC segments of mRNA encoding the adenosine A1, A2a, A2b or A3 receptors, and
 CC has A1, A2b or A3 agonist activity or A2a antagonist activity (or at
 CC least no agonist activity at this receptor). (I) may be a mixture of (Ia)
 CC and (Ib), and optionally also contains one or more surfactants. The

CC compositions are used to prevent, alleviate and/or treat adenosine
 CC receptor-mediated cardiac, lung and/or renal damage or failure
 CC (particularly where associated with ischaemia, toxin release and/or
 CC administration of drugs or imaging agents, e.g. adenosine for treating
 CC supraventricular tachycardia); (adult) respiratory distress syndrome
 CC (e.g. associated with sepsis); allergic rhinitis; chronic obstructive
 CC pulmonary disease; cardiopulmonary hypoxia associated with administration
 CC of stress-test agents, particularly where such conditions are associated
 CC with acute inflammation. AAA02717, AAA02719, AAA02721 and AAA02723 to
 CC AAA03715 represent specifically claimed phosphorothioate antisense
 CC oligonucleotides for use in the composition of the present invention.
 CC AAA02718, AAA02720, AAA02722 and AAA03716 to AAA03720 represent other
 CC phosphorothioate oligonucleotides used in the exemplification of the
 CC present invention
 XX

Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02; Mismatches 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 1530 GCCCAGCCTCTCCCGC 1546

DB 17 GCCCAGCCTGTGCCGC 1

RESULT 290

AAA03660/c

ID AAA03660 standard; DNA; 17 BP.

XX
 AC AAA03660;

XX
 DT 19-MAY-2000 (first entry)

XX Human adenosine A1 receptor antisense oligonucleotide SEQ ID NO:944.

XX Human; adenosine A1 receptor; antisense oligonucleotide; hypoxia;
 KW adenosine A2a receptor; adenosine Ab receptor; adenosine A3 receptor;
 KW phosphorothioate; cardiopulmonary failure; renal failure; ischaemia;
 KW endotoxin release; ARDS; acute respiratory distress syndrome;
 KW cytoprotective; anti-allergic; anti-inflammatory; anti-hypoxic;
 KW supraventricular tachycardia; allergic rhinitis; acute inflammation;
 KW chronic obstructive pulmonary disease; ss.

XX Homo sapiens.

OS Synthetic.

XX WO9963938-A2.

XX 16-DEC-1999.

XX 08-JUN-1999; 99WO-US012775.

XX 08-JUN-1998; 98US-0088501P.

XX 09-JUN-1998; 98US-00093972.

XX 09-JUN-1998; 98US-0088657P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Hill JL;

XX WPI; 2000-116433/10.

XX Novel composition for treating or preventing e.g. cardiopulmonary and renal injury.

XX Claim 17; Page 37; 252pp; English.

XX The present invention describes a pharmaceutical composition, comprising
 CC at least one agent (I) that prevents, alleviates and/or inhibits
 CC adenosine-mediated cardiopulmonary and/or renal damage and/or failure.
 CC (I) is an adenosine A2a receptor agonist (Ia), or an oligonucleotide
 CC (Ib), containing less than 15% adenosine (A), that is antisense to target

CC genes or corresponding RNA, to genomic flanking regions (i.e. 5' or 3'
 CC ends or segments between coding and non-coding sequences), or to all
 CC segments of mRNA encoding the adenosine A1, A2a, A2b or A3 receptors, and
 CC has A1, A2b or A3 agonist activity or A2a antagonist activity (or at
 CC least no agonist activity at this receptor). (I) may be a mixture of (Ia)
 CC and (Ib), and optionally also contains one or more surfactants. The
 CC compositions are used to prevent, alleviate and/or treat adenosine
 CC receptor-mediated cardiac, lung and/or renal damage or failure
 CC (particularly where associated with ischaemia, toxin release and/or
 CC administration of drugs or imaging agents, e.g. adenosine for treating
 CC supraventricular tachycardia); (adult) respiratory distress syndrome
 CC (e.g. associated with sepsis); allergic rhinitis; chronic obstructive
 CC pulmonary disease; cardiopulmonary hypoxia associated with administration
 CC of stress-test agents, particularly where such conditions are associated
 CC with acute inflammation. AAA02717, AAA02719, AAA02721 and AAA02723 to
 CC AAA03715 represent specifically claimed phosphorothioate antisense
 CC oligonucleotides for use in the composition of the present invention.
 CC AAA02718, AAA02720, AAA02722 and AAA03716 to AAA03720 represent other
 CC phosphorothioate oligonucleotides used in the exemplification of the
 CC present invention
 XX SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1530 GCCCAGCCTCTCCCGC 1546
 Db 17 GCCCAGCCTGTGCCGC 1
 RESULT 291
 AAF19353/c
 ID AAF19353 standard; DNA; 17 BP.
 XX AC AAF19353;
 XX 14-MAR-2001 (first entry)
 XX Human adenosine A1 receptor polynucleotide fragment #920.
 XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pulmonary vasoconstriction; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX Homo sapiens.
 OS WO200062736-A2.
 XX 26-OCT-2000.
 XX 24-MAR-2000; 2000WO-US008020.
 PF 06-APR-1999; 99US-0127958P.
 PR (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX Nyce JW;
 XX WPI; 2000-679539/66.
 DR Low adenosine (A) content antisense oligonucleotides which do not trigger
 PT adenosine receptors during metabolism, useful e.g. for treating cancers
 PT and respiratory obstructions.

XX Claim 14; Page 120; 1592pp; English.
 PS The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors and
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1530 GCCCAGCCTCTCCCGC 1546
 Db 17 GCCCAGCCTGTGCCGC 1
 RESULT 292
 AAF18477/c
 ID AAF18477 standard; DNA; 17 BP.
 XX AC AAF18477;
 XX 14-MAR-2001 (first entry)
 XX Human adenosine A1 receptor polynucleotide fragment #44.
 XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX Homo sapiens.
 OS WO200062736-A2.
 XX 26-OCT-2000.
 XX 24-MAR-2000; 2000WO-US008020.

PR 06-APR-1999; 99US-0127958P.
 XX (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX Nyce JW;
 PI
 XX WPI; 2000-679539/66.
 DR
 XX Low adenosine (A) content antisense oligonucleotides which do not trigger
 XX adenosine receptors during metabolism, useful e.g. for treating cancers
 PT and respiratory obstructions.
 PT
 XX Claim 14; Page 106; 1592pp; English.
 PS
 XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1530 GCCCAGCCTCTCCCGC 1546
 Db 17 GCCCAGCCTGTCCCGC 1
 RESULT 293
 AAF02647
 ID AAF02647 standard; DNA; 17 BP.
 XX AAF02647;
 AC
 XX 16-FEB-2001 (first entry)
 DT
 XX Hammerhead ribozyme substrate #942.
 DE
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 KW
 XX Homo sapiens.
 OS
 XX WO200061729-A2.
 PN

PD 19-OCT-2000.
 XX
 PF 11-APR-2000; 2000WO-US009721.
 XX
 PR 12-APR-1999; 99US-0129390P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
 PI WPI; 2000-647423/62.
 DR
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 PT
 XX Claim 37; Page 77; 164pp; English.
 PS
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 116 CCAGACGCTCTCAGACA 132
 Db 1 CCAGACGCTCTCAGTCA 17
 RESULT 294
 ASK01885/c
 ID ASK01885 standard; RNA; 17 BP.
 XX ASK01885;
 AC
 XX 12-MAR-2002 (first entry)
 DT
 XX Human Nogo Zinzyme #207.
 DE
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; Nogo; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 XX 09-FEB-2001; 2001WO-US004273.
 PF
 XX 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187138P.
 PR

XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
XX Claim 88; Page 99; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an amberyyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a zinzyme molecule of the invention
XX
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1621 CAATTAACACTGCTTGT 1637
DB 17 CATTAAACACTGCTTTT 1
RESULT 295
ABK01053/c
ID ABK01053 standard; RNA; 17 BP.
XX
AC ABK01053;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Inozyme #323.
XX
Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;

KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens. OS
XX Synthetic. OS
XX WO200159103-A2. FN
XX 16-AUG-2001. PD
XX 09-FEB-2001; 2001WO-US004273. PF
XX 11-FEB-2000; 2000US-0181797P. XX
PR 28-FEB-2000; 2000US-0185516P. PR
PR 06-MAR-2000; 2000US-0187128P. PR
XX (RIBO-) RIBOZYME PHARM INC. PA
PA (BLAT/) BLATT L. PA
PA (MCSW/) MCSWIGGEN J. PA
PA (CHOW/) CHOWRIRA B M. PA
XX Blatt L, Mcswiggen J, Chowrira BM; PI
WPI; 2001-607195/69. DR
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
XX Claim 88; Page 83; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an amberyyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a zinzyme molecule of the invention
XX
SQ Sequence 17 BP; 8 A; 2 C; 2 G; 0 T; 5 U; 0 Other;


```

AAF79852
ID  AAF79852 standard; DNA; 17 BP.
AC  AAF79852;
XX
XX  30-MAY-2001 (first entry)
XX
DE  DNA sequencing method DNA fragment.
XX
XX  DNA sequencing; sequence analysis; chromophore; fluorophore; ds.
XX
XX  Synthetic.
XX
XX  US6200748-B1.
XX
XX  13-MAR-2001.
XX
XX  07-JUN-1995; 95US-00484340.
XX
XX  16-JAN-1984; 84US-00570973.
XX
XX  02-JAN-1985; 85US-00689013.
XX
XX  11-APR-1985; 85US-00722742.
XX
XX  07-OCT-1987; 87US-00106232.
XX
XX  21-FEB-1991; 91US-00660160.
XX
XX  12-JUN-1992; 92US-00898019.
XX
XX  21-DEC-1994; 94US-00361176.
XX
XX  (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
XX  Smith LM, Hood LE, Hunkapiller MW, Hunkapiller TJ, Connell CR;
XX
XX  WPI; 2001-256466/26.
XX
XX  Novel duplex useful in sequencing reactions, comprising an
XX  oligonucleotide primer covalently coupled to a chromophore or fluorophore
XX  so as to allow chain extension by a polymerase, and a template.
XX
XX  Disclosure; Fig 1A; 15pp; English.
XX
XX  The present invention describes a duplex comprising a template and a
XX  primer joined to a chromophore or fluorophore to enable chain extension
XX  by a polymerase. Also described is a method of sequencing a nucleic acid
XX  using said primer, where the chromophore or fluorophore is used to
XX  determine the sequence of the oligonucleotide. This is useful in sequence
XX  analysis. The present sequence was used to demonstrate the method of the
XX  invention
XX
XX  Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX  Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX  Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX  1357 AAGCGCTCGAGGATAC 1373
XX  |||||
XX  1 ATGCTCTCGAGGATAC 17
XX
XX
XX
XX  RESULT 299
XX  ABL46807/c
XX  ABL46807 standard; RNA; 17 BP.
XX
XX
XX  ABL46807;
XX
XX  27-JUN-2003 (first entry)
XX
XX  Human GRID NCH ribozyme substrate oligonucleotide #261.
XX
XX  Human; Grb2-related with Insert Domain; GRID; T-cell;
XX  co-stimulatory adaptor protein; tissue rejection; graft rejection;
XX  leukaemia; cytostatic; ss.
XX
XX  Homo sapiens.
XX

```

```

XX  WO200162911-A2.
XX
XX  30-AUG-2001.
XX
XX  23-FEB-2001; 2001WO-US005957.
XX
XX  24-FEB-2000; 2000US-0184594P.
XX
XX  (RIBO-) RIBOZYME PHARM INC.
XX  (GLAX ) GLAXO GROUP LTD.
XX
XX  Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX  WPI; 2001-550088/61.
XX
XX  New nucleic acid(s) for regulating the Grb2-related with Insert Domain
XX  (GRID) gene comprises using antisense and enzymatic nucleic acid
XX  molecules such as hammerhead ribozymes.
XX
XX  Claim 4; Page 67; 108pp; English.
XX
XX  The present invention relates to oligonucleotides that downregulate the
XX  expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
XX  a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
XX  for modulating the expression of GRID, to treat conditions such as
XX  tissue/graft rejection and leukaemia. The oligonucleotides can also be
XX  administered in conjunction with other therapies such as radiation,
XX  chemotherapy and cyclosporin treatment. The present oligonucleotide was
XX  used to illustrate the invention
XX
XX  Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
XX
XX  Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX  Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX  1539 CTCGCCGCTCTGGATCC 1555
XX  |||||
XX  17 CTCGCCGCTCTGGAAACC 1
XX
XX  RESULT 300
XX  AAD41482
XX  ID  AAD41482 standard; DNA; 17 BP.
XX
XX  AAD41482;
XX
XX  30-OCT-2002 (first entry)
XX
XX  Mouse Ob receptor (Obr) gene amplifying forward PCR primer #2.
XX
XX  Mouse; obese receptor; Obr; receptor; body weight disorder; obesity;
XX  cachexia; anorexia; anorectic; anabolic; immunomodulator; PCR; primer;
XX  ss.
XX
XX  Mus sp.
XX
XX  US6395498-B1.
XX
XX  28-MAY-2002.
XX
XX  28-MAY-1997; 97US-00864564.
XX
XX  27-NOV-1995; 95US-00562663.
XX
XX  04-DEC-1995; 95US-00566622.
XX
XX  08-DEC-1995; 95US-00569485.
XX
XX  11-DEC-1995; 95US-00570142.
XX
XX  28-DEC-1995; 95US-00583153.
XX
XX  22-JAN-1996; 96US-00599455.
XX
XX  26-APR-1996; 96US-00638524.
XX
XX  03-SEP-1996; 96US-00708123.
XX

```

PA (MILL-) MILLENNIUM PHARM INC.
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;
PI WPI; 2002-535640/57.
DR
XX
XX Identifying candidate therapeutic agents for treating body weight
PT disorders, comprises contacting test compound with cell expressing
PT mammalian obese receptor and reporter protein, and measuring expression
PT of reporter protein.
XX
XX Example; Col 119; 110pp; English.
PS
XX The present invention relates to novel obese (Ob) receptor (OBR) proteins
CC and polynucleotides encoding them. The invention relates to a method of
CC identifying candidate therapeutic agents to treat body weight disorder.
CC The method involves providing a cell which expresses a mammalian OBR on
CC the cell surface, binds leptin, the cell harbouring a reporter construct
CC comprising a sequence encoding a reporter protein, contacting the cell
CC with a test compound and measuring the expression of the reporter protein
CC in the presence of the test compound. The method is useful to identify an
CC agent, preferably a small molecule or antibody for the treatment of body
CC weight disorders such as obesity, cachexia, and anorexia. The present DNA
CC sequence is a PCR primer which is used for amplifying mouse OBR genomic
CC DNA. This sequence is used in the exemplification of the invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 660 CACTACCTGCGCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17
RESULT 301
AAD41484
ID AAD41484 standard; DNA; 17 BP.
XX
XX AAD41484;
AC
XX 30-OCT-2002 (first entry)
DT
XX Mouse Ob receptor (OBR) gene amplifying forward PCR primer #3.
DE
XX
KW Mouse; obese receptor; OBR; receptor; body weight disorder; obesity;
KW cachexia; anorexia; anorectic; anabolic; immunomodulator; PCR; primer;
KW ss.
XX
XX Mus sp.
OS
XX US6395498-B1.
FN
XX 28-MAY-2002.
PD
XX 28-MAY-1997; 97US-00864564.
PF
XX 27-NOV-1995; 95US-00562663.
PR
XX 04-DEC-1995; 95US-00566622.
PR
XX 08-DEC-1995; 95US-00569485.
PR
XX 11-DEC-1995; 95US-00570142.
PR
XX 28-DEC-1995; 95US-00583153.
PR
XX 22-JAN-1996; 96US-00599455.
PR
XX 26-APR-1996; 96US-00638524.
PR
XX 03-SEP-1996; 96US-00708123.
XX
XX (MILL-) MILLENNIUM PHARM INC.
PA
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;
PI WPI; 2002-535640/57.
DR

XX Identifying candidate therapeutic agents for treating body weight
PT disorders, comprises contacting test compound with cell expressing
PT mammalian obese receptor and reporter protein, and measuring expression
PT of reporter protein.
XX
XX Example; Col 121; 110pp; English.
PS
XX The present invention relates to novel obese (Ob) receptor (OBR) proteins
CC and polynucleotides encoding them. The invention relates to a method of
CC identifying candidate therapeutic agents to treat body weight disorder.
CC The method involves providing a cell which expresses a mammalian OBR on
CC the cell surface, binds leptin, the cell harbouring a reporter construct
CC comprising a sequence encoding a reporter protein, contacting the cell
CC with a test compound and measuring the expression of the reporter protein
CC in the presence of the test compound. The method is useful to identify an
CC agent, preferably a small molecule or antibody for the treatment of body
CC weight disorders such as obesity, cachexia, and anorexia. The present DNA
CC sequence is a PCR primer which is used for amplifying mouse OBR genomic
CC DNA. This sequence is used in the exemplification of the invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 660 CACTACCTGCGCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17
RESULT 302
AAD42341
ID AAD42341 standard; DNA; 17 BP.
XX
XX AAD42341;
AC
XX 04-NOV-2002 (first entry)
DT
XX Mouse obesity receptor (OBR) gene amplifying forward primer #3.
DE
XX
KW Obesity receptor; OBR; body weight disorder; therapy; food intake;
KW anorexia; cachexia; acquired immune deficiency syndrome; cytostatic;
KW AIDS-related wasting; cancer-related wasting; metabolic; anti-HIV;
KW immunomodulator; human immunodeficiency virus; mouse; PCR; primer; ss.
XX
XX Mus sp.
OS
XX US6403552-B1.
FN
XX 11-JUN-2002.
PD
XX 09-JUN-1998; 98US-00094410.
PF
XX 27-NOV-1995; 95US-00562663.
PR
XX 04-DEC-1995; 95US-00566622.
PR
XX 08-DEC-1995; 95US-00569485.
PR
XX 11-DEC-1995; 95US-00570142.
PR
XX 28-DEC-1995; 95US-00583153.
PR
XX 22-JAN-1996; 96US-00599455.
PR
XX 26-APR-1996; 96US-00638524.
PR
XX 03-SEP-1996; 96US-00708123.
XX
XX 28-MAY-1997; 97US-00864564.
XX
XX (MILL-) MILLENNIUM PHARM INC.
PA
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;
PI WPI; 2002-536045/57.
DR
XX Increasing food intake in a mammal having a low body weight disorder such
PT as anorexia, involves administering to the mammal a soluble polypeptide

comprising the extracellular domain of an obesity receptor protein.
Example; Col 63; 114pp; English.
The invention relates to obesity receptor (OBR) protein and its corresponding nucleic acid. The invention also relates to a method for the diagnosis and treatment of body weight disorders. The method is useful for increasing food intake in a mammal having a disorder characterised by low body weight, where the disorder is anorexia, cachexia, acquired immunodeficiency syndrome (AIDS)-related wasting or cancer-related wasting. The present sequence is a PCR primer used for amplifying mouse OBR gene. This sequence is used in the exemplification of the invention
Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 660 CACTACCTGCGCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17
RESULT 304
ABN01903/c
ID ABN01903 standard; DNA; 17 BP.
XX AC ABN01903;
XX AC
DT 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1895.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 1895; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1

comprising the extracellular domain of an obesity receptor protein.
Example; Col 63; 114pp; English.
The invention relates to obesity receptor (OBR) protein and its corresponding nucleic acid. The invention also relates to a method for the diagnosis and treatment of body weight disorders. The method is useful for increasing food intake in a mammal having a disorder characterised by low body weight, where the disorder is anorexia, cachexia, acquired immunodeficiency syndrome (AIDS)-related wasting or cancer-related wasting. The present sequence is a PCR primer used for amplifying mouse OBR gene. This sequence is used in the exemplification of the invention
Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 660 CACTACCTGCGCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17
RESULT 303
AAD42339
ID AAD42339 standard; DNA; 17 BP.
XX AC AAD42339;
XX AC
DT 04-NOV-2002 (first entry)
XX Mouse obesity receptor (OBR) gene amplifying forward primer #2.
XX
XX Obesity receptor; OBR; body weight disorder; therapy; food intake;
KW anorexia; cachexia; acquired immune deficiency syndrome; cytostatic;
KW AIDS-related wasting; cancer-related wasting; metabolic; anti-HIV;
KW immunomodulator; human immunodeficiency virus; mouse; PCR; primer; ss.
XX
XX Mus sp.
XX
XX US6403552-B1.
XX
XX 11-JUN-2002.
XX
XX 09-JUN-1998; 98US-00094410.
XX
XX 27-NOV-1995; 95US-00562663.
PR 04-DEC-1995; 95US-00566622.
PR 08-DEC-1995; 95US-00569485.
PR 11-DEC-1995; 95US-00570142.
PR 28-DEC-1995; 95US-00583153.
PR 22-JAN-1996; 96US-00599455.
PR 26-APR-1996; 96US-00638524.
PR 03-SEP-1996; 96US-00708123.
PR 28-MAY-1997; 97US-00864564.
XX (MILL-) MILLENIUM PHARM INC.
XX
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;
XX
XX WPI; 2002-536045/57.
XX
XX Increasing food intake in a mammal having a low body weight disorder such
PT as anorexia, involves administering to the mammal a soluble polypeptide
PT comprising the extracellular domain of an obesity receptor protein.
XX
XX Example; Col 62; 114pp; English.
XX
XX The invention relates to obesity receptor (OBR) protein and its
CC corresponding nucleic acid. The invention also relates to a method for
CC the diagnosis and treatment of body weight disorders. The method is

CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGTCT 109

Db 17 GAGAGAGGCCAGGTCT 1

RESULT 305
ABN07493/C

ID ABN07493 standard; DNA; 17 BP.

XX AC ABN07493;

XX 29-MAY-2002 (first entry)

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7485.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001US-0268860P.

XX (AEOM-) AEOMICA INC.

PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 7485; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 4 A; 3 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546

Db 17 GTCCAGCCTCTCTCGC 1

RESULT 306

ABN08576

ID ABN08576 standard; DNA; 17 BP.

XX AC ABN08576;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8588.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

XX

PR	30-JAN-2001; 2001WO-US000669.
PR	30-JAN-2001; 2001WO-US000670.
PR	05-FEB-2001; 2001US-026860P.
PA	(AEOM-) AEOMICA INC.
XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI	WPI; 2002-179446/23.
DR	New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT	or as specific biomolecule capture probes for surface-enhanced laser
PT	desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX	Disclosure; SEQ ID NO 8568; 214pp; English.
PS	The present invention describes a human genome-derived myosin-like
CC	protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC	1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC	nucleic acids can be used as probes to detect, characterise and quantify
CC	hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substrates for the recombinant engineering of hGDMPLP-1
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption/ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGDMPLP-1, in particular heart
CC	and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
XX	Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	292 AGGATGCCCTTAATGAG 308
DB	1 AGGATGACTTGATGAG 17
RESULT 307	
ABN09695/c	
ID	ABN09695 standard; DNA; 17 BP.
XX	AC ABN09695;
XX	29-MAY-2002 (first entry)
DT	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9687.
DE	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMPLP-1; heart;
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	skeletal muscle disorder; amplicon; screening; ss.
XX	Homo sapiens.
OS	WO200192524-A2.
PN	06-DEC-2001.
PD	25-MAY-2001; 2001WO-US016981.
XX	26-MAY-2000; 2000US-0207456P.
PR	

PR	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000666.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000669.
PR	05-FEB-2001; 2001WO-US000670.
XX	05-FEB-2001; 2001US-026860P.
XX	(AEOM-) AEOMICA INC.
PA	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI	WPI; 2002-179446/23.
DR	New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT	or as specific biomolecule capture probes for surface-enhanced laser
PT	desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX	Disclosure; SEQ ID NO 9687; 214pp; English.
PS	The present invention describes a human genome-derived myosin-like
CC	protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC	1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC	nucleic acids can be used as probes to detect, characterise and quantify
CC	hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substrates for the recombinant engineering of hGDMPLP-1
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption/ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGDMPLP-1, in particular heart
CC	and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
XX	Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	292 AGGATGCCCTTAATGAG 308
DB	1 AGGATGACTTGATGAG 17
RESULT 307	
ABN09695/c	
ID	ABN09695 standard; DNA; 17 BP.
XX	AC ABN09695;
XX	29-MAY-2002 (first entry)
DT	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9687.
DE	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMPLP-1; heart;
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	skeletal muscle disorder; amplicon; screening; ss.
XX	Homo sapiens.
OS	WO200192524-A2.
PN	06-DEC-2001.
PD	25-MAY-2001; 2001WO-US016981.
XX	26-MAY-2000; 2000US-0207456P.
PR	

KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 8663; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 270 GAAGAACCAAGAA 286
XX Db 1 GAGGAAGCCAGAGGA 17
XX
XX RESULT 309

ABN09696/c
ID ABN09696 standard; DNA; 17 BP.
XX
AC ABN09696;
XX
XX 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9688.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 05-FEB-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 9688; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 92 GGAGAGTGGGACAGTCC 108
   |||||
Db 17 GGAGAGTGGGACAGTCC 1

RESULT 310
ABN09697/c
ID ABN09697 standard; DNA; 17 BP.
XX
AC ABN09697;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9689.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 9689; 214pp; English.
XX

The present invention describes a human genome-derived myosin-like
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
1 can be used in gene therapy and vaccine production. The hGDMPLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMPLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMPLP
-1 proteins, as standards in assays used to determine the concentration
and/or amount specifically of hGDMPLP proteins, as specific biomolecule
capture probes for surface-enhanced laser desorption ionisation, as
therapeutic supplement in patients having specific deficiency in hGDMPLP-1
```

```
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GGGAGAGTGGGACAGTCC 107
   |||||
Db 17 GGGAGAGTGGGACAGTCC 1

RESULT 311
ABN07363
ID ABN07363 standard; DNA; 17 BP.
XX
AC ABN07363;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7355.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 7355; 214pp; English.
XX

The present invention describes a human genome-derived myosin-like
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
1 can be used in gene therapy and vaccine production. The hGDMPLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMPLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMPLP
-1 proteins, as standards in assays used to determine the concentration
and/or amount specifically of hGDMPLP proteins, as specific biomolecule
capture probes for surface-enhanced laser desorption ionisation, as
therapeutic supplement in patients having specific deficiency in hGDMPLP-1
```


CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 8 A; 4 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAGAA 286
|||||||
DB 1 GAAGAAGCCCAAGAGAA 17

RESULT 312
ABN08672
ID ABN08672 standard; DNA; 17 BP.
XX AC ABN08672;
XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8664.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; Gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI

XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 8664; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAGAA 287
|||||||
DB 1 AGGAAGCCCAAGAGAG 17

RESULT 313
ABN08669
ID ABN08669 standard; DNA; 17 BP.
XX AC ABN08669;
XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8661.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; Gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.

```

PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 8661; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 268 TAGAAGAAGCCCAAGAG 284
XX |||||
XX 1 TGGAGGAGCCCAAGAG 17
XX
XX RESULT 314
XX ABN02651/C
XX ID ABN02651 standard; DNA; 17 BP.
XX AC ABN02651;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2643.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-026860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2643; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 1 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 845 CTTCCAGACCCGCCCAA 861
XX |||||
XX 17 CTGCCAGACCCGCCCAA 1
XX
XX RESULT 315
XX ABN08668
XX ID ABN08668 standard; DNA; 17 BP.
XX
XX AC ABN08668;
XX
XX 29-MAY-2002 (first entry)
XX
XX

```



```
Db          1  ||||| |||||
              1 CTACTCCGAGCTGGAGA 17

RESULT 317
ABQ63734
ID  ABQ63734 standard; DNA; 17 BP.
AC  ABQ63734;
XX
DT  20-AUG-2002 (first entry)
DE  Human KTOM1a portion (ABQ63232) probe # 447.
KW  Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW  gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW  kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS  Homo sapiens.
XX
PN  WO200224750-A2.
XX
PD  28-MAR-2002.
XX
PF  21-SEP-2001; 2001WO-US029656.
PR  21-SEP-2000; 2000US-0234687P.
PR  27-SEP-2000; 2000US-0236359P.
PR  04-OCT-2000; 2000GB-00024283.
PR  30-JAN-2001; 2001WO-US000661.
PR  30-JAN-2001; 2001WO-US000662.
PR  30-JAN-2001; 2001WO-US000663.
PR  30-JAN-2001; 2001WO-US000664.
PR  30-JAN-2001; 2001WO-US000665.
PR  30-JAN-2001; 2001WO-US000666.
PR  30-JAN-2001; 2001WO-US000667.
PR  30-JAN-2001; 2001WO-US000668.
PR  30-JAN-2001; 2001WO-US000669.
PR  30-JAN-2001; 2001WO-US000670.
PR  23-MAY-2001; 2001US-00864761.
PR  28-AUG-2001; 2001US-0315676P.
XX
PA  (AEOM-) AEOMICA INC.
XX
PI  Zhang J;
XX
WPI; 2002-479509/51.
XX
PT  New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT  acids encoding the protein, useful for treating subjects having defects
PT  in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT  e.g., liver or bone.
XX
PS  Example 2; Page 216; 418pp; English.
XX
CC  The invention relates to a novel isolated nucleic acid encoding human
CC  KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC  invention has cytostatic activity. The nucleotide may have a use in gene
CC  therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC  monitor a disease caused by altered expression of human KTOM1.
CC  Compositions comprising the nucleic acids, proteins or antibodies may be
CC  used to treat subjects having defects in KTOM1 which can manifest as
CC  cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC  heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC  function. The sequence represents a probe used in the invention to scan
CC  the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ  Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db          522 ATCGACTCCCTGCTGGA 538
              ||| ||||| |||||
              1 ATCTACTCCGAGCTGGA 17

RESULT 318
ABQ63732
ID  ABQ63732 standard; DNA; 17 BP.
AC  ABQ63732;
XX
DT  20-AUG-2002 (first entry)
DE  Human KTOM1a portion (ABQ63232) probe # 445.
KW  Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW  gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW  kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS  Homo sapiens.
XX
PN  WO200224750-A2.
XX
PD  28-MAR-2002.
XX
PF  21-SEP-2001; 2001WO-US029656.
PR  21-SEP-2000; 2000US-0234687P.
PR  27-SEP-2000; 2000US-0236359P.
PR  04-OCT-2000; 2000GB-00024263.
PR  30-JAN-2001; 2001WO-US000661.
PR  30-JAN-2001; 2001WO-US000662.
PR  30-JAN-2001; 2001WO-US000663.
PR  30-JAN-2001; 2001WO-US000664.
PR  30-JAN-2001; 2001WO-US000665.
PR  30-JAN-2001; 2001WO-US000666.
PR  30-JAN-2001; 2001WO-US000667.
PR  30-JAN-2001; 2001WO-US000668.
PR  30-JAN-2001; 2001WO-US000669.
PR  30-JAN-2001; 2001WO-US000670.
PR  23-MAY-2001; 2001US-00864761.
PR  28-AUG-2001; 2001US-0315676P.
XX
PA  (AEOM-) AEOMICA INC.
XX
PI  Zhang J;
XX
WPI; 2002-479509/51.
XX
PT  New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT  acids encoding the protein, useful for treating subjects having defects
PT  in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT  e.g., liver or bone.
XX
PS  Example 2; Page 216; 418pp; English.
XX
CC  The invention relates to a novel isolated nucleic acid encoding human
CC  KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC  invention has cytostatic activity. The nucleotide may have a use in gene
CC  therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC  monitor a disease caused by altered expression of human KTOM1.
CC  Compositions comprising the nucleic acids, proteins or antibodies may be
CC  used to treat subjects having defects in KTOM1 which can manifest as
CC  cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC  heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC  function. The sequence represents a probe used in the invention to scan
CC  the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ  Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      520 GCATCGACTCCCTGCTGG 536
      ||||| ||||| |||||
Db      1 GCATCTACTCCCAGCTG 17

RESULT 319
ABQ63733
ID ABQ63733 standard; DNA; 17 BP.
XX
AC ABQ63733;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 446.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PR 30-JAN-2001; 2001WO-US000661.
XX
PR 30-JAN-2001; 2001WO-US000662.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
WPI; 2002-479509/51.
XX
New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
Example 2; Page 216; 418pp; English.
XX
The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      521 CATCGACTCCCTGCTGG 537
      ||||| ||||| |||||
Db      1 CATCTACTCCCAGCTG 17

RESULT 320
ABQ63735
ID ABQ63735 standard; DNA; 17 BP.
XX
AC ABQ63735;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 448.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PR 30-JAN-2001; 2001WO-US000661.
XX
PR 30-JAN-2001; 2001WO-US000662.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
WPI; 2002-479509/51.
XX
New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
Example 2; Page 216; 418pp; English.
XX
The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
```

Tue Sep 13 10:53:20 2005

10828394-1_1-1643.rng.s1

Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 TCGACTCCCTGCTGGAG 539
| | | | | | | | | | | | | | |
Db 1 TCTACTCCAGCTGGAG 17

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 526 ACTCCCTGCTGGAGAAC 542
| | | | | | | | | | | | | | |
Db 1 ACTCCAGCTGGAGACC 17

RESULT 321
ABQ63738
ID ABQ63738 standard; DNA; 17 BP.
XX
AC ABQ63738;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 451.
XX
KW Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (ABOM-) AEOMICA INC.
XX
PI Zhang J;
XX
PI WPI; 2002-479509/51.
XX
DR New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
PS Example 2; Page 216; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
XX invention has cytostatic activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

RESULT 322
ABQ64165
ID ABQ64165 standard; DNA; 17 BP.
XX
AC ABQ64165;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 878.
XX
KW Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (ABOM-) AEOMICA INC.
XX
PI Zhang J;
XX
PI WPI; 2002-479509/51.
XX
DR New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
PS Example 2; Page 272; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
XX invention has cytostatic activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1203 GTCACACCGTGGCTTC 1219
    ||||| |||||
Db 1 GTCACCACTGTGGCTGC 17

RESULT 323
ABV79503
ID ABV79503 standard; DNA; 17 BP.
XX
AC ABV79503;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 749.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
WPI; 2002-676582/73.

Novel isolated human testis expressed Patched like protein (HTPL), useful
for identifying agonist and antagonist and specific binding partners, and
for treating subjects having defects in HTPL.

Example 2; Page 162; 718pp; English.

The present invention relates to human testis expressed Patched like
protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
has two isoforms, with a few single base pair differences between the
two. One of the single base pair changes introduces a premature stop
codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
shares an overall structure organisation with the Patched protein. The
shared structural features strongly imply that HTPL plays a role similar
to that of Patched, and is a potential tumour suppressor. HTPL is
important in regulating male germ cell development, and the HTPL gene was
mapped to human chromosome 10p12.1. HTPL and its coding sequence are
useful for diagnosing a disorder caused by mutation in HTPL, and in
therapy and manufacture of a medicament for treatment or prevention of
such disorder associated with decreased expression or activity of human
HTPL. Such disorders include disorders of testis, or adrenal, adult and
foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
skeletal muscle or colon function. HTPL proteins and nucleic acids are
clinically useful diagnostic markers and potential therapeutic agents for
male infertility and cancer. The present oligonucleotide was used in an
example from the invention
```

```
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 522 ATCGACTCCCTGCTGGA 538
    ||||| |||||
Db 1 AGCGACTCACTGCTGGA 17

RESULT 324
ABV79992
ID ABV79992 standard; DNA; 17 BP.
XX
AC ABV79992;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 1238.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
WPI; 2002-676582/73.

Novel isolated human testis expressed Patched like protein (HTPL), useful
for identifying agonist and antagonist and specific binding partners, and
for treating subjects having defects in HTPL.

Example 2; Page 226; 718pp; English.

The present invention relates to human testis expressed Patched like
protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
has two isoforms, with a few single base pair differences between the
two. One of the single base pair changes introduces a premature stop
codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
shares an overall structure organisation with the Patched protein. The
shared structural features strongly imply that HTPL plays a role similar
to that of Patched, and is a potential tumour suppressor. HTPL is
important in regulating male germ cell development, and the HTPL gene was
mapped to human chromosome 10p12.1. HTPL and its coding sequence are
useful for diagnosing a disorder caused by mutation in HTPL, and in
therapy and manufacture of a medicament for treatment or prevention of
such disorder associated with decreased expression or activity of human
HTPL. Such disorders include disorders of testis, or adrenal, adult and
foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
skeletal muscle or colon function. HTPL proteins and nucleic acids are
clinically useful diagnostic markers and potential therapeutic agents for
male infertility and cancer. The present oligonucleotide was used in an
example from the invention
```


CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 2 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1273 TCTTGACTCTGATCCC 1289
||| ||||| ||||| |||||
Db 1 TCTGTGACTGTGATCCC 17

RESULT 325
ABV79502
ID ABV79502 standard; DNA; 17 BP.
XX AC
ABV79502;
DT
DT
XX 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 748.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
XX WPI; 2002-676582/73.
XX
XX
XX Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
XX Example 2; Page 161; 719pp; English.

CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABV98519 to ABV98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,

CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 521 CATCGACTCCCTGCTGG 537
||| ||||| ||||| |||||
Db 1 CAGCGACTCACTGCTGG 17

RESULT 326
ABK18229
ID ABK18229 standard; RNA; 17 BP.
XX AC
ABK18229;
XX
DT 09-APR-2002 (first entry)
XX
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 876.
XX
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnaray; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberyzyme.
XX
OS Homo sapiens.
XX
PN WO200188124-A2.
XX
PD 22-NOV-2001.
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
XX WPI; 2002-082995/11.
XX
XX Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
XX Claim 4; Page 74; 149pp; English.

CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or

CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 XX Sequence 17 BP; 2 A; 12 C; 2 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1504 GCCCGAGCTCCAGGCC 1520
 DB 1 GCCCCACCCUCCAGGCC 17
 RESULT 327
 ID ABK19135 standard; RNA; 17 BP.
 AC ABK19135;
 XX
 XX 09-APR-2002 (first entry)
 DT
 XX
 DE Human ERG Amberzyme target sequence Seq ID No 1782.
 KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulvar; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Oslar-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;
 KW amberzyme.
 XX
 XX Homo sapiens.
 OS
 XX WO200188124-A2.
 PN
 XX 22-NOV-2001.
 PD
 XX 16-MAY-2001; 2001WO-US015866.
 PF
 XX 16-MAY-2000; 2000US-00572021.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAXO) GLAXO GROUP LTD.
 XX
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 PI WPI; 2002-082995/11.
 XX
 DR Novel polynucleotide which down regulates expression of Ets-related gene,
 XX useful for treating cancer, diabetic retinopathy, macular degeneration,
 XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 PT
 XX Claim 4; Page 120; 149pp; English.
 SS
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Oslar-Weber-rendu

CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 XX Sequence 17 BP; 10 A; 3 C; 3 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 218 GACTCTCATAGAAAAA 234
 DB 1 GACUCACAGAGAAAAA 17
 RESULT 328
 AAD38269
 ID AAD38269 standard; DNA; 17 BP.
 AC AAD38269;
 XX
 XX 10-SEP-2002 (first entry)
 DT
 DE Mouse Ob receptor genomic DNA amplifying forward PCR primer #2.
 XX
 XX Mouse; Ob receptor; ObR; leptin; body weight disorder; drug screening;
 KW gene therapy; obesity; cachexia; anorexia; anorectic; anabolic; PCR;
 KW primer; ss.
 XX
 XX Mus sp.
 OS
 XX US6380363-B1.
 PN
 XX 30-APR-2002.
 PD
 XX 19-AUG-1998; 98US-00137132.
 PF
 XX 27-NOV-1995; 95US-00562663.
 PR 04-DEC-1995; 95US-00566622.
 PR 08-DEC-1995; 95US-00569485.
 PR 11-DEC-1995; 95US-00570142.
 PR 28-DEC-1995; 95US-00583153.
 PR 22-JAN-1996; 96US-00599455.
 PR 26-APR-1996; 96US-00638524.
 PR 03-SEP-1996; 96US-00708123.
 PR 28-MAY-1997; 97US-00864584.
 XX
 XX (TART/) TARTAGLIA L A.
 PA (TEPP/) TEPPER R I.
 PA (CULP/) CULPEPPER J A.
 PA (WHIT/) WHITE D W.
 XX
 XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;
 PI WPI; 2002-413726/44.
 DR
 XX Antibodies which selectively bind mammalian Ob receptors and inhibits the
 PT binding of leptin to the mammalian Ob receptor, useful for diagnosing and

```

PT treating weight disorders.
PS Example; Col 62; 108pp; English.
XX
XX The present invention relates to novel antibodies which selectively bind
XX mammalian Ob receptors (OBR) and inhibit the binding of leptin to the
XX mammalian Ob receptor. OBR sequences are novel receptor proteins that
XX participate in the control of mammalian body weight. The antibodies of
XX the invention may be used to detect of Ob receptor in a biological sample
XX and utilised as a part of diagnostic or prognostic technique in which
XX patients may be tested for abnormal amounts of Ob receptors. They may be
XX utilised in conjunction with, for example, compound screening schemes for
XX the evaluation of the effect of test compounds on expression and/or
XX activity of the Ob receptor gene product. The antibodies can be used in
XX conjunction with the gene therapy techniques, for example, to evaluate
XX the normal and/or engineered Ob receptor-expressing cells prior to their
XX introduction into the patient. They may be used in the method for the
XX screening, clinical trial monitoring and/or the treatment of body weight
XX disorders including but not limited to obesity, cachexia and anorexia.
XX The present DNA sequence is a PCR primer which is used for amplifying
XX mouse OBR genomic DNA. This sequence is used in the exemplification of
XX the invention
XX
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTTCCTTCAG 17
XX
RESULT 329
AAD38271
ID AAD38271 standard; DNA; 17 BP.
XX
AC AAD38271;
XX
DT 10-SEP-2002 (first entry)
XX
DE Mouse Ob receptor genomic DNA amplifying forward PCR primer #3.
XX
KW Mouse; Ob receptor; OBR; leptin; body weight disorder; drug screening;
KW gene therapy; obesity; cachexia; anorexia; anorectic; anabolic; PCR;
KW primer; ss.
XX
OS Mus sp.
XX
XX US6380363-B1.
XX
XX 30-APR-2002.
XX
XX 19-AUG-1998; 98US-00137132.
XX
XX 27-NOV-1995; 95US-00562663.
XX 04-DEC-1995; 95US-00566622.
XX 08-DEC-1995; 95US-00569485.
XX 11-DEC-1995; 95US-00570142.
XX 28-DEC-1995; 95US-00583153.
XX 22-JAN-1996; 96US-00599455.
XX 26-APR-1996; 96US-00638524.
XX 03-SEP-1996; 96US-00708123.
XX 28-MAY-1997; 97US-00864564.
XX
XX (TART/) TARTAGLIA L A.
XX (TEPP/) TEPPER R I.
XX (CULP/) CULPEPPER J A.
XX (WHIT/) WHITE D W.
XX
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;
PI

```

```

XX WPI; 2002-413726/44.
XX
XX Antibodies which selectively bind mammalian Ob receptors and inhibits the
XX binding of leptin to the mammalian Ob receptor, useful for diagnosing and
XX treating weight disorders.
XX
XX Example; Col 62; 108pp; English.
XX
XX The present invention relates to novel antibodies which selectively bind
XX mammalian Ob receptors (OBR) and inhibit the binding of leptin to the
XX mammalian Ob receptor. OBR sequences are novel receptor proteins that
XX participate in the control of mammalian body weight. The antibodies of
XX the invention may be used to detect of Ob receptor in a biological sample
XX and utilised as a part of diagnostic or prognostic technique in which
XX patients may be tested for abnormal amounts of Ob receptors. They may be
XX utilised in conjunction with, for example, compound screening schemes for
XX the evaluation of the effect of test compounds on expression and/or
XX activity of the Ob receptor gene product. The antibodies can be used in
XX conjunction with the gene therapy techniques, for example, to evaluate
XX the normal and/or engineered Ob receptor-expressing cells prior to their
XX introduction into the patient. They may be used in the method for the
XX screening, clinical trial monitoring and/or the treatment of body weight
XX disorders including but not limited to obesity, cachexia and anorexia.
XX The present DNA sequence is a PCR primer which is used for amplifying
XX mouse OBR genomic DNA. This sequence is used in the exemplification of
XX the invention
XX
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTTCCTTCAG 17
XX
RESULT 330
ACN05936/C
ID ACN05936 standard; RNA; 17 BP.
XX
AC ACN05936;
XX
XX 22-APR-2004 (first entry)
XX
DE WNV Amberzyme substrate SEQ ID NO 5939.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX

```

XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 5939; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1226 TTCTGACTCGGAGTTC 1242
DB 17 TTCTGAGTCGGACATTC 1
RESULT 331
ACN08391
ID ACN08391 standard; RNA; 17 BP.
XX
XX ACN08391;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8394.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
PN
XX
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-024241P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 8394; 495pp; English.
XX

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 0 A; 9 C; 0 G; 0 T; 8 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 488 CTCGCCCTCTACTTCT 504
DB 1 CUCUCCUUCUUCUUCU 17
RESULT 332
ACN15008
ID ACN15008 standard; RNA; 17 BP.
XX
XX ACN15008;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Amberzyme substrate SEQ ID NO 15011.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
PN
XX
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-024241P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 15011; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX

CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3', inverted basic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
XX	
XX	Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX	
XX	Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX	Best Local Similarity 58.8%; Pred. No. 1.9e+02;
XX	Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps
XX	
QY	1227 TCTGACTCGGACGTTC 1243
	: : :
DB	1 UCUGAGUCGCAUUC 17
RESULT 333	
ACN00398/c	
ID ACN00398	standard; RNA; 17 BP.
XX	
AC	ACN00398;
XX	
DT	22-APR-2004 (first entry)
XX	
DE	WNV Hammerhead Ribozyme substrate SEQ ID NO 388.
XX	
XX	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW	viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;
KW	liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNazyme;
KW	Amberzyme; Zinzyme; ss.
XX	
OS	West Nile Virus.
XX	
PN	WO200268637-A2.
XX	
PD	06-SEP-2002.
XX	
PF	19-OCT-2001; 2001WO-US048350.
XX	
PR	20-OCT-2000; 2000US-0242411P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
PA	(MCSW/) MCSWIGGEN J A.
XX	
PI	Blatt L, Mcswiggen JA;
XX	
DR	WPI; 2002-706994/76.
XX	
PT	New nucleic acid molecule that modulates replication of West Nile Virus
PT	(WNV), useful for treating a condition related to WNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX	
PS	Claim 23; SEQ ID NO 388; 495pp; English.
XX	
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3', inverted basic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention

XX	Seq	Sequence	17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;	
		Query Match	0.8%; Score 13.8; DB 1; Length 17;	
		Best Local Similarity	88.2%; Pred. No. 1.9e+02;	
		Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	1228	CTGACTCGGAGCTTCCT	1244	
DB	17	CTGAGTCGGACATTCCT	1	
RESULT	334			
ACN14016				
ID	ACN14016	standard; RNA; 17 BP.		
XX				
AC	ACN14016;			
XX				
DT	22-APR-2004	(first entry)		
DE	WNV minus strand DNase substrate	SEQ ID NO 14019.		
XX				
XX	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;			
KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;			
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;			
KW	liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNase;			
KW	Amberzyme; Zinzyme; ss.			
XX				
OS	West Nile Virus.			
XX				
FN	WO200268637-A2.			
XX				
PD	06-SEP-2002.			
XX				
PF	19-OCT-2001; 2001WO-US048350.			
XX				
PR	20-OCT-2000; 2000US-0242411P.			
XX				
PA	(RIBO-) RIBOZYME PHARM INC.			
PA	(BLAT/) BLATT L.			
PA	(MCSW/) MCSWIGGEN J A.			
XX				
PI	Blatt L, Mcswiggen JA;			
XX				
DR	WPI; 2002-706994/76.			
XX				
PT	New nucleic acid molecule that modulates replication of West Nile Virus			
PT	(WNV), useful for treating a condition related to WNV infection e.g.			
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.			
XX				
PS	Claim 23; SEQ ID NO 14019; 495pp; English.			
XX				
CC	The invention relates to nucleic acid molecules that modulate replication			
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for			
CC	treating a condition related to WNV infection e.g. pancreatitis,			
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,			
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid			
CC	molecule is selected from the group of ribozymes consisting of			
CC	Hammerhead, inozyme, G-cleaver, DNase, Amberzyme and Zinzyme. The			
CC	nucleic acid molecules further comprise at least five ribose residues, at			
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at			
CC	least three of the 5' terminal nucleotides and a 3' end modification of a			
CC	3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080			
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given			
CC	in the specification. The present sequence is that of a nucleic acid			
CC	molecule of the invention			
XX				
Seq	Sequence	17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;		
	Query Match	0.8%; Score 13.8; DB 1; Length 17;		
	Best Local Similarity	52.9%; Pred. No. 1.9e+02;		
	Matches	9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;		

QY 1229 TGACTCGGACGTTCCCT 1245
DB 1 UGAGUCGGACAUCCU 17

RESULT 335

ACN15009
ID ACN15009 standard; RNA; 17 BP.

AC ACN15009;

DT 22-APR-2004 (first entry)

XX WNV minus strand Amberzyme substrate SEQ ID NO 15012.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 15012; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;

XX Query Match 0.8%; Score 13.8; DB 1; Length 17;

XX Best Local Similarity 58.8%; Pred. No. 1.9e+02;

XX Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1228 CTGACTCGGACGTTCCCT 1244

DB 1 CUGAGUCGGACAUCCU 17

RESULT 336

ACN06460/C

ID ACN06460 standard; RNA; 17 BP.

XX ACN06460;

XX 22-APR-2004 (first entry)

XX WNV Amberzyme substrate SEQ ID NO 6463.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 6463; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 8 A; 1 C; 8 G; 0 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 13.8; DB 1; Length 17;

XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 TCGCCCTTCTACTTCTG 505

DB 17 TCTCCCTTCTCTCTG 1

RESULT 337

ACN01953/C

ID ACN01953 standard; RNA; 17 BP.

XX ACN01953;

XX 22-APR-2004 (first entry)

XX WNV Inozyme substrate SEQ ID NO 1943.

```
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
PS WPI; 2002-706994/76.
XX
DR
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 1943; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1227 TCTGACTCGGAGCTTCC 1243
DB 17 TCTGACTCGGACATCC 1
RESULT 338
ACN08392
ID ACN08392 standard; RNA; 17 BP.
XX
AC ACN08392;
XX
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8395.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
```

```
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
PS WPI; 2002-706994/76.
XX
DR
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 8395; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 0 A; 8 C; 1 G; 0 T; 8 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 489 TCGCCCTTCTACTCTG 505
DB 1 UCUCUCCUUCUCCUUCUG 17
RESULT 339
ACN11835/C
ID ACN11835 standard; RNA; 17 BP.
XX
AC ACN11835;
XX
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand Inozyme substrate SEQ ID NO 11838.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
```

XX 20-OCT-2000; 2000US-0242411P.
PR (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
DR
XX
XX The invention relates to nucleic acid molecules that modulate replication
PT of the West Nile Virus (WNV). The nucleic acid molecules are useful for
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 11838; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1470 CCAGAGGAGGCTCTGCA 1486
DB 17 CAAGAGGAGGCTCTGCA 1
RESULT 340
ACN05385/c
ID ACN05385 standard; RNA; 17 BP.
XX
AC ACN05385;
XX
DT 22-APR-2004 (first entry)
XX
XX WNV DNazyme substrate SEQ ID NO 5388.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 11838; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1470 CCAGAGGAGGCTCTGCA 1486
DB 17 CAAGAGGAGGCTCTGCA 1

PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 5388; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1232 CTCGGACGTTCTCTCCG 1248
DB 17 CGCGGACGTTCTCATCCG 1
RESULT 341
ACN08973
ID ACN08973 standard; RNA; 17 BP.
XX
AC ACN08973;
XX
DT 22-APR-2004 (first entry)
XX
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8976.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX

DT 03-JUN-2003 (first entry)
DE NFKB sub-unit modulating DNazyme substrate #24.
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS Homo sapiens.
XX
XX US2002177568-A1.
XX
XX 28-NOV-2002.
XX
XX 23-MAY-2001; 2001US-00864785.
XX
XX 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-00245466.
PR 15-AUG-1994; 94US-00291932.
PR 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCHCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
PI WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 43; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
XX Sequence 17 BP; 6 A; 9 C; 0 G; 0 T; 2 U; 0 Other;
SQ

Best Local Similarity 82.4%; Pred. No. 1.9e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 989 CACCAACAAACCCCTCCC 1005
DB 1 CAACACACACCCCUCC 17
RESULT 348
ACA06298
ID ACA06298 standard; RNA; 17 BP.
XX ACA06298;
XX
XX 03-JUN-2003 (first entry)
DE NFKB sub-unit modulating inozyme substrate #117.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS Homo sapiens.
XX
XX US2002177568-A1.
XX
XX 28-NOV-2002.
XX
XX 23-MAY-2001; 2001US-00864785.
XX
XX 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-00245466.
PR 15-AUG-1994; 94US-00291932.
PR 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCHCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
PI WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 29; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule

Query Match

0.8%; Score 13.8; DB 1; Length 17;

CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 6 A; 8 C; 1 G; 0 T; 2 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 952 CAACAACCCCTCCAGG 1008
 DB 1 CAACAACCCCTCCAGG 17
 RESULT 349
 ID ACA06394 standard; RNA; 17 BP.
 AC ACA06394;
 XX
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFkB sub-unit modulating inozyme substrate #213.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherpay; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 XX 18-MAY-1994; 94US-00245466.
 XX 15-AUG-1994; 94US-00291932.
 XX 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 DR
 DR WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 30; 72pp; English.
 PS
 XX

CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherpay including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 4 G; 0 T; 1 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1501 CAGGCCCCGCTCCAG 1517
 DB 1 CAGACCCCGCCGCGAG 17
 RESULT 350
 ID ACA06396 standard; RNA; 17 BP.
 AC ACA06396;
 XX
 XX 03-JUN-2003 (first entry)
 DT
 DE NFkB sub-unit modulating inozyme substrate #215.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherpay; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 XX 18-MAY-1994; 94US-00245466.
 XX 15-AUG-1994; 94US-00291932.
 XX 23-DEC-1996; 96US-00777916.
 XX

PA (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 PT
 XX Claim 3; Page 30; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 XX Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1505 CCCAGCCCTCCAGGCC 1521
 Db 1 CCCAGCCCTCCAGGCCUC 17
 RESULT 351
 ID ACA06517 standard; RNA; 17 BP.
 XX
 XX ACA06517;
 XX
 XX 03-JUN-2003 (first entry)
 XX
 XX NFKB sub-unit modulating inozyme substrate #336.
 DE
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 XX 18-MAY-1994; 94US-00245466.
 XX 15-AUG-1994; 94US-00291932.
 XX 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 PT
 XX Claim 3; Page 32; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 XX Sequence 17 BP; 2 A; 11 C; 3 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1505 CCCAGCCCTCCAGGCC 1521
 Db 1 CCCAGCCCTCCAGGCC 17
 RESULT 352
 ID ADA99701 standard; DNA; 17 BP.
 XX
 XX ADA99701;
 XX
 XX 20-NOV-2003 (first entry)
 XX
 XX Human MD23 scanning oligonucleotide SEQ ID 690.

```
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
PI WPI; 2003-423107/40.
XX
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
PS Example 8; SEQ ID NO 690; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 788 CCTGAGATGATACACG 804
Db 1 CCTGGAGATGAGACG 17
RESULT 353
ADB00467/C
ID ADB00467 standard; DNA; 17 BP.
XX
XX ADB00467;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human MD23 scanning oligonucleotide SEQ ID 1453.
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
```

```
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
PI WPI; 2003-423107/40.
XX
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
PS Example 8; SEQ ID NO 1453; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 926 GGGCTGCTGGCGATGA 942
Db 17 GTGCTGCTGGCGCTGA 1
RESULT 354
ADB02413
ID ADB02413 standard; DNA; 17 BP.
XX
XX ADB02413;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human MD24 scanning oligonucleotide SEQ ID 3399.
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
```

```

PA (AEOM-) AEOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 3399; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2.
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 464 GCTTGAGGAGTTCCTGA 480
DB 1 GCTGGAGCAGTTCCTGA 17
RESULT 355
ACD58046
ID ACD58046 standard; RNA; 17 BP.
XX
XX ACD58046;
XX
XX 23-SEP-2003 (first entry)
DE HCV DNazyme substrate sequence #632.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX 08-JUN-2001; 2001US-0296876P.
XX
XX 24-OCT-2001; 2001US-0335059P.
XX
XX 05-DEC-2001; 2001US-0337055P.
XX

```

```

PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 245; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention.
XX
XX Sequence 17 BP; 2 A; 1 C; 7 G; 0 T; 7 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 1400 TGTGATGTTGCTTTTG 1416
DB 1 UGUGGAUGAUGCUGUUG 17
RESULT 356
ACD61087
ID ACD61087 standard; RNA; 17 BP.
XX
XX ACD61087;
XX
XX 24-SEP-2003 (first entry)
DE HCV DNazyme substrate sequence #2161.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
XX

```


XX PD 17-OCT-2002.
XX PF 26-MAR-2002; 2002WO-US0009187.
XX PR 26-MAR-2001; 2001US-00817879.
XX PR 08-JUN-2001; 2001US-00877478.
XX PR 08-JUN-2001; 2001US-0296876P.
XX PR 24-OCT-2001; 2001US-0335059P.
XX PR 05-DEC-2001; 2001US-0337055P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MACE/) MACEJAK D.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (MORR/) MORRISSEY D.
XX PA (PAVC/) PAVCO P.
XX PA (LEEP/) LEE P.
XX PA (DRAP/) DRAPER K.
XX PA (ROBE/) ROBERTS E.
XX PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX PI Draper K, Roberts E;
XX WI WI; 2003-229207/22.
XX PT Novel compound useful for treating cirrhosis, liver failure,
XX PT hepatocellular carcinoma, or condition associated with hepatitis C virus
XX PT infection.
XX PS Claim 1; Page 272; 387pp; English.
XX CC The present invention relates to nucleic acid molecules which modulate
XX CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
XX CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX CC as oligonucleotides that specifically bind the Enhancer I region of HBV
XX CC DNA. The nucleic acids may be used to modulate the expression of HBV
XX CC genes and HBV viral replication. Also disclosed is a method for screening
XX CC compounds and/or potential therapies directed against HBV, and compounds
XX CC that modulate the expression and/or replication of HCV. The compounds and
XX CC methods of the invention are useful for the treatment of degenerative and
XX CC disease states related to HBV and HCV infection, replication and gene
XX CC expression such as cirrhosis, liver failure, and hepatocellular
XX CC carcinoma. The present sequence represents a substrate for one of the HCV
XX CC DNazyme or minus strand DNazyme sequences disclosed in the present
XX CC invention
XX SQ Sequence 17 BP; 3 A; 5 C; 2 G; 0 T; 7 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.9e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 689 GAGGCCTCACTTCTTCT 705
DB 1 GAUGACUCACUUCUUCU 17
RESULT 357
ACD62816/c
ID ACD62816 standard; RNA; 17 BP.
XX AC ACD62816;
XX DT 24-SEP-2003 (first entry)
XX DE HCV minus strand DNazyme substrate sequence #735.
XX XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;

KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX OS Hepatitis C virus.
XX OS WO200281494-A1.
XX PN 17-OCT-2002.
XX PD 26-MAR-2002; 2002WO-US0009187.
XX PF 26-MAR-2001; 2001US-00817879.
XX PR 08-JUN-2001; 2001US-00877478.
XX PR 08-JUN-2001; 2001US-0296876P.
XX PR 24-OCT-2001; 2001US-0335059P.
XX PR 05-DEC-2001; 2001US-0337055P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MACE/) MACEJAK D.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (MORR/) MORRISSEY D.
XX PA (PAVC/) PAVCO P.
XX PA (LEEP/) LEE P.
XX PA (DRAP/) DRAPER K.
XX PA (ROBE/) ROBERTS E.
XX PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX PI Draper K, Roberts E;
XX WI WI; 2003-229207/22.
XX PT Novel compound useful for treating cirrhosis, liver failure,
XX PT hepatocellular carcinoma, or condition associated with hepatitis C virus
XX PT infection.
XX PS Claim 1; Page 288; 387pp; English.
XX CC The present invention relates to nucleic acid molecules which modulate
XX CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
XX CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX CC as oligonucleotides that specifically bind the Enhancer I region of HBV
XX CC DNA. The nucleic acids may be used to modulate the expression of HBV
XX CC genes and HBV viral replication. Also disclosed is a method for screening
XX CC compounds and/or potential therapies directed against HBV, and compounds
XX CC that modulate the expression and/or replication of HCV. The compounds and
XX CC methods of the invention are useful for the treatment of degenerative and
XX CC disease states related to HBV and HCV infection, replication and gene
XX CC expression such as cirrhosis, liver failure, and hepatocellular
XX CC carcinoma. The present sequence represents a substrate for one of the HCV
XX CC DNazyme or minus strand DNazyme sequences disclosed in the present
XX CC invention
XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 769 ACGCCATGTTCCAGCCC 785
DB 17 ACGCCATGTTCCGGCTC 1


```
RESULT 358
ACC67637
ID ACC67637 standard; DNA; 17 BP.
XX
XX ACC67637;
AC
XX
XX 01-JUL-2003 (first entry)
DT
XX
XX Murine oligonucleotide associated with tumour suppression, SEQ ID 4884.
DE
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
XX Mus musculus.
OS
XX
XX WO2003025176-A2.
PN
XX
XX 27-MAR-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004210.
PF
XX
XX 17-SEP-2001; 2001FR-00011979.
PR
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX
XX Telerman A, Amson R, Tuijnder M;
PI
XX
XX WPI; 2003-333167/31.
DR
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
PT
XX
XX Disclosure; Page 602; 739pp; French.
PS
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
CC
XX
XX Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1551 GATCCTGCACTCTTAACA 1567
DB 1 GATCCTGTACTCTTAATA 17
RESULT 359
ADB39727/c
ID ADB39727 standard; DNA; 17 BP.
XX
XX ADB39727;
AC
XX
XX 18-DEC-2003 (revised)
DT
XX
XX 04-DEC-2003 (first entry)
DT
XX
XX Tumour suppression/reversion associated nucleotide #50.
DE
XX
XX Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
```

```
diagnosis.
KW
XX
XX Homo sapiens.
XX
XX WO2003040369-A2.
PN
XX
XX 15-MAY-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004219.
PF
XX
XX 17-SEP-2001; 2001FR-00011981.
PR
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX
XX Telerman A, Amson R, Tuijnder M;
PI
XX
XX WPI; 2003-441574/41.
DR
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
PT
XX
XX Disclosure; Page 37; 771pp; French.
PS
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
XX Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 91 GGGAGAGTGGGCAGGTC 107
DB 17 GGGAGGTGGGCAGATC 1
RESULT 360
ADI47981
ID ADI47981 standard; DNA; 17 BP.
XX
XX ADI47981;
AC
XX
XX 15-APR-2004 (first entry)
DT
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID484.
DE
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX Homo sapiens.
XX
```

```

PN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telferman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; SEQ ID NO 484; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration.
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1551 GATCCTGCACCTACACA 1567
Db 1 GATCCTGTACTCTAATA 17

RESULT 361
ABZ94171/C
ID ABZ94171 standard; DNA; 17 BP.
XX
XX AC ABZ94171;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human adenosine A1 receptor antisense fragment no.34.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX OS
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX

```

```

PR 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 9413; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCCCG 1

RESULT 362
ABZ95047/C
ID ABZ95047 standard; DNA; 17 BP.
XX
XX AC ABZ95047;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human adenosine A1 receptor antisense fragment no.910.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX OS
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX

```

PR 24-APR-2001; 2001US-0286137P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandraagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shanabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 10289; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1530 GCCAGCCTCTCCCGC 1546
DB 17 GCCAGCCTGTCCCGC 1
RESULT 363
ADL48005
ID ADL48005 standard; RNA; 17 BP.
XX
AC ADL48005;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #515.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX

PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1538; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.9e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
OY 697 ACTTCTTCTTTCCCAAG 713
DB 1 ACUUCUGUGUCCCAAG 17
RESULT 364
ADL50256/c
ID ADL50256 standard; RNA; 17 BP.
XX
AC ADL50256;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1370.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX

PD 17-OCT-2002.
XX 03-APR-2002; 2002WO-US010512.
PF 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT Claim 59; SEQ ID NO 3789; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX Sequence 17 BP; 8 A; 6 C; 1 G; 0 T; 2 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1400 TGTGGATGTTGCTTTG 1416
|||||
DB 17 TGTGGATGTTGATCTG 1
|||||
RESULT 365
ADL48380
ID ADL48380 standard; RNA; 17 BP.
XX ADL48380;
AC ADL48380;
XX 20-MAY-2004 (first entry)
DT Human IKK-gamma substrate sequence #890.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
OS WO200281628-A2.
XX PN
XX

PD 17-OCT-2002.
XX 03-APR-2002; 2002WO-US010512.
PF 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT Claim 59; SEQ ID NO 1913; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.9e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
OY 698 CTTCTCTTCCCAAGT 714
|::|:|:|:|:|:|:|:
DB 1 CUUCUGCUGUCCCAAGU 17
|:|:|:|:|:|:|:
RESULT 366
ADM09485
ID ADM09485 standard; RNA; 17 BP.
XX ADM09485;
AC ADM09485;
XX 20-MAY-2004 (first entry)
DT Human NOGO receptor amberzyme substrate sequence #40.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor amberzyme; substrate; ss.
XX Unidentified.
OS WO200281628-A2.
XX PN
XX

PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 880; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/perfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor amberzyme substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 1.9e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 1117 CCTGCTGGAGCAGCTG 1133
 || : ||:|||||:
 Db 1 CCUCUCGAGCAGCUG 17
 RESULT 367
 ADM54165/c
 ID ADM54165 standard; mRNA; 17 BP.
 XX
 AC ADM54165;
 XX
 XX 03-JUN-2004 (first entry)
 XX
 DE Human GRID mRNA substrate sequence #440.
 XX
 KW Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
 KW NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNzyme; amberzyme; inozyme;
 KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
 XX
 OS Homo sapiens.
 XX
 XX US2003134806-A1.
 PN
 XX 17-JUL-2003.
 PD
 XX 23-FEB-2001; 2001US-00792818.
 PF
 XX 10-FEB-2000; 2000US-0181594P.
 PR
 XX (JARV/) JARVIS T.

PA (CARL/) CARLOWITZ I V.
 PA (MCSW/) MCSWIGGEN J.
 PA (HAMB/) HAMBLIN P A.
 PA (ELLI/) ELLIS J H.
 XX
 PI Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
 XX WPI; 2003-829646/77.
 DR
 XX New nucleic acid molecule that down-regulates expression of Grb2-related
 PT with insert domain (GRID) gene, useful for treating a condition
 PT associated with the level of GRID, e.g. tissue/graft rejection and
 PT leukemia.
 XX
 PS Claim 4; SEQ ID NO 440; 74pp; English.
 XX
 CC The invention relates to a nucleic acid molecule that down-regulates
 CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
 CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNzyme,
 CC amberzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell
 CC including the novel nucleic acid molecule, reducing GRID activity in a
 CC cell by contacting the cell with the novel nucleic acid molecule,
 CC treating a patient having a condition associated with the level of GRID
 CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
 CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
 CC contacting the cell with the novel nucleic acid molecule, an expression
 CC vector comprising a nucleic acid sequences (encoding at least the novel
 CC nucleic acid molecule in a manner that allows its expression), a
 CC mammalian cell including the expression vector and an enzymatic nucleic
 CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
 CC molecule is useful for treating a condition associated with the level of
 CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
 CC a target region for the enzymatic nucleic acids of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1539 CTCGCCGCTCTGGATCC 1555
 |||||:|||||:
 Db 17 CTCGCCGCTGTGAACC 1
 RESULT 368
 ABD18019/c
 ID ABD18019 standard; DNA; 17 BP.
 XX
 AC ABD18019;
 XX
 XX 29-JUL-2004 (first entry)
 XX
 DE Human adenosine A1 receptor oligonucleotide fragment 34.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ds.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR

```

XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX XX
XX DR WPI; 2003-093058/08.
XX XX
XX PT Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX PS Claim 15; SEQ ID NO 9413; 763pp; English.
XX CC
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposcretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes (a) that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC instructions for adding a carrier and for use of the kit. The composition
XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC inflammation, allergies, asthma, impeded respiration, respiratory
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX CC prevent any unwanted effects due to it
XX SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCCGC 1

RESULT 369
ID ABD18895/c
XX ABD18895 standard; DNA; 17 BP.
XX AC ABD18895;
XX XX
XX DT 29-JUL-2004 (first entry)
XX DE Human adenosine A1 receptor oligonucleotide fragment 910.
XX KW Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
XX KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection; ds.
Homo sapiens.
WO200285309-A2.
31-OCT-2002.
23-APR-2002; 2002WO-US013143.
24-APR-2001; 2001US-0286036P.
(EPIG-) EPIGENESIS PHARM INC.
Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
Miller S, Tang L, Shahabuddin S;
WPI; 2003-093058/08.
Pharmaceutical composition for treating asthma, has antisense
oligonucleotide containing less percentage of adenosine, targeted to
nucleic acids associated with lung airway or lung dysfunction, and
bronchodilating agent.
Claim 15; SEQ ID NO 10289; 763pp; English.
This invention describes a novel composition (a) a first active agent,
comprising oligonucleotides, effective for alleviating
bronchoconstriction, respiratory tract inflammation, allergies and
reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
surfactant depletion or hyposcretion, when administered to a mammal. The
oligonucleotides are derived from a gene encoding or regulating
expression of a target polypeptide associated with lung airway or lung
dysfunction or cancer and can be anti-sense to the corresponding mRNA.
The invention also describes (a) that comprises: (a) a delivery
device, in separate containers, (b) the oligonucleotides, (c)
instructions for adding a carrier and for use of the kit. The composition
of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
beta-adrenergic agonist. The composition is useful for preventing or
treating a respiratory, lung or malignant disease. The administered
composition comprises oligo and is administered to reduce the production
or availability, or to increase the degradation of the target mRNA or to
reduce the amount of target polypeptide present in the lungs. The
pulmonary obstruction, and/or bronchoconstriction and/or lung
inflammation, allergies and/or surfactant hypoproduction are associated
with a disease or condition such as pulmonary vasoconstriction,
inflammation, allergies, asthma, impeded respiration, respiratory
distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
transplantation rejection, pulmonary infections, bronchitis or cancer.
The reduced adenosine content of the anti-sense oligos corresponding to
thymidines present in the target RNA serves to prevent the breakdown of
the oligonucleotides into products that free adenosine into the system
e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
prevent any unwanted effects due to it
Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCCGC 1

RESULT 370
ADG63002
ID ADG63002 standard; DNA; 17 BP.
XX

```



```

PR 08-MAR-2002; 2002JP-00064373.
XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX WPI; 2004-093977/10.
XX Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX
XX Claim 2; SEQ ID NO 7308; 2627pp; Japanese.
XX
XX The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
SQ
    Query Match      0.8%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 1.9e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 666 CTGCCCTTCAGCGCTGCC 682
DB 17 CTGGCATTGAGCGCTGCC 1
RESULT 373
ADI84915
ID ADI84915 standard; RNA; 17 BP.
XX
XX AC ADI84915;
XX
XX 03-JUN-2004 (first entry)
XX
XX HCV DNzyme substrate sequence #2161.
DE
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
OS
XX
XX US2003125270-A1.
PN
XX
XX 03-JUL-2003.
PD
XX
XX 18-DEC-2000; 2000US-00740332.
PF
XX
XX 18-DEC-2000; 2000US-00740332.
PR
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI
XX
XX WPI; 2004-031273/03.
DR
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 2161; 198pp; English.
PS
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC in the specification. The nucleic acid molecule may be administered for
CC

```

```

CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 3 A; 5 C; 2 G; 0 T; 7 U; 0 Other;
SQ
    Query Match      0.8%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 52.9%; Pred. No. 1.9e+02;
    Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 689 GAGGCCTCACCTTCTCT 705
DB 1 GAUGACUCACUUCUUCU 17
RESULT 374
ADI83386
ID ADI83386 standard; RNA; 17 BP.
XX
XX AC ADI83386;
XX
XX 03-JUN-2004 (first entry)
XX
XX HCV DNzyme substrate sequence #632.
DE
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
OS
XX
XX US2003125270-A1.
PN
XX
XX 03-JUL-2003.
PD
XX
XX 18-DEC-2000; 2000US-00740332.
PF
XX
XX 18-DEC-2000; 2000US-00740332.
PR
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI
XX
XX WPI; 2004-031273/03.
DR
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 632; 198pp; English.
PS
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 1 C; 7 G; 1 T; 6 U; 0 Other;
SQ
    Query Match      0.8%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 52.9%; Pred. No. 1.9e+02;
    Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 1400 TGTGGATGTTGCTTTTG 1416
DB 1 UGUGGAUGATGCUUGUUG 17

```



```
RESULT 375
ACN64993/C
ID ACN64993 standard; DNA; 17 BP.
XX
AC ACN64993;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:1895.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 1895; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
```

```
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 1.9e-02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCGAGGTCCT 109
DB 17 GAGAGAGCCAGGTCCT 1

RESULT 376
ACN71759
ID ACN71759 standard; DNA; 17 BP.
XX
AC ACN71759;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:8661.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 8661; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
```

CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103

SQ Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 268 TAGAGAGCCCAAG 284

Db 1 TGGAGGAGCCCAAG 17

RESULT 377

ACN72785/c

ID ACN72785 standard; DNA; 17 BP.

XX AC ACN72785;

DT 02-DEC-2004 (first entry)

DE Human GDMPLP-1 probe SEQ ID NO:9687.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

PA (JIY/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

PI WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.

XX

PS Disclosure; SEQ ID NO 9687; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103

XX Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 93 GAGAGTGGCAGGTCCT 109

Db 17 GAGAGTGGCAGGTCCT 1

RESULT 378

ACN72787/c

ID ACN72787 standard; DNA; 17 BP.

XX AC ACN72787;

XX 02-DEC-2004 (first entry)

DE Human GDMPLP-1 probe SEQ ID NO:9689.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

PA (JIY/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

PI

XX WPI; 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 XX PT associated with decreased expression or activity of human genome-derived
 XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX PT function.
 XX
 XX Disclosure; SEQ ID NO 9689; Opp; English.
 XX
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 91 GGGAGAGTGGCAGGTC 107
 Db 17 GGGAGAGTGGCAGGTC 1
 RESULT 379
 ACN71758
 ID ACN71758 standard; DNA; 17 BP.
 XX AC ACN71758;
 XX
 XX 02-DEC-2004 (first entry)
 XX
 XX Human GDMLP-1 probe SEQ ID NO:8660.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
 KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.

PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.
 XX
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 XX PT associated with decreased expression or activity of human genome-derived
 XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX PT function.
 XX
 XX Disclosure; SEQ ID NO 8660; Opp; English.
 XX
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 267 CTAGAGAGGCCAGAA 283
 Db 1 CTGAGAGAGGCCAGAA 17
 RESULT 380
 ACN71761
 ID ACN71761 standard; DNA; 17 BP.
 XX AC ACN71761;
 XX
 XX 02-DEC-2004 (first entry)
 XX
 XX Human GDMLP-1 probe SEQ ID NO:8663.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
 KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.

```

PR 30-JAN-2001; 2001WO-US000657.
PR 30-JAN-2001; 2001WO-US000658.
PR 30-JAN-2001; 2001WO-US000659.
PR 30-JAN-2001; 2001WO-US000660.
PR 30-JAN-2001; 2001WO-US000661.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 8663; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 270 GAAGAGCCAGAGCAA 286
Db 1 GAGGAAGCCAGAGGA 17
XX
RESULT 381
ACN65741/c
ID ACN65741 standard; DNA; 17 BP.
XX
AC ACN65741;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:2643.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.

```

```

PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 2643; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 1 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 845 CTTCCAGCACCCGCCAA 861
Db 17 CTGCCAGGACCCGCCAA 1
XX
RESULT 382
ACN70453
ID ACN70453 standard; DNA; 17 BP.
XX
AC ACN70453;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:7355.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX

```


Query Match 0.8%; Score 13.8; DB 1; Length 17;

CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103

XX SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 292 AGGATGCCCTAAATGAG 308

||||| ||| |||||

Db 1 AGGATGACCTGAATGAG 17

RESULT 386

ACN72786/c

ID ACN72786 standard; DNA; 17 BP.

XX AC

ACN72786;

DT 02-DEC-2004 (first entry)

DE Human GDMLP-1 probe SEQ ID NO:9688.

XX KW

Human; ss; probe; myosin-like protein-1; hGDMLP-1;

hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

XX KW skeletal muscle function.

XX OS

Homo sapiens.

XX PN US2004137589-A1.

XX PD

15-JUL-2004.

XX PF

26-NOV-2003; 2003US-00723361.

XX PR

26-MAY-2000; 2000US-0207456P.

XX PR

21-SEP-2000; 2000US-0234687P.

XX PR

27-SEP-2000; 2000US-0236359P.

XX PR

04-OCT-2000; 2000GB-00024263.

XX PR

30-JAN-2001; 2001WO-US000661.

XX PR

30-JAN-2001; 2001WO-US000662.

XX PR

30-JAN-2001; 2001WO-US000663.

XX PR

30-JAN-2001; 2001WO-US000664.

XX PR

30-JAN-2001; 2001WO-US000665.

XX PR

30-JAN-2001; 2001WO-US000666.

XX PR

30-JAN-2001; 2001WO-US000667.

XX PR

30-JAN-2001; 2001WO-US000668.

XX PR

30-JAN-2001; 2001WO-US000669.

XX PR

05-FEB-2001; 2001WO-US000670.

XX PR

25-MAY-2001; 2001US-0086610P.

XX PA

(GUY/) GU Y.

XX PA

(JIY/) JI Y.

XX PA

(PENN/) PENN S G.

XX PA

(HANZ/) HANZEL D K.

XX PA

(RANK/) RANK D.

XX PA

(CHEN/) CHEN W.

XX PA

(SHAN/) SHANNON M E.

XX PI

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WIPI; 2004-533378/51.

XX PT

Novel myosin-like protein-1, useful for treating or preventing disorder

associated with decreased expression or activity of human genome-derived

myosin-like protein-1 such as disorder of heart and/or skeletal muscle

function.

XX PS

Disclosure; SEQ ID NO 9688; 0pp; English.

XX

The invention relates to a novel polypeptide (I) comprising a sequence
(S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
defined in the specification, a fragment of at least 8 amino acids of
(S1), 95% deviation from (S1) which are conservative substitutions, and
(S1), 95% identity to (S1). A polypeptide of the invention acts as an agonist or
antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
pharmaceutical composition of the invention is useful for treating or
preventing a disorder associated with decreased expression or activity of
hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
The present sequence represents a 17-mer nucleotide, used in the
invention for scanning the sequence represented in ACN63103

SQ Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 92 GGAGAGTGGCGAGGTCC 108

||||| ||| |||||

Db 17 GGAGAGTGGCGAGGTCC 1

RESULT 387

ABL52123/c

ID ABL52123 standard; DNA; 15 BP.

XX AC

ABL52123;

XX DT

12-JUL-2002 (first entry)

XX DE

Human PER1 allele specific oligonucleotide primer SEQ ID NO:48.

XX KW

Human; period (Drosophila) homologue 1; PER1; polymorphic variant;

polymorphic site; genotyping; haplotyping; circadian rhythm regulation;

XX KW single nucleotide polymorphism; SNP; gene; primer; ss.

XX OS

Homo sapiens.

XX FH

Key Location/Qualifiers

XX FT misc_feature 14

FT /tag= a

FT /note= "polymorphic site indicated by an ambiguity base"

XX FT

WO200222650-A2.

XX PN

21-MAR-2002.

XX PD

13-SEP-2001; 2001WO-US028780.

XX PF

13-SEP-2000; 2000US-0232468P.

XX PR

(GENA-) GENAISSANCE PHARM INC.

XX PA

Duda A, Kliem SE, Koshiy B;

XX PI

WPI; 2002-393941/42.

XX DR

Novel isolated human period Drosophila homolog 1 polynucleotide, useful
for therapeutic purposes, for studying the expression and function of the
polynucleotide, and for expressing the homolog.

XX PT

Claim 17; Page 15; 162pp; English.

XX PS

The present invention describes an isolated human period (Drosophila)

homologue 1, (PER1) polynucleotide (I) comprising a sequence which is a
polymorphic variant for a reference sequence (ABL52077) for the PER1 gene

or its fragment, or a polymorphic variant of a reference sequence
(ABL52078) for a PER1 cDNA or its fragment. The present invention also

describes methods for genotyping and haplotyping the PER1 gene of an
individual. (I) is useful in studying the expression and function of

PER1, and in expressing PER1 protein for use in screening for candidate

CC drugs to treat diseases related to PER1 activity. (I) is useful for
CC therapeutic purposes. A recombinant non-human organism transformed or
CC transfected with (I) can be used for studying expression of the PER1
CC isogenes in vivo, for in vivo screening and testing of drugs targeted
CC against PER1 protein, and for testing the efficacy of therapeutic agents
CC and compounds for disorders associated with circadian rhythm regulation.
CC The present sequence represents an allele specific oligonucleotide primer
CC for human PER1, which is used in the exemplification of the present
CC invention
XX
SQ Sequence 15 BP; 1 A; 3 C; 8 G; 2 T; 0 U; 1 Other;
Query Match 0.8%; Score 13.6; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1500 CCAGGCCCGCCT 1513
Db :|||||
14 YCAGGCCCGCCT 1
RESULT 388
AAS95535
ID AAS95535 standard; DNA; 15 BP.
XX
AC AAS95535;
XX
DT 14-FEB-2002 (first entry)
XX
DE Human IL8RB gene allele-specific oligonucleotide probe #11.
XX
KW Human; interleukin 8 receptor beta; IL8RB; ss; antiinflammatory; probe;
KW haplotyping; haplotype pair; single nucleotide polymorphism; genotyping;
KW gene therapy; drug screening; chronic obstructive pulmonary disease;
KW inflammatory disease; sequencing primer; PCR primer.
XX
OS Homo sapiens.
XX
PN WO200179221-A2.
XX
PD 25-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US011942.
XX
PR 12-APR-2000; 2000US-0196734P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bentivegna SC, Chew A, Choi JY, Denton RR, Nandabalan K;
XX
PP WPI; 2002-055250/07.
XX
PT New polymorphic variants comprising interleukin-8 receptor beta (IL8RB)
PT isogene, useful in expressing IL8RB protein for use in screening for
PT candidate drugs to treat diseases related to IL8RB activity, e.g.
PT inflammatory disorders.
XX
PS Claim 16; Page 13; 74pp; English.
XX
CC The invention relates to single nucleotide polymorphisms in the human
CC interleukin 8 receptor beta (IL8RB) gene. A method for haplotyping the
CC IL8RB gene in an individual comprises identifying the nucleotide at one
CC or more polymorphic sites and determining whether one of the copies of
CC the gene is defined by one of the IL8RB haplotypes given in the
CC specification or whether both copies are defined by a haplotype pair.
CC This method is useful in genotyping, whereby all possible haplotype pairs
CC can be assigned to specific genotypes. An association between a trait and
CC a haplotype or haplotype pair of the IL8RB gene can be identified by
CC comparing the frequency of the haplotype or haplotype pair in a
CC population exhibiting the trait with the frequency of the haplotype or
CC haplotype pair in a reference population, where a higher haplotype
CC frequency in the trait population indicates the trait is associated with
CC the haplotype or haplotype pair. IL8RB and its corresponding DNA are used

CC for studying the expression and function of IL8RB, for use in screening
CC for candidate drugs to treat diseases related to IL8RB activity, such as
CC chronic obstructive pulmonary disease and other inflammatory disorders.
CC The sequences are also useful for studying the effect of variation on the
CC biological activity of IL8RB as well as on the binding affinity of
CC candidate drugs targeting IL8RB. Sequences AAS95525-AAS95579 represent
CC allele-specific oligonucleotide probes, sequencing primers and PCR
XX primers used to detect IL8RB gene polymorphisms
XX

SQ Sequence 15 BP; 5 A; 4 C; 4 G; 1 T; 0 U; 1 Other;

Query Match 0.8%; Score 13.6; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 197 CAACGGGGTGAAC 210
Db :|||||
1 CAACGGGGTGAAC 14

RESULT 389
AAT54903
ID AAT54903 standard; RNA; 15 BP.
XX
AC AAT54903;
XX
DT 25-MAR-2003 (revised)
DT 07-APR-1997 (first entry)
XX
DE Mouse relA hammerhead ribozyme target sequence (nt. position 1250).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
XX ss.
XX Mus musculus.
XX
XX WO9523225-A2.
XX
XX 31-AUG-1995.
XX
XX 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX 29-MAR-1994; 94US-00218934.
XX 04-APR-1994; 94US-0022795.
XX 07-APR-1994; 94US-00224483.
XX 15-APR-1994; 94US-00227958.
XX 15-APR-1994; 94US-00228041.
XX 18-MAY-1994; 94US-00245736.
XX 06-JUL-1994; 94US-00271280.
XX 15-AUG-1994; 94US-00291932.
XX 16-AUG-1994; 94US-00291433.
XX 17-AUG-1994; 94US-00292620.
XX 19-AUG-1994; 94US-00293520.
XX 02-SEP-1994; 94US-00300000.
XX 08-SEP-1994; 94US-00303039.
XX 23-SEP-1994; 94US-00311486.
XX 23-SEP-1994; 94US-00311749.
XX 28-SEP-1994; 94US-00314397.
XX 03-OCT-1994; 94US-00316771.
XX 07-OCT-1994; 94US-00319492.
XX 11-OCT-1994; 94US-00321993.
XX 04-NOV-1994; 94US-00334847.
XX 10-NOV-1994; 94US-00337608.

PR 28-NOV-1994; 94US-00345516.
 PR 16-DEC-1994; 94US-00357577.
 PR 23-DEC-1994; 94US-00363233.
 PR 30-JAN-1995; 95US-00380734.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Chowkira B, Dorenzo A, Draper KG, Dudycz LM;
 PI Grimm S, Karpaisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
 PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
 PI Tracz D, Usman N, Wincott FE, Woolf T;
 XX
 DR WPI; 1995-351090/45.
 XX
 PR Ribozymes having modified bases and methods for producing them - for use
 PT in inhibiting disease related genes.
 XX
 XX Claim 2; Page 226; 407pp; English.
 XX
 CC The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves relA mRNA at the
 CC nucleotide base position indicated in the DE line. The relA gene product
 CC is a subunit of the transcriptional regulator NF-kappaB and is implicated
 CC specifically in the induction of inflammatory responses. Regions of the
 CC mRNA that do not form secondary folding structures and that contain
 CC potential hammerhead and hairpin ribozyme cleavage sites were identified
 CC by computer analysis. Ribozymes directed against these mRNA sequences
 CC were designed and synthesised with modifications that improve their
 CC nuclease resistance. The ribozymes are designed to cleave the target
 CC sequences and thereby inhibit relA expression, making them potentially
 CC useful for treating rheumatoid arthritis, restenosis and asthma as well
 CC as for increasing tolerance to transplanted tissues. The potential
 CC immunosuppressive properties of a ribozyme that cleaves relA mRNA means
 CC that uses are limited to local delivery, acute indications or ex vivo
 CC treatment. (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 15 BP; 2 A; 8 C; 3 G; 0 T; 2 U; 0 Other;
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.4e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1507 CCAGCCTCCAGGCC 1521
 Db 1 CCAGCCUCCAGGCUC 15
 RESULT 390
 AAV31969/c
 ID AAV31969 standard; DNA; 15 BP.
 XX
 AC AAV31969;
 XX
 DT 21-AUG-1998 (first entry)
 XX
 DE Peptide nucleic acid probe 112.
 XX
 KW Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
 KW ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
 XX
 OS Synthetic.
 OS Mycobacterium sp.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..15
 FT /*tag= a
 FT /note= "This sequence contains a polyamide backbone
 FT instead of a deoxyribose backbone"
 XX
 PN WO9815648-A1.
 XX
 PD 16-APR-1998.

PF 03-OCT-1997; 97WO-DK000425.
 XX
 PR 04-OCT-1996; 96DK-00001096.
 PR 18-OCT-1996; 96DK-00001156.
 PR 05-MAY-1997; 97DK-00000512.
 XX
 PA (DAKO-) DAKO AS.
 XX
 XX Stender H, Lund K, Mollerup TA;
 XX
 DR WPI; 1998-240831/21.
 XX
 PT Peptide nucleic acid probes for detection of ribosomal nucleic acid of
 PT mycobacteria - allow differentiation between species of tuberculosis
 PT complex and others and can penetrate cell membranes without pretreatment.
 XX
 XX Claim 22; Page 67; 106pp; English.
 XX
 CC This is the nucleotide sequence of the peptide nucleic acid (PNA) probe
 CC used in the method of the invention, to detect ribosomal nucleic acid of
 CC mycobacteria. The probes are used, in situ or in vitro, for detection of
 CC the Mycobacterium tuberculosis complex (MTC), specifically M.
 CC tuberculosis, and especially in sputum samples, but also in other body
 CC fluids, biopsy specimens, foods, soil, air and water. Particularly, they
 CC are used to diagnose, stage or monitor infection, or for identification
 CC of drug-resistant strains (which generally have mutations in rRNA)
 XX
 SQ Sequence 15 BP; 2 A; 3 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 177 AAGGAAATTCAAAAT 191
 Db 15 AAGGAAAGTCAAAAT 1
 RESULT 391
 AAV31970/c
 ID AAV31970 standard; DNA; 15 BP.
 XX
 AC AAV31970;
 XX
 DT 21-AUG-1998 (first entry)
 XX
 DE Peptide nucleic acid probe 113.
 XX
 KW Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
 KW ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
 XX
 OS Synthetic.
 OS Mycobacterium sp.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..15
 FT /*tag= a
 FT /note= "This sequence contains a polyamide backbone
 FT instead of a deoxyribose backbone"
 XX
 PN WO9815648-A1.
 XX
 PD 16-APR-1998.
 XX
 PF 03-OCT-1997; 97WO-DK000425.
 XX
 PR 04-OCT-1996; 96DK-00001096.
 PR 18-OCT-1996; 96DK-00001156.
 PR 05-MAY-1997; 97DK-00000512.
 XX
 XX (DAKO-) DAKO AS.
 XX
 XX Stender H, Lund K, Mollerup TA;
 XX

```

XX DR WPI; 1998-240831/21.
XX
XX Peptide nucleic acid probes for detection of ribosomal nucleic acid of
PT mycobacteria - allow differentiation between species of tuberculosis
PT complex and others and can penetrate cell membranes without pretreatment.
XX
XX Claim 22; Page 67; 106pp; English.
XX
CC This is the nucleotide sequence of the peptide nucleic acid (PNA) probe
CC used in the method of the invention, to detect ribosomal nucleic acid of
CC mycobacteria. The probes are used, in situ or in vitro, for detection of
CC the Mycobacterium tuberculosis complex (MTC), specifically M.
CC tuberculosis, and especially in sputum samples, but also in other body
CC fluids, biopsy specimens, foods, soil, air and water. Particularly, they
CC are used to diagnose, stage or monitor infection, or for identification
CC of drug-resistant strains (which generally have mutations in rRNA)
XX
XX SQ Sequence 15 BP; 2 A; 2 C; 1 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 1.4e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 177 AAGGAAATTCAAAAT 191
DB 15 AAGGAAATTCAAAAT 1
XX
RESULT 392
AAV31967/c
ID AAV31967 standard; DNA; 15 BP.
XX
XX AC AAV31967;
XX
XX DT 21-AUG-1998 (first entry)
XX
XX DE Peptide nucleic acid probe 110.
XX
XX KW Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
XX ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
XX
XX OS Synthetic.
XX OS Mycobacterium sp.
XX
XX FH Key Location/Qualifiers
XX modified_base 1..15
XX /*tag= a
XX /note= "This sequence contains a polyamide backbone
XX instead of a deoxyribose backbone"
XX
XX PN W09815648-A1.
XX
XX PD 16-APR-1998.
XX
XX PF 03-OCT-1997; 97WO-DK000425.
XX
XX PR 04-OCT-1996; 96DK-00001096.
XX PR 18-OCT-1996; 96DK-00001156.
XX PR 05-MAY-1997; 97DK-00000512.
XX
XX PA (DAKO-) DAKO AS.
XX
XX PI Stender H, Lund K, Mollerup TA;
XX
XX DR WPI; 1998-240831/21.
XX
XX KW Peptide nucleic acid probes for detection of ribosomal nucleic acid of
PT mycobacteria - allow differentiation between species of tuberculosis
PT complex and others and can penetrate cell membranes without pretreatment.
XX
XX Claim 22; Page 67; 106pp; English.
XX
XX
XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe
XX used in the method of the invention, to detect ribosomal nucleic acid of
XX mycobacteria. The probes are used, in situ or in vitro, for detection of
XX the Mycobacterium tuberculosis complex (MTC), specifically M.
XX tuberculosis, and especially in sputum samples, but also in other body
XX fluids, biopsy specimens, foods, soil, air and water. Particularly, they
XX are used to diagnose, stage or monitor infection, or for identification
XX of drug-resistant strains (which generally have mutations in rRNA)
XX
XX SQ Sequence 15 BP; 2 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 1.4e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 177 AAGGAAATTCAAAAT 191
DB 15 AAGGAAATTCAAAAT 1
XX
RESULT 393
AAAX31120/c
ID AAAX31120 standard; DNA; 15 BP.
XX
XX AC AAAX31120;
XX
XX DT 21-MAY-1999 (first entry)
XX
XX DE Tag sequence of a transcript increased in colorectal cancer.
XX
XX KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
XX diagnosis; prognosis; treatment; ss.
XX
XX OS Homo sapiens.
XX
XX PN W09853319-A2.
XX
XX PD 26-NOV-1998.
XX
XX PF 20-MAY-1998; 98WO-US010277.
XX
XX PR 21-MAY-1997; 97US-0047352P.
XX
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX
XX PI Vogelstein B, Kinzler KW;
XX
XX DR WPI; 1999-070161/06.
XX
XX PT Use of isolated gene transcripts - useful for developing products for the
XX diagnosis, prognosis and treatment of cancers, particularly colon and
XX pancreatic cancer.
XX
XX PS Claim 2; Page 31; 120pp; English.
XX
XX CC AAAX30947-31815 represent tag sequences of transcripts that are
XX differentially expressed in colorectal cancer, in pancreatic cancer, or
XX in both. The tag sequences can be used to identify genes by matching the
XX tag to a gen data base member, or by using the tag sequences as probes to
XX isolate unidentified genes from cDNA libraries. The tag sequences can
XX also be used in a method for diagnosing colon or pancreatic cancer in a
XX sample suspected of being neoplastic. The method comprises comparing the
XX level of at least one transcript in a first sample of a tissue to a
XX second sample, where the first sample is a colonic tissue suspected of
XX being neoplastic and the second sample is a normal human colonic tissue.
XX The transcript is identified by a tag selected from AAAX30947-31815. The
XX methods of the invention can be used in the diagnosis, prognosis and
XX treatment of cancer
XX
XX SQ Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 1.4e+02;

```

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
 |||||
 Db 15 GCCCAGCAGGCCATG 1

RESULT 394
 AAX31728/c
 ID AAX31728 standard; DNA; 15 BP.
 XX
 AC AAX31728;
 XX
 DT 21-MAY-1999 (first entry)
 XX
 DE Transcript tag sequence increased in pancreatic and colorectal cancer.
 XX
 KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
 KW diagnosis; prognosis; treatment; SS.
 XX
 OS Homo sapiens.
 XX
 PN WO9853319-A2.
 XX
 PD 26-NOV-1998.
 XX
 PF 20-MAY-1998; 98WO-US010277.
 XX
 PR 21-MAY-1997; 97US-0047352P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Vogelstein B, Kinzler KW;
 XX
 DR WPI; 1999-070161/06.
 XX

Use of isolated gene transcripts - useful for developing products for the diagnosis, prognosis and treatment of cancers, particularly colon and pancreatic cancer.

PS Disclosure; Page 73; 120pp; English.

CC AAX30947-31815 represent tag sequences of transcripts that are differentially expressed in colorectal cancer, in pancreatic cancer, or in both. The tag sequences can be used to identify genes by matching the tag to a gen data base member, or by using the tag sequences as probes to isolate unidentified genes from cDNA libraries. The tag sequences can also be used in a method for diagnosing colon or pancreatic cancer in a sample suspected of being neoplastic. The method comprises comparing the level of at least one transcript in a first sample of a tissue to a second sample, where the first sample is a colonic tissue suspected of being neoplastic and the second sample is a normal human colonic tissue. The transcript is identified by a tag selected from AAX30947-31815. The methods of the invention can be used in the diagnosis, prognosis and treatment of cancer

QY 807 GCTCAGCAGGCCATG 821
 |||||
 Db 15 GCCCAGCAGGCCATG 1

RESULT 395
 AAF50848
 ID AAF50848 standard; DNA; 15 BP.
 XX
 AC AAF50848;
 XX

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
 |||||
 Db 15 GCCCAGCAGGCCATG 1

Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 532 TCGTGGAGACGACC 546
 |||||
 Db 1 TGGTGGAGACGACC 15

Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 396
 ABK32682/c
 ID ABK32682 standard; DNA; 15 BP.
 XX
 AC ABK32682;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Human colorectal and pancreatic cancer SAGE tag #49.
 XX

DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #1808.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.

Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

PS Example 8; Page 72; 201pp; English.

CC The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAF45151 and AAF45153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

QY Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 532 TCGTGGAGACGACC 546
 |||||
 Db 1 TGGTGGAGACGACC 15

Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 396
 ABK32682/c
 ID ABK32682 standard; DNA; 15 BP.
 XX
 AC ABK32682;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Human colorectal and pancreatic cancer SAGE tag #49.
 XX

KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
 KW serial analysis of gene expression; diagnostic; prognostic; probe;
 KW cancer marker; ss.
 XX
 XX Homo sapiens.
 OS
 XX US6333152-B1.
 PN
 XX 25-DEC-2001.
 PD
 XX 20-MAY-1998; 98US-00081646.
 PF
 XX 20-MAY-1998; 98US-00081646.
 PR
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA
 XX Vogelstein B, Kinzler KW, Zhang L, Zhou W;
 PI
 XX WPI; 2002-153821/20.
 DR
 XX New human nucleic acid containing specific SAGE tags, useful as
 PT diagnostic markers for cancer, also derived probes.
 PT
 XX Disclosure; Col 87; 161pp; English.
 PS
 XX The invention relates to an isolated, purified human nucleic acid (I)
 CC that has the same sequence as a mRNA found in humans and is a SAGE
 CC (serial analysis of gene expression) tag comprising a single stranded
 CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
 CC diagnostic and prognostic markers of cancer, especially of the colon and
 CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
 CC SAGE tags of the invention
 CC
 XX Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 807 GCTCAGCAGGCCATG 821
 DB 15 GCCCAGCAGGCCATG 1
 RESULT 397
 ABK32073/c
 ID ABK32073 standard; DNA; 15 BP.
 XX
 XX AC ABK32073;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Human colon cancer SAGE tag #174.
 XX
 KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
 KW serial analysis of gene expression; diagnostic; prognostic; probe;
 KW cancer marker; ss.
 XX
 XX Homo sapiens.
 OS
 XX US6333152-B1.
 PN
 XX 25-DEC-2001.
 PD
 XX 20-MAY-1998; 98US-00081646.
 PF
 XX 20-MAY-1998; 98US-00081646.
 PR
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA
 XX Vogelstein B, Kinzler KW, Zhang L, Zhou W;
 PI
 XX WPI; 2002-153821/20.
 DR

XX
 PT New human nucleic acid containing specific SAGE tags, useful as
 PT diagnostic markers for cancer, also derived probes.
 XX
 XX Disclosure; Col 25; 161pp; English.
 PS
 XX The invention relates to an isolated, purified human nucleic acid (I)
 CC that has the same sequence as a mRNA found in humans and is a SAGE
 CC (serial analysis of gene expression) tag comprising a single stranded
 CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
 CC diagnostic and prognostic markers of cancer, especially of the colon and
 CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
 CC SAGE tags of the invention
 CC
 XX Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 807 GCTCAGCAGGCCATG 821
 DB 15 GCCCAGCAGGCCATG 1
 RESULT 398
 ABX01805
 ID ABX01805 standard; RNA; 15 BP.
 XX
 XX AC ABX01805;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Hepatitis C virus (HCV) ribozyme related RNA sequence #74.
 XX
 KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
 KW ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
 KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KW type I interferon; interferon alpha; interferon beta; cytostatic; ss;
 KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory.
 XX
 XX Unidentified.
 OS
 XX US2002082225-A1.
 PN
 XX 27-JUN-2002.
 PD
 XX 23-MAR-1999; 99US-00274553.
 PF
 XX 23-MAR-1999; 99US-00274553.
 PR
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 PA (ROBE/) ROBERTS B.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX
 XX Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;
 PI
 XX WPI; 2002-617759/66.
 DR
 XX New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
 PT replication and are useful to treat hepatitis C virus infections and
 PT cirrhosis, liver failure or hepatocellular carcinoma.
 XX
 XX Disclosure; SEQ ID NO 1587; 80pp; English.
 PS
 XX The present invention relates to enzymatic nucleic acids which
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
 CC (HP) motif where the binding arms comprise sequences complementary to one
 CC of the substrate sequences defined in the specification. The HCV
 CC ribozymes are useful for modulating the expression and/or replication of

CC HCV. They can be used to treat cirrhosis, liver failure and/or
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
 CC a condition associated with HCV infection in conjunction with one or more
 CC other drug therapies, particularly type I interferon, especially
 CC interferon alpha, beta or gamma or consensus interferon. The present
 CC sequence represents a RNA sequence of unknown function. Note: The present
 CC sequence is given in the sequence data but is not mentioned elsewhere in
 CC the specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdIDEntry.html

XX Sequence 15 BP; 3 A; 8 C; 3 G; 0 T; 1 U; 0 Other;
 SQ Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.4e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1509 AGCCTCCAGGCCCC 1523
 Db 1 AGCCUCCAGGCCCC 15

RESULT 399
 ABX01804
 ID ABX01804 standard; RNA; 15 BP.
 AC
 XX ABX01804;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Hepatitis C virus (HCV) ribozyme related RNA sequence #73.
 XX
 KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
 KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
 KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KW type I interferon; interferon alpha; interferon beta; cytostatic; 86;
 KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory.
 XX
 OS Unidentified.
 XX
 PN US2002082225-A1.
 XX
 XX 27-JUN-2002.
 PD
 XX
 PF 23-MAR-1999; 99US-00274553.
 XX
 XX 23-MAR-1999; 99US-00274553.
 XX
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 PA (ROBE/) ROBERTS B.
 PA (PVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX
 PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;
 XX
 XX WPI; 2002-617759/66.
 XX
 PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
 PT replication and are useful to treat hepatitis C virus infections and
 PT cirrhosis, liver failure or hepatocellular carcinoma.
 XX
 PS Disclosure; SEQ ID NO 1586; 80pp; English.
 XX
 CC The present invention relates to enzymatic nucleic acids which
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
 CC (HP) motif where the binding arms comprise sequences complementary to one
 CC of the substrate sequences defined in the specification. The HCV
 CC ribozymes are useful for modulating the expression and/or replication of
 CC HCV. They can be used to treat cirrhosis, liver failure and/or
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
 CC a condition associated with HCV infection in conjunction with one or more

CC other drug therapies, particularly type I interferon, especially
 CC interferon alpha, beta or gamma or consensus interferon. The present
 CC sequence represents a RNA sequence of unknown function. Note: The present
 CC sequence is given in the sequence data but is not mentioned elsewhere in
 CC the specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdIDEntry.html

XX Sequence 15 BP; 3 A; 8 C; 3 G; 0 T; 1 U; 0 Other;
 SQ Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.4e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1522
 Db 1 CAGCCUCCAGGCCCC 15

RESULT 400
 AAV70490
 ID AAV70490 standard; DNA; 16 BP.
 AC
 XX AAV70490;
 XX
 DT 08-APR-1999 (first entry)
 XX
 DE Sequence ID# 68 from patent specification WO9850403.
 XX
 KW Nucleic acid detection; nucleic acid characterisation; hybridisation;
 KW infection; disease; cancer; forensic; paternity; multiplexing; ss.
 XX
 OS Unidentified.
 XX
 PN WO9850403-A1.
 XX
 PD 12-NOV-1998.
 XX
 PF 05-MAY-1998; 98WO-US003194.
 XX
 XX 05-MAY-1997; 97US-00851588.
 PR 19-SEP-1997; 97US-00934097.
 PR 03-MAR-1998; 98US-00034205.
 XX
 PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
 XX
 PI Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;
 PI Anderson TA, Dahlberg JE;
 XX
 DR WPI; 1998-610317/51.
 XX
 PT Detection and characterisation of nucleic acid sequences - by mixing a
 PT folded target and one or more probes to form a probe/folded target
 PT complex and detecting and characterising the complexes.
 XX
 PS Disclosure; Page 180; 279pp; English.
 XX
 CC The invention relates to methods and compositions of detection and
 CC characterisation of nucleic acid sequences and sequence changes. One
 CC method of detection and characterisation comprises: (a) providing: (i) a
 CC folded target having a DNA sequence comprising at least 1 double stranded
 CC region and at least 1 single stranded region; and (ii) at least 1 probe
 CC complementary to at least a portion of the folded target; and (b) mixing
 CC the target and probes so that the probe hybridises to form a probe
 CC /folded target complex. Also provided are methods for determination of
 CC structure formation in nucleic acid targets; for analysing folded nucleic
 CC acids targets; and for analysis of nucleic acid structures. The methods
 CC can be used for the detection and characterisation of nucleic acid
 CC sequences to detect the presence of pathogenic nucleic acid sequences
 CC indicative of an infection, the presence of variants or alleles of
 CC mammalian genes associated with disease and cancers, and the
 CC identification of the source of nucleic acids found in forensic samples,
 CC as well as in paternity determinations. The methods allow simultaneous

CC analysis of both strands (e.g. the sense and antisense strands) and are
CC ideal for high-level multiplexing. The products produced are amenable to
CC qualitative, quantitative and positional analysis. The methods may be
CC performed in solution or in the solid phase (e.g. on a solid support).
CC The methods are powerful in that they allow for analysis of longer
CC fragments of nucleic acid than current methodologies. The present
CC sequence represents the sequence no:67 in the specification for which no
CC information is provided
XX
SQ Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. NO. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCC 1522
DB 2 CAGCCTCCAGGCC 16
RESULT 401
AAV70489
ID AAV70489 standard; DNA; 16 BP.
AC AAV70489;
XX
DT 08-APR-1999 (first entry)
XX
DE Sequence ID# 67 from patent specification WO9850403.
XX
KW Nucleic acid detection; nucleic acid characterisation; hybridisation;
KW infection; disease; cancer; forensic; paternity; multiplexing; ss.
XX
OS Unidentified.
XX
XX WO9850403-A1.
XX
XX 12-NOV-1998.
XX
XX 05-MAY-1998; 98WO-US003194.
XX
XX 05-MAY-1997; 97US-00851588.
XX
XX 19-SEP-1997; 97US-00934097.
XX
XX 03-MAR-1998; 98US-00034205.
XX
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
XX Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;
XX Anderson TA, Dahlberg JE;
XX WPI; 1998-610317/51.
XX
XX Detection and characterisation of nucleic acid sequences - by mixing a
XX folded target and one or more probes to form a probe/folded target
XX complex and detecting and characterising the complexes.
XX
XX Disclosure; Page 180; 279pp; English.
XX
XX The invention relates to methods and compositions of detection and
XX characterisation of nucleic acid sequences and sequence changes. One
XX method of detection and characterisation comprises: (a) providing: (i) a
XX folded target having a DNA sequence comprising at least 1 double stranded
XX region and at least 1 single stranded region; and (ii) at least 1 probe
XX complementary to at least a portion of the folded target; and (b) mixing
XX the target and probes so that the probe hybridises to form a probe
XX /folded target complex. Also provided are methods for determination of
XX structure formation in nucleic acid targets; for analysing folded nucleic
XX acids targets; and for analysis of nucleic acid structures. The methods
XX can be used for the detection and characterisation of nucleic acid
XX sequences to detect the presence of pathogenic nucleic acid sequences
XX indicative of an infection, the presence of variants or alleles of
XX mammalian genes associated with disease and cancers, and the
XX identification of the source of nucleic acids found in forensic samples,
CC

CC as well as in paternity determinations. The methods allow simultaneous
CC analysis of both strands (e.g. the sense and antisense strands) and are
CC ideal for high-level multiplexing. The products produced are amenable to
CC qualitative, quantitative and positional analysis. The methods may be
CC performed in solution or in the solid phase (e.g. on a solid support).
CC The methods are powerful in that they allow for analysis of longer
CC fragments of nucleic acid than current methodologies. The present
CC sequence represents the sequence no:67 in the specification for which no
CC information is provided
XX
SQ Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. NO. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCC 1522
DB 2 CAGCCTCCAGGCC 16
RESULT 402
AAV70489
ID AAV70489 standard; DNA; 16 BP.
AC AAV70489;
XX
DT 24-MAR-1999 (first entry)
XX
DE Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX
KW Triple helix formation; DNA detection; triple helix; identification; bacteria;
KW oncogene; virus; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX US5861244-A.
XX
XX 19-JAN-1999.
XX
XX 22-DEC-1993; 93US-00173489.
XX
XX 29-OCT-1992; 92US-00968436.
XX
XX (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
XX Hepburn AG, Wang C;
XX WPI; 1999-130384/11.
XX
XX Assay of genetic sequences based on triplex formation from double
XX stranded analyte - and hybrid of anchor and reporter sequences, with
XX reporter released if triplex formation occurs, used e.g. to identify
XX bacteria.
XX
XX Disclosure; Col 15-16; 168pp; English.
XX
XX The present sequence represents a polynucleotide that is able to form a
XX triple helix with a double stranded sequence. Cytosine bases in the
XX present can be replaced with 5-methylcytosine for increased triplex
XX stability. The present sequence is used in the assay of the invention,
XX where it can be part of the anchor DNA or reporter DNA sequence. The
XX assay comprises adding a sample containing double-stranded DNA test
XX sequences to an aqueous medium containing at least one complex of anchor
XX DNA, attached to a solid support, and reporter DNA, where either a part
XX of the anchor DNA or reporter DNA is designed to form a triplex-strand
XX structure with part of the test sequence. Triplex formation results in
XX displacement of the reporter DNA which is detected as an indication of
XX the presence of the DNA test sequence. The method is used to detect DNA
XX sequences, particularly for identification of bacteria (by detecting
XX genes for ribosomal RNA) in clinical samples, but also detection of
XX oncogenes and Hepatitis B virus
CC

```
XX
SQ Sequence 16 BP; 0 A; 4 C; 1 G; 11 T; 0 U; 0 Other;
  Query Match      0.8%; Score 13.4; DB 1; Length 16;
  Best Local Similarity 93.3%; Pred. NO. 1.7e+02;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAAGA 285
Db 15 AAGAAGCAAGAAGA 1

RESULT 403
ABL46101
ID ABL46101 standard; DNA; 16 BP.
XX
AC ABL46101;
XX
DT 26-APR-2002 (first entry)
XX
DE Hepatitis C virus PCR primer SEQ ID NO:68.
XX
KW Nucleic acid accessible hybridisation site; detection; hybridisation;
KW characterisation; identification; nucleic acid structure; diagnosis;
KW PCR primer; probe; ss.
XX
OS Hepatitis C virus.
OS Synthetic.
XX
PN WO200198537-A2.
XX
PD 27-DEC-2001.
XX
PF 15-JUN-2001; 2001WO-US019401.
XX
PR 17-JUN-2000; 2000US-0212308P.
PR 15-JUN-2001; 2001US-00212308.
XX
XX
PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX
DR WPI; 2002-049698/06.
XX
PT Identifying oligonucleotides hybridizing to nucleic acids containing
PT secondary structure, useful in clinical diagnosis, comprises identifying
PT primers that interact with the target to form an extension product under
PT amplification conditions.
XX
PS Example 8; Page 370; 409pp; English.
XX
CC The present invention describes a method for identifying oligonucleotides
CC with desired hybridisation properties to nucleic acid targets containing
CC secondary structure. The method comprises amplifying a target nucleic
CC acid having at least one accessible and one inaccessible site. Primers
CC that form an extension product are identified as the oligonucleotides
CC which can interact with the folded target nucleic acid. Oligonucleotides
CC from the present invention can be used in novel detection methods for
CC clinical diagnostic purposes, including the detection and identification
CC of pathogenic organisms (e.g. HIV). The method allows the ability to
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
CC sequences used in the exemplification of the present invention
XX
SQ Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
  Query Match      0.8%; Score 13.4; DB 1; Length 16;
  Best Local Similarity 93.3%; Pred. NO. 1.7e+02;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1522
Db 2 CAGCCTCCAGGCCCC 16

RESULT 404
ABL46100
ID ABL46100 standard; DNA; 16 BP.
XX
AC ABL46100;
XX
DT 26-APR-2002 (first entry)
XX
DE Hepatitis C virus PCR primer SEQ ID NO:67.
XX
KW Nucleic acid accessible hybridisation site; detection; hybridisation;
KW characterisation; identification; nucleic acid structure; diagnosis;
KW PCR primer; probe; ss.
XX
OS Hepatitis C virus.
OS Synthetic.
XX
PN WO200198537-A2.
XX
PD 27-DEC-2001.
XX
PF 15-JUN-2001; 2001WO-US019401.
XX
PR 17-JUN-2000; 2000US-0212308P.
PR 15-JUN-2001; 2001US-00212308.
XX
XX
PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX
DR WPI; 2002-049698/06.
XX
PT Identifying oligonucleotides hybridizing to nucleic acids containing
PT secondary structure, useful in clinical diagnosis, comprises identifying
PT primers that interact with the target to form an extension product under
PT amplification conditions.
XX
PS Example 8; Page 370; 409pp; English.
XX
CC The present invention describes a method for identifying oligonucleotides
CC with desired hybridisation properties to nucleic acid targets containing
CC secondary structure. The method comprises amplifying a target nucleic
CC acid having at least one accessible and one inaccessible site. Primers
CC that form an extension product are identified as the oligonucleotides
CC which can interact with the folded target nucleic acid. Oligonucleotides
CC from the present invention can be used in novel detection methods for
CC clinical diagnostic purposes, including the detection and identification
CC of pathogenic organisms (e.g. HIV). The method allows the ability to
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
CC sequences used in the exemplification of the present invention
XX
SQ Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
  Query Match      0.8%; Score 13.4; DB 1; Length 16;
  Best Local Similarity 93.3%; Pred. NO. 1.7e+02;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1522
Db 2 CAGCCTCCAGGCCCC 16

RESULT 405
ADR82290
ID ADR82290 standard; DNA; 16 BP.
XX
AC ADR82290;
XX
DT 03-JUN-2004 (first entry)
XX
XX
DE Nucleic acid analysis method associated oligonucleotide seqid 67.
XX
```

```

KW nucleic acid analysis; hepatitis C virus;
KW non-contiguous single-stranded region; NCSR; cleavage structure;
KW clinical; diagnostic; microorganism detection;
KW microorganism identification; ss.
XX Synthetic.
XX US6709815-B1.
XX 23-MAR-2004.
XX 18-JUL-2000; 2000US-00402618.
XX 05-MAY-1997; 97US-00851588.
XX 19-SEP-1997; 97US-00934097.
XX 03-MAR-1998; 98US-00034205.
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX Dong F, Lyamichiev VI, Prudent JR, Fors L, Neri BP, Brow MAD;
XX Anderson TA, Dahlberg JE;
XX WPI; 2004-256067/24.
XX Analyzing nucleic acids, comprises mixing target nucleic acid such as
XX hepatitis C virus nucleic acid, bridging oligonucleotide, second
XX oligonucleotide and cleavage agent to form cleavage structure.
XX Disclosure; SEQ ID NO 67; 143pp; English.
XX The invention describes a method of analysing nucleic acids comprising
XX providing a target nucleic acid, e.g. hepatitis C virus nucleic acid
XX having non-contiguous single-stranded regions (NCSR) separated by an
XX intervening region, a bridging oligonucleotide capable of binding to the
XX first and second NCSR; a second oligonucleotide binding to a portion of
XX the first NCSR and a cleavage agent, and mixing the contents to form a
XX cleavage structure. The method is useful for analysing nucleic acids,
XX e.g. hepatitis C virus nucleic acid useful for clinical diagnostic
XX purposes and detection and identification of pathogenic microorganisms
XX such as hepatitis C virus. This sequence represents an oligonucleotide
XX associated with the nucleic acid analysis method of the invention.
XX Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
XX Query Match 0.8%; Score 13.4; DB 1; Length 16;
XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
DB 2 CAGCCTCCAGGCCCC 16
RESULT 406
ADK82291
ID ADK82291 standard; DNA; 16 BP.
XX
XX ADK82291;
XX 03-JUN-2004 (first entry)
XX Nucleic acid analysis method associated oligonucleotide seqid 68.
XX nucleic acid analysis; hepatitis C virus;
XX non-contiguous single-stranded region; NCSR; cleavage structure;
XX clinical; diagnostic; microorganism detection;
XX microorganism identification; ss.
XX Synthetic.
XX US6709815-B1.
XX 23-MAR-2004.
XX 18-JUL-2000; 2000US-00402618.
XX 05-MAY-1997; 97US-00851588.
XX 19-SEP-1997; 97US-00934097.
XX 03-MAR-1998; 98US-00034205.
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX Dong F, Lyamichiev VI, Prudent JR, Fors L, Neri BP, Brow MAD;
XX Anderson TA, Dahlberg JE;
XX WPI; 2004-256067/24.
XX Analyzing nucleic acids, comprises mixing target nucleic acid such as
XX hepatitis C virus nucleic acid, bridging oligonucleotide, second
XX oligonucleotide and cleavage agent to form cleavage structure.
XX Disclosure; SEQ ID NO 67; 143pp; English.
XX The invention describes a method of analysing nucleic acids comprising
XX providing a target nucleic acid, e.g. hepatitis C virus nucleic acid
XX having non-contiguous single-stranded regions (NCSR) separated by an
XX intervening region, a bridging oligonucleotide capable of binding to the
XX first and second NCSR; a second oligonucleotide binding to a portion of
XX the first NCSR and a cleavage agent, and mixing the contents to form a
XX cleavage structure. The method is useful for analysing nucleic acids,
XX e.g. hepatitis C virus nucleic acid useful for clinical diagnostic
XX purposes and detection and identification of pathogenic microorganisms
XX such as hepatitis C virus. This sequence represents an oligonucleotide
XX associated with the nucleic acid analysis method of the invention.
XX Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
XX Query Match 0.8%; Score 13.4; DB 1; Length 16;
XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1508 CAGCCTCCAGGCCCC 1522
DB 2 CAGCCTCCAGGCCCC 16
RESULT 407
ADM80152/c
ID ADM80152 standard; DNA; 16 BP.
XX
XX ADM80152;
XX 03-JUN-2004 (first entry)
XX Linker peptide encoding DNA SEQ ID NO:11.
XX ds; gene; in vitro diagnosis; virus-related disease; HIV-1; HIV-2;
XX linker.
XX Synthetic.
XX Key Location/Qualifiers
XX CDS 2..16
XX /tag= a
XX /partial
XX /note= "No start/stop codon given"
XX FR2844519-A1.
XX 19-MAR-2004.
XX 17-SEP-2002; 2002FR-00011485.
XX 17-SEP-2002; 2002FR-00011485.
XX (INMR ) BIO MERIEUX.
XX PA
```


XX Letourneur O;
PI WPI: 2004-259482/25.
DR P-PSDB; ADM80153.
XX
PT New recombinant DNA encoding chimeric protein, useful for in vitro
PT diagnosis of viral infections, comprises sequences encoding epitopic
PT regions, a linker and a binding region.
XX
XX Claim 5; SEQ ID NO 11; 33pp; French.
PS
CC The invention relates to a novel recombinant DNA (I) encoding a
CC recombinant chimeric protein (II). The protein consists of at least two
CC nucleotide fragments, each encoding an epitopic region of at least one
CC microorganism; at least one sequence encoding a linker, and at least one
CC sequence encoding a binding region. The DNA and/or protein are used for
CC in vitro diagnosis, especially of virus-related diseases, specifically
CC HIV-1 or -2 infections. The protein is easy to purify and synthesize, and
CC has strong immunoreactivity with sera from virus-infected subjects. The
CC present sequence encodes a linker of the recombinant chimeric peptide of
CC the invention.
XX
SQ Sequence 16 BP; 2 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 476 CCTGAACCGAGCTC 490
DB 15 CCTGAACCGAGCTC 1
RESULT 408
ADR32381
ID ADR32381 standard; DNA; 16 BP.
XX
AC ADR32381;
XX
DT 04-NOV-2004 (first entry)
XX
DE E. coli nicking agent target DNA #26.
XX
DE ss; nicking agent; assay panel; diagnosis; expression pattern;
KW DNA fingerprinting; nosocomial infection; microbiological assay;
KW bacterial contamination; genome mapping; bioremediation.
XX
OS Escherichia coli.
XX
XX WO2004067765-A2.
XX
PD 12-AUG-2004.
XX
XX 29-JAN-2004; 2004WO-US002720.
XX
XX 29-JAN-2003; 2003US-0443811P.
XX
XX (KECK-) KECK GRADUATE INST.
XX
XX Van Ness J, Galas DJ, Van Ness LK;
XX
XX WPI: 2004-581010/56.
XX
XX Identifying nucleic acid sample source, useful for identifying bacterial
PT strains involved in nosocomial infections, comprises treating the nucleic
PT acid sample with components comprising a nicking agent under nicking
PT conditions.
XX
XX Example 1; Page 65; 238pp; English.
XX
XX The invention relates to a method of treating a nucleic acid sample with
CC components under nicking conditions, where the components comprise a

CC nicking agent, and the conditions cause the nicking agent to nick the
CC nucleic acid sample to thus produce a family of initiating
CC oligonucleotide fragments, and subjecting one or more members of the
CC family of initiating oligonucleotide fragments to a characterization
CC process to thus provide results. The method is useful for creating an
CC assay panel of diagnostic oligonucleotides that can identify any organism
CC or individual. The method is useful for characterizing other DNA
CC molecules e.g., cDNA, and for characterizing cDNA expression patterns.
CC The method, kit or composition is useful for identifying the source
CC organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,
CC non-human animal or human. The method is particularly useful for rapidly
CC fingerprinting DNA to identifying prokaryotic and eukaryotic species, it
CC subpecies, and especially strains or individuals of the subpecies. It
CC is especially useful for identifying different bacterial strains involved
CC in e.g., nosocomial infections. Furthermore, the method is useful for
CC diagnosing bacterial disease in plants and humans, monitoring for
CC bacterial content and/or contamination in the environment, monitoring
CC food for bacterial contamination, monitoring manufacturing processes for
CC bacterial contamination, monitoring quality assurance/quality control of
CC laboratory tests involving microbiological assays, tracing bacterial
CC contamination and/or outbreaks of bacterial infections, genome mapping,
CC monitoring bioremediation sites, and for monitoring agricultural sites
CC for test crops, bacteria and recombinant molecules. This sequence
CC corresponds to nucleic acid used in the method of the invention.
XX
SQ Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 501 TTCTGGATGAATGGT 515
DB 1 TTCTGGATGAATGGT 15
RESULT 409
ADR32430
ID ADR32430 standard; DNA; 16 BP.
XX
AC ADR32430;
XX
DT 04-NOV-2004 (first entry)
XX
DE E. coli fingerprint oligonucleotide #12.
XX
DE ss; nicking agent; assay panel; diagnosis; expression pattern;
KW DNA fingerprinting; nosocomial infection; microbiological assay;
KW bacterial contamination; genome mapping; bioremediation.
XX
OS Escherichia coli.
XX
XX WO2004067765-A2.
XX
PD 12-AUG-2004.
XX
XX 29-JAN-2004; 2004WO-US002720.
XX
XX 29-JAN-2003; 2003US-0443811P.
XX
XX (KECK-) KECK GRADUATE INST.
XX
XX Van Ness J, Galas DJ, Van Ness LK;
XX
XX WPI: 2004-581010/56.
XX
XX Identifying nucleic acid sample source, useful for identifying bacterial
PT strains involved in nosocomial infections, comprises treating the nucleic
PT acid sample with components comprising a nicking agent under nicking
PT conditions.
XX
XX Example 1; Page 70; 238pp; English.
XX

PS	Example 2; Page 94; 238pp; English.
XX	The invention relates to a method of treating a nucleic acid sample with components under nicking conditions, where the components comprise a nicking agent, and the conditions cause the nicking agent to nick the nucleic acid sample to thus produce a family of initiating oligonucleotide fragments, and subjecting one or more members of the family of initiating oligonucleotide fragments to a characterization process to thus provide results. The method is useful for creating an assay panel of diagnostic oligonucleotides that can identify any organism or individual. The method is useful for characterizing other DNA molecules e.g., cDNA, and for characterizing cDNA expression patterns. The method, kit or composition is useful for identifying the source organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant, non-human animal or human. The method is particularly useful for rapidly fingerprinting DNA to identifying prokaryotic and eukaryotic species, subspecies, and especially strains or individuals of the subspecies. It is especially useful for identifying different bacterial strains involved in e.g., nosocomial infections. Furthermore, the method is useful for diagnosing bacterial disease in plants and humans, monitoring for bacterial content and/or contamination in the environment, monitoring food for bacterial contamination, monitoring quality assurance/quality control of bacterial contamination, monitoring microbiological assays, tracing bacterial laboratory tests involving microbiological assays, genome mapping, contamination and/or outbreaks of bacterial infections, tracing bacterial monitoring bioremediation sites, and for monitoring agricultural sites for test crops, bacteria and recombinant molecules. This sequence corresponds to an oligonucleotide used in the method of the invention to detect an E. coli strain K12 sequence.
XX	Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.4; DB 1; Length 16; Best Local Similarity 93.3%; Pred. No. 1.7e+02; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	501 TTCTGGATGAATGGT 515
Db	1 TTCTGGATGAATGTT 15
RESULT 411	
ID	ADR69939/C
XX	ADR69939 standard; DNA; 16 BP.
XX	ADR69939;
XX	04-NOV-2004 (first entry)
DT	Human survivin gene modulatory oligonucleotide #7.
DE	ss; antiangiogenic; cytostatic; antiarteriosclerotic; antipsoriatic; antidiabetic; ophthalmological; antiarthritic; antirheumatic; antiasthmatic; antiallergic; antiinflammatory; dermatological; anti-HIV; virucide; survivin antagonist; apoptosis inhibitor; cellular proliferation inhibitor; chemotherapeutic agent; busulfan; myleran; abnormal angiogenesis; doxorubicin; adriamycin; atherosclerosis; carboplatin; paraptatin; Taxol; rheumatoid arthritis; asthma; warts; psoriasis; diabetic retinopathy; rheumatoid arthritis; glioma; carcinoma; allergic dermatitis; cancer; tumour; sarcoma; chondrosarcoma; melanoma; osteosarcoma; Ewing's sarcoma; fibrosarcoma; malignant fibrous histiocytoma; Kaposi's sarcoma; Paclitaxel; Docetaxel.
XX	Homo sapiens.
OS	Synthetic.
XX	
XX	Key Location/Qualifiers
PH	modified_base 1..16
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "OTHER = phosphorothioate internucleotide
FT	linkages, all locked nucleic acid (LNA) residues are 5'-
FT	

```

Qy      278 CAAGAAGAGAGAAGA 292
      |||||
Db      16 CAATAAGAAGAGAAGA 2

```

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:53:12 ; Search time 0.001 Seconds
(without alignments)
824.786 Million cell updates/sec

Title: us-10-828-394-1
Perfect score: 1643
Sequence: 1 gaattccgcgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 8 seqs, 251 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 5000 summaries

Database : rstdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	47	2.9	48	1 H93557	ACCESSION:H93557
2	40.2	2.4	46	1 T74174	ACCESSION:T74174
3	39	2.4	39	1 BF339449	ACCESSION:BF339449
4	39	2.4	39	1 BF342092	ACCESSION:BF342092
5	39	2.4	40	1 T71848	ACCESSION:T71848
6	16	1.0	48	1 H93557	ACCESSION:H93557
7	12.8	0.8	39	1 BF339449	ACCESSION:BF339449
8	12.8	0.8	39	1 BF342092	ACCESSION:BF342092
9	12.8	0.8	46	1 T74174	ACCESSION:T74174
10	12.6	0.8	40	1 T71848	ACCESSION:T71848
11	11.4	0.7	13	1 CW020522	ACCESSION:CW020522
12	11.4	0.7	14	1 CF278327	ACCESSION:CF278327
13	11	0.7	12	1 CN752857	ACCESSION:CN752857
14	9	0.5	12	1 CN752857	ACCESSION:CN752857
15	8.2	0.5	13	1 CW020522	ACCESSION:CW020522
16	8.2	0.5	14	1 CF278327	ACCESSION:CF278327

ALIGNMENTS

RESULT 1
LOCUS H93557 48 bp mRNA linear EST 01-DEC-1995
DEFINITION Y714d11.r1 Soares fetal liver spleen INFLS Homo sapiens cDNA clone
IMAGE:242709 5' similar to gb:X14723 CLUSTERIN PRECURSOR (HUMAN);,
mRNA sequence.
ACCESSION H93557
VERSION H93557.1 GI:1099885
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE
AUTHORS

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
1 (bases 1 to 48)
Hallier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
Trevaaskis,E., Waterston,R., Williamson,A., Wohlmann,P. and
Wilson,R.
The WashU-Merck EST Project
Unpublished (1995)
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
High quality sequence starts: 1
High quality sequence stops: 1
Source: IMAGE Consortium, LLNL
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Seq primer: M13RP1
High quality sequence stop: 1.
Location/Qualifiers
1..48
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3791842"
/db_xref="taxon:9606"
/clone="IMAGE:242709"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares fetal liver spleen INFLS"
/note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia)
with a modified polylinker; Site 1: Pac 1; Site 2: Eco RI;
1st strand cDNA was primed with a Pac 1 - oligo(dT) primer
[5' AACTGGAGAAATTAATAAGATCTTTTCTTTTCTTTTCTTTT 3'],
double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Pac I and cloned into the Pac I
and Eco RI sites of the modified pT7T3 vector. Library
went through one round of normalization. Library
constructed by Bento Soares and M.Fatima Bonaldo."

TITLE
JOURNAL
COMMENT

FEATURES
source

Query Match 2.9%; Score 47; DB 1; Length 48;
Best Local Similarity 97.9%; Pred. No. 0.54;
Matches 47; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1136 CGACGAGTTTAACTGGGTGTCCTCGGCTGGCAACCTCAGCAAGCGA 1183
|||||
Db 1 CGACGAGTTTAACTGGGTGTCCTCGGCTGGCAACCTCAGCAAGCGA 48
|||||
RESULT 2
LOCUS T74174/c
DEFINITION T74174
T74174 46 bp mRNA linear EST 02-MAR-1995
IMAGE:85055 3' similar to gb:X14723 CLUSTERIN PRECURSOR (HUMAN);,
mRNA sequence.
T74174
T74174.1 GI:690849
EST.
T74174.1
Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
1 (bases 1 to 46)
Hallier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiappelli,B.,
Chisoe,S., Dietrich,N., DuBuque,T., Favello,A., Gish,W.,
Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N.,
Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L.,
Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Mieg,J.,
Trevaaskis,E., Underwood,K., Wohlmann,P., Waterston,R., Wilson,R.


```

RESULT 5
LOCUS       T71848
DEFINITION  y64e06.s1 Stragatene liver (#937224) Homo sapiens cDNA clone
            IMAGE:85474 3' similar to gb:X14723 CLUSTERIN PRECURSOR (HUMAN);,
            mRNA sequence.
ACCESSION   T71848
VERSION     T71848.1 GI:686369
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 40)
Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B.,
Chissoe,S., Dietrich,N., Dubuque,T., Favello,A., Gish,W.,
Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N.,
Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L.,
Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Mieg,J.,
Trevaaskis,E., Underwood,K., Wohlmann,P., Waterston,R., Wilson,R.
and Marra,M.
Generation and analysis of 280,000 human expressed sequence tags
Genome Res. 6 (9), 807-828 (1996)
97044478
8889549
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 26
High quality sequence starts: 1 High quality sequence stops: 1
Source: IMAGE Consortium, LLNL This clone is available royalty-free
through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
for further information. Trace considered overall poor quality
Seq primer: -21m13
High quality sequence stop: 1.
FEATURES             source
    Location/Qualifiers
        1..40
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="GDB:502531"
            /db_xref="taxon:9606"
            /clone="IMAGE:85474"
            /sex="male"
            /dev_stage="49 years old"
            /lab_host="SOLR cells (kanamycin resistant)"
            /clone_lib="Stratagene liver (#937224)"
            /note="Organ: liver; Vector: pBluescript SK; Site 1:
            EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer:
            Oligo dt. Hepatectomy from normal male caucasian. Average
            insert size: 1.1 kb; Uni-ZAP XR Vector; ~5' adaptor
            sequence: 5' GAATTCGACGAG 3' ~3' adaptor sequence: 5'
            CTCGAGTTTTTTTTTTTTTTT 3'"
Query Match      2.4%; Score 39; DB 1; Length 40;
Best Local Similarity 97.5%; Pred. No. 1.2;
Matches 39; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1512 CTCAGGCCCCCACTCGCCGAGCCTCTCCCGCTCTGG 1551
      |||||
Db 40 CTCAGGCCCCCACTCGCCGAGCCTCTCCCGCTCTGG 1

RESULT 6
LOCUS       H93557
DEFINITION  yv14dl1.r1 Soares fetal liver spleen lNFLS Homo sapiens cDNA clone
            IMAGE:242709 5' similar to gb:X14723 CLUSTERIN PRECURSOR (HUMAN);,
            mRNA sequence.
ACCESSION   H93557
VERSION     H93557.1 GI:1099885
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 39)
Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B.,
Chissoe,S., Dietrich,N., Dubuque,T., Favello,A., Gish,W.,
Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N.,
Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L.,
Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Mieg,J.,
Trevaaskis,E., Underwood,K., Wohlmann,P., Waterston,R., Wilson,R.
and Marra,M.
Generation and analysis of 280,000 human expressed sequence tags
Genome Res. 6 (9), 807-828 (1996)
97044478
8889549
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 26
High quality sequence starts: 1 High quality sequence stops: 1
Source: IMAGE Consortium, LLNL This clone is available royalty-free
through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
for further information. Trace considered overall poor quality
Seq primer: -21m13
High quality sequence stop: 1.
FEATURES             source
    Location/Qualifiers
        1..40
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="GDB:502531"
            /db_xref="taxon:9606"
            /clone="IMAGE:85474"
            /sex="male"
            /dev_stage="49 years old"
            /lab_host="SOLR cells (kanamycin resistant)"
            /clone_lib="Stratagene liver (#937224)"
            /note="Organ: liver; Vector: pBluescript SK; Site 1:
            EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer:
            Oligo dt. Hepatectomy from normal male caucasian. Average
            insert size: 1.1 kb; Uni-ZAP XR Vector; ~5' adaptor
            sequence: 5' GAATTCGACGAG 3' ~3' adaptor sequence: 5'
            CTCGAGTTTTTTTTTTTTTTT 3'"
Query Match      2.4%; Score 39; DB 1; Length 40;
Best Local Similarity 97.5%; Pred. No. 1.2;
Matches 39; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1512 CTCAGGCCCCCACTCGCCGAGCCTCTCCCGCTCTGG 1551
      |||||
Db 40 CTCAGGCCCCCACTCGCCGAGCCTCTCCCGCTCTGG 1

RESULT 7
LOCUS       BF339449/c
DEFINITION  602039103F1 NCI CGAP_Brn64 Homo sapiens cDNA clone IMAGE:4186752
            5', mRNA sequence.
ACCESSION   BF339449
VERSION     BF339449.1 GI:11285904
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 39)
Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B.,
Chissoe,S., Dietrich,N., Dubuque,T., Favello,A., Gish,W.,
Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N.,
Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L.,
Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Mieg,J.,
Trevaaskis,E., Underwood,K., Wohlmann,P., Waterston,R., Wilson,R.
and Marra,M.
Generation and analysis of 280,000 human expressed sequence tags
Genome Res. 6 (9), 807-828 (1996)
97044478
8889549
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 26
High quality sequence starts: 1 High quality sequence stops: 1
Source: IMAGE Consortium, LLNL This clone is available royalty-free
through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
for further information. Trace considered overall poor quality
Seq primer: M13RPI
High quality sequence stop: 1.
FEATURES             source
    Location/Qualifiers
        1..48
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="GDB:3791842"
            /db_xref="taxon:9606"
            /clone="IMAGE:242709"
            /sex="male"
            /dev_stage="20 week-post conception.fetus"
            /lab_host="DHI0B (ampicillin resistant)"
            /clone_lib="Soares fetal liver spleen lNFLS"
            /note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia)
            with a modified polylinker; Site 1: Pac I; Site 2: Eco RI;
            1st strand cDNA was primed with a Pac I - oligo(dT) primer
            [5' AACCTGGAGATTAATTAAGATCTTTTCTTTTCTTTT 3'],
            double-stranded cDNA was ligated to Eco RI adaptors
            (Pharmacia), digested with Pac I and cloned into the Pac I
            and Eco RI sites of the modified pT7T3 vector. Library
            went through one round of normalization. Library
            constructed by Bento Soares and M.Fatima Bonaldo."
Query Match      1.0%; Score 16; DB 1; Length 48;
Best Local Similarity 66.7%; Pred. No. 9;
Matches 22; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 627 AGTTCTTCCACCGGGAGCCCGAGTACCTAC 659
      |||||
Db 36 AGGTTTNCAGCGCGGACACCCAGTTAAACTGC 4

RESULT 7
LOCUS       BF339449/c
DEFINITION  602039103F1 NCI CGAP_Brn64 Homo sapiens cDNA clone IMAGE:4186752
            5', mRNA sequence.
ACCESSION   BF339449
VERSION     BF339449.1 GI:11285904
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 39)
Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B.,
Chissoe,S., Dietrich,N., Dubuque,T., Favello,A., Gish,W.,
Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N.,
Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L.,
Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Mieg,J.,
Trevaaskis,E., Underwood,K., Wohlmann,P., Waterston,R., Wilson,R.
and Marra,M.
Generation and analysis of 280,000 human expressed sequence tags
Genome Res. 6 (9), 807-828 (1996)
97044478
8889549
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 26
High quality sequence starts: 1 High quality sequence stops: 1
Source: IMAGE Consortium, LLNL This clone is available royalty-free
through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
for further information. Trace considered overall poor quality
Seq primer: M13RPI
High quality sequence stop: 1.
FEATURES             source
    Location/Qualifiers
        1..48
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="GDB:3791842"
            /db_xref="taxon:9606"
            /clone="IMAGE:242709"
            /sex="male"
            /dev_stage="20 week-post conception.fetus"
            /lab_host="DHI0B (ampicillin resistant)"
            /clone_lib="Soares fetal liver spleen lNFLS"
            /note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia)
            with a modified polylinker; Site 1: Pac I; Site 2: Eco RI;
            1st strand cDNA was primed with a Pac I - oligo(dT) primer
            [5' AACCTGGAGATTAATTAAGATCTTTTCTTTTCTTTT 3'],
            double-stranded cDNA was ligated to Eco RI adaptors
            (Pharmacia), digested with Pac I and cloned into the Pac I
            and Eco RI sites of the modified pT7T3 vector. Library
            went through one round of normalization. Library
            constructed by Bento Soares and M.Fatima Bonaldo."
Query Match      1.0%; Score 16; DB 1; Length 48;
Best Local Similarity 66.7%; Pred. No. 9;
Matches 22; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 627 AGTTCTTCCACCGGGAGCCCGAGTACCTAC 659
      |||||
Db 36 AGGTTTNCAGCGCGGACACCCAGTTAAACTGC 4

```

COMMENT

Contact: Robert Strausberg, Ph.D.
 Email: cgapsb@mail.nih.gov
 Tissue Procurement: David N. Louis, M.D.
 cDNA Library Preparation: Life Technologies, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Incyte Genomics, Inc.
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
 Plate: LHAM9508 row: f column: 01
 High quality sequence stop: 38.
 Location/Qualifiers
 1. .39
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:4186752"
 /tissue_type="glioblastoma with EGFR amplification"
 /lab_host="DH10B (T1 phage-resistant)"
 /clone_lib="NCI CGAP Brn64"
 /notes="Organ: brain; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 1.57 Kb. Constructed by Life Technologies. Note: this is a NCI_CGAP Library."

Query Match

Best Local Similarity 0.8%; Score 12.8; DB 1; Length 39;
 Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 415 AGTTCTACGACGCGTCTGCAGAA 438

Db 25 ACTTCTGCAGACGCGTGGTAGAA 2

RESULT 8

BF342092/c
 LOCUS
 DEFINITION 602012848F1 NCI CGAP_Brn64 Homo sapiens cDNA clone IMAGE:4148962
 5', mRNA sequence.
 ACCESSION BF342092
 VERSION BF342092.1 GI:11288842
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 39)
 REFERENCE NIH-MGC <http://mgc.nci.nih.gov/>.
 AUTHORS National Institutes of Health, Mammalian Gene Collection (MGC)
 TITLE Unpublished (1999)
 JOURNAL
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgapsb@mail.nih.gov
 Tissue Procurement: David N. Louis, M.D.
 cDNA Library Preparation: Life Technologies, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Incyte Genomics, Inc.
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
 Plate: LHAM9409 row: o column: 11
 High quality sequence stop: 37.
 Location/Qualifiers

FEATURES

source
 1. .39
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:4148962"
 /tissue_type="glioblastoma with EGFR amplification"
 /lab_host="DH10B (T1 phage-resistant)"
 /clone_lib="NCI CGAP Brn64"
 /notes="Organ: brain; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 1.57 Kb. Constructed by Life

Technologies. Note: this is a NCI_CGAP Library."

Query Match 0.8%; Score 12.8; DB 1; Length 39;
 Best Local Similarity 70.8%; Pred. No. 11;
 Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 415 AGTTCTACGACGCGTCTGCAGAA 438

Db 25 ACTTCTGCAGACGCGTGGTAGAA 2

RESULT 9

T74174
 LOCUS
 DEFINITION yc60b12.s1 Stratagene liver (#937224) Homo sapiens cDNA clone IMAGE:85055 3' similar to gb:X14723 CLUSTERIN PRECURSOR (HUMAN); mRNA sequence.
 T74174
 ACCESSION T74174.1 GI:690849
 VERSION
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 46)
 REFERENCE Hillier, L., Lennon, G., Becker, M., Bonaldo, M.P., Chiapelli, B., Chisoe, S., Dietrich, N., DuBuque, T., Favello, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N., Madis, B., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, P., Thierry-Mieg, J., Trevaskis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R. and Marra, M.
 TITLE Generation and analysis of 280,000 human expressed sequence tags
 JOURNAL Genome Res. 6 (9), 807-828 (1996)
 MEDLINE 97044478
 PUBMED 8889549
 COMMENT Contact: Wilson RK
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu
 High quality sequence starts: 1
 High quality sequence stops: 1
 Source: IMAGE Consortium, LLNL
 This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
 Trace considered overall poor quality
 Seq primer: -21mi3
 High quality sequence stop: 1.
 Location/Qualifiers

FEATURES

source
 1. .46
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="GDB:502112"
 /db_xref="taxon:9606"
 /clone="IMAGE:85055"
 /sex="male"
 /dev_stage="49 years old"
 /lab_host="SOLR cells (kanamycin resistant)"
 /clone_lib="Stratagene liver (#937224)"
 /note="Organ: liver; Vector: pBluescript SK; Site 1: EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer: Oligo dt. Hepatectomy from normal male caucasian. Average insert size: 1.1 kb; Uni-ZAP XR Vector; -5' adaptor sequence: 5' GAATTCGGCAGG 3' -3' adaptor sequence: 5' CTCGAGTTTTTTTTTTT 3' "

Query Match

Best Local Similarity 56.1%; Pred. No. 10;
 Matches 23; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 1573 CTCTGCTGCTATGGGAAGACAGAAATTGCTCTCTGCATGCA 1613

Fax: 82 31 321 6355
Email: bhnam@qgbio.com, bhnam@bio.myongji.ac.kr.

```

FEATURES
source
Location/Qualifiers
1..14
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/db_xref="taxon:39947"
/clone="14ETL--04-D06"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice etiolated leaf plasmid cDNA library (14ETL)"
/notes="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.7%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 272 AGAAGCCAGAG 284
Db 14 AGAAGCCAGAG 2

RESULT 13
CN752857/c
LOCUS
DEFINITION
AphL3LD-VII-F11 AphL3LD Acyrthosiphon pisum cDNA clone
APHL3LDVIIIF11 5', mRNA sequence.
ACCESSION
CN752857
VERSION
EST.
KEYWORDS
Acyrtthosiphon pisum (pea aphid)
ORGANISM
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;
Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.
REFERENCE
1 (bases 1 to 12)
Hunzer,W., Martinez-Torres,D., Rahbe,Y., Sabater-Munoz,B.,
Stern,D., Tagu,D. and Wincker,P.
An expressed sequence tags database for the pea aphid Acyrthosiphon
pisum
Unpublished (2004)
Contact: D. Tagu
INRA Rennes
UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France
Tel: +33.2.23.48.51.65
Fax: +33.2.23.48.51.50
Risk of contamination by bacterial sequences from obligatory
(Buchnera) or facultative endosymbionts.
PCR Primers
FORWARD: GCCGCATAACTTCGTATAGCA
Plate: VII row: F column: 11.

FEATURES
source
Location/Qualifiers
1..12
/organism="Acyrtthosiphon pisum"
/mol_type="mRNA"
/cultivar="yr2"
/db_xref="taxon:7029"
/clone="AphL3LDVIIIF11"
/tissue_type="head"
/dev_stage="third instar nymph (L3)"
/lab_host="TOP10"
/clone_lib="AphL3LD"
/notes="Vector: pDNR-LIB; Site 1: SfiIA; Site 2: SfiIB;
Sample name: AphL3LD ; Plant growth place: INRA-Rennes,
UMR BIO3P, BP 35327, 35653 Le Rheu cedex, France ; Soil
conditions: peat ; Sowing date: 18/01/2003 ; Harvesting
date: 03/02/2003 ; Stress date: no stress ; Description:
aphids inoculated on one-week old Vicia faba germinations
under non sterile conditions. ; experimental condition:
long photoperiod (16-hr light/8-hr dark at 18 c)"

Query Match 0.5%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 698 CTTCTTCTT 706
Db 3 CTTCTTCTT 11

RESULT 15
CN752852
LOCUS
DEFINITION
GC0792 TIGEM gene trap library Mus musculus cDNA clone m4.E4.D08,
mRNA sequence.

```

ACCESSION CW020522
 VERSION CW020522.1 GI:52789782
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 13)
 REFERENCE Cobellis, G., Niclaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.
 AUTHORS Tagging genes with cassette-exchange sites
 TITLE Tagging genes with cassette-exchange sites
 JOURNAL Unpublished (2004)
 COMMENT Contact: TIGEM
 107

TIGEM
 Via P. Castellino, 111, 80131 NAPOLI, ITALY
 Tel: +390816132205
 Fax: +390815790919
 Email: cobellis@tigem.it
 Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM

Class: Gene Trap.

Location/Qualifiers

1. .13
 /organism="Mus musculus"
 /mol_type="mRNA"
 /strain="129 Ola"
 /db_xref="taxon:10090"
 /clone="m4.E4.D08"
 /sex="male"
 /cell_type="Embryonic stem cell"
 /cell_lines="E14"
 /clone_lib="TIGEM gene trap library"
 /note="Vector: pFLPI"

Query Match 0.5%; Score 8.2; DB 1; Length 13;
 Best Local Similarity 76.9%; Pred. No. 18;
 Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 443 CTCAGGCTGGTT 455
 |||
 Db 1 CTGGACCTGGTT 13

RESULT 16
 CF278327 14 bp mRNA linear EST 14-AUG-2003
 LOCUS 14ETL--04-D06.b1 Rice etiolated leaf plasmid cDNA library (14ETL)
 DEFINITION Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--04-D06, mRNA sequence.

ACCESSION CF278327 GI:33655713
 VERSION CF278327.1
 KEYWORDS EST.
 SOURCE Oryza sativa (japonica cultivar-group)
 ORGANISM Oryza sativa (japonica cultivar-group)
 Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.

1 (bases 1 to 14)
 REFERENCE Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
 AUTHORS Large-scale Sequencing Analysis of Rice ESTs
 TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)
 COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bnhnm@gbio.com, bnhnm@bio.myongji.ac.kr.

FEATURES

Location/Qualifiers

source

1. .14
 /organism="Oryza sativa (japonica cultivar-group)"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:39947"
 /clone="14ETL--04-D06"
 /tissue_type="leaf"
 /dev_stage="14 days after germination"
 /lab_host="E.coli DH10B"
 /clone_lib="Rice etiolated leaf plasmid cDNA library (14ETL)"
 /note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.5%; Score 8.2; DB 1; Length 14;
 Best Local Similarity 76.9%; Pred. No. 18;
 Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 697 ACTTCTTTCTTCC 709
 |||||
 Db 1 ACTTCTTCGCTC 13

Search completed: September 13, 2005, 10:53:12
 Job time : 0.001 secs

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)